0001125376-22-000114.txt : 20220801 0001125376-22-000114.hdr.sgml : 20220801 20220801160351 ACCESSION NUMBER: 0001125376-22-000114 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 108 CONFORMED PERIOD OF REPORT: 20220630 FILED AS OF DATE: 20220801 DATE AS OF CHANGE: 20220801 FILER: COMPANY DATA: COMPANY CONFORMED NAME: ENSIGN GROUP, INC CENTRAL INDEX KEY: 0001125376 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-SKILLED NURSING CARE FACILITIES [8051] IRS NUMBER: 330861263 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-33757 FILM NUMBER: 221124731 BUSINESS ADDRESS: STREET 1: 29222 RANCHO VIEJO RD. STREET 2: SUITE 127 CITY: SAN JUAN CAPISTRANO STATE: CA ZIP: 92675 BUSINESS PHONE: (949) 487-9500 MAIL ADDRESS: STREET 1: 29222 RANCHO VIEJO RD. STREET 2: SUITE 127 CITY: SAN JUAN CAPISTRANO STATE: CA ZIP: 92675 FORMER COMPANY: FORMER CONFORMED NAME: ENSIGN GROUP INC DATE OF NAME CHANGE: 20000930 10-Q 1 ensg-20220630.htm 10-Q ensg-20220630
00011253762022Q2false12/31P3Y0M0DP10YP4M0DP5Y0MP10Y0MP10Y0MP5Y0MP3Y0M00011253762022-01-012022-06-3000011253762022-07-27xbrli:shares00011253762022-06-30iso4217:USD00011253762021-12-31iso4217:USDxbrli:shares0001125376us-gaap:ServiceMember2022-04-012022-06-300001125376us-gaap:ServiceMember2021-04-012021-06-300001125376us-gaap:ServiceMember2022-01-012022-06-300001125376us-gaap:ServiceMember2021-01-012021-06-300001125376ensg:RentalMember2022-04-012022-06-300001125376ensg:RentalMember2021-04-012021-06-300001125376ensg:RentalMember2022-01-012022-06-300001125376ensg:RentalMember2021-01-012021-06-3000011253762022-04-012022-06-3000011253762021-04-012021-06-3000011253762021-01-012021-06-300001125376us-gaap:CommonStockMember2021-12-310001125376us-gaap:AdditionalPaidInCapitalMember2021-12-310001125376us-gaap:RetainedEarningsMember2021-12-310001125376us-gaap:TreasuryStockMember2021-12-310001125376us-gaap:NoncontrollingInterestMember2021-12-310001125376us-gaap:CommonStockMember2022-01-012022-03-310001125376us-gaap:AdditionalPaidInCapitalMember2022-01-012022-03-3100011253762022-01-012022-03-310001125376us-gaap:TreasuryStockMember2022-01-012022-03-310001125376us-gaap:RetainedEarningsMember2022-01-012022-03-310001125376us-gaap:NoncontrollingInterestMember2022-01-012022-03-310001125376us-gaap:CommonStockMember2022-03-310001125376us-gaap:AdditionalPaidInCapitalMember2022-03-310001125376us-gaap:RetainedEarningsMember2022-03-310001125376us-gaap:TreasuryStockMember2022-03-310001125376us-gaap:NoncontrollingInterestMember2022-03-3100011253762022-03-310001125376us-gaap:CommonStockMember2022-04-012022-06-300001125376us-gaap:AdditionalPaidInCapitalMember2022-04-012022-06-300001125376us-gaap:TreasuryStockMember2022-04-012022-06-300001125376us-gaap:RetainedEarningsMember2022-04-012022-06-300001125376us-gaap:NoncontrollingInterestMember2022-04-012022-06-300001125376us-gaap:CommonStockMember2022-06-300001125376us-gaap:AdditionalPaidInCapitalMember2022-06-300001125376us-gaap:RetainedEarningsMember2022-06-300001125376us-gaap:TreasuryStockMember2022-06-300001125376us-gaap:NoncontrollingInterestMember2022-06-300001125376us-gaap:CommonStockMember2020-12-310001125376us-gaap:AdditionalPaidInCapitalMember2020-12-310001125376us-gaap:RetainedEarningsMember2020-12-310001125376us-gaap:TreasuryStockMember2020-12-310001125376us-gaap:NoncontrollingInterestMember2020-12-3100011253762020-12-310001125376us-gaap:CommonStockMember2021-01-012021-03-310001125376us-gaap:AdditionalPaidInCapitalMember2021-01-012021-03-3100011253762021-01-012021-03-310001125376us-gaap:TreasuryStockMember2021-01-012021-03-310001125376us-gaap:RetainedEarningsMember2021-01-012021-03-310001125376us-gaap:NoncontrollingInterestMember2021-01-012021-03-310001125376us-gaap:CommonStockMember2021-03-310001125376us-gaap:AdditionalPaidInCapitalMember2021-03-310001125376us-gaap:RetainedEarningsMember2021-03-310001125376us-gaap:TreasuryStockMember2021-03-310001125376us-gaap:NoncontrollingInterestMember2021-03-3100011253762021-03-310001125376us-gaap:CommonStockMember2021-04-012021-06-300001125376us-gaap:AdditionalPaidInCapitalMember2021-04-012021-06-300001125376us-gaap:TreasuryStockMember2021-04-012021-06-300001125376us-gaap:RetainedEarningsMember2021-04-012021-06-300001125376us-gaap:NoncontrollingInterestMember2021-04-012021-06-300001125376us-gaap:CommonStockMember2021-06-300001125376us-gaap:AdditionalPaidInCapitalMember2021-06-300001125376us-gaap:RetainedEarningsMember2021-06-300001125376us-gaap:TreasuryStockMember2021-06-300001125376us-gaap:NoncontrollingInterestMember2021-06-3000011253762021-06-30ensg:facilityensg:bedensg:seniorLivingUnit0001125376us-gaap:WhollyOwnedPropertiesMember2022-06-300001125376ensg:SeniorLivingFacilitiesMemberus-gaap:SpinoffMemberensg:ThePennantGroupInc.Member2022-06-30ensg:seniorLivingCommunity0001125376us-gaap:SpinoffMemberensg:SkilledNursingOperationsMemberensg:StandardBearerHealthcareREITIncMemberensg:RemainingCompanyMember2022-06-30ensg:operation0001125376srt:MinimumMember2022-01-012022-06-300001125376srt:MaximumMember2022-01-012022-06-300001125376srt:MinimumMember2022-06-300001125376srt:MaximumMember2022-06-300001125376srt:MinimumMemberensg:AssembledOccupancyAcquiredMember2022-01-012022-06-300001125376srt:MaximumMemberensg:AssembledOccupancyAcquiredMember2022-01-012022-06-300001125376us-gaap:TradeNamesMember2022-01-012022-06-300001125376us-gaap:CustomerRelationshipsMember2022-01-012022-06-300001125376ensg:SelfInsuranceRetentionPerClaimMemberus-gaap:GeneralLiabilityMembersrt:ParentCompanyMember2022-06-300001125376us-gaap:GeneralLiabilityMemberensg:AggregateDeductibleMembersrt:ParentCompanyMemberstpr:CA2022-06-300001125376us-gaap:GeneralLiabilityMemberensg:AggregateDeductibleMembersrt:ParentCompanyMemberensg:NonCaliforniaMember2022-06-300001125376us-gaap:GeneralLiabilityMemberensg:PerOccurenceMembernaics:ZZ524292ensg:AllStatesExceptColoradoMember2022-06-300001125376us-gaap:GeneralLiabilityMembernaics:ZZ524292ensg:AllStatesExceptColoradoMemberensg:PerFacilityMember2022-06-300001125376us-gaap:GeneralLiabilityMembernaics:ZZ524292ensg:AllStatesExceptColoradoMemberensg:BlanketAggregateMember2022-06-300001125376us-gaap:GeneralLiabilityMemberensg:PerOccurenceMemberstpr:COnaics:ZZ5242922022-06-300001125376us-gaap:GeneralLiabilityMemberstpr:COnaics:ZZ524292ensg:PerFacilityMember2022-06-300001125376us-gaap:ProfessionalMalpracticeLiabilityMember2022-06-300001125376us-gaap:ProfessionalMalpracticeLiabilityMember2021-12-310001125376us-gaap:WorkersCompensationInsuranceMember2022-06-300001125376us-gaap:WorkersCompensationInsuranceMemberstpr:TX2022-06-300001125376ensg:LossSensitivelimitperclaimMemberMemberus-gaap:WorkersCompensationInsuranceMemberensg:OtherStatesExceptCaliforniaTexasAndWashingtonMember2022-06-300001125376ensg:SelfInsuranceRetentionPerClaimMemberus-gaap:GeneralLiabilityMember2022-06-300001125376us-gaap:WorkersCompensationInsuranceMember2022-06-300001125376us-gaap:WorkersCompensationInsuranceMember2021-12-310001125376ensg:StopLossInsuranceLimitPerClaimMemberensg:HealthLiabilityInsuranceMember2022-06-300001125376us-gaap:HealthInsuranceProductLineMember2022-06-300001125376us-gaap:HealthInsuranceProductLineMember2021-12-310001125376ensg:TruistBankMemberus-gaap:RevolvingCreditFacilityMember2022-04-012022-06-300001125376ensg:TruistBankMemberus-gaap:RevolvingCreditFacilityMember2022-04-0800011253762020-01-012020-12-3100011253762021-03-012021-03-310001125376ensg:MedicaidAndMedicareMemberus-gaap:ServiceMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:SalesRevenueNetMember2022-04-012022-06-30xbrli:pure0001125376ensg:MedicaidAndMedicareMemberus-gaap:ServiceMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:SalesRevenueNetMember2022-01-012022-06-300001125376ensg:MedicaidAndMedicareMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:SalesRevenueNetMember2021-04-012021-06-300001125376ensg:MedicaidAndMedicareMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:SalesRevenueNetMember2021-01-012021-06-300001125376ensg:MedicaidMemberus-gaap:ServiceMember2022-04-012022-06-300001125376ensg:MedicaidMemberus-gaap:ServiceMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:SalesRevenueNetMember2022-04-012022-06-300001125376ensg:MedicaidMemberus-gaap:ServiceMember2021-04-012021-06-300001125376ensg:MedicaidMemberus-gaap:ServiceMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:SalesRevenueNetMember2021-04-012021-06-300001125376us-gaap:ServiceMemberensg:MedicareMember2022-04-012022-06-300001125376us-gaap:ServiceMemberensg:MedicareMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:SalesRevenueNetMember2022-04-012022-06-300001125376us-gaap:ServiceMemberensg:MedicareMember2021-04-012021-06-300001125376us-gaap:ServiceMemberensg:MedicareMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:SalesRevenueNetMember2021-04-012021-06-300001125376us-gaap:ServiceMemberensg:MedicaidSkilledMember2022-04-012022-06-300001125376us-gaap:ServiceMemberus-gaap:CustomerConcentrationRiskMemberensg:MedicaidSkilledMemberus-gaap:SalesRevenueNetMember2022-04-012022-06-300001125376us-gaap:ServiceMemberensg:MedicaidSkilledMember2021-04-012021-06-300001125376us-gaap:ServiceMemberus-gaap:CustomerConcentrationRiskMemberensg:MedicaidSkilledMemberus-gaap:SalesRevenueNetMember2021-04-012021-06-300001125376ensg:MedicaidAndMedicareMemberus-gaap:ServiceMember2022-04-012022-06-300001125376ensg:MedicaidAndMedicareMemberus-gaap:ServiceMember2021-04-012021-06-300001125376ensg:MedicaidAndMedicareMemberus-gaap:ServiceMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:SalesRevenueNetMember2021-04-012021-06-300001125376us-gaap:ServiceMemberensg:ManagedCareMember2022-04-012022-06-300001125376us-gaap:ServiceMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:SalesRevenueNetMemberensg:ManagedCareMember2022-04-012022-06-300001125376us-gaap:ServiceMemberensg:ManagedCareMember2021-04-012021-06-300001125376us-gaap:ServiceMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:SalesRevenueNetMemberensg:ManagedCareMember2021-04-012021-06-300001125376us-gaap:ServiceMemberensg:PrivatePayAndOtherMember2022-04-012022-06-300001125376us-gaap:ServiceMemberensg:PrivatePayAndOtherMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:SalesRevenueNetMember2022-04-012022-06-300001125376us-gaap:ServiceMemberensg:PrivatePayAndOtherMember2021-04-012021-06-300001125376us-gaap:ServiceMemberensg:PrivatePayAndOtherMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:SalesRevenueNetMember2021-04-012021-06-300001125376us-gaap:ServiceMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:SalesRevenueNetMember2022-04-012022-06-300001125376us-gaap:ServiceMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:SalesRevenueNetMember2021-04-012021-06-300001125376ensg:MedicaidMemberus-gaap:ServiceMember2022-01-012022-06-300001125376ensg:MedicaidMemberus-gaap:ServiceMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:SalesRevenueNetMember2022-01-012022-06-300001125376ensg:MedicaidMemberus-gaap:ServiceMember2021-01-012021-06-300001125376ensg:MedicaidMemberus-gaap:ServiceMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:SalesRevenueNetMember2021-01-012021-06-300001125376us-gaap:ServiceMemberensg:MedicareMember2022-01-012022-06-300001125376us-gaap:ServiceMemberensg:MedicareMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:SalesRevenueNetMember2022-01-012022-06-300001125376us-gaap:ServiceMemberensg:MedicareMember2021-01-012021-06-300001125376us-gaap:ServiceMemberensg:MedicareMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:SalesRevenueNetMember2021-01-012021-06-300001125376us-gaap:ServiceMemberensg:MedicaidSkilledMember2022-01-012022-06-300001125376us-gaap:ServiceMemberus-gaap:CustomerConcentrationRiskMemberensg:MedicaidSkilledMemberus-gaap:SalesRevenueNetMember2022-01-012022-06-300001125376us-gaap:ServiceMemberensg:MedicaidSkilledMember2021-01-012021-06-300001125376us-gaap:ServiceMemberus-gaap:CustomerConcentrationRiskMemberensg:MedicaidSkilledMemberus-gaap:SalesRevenueNetMember2021-01-012021-06-300001125376ensg:MedicaidAndMedicareMemberus-gaap:ServiceMember2022-01-012022-06-300001125376ensg:MedicaidAndMedicareMemberus-gaap:ServiceMember2021-01-012021-06-300001125376ensg:MedicaidAndMedicareMemberus-gaap:ServiceMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:SalesRevenueNetMember2021-01-012021-06-300001125376us-gaap:ServiceMemberensg:ManagedCareMember2022-01-012022-06-300001125376us-gaap:ServiceMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:SalesRevenueNetMemberensg:ManagedCareMember2022-01-012022-06-300001125376us-gaap:ServiceMemberensg:ManagedCareMember2021-01-012021-06-300001125376us-gaap:ServiceMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:SalesRevenueNetMemberensg:ManagedCareMember2021-01-012021-06-300001125376us-gaap:ServiceMemberensg:PrivatePayAndOtherMember2022-01-012022-06-300001125376us-gaap:ServiceMemberensg:PrivatePayAndOtherMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:SalesRevenueNetMember2022-01-012022-06-300001125376us-gaap:ServiceMemberensg:PrivatePayAndOtherMember2021-01-012021-06-300001125376us-gaap:ServiceMemberensg:PrivatePayAndOtherMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:SalesRevenueNetMember2021-01-012021-06-300001125376us-gaap:ServiceMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:SalesRevenueNetMember2022-01-012022-06-300001125376us-gaap:ServiceMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:SalesRevenueNetMember2021-01-012021-06-300001125376ensg:MedicaidMember2022-06-300001125376ensg:MedicaidMember2021-12-310001125376ensg:ManagedCareMember2022-06-300001125376ensg:ManagedCareMember2021-12-310001125376ensg:MedicareMember2022-06-300001125376ensg:MedicareMember2021-12-310001125376ensg:PrivatePayAndOtherMember2022-06-300001125376ensg:PrivatePayAndOtherMember2021-12-310001125376us-gaap:FairValueInputsLevel1Member2022-06-300001125376us-gaap:FairValueInputsLevel1Member2021-12-310001125376us-gaap:FairValueInputsLevel2Member2022-06-300001125376us-gaap:FairValueInputsLevel2Member2021-12-310001125376us-gaap:DomesticCorporateDebtSecuritiesMember2022-06-300001125376us-gaap:DomesticCorporateDebtSecuritiesMember2021-12-310001125376ensg:StandardBearerHealthcareREITIncMember2022-06-300001125376us-gaap:WhollyOwnedPropertiesMemberensg:StandardBearerHealthcareREITIncMember2022-06-300001125376ensg:ThirdPartiesMemberensg:StandardBearerHealthcareREITIncMember2022-06-300001125376ensg:OwnedPropertiesMemberensg:StandardBearerHealthcareREITIncMember2022-01-012022-06-300001125376ensg:OwnedPropertiesMemberensg:StandardBearerHealthcareREITIncMemberus-gaap:SubsequentEventMember2022-07-012022-08-01ensg:skilledNursingProperty0001125376ensg:CampusOperationMemberus-gaap:SubsequentEventMember2022-07-012022-08-01ensg:campusProperty00011253762022-01-012022-01-31ensg:lease0001125376ensg:StandardBearerMasterLeasesMembersrt:MinimumMember2022-06-300001125376ensg:StandardBearerMasterLeasesMembersrt:MaximumMember2022-06-300001125376ensg:StandardBearerMasterLeasesMember2022-01-31ensg:renewal0001125376ensg:StandardBearerMasterLeasesMember2022-04-012022-06-300001125376ensg:StandardBearerMasterLeasesMember2022-01-012022-06-300001125376ensg:StandardBearerMasterLeasesMember2021-04-012021-06-300001125376ensg:StandardBearerMasterLeasesMember2021-01-012021-06-300001125376ensg:StandardBearerMasterLeasesMemberus-gaap:ManagementServiceBaseMember2022-01-012022-01-310001125376ensg:StandardBearerMasterLeasesMemberus-gaap:ManagementServiceIncentiveMember2022-01-012022-01-310001125376ensg:StandardBearerMasterLeasesMemberus-gaap:ManagementServiceBaseMember2022-04-012022-06-300001125376ensg:StandardBearerMasterLeasesMemberus-gaap:ManagementServiceBaseMember2022-01-012022-06-300001125376ensg:StandardBearerMasterLeasesMemberensg:ManagementServiceTotalMember2022-04-012022-06-300001125376ensg:StandardBearerMasterLeasesMemberensg:ManagementServiceTotalMember2022-01-012022-06-300001125376us-gaap:BaseRateMemberensg:TruistBankMemberus-gaap:RevolvingCreditFacilityMembersrt:MinimumMember2022-04-082022-04-080001125376us-gaap:BaseRateMemberensg:TruistBankMembersrt:MaximumMemberus-gaap:RevolvingCreditFacilityMember2022-04-082022-04-080001125376ensg:TruistBankMemberus-gaap:RevolvingCreditFacilityMemberus-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMembersrt:MinimumMember2022-04-082022-04-080001125376ensg:TruistBankMembersrt:MaximumMemberus-gaap:RevolvingCreditFacilityMemberus-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember2022-04-082022-04-080001125376ensg:StandardBearerEquityPlanMember2022-01-012022-01-310001125376ensg:StandardBearerEquityPlanMember2022-01-012022-06-300001125376ensg:StandardBearerEquityPlanMember2022-04-012022-06-30ensg:segment0001125376us-gaap:OperatingSegmentsMemberus-gaap:ServiceMemberensg:SkilledServicesSegmentMember2022-04-012022-06-300001125376us-gaap:OperatingSegmentsMemberus-gaap:ServiceMemberensg:StandardBearerSegmentMember2022-04-012022-06-300001125376us-gaap:AllOtherSegmentsMemberus-gaap:OperatingSegmentsMemberus-gaap:ServiceMember2022-04-012022-06-300001125376us-gaap:ServiceMembersrt:ConsolidationEliminationsMember2022-04-012022-06-300001125376us-gaap:OperatingSegmentsMemberensg:RentalMemberensg:SkilledServicesSegmentMember2022-04-012022-06-300001125376us-gaap:OperatingSegmentsMemberensg:RentalMemberensg:StandardBearerSegmentMember2022-04-012022-06-300001125376us-gaap:AllOtherSegmentsMemberus-gaap:OperatingSegmentsMemberensg:RentalMember2022-04-012022-06-300001125376ensg:RentalMembersrt:ConsolidationEliminationsMember2022-04-012022-06-300001125376us-gaap:OperatingSegmentsMemberensg:SkilledServicesSegmentMember2022-04-012022-06-300001125376us-gaap:OperatingSegmentsMemberensg:StandardBearerSegmentMember2022-04-012022-06-300001125376us-gaap:AllOtherSegmentsMemberus-gaap:OperatingSegmentsMember2022-04-012022-06-300001125376srt:ConsolidationEliminationsMember2022-04-012022-06-300001125376us-gaap:OperatingSegmentsMemberus-gaap:ServiceMemberensg:SkilledServicesSegmentMember2021-04-012021-06-300001125376us-gaap:OperatingSegmentsMemberus-gaap:ServiceMemberensg:StandardBearerSegmentMember2021-04-012021-06-300001125376us-gaap:AllOtherSegmentsMemberus-gaap:OperatingSegmentsMemberus-gaap:ServiceMember2021-04-012021-06-300001125376us-gaap:ServiceMembersrt:ConsolidationEliminationsMember2021-04-012021-06-300001125376us-gaap:OperatingSegmentsMemberensg:RentalMemberensg:SkilledServicesSegmentMember2021-04-012021-06-300001125376us-gaap:OperatingSegmentsMemberensg:RentalMemberensg:StandardBearerSegmentMember2021-04-012021-06-300001125376us-gaap:AllOtherSegmentsMemberus-gaap:OperatingSegmentsMemberensg:RentalMember2021-04-012021-06-300001125376ensg:RentalMembersrt:ConsolidationEliminationsMember2021-04-012021-06-300001125376us-gaap:OperatingSegmentsMemberensg:SkilledServicesSegmentMember2021-04-012021-06-300001125376us-gaap:OperatingSegmentsMemberensg:StandardBearerSegmentMember2021-04-012021-06-300001125376us-gaap:AllOtherSegmentsMemberus-gaap:OperatingSegmentsMember2021-04-012021-06-300001125376srt:ConsolidationEliminationsMember2021-04-012021-06-300001125376srt:ConsolidationEliminationsMember2021-01-012021-06-300001125376us-gaap:OperatingSegmentsMemberus-gaap:ServiceMemberensg:SkilledServicesSegmentMember2022-01-012022-06-300001125376us-gaap:OperatingSegmentsMemberus-gaap:ServiceMemberensg:StandardBearerSegmentMember2022-01-012022-06-300001125376us-gaap:AllOtherSegmentsMemberus-gaap:OperatingSegmentsMemberus-gaap:ServiceMember2022-01-012022-06-300001125376us-gaap:ServiceMembersrt:ConsolidationEliminationsMember2022-01-012022-06-300001125376us-gaap:OperatingSegmentsMemberensg:RentalMemberensg:SkilledServicesSegmentMember2022-01-012022-06-300001125376us-gaap:OperatingSegmentsMemberensg:RentalMemberensg:StandardBearerSegmentMember2022-01-012022-06-300001125376us-gaap:AllOtherSegmentsMemberus-gaap:OperatingSegmentsMemberensg:RentalMember2022-01-012022-06-300001125376ensg:RentalMembersrt:ConsolidationEliminationsMember2022-01-012022-06-300001125376us-gaap:OperatingSegmentsMemberensg:SkilledServicesSegmentMember2022-01-012022-06-300001125376us-gaap:OperatingSegmentsMemberensg:StandardBearerSegmentMember2022-01-012022-06-300001125376us-gaap:AllOtherSegmentsMemberus-gaap:OperatingSegmentsMember2022-01-012022-06-300001125376srt:ConsolidationEliminationsMember2022-01-012022-06-300001125376us-gaap:OperatingSegmentsMemberus-gaap:ServiceMemberensg:SkilledServicesSegmentMember2021-01-012021-06-300001125376us-gaap:OperatingSegmentsMemberus-gaap:ServiceMemberensg:StandardBearerSegmentMember2021-01-012021-06-300001125376us-gaap:AllOtherSegmentsMemberus-gaap:OperatingSegmentsMemberus-gaap:ServiceMember2021-01-012021-06-300001125376us-gaap:ServiceMembersrt:ConsolidationEliminationsMember2021-01-012021-06-300001125376us-gaap:OperatingSegmentsMemberensg:RentalMemberensg:SkilledServicesSegmentMember2021-01-012021-06-300001125376us-gaap:OperatingSegmentsMemberensg:RentalMemberensg:StandardBearerSegmentMember2021-01-012021-06-300001125376us-gaap:AllOtherSegmentsMemberus-gaap:OperatingSegmentsMemberensg:RentalMember2021-01-012021-06-300001125376ensg:RentalMembersrt:ConsolidationEliminationsMember2021-01-012021-06-300001125376us-gaap:OperatingSegmentsMemberensg:SkilledServicesSegmentMember2021-01-012021-06-300001125376us-gaap:OperatingSegmentsMemberensg:StandardBearerSegmentMember2021-01-012021-06-300001125376us-gaap:AllOtherSegmentsMemberus-gaap:OperatingSegmentsMember2021-01-012021-06-300001125376ensg:MedicaidMemberus-gaap:OperatingSegmentsMemberus-gaap:ServiceMemberensg:SkilledServicesSegmentMember2022-04-012022-06-300001125376us-gaap:CorporateNonSegmentMemberensg:MedicaidMemberus-gaap:ServiceMember2022-04-012022-06-300001125376us-gaap:OperatingSegmentsMemberus-gaap:ServiceMemberensg:SkilledServicesSegmentMemberensg:MedicareMember2022-04-012022-06-300001125376us-gaap:CorporateNonSegmentMemberus-gaap:ServiceMemberensg:MedicareMember2022-04-012022-06-300001125376us-gaap:OperatingSegmentsMemberus-gaap:ServiceMemberensg:SkilledServicesSegmentMemberensg:MedicaidSkilledMember2022-04-012022-06-300001125376us-gaap:CorporateNonSegmentMemberus-gaap:ServiceMemberensg:MedicaidSkilledMember2022-04-012022-06-300001125376us-gaap:OperatingSegmentsMemberensg:MedicaidAndMedicareMemberus-gaap:ServiceMemberensg:SkilledServicesSegmentMember2022-04-012022-06-300001125376us-gaap:CorporateNonSegmentMemberensg:MedicaidAndMedicareMemberus-gaap:ServiceMember2022-04-012022-06-300001125376us-gaap:OperatingSegmentsMemberus-gaap:ServiceMemberensg:SkilledServicesSegmentMemberensg:ManagedCareMember2022-04-012022-06-300001125376us-gaap:CorporateNonSegmentMemberus-gaap:ServiceMemberensg:ManagedCareMember2022-04-012022-06-300001125376us-gaap:OperatingSegmentsMemberus-gaap:ServiceMemberensg:PrivatePayAndOtherMemberensg:SkilledServicesSegmentMember2022-04-012022-06-300001125376us-gaap:CorporateNonSegmentMemberus-gaap:ServiceMemberensg:PrivatePayAndOtherMember2022-04-012022-06-300001125376us-gaap:CorporateNonSegmentMemberus-gaap:ServiceMember2022-04-012022-06-300001125376ensg:MedicaidMemberus-gaap:OperatingSegmentsMemberus-gaap:ServiceMemberensg:SkilledServicesSegmentMember2021-04-012021-06-300001125376us-gaap:CorporateNonSegmentMemberensg:MedicaidMemberus-gaap:ServiceMember2021-04-012021-06-300001125376us-gaap:OperatingSegmentsMemberus-gaap:ServiceMemberensg:SkilledServicesSegmentMemberensg:MedicareMember2021-04-012021-06-300001125376us-gaap:CorporateNonSegmentMemberus-gaap:ServiceMemberensg:MedicareMember2021-04-012021-06-300001125376us-gaap:OperatingSegmentsMemberus-gaap:ServiceMemberensg:SkilledServicesSegmentMemberensg:MedicaidSkilledMember2021-04-012021-06-300001125376us-gaap:CorporateNonSegmentMemberus-gaap:ServiceMemberensg:MedicaidSkilledMember2021-04-012021-06-300001125376us-gaap:OperatingSegmentsMemberensg:MedicaidAndMedicareMemberus-gaap:ServiceMemberensg:SkilledServicesSegmentMember2021-04-012021-06-300001125376us-gaap:CorporateNonSegmentMemberensg:MedicaidAndMedicareMemberus-gaap:ServiceMember2021-04-012021-06-300001125376us-gaap:OperatingSegmentsMemberus-gaap:ServiceMemberensg:SkilledServicesSegmentMemberensg:ManagedCareMember2021-04-012021-06-300001125376us-gaap:CorporateNonSegmentMemberus-gaap:ServiceMemberensg:ManagedCareMember2021-04-012021-06-300001125376us-gaap:OperatingSegmentsMemberus-gaap:ServiceMemberensg:PrivatePayAndOtherMemberensg:SkilledServicesSegmentMember2021-04-012021-06-300001125376us-gaap:CorporateNonSegmentMemberus-gaap:ServiceMemberensg:PrivatePayAndOtherMember2021-04-012021-06-300001125376us-gaap:CorporateNonSegmentMemberus-gaap:ServiceMember2021-04-012021-06-300001125376ensg:MedicaidMemberus-gaap:OperatingSegmentsMemberus-gaap:ServiceMemberensg:SkilledServicesSegmentMember2022-01-012022-06-300001125376us-gaap:CorporateNonSegmentMemberensg:MedicaidMemberus-gaap:ServiceMember2022-01-012022-06-300001125376us-gaap:OperatingSegmentsMemberus-gaap:ServiceMemberensg:SkilledServicesSegmentMemberensg:MedicareMember2022-01-012022-06-300001125376us-gaap:CorporateNonSegmentMemberus-gaap:ServiceMemberensg:MedicareMember2022-01-012022-06-300001125376us-gaap:OperatingSegmentsMemberus-gaap:ServiceMemberensg:SkilledServicesSegmentMemberensg:MedicaidSkilledMember2022-01-012022-06-300001125376us-gaap:CorporateNonSegmentMemberus-gaap:ServiceMemberensg:MedicaidSkilledMember2022-01-012022-06-300001125376us-gaap:OperatingSegmentsMemberensg:MedicaidAndMedicareMemberus-gaap:ServiceMemberensg:SkilledServicesSegmentMember2022-01-012022-06-300001125376us-gaap:CorporateNonSegmentMemberensg:MedicaidAndMedicareMemberus-gaap:ServiceMember2022-01-012022-06-300001125376us-gaap:OperatingSegmentsMemberus-gaap:ServiceMemberensg:SkilledServicesSegmentMemberensg:ManagedCareMember2022-01-012022-06-300001125376us-gaap:CorporateNonSegmentMemberus-gaap:ServiceMemberensg:ManagedCareMember2022-01-012022-06-300001125376us-gaap:OperatingSegmentsMemberus-gaap:ServiceMemberensg:PrivatePayAndOtherMemberensg:SkilledServicesSegmentMember2022-01-012022-06-300001125376us-gaap:CorporateNonSegmentMemberus-gaap:ServiceMemberensg:PrivatePayAndOtherMember2022-01-012022-06-300001125376us-gaap:CorporateNonSegmentMemberus-gaap:ServiceMember2022-01-012022-06-300001125376ensg:MedicaidMemberus-gaap:OperatingSegmentsMemberus-gaap:ServiceMemberensg:SkilledServicesSegmentMember2021-01-012021-06-300001125376us-gaap:CorporateNonSegmentMemberensg:MedicaidMemberus-gaap:ServiceMember2021-01-012021-06-300001125376us-gaap:OperatingSegmentsMemberus-gaap:ServiceMemberensg:SkilledServicesSegmentMemberensg:MedicareMember2021-01-012021-06-300001125376us-gaap:CorporateNonSegmentMemberus-gaap:ServiceMemberensg:MedicareMember2021-01-012021-06-300001125376us-gaap:OperatingSegmentsMemberus-gaap:ServiceMemberensg:SkilledServicesSegmentMemberensg:MedicaidSkilledMember2021-01-012021-06-300001125376us-gaap:CorporateNonSegmentMemberus-gaap:ServiceMemberensg:MedicaidSkilledMember2021-01-012021-06-300001125376us-gaap:OperatingSegmentsMemberensg:MedicaidAndMedicareMemberus-gaap:ServiceMemberensg:SkilledServicesSegmentMember2021-01-012021-06-300001125376us-gaap:CorporateNonSegmentMemberensg:MedicaidAndMedicareMemberus-gaap:ServiceMember2021-01-012021-06-300001125376us-gaap:OperatingSegmentsMemberus-gaap:ServiceMemberensg:SkilledServicesSegmentMemberensg:ManagedCareMember2021-01-012021-06-300001125376us-gaap:CorporateNonSegmentMemberus-gaap:ServiceMemberensg:ManagedCareMember2021-01-012021-06-300001125376us-gaap:OperatingSegmentsMemberus-gaap:ServiceMemberensg:PrivatePayAndOtherMemberensg:SkilledServicesSegmentMember2021-01-012021-06-300001125376us-gaap:CorporateNonSegmentMemberus-gaap:ServiceMemberensg:PrivatePayAndOtherMember2021-01-012021-06-300001125376us-gaap:CorporateNonSegmentMemberus-gaap:ServiceMember2021-01-012021-06-300001125376ensg:SkilledNursingOperationsMember2022-01-012022-06-300001125376ensg:SeniorLivingFacilitiesMember2022-01-012022-06-300001125376ensg:SkilledNursingOperationsMember2022-06-300001125376ensg:SeniorLivingFacilitiesMember2022-06-300001125376ensg:TwoAcquisitionsConcentratedInPropertyPlantAndEquipmentMember2022-01-012022-06-300001125376ensg:TwoAcquisitionsConcentratedInGoodwillMember2022-01-012022-06-300001125376ensg:SkilledNursingOperationsMemberus-gaap:SubsequentEventMember2022-07-012022-08-01ensg:realEstateProperty0001125376ensg:SkilledNursingOperationsMemberus-gaap:SubsequentEventMember2022-08-010001125376ensg:SeniorLivingFacilitiesMemberus-gaap:SubsequentEventMember2022-08-010001125376ensg:SkilledNursingOperationsMemberus-gaap:SubsequentEventMember2022-07-012022-08-010001125376ensg:SkilledNursingOperationsMember2021-01-012021-06-300001125376ensg:SkilledNursingOperationsMember2021-06-300001125376ensg:AssetAcquisitionMember2021-01-012021-06-300001125376ensg:AssetAcquisitionMember2021-01-012021-06-300001125376ensg:BusinessCombinationMember2021-01-012021-06-300001125376us-gaap:LandMember2022-06-300001125376us-gaap:LandMember2021-12-310001125376us-gaap:BuildingAndBuildingImprovementsMember2022-06-300001125376us-gaap:BuildingAndBuildingImprovementsMember2021-12-310001125376us-gaap:LeaseholdImprovementsMember2022-06-300001125376us-gaap:LeaseholdImprovementsMember2021-12-310001125376us-gaap:EquipmentMember2022-06-300001125376us-gaap:EquipmentMember2021-12-310001125376us-gaap:FurnitureAndFixturesMember2022-06-300001125376us-gaap:FurnitureAndFixturesMember2021-12-310001125376us-gaap:ConstructionInProgressMember2022-06-300001125376us-gaap:ConstructionInProgressMember2021-12-310001125376us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMemberensg:SeniorLivingOperationsMember2022-04-012022-06-300001125376ensg:AssembledOccupancyAcquiredMember2022-01-012022-06-300001125376ensg:AssembledOccupancyAcquiredMember2022-06-300001125376ensg:AssembledOccupancyAcquiredMember2021-12-310001125376us-gaap:TradeNamesMember2022-06-300001125376us-gaap:TradeNamesMember2021-12-310001125376us-gaap:CustomerRelationshipsMember2022-06-300001125376us-gaap:CustomerRelationshipsMember2021-12-310001125376ensg:DepreciationAndAmortizationMember2022-04-012022-06-300001125376ensg:DepreciationAndAmortizationMember2022-01-012022-06-300001125376ensg:DepreciationAndAmortizationMember2021-04-012021-06-300001125376ensg:DepreciationAndAmortizationMember2021-01-012021-06-300001125376us-gaap:OperatingSegmentsMemberensg:SkilledServicesSegmentMember2021-12-310001125376us-gaap:CorporateNonSegmentMember2021-12-310001125376us-gaap:CorporateNonSegmentMember2022-01-012022-06-300001125376us-gaap:OperatingSegmentsMemberensg:SkilledServicesSegmentMember2022-06-300001125376us-gaap:CorporateNonSegmentMember2022-06-300001125376us-gaap:TradeNamesMember2022-06-300001125376us-gaap:TradeNamesMember2021-12-310001125376ensg:MedicareandMedicaidLicensesMember2022-06-300001125376ensg:MedicareandMedicaidLicensesMember2021-12-310001125376us-gaap:NotesPayableOtherPayablesMemberus-gaap:CollateralizedDebtObligationsMember2022-06-300001125376us-gaap:NotesPayableOtherPayablesMemberus-gaap:CollateralizedDebtObligationsMember2021-12-310001125376ensg:TruistBankMemberus-gaap:RevolvingCreditFacilityMember2019-10-010001125376ensg:TruistBankMemberus-gaap:RevolvingCreditFacilityMembersrt:MinimumMember2022-04-082022-04-080001125376ensg:TruistBankMembersrt:MaximumMemberus-gaap:RevolvingCreditFacilityMember2022-04-082022-04-080001125376ensg:TruistBankMemberus-gaap:RevolvingCreditFacilityMember2022-06-300001125376ensg:TruistBankMemberus-gaap:RevolvingCreditFacilityMemberus-gaap:SubsequentEventMember2022-07-270001125376us-gaap:MortgagesMemberus-gaap:CollateralizedDebtObligationsMemberensg:TwentyThreeSubsidiariesMember2022-06-30ensg:subsidiary0001125376us-gaap:NotesPayableToBanksMembersrt:MinimumMemberus-gaap:CollateralizedDebtObligationsMember2022-06-300001125376us-gaap:NotesPayableToBanksMembersrt:MaximumMemberus-gaap:CollateralizedDebtObligationsMember2022-06-300001125376us-gaap:MortgagesMemberus-gaap:CollateralizedDebtObligationsMember2022-06-300001125376us-gaap:MortgagesMembersrt:MinimumMemberus-gaap:CollateralizedDebtObligationsMember2022-01-012022-06-300001125376us-gaap:MortgagesMembersrt:MaximumMemberus-gaap:CollateralizedDebtObligationsMember2022-01-012022-06-300001125376us-gaap:CollateralizedDebtObligationsMember2022-01-012022-06-30ensg:promissoryNote0001125376us-gaap:CollateralizedDebtObligationsMemberensg:PromissoryNote50Member2022-06-300001125376ensg:PromissoryNote53Memberus-gaap:CollateralizedDebtObligationsMember2022-06-300001125376us-gaap:CollateralizedDebtObligationsMemberensg:PromissoryNote50Member2022-01-012022-06-300001125376ensg:PromissoryNote53Memberus-gaap:CollateralizedDebtObligationsMember2022-01-012022-06-300001125376ensg:A2022PlanMember2022-06-300001125376ensg:A2022PlanMember2017-12-310001125376ensg:A2022PlanMember2022-01-012022-06-300001125376us-gaap:ShareBasedPaymentArrangementNonemployeeMemberensg:A2022PlanMember2022-01-012022-06-30ensg:installment0001125376ensg:ExercisePriceRangeOneMember2022-01-012022-06-300001125376ensg:ExercisePriceRangeOneMember2022-06-300001125376ensg:ExercisePriceRangeTwoMember2022-01-012022-06-300001125376ensg:ExercisePriceRangeTwoMember2022-06-300001125376ensg:ExercisePriceRangeThreeMember2022-01-012022-06-300001125376ensg:ExercisePriceRangeThreeMember2022-06-300001125376ensg:ExercisePriceRangeFourMember2022-01-012022-06-300001125376ensg:ExercisePriceRangeFourMember2022-06-300001125376ensg:ExercisePriceRangeFiveMember2022-01-012022-06-300001125376ensg:ExercisePriceRangeFiveMember2022-06-300001125376ensg:ExercisePriceRangeSixMember2022-01-012022-06-300001125376ensg:ExercisePriceRangeSixMember2022-06-300001125376ensg:ExercisePriceRangeSevenMember2022-01-012022-06-300001125376ensg:ExercisePriceRangeSevenMember2022-06-300001125376ensg:ExercisePriceRangeEightMember2022-01-012022-06-300001125376ensg:ExercisePriceRangeEightMember2022-06-300001125376ensg:ExercisePriceRangeNineMember2022-01-012022-06-300001125376ensg:ExercisePriceRangeNineMember2022-06-300001125376ensg:ExercisePriceRangeTenMember2022-01-012022-06-300001125376ensg:ExercisePriceRangeTenMember2022-06-300001125376ensg:ExercisePriceRangeElevenMember2022-01-012022-06-300001125376ensg:ExercisePriceRangeElevenMember2022-06-300001125376us-gaap:EmployeeStockOptionMember2022-01-012022-06-300001125376us-gaap:EmployeeStockOptionMember2021-01-012021-06-300001125376us-gaap:RestrictedStockMember2022-04-012022-06-300001125376us-gaap:RestrictedStockMember2022-01-012022-06-300001125376us-gaap:RestrictedStockMember2021-04-012021-06-300001125376us-gaap:RestrictedStockMember2021-01-012021-06-300001125376us-gaap:RestrictedStockMembersrt:MinimumMember2022-01-012022-06-300001125376us-gaap:RestrictedStockMembersrt:MaximumMember2022-01-012022-06-300001125376us-gaap:RestrictedStockMembersrt:MinimumMember2021-01-012021-06-300001125376us-gaap:RestrictedStockMembersrt:MaximumMember2021-01-012021-06-300001125376us-gaap:RestrictedStockMember2021-12-310001125376us-gaap:RestrictedStockMember2022-06-300001125376us-gaap:RestrictedStockMemberus-gaap:ShareBasedPaymentArrangementNonemployeeMember2022-04-012022-06-300001125376us-gaap:RestrictedStockMemberus-gaap:ShareBasedPaymentArrangementNonemployeeMember2022-01-012022-06-300001125376us-gaap:RestrictedStockMemberus-gaap:ShareBasedPaymentArrangementNonemployeeMembersrt:MinimumMember2022-01-012022-06-300001125376us-gaap:RestrictedStockMembersrt:MaximumMemberus-gaap:ShareBasedPaymentArrangementNonemployeeMember2022-01-012022-06-300001125376us-gaap:SpinoffMemberensg:A2019LTIPlanMember2019-08-270001125376us-gaap:SpinoffMemberensg:A2019LTIPlanMember2019-08-272019-08-270001125376us-gaap:SpinoffMemberensg:A2019LTIPlanMember2022-04-012022-06-300001125376us-gaap:SpinoffMemberensg:A2019LTIPlanMember2022-01-012022-06-300001125376us-gaap:SpinoffMemberensg:A2019LTIPlanMember2021-04-012021-06-300001125376us-gaap:SpinoffMemberensg:A2019LTIPlanMember2021-01-012021-06-300001125376us-gaap:EmployeeStockOptionMember2022-04-012022-06-300001125376us-gaap:EmployeeStockOptionMember2021-04-012021-06-300001125376ensg:StockAwardsMember2022-04-012022-06-300001125376ensg:StockAwardsMember2021-04-012021-06-300001125376ensg:StockAwardsMember2022-01-012022-06-300001125376ensg:StockAwardsMember2021-01-012021-06-300001125376us-gaap:EmployeeStockOptionMember2022-06-300001125376ensg:CareTrustREITMember2022-06-300001125376ensg:CareTrustREITMemberensg:ThirdPartyTenantsUnderTripleNetLeaseArrangementsMember2022-06-30ensg:agreement0001125376ensg:CareTrustREITMembersrt:MinimumMember2022-06-300001125376ensg:CareTrustREITMembersrt:MaximumMember2022-06-300001125376ensg:CareTrustREITMemberensg:PurchaseOptionMember2022-06-300001125376ensg:CareTrustREITMember2022-01-012022-06-300001125376ensg:CareTrustREITMember2022-04-012022-06-300001125376ensg:CareTrustREITMember2021-04-012021-06-300001125376ensg:CareTrustREITMember2021-01-012021-06-300001125376ensg:VariousLandlordsMembersrt:MinimumMember2022-06-300001125376srt:MaximumMemberensg:VariousLandlordsMember2022-06-300001125376ensg:VariousLandlordsMember2022-06-300001125376us-gaap:EquipmentMemberensg:VariousLandlordsMembersrt:MinimumMember2022-06-300001125376us-gaap:EquipmentMembersrt:MaximumMemberensg:VariousLandlordsMember2022-06-300001125376ensg:CostofSalesandGeneralandAdministrativeExpenseMember2022-04-012022-06-300001125376ensg:CostofSalesandGeneralandAdministrativeExpenseMember2022-01-012022-06-300001125376ensg:CostofSalesandGeneralandAdministrativeExpenseMember2021-04-012021-06-300001125376ensg:CostofSalesandGeneralandAdministrativeExpenseMember2021-01-012021-06-300001125376ensg:AffiliatedFacilityMasterLeaseOneMember2022-03-310001125376ensg:AffiliatedFacilityMasterLeaseOneMember2022-01-012022-03-310001125376ensg:RentCostOfServicesMember2022-04-012022-06-300001125376ensg:RentCostOfServicesMember2021-04-012021-06-300001125376ensg:RentCostOfServicesMember2022-01-012022-06-300001125376ensg:RentCostOfServicesMember2021-01-012021-06-300001125376us-gaap:GeneralAndAdministrativeExpenseMember2022-04-012022-06-300001125376us-gaap:GeneralAndAdministrativeExpenseMember2021-04-012021-06-300001125376us-gaap:GeneralAndAdministrativeExpenseMember2022-01-012022-06-300001125376us-gaap:GeneralAndAdministrativeExpenseMember2021-01-012021-06-300001125376ensg:CostOfServicesMember2022-04-012022-06-300001125376ensg:CostOfServicesMember2021-04-012021-06-300001125376ensg:CostOfServicesMember2022-01-012022-06-300001125376ensg:CostOfServicesMember2021-01-012021-06-300001125376ensg:SkilledNursingOperationsMemberensg:AmendedMasterLeaseMemberus-gaap:SubsequentEventMember2022-07-012022-08-01ensg:repurchaseProgram0001125376ensg:AmendedMasterLeaseMemberus-gaap:SubsequentEventMember2022-08-010001125376ensg:AmendedMasterLeaseMemberus-gaap:SubsequentEventMember2022-07-012022-08-010001125376us-gaap:SubsequentEventMember2022-07-012022-08-010001125376ensg:SeniorLivingFacilitiesMemberus-gaap:SpinoffMemberensg:ThePennantGroupInc.Member2019-10-310001125376ensg:SeniorLivingFacilitiesMemberus-gaap:SpinoffMember2022-06-300001125376us-gaap:SpinoffMembersrt:MinimumMember2019-10-010001125376us-gaap:SpinoffMembersrt:MaximumMember2019-10-010001125376ensg:ThePennantGroupInc.Member2022-04-012022-06-300001125376ensg:ThePennantGroupInc.Member2021-04-012021-06-300001125376ensg:ThePennantGroupInc.Member2022-01-012022-06-300001125376ensg:ThePennantGroupInc.Member2021-01-012021-06-300001125376ensg:ThirdPartyTenantsMember2022-04-012022-06-300001125376ensg:ThirdPartyTenantsMember2021-04-012021-06-300001125376ensg:ThirdPartyTenantsMember2022-01-012022-06-300001125376ensg:ThirdPartyTenantsMember2021-01-012021-06-300001125376ensg:ThePennantGroupInc.Member2022-04-012022-06-300001125376ensg:ThePennantGroupInc.Member2022-01-012022-06-300001125376ensg:ThePennantGroupInc.Member2021-04-012021-06-300001125376ensg:ThePennantGroupInc.Member2021-01-012021-06-300001125376ensg:MedicaidAndMedicareMemberus-gaap:AccountsReceivableMemberus-gaap:CustomerConcentrationRiskMember2022-01-012022-06-300001125376ensg:MedicaidAndMedicareMemberus-gaap:AccountsReceivableMemberus-gaap:CustomerConcentrationRiskMember2021-01-012021-12-310001125376ensg:MedicaidAndMedicareMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:SalesRevenueNetMember2022-01-012022-06-300001125376ensg:MedicaidAndMedicareMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:SalesRevenueNetMember2022-04-012022-06-300001125376us-gaap:SubsequentEventMember2022-07-270001125376ensg:February92022RepurchaseProgramMember2022-02-090001125376ensg:February92022RepurchaseProgramMember2022-02-092022-02-090001125376ensg:October212021RepurchaseProgramMember2022-04-012022-06-300001125376ensg:October212021RepurchaseProgramMember2021-10-210001125376ensg:October212021RepurchaseProgramMember2021-10-212021-10-210001125376ensg:October212021RepurchaseProgramMember2022-01-012022-03-310001125376ensg:October212021RepurchaseProgramMember2021-10-012021-12-310001125376ensg:July2022RepurchaseProgramMemberus-gaap:SubsequentEventMember2022-07-280001125376ensg:July2022RepurchaseProgramMemberus-gaap:SubsequentEventMember2022-07-282022-07-28
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
_____________________________
FORM 10-Q
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934.
For the quarterly period ended June 30, 2022.
OR
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934.
For the transition period from                      to                     .
Commission file number: 001-33757
_____________________________
ensg-20220630_g1.jpg
THE ENSIGN GROUP, INC.
(Exact Name of Registrant as Specified in Its Charter)

Delaware33-0861263
(State or Other Jurisdiction of(I.R.S. Employer
Incorporation or Organization)Identification No.)

29222 Rancho Viejo Road, Suite 127
San Juan Capistrano, CA 92675
(Address of Principal Executive Offices and Zip Code)

(949487-9500
(Registrant’s Telephone Number, Including Area Code)
_____________________________
Securities registered pursuant to Section 12(b) of the Act:

Title of each classTrading Symbol(s)Name of each exchange on which registered
Common Stock, par value $0.001 per shareENSGNASDAQ Global Select Market

Indicate by check mark:
whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.þYesNo
whether the registrant has submitted electronically, every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).þYesNo
whether the registrant is a large accelerated filer, an accelerated filer, non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and "emerging growth company" in Rule 12b-2 of the Exchange Act:
Large accelerated filerþAccelerated filerNon-accelerated filerSmaller reporting companyEmerging growth company
If an emerging growth company, indicate if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.YesNo
whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).YesþNo
As of July 27, 2022, 55,289,903 shares of the registrant’s common stock, $0.001 par value, were outstanding.


THE ENSIGN GROUP, INC.
QUARTERLY REPORT ON FORM 10-Q
FOR THE THREE MONTHS AND SIX MONTHS ENDED JUNE 30, 2022
TABLE OF CONTENTS

Pg.
Notes to Condensed Consolidated Financial Statements






PART I.
Item 1.        FINANCIAL STATEMENTS

THE ENSIGN GROUP, INC.
UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS
June 30, 2022December 31, 2021
(In thousands, except par values)
ASSETS  
Current assets:   
Cash and cash equivalents$285,580 $262,201 
Accounts receivable—less allowance for doubtful accounts of $7,827 and $11,213 at June 30, 2022 and December 31, 2021, respectively
339,001 328,731 
Investments—current8,991 13,763 
Prepaid income taxes16,336 5,452 
Prepaid expenses and other current assets32,774 29,562 
Total current assets682,682 639,709 
Property and equipment, net908,228 888,434 
Right-of-use assets 1,305,009 1,138,872 
Insurance subsidiary deposits and investments40,077 36,567 
Escrow deposits15,571  
Deferred tax assets32,883 33,147 
Restricted and other assets 57,010 47,046 
Intangible assets, net 2,535 2,652 
Goodwill 76,869 60,469 
Other indefinite-lived intangibles 3,807 3,727 
TOTAL ASSETS$3,124,671 $2,850,623 
LIABILITIES AND EQUITY  
Current liabilities:  
Accounts payable$60,414 $58,116 
Accrued wages and related liabilities (Note 3)
273,276 278,770 
Lease liabilities—current 58,769 52,181 
Accrued self-insurance liabilities—current49,728 40,831 
Other accrued liabilities 85,793 89,410 
Current maturities of long-term debt3,944 3,760 
Total current liabilities531,924 523,068 
Long-term debt—less current maturities151,105 152,883 
Long-term lease liabilities—less current portion 1,216,335 1,056,515 
Accrued self-insurance liabilities—less current portion76,793 69,308 
Other long-term liabilities27,821 27,135 
TOTAL LIABILITIES$2,003,978 $1,828,909 
Commitments and contingencies (Notes 16, 18 and 19)
EQUITY  
Ensign Group, Inc. stockholders' equity:
Common stock: $0.001 par value; 100,000 shares authorized; 58,646 and 55,278 shares issued and outstanding at June 30, 2022, respectively, and 58,134 and 55,190 shares issued and outstanding at December 31, 2021, respectively
58 58 
Additional paid-in capital398,793 369,760 
Retained earnings835,941 733,992 
Common stock in treasury, at cost, 3,368 and 2,944 shares at June 30, 2022 and December 31, 2021, respectively (Note 20)
(114,626)(83,042)
Total Ensign Group, Inc. stockholders' equity1,120,166 1,020,768 
Non-controlling interest527 946 
Total equity$1,120,693 $1,021,714 
TOTAL LIABILITIES AND EQUITY$3,124,671 $2,850,623 
See accompanying notes to condensed consolidated financial statements.
1

THE ENSIGN GROUP, INC.
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF INCOME

Three Months Ended June 30,Six Months Ended June 30,
 2022202120222021
(In thousands, except per share data)
REVENUE
Service revenue$728,347 $634,609 $1,437,503 $1,257,885 
Rental revenue4,139 3,927 8,428 7,904 
TOTAL REVENUE$732,486 $638,536 $1,445,931 $1,265,789 
Expense:
Cost of services563,641 488,524 1,119,282 970,710 
Rent—cost of services 37,228 34,455 72,990 67,911 
General and administrative expense38,527 36,908 76,783 71,181 
Depreciation and amortization14,858 13,795 29,534 27,454 
TOTAL EXPENSES654,254 573,682 1,298,589 1,137,256 
Income from operations78,232 64,854 147,342 128,533 
Other (expense) income:
Interest expense(2,688)(1,634)(4,756)(3,275)
Other (expense) income(2,587)1,121 (3,403)1,869 
Other expense, net(5,275)(513)(8,159)(1,406)
Income before provision for income taxes72,957 64,341 139,183 127,127 
Provision for income taxes15,154 13,758 31,292 26,707 
NET INCOME57,803 50,583 107,891 100,420 
Less:
Net income (loss) attributable to noncontrolling interests112 1,158 (140)1,789 
Net income attributable to The Ensign Group, Inc.$57,691 $49,425 $108,031 $98,631 
NET INCOME PER SHARE ATTRIBUTABLE TO THE ENSIGN GROUP INC.
Basic $1.05 $0.91 $1.97 $1.82 
Diluted$1.01 $0.87 $1.90 $1.73 
WEIGHTED AVERAGE COMMON SHARES OUTSTANDING
Basic54,906 54,468 54,788 54,331 
Diluted56,853 56,997 56,862 56,945 
See accompanying notes to condensed consolidated financial statements.
2

THE ENSIGN GROUP, INC.
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY
 Common Stock Additional Paid-In Capital Retained Earnings Treasury StockNon-Controlling Interest
(In thousands)Shares Amount   Shares AmountTotal
BALANCE - JANUARY 1, 202255,190 $58 $369,760 $733,992 2,944 $(83,042)$946 $1,021,714 
Issuance of common stock to employees and directors resulting from the exercise of stock options147 — 2,768 — — — — 2,768 
Issuance of restricted stock, net of forfeitures104 — 5,241 — — — — 5,241 
Shares of common stock used to satisfy tax withholding obligations— — — — — (15)— (15)
Dividends declared ($0.0550 per share)
— — — (3,042)— — — (3,042)
Employee stock award compensation— — 5,167 — — — — 5,167 
Repurchase of common stock (Note 20)
(133)— — — 133 (9,882)— (9,882)
Acquisition of noncontrolling interest shares— — 245 — — — (271)(26)
Net loss attributable to noncontrolling interest— — — — — — (252)(252)
Net income attributable to the Ensign Group, Inc.— — — 50,340 — — — 50,340 
BALANCE - MARCH 31, 202255,308 $58 $383,181 $781,290 3,077 $(92,939)$423 $1,072,013 
Issuance of common stock to employees and directors resulting from the exercise of stock options223 — 3,303 — — — — 3,303 
Issuance of restricted stock, net of forfeitures38 — — — — — — — 
Shares of common stock used to satisfy tax withholding obligations (20)— — — 20 (1,687)— (1,687)
Dividends declared ($0.0550 per share)
— — — (3,040)— — — (3,040)
Employee stock award compensation— — 5,616 — — — — 5,616 
Repurchase of common stock (Note 19)(271)— — — 271 (20,000)— (20,000)
Issuance of noncontrolling interests through subsidiary equity plan— — 6,693 — — — — 6,693 
Net income attributable to noncontrolling interest— — — — — — 112 112 
Distribution to noncontrolling interest holder— — — — — — (8)(8)
Net income attributable to the Ensign Group, Inc.— — — 57,691 — — — 57,691 
BALANCE - JUNE 30, 202255,278 $58 $398,793 $835,941 3,368 $(114,626)$527 $1,120,693 

3

 Common Stock Additional Paid-In Capital Retained Earnings Treasury StockNon-Controlling Interest
(In thousands)Shares Amount   Shares AmountTotal
BALANCE - JANUARY 1, 202154,626 $58 $338,177 $551,055 2,791 $(71,213)$150 $818,227 
Issuance of common stock to employees and directors resulting from the exercise of stock options246 — 3,880 — — — — 3,880 
Issuance of restricted stock, net of forfeitures81 — 3,725 — — — — 3,725 
Shares of common stock used to satisfy tax withholding obligations— — — — — (9)— (9)
Dividends declared ($0.0525 per share)
— — — (2,886)— — — (2,886)
Employee stock award compensation— — 4,054 — — — — 4,054 
Net income attributable to noncontrolling interest— — — — — — 631 631 
Distribution to noncontrolling interest holder— — — — — — (1,248)(1,248)
Net income attributable to the Ensign Group, Inc.— — — 49,206 — — — 49,206 
BALANCE - MARCH 31, 202154,953 $58 $349,836 $597,375 2,791 $(71,222)$(467)$875,580 
Issuance of common stock to employees and directors resulting from the exercise of stock options148 — 2,982 — — — — 2,982 
Issuance of restricted stock, net of forfeitures49 — — — — — — — 
Shares of common stock used to satisfy tax withholding obligations(20)— — — 20 (1,600)— (1,600)
Dividends declared ($0.0525 per share)
— — — (2,894)— — — (2,894)
Employee stock award compensation— — 4,633 — — — — 4,633 
Net income attributable to noncontrolling interest— — — — — — 1,158 1,158 
Distribution to noncontrolling interest holder— — — — — — (641)(641)
Net income attributable to the Ensign Group, Inc.— — — 49,425 — — — 49,425 
BALANCE - JUNE 30, 202155,130 $58 $357,451 $643,906 2,811 $(72,822)$50 $928,643 
See accompanying notes to condensed consolidated financial statements.

4

THE ENSIGN GROUP, INC.
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
Six Months Ended June 30,
(In thousands)20222021
Cash flows from operating activities:  
Net income $107,891 $100,420 
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization29,534 27,454 
Amortization of deferred financing fees505 420 
Non-cash leasing arrangement 240 221 
Write-off of deferred financing fees566  
Deferred income taxes 264 27 
Provision for doubtful accounts 2,169 1,899 
Stock-based compensation10,783 8,687 
Gain on sale of assets (2,567)(540)
Loss on insurance claims, legal finding and asset disposals4,474 745 
Change in operating assets and liabilities 
Accounts receivable (12,852)(15,928)
Prepaid income taxes(10,884)(7,590)
Prepaid expenses and other assets(3,996)(9,476)
Cash surrender value of life insurance policy premiums(5,621)(8,861)
Deferred compensation liability5,617 8,930 
Operating lease obligations(547)(131)
Accounts payable2,197 7,725 
Accrued wages and related liabilities(5,162)(9,063)
Income taxes payable (136)
Other accrued liabilities(7,471)(1,966)
Accrued self-insurance liabilities14,696 5,717 
Other long-term liabilities(23)(157)
NET CASH PROVIDED BY OPERATING ACTIVITIES
129,813 108,397 
Cash flows from investing activities:  
Purchase of property and equipment(37,082)(33,795)
Cash payments for business acquisitions (Note 9)
(16,400)(6,000)
Cash payments for asset acquisitions (Note 9)
(17,492)(5,183)
Escrow deposits(15,571) 
Cash from insurance proceeds653 6,705 
Cash proceeds from the sale of assets7,665 877 
Purchases of investments(3,518)(23,706)
Maturities of investments4,780 20,399 
Other restricted assets369 (159)
NET CASH USED IN INVESTING ACTIVITIES
(76,596)(40,862)
Cash flows from financing activities:  
Proceeds from debt (Note 16)
211 224 
Payments on debt (Note 16)
(1,921)(1,497)
Issuance of common stock upon exercise of options6,071 6,862 
Repurchase of shares of common stock to satisfy tax withholding obligations(1,702)(1,609)
Repurchase of shares of common stock (Note 20)
(29,882) 
Dividends paid(6,077)(5,754)
Proceeds from sale of subsidiary shares (Note 7)
6,693  
Non-controlling interest distribution(8)(1,889)
Purchase of non-controlling interest(26) 
Payments of deferred financing costs(3,197) 
Proceeds from CARES Act Provider Relief Fund and Medicare Advance Payment Program (Note 3)
 11,538 
Repayments of CARES Act Provider Relief Fund and Medicare Advance Payment Program (Note 3)
 (113,561)
NET CASH USED IN FINANCING ACTIVITIES
(29,838)(105,686)
Net increase (decrease) in cash and cash equivalents23,379 (38,151)
Cash and cash equivalents beginning of period262,201 236,562 
Cash and cash equivalents end of period$285,580 $198,411 


Six Months Ended June 30,
(In thousands)20222021
SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION  
Cash paid during the period for:  
Interest$3,950 $2,836 
Income taxes$41,905 $34,540 
Lease liabilities$72,919 $67,539 
Non-cash financing and investing activity 
Accrued capital expenditures$3,800 $3,600 
Accrued dividends declared$3,040 $2,894 
Right-of-use assets obtained in exchange for new and modified operating lease obligations$194,342 $112,192 

See accompanying notes to condensed consolidated financial statements.
5

THE ENSIGN GROUP, INC.
NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Dollars, shares and options in thousands, except per share data)

1. DESCRIPTION OF BUSINESS
The Company — The Ensign Group, Inc. (collectively, Ensign or the Company), is a holding company with no direct operating assets, employees or revenue. The Company, through its operating subsidiaries, is a provider of health care services across the post-acute care continuum, engaged in the ownership, acquisition, development and leasing of skilled nursing, senior living and other healthcare-related properties and other ancillary businesses. As of June 30, 2022, the Company operated 251 facilities and other ancillary operations located in Arizona, California, Colorado, Idaho, Iowa, Kansas, Nebraska, Nevada, South Carolina, Texas, Utah, Washington and Wisconsin. The Company's operating subsidiaries have a collective capacity of approximately 25,500 operational skilled nursing beds and 3,000 senior living units. As of June 30, 2022, the Company operated 180 facilities under long-term lease arrangements, and had options to purchase 11 of those 180 facilities. The Company's real estate portfolio includes 100 owned real estate properties, which included 71 facilities operated and managed by the Company, 29 senior living operations leased to and operated by The Pennant Group, Inc. (Pennant) as part of the spin-off transaction that occurred in October 2019 (Spin-Off), and the Service Center location. Of those 29 senior living operations, one is located on the same real estate property as a skilled nursing facility that the Company owns and operates.
Certain of the Company’s wholly-owned independent subsidiaries, collectively referred to as the Service Center, provide specific accounting, payroll, human resources, information technology, legal, risk management and other centralized services to the other operating subsidiaries through contractual relationships with such subsidiaries. The Company also has a wholly-owned captive insurance subsidiary that provides some claims-made coverage to the Company’s operating subsidiaries for general and professional liabilities, as well as coverage for certain workers’ compensation insurance liabilities.
In January of 2022, the Company formed a captive real estate investment trust (REIT), which owns and manages its real estate business, called Standard Bearer Healthcare REIT, Inc. (Standard Bearer). The Company expects the REIT structure will provide it with an efficient vehicle for future acquisitions of properties that could be operated by Ensign affiliates or other third parties. Refer to Note 7, Standard Bearer for additional information on Standard Bearer.
Each of the Company's affiliated operations are operated by separate, wholly-owned, independent subsidiaries that have their own management, employees and assets. References herein to the consolidated “Company” and “its” assets and activities in this Quarterly Report is not meant to imply, nor should it be construed as meaning that The Ensign Group, Inc. has direct operating assets, employees or revenue, or that any of the subsidiaries, are operated by The Ensign Group, Inc.
Other Information The accompanying condensed consolidated financial statements as of June 30, 2022 and for the three and six months ended June 30, 2022 and 2021 (collectively, the Interim Financial Statements) are unaudited. Certain information and note disclosures normally included in annual consolidated financial statements have been condensed or omitted, as permitted under applicable rules and regulations. Readers of the Interim Financial Statements should refer to the Company’s audited consolidated financial statements and notes thereto for the year ended December 31, 2021 which are included in the Company’s Annual Report on Form 10-K, File No. 001-33757 (the Annual Report) filed with the Securities and Exchange Commission (SEC). Management believes that the Interim Financial Statements reflect all adjustments which are of a normal and recurring nature necessary to present fairly the Company’s financial position and results of operations in all material respects. The results of operations presented in the Interim Financial Statements are not necessarily representative of operations for the entire year.

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
Basis of Presentation The accompanying Interim Financial Statements have been prepared in accordance with accounting principles generally accepted in the United States (GAAP). The Company is the sole member or stockholder of various consolidated limited liability companies and corporations established to operate various acquired skilled nursing operations, senior living operations and related ancillary services. All intercompany transactions and balances have been eliminated in consolidation. The Company presents noncontrolling interests within the equity section of its condensed consolidated balance sheets and the amount of consolidated net income that is attributable to The Ensign Group, Inc. and the noncontrolling interest in its condensed consolidated statements of income.

6

THE ENSIGN GROUP, INC.
NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - (Continued)

The condensed consolidated financial statements include the accounts of all entities controlled by the Company through its ownership of a majority voting interest. Additionally, the accounts of any variable interest entities (VIEs) where the Company is subject to a majority of the risk of loss from the VIE's activities are entitled to receive a majority of the entity's residual returns, or both. The Company assesses the requirements related to the consolidation of VIEs, including a qualitative assessment of power and economics that considers which entity has the power to direct the activities that "most significantly impacts" the VIE's economic performance and has the obligation to absorb losses of, or the right to receive benefits that could be potentially significant to, the VIE. On October 1, 2021, the Company deconsolidated its VIE, which was not material, as this entity no longer met the requirements for consolidation. As of June 30, 2022 and December 31, 2021, the Company had no VIEs.
ReclassificationsPrior period results reflect reclassifications, for comparative purposes, related to the change in the Company's segment structure as a result of the formation of Standard Bearer. Refer to Note 8, Business Segments, for additional information related to segments.
Estimates and Assumptions The preparation of the Interim Financial Statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the Interim Financial Statements and the reported amounts of revenue and expenses during the reporting periods. The most significant estimates in the Company’s Interim Financial Statements relate to revenue, acquired property and equipment, intangible assets and goodwill, right-of-use assets, impairment of long-lived assets, lease liabilities, general and professional liabilities, workers' compensation and healthcare claims included in accrued self-insurance liabilities, and income taxes. Actual results could differ from those estimates.
Fair Value of Financial InstrumentsThe Company’s financial instruments consist principally of cash and cash equivalents, debt security investments, accounts receivable, insurance subsidiary deposits, accounts payable and borrowings. The Company believes all of the financial instruments’ recorded values approximate fair values because of their nature or respective short durations. Contracts insuring the lives of certain employees who are eligible to participate in non-qualified deferred compensation plans are held in a rabbi trust. Cash surrender value of the contracts is based on funds that shadow the investment allocations specified by participants in the deferred compensation plan. The fair value of the investment funds is derived using Level 2 inputs. See Note 6, Fair Value Measurements.
Service Revenue RecognitionThe Company recognizes revenue in accordance with Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) Topic 606, Revenue from Contracts with Customers (ASC 606). See Note 4, Revenue and Accounts Receivable.
Rental Revenue Recognition The Company recognizes rental revenue for operating leases on a straight-line basis over the lease term when collectability of all minimum lease payments is probable in accordance with FASB ASC Topic 842, Leases (ASC 842). See Note 4, Revenue and Accounts Receivable.
Accounts Receivable Accounts receivable consist primarily of amounts due from Medicare and Medicaid programs, other government programs, managed care health plans and private payor sources, net of estimates for variable consideration.
Property and Equipment Property and equipment are initially recorded at their historical cost. Repairs and maintenance are expensed as incurred. Depreciation is computed using the straight-line method over the estimated useful lives of the depreciable assets (ranging from three to 59 years). Leasehold improvements are amortized on a straight-line basis over the shorter of their estimated useful lives or the remaining lease term.
Leases and Leasehold Improvements The Company leases skilled nursing facilities, senior living facilities and commercial office space. The Company determines if an arrangement is a lease at the inception of each lease. Leases commencing prior to the ASC 842 adoption date were classified as operating lease under historical guidance. As the Company has elected the package of practical expedients allowing it to not reassess lease classification, these leases are classified as operating leases under ASC 842 as well. For leases commencing subsequent to the ASC 842 adoption date, the Company performs an evaluation to determine whether the lease should be classified as an operating or finance lease at the inception of the lease. As of June 30, 2022, the Company does not have any leases that are classified as finance leases. Rights and obligations of operating leases are included as right-of-use assets, current lease liabilities and long-term lease liabilities on the Company's condensed consolidated balance sheets. As the Company's leases do not provide an implicit rate, the Company uses its incremental borrowing rate based on the information available at lease commencement date in determining the present value of future lease payments. The Company utilized a third-party valuation specialist to assist in estimating the incremental borrowing rate.
7

THE ENSIGN GROUP, INC.
NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - (Continued)

The Company records rent expense for operating leases on a straight-line basis over the term of the lease. The lease term used for straight-line rent expense is calculated from the date the Company is given control of the leased premises through the end of the lease term. Renewals are not assumed in the determination of the lease term unless they are deemed to be reasonably assured at the inception of the lease. The lease term used for this evaluation also provides the basis for establishing depreciable lives for buildings subject to lease and leasehold improvements.
The Company's real estate leases generally have initial lease terms of ten years or more and typically include one or more options to renew, with renewal terms that generally extend the lease term for an additional ten to 15 years. Exercise of the renewal options is generally subject to the satisfaction of certain conditions which vary by contract and generally follow payment terms that are consistent with those in place during the initial term. The Company reassesses the renewal option using a "reasonably certain" threshold, which is understood to be a high threshold. For leases where the Company is reasonably certain to exercise its renewal option, the option periods are included within the lease term and, therefore, the measurement of the right-of-use asset and lease liability. The Company's leases generally contain annual escalation clauses that are either fixed or variable in nature, some of which are dependent upon published indices. The Company recognizes lease expense for leases with an initial term of 12 months or less on a straight-line basis over the lease term. These leases are not recorded on the condensed consolidated balance sheets. Certain of the Company's lease agreements include rental payments that are adjusted periodically for inflation. The lease agreements do not contain any material residual value guarantees or material restrictive covenants. The Company does not have material subleases.
Impairment of Long-Lived Assets The Company reviews the carrying value of long-lived assets that are held and used in the Company’s operating subsidiaries for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of these assets is determined based upon expected undiscounted future net cash flows from the operating subsidiaries to which the assets relate, utilizing management’s best estimate, appropriate assumptions, and projections at the time. If the carrying value is determined to be unrecoverable from future operating cash flows, the asset is deemed impaired and an impairment loss would be recognized to the extent the carrying value exceeded the estimated fair value of the asset. The Company estimates the fair value of assets based on the estimated future discounted cash flows of the asset. Management has evaluated its long-lived assets and determined there was no impairment during the three and six months ended June 30, 2022 and 2021.
Intangible Assets and Goodwill Definite-lived intangible assets consist primarily of patient base, facility trade names and customer relationships. Patient base is amortized over a period of four to eight months, depending on the classification of the patients and the level of occupancy in a new acquisition on the acquisition date. Trade names at affiliated facilities are amortized over 30 years and customer relationships are amortized over a period of up to 20 years.
The Company's indefinite-lived intangible assets consist of trade names, and Medicare and Medicaid licenses. The Company tests indefinite-lived intangible assets for impairment on an annual basis or more frequently if events or changes in circumstances indicate that the carrying amount of the intangible asset may not be recoverable.
Goodwill represents the excess of the purchase price over the fair value of identifiable net assets acquired in business combinations. Goodwill is subject to annual testing for impairment. In addition, goodwill is tested for impairment if events occur or circumstances indicate that its carrying value may not be recoverable. The Company performs its annual test for impairment during the fourth quarter of each year. The Company did not identify any goodwill or intangible asset impairment during the three and six months ended June 30, 2022 and 2021.
Self-Insurance — The Company is partially self-insured for general and professional liability claims up to a base amount per claim (the self-insured retention) with an aggregate, one-time deductible above this limit. Losses beyond these amounts are insured through third-party policies with coverage limits per claim, per location and on an aggregate basis for the Company. The combined self-insured retention is $500 per claim, subject to an additional one-time deductible of $1,000 for California affiliated operations and a separate, one-time, deductible of $1,250 for non-California operations. For all affiliated operations, except those located in Colorado, the third-party coverage above these limits is $1,000 per claim, $3,000 per operation, with a $5,000 blanket aggregate limit and an additional state-specific aggregate where required by state law. In Colorado, the third-party coverage above these limits is $1,000 per claim and $3,000 per operation, which is independent of the aforementioned blanket aggregate limits that apply outside of Colorado.
The majority of the self-insured retention and deductible limits for general and professional liabilities and workers' compensation liabilities are self-insured through the captive insurance subsidiary, the related assets and liabilities of which are included in the accompanying condensed consolidated balance sheets. The captive insurance subsidiary is subject to certain statutory requirements as an insurance provider.
8

THE ENSIGN GROUP, INC.
NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - (Continued)

The Company’s policy is to accrue amounts equal to the actuarial estimated costs to settle open claims of insureds, as well as an estimate of the cost of insured claims that have been incurred but not reported. The Company develops information about the size of the ultimate claims based on historical experience, current industry information and actuarial analysis, and evaluates the estimates for claim loss exposure on a quarterly basis. The Company uses actuarial valuations to estimate the liability based on historical experience and industry information. Accrued general liability and professional malpractice liabilities on an undiscounted basis, net of anticipated insurance recoveries, were $76,145 and $66,158 as of June 30, 2022 and December 31, 2021, respectively.
The Company’s operating subsidiaries are self-insured for workers’ compensation liabilities in California. To protect itself against loss exposure in California with this policy, the Company has purchased individual specific excess insurance coverage that insures individual claims that exceed $625 per occurrence. In Texas, the operating subsidiaries have elected non-subscriber status for workers’ compensation claims and the Company has purchased individual stop-loss coverage that insures individual claims that exceed $750 per occurrence. The Company’s operating subsidiaries in all other states, with the exception of Washington, are under a loss sensitive plan that insures individual claims that exceed $350 per occurrence. In the state of Washington, the Company is self insured and has purchased individual specific excess insurance coverage that insures individual claims that exceed $500 per occurrence. For all of the self insured plans and retention, the Company accrues amounts equal to the estimated costs to settle open claims, as well as an estimate of the cost of claims that have been incurred but not reported. The Company uses actuarial valuations to estimate the liability based on historical experience and industry information. Accrued workers’ compensation liabilities are recorded on an undiscounted basis in the accompanying condensed consolidated balance sheets and were $28,365 and $27,335 as of June 30, 2022 and December 31, 2021, respectively.
In addition, the Company has recorded an asset and equal liability of $8,440 and $6,755 as of June 30, 2022 and December 31, 2021, respectively, in order to present the ultimate costs of malpractice and workers' compensation claims and the anticipated insurance recoveries on a gross basis. See Note 13, Restricted and Other Assets.
The Company self-funds medical (including prescription drugs) and dental healthcare benefits to the majority of its employees. The Company is fully liable for all financial and legal aspects of these benefit plans. To protect itself against loss exposure with this policy, the Company has purchased individual stop-loss insurance coverage that insures individual claims that exceed $525 for each covered person for fiscal year 2022. The Company’s accrued liability under these plans recorded on an undiscounted basis in the accompanying condensed consolidated balance sheets was $13,571 and $9,891 as of June 30, 2022 and December 31, 2021, respectively.
The Company believes that adequate provision has been made in the Interim Financial Statements for liabilities that may arise out of patient care, workers’ compensation, healthcare benefits and related services provided to date. The amount of the Company’s reserves was determined based on an estimation process that uses information obtained from both company-specific and industry data. This estimation process requires the Company to continuously monitor and evaluate the life cycle of the claims. Using data obtained from this monitoring and the Company’s assumptions about emerging trends, the Company, with the assistance of an independent actuary, develops information about the size of ultimate claims based on the Company’s historical experience and other available industry information. The most significant assumptions used in the estimation process include determining the trend in costs, the expected cost of claims incurred but not reported and the expected costs to settle or pay damage awards with respect to unpaid claims. The self-insured liabilities are based upon estimates, and while management believes that the estimates of loss are reasonable, the ultimate liability may be in excess of or less than the recorded amounts. Due to the inherent volatility of actuarially determined loss estimates, it is reasonably possible that the Company could experience changes in estimated losses that could be material to net income. If the Company’s actual liabilities exceed its estimates of losses, its future earnings, cash flows and financial condition would be adversely affected.
Income Taxes — Deferred tax assets and liabilities are established for temporary differences between the financial reporting basis and the tax basis of the Company’s assets and liabilities at tax rates in effect when such temporary differences are expected to reverse. The Company generally expects to fully utilize its deferred tax assets; however, when necessary, the Company records a valuation allowance to reduce its net deferred tax assets to the amount that is more likely than not to be realized.
In determining the need for a valuation allowance or the need for and magnitude of liabilities for uncertain tax positions, the Company makes certain estimates and assumptions. These estimates and assumptions are based on, among other things, knowledge of operations, markets, historical trends and likely future changes and, when appropriate, the opinions of advisors with knowledge and expertise in certain fields. Due to certain risks associated with the Company’s estimates and assumptions, actual results could differ.
9

THE ENSIGN GROUP, INC.
NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - (Continued)

Noncontrolling Interest The noncontrolling interest in a subsidiary is initially recognized at estimated fair value on the acquisition date and is presented within total equity in the Company's condensed consolidated balance sheets. The Company presents the noncontrolling interest and the amount of consolidated net income attributable to The Ensign Group, Inc. in its condensed consolidated statements of income. Net income per share is calculated based on net income attributable to The Ensign Group, Inc.'s stockholders. The carrying amount of the noncontrolling interest is adjusted based on an allocation of subsidiary earnings based on ownership interest.
Stock-Based CompensationThe Company measures and recognizes compensation expense for all stock-based payment awards made to employees and directors including employee stock options based on estimated fair values, ratably over the requisite service period of the award. Net income has been reduced as a result of the recognition of the fair value of all stock options and restricted stock awards issued, the amount of which is contingent upon the number of future grants and other variables.
Recent Accounting Pronouncements Except for rules and interpretive releases of the Securities and Exchange Commission (SEC) under authority of federal securities laws and a limited number of grandfathered standards, the FASB ASC is the sole source of authoritative GAAP literature recognized by the FASB and applicable to the Company. For any new pronouncements announced, the Company considers whether the new pronouncements could alter previous generally accepted accounting principles and determines whether any new or modified principles will have a material impact on the Company's reported financial position or operations in the near term. The applicability of any standard is subject to the formal review of the Company's financial management and certain standards are under consideration.

Recent Accounting Standards Adopted by the Company In November 2021, the FASB issued ASU 2021-10 “Government Assistance (Topic 832): Disclosures by Business Entities about Government Assistance,” which created FASB ASC Topic 832, Government Assistance (ASC 832). ASC 832 requires business entities to disclose information about certain government assistance they receive. The Company adopted this standard on January 1, 2022 and determined there was no material impact on the Company's condensed consolidated financial statements.

Accounting Standards Recently Issued but Not Yet Adopted by the Company In February 2020, the FASB issued ASU 2020-04 "Reference Rate Reform (Topic 848)," which provides temporary, optional practical expedients and exceptions to enable a smoother transition to reference rates which are expected to replace London Interbank Offered Rate (LIBOR) reference rates. Adoption of the provisions of ASU 2020-04 is optional. The amendments are effective for all entities from the beginning of the interim period that includes the issuance date of the ASU. An entity may elect to apply the amendments prospectively through December 31, 2022. During the quarter ended June 30, 2022, the Company and its subsidiaries including Standard Bearer, entered into the Second Amendment to Third Amended and Restated Credit Agreement (such agreement, the Amended Credit Agreement, and the revolving credit facility thereunder, the Revolving Credit Facility), which increased the Revolving Credit Facility by $250,000 to an aggregate principal amount of up to $600,000. Pursuant to the Amended Credit Agreement, the Company transitioned from LIBOR to the Secured Overnight Financing Rate (SOFR) as the applicable reference rate for borrowings under the Revolving Credit Facility and determined there was no resulting material impact on the Company's condensed consolidated financial statements.

3. COVID-19 UPDATE

The COVID-19 pandemic has continued to impact the Company's affiliated operations. In prior years, as part of the Coronavirus Aid, Relief, and Economic Security Act of 2020 (the CARES Act), the Company received cash distributions of relief fund payments (Provider Relief Funds) and funds authorized by U.S. Department of Health and Human Services (HHS) to be used to protect residents of nursing homes and long-term care (LTC) facilities from the impact of COVID-19. During the three and six months ended June 30, 2022, the Company did not receive Provider Relief Funds. During the three and six months ended June 30, 2021, the Company received and returned $2,399 and $11,538, respectively, in Provider Relief Funds. The Company may continue to receive additional funding in future periods.

In fiscal year 2020, the Company applied for and received $105,255 through the Medicare Accelerated and Advance Payment Program under the CARES Act. The purpose of the program is to assist in providing needed liquidity to care delivery providers. The Company repaid $3,232 of the funds in 2020. In March 2021, the Company repaid the remaining funds of $102,023.


10

THE ENSIGN GROUP, INC.
NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - (Continued)

The Family First Coronavirus Response Act was signed into law in 2020 to provide a temporary 6.2% increase to the Federal Medical Assistance Percentage (FMAP) effective January 1, 2020. The law permits states to retroactively change their state's Medicaid program rates effective as of January 1, 2020. The law provides discretion to each state and specifies the funds are to be used to reimburse the recipient for healthcare related expenses that are attributable to COVID-19 and associated with providing patient care. In addition, increases in Medicaid rates can come from other areas of the state's budget outside of FMAP funding. Revenues from these additional payments are recognized in accordance with ASC 606, subject to variable consideration constraints. In certain operations where the Company received additional payments that exceeded expenses incurred related to COVID-19, the Company characterized such payments as variable revenue that required additional consideration and accordingly, the amount of state relief revenue recognized is limited to the actual COVID-19 related expenses incurred. As of June 30, 2022 and December 31, 2021, the Company had $4,356 and $1,781 in unapplied state relief funds, respectively. During the three and six months ended June 30, 2022, the Company received an additional $27,345 and $44,662 in state relief funding and recognized $24,489 and $42,088, respectively, as revenue. During the three and six months ended June 30, 2021, the Company received an additional $16,776 and $32,421 in state relief funding and recognized $16,692 and $33,157, respectively, as revenue.

The CARES Act also provides for deferred payment of the employer portion of social security taxes through the end of 2020, with 50% of the deferred amount due by December 31, 2021 and the remaining 50% due by December 31, 2022. The Company recorded $48,309 of deferred payments of social security taxes as a liability during 2020. The Company paid $24,154 during the year ended December 31, 2021 and the remaining short-term balance of $24,155 is included in accrued wages and related liabilities within the condensed consolidated balance sheets as of June 30, 2022.

4.  REVENUE AND ACCOUNTS RECEIVABLE
Service Revenue

The Company's service revenue is derived primarily from providing healthcare services to its patients. Revenue is recognized when services are provided to the patients at the amount that reflects the consideration to which the Company expects to be entitled from patients and third-party payors, including Medicaid, Medicare and insurers (private and Medicare replacement plans), in exchange for providing patient care. The healthcare services in skilled patient contracts include routine services in exchange for a contractual agreed-upon amount or rate. Routine services are treated as a single performance obligation satisfied over time as services are rendered. As such, patient care services represent a bundle of services that are not capable of being distinct. Additionally, there may be ancillary services which are not included in the daily rates for routine services, but instead are treated as separate performance obligations satisfied at a point in time, if and when those services are rendered.

Revenue recognized from healthcare services are adjusted for estimates of variable consideration to arrive at the transaction price. The Company determines the transaction price based on contractually agreed-upon amounts or rate on a per day basis, adjusted for estimates of variable consideration. The Company uses the expected value method in determining the variable component that should be used to arrive at the transaction price, using contractual agreements and historical reimbursement experience within each payor type. The amount of variable consideration which is included in the transaction price may be constrained, and is included in net revenue only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized will not occur in a future period. If actual amounts of consideration ultimately received differ from the Company’s estimates, the Company adjusts these estimates, which would affect net revenue in the period such variances become known.

Revenue from the Medicare and Medicaid programs accounted for 73.4% of all service revenue for both the three and six months ended June 30, 2022 and 73.1% and 73.6% for the three and six months ended June 30, 2021, respectively. Settlements with Medicare and Medicaid payors for retroactive adjustments due to audits and reviews are considered variable consideration and are included in the determination of the estimated transaction price. These settlements are estimated based on the terms of the payment agreement with the payor, correspondence from the payor and the Company’s historical settlement activity. Consistent with healthcare industry practices, any changes to these revenue estimates are recorded in the period the change or adjustment becomes known based on the final settlement. The Company recorded adjustments to revenue which were not material to the Company's revenue for the three and six months ended June 30, 2022 and 2021.

11

THE ENSIGN GROUP, INC.
NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - (Continued)

Rental Revenue

The Company's rental revenues are primarily generated by leasing healthcare-related properties through triple-net lease arrangements, under which the tenant is solely responsible for the costs related to the property. Revenue is recognized on a straight-line basis over the lease term if it has been deemed probable of collection. The Company has elected the single component practical expedient, which allows a lessor, by class of underlying asset, not to allocate the total consideration to the lease and non-lease components based on their relative stand-alone selling prices where certain criteria are met.

Tenant reimbursements related to property taxes and insurance are neither considered lease nor non-lease components under the new lease standards. Lessee payments for taxes and insurance paid directly to a third party, on behalf of the Company, are excluded from variable lease payments and rental revenue in the Company’s condensed consolidated statements of income. Otherwise, tenant reimbursements for taxes and insurance that are paid by the Company directly to a third party are classified as additional rental revenue and expense and recognized by the Company on a gross basis.
Disaggregation of Revenue
The Company disaggregates revenue from contracts with its patients by payors. The Company determines that disaggregating revenue into these categories achieves the disclosure objectives to depict how the nature, amount, timing and uncertainty of revenue and cash flows are affected by economic factors.
Revenue by Payor

The Company’s revenue is derived primarily from providing healthcare services to patients and is recognized on the date services are provided at amounts billable to individual patients, adjusted for estimates for variable consideration. For patients under reimbursement arrangements with third-party payors, including Medicaid, Medicare and private insurers, revenue is recorded based on contractually agreed-upon amounts or rates, adjusted for estimates for variable consideration, on a per patient, daily basis or as services are performed.
Service revenue for the three and six months ended June 30, 2022 and 2021 is summarized in the following tables:
 Three Months Ended June 30,
20222021
Revenue% of RevenueRevenue% of Revenue
Medicaid(1)
$294,128 40.4 %$251,455 39.6 %
Medicare190,494 26.2 170,008 26.8 
Medicaid — skilled49,763 6.8 42,740 6.7 
Total Medicaid and Medicare534,385 73.4 464,203 73.1 
Managed care128,587 17.7 112,963 17.8 
Private and other(2)
65,375 8.9 57,443 9.1 
SERVICE REVENUE$728,347 100.0 %$634,609 100.0 %
(1) Medicaid payor includes revenue for senior living operations and revenue related to FMAP.
(2) Private and other payors also includes revenue from senior living operations and all payors generated in other ancillary services.
 Six Months Ended June 30,
20222021
Revenue% of RevenueRevenue% of Revenue
Medicaid(1)
$560,476 39.0 %$482,813 38.4 %
Medicare398,905 27.7 360,311 28.6 
Medicaid — skilled95,712 6.7 82,733 6.6 
Total Medicaid and Medicare1,055,093 73.4 925,857 73.6 
Managed care256,373 17.8 221,308 17.6 
Private and other(2)
126,037 8.8 110,720 8.8 
SERVICE REVENUE$1,437,503 100.0 %$1,257,885 100.0 %
(1) Medicaid payor includes revenue for senior living operations and revenue related to FMAP.
(2) Private and other payors also includes revenue from senior living operations and all payors generated in other ancillary services.

12

THE ENSIGN GROUP, INC.
NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - (Continued)

In addition to the service revenue above, the Company's rental revenue derived from triple-net lease arrangements with third parties was $4,139 and $8,428, respectively, for the three and six months ended June 30, 2022 and $3,927 and $7,904, respectively, for the three and six months ended June 30, 2021.
Balance Sheet Impact

Included in the Company’s condensed consolidated balance sheets are contract balances, comprised of billed accounts receivable and unbilled receivables, which are the result of the timing of revenue recognition, billings and cash collections, as well as, contract liabilities, which primarily represent payments the Company receives in advance of services provided. The Company had no material contract liabilities and contract assets as of June 30, 2022 and December 31, 2021, or activity during the three and six months ended June 30, 2022 and 2021.

Accounts receivable as of June 30, 2022 and December 31, 2021, is summarized in the following table:
June 30, 2022December 31, 2021
Medicaid$125,348 $123,647 
Managed care86,995 79,722 
Medicare58,067 59,797 
Private and other payors76,418 76,778 
 346,828 339,944 
Less: allowance for doubtful accounts(7,827)(11,213)
ACCOUNTS RECEIVABLE, NET$339,001 $328,731 
Practical Expedients and Exemptions

As the Company’s contracts with its patients have an original duration of one year or less, the Company uses the practical expedient applicable to its contracts and does not consider the time value of money. Further, because of the short duration of these contracts, the Company has not disclosed the transaction price for the remaining performance obligations as of the end of each reporting period or when the Company expects to recognize this revenue. In addition, the Company has applied the practical expedient provided by ASC 340, Other Assets and Deferred Costs, and all incremental customer contract acquisition costs are expensed as they are incurred because the amortization period would have been one year or less.

5. COMPUTATION OF NET INCOME PER COMMON SHARE

Basic net income per share is computed by dividing income from operations attributable to stockholders of The Ensign Group, Inc. by the weighted average number of outstanding common shares for the period. The computation of diluted net income per share is similar to the computation of basic net income per share, except that the denominator is increased to include the number of additional common shares that would have been outstanding if the dilutive potential common shares had been issued.

A reconciliation of the numerator and denominator used in the calculation of basic net income per common share follows:

Three Months Ended June 30,Six Months Ended June 30,
 2022202120222021
NUMERATOR:  
Net income$57,803 $50,583 $107,891 $100,420 
Less: net (loss) income attributable to noncontrolling interests 112 1,158 (140)1,789 
Net income attributable to The Ensign Group, Inc. $57,691 $49,425 $108,031 $98,631 
DENOMINATOR: 
Weighted average shares outstanding for basic net income per share54,906 54,468 54,788 54,331 
Basic net income per common share:$1.05 $0.91 $1.97 $1.82 


13

THE ENSIGN GROUP, INC.
NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - (Continued)

A reconciliation of the numerator and denominator used in the calculation of diluted net income per common share follows:

Three Months Ended June 30,Six Months Ended June 30,
 2022202120222021
NUMERATOR:  
Net income $57,803 $50,583 $107,891 $100,420 
Less: net (loss) income attributable to noncontrolling interests112 1,158 (140)1,789 
Net income attributable to The Ensign Group, Inc. $57,691 $49,425 $108,031 $98,631 
DENOMINATOR:  
Weighted average common shares outstanding54,906 54,468 54,788 54,331 
Plus: incremental shares from assumed conversion (1)
1,947 2,529 2,074 2,614 
Adjusted weighted average common shares outstanding56,853 56,997 56,862 56,945 
Diluted net income per common share:$1.01 $0.87 $1.90 $1.73 
(1) Options outstanding which are anti-dilutive and therefore not factored into the weighted average common shares amount above were 789 and 697 for the three and six months ended June 30, 2022, respectively, and 167 and 80 for the three and six months ended June 30, 2021, respectively.

6. FAIR VALUE MEASUREMENTS

Fair value measurements are based on a three-tier hierarchy that prioritizes the inputs used to measure fair value. These tiers include: Level 1, defined as observable inputs such as quoted market prices in active markets; Level 2, defined as inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly; and Level 3, defined as unobservable inputs for which little or no market data exists, therefore requiring an entity to develop its own assumptions.

The fair value of cash and cash equivalents of $285,580 and $262,201 as of June 30, 2022 and December 31, 2021, respectively, is derived using Level 1 inputs. The Company's other financial assets include contracts insuring the lives of certain employees who are eligible to participate in non-qualified deferred compensation plans which are held in a rabbi trust. The cash surrender value of these contracts is based on funds that shadow the investment allocations specified by participants in the deferred compensation plan. As of June 30, 2022, and December 31, 2021, the fair value of the investment funds of $23,151 and $17,530, respectively, is derived using Level 2 inputs. The investment funds are included in restricted and other assets in the condensed consolidated balance sheets. See Note 13, Restricted and Other Assets.

The Company's non-financial assets, which includes goodwill, intangible assets, property and equipment and right-of-use assets, are not required to be measured at fair value on a recurring basis. However, on a periodic basis, or whenever events or changes in circumstances indicate that their carrying value may not be recoverable, the Company assesses its long-lived assets for impairment. When impairment has occurred, such long-lived assets are written down to fair value.
Debt Security Investments - Held to Maturity

As of June 30, 2022 and December 31, 2021, the Company had approximately $49,068 and $50,330, respectively, in debt security investments which were classified as held to maturity and carried at amortized cost. The carrying value of the debt securities approximates fair value based on Level 1 inputs. The Company has the intent and ability to hold these debt securities to maturity. Further, as of June 30, 2022, the debt security investments were held in AA, A and BBB rated debt securities.

The Company believes its debt security investments and investment funds that were in an unrealized loss position as of June 30, 2022 were not other-than-temporarily impaired, nor has any event occurred subsequent to that date that would indicate any other-than-temporary impairment.


14

THE ENSIGN GROUP, INC.
NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - (Continued)

7. STANDARD BEARER
Standard Bearer's real estate portfolio consists of 95 of the Company's 100 owned real estate properties, of which 67 are operated and managed by the Company and 29 are leased to and operated by Pennant. Of those 29 senior living operations, one is located on the same real estate property as a skilled nursing facility that the Company owns and operates. Standard Bearer intends to qualify and elect to be taxed as a REIT, for U.S. federal income tax purposes, commencing with its taxable year ending December 31, 2022. During the six months ended June 30, 2022, Standard Bearer acquired the real estate of two skilled nursing facilities for a purchase price of $17,412, both of which are operated and managed by Ensign's affiliated operations. Refer to Note 9, Operation Expansions for additional information.
Subsequent to June 30, 2022, Standard Bearer expanded its real estate portfolio with the addition of five skilled nursing properties and one campus property for a total purchase price of $47,900.
As part of the formation of Standard Bearer, certain of the Company's operating subsidiaries, Standard Bearer and Standard Bearer's subsidiaries entered into several agreements that include leasing, management services and debt arrangements between the operations. As these intercompany arrangements were entered into when Standard Bearer was formed in January 2022, the transactions related to these agreements are reflected in Standard Bearer's segment income during three and six months ended June 30, 2022. All intercompany transactions have been eliminated in consolidation. Refer to Note 8, Business Segments, for additional information related to these intercompany eliminations as well as Standard Bearer as a reportable segment.
Intercompany master lease agreements
Certain of the Company's operating subsidiaries and the 67 Standard Bearer subsidiaries entered into five "triple-net" master lease agreements (collectively, the Standard Bearer Master Leases) in January 2022. The lease periods range from 15 to 19 years with three five-year renewal options beyond the initial term, on the same terms and conditions. The rent structure under the Standard Bearer Master Leases includes a fixed component, subject to annual escalation equal to the lesser of (1) the percentage change in the Consumer Price Index (but not less than zero) or (2) 2.5%. In addition to rent, the operating subsidiaries are required to pay the following: (1) all impositions and taxes levied on or with respect to the leased properties; (2) all utilities and other services necessary or appropriate for the leased properties and the business conducted on the leased properties; (3) all insurance required in connection with the leased properties and the business conducted on the leased properties; (4) all facility maintenance and repair costs; and (5) all fees in connection with any licenses or authorizations necessary or appropriate for the leased properties and the business conducted on the leased properties. The two real estate properties acquired during six months ended June 30, 2022 were added to the Standard Bearer Master Leases. Rental revenue generated from Ensign affiliated operations was $13,894 and $27,319, respectively, for the three and six months ended June 30, 2022 and $10,784 and $21,375, respectively, for the three and six months ended June 30, 2021.
Intercompany management agreement
Standard Bearer has no employees. The Service Center provides personnel and services to Standard Bearer pursuant to the management agreement between Standard Bearer and the Service Center. The management agreement provides for a base management fee that is equal to 5% of total rental revenue and an incentive management fee that is equal to 5% of funds from operations (FFO) and is capped at 1% of total rental revenue. Management fee generated between Standard Bearer and the Service Center for the three and six months ended June 30, 2022 was $1,056 and $2,078, respectively, both of which represent 6% of total Standard Bearer rental revenue. No management fees were recorded in 2021, which was prior to the formation of Standard Bearer.
Intercompany debt arrangements

Standard Bearer obtains its funding through various sources including operating cash flows, access to debt arrangements and intercompany loans. The intercompany debt arrangements include mortgage loans and the Revolving Credit Facility to fund acquisitions and working capital needs. The interest rate under the Amended Credit Agreement is a base rate plus a margin ranging from 0.25% to 1.25% per annum or SOFR plus a margin range from 1.25% to 2.25% per annum.

In addition, as the Department of Housing and Urban Development (HUD) mortgage loans and promissory notes are entered into by real estate subsidiaries of Standard Bearer, the interest expense incurred from these debts are included in Standard Bearer's segment income. Refer to Note 16, Debt, for additional information related to these debts.

15

THE ENSIGN GROUP, INC.
NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - (Continued)

Equity Instrument Denominated in the Shares of a Subsidiary
As part of the formation of Standard Bearer in January of 2022, the Company established the Standard Bearer Healthcare REIT, Inc. 2022 Omnibus Incentive Plan (Standard Bearer Equity Plan). The Company may grant stock options and restricted stock awards under the Standard Bearer Equity Plan to employees and management of Ensign's affiliated subsidiaries. These awards generally vest over a period of five years or upon the occurrence of certain prescribed events. The value of the stock options and restricted stock awards is tied to the value of the common stock of Standard Bearer, which is determined based on an independent valuation of Standard Bearer. The awards can be put to the Company at various prescribed dates, which in no event is earlier than six months after vesting of the restricted awards or exercise of the stock options. The Company can also call the awards, generally upon employee termination. During the three months ended June 30, 2022, Standard Bearer sold fully vested common shares from the Standard Bearer Equity Plan to shareholders for cash of $6,544. During the three and six months ended June 30, 2022, the Company did not grant any stock options nor restricted shares under the Standard Bearer Equity Plan.
During the three months ended June 30, 2022, Standard Bearer established shareholders of its preferred shares through contributions of cash of $149. These preferred shares were fully vested at the time of the contributions by the shareholders.

8. BUSINESS SEGMENTS

In conjunction with the formation Standard Bearer in January 2022, the Company's Chief Executive Officer, who is its chief operating decision maker, or CODM, began reviewing the results of Standard Bearer instead of all real estate properties. Accordingly, the Company revised its former real estate segment to include only real estate properties that are part of Standard Bearer. This change in organizational structure demonstrates that Standard Bearer's real estate is a core part of the Company's expansion of its real estate investment strategy. As of the first quarter of 2022, the Company has two reportable segments: (1) skilled services, which includes the operation of skilled nursing facilities and rehabilitation therapy services and (2) Standard Bearer, which is comprised of selected real estate properties owned by Standard Bearer and leased to skilled nursing and senior living operators. Segment information for prior periods has been recast to reflect the change of the Company’s segment structure.

As of June 30, 2022, the skilled services segment includes 215 skilled nursing operations and 25 campus operations that provide both skilled nursing and rehabilitative care services and senior living services. The Company's Standard Bearer segment consists of 95 owned real estate properties. These properties include 67 operations the Company operated and managed and 29 senior living operations that are leased to and operated by third parties. Of the 29 real estate operations leased to third parties, one senior living operation is located on the same real estate property as a skilled nursing facility that the Company owns and operates.

The Company also reports an “All Other” category that includes results from its senior living operations, which includes eleven stand-alone senior living operations and the senior living operations at 25 campus operations that provide both skilled nursing and rehabilitative care services and senior living services. In addition, the "All Other" category includes mobile diagnostics, medical transportation, other real estate and other ancillary operations. Services included in the “All Other” category are insignificant individually, and therefore do not constitute a reportable segment.

The Company’s reportable segments are significant operating segments that offer differentiated services. The Company's CODM reviews financial information for each operating segment to evaluate performance and allocate capital resources. This structure reflects its current operational and financial management and provides the best structure to maximize the quality of care and investment strategy provided, while maintaining financial discipline. The Company's CODM does not review assets by segment in his resource allocation and therefore assets by segment are not disclosed below.

The accounting policies of the reportable segments are the same as those described in Note 2, Summary of Significant Accounting Policies. Intercompany revenue is eliminated in consolidation, along with corresponding intercompany expenses. Segment income and loss is defined as profit or loss from operations before provision for income taxes, excluding gain or loss from sale of real estate, insurance recoveries and impairment charges from operations. Included in segment income for Standard Bearer is expense for intercompany services provided by the Service Center as described in Note 7, Standard Bearer, as it is part of the CODM financial information.


16

THE ENSIGN GROUP, INC.
NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - (Continued)

The following tables set forth financial information for the segments:
 Three Months Ended June 30, 2022
 Skilled ServicesStandard Bearer
All Other(1)
Intercompany EliminationTotal
Service revenue(2)
$702,478 $ $28,787 $(2,918)$728,347 
Rental revenue(3)
 17,598 1,832 (15,291)4,139 
TOTAL REVENUE$702,478 $17,598 $30,619 $(18,209)$732,486 
Segment income (loss)102,266 6,838 (38,614) 70,490 
Gain on sale of assets2,467 
Income before provision for income taxes $72,957 
Depreciation and amortization8,113 5,216 1,529  14,858 
Interest expense(4)
$ $3,743 $889 $(1,944)$2,688 
(1) All other primarily includes all ancillary operations, stand-alone senior living operations and the Service Center.
(2) Intercompany service revenue represents service revenue generated by ancillary operations provided to the Company's affiliated wholly-owned healthcare facilities and management service revenue generated by the Service Center with Standard Bearer. Intercompany service revenue is eliminated in consolidation along with corresponding intercompany cost of service.
(3) Intercompany rental revenue represents rental income generated by both Standard Bearer and other real estate properties with the Company's affiliated wholly-owned healthcare facilities. Intercompany rental revenue is eliminated in consolidation along with corresponding intercompany rent expense.
(4) Included in interest expense in Standard Bearer is interest expense incurred from intercompany debt arrangements between Standard Bearer and The Ensign Group, Inc. The intercompany interest expense is eliminated in the "Intercompany Elimination" column.

 Three Months Ended June 30, 2021
 Skilled ServicesStandard Bearer
All Other(1)
Intercompany EliminationTotal
Service revenue(2)
$612,882 $ $23,428 $(1,701)$634,609 
Rental revenue(3)
 14,214 1,817 (12,104)3,927 
TOTAL REVENUE$612,882 $14,214 $25,245 $(13,805)$638,536 
Segment income (loss)90,010 7,906 (33,575) 64,341 
Income before provision for income taxes $64,341 
Depreciation and amortization7,703 4,248 1,844  13,795 
Interest expense$ $1,634 $ $1,634 
(1) All other primarily includes all ancillary operations, stand-alone senior living operations and the Service Center.
(2) Intercompany service revenue represents service revenue generated by ancillary operations provided to the Company's affiliated wholly-owned healthcare facilities. Intercompany service revenue is eliminated in consolidation along with corresponding intercompany cost of service.
(3) Intercompany rental revenue represents rental income generated by both Standard Bearer and other real estate properties with the Company's affiliated wholly-owned healthcare facilities. Intercompany rental revenue is eliminated in consolidation along with corresponding intercompany rent expense.

 Six Months Ended June 30, 2022
 Skilled ServicesStandard Bearer
All Other(1)
Intercompany EliminationTotal
Service revenue(2)
$1,389,249 $ $54,254 $(6,000)$1,437,503 
Rental revenue(3)
 34,791 3,695 (30,058)8,428 
TOTAL REVENUE$1,389,249 $34,791 $57,949 $(36,058)$1,445,931 
Segment income (loss)200,522 13,738 (77,544) 136,716 
Gain on sale of assets2,467 
Income before provision for income taxes$139,183 
Depreciation and amortization16,014 10,237 3,283  29,534 
Interest expense(4)
$ $7,305 $1,247 $(3,796)$4,756 
(1) All other primarily includes all ancillary operations, stand-alone senior living operations and the Service Center.
(2) Intercompany service revenue represents service revenue generated by ancillary operations provided to the Company's affiliated wholly-owned healthcare facilities and management service revenue generated by the Service Center with Standard Bearer. Intercompany service revenue is eliminated in consolidation along with corresponding intercompany cost of service.
(3) Intercompany rental revenue represents rental income generated by both Standard Bearer and other real estate properties with the Company's affiliated wholly-owned healthcare facilities. Intercompany rental revenue is eliminated in consolidation along with corresponding intercompany rent expense.
(4) Included in interest expense in Standard Bearer is interest expense incurred from intercompany debt arrangements between Standard Bearer and The Ensign Group, Inc. The intercompany interest expense is eliminated in the "Intercompany Elimination" column.
17

THE ENSIGN GROUP, INC.
NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - (Continued)


 Six Months Ended June 30, 2021
 Skilled ServicesStandard Bearer
All Other(1)
Intercompany EliminationTotal
Service revenue(2)
$1,213,918 $ $47,347 $(3,380)$1,257,885 
Rental revenue(3)
 28,283 3,627 (24,006)7,904 
TOTAL REVENUE$1,213,918 $28,283 $50,974 $(27,386)$1,265,789 
Segment income (loss)178,941 15,619 (67,873) 126,687 
Gain on sale of assets440 
Income before provision for income taxes$127,127 
Depreciation and amortization15,178 8,403 3,873  27,454 
Interest expense$ $3,275 $ $ $3,275 
(1) All other primarily includes all ancillary operations, stand-alone senior living operations and the Service Center.
(2) Intercompany service revenue represents service revenue generated by ancillary operations provided to the Company's affiliated wholly-owned healthcare facilities. Intercompany service revenue is eliminated in consolidation along with corresponding intercompany cost of service.
(3) Intercompany rental revenue represents rental income generated by both Standard Bearer and other real estate properties with the Company's affiliated wholly-owned healthcare facilities. Intercompany rental revenue is eliminated in consolidation along with corresponding intercompany rent expense.
Service revenue by major payor source were as follows:
 Three Months Ended June 30, 2022
 Skilled ServicesAll OtherTotal Service RevenueRevenue %
Medicaid(1)
$287,827 $6,301 $294,128 40.4 %
Medicare190,494  190,494 26.2 
Medicaid-skilled49,763  49,763 6.8 
Subtotal528,084 6,301 534,385 73.4 
Managed care128,587  128,587 17.7 
Private and other(2)
45,807 19,568 65,375 8.9 
TOTAL SERVICE REVENUE$702,478 $25,869 $728,347 100.0 %
(1) Medicaid payor includes revenue generated from senior living operations and revenue related to FMAP.
(2) Private and other payors also includes revenue from senior living operations and all payors generated in other ancillary services.

 Three Months Ended June 30, 2021
 Skilled ServicesAll OtherTotal Service RevenueRevenue %
Medicaid(1)
$247,671 $3,784 $251,455 39.6 %
Medicare170,008  170,008 26.8 
Medicaid-skilled42,740  42,740 6.7 
Subtotal460,419 3,784 464,203 73.1 
Managed care112,963  112,963 17.8 
Private and other(2)
39,500 17,943 57,443 9.1 
TOTAL SERVICE REVENUE$612,882 $21,727 $634,609 100.0 %
(1) Medicaid payor includes revenue generated from senior living operations and revenue related to FMAP.
(2) Private and other payors also includes revenue from senior living operations and all payors generated in other ancillary services.
18

THE ENSIGN GROUP, INC.
NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - (Continued)

 Six Months Ended June 30, 2022
 Skilled ServicesOther Service Revenue Total Service RevenueRevenue %
Medicaid(1)
$549,414 $11,062 $560,476 39.0 %
Medicare398,905  398,905 27.7 
Medicaid-skilled95,712  95,712 6.7 
Subtotal1,044,031 11,062 1,055,093 73.4 
Managed care256,373  256,373 17.8 
Private and other(2)
88,845 37,192 126,037 8.8 
TOTAL SERVICE REVENUE$1,389,249 $48,254 $1,437,503 100.0 %
(1) Medicaid payor includes revenue generated from senior living operations and revenue related to FMAP.
(2) Private and other payors also includes revenue from senior living operations and all payors generated in other ancillary services.

 Six Months Ended June 30, 2021
 Skilled ServicesOther Service Revenue Total Service RevenueRevenue %
Medicaid(1)
$475,412 $7,401 $482,813 38.4 %
Medicare360,311  360,311 28.6 
Medicaid-skilled82,733  82,733 6.6 
Subtotal918,456 7,401 925,857 73.6 
Managed care221,308  221,308 17.6 
Private and other(2)
74,154 36,566 110,720 8.8 
TOTAL SERVICE REVENUE$1,213,918 $43,967 $1,257,885 100.0 %
(1) Medicaid payor includes revenue generated from senior living operations and revenue related to FMAP.
(2) Private and other payors also includes revenue from senior living operations and all payors generated in other ancillary services.
In addition to the service revenue above, the Company's rental revenue derived from triple-net lease arrangements with third parties is $4,139 and $8,428, respectively, for the three and six months ended June 30, 2022 and $3,927 and $7,904, respectively, for the three and six months ended June 30, 2021. This revenue is included in both Standard Bearer and the all other category.

9. OPERATION EXPANSIONS
The Company's subsidiaries expansion focus is to purchase or lease operations that are complementary to the current affiliated operations, accretive to the business, or otherwise advance the Company's strategy. The results of all operating subsidiaries are included in the Interim Financial Statements subsequent to the date of acquisition. Acquisitions are accounted for using the acquisition method of accounting. The Company's affiliated operations also enter into long-term leases that may include options to purchase the facilities. As a result, from time to time, a real estate affiliated subsidiary will acquire the property of facilities that have previously been operated under third-party leases.
FASB ASC Topic 805, Clarifying the Definition of a Business (ASC 805) defined the definition of a business to assist entities with evaluating when a set of transferred assets and activities is deemed to be a business. Determining whether a transferred set constitutes a business is important because the accounting for a business combination differs from that of an asset acquisition. The definition of a business also affects the accounting for dispositions. When substantially all of the fair value of assets acquired is concentrated in a single asset, or a group of similar assets, the assets acquired would not represent a business and business combination accounting would not be required.

19

THE ENSIGN GROUP, INC.
NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - (Continued)

2022 Expansions
During the six months ended June 30, 2022, the Company expanded its operations through a combination of long-term leases and real estate purchases, with the addition of four stand-alone skilled nursing operations. Of these additions, Standard Bearer acquired the real estate of two of the stand-alone skilled nursing operations, which were leased back to Ensign affiliated entities. Refer to Note 7, Standard Bearer, for additional information on the purchase of real estate properties. In addition, the Company added five senior living operations that were transferred from Pennant, three of which are part of campuses operated by the Company's affiliated operating subsidiaries. These new operations added a total of 453 operational skilled nursing beds and 633 operational senior living units to be operated by the Company's affiliated operating subsidiaries. The Company also invested in new ancillary services that are complementary to its existing businesses. The aggregate purchase price for these expansions during the six months ended June 30, 2022 was $33,892.
In connection with the new operations made through long-term leases, the Company did not acquire any material assets or assume any liabilities other than the tenant's post-assumption rights and obligations under the long-term lease. The Company entered into a separate operations transfer agreement with the prior operator as part of each transaction.
The aggregate purchase price for the transactions that were classified as asset acquisitions during the six months ended June 30, 2022 was $17,492, consisting of real estate properties and indefinite-lived intangible assets. The remaining aggregate purchase price for transactions during the six months ended June 30, 2022 is concentrated in goodwill of $16,400 and accordingly, the transactions were classified as business combinations.
Subsequent to June 30, 2022, the Company expanded its operations through a combination of long-term leases and real estate purchases, with the addition of seven stand-alone skilled nursing operations and one campus operation. Of these additions, Standard Bearer acquired the real estate of three of these operations, which were leased back to Ensign affiliated entities. These new operations added 1,100 operational skilled nursing beds and 61 operational senior living units to be operated by the Company's affiliated operating subsidiaries. In addition, the Company purchased the real estate at three skilled nursing properties that the Company was already operating, further expanding the Company's real estate portfolio. The aggregate purchase price for these expansions was $47,900.
2021 Expansions
During the six months ended June 30, 2021, the Company expanded its operations through a combination of long-term leases and a real estate purchase, with the addition of twelve stand-alone skilled nursing operations. Of these additions, one is related to the purchase of real estate property, further expanding the Company's real estate portfolio. These new operations added a total of 1,263 operational skilled nursing beds operated by the Company's affiliated operating subsidiaries. The aggregate purchase price for these acquisitions during the six months ended June 30, 2021 was $11,183.
In connection with the new operations made through long-term leases, the Company did not acquire any material assets or assume any liabilities other than the tenant's post-assumption rights and obligations under the long-term lease. The Company entered into a separate operations transfer agreement with the prior operator as part of each transaction.
The fair value of assets for nine of the acquisitions was concentrated in property and equipment and as such, these transactions were classified as asset acquisitions. The aggregate purchase price for the asset acquisitions during the six months ended June 30, 2021 was $5,183. The fair value of assets for the remaining four additions was concentrated in goodwill of $6,000 and as such, the transaction was classified as a business combination.
The Company’s acquisition strategy has been focused on identifying both opportunistic and strategic acquisitions within its target markets that offer strong opportunities for return. The operations added by the Company are frequently underperforming financially and can have regulatory and clinical challenges to overcome. Financial information, especially with underperforming operations, is often inadequate, inaccurate or unavailable. Consequently, the Company believes that prior operating results are not a meaningful representation of the Company’s current operating results or indicative of the integration potential of its newly acquired operating subsidiaries. The assets added during the six months ended June 30, 2022 were not material operations to the Company individually or in the aggregate. Accordingly, pro forma financial information is not presented. These additions have been included in the June 30, 2022 condensed consolidated balance sheets of the Company, and the operating results have been included in the condensed consolidated statements of operations of the Company since the date the Company gained effective control.

20

THE ENSIGN GROUP, INC.
NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - (Continued)

10. PROPERTY AND EQUIPMENT - NET
Property and equipment, net consists of the following:
June 30, 2022December 31, 2021
Land$121,381 $121,164 
Buildings and improvements669,215 646,221 
Leasehold improvements145,522 140,012 
Equipment279,231 262,246 
Furniture and fixtures4,373 4,305 
Construction in progress11,000 10,253 
 1,230,722 1,184,201 
Less: accumulated depreciation(322,494)(295,767)
PROPERTY AND EQUIPMENT, NET$908,228 $888,434 
The Company completed the sale of assets for a sale price of $7,707 and recorded a gain of $2,567 within the Company's condensed consolidated statement of income as cost of services during the three months ended June 30, 2022. See also Note 7, Standard Bearer and Note 9, Operation Expansions for information on acquisitions during the six months ended June 30, 2022.
11. INTANGIBLE ASSETS - NET
 June 30, 2022December 31, 2021
Weighted Average Life (Years)
Gross Carrying AmountAccumulated AmortizationGross Carrying AmountAccumulated Amortization
Intangible AssetsNetNet
Assembled occupancy0.4$196 $(196)$ $68 $(68)$ 
Facility trade name30.0733 (403)330 733 (391)342 
Customer relationships18.44,582 (2,377)2,205 4,582 (2,272)2,310 
TOTAL $5,511 $(2,976)$2,535 $5,383 $(2,731)$2,652 

During the three and six months ended June 30, 2022, amortization expense was $418 and $822, respectively, of which $288 and $577 was related to the amortization of right-of-use assets, respectively. Amortization expense was $363 and $724, respectively, of which $290 and $580 was related to the amortization of right-of-use assets for the three and six months ended June 30, 2021, respectively.

Estimated amortization expense for each of the years ending December 31 is as follows:
YearAmount
2022 (remainder)$117 
2023234 
2024234 
2025234 
2026234 
2027234 
Thereafter1,248 
 $2,535 


21

THE ENSIGN GROUP, INC.
NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - (Continued)

12. GOODWILL AND OTHER INDEFINITE-LIVED INTANGIBLE ASSETS

The Company tests goodwill during the fourth quarter of each year or more often if events or circumstances indicate there may be impairment. The Company performs its analysis for each reporting unit that constitutes a business for which discrete financial information is produced and reviewed by operating segment management and provides services that are distinct from the other components of the operating segment, in accordance with the provisions of FASB ASC Topic 350, Intangibles—Goodwill and Other (ASC 350). This guidance provides the option to first assess qualitative factors to determine whether it is more likely than not that the fair value of a reporting unit is less than its carrying value. If, based on a review of qualitative factors, it is more likely than not that the fair value of a reporting unit is less than its carrying value, the Company performs a goodwill impairment test by comparing the carrying value of each reporting unit to its respective fair value. The Company determines the estimated fair value of each reporting unit using a discounted cash flow analysis. The fair value of the reporting unit is the implied fair value of goodwill. In the event a reporting unit's carrying value exceeds its fair value, an impairment loss will be recognized. An impairment loss is measured by the difference between the carrying value of the reporting unit and its fair value.
The Company anticipates that the majority of total goodwill recognized will be fully deductible for tax purposes as of June 30, 2022.

Provided that goodwill corresponds to the acquisition of a business and not merely the acquisition of real estate property, the Company's Standard Bearer segment appropriately does not carry a goodwill balance. The following table represents activity in goodwill by skilled service segment and "all other" category as of and for the six months ended June 30, 2022:
Goodwill
 Skilled ServicesAll OtherTotal
January 1, 2022$51,486 $8,983 $60,469 
Additions16,400  16,400 
June 30, 2022$67,886 $8,983 $76,869 

Other indefinite-lived intangible assets consist of the following:
June 30, 2022December 31, 2021
Trade name$889 $889 
Medicare and Medicaid licenses2,918 2,838 
TOTAL$3,807 $3,727 

13. RESTRICTED AND OTHER ASSETS

Restricted and other assets consist of the following:
June 30, 2022December 31, 2021
Debt issuance costs, net$4,195 $1,953 
Long-term insurance losses recoverable asset8,440 6,755 
Deposits with landlords14,725 13,705 
Capital improvement reserves with landlords and lenders6,499 7,103 
Deferred compensation plan investments23,151 17,530 
RESTRICTED AND OTHER ASSETS$57,010 $47,046 

Included in restricted and other assets as of June 30, 2022 and December 31, 2021 are anticipated insurance recoveries related to the Company's workers' compensation liabilities and general and professional liability reserves that are recorded on a gross rather than net basis in accordance with GAAP.

22

THE ENSIGN GROUP, INC.
NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - (Continued)

The Company implemented a non-qualified deferred compensation plan (the DCP) that was effective in 2019 for certain employees and was expanded to other employees in 2020. The DCP allows for the employee deferrals to be deposited into a rabbi trust and these funds are generally invested in individual variable life insurance contracts owned by the Company that are specifically designed to fund the deferrals. The cash surrender value of the insurance contracts is based on funds that shadow the investment allocations specified by participants in the deferred compensation plan.

For the three and six months ended June 30, 2022, the Company recorded a loss on these investments of $3,313 and $4,515, respectively, which is included in other (expense) income, net. During the same periods, the Company recorded an offsetting reduction in expense of $3,300 and $4,511, respectively, allocated between cost of services and general and administrative expenses.

For the three and six months ended June 30, 2021, the Company recorded a gain on the deferral investment of $751 and $1,057, respectively, which is included in other (expense) income, net. During the same periods, the Company recorded an offsetting expense of $780 and $1,131, respectively, allocated between cost of services and general and administrative expenses.

14. OTHER ACCRUED LIABILITIES

Other accrued liabilities consists of the following:
June 30, 2022December 31, 2021
Quality assurance fee$6,669 $6,474 
Refunds payable36,912 34,814 
Resident advances6,273 9,337 
Unapplied state relief funds4,356 1,781 
Cash held in trust for patients5,757 6,430 
Dividends payable3,040 3,035 
Property taxes7,670 9,124 
Legal finding accrued3,626  
Other11,490 18,415 
OTHER ACCRUED LIABILITIES$85,793 $89,410 

Quality assurance fee represents the aggregate of amounts payable to Arizona, California, Colorado, Idaho, Iowa, Kansas, Nebraska, Nevada, Utah, Washington and Wisconsin as a result of a mandated fee based on patient days or licensed beds. Refunds payable includes payables related to overpayments, duplicate payments and credit balances from various payor sources. Resident advances occur when the Company receives payments in advance of services provided. Resident deposits include refundable deposits to patients. Cash held in trust for patients reflects monies received from or on behalf of patients. Maintaining a trust account for patients is a regulatory requirement and, while the trust assets offset the liabilities, the Company assumes a fiduciary responsibility for these funds. The cash balance related to this liability is included in other current assets in the condensed consolidated balance sheets.

15. INCOME TAXES
The Company recorded income tax expense of $31,292 and $26,707 during the six months ended June 30, 2022 and 2021, respectively, or 22.5% of earnings before income taxes for the six months ended June 30, 2022, compared to 21.0% for the six months ended June 30, 2021. The effective tax rate for both periods is driven by the impact of excess tax benefits from stock-based compensation, offset by non-deductible expenses including non-deductible compensation.

The Company is not currently under examination by any major income tax jurisdiction. During 2022, the statutes of limitations will lapse on the Company's 2018 Federal tax year and certain 2017 and 2018 state tax years. The Company does not believe the Federal or state statute lapses or any other event will significantly impact the balance of unrecognized tax benefits in the next twelve months. The net balance of unrecognized tax benefits was not material to the Interim Financial Statements for the six months ended June 30, 2022 and 2021.


23

THE ENSIGN GROUP, INC.
NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - (Continued)

16. DEBT
Debt consists of the following:
June 30, 2022December 31, 2021
Mortgage loans and promissory notes$158,258 $159,967 
Less: current maturities(3,944)(3,760)
Less: debt issuance costs, net(3,209)(3,324)
LONG-TERM DEBT LESS CURRENT MATURITIES$151,105 $152,883 
Credit Facility with a Lending Consortium Arranged by Truist

The Company maintains a revolving credit facility between the Company and its subsidiaries, including Standard Bearer as co-borrowers, and Truist Securities (Truist) (the Revolving Credit Facility). Borrowings are supported by a lending consortium arranged by Truist. On April 8, 2022, the Company and its subsidiaries, including Standard Bearer, entered into the Amended Credit Agreement, which amended the Revolving Credit Facility to increase the revolving line of credit from $350,000 to $600,000 in aggregate principal amount. The Amended Credit Agreement also extended the maturity date of the Revolving Credit Facility to April 8, 2027 and modified the reference rate from LIBOR to SOFR. The interest rates applicable to loans under the Amended Credit Facility are, at the Company's option, equal to either a base rate plus a margin ranging from 0.25% to 1.25% per annum or SOFR plus a margin range from 1.25% to 2.25% per annum, based on the Consolidated Total Net Debt to Consolidated EBITDA ratio (as defined in the agreement). In addition, the Company and its subsidiaries, including Standard Bearer, will pay a commitment fee on the unused portion of the commitments that will range from 0.20% to 0.40% per annum, depending on the Consolidated Total Net Debt to Consolidated EBITDA ratio. Except as set forth in the Amended Credit Facility, all other terms and conditions of the Credit Facility remained in full force and effect as described below. As part of the entry into the Amended Credit Agreement, deferred financing costs of $566 were written off and additional deferred financing costs of $3,197 were capitalized during the three months ended June 30, 2022.

Borrowings made under the Revolving Credit Facility are guaranteed, jointly and severally, by certain of the Company’s wholly-owned subsidiaries, and are secured by a pledge of stock of the Company's material operating subsidiaries as well as a first lien on substantially all of their personal property. The Amended Credit Agreement contains customary covenants that, among other things, restrict, subject to certain exceptions, the ability of the Company and its operating subsidiaries to grant liens on their assets, incur indebtedness, sell assets, make investments, engage in acquisitions, mergers or consolidations, amend certain material agreements and pay certain dividends and other restricted payments. Under the Amended Credit Agreement, the Company must comply with financial maintenance covenants to be tested quarterly, consisting of (i) a maximum consolidated total net debt to consolidated EBITDA ratio (which shall not be greater than 3.00:1.00; provided that if the aggregate consideration for approved acquisitions in a six month period is greater than $50,000, then the ratio can be increased at the election of the Company with notice to the administrative agent to 3.50:1.00 for the first fiscal quarter and the immediately following three fiscal quarters), and (ii) a minimum interest/rent coverage ratio (which cannot be less than 1.50:1.00). As of June 30, 2022, and July 27, 2022, there was no outstanding debt under the Revolving Credit Facility. The Company was in compliance with all loan covenants as of June 30, 2022.
Mortgage Loans and Promissory Notes

As of June 30, 2022, the Company's operating subsidiaries had $158,258 outstanding under the mortgage loans and notes, of which $3,944 is classified as short-term and the remaining $154,314 is classified as long-term. The Company was in compliance with all loan covenants as of June 30, 2022.

As of June 30, 2022, 23 of the Company's subsidiaries have mortgage loans insured with HUD in the aggregate amount of $155,074, which subjects these subsidiaries to HUD oversight and periodic inspections. The mortgage loans bear effective interest rates in a range of 3.1% to 4.2%, including fixed interest rates in a range of 2.4% to 3.3% per annum. In addition to the interest rate, we incur other fees for HUD placement, including but not limited to audit fees. Amounts borrowed under the mortgage loans may be prepaid, subject to prepayment fees based on the principal balance on the date of prepayment. For the majority of the loans, during the first three years, the prepayment fee is 10.0% and is reduced by 3.0% in the fourth year of the loan, and reduced by 1.0% per year for years five through ten of the loan. There is no prepayment penalty after year ten. The terms for all the mortgage loans are 25 to 35 years.

24

THE ENSIGN GROUP, INC.
NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - (Continued)

In addition to the HUD mortgage loans above, the Company has two promissory notes. The notes bear fixed interest rates of 6.3% and 5.3% per annum and the term of the notes are 10 months and 12 years, respectively. The 12 year note which was used for an acquisition is secured by the real property comprising the facility and the rent, issues and profits thereof, as well as all personal property used in the operation of the facility.

Based on Level 2, the carrying value of the Company's long-term debt is considered to approximate the fair value of such debt for all periods presented based upon the interest rates that the Company believes it can currently obtain for similar debt.
Off-Balance Sheet Arrangements

As of June 30, 2022, the Company had approximately $6,710 of borrowing capacity under the Revolving Credit Facility pledged as collateral to secure outstanding letters of credit.

17. OPTIONS AND AWARDS
Stock-based compensation expense consists of stock-based payment awards made to employees and directors, including employee stock options and restricted stock awards, based on estimated fair values. As stock-based compensation expense recognized in the Company’s condensed consolidated statements of income for the three and six months ended June 30, 2022 and 2021 was based on awards ultimately expected to vest, it has been reduced for estimated forfeitures. The Company estimates forfeitures at the time of grant and, if necessary, revises the estimate in subsequent periods if actual forfeitures differ.
The Company has an option plan, the 2022 Omnibus Incentive Plan (the 2022 Plan), which was approved by the Company's stockholders on May 26, 2022, and replaced the Company's prior option plan, the 2017 Omnibus Incentive Plan (the 2017 Plan). The total number of shares available for issuance under the 2022 Plan was 3,268 as of June 30, 2022.

2022 Omnibus Incentive Plan - During the second quarter of 2022, the Company's shareholders approved the 2022 Plan. Including the shares rolled over from the 2017 Plan, the 2022 Plan provides for the issuance of 3,452 shares of common stock. The number of shares available to be issued under the 2022 Plan will be reduced by (i) one share for each share that relates to an option or stock appreciation right award and (ii) two shares for each share which relates to an award other than a stock option or stock appreciation right award (a full-value award). Non-employee director options, to the extent granted, will vest and become exercisable in three equal annual installments, or the length of the term if less than three years, on the completion of each year of service measured from the grant date. All other options generally vest over five years at 20% per year on the anniversary of the grant date. Options expire ten years from the date of grant. As of June 30, 2022, there were approximately 3,268 unissued shares of common stock available for issuance under this plan. The Company retired the 2017 Plan as a result of the approval of the 2022 Plan.
The Company uses the Black-Scholes option-pricing model to recognize the value of stock-based compensation expense for stock option awards. Determining the appropriate fair-value model and calculating the fair value of stock option awards at the grant date requires judgment, including estimating stock price volatility, expected option life, and forfeiture rates. The fair-value of the restricted stock awards at the grant date is based on the market price on the grant date, adjusted for forfeiture rates. The Company develops estimates based on historical data and market information, which can change significantly over time.
Stock Options
The Company granted 154 and 318 stock options from the available plans during the three and six months ended June 30, 2022, respectively. The Company used the following assumptions for stock options granted during the three months ended June 30, 2022 and 2021:
Grant YearOptions GrantedWeighted Average Risk-Free RateExpected LifeWeighted Average VolatilityWeighted Average Dividend Yield
20221542.7%6.1 years42.1%0.3%
20212091.0%6.3 years42.3%0.3%

25

THE ENSIGN GROUP, INC.
NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - (Continued)

The Company used the following assumptions for stock options granted during the six months ended June 30, 2022 and 2021:
Grant YearOptions GrantedWeighted Average Risk-Free RateExpected LifeWeighted Average VolatilityWeighted Average Dividend Yield
20223182.3%6.1 years42.2%0.3%
20213450.9%6.3 years42.2%0.2%
For the six months ended June 30, 2022 and 2021, the following represents the exercise price and fair value displayed at grant date for stock option grants:
Grant YearGrantedWeighted Average Exercise PriceWeighted Average Fair Value of Options
2022318$80.18 $34.29 
2021345$82.77 $33.86 
The weighted average exercise price equaled the weighted average fair value of common stock on the grant date for all options granted during the periods ended June 30, 2022 and 2021 and therefore, the intrinsic value was $0 at the date of grant.
The following table represents the employee stock option activity during the six months ended June 30, 2022:
Number of Options OutstandingWeighted Average
Exercise Price
Number of
Options Vested
Weighted Average Exercise Price of Options Vested
January 1, 20224,038 $36.60 2,183 $21.02 
Granted318 80.18 — — 
Forfeited(68)57.40 — — 
Exercised(370)16.40 — — 
June 30, 20223,918 $41.69 2,151 $25.53 
The following summary information reflects stock options outstanding, vested and related details as of June 30, 2022:
Stock Options OutstandingStock Options Vested
 
Number OutstandingBlack-Scholes Fair ValueRemaining Contractual Life (Years)Vested and Exercisable
Year of GrantExercise Price
2012$5.56-$6.7510 $32 010 
20136.76-9.74125 476 1125 
20148.94-16.05457 2,204 2457 
201518.20-21.39246 1,910 3246 
201615.93-16.86233 1,377 4233 
201715.80-19.41267 1,583 5236 
201822.49-32.71496 4,806 6326 
201941.07-45.76615 9,651 7292 
202044.84-59.49569 11,205 8162 
202173.47-83.64586 19,222 964 
2022$79.79$80.60314 10,782 10 
TOTAL 3,918 $63,248  2,151 

26

THE ENSIGN GROUP, INC.
NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - (Continued)

The aggregate intrinsic value of options outstanding, vested and expected to vest as of June 30, 2022 and December 31, 2021 is as follows:
OptionsJune 30, 2022December 31, 2021
Outstanding$130,564 $191,242 
Vested103,713 137,382 
Expected to vest24,561 48,548 
The intrinsic value is calculated as the difference between the market value of the underlying common stock and the exercise price of the options. The aggregate intrinsic value of options that vested during the six months ended June 30, 2022 and 2021 was $10,409 and $17,618, respectively. The total intrinsic value of options exercised during the six months ended June 30, 2022 and 2021 was $25,642 and $26,715, respectively.
Restricted Stock Awards
The Company granted 46 and 158 restricted stock awards from the available plans during the three and six months ended June 30, 2022, respectively. The Company granted 54 and 144 restricted stock awards during the three and six months ended June 30, 2021, respectively. All awards were granted at an issue price of $0 and generally vest over five years. The fair value per share of restricted awards granted during the six months ended June 30, 2022 and 2021 ranged from $73.17 to $83.93 and $82.20 to $93.31, respectively. The fair value per share includes quarterly stock awards to non-employee directors.
A summary of the status of the Company's non-vested restricted stock awards as of June 30, 2022 and changes during the six months ended June 30, 2022 is presented below:
Non-Vested Restricted AwardsWeighted Average Grant Date Fair Value
Non-vested at January 1, 2022549 $52.16 
Granted158 77.06 
Vested(199)54.74 
Forfeited(16)55.86 
Non-vested at June 30, 2022492 $59.01 
During the three and six months ended June 30, 2022, respectively, the Company granted 5 and 9 automatic quarterly stock awards to non-employee directors for their service on the Company's board of directors from the 2017 Plan. The fair value per share of these stock awards ranged from $77.39 to $83.93 based on the market price on the grant date.
Long-Term Incentive Plan
On August 27, 2019, the Board approved the Long-Term Incentive Plan (the 2019 LTI Plan). The 2019 LTI Plan provides that certain employees of the Company who assisted in the consummation of the Spin-Off transaction are granted shares of restricted stock upon the successful completion of the Spin-Off. The 2019 LTI Plan provides for the issuance of 500 shares of Pennant restricted stock. The shares are vested over five years at 20% per year on the anniversary of the grant date. If a recipient is terminated or voluntarily leaves the Company, all shares subject to restriction or not yet vested shall be entirely forfeited. The total stock-based compensation related to the 2019 LTI Plan was approximately $195 and $390 for the three and six months ended June 30, 2022, respectively, compared to $202 and $403 for the three and six months ended June 30, 2021, respectively.

27

THE ENSIGN GROUP, INC.
NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - (Continued)

Stock-based compensation expense recognized for the Company's equity incentive plans and long-term incentive plan for the three and six months ended June 30, 2022 and 2021 was as follows:

Three Months Ended June 30,Six Months Ended June 30,
 2022202120222021
Stock-based compensation expense related to stock options$2,786 $2,026 $5,306 $3,759 
Stock-based compensation expense related to restricted stock awards2,456 2,076 4,758 3,914 
Stock-based compensation expense related to stock options and restricted stock awards to non-employee directors374 531 719 1,014 
TOTAL$5,616 $4,633 $10,783 $8,687 

In future periods, the Company expects to recognize approximately $39,110 and $28,748 in stock-based compensation expense for unvested options and unvested restricted stock awards, respectively, that were outstanding as of June 30, 2022. Future stock-based compensation expense will be recognized over 3.7 and 3.4 weighted average years for unvested options and restricted stock awards, respectively. There were 1,767 unvested and outstanding options as of June 30, 2022, of which 1,669 shares are expected to vest. The weighted average contractual life for options outstanding, vested and expected to vest as of June 30, 2022 was 6.0 years.

18. LEASES
The Company leases from CareTrust REIT, Inc. (CareTrust) real property associated with 97 affiliated skilled nursing and senior living facilities used in the Company’s operations, 96 of which are under nine “triple-net” master lease agreements (collectively, the Master Leases), which range in terms from 13 to 20 years. At the Company’s option, the Master Leases may be extended for two or three five-year renewal terms beyond the initial term, on the same terms and conditions. The extension of the term of any of the Master Leases is subject to the following conditions: (1) no event of default under any of the Master Leases having occurred and being continuing; and (2) the tenants providing timely notice of their intent to renew. The term of the Master Leases is subject to termination prior to the expiration of the then current term upon default by the tenants in their obligations, if not cured within any applicable cure periods set forth in the Master Leases. If the Company elects to renew the term of a Master Lease, the renewal will be effective to all, but not less than all, of the leased property then subject to the Master Lease. Additionally, four of the 97 facilities leased from CareTrust include an option to purchase that the Company can exercise starting on December 1, 2024.
The Company does not have the ability to terminate the obligations under a Master Lease prior to its expiration without CareTrust’s consent. If a Master Lease is terminated prior to its expiration other than with CareTrust’s consent, the Company may be liable for damages and incur charges such as continued payment of rent through the end of the lease term as well as maintenance and repair costs for the leased property.
The rent structure under the Master Leases includes a fixed component, subject to annual escalation equal to the lesser of (1) the percentage change in the Consumer Price Index (but not less than zero) or (2) 2.5%. In addition to rent, the Company is required to pay the following: (1) all impositions and taxes levied on or with respect to the leased properties (other than taxes on the income of the lessor); (2) all utilities and other services necessary or appropriate for the leased properties and the business conducted on the leased properties; (3) all insurance required in connection with the leased properties and the business conducted on the leased properties; (4) all facility maintenance and repair costs; and (5) all fees in connection with any licenses or authorizations necessary or appropriate for the leased properties and the business conducted on the leased properties. The terms and conditions of the one stand-alone lease are substantially the same as those for the master leases described above. Total rent expense under the Master Leases was approximately $16,007 and $31,652 for the three and six months ended June 30, 2022, respectively, and $14,419 and $28,499 for the three and six months ended June 30, 2021, respectively.
Among other things, under the Master Leases, the Company must maintain compliance with specified financial covenants measured on a quarterly basis, including a portfolio coverage ratio and a minimum rent coverage ratio. The Master Leases also include certain reporting, legal and authorization requirements. The Company is in compliance with requirements of the Master Leases as of June 30, 2022.
In connection with the Spin-Off, the Company guaranteed certain leases of Pennant based on the underlying terms of the leases. The Company does not consider these guarantees to be probable and the likelihood of Pennant defaulting is remote, and therefore no liabilities have been accrued.
28

THE ENSIGN GROUP, INC.
NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - (Continued)

The Company also leases certain affiliated operations and certain administrative offices under non-cancelable operating leases, most of which have initial lease terms ranging from five to 20 years. The Company has entered into multiple lease agreements with various landlords to operate newly constructed state-of-the-art, full-service healthcare resorts. The term of each lease is 15 years with two five-year renewal options and is subject to annual escalation equal to the percentage change in the Consumer Price Index with a stated cap percentage. In addition, the Company leases certain of its equipment under non-cancelable operating leases with initial terms ranging from three to five years. Most of these leases contain renewal options, certain of which involve rent increases. Total rent expense for continuing operations inclusive of straight-line rent adjustments and rent associated with the Master Leases noted above, was $37,251 and $73,036 for the three and six months ended June 30, 2022, respectively, and $34,476 and $67,952 for the three and six months ended June 30, 2021, respectively.
Forty-four of the Company’s affiliated facilities, excluding the facilities that are operated under the Master Leases with CareTrust, are operated under eight separate master lease arrangements. In the first quarter of 2022, the Company added an operation and extended the term for one of the master leases to 14 remaining years. As a result, the lease liabilities and right-of-use assets increased by $120,349 to reflect the new lease obligations. Under these master leases, a breach at a single facility could subject one or more of the other facilities covered by the same master lease to the same default risk. Failure to comply with Medicare and Medicaid provider requirements is a default under several of the Company’s leases, master lease agreements and debt financing instruments. In addition, other potential defaults related to an individual facility may cause a default of an entire master lease portfolio and could trigger cross-default provisions in the Company’s outstanding debt arrangements and other leases. With an indivisible lease, it is difficult to restructure the composition of the portfolio or economic terms of the lease without the consent of the landlord.

The components of operating lease expense are as follows:
Three Months Ended June 30,Six Months Ended June 30,
2022202120222021
Rent - cost of services(1)
$37,228 $34,455 $72,990 $67,911 
General and administrative expense23 21 46 41 
Depreciation and amortization(2)
288 290 577 580 
Variable lease costs(3)
3,772 3,694 9,135 7,137 
$41,311 $38,460 $82,748 $75,669 
(1)Rent- cost of services includes deferred rent expense adjustments of $116 and $240 for the three and six months ended June 30, 2022, respectively and $109 and $221 for the three and six months ended June 30, 2021, respectively. Additionally, rent- cost of services includes other variable lease costs such as CPI increases and short-term leases of $1,302 and $2,239 for the three and six months ended June 30, 2022, respectively, and $832 and $1,416 for the three and six months ended June 30, 2021, respectively.
(2)Depreciation and amortization is related to the amortization of favorable and direct lease costs.
(3)Variable lease costs, including property taxes and insurance, are classified in cost of services in the Company's condensed consolidated statements of income.

Future minimum lease payments for all leases as of June 30, 2022 are as follows:
YearAmount
2022 (remainder)$71,530 
2023141,887 
2024141,296 
2025141,187 
2026141,082 
2027140,564 
Thereafter1,254,424 
TOTAL LEASE PAYMENTS2,031,970 
Less: present value adjustment (756,866)
PRESENT VALUE OF TOTAL LEASE LIABILITIES1,275,104 
Less: current lease liabilities(58,769)
LONG-TERM OPERATING LEASE LIABILITIES$1,216,335 
Operating lease liabilities are based on the net present value of the remaining lease payments over the remaining lease term. In determining the present value of lease payments, the Company used its incremental borrowing rate based on the information available at the lease commencement date. As of June 30, 2022, the weighted average remaining lease term is 15.1 years and the weighted average discount rate used to determine the operating lease liabilities is 6.8%.
29

THE ENSIGN GROUP, INC.
NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - (Continued)

Subsequent to June 30, 2022, the Company expanded its operations through long-term lease arrangements with the addition of five stand-alone skilled nursing operations, four of which are part of an amended separate master lease agreement, adding a total of 779 operational skilled nursing beds operated by the Company's affiliated operating subsidiaries. The term of the amended separate master lease agreement was extended to 20 remaining years. The aggregate impact to the fair value of lease liabilities and right-of-use assets related to both the new long-term lease arrangement and the amended separate master lease agreement is estimated to be approximately $70,614. Additionally, Standard Bearer acquired the real estate of three skilled nursing operations, which were previously under long-term lease arrangements. The aggregate reduction in the fair value of lease liabilities and right-of-use assets related to this acquisition is estimated to be approximately $10,080.
Lessor Activities

In connection with the Spin-Off, Ensign affiliates retained ownership of the real estate at 29 senior living operations that were contributed to Pennant. Between October 2019 and June 30, 2022, the Company transferred three additional senior living operations to Pennant. During the three months ended June 30, 2022, the Company completed the sale of real estate associated with two of the senior living operations operated by Pennant and also transferred one senior living operation operated by Pennant back to Ensign affiliates. As of June 30, 2022, Ensign affiliates retained ownership of the real estate for these 29 senior living communities. All of these properties are leased to Pennant on a triple-net basis, whereas the respective Pennant affiliates are responsible for all costs at the properties including: (1) all impositions and taxes levied on or with respect to the leased properties (other than taxes on the income of the lessor); (2) all utilities and other services necessary or appropriate for the leased properties and the business conducted on the leased properties; (3) all insurance required in connection with the leased properties and the business conducted on the leased properties; (4) all facility maintenance and repair costs; and (5) all fees in connection with any licenses or authorizations necessary or appropriate for the leased properties and the business conducted on the leased properties. The initial terms range between 14 to 16 years.

Total rental income from all third-party sources for the three and six months ended June 30, 2022 and 2021 is as follows:

Three Months Ended June 30,Six Months Ended June 30,
2022202120222021
Pennant(1)
$3,690 $3,440 $7,505 $6,928 
Other third-party449 487 923 976 
$4,139 $3,927 $8,428 $7,904 
(1) Pennant rental income includes variable rent such as property taxes of $327 and $657 during the three and six months ended June 30, 2022 and $266 and $580 for the three and six months ended June 30, 2021.

Future annual rental income for all leases as of June 30, 2022 were as follows:
Year
Amount(1)
2022 (remainder)$8,098 
202315,820 
202415,373 
202515,032 
202614,821 
202714,821 
Thereafter77,369 
TOTAL$161,334 
(1) Annual rental income includes base rents and variable rental income pursuant to existing leases as of June 30, 2022.


30

THE ENSIGN GROUP, INC.
NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - (Continued)

19. COMMITMENTS AND CONTINGENCIES
Regulatory Matters Laws and regulations governing Medicare and Medicaid programs are complex and subject to review and interpretation. Compliance with such laws and regulations is evaluated regularly, the results of which can be subject to future governmental review and interpretation, and can include significant regulatory action including fines, penalties, and exclusion from certain governmental programs. Included in these laws and regulations is monitoring performed by the Office of Civil Rights which covers the Health Insurance Portability and Accountability Act of 1996, the terms of which require healthcare providers (among other things) to safeguard the privacy and security of certain patient protected health information.
Cost-Containment Measures Both government and private pay sources have instituted cost-containment measures designed to limit payments made to providers of healthcare services, and there can be no assurance that future measures designed to limit payments made to providers will not adversely affect the Company.
Indemnities From time to time, the Company enters into certain types of contracts that contingently require the Company to indemnify parties against third-party claims. These contracts primarily include (i) certain real estate leases, under which the Company may be required to indemnify property owners or prior facility operators for post-transfer environmental obligations or other liabilities and other claims arising from the Company’s use of the applicable premises, (ii) operations transfer agreements, in which the Company agrees to indemnify past operators of facilities the Company acquires against certain liabilities arising from the transfer of the operation and/or the operation thereof after the transfer to the Company's independent operating subsidiary, (iii) certain lending agreements, under which the Company may be required to indemnify the lender against various claims and liabilities, and (iv) certain agreements with the Company’s officers, directors and others, under which the Company may be required to indemnify such persons for liabilities arising out of the nature of their relationship to the Company. The terms of such obligations vary by contract and, in most instances, do not expressly state or include a specific or maximum dollar amount. Generally, amounts under these contracts cannot be reasonably estimated until a specific claim is asserted. Consequently, because no claims have been asserted, no liabilities have been recorded for these obligations on the Company’s condensed consolidated balance sheets for any of the periods presented.

In connection with the Spin-Off, certain landlords required, in exchange for their consent to the transaction, that the Company's lease guarantees remain in place for a certain period of time following the Spin-Off. These guarantees could result in significant additional liabilities and obligations for the Company if Pennant were to default on their obligations under their leases with respect to these properties.

U.S. Department of Justice Civil Investigative DemandOn May 31, 2018, the Company received a Civil Investigative Demand (CID) from the U.S. Department of Justice stating that it was investigating whether there had been a violation of the False Claims Act and/or the Anti-Kickback Statute with respect to relationships between certain of the Company’s independently operated skilled nursing facilities and persons who serve or have served as medical directors, advisory board participants or other potential referral sources. The CID covered the period from October 3, 2013 through 2018, and was limited in scope to ten of the Company’s Southern California independent operating entities. In October 2018, the Department of Justice made an additional request for information covering the period of January 1, 2011 through 2018, relating to the same topic. As a general matter, the Company’s independent operating entities have established and maintain policies and procedures to promote compliance with the False Claims Act, the Anti-Kickback Statute, and other applicable regulatory requirements. The Company fully cooperated with the U.S. Department of Justice and promptly responded to its requests for information; in April 2020, the Company was advised that the U.S. Department of Justice declined to intervene in any subsequent action filed by a relator in connection with the subject matter of this investigation.
U.S. House of Representatives Select Subcommittee Request In 2020, the U.S. House of Representatives Select Subcommittee on the Coronavirus Crisis launched a nation-wide investigation into the COVID-19 pandemic, which included the impact of the coronavirus on residents and employees in nursing homes. In June 2020, the Company received a document and information request from the House Select Subcommittee in connection with its investigation. The Company has cooperated in responding to this inquiry. In July 2022, the Company received a follow up request for additional documents and information. The Company is cooperating in responding to this inquiry. However, it is not possible to predict the ultimate outcome of any such investigation or whether and what other investigations or regulatory responses may result from the investigation, which could have a material adverse effect on our reputation, business, financial condition, and results of operations.

31

THE ENSIGN GROUP, INC.
NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - (Continued)

Litigation — The skilled nursing business involves a significant risk of liability given the age and health of the patients and residents served by the Company's independent operating subsidiaries. The Company, its independent operating subsidiaries, and others in the industry are subject to an increasing number of claims and lawsuits, including professional liability claims, alleging that services provided have resulted in personal injury, elder abuse, wrongful death or other related claims. In addition, the Company, its independent operating subsidiaries, and others in the industry are subject to claims and lawsuits in connection with COVID-19 and a facility's preparation for and/or response to COVID-19. The defense of these lawsuits may result in significant legal costs, regardless of the outcome, and can result in large settlement amounts or damage awards.

In addition to the potential lawsuits and claims described above, the Company and its independent operating subsidiaries are also subject to potential lawsuits under the Federal False Claims Act and comparable state laws alleging submission of fraudulent claims for services to any healthcare program (such as Medicare or Medicaid) or other payor. A violation may provide the basis for exclusion from Federally-funded healthcare programs. Such exclusions could have a correlative negative impact on the Company’s financial performance. Under the qui tam or "whistleblower" provisions of the False Claims Act, a private individual with knowledge of fraud or potential fraud may bring a claim on behalf of the Federal Government and receive a percentage of the Federal Government's recovery. Due to these whistleblower incentives, qui tam lawsuits have become more frequent. For example, and despite the decision of the U.S. Department of Justice to decline to participate in litigation based on the subject matter of its previously issued Civil Investigative Demand, the involved qui tam relator has continued on with the lawsuit and is pursuing claims that the Company and certain of its independent operating subsidiaries have allegedly violated the False Claims Act and/or the Anti-Kickback Statute (AKS).
In addition to the Federal False Claims Act, some states, including California, Arizona and Texas, have enacted similar whistleblower and false claims laws and regulations. Further, the Deficit Reduction Act of 2005 created incentives for states to enact anti-fraud legislation modeled on the Federal False Claims Act. As such, the Company and its independent operating subsidiaries could face increased scrutiny, potential liability and legal expenses and costs based on claims under state false claims acts in markets in which its independent operating subsidiaries do business.
In May 2009, Congress passed the Fraud Enforcement and Recovery Act (FERA) which made significant changes to the Federal False Claims Act and expanded the types of activities subject to prosecution and whistleblower liability. Following changes by FERA, health care providers face significant penalties for the knowing retention of government overpayments, even if no false claim was involved. Health care providers can now be liable for knowingly and improperly avoiding or decreasing an obligation to pay money or property to the government. This includes the retention of any government overpayment. The government can argue, therefore, that a Federal False Claims Act violation can occur without any affirmative fraudulent action or statement, as long as the action or statement is knowingly improper. In addition, FERA extended protections against retaliation for whistleblowers, including protections not only for employees, but also contractors and agents. Thus, an employment relationship is generally not required in order to qualify for protection against retaliation for whistleblowing.
Healthcare litigation (including class action litigation) is common and is filed based upon a wide variety of claims and theories, and the Company's independent operating subsidiaries are routinely subjected to varying types of claims, including class action "staffing" suits where the allegation is understaffing at the facility level. These class-action “staffing” suits have the potential to result in large jury verdicts and settlements, and may result in significant legal costs. The Company expects the plaintiffs' bar to continue to be aggressive in their pursuit of these staffing and similar claims. While the Company has been able to settle these claims without an ongoing material adverse effect on its business, future claims could be brought that may materially affect its business, financial condition and results of operations.
Other claims and suits, including class actions, continue to be filed against the Company and other companies in its industry. The Company and its independent operating subsidiaries have been subjected to, and are currently involved in, class action litigation alleging violations (alone or in combination) of state and federal wage and hour laws as related to the alleged failure to pay wages, to timely provide and authorize meal and rest breaks, and related causes of action. The Company does not believe that the ultimate resolution of these actions will have an ongoing material adverse effect on the Company’s business, cash flows, financial condition or results of operations.

32

THE ENSIGN GROUP, INC.
NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - (Continued)

The Company and its independent operating subsidiaries have been, and continue to be, subject to claims, findings and legal actions that arise in the ordinary course of the various businesses, including healthcare and non-healthcare services. These claims include, but are not limited to, potential claims filed by residents, customers, patients and responsible parties related to patient care and treatment (professional negligence claims); to non-care based activities of certain of the subsidiaries; and to employment related claims filed by current or former employees. A significant increase in the number of these claims, or an increase in the amounts owing should plaintiffs be successful in their prosecution of these claims, could materially adversely affect the Company’s business, financial condition, results of operations and cash flows. In addition, these claims could impact the Company's ability to procure insurance to cover its exposure related to the various services provided by its independent operating subsidiaries to their residents, customers and patients.
The Company and its independent subsidiaries are also subject to requests for information and investigations by other State and Federal governmental entities (e.g., offices of the attorney general and offices of the inspector general). The Company cannot predict or provide any assurance as to the possible outcome of any inquiry, investigation or litigation. If any such inquiry, investigation or litigation were to proceed, and the Company and its independent operating subsidiaries are subjected to, alleged to be liable for, or agree to a settlement of, claims or obligations under Federal Medicare statutes, the Federal False Claims Act, or similar state and federal statutes and related regulations, or if the Company or its independent operating subsidiaries are alleged or found to be liable on theories of general or professional negligence or wage and hour violations, the Company's business, financial condition and results of operations and cash flows could be materially and adversely affected and its stock price could be adversely impacted. Among other things, any settlement or litigation could involve the payment of substantial sums to settle any alleged violations, and may also include the assumption of specific procedural and financial obligations by the Company or its independent operating subsidiaries under a corporate integrity agreement and/or other such arrangement.
Medicare Revenue Recoupments The Company's independent operating entities are subject to regulatory reviews relating to the provision of Medicare services, billings and potential overpayments as a result of Recovery Audit Contractors (RAC), Program Safeguard Contractors, and Medicaid Integrity Contractors programs (collectively referred to as Reviews). For several months during the COVID-19 pandemic, the Centers for Medicare and Medicaid Services (CMS) suspended its Targeted Probe and Educate Program. Beginning in August 2020, CMS resumed Targeted Probe and Educate Program activity. If an operation fails a Review and/or subsequent Reviews, the operation could then be subject to extended review or an extrapolation of the identified error rate to billings in the same time period. The Company anticipates that these Reviews could increase in frequency in the future. As of June 30, 2022 and since, 22 of the Company's independent operating subsidiaries had Reviews scheduled, on appeal, or in a dispute resolution process.
Concentrations
Credit Risk — The Company has significant accounts receivable balances, the collectability of which is dependent on the availability of funds from certain governmental programs, primarily Medicare and Medicaid. These receivables represent the only significant concentration of credit risk for the Company. The Company does not believe there are significant credit risks associated with these governmental programs. The Company believes that an appropriate allowance has been recorded for the possibility of these receivables proving uncollectible, and continually monitors and adjusts these allowances as necessary. The Company’s receivables from Medicare and Medicaid payor programs accounted for 52.9% and 54.0% of its total accounts receivable as of June 30, 2022 and December 31, 2021, respectively. Revenue from reimbursement under the Medicare and Medicaid programs accounted for 73.4% of the Company's revenue for both the three and six months ended June 30, 2022, and 73.1% and 73.6% for the three and six months ended June 30, 2021, respectively.
Cash in Excess of FDIC Limits — The Company currently has bank deposits with financial institutions in the U.S. that exceed FDIC insurance limits. FDIC insurance provides protection for bank deposits up to $250. In addition, the Company has uninsured bank deposits with a financial institution outside the U.S. As of July 27, 2022, the Company had approximately $567 in uninsured cash deposits. All uninsured bank deposits are held at high quality credit institutions.

20. COMMON STOCK REPURCHASE PROGRAM

On February 9, 2022, the Board of Directors approved the Company to enter into a stock repurchase program pursuant to which the Company could repurchase up to $20,000 of its common stock under the program for a period of approximately 12 months from February 10, 2022. Under this program, the Company was authorized to repurchase its issued and outstanding common shares from time to time in open-market and privately negotiated transactions and block trades in accordance with federal securities laws. During the three months ended June 30, 2022, the Company repurchased 271 shares of its common stock for $20,000. This repurchase program expired upon the repurchase of the fully authorized amount under the plan.

33

THE ENSIGN GROUP, INC.
NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - (Continued)

As approved by the Board of Directors on October 21, 2021, the Company entered into a stock repurchase program pursuant to which the Company could repurchase up to $20,000 of its common stock under the program for a period of approximately 12 months that started on October 29, 2021. Under this program, the Company was authorized to repurchase its issued and outstanding common shares from time to time in open-market and privately negotiated transactions and block trades in accordance with federal securities laws. During the three months ended March 31, 2022, the Company repurchased 133 shares of its common stock for $9,882. During the fourth quarter of 2021, the Company repurchased 132 shares of its common stock for $10,118. This repurchase program expired upon the repurchase of the fully authorized amount under the plan.

On July 28, 2022, the Board of Directors approved the Company to enter into a stock repurchase program pursuant to which the Company may repurchase up to $20,000 of its common stock under the program for a period of approximately 12 months from August 2, 2022. Under this program, the Company is authorized to repurchase its issued and outstanding common shares from time to time in open-market and privately negotiated transactions and block trades in accordance with federal securities laws.

Item 2.    MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
The following discussion should be read in conjunction with the condensed consolidated financial statements and accompanying notes, which appear elsewhere in this Quarterly Report on Form 10-Q. We urge you to carefully review and consider the various disclosures made by us in this Quarterly Report and in our other reports filed with the Securities and Exchange Commission (SEC), including our Annual Report on Form 10-K for the year ended December 31, 2021 (Annual Report), which discusses our business and related risks in greater detail, as well as subsequent reports we may file from time to time on Form 10-Q and Form 8-K, for additional information. The section entitled “Risk Factors” contained in Part II, Item 1A of this Quarterly Report on Form 10-Q, and similar discussions in our other SEC filings, also describe some of the important risk factors that may affect our business, financial condition, results of operations and/or liquidity. You should carefully consider those risks, in addition to the other information in this Quarterly Report on Form 10-Q and in our other filings with the SEC, before deciding to purchase, hold or sell our common stock.
This Quarterly Report on Form 10-Q contains "forward-looking statements," within the meaning of the Private Securities Litigation Reform Act of 1995, which include, but are not limited to our expected future financial position, results of operations, cash flows, financing plans, business strategy, budgets, capital expenditures, competitive positions, growth opportunities, and plans and objectives of management. Forward-looking statements can often be identified by words such as “anticipates,” “expects,” “intends,” “plans,” “predicts,” “believes,” “seeks,” “estimates,” “may,” “will,” “should,” “would,” “could,” “potential,” “continue,” “ongoing,” similar expressions, and variations or negatives of these words. These statements are not guarantees of future performance and are subject to risks, uncertainties and assumptions that are difficult to predict. Additionally, our business and operations for 2022 continue to be impacted by the COVID-19 pandemic. Because of the unprecedented nature of the pandemic, we are unable to predict the full extent and duration of the financial impact of COVID-19 on our business, financial condition and results of operations. Our actual results could differ materially from those expressed in any forward-looking statements as a result of various factors, some of which are listed under the section “Risk Factors” contained in Part II, Item 1A of this Quarterly Report on Form 10-Q. These forward-looking statements speak only as of the date of this Quarterly Report on Form 10-Q, and are based on our current expectations, estimates and projections about our industry and business, management’s beliefs, and certain assumptions made by us, all of which are subject to change. We undertake no obligation to revise or update publicly any forward-looking statement for any reason, except as otherwise required by law.
As used in this Management’s Discussion and Analysis of Financial Condition and Results of Operations, the words, "Ensign," "Company," “we,” “our” and “us” refer to The Ensign Group, Inc. and its consolidated subsidiaries. All of our affiliated operations, the Service Center, our wholly-owned captive insurance subsidiary and our captive real estate investment trust (REIT) called Standard Bearer Healthcare REIT, Inc. (Standard Bearer) are operated by separate, wholly-owned, independent subsidiaries that have their own management, employees and assets. The use of "Ensign," "Company," “we,” “us,” “our” and similar verbiage in this Quarterly Report on Form 10-Q is not meant to imply that any of our affiliated operations, the Service Center, the captive insurance subsidiary or Standard Bearer are operated by the same entity. This Management’s Discussion and Analysis of Financial Condition and Results of Operations should be read in conjunction with our consolidated financial statements and related notes included the Annual Report.

34

Overview
We are a provider of health care services across the post-acute care continuum, engaged in the operation, ownership, acquisition, development and leasing of skilled nursing, senior living and other healthcare related properties and other ancillary businesses located in Arizona, California, Colorado, Idaho, Iowa, Kansas, Nebraska, Nevada, South Carolina, Texas, Utah, Washington and Wisconsin. Our operating subsidiaries, each of which strives to be the operation of choice in the community it serves, provide a broad spectrum of skilled nursing, senior living and other ancillary services. As of June 30, 2022, we offered skilled nursing, senior living and rehabilitative care services through 251 skilled nursing and senior living facilities. Of the 251 facilities, we operated 180 facilities under long-term lease arrangements and have options to purchase 11. Our real estate portfolio includes 100 owned real estate properties, which included 71 facilities operated and managed by us, 29 senior living operations leased to and operated by The Pennant Group, Inc., or Pennant, as part of the spin-off transaction that occurred in October 2019 (Spin-Off), and the Service Center location. Of the 29 real estate operations leased to Pennant, one senior living operation is located on the same real estate property as a skilled nursing facility that we own and operate.
The following table summarizes our affiliated facilities and operational skilled nursing beds and senior living units by ownership status as of June 30, 2022:
Owned and OperatedLeased (with a Purchase Option)Leased (without a Purchase Option)Total for Facilities Operated
Number of facilities71 11 169 251 
Percentage of total28.3 %4.4 %67.3 %100.0 %
Operational skilled nursing beds7,014 1,145 17,390 25,549 
Percentage of total27.5 %4.5 %68.0 %100.0 %
Senior living units1,649 178 1,146 2,973 
Percentage of total55.5 %6.0 %38.5 %100.0 %
Ensign is a holding company with no direct operating assets, employees or revenues. Our operating subsidiaries are operated by separate, independent entities, each of which has its own management, employees and assets. In addition, certain of our wholly-owned subsidiaries, referred to collectively as the Service Center, provide centralized accounting, payroll, human resources, information technology, legal, risk management and other centralized services to the other operating subsidiaries through contractual relationships with such subsidiaries. We also have a wholly-owned captive insurance subsidiary that provides some claims-made coverage to our operating subsidiaries for general and professional liability, as well as coverage for certain workers’ compensation insurance liabilities and our captive real estate trust owns and operates our real estate portfolio. Our captive real estate investment trust, Standard Bearer, owns and manages our real estate business. References herein to the consolidated “Company” and “its” assets and activities, as well as the use of the terms “we,” “us,” “our” and similar terms in this Quarterly Report, are not meant to imply, nor should they be construed as meaning, that The Ensign Group, Inc. has direct operating assets, employees or revenue, or that any of the subsidiaries are operated by The Ensign Group.
Recent Activities
Revolving Credit Facility Amendment On April 8, 2022, we entered into the Second Amendment to the Third Amended and Restated Credit Facility (such agreement, the Amended Credit Agreement, and the revolving credit facility thereunder, the Revolving Credit Facility), which increased the Revolving Credit Facility by $250.0 million to an aggregate principal amount of up to $600.0 million. Pursuant to the Amended Credit Agreement, the Company transitioned from the London Interbank Offered Rate (LIBOR) to the Secured Overnight Financing Rate (SOFR) as the applicable reference rate for borrowings under the Revolving Credit Facility. The maturity date of the Amended Credit Facility is April 8, 2027. Borrowings are supported by a lending consortium arranged by Truist Securities (Truist). The interest rates applicable to loans under the Revolving Credit Facility are, at our option, equal to either a base rate plus a margin ranging from 0.25% to 1.25% per annum or SOFR plus a margin range from 1.25% to 2.25% per annum, based on the Consolidated Total Net Debt to Consolidated EBITDA ratio (as defined in the Amended Credit Agreement). In addition, we will pay a commitment fee on the unused portion of the commitments, which will range from 0.20% to 0.40% per annum, depending on the Consolidated Total Net Debt to Consolidated EBITDA ratio. As part of the entry into the Amended Credit Agreement, deferred financing costs of $0.6 million were written off and additional deferred financing costs of $3.2 million were capitalized during the three months ended June 30, 2022.
35

Captive Real Estate Investment Trust In January of 2022, we formed Standard Bearer Healthcare REIT, Inc. or Standard Bearer, a captive REIT. Standard Bearer is a holding company with subsidiaries that own most of our real estate portfolio. We expect the REIT structure will allow us to better demonstrate the growing value of our owned real estate and provides us with an efficient vehicle for future acquisitions of properties that could be operated by Ensign affiliates or other third parties. We believe this structure will give us new pathways to growth with transactions we would not have considered in the past. Standard Bearer intends to qualify and elects to be taxed as a REIT, for U.S. federal income tax purposes, commencing with its taxable year ending December 31, 2022.
The real estate portfolio in Standard Bearer consists of a select 95 of our 100 owned real estate properties. Of the 95 owned real estate properties in Standard Bearer, 67 facilities are operated by Ensign operating subsidiaries and 29 facilities are leased to and operated by Pennant. Of the 29 real estate operations leased to Pennant, one senior living operation is located on the same real estate property as a skilled nursing facility that we own and operate. During six months ended June 30, 2022, we acquired the real estate of two skilled nursing facilities for a purchase price of $17.4 million and leased these facilities to certain of our operating subsidiaries through the Standard Bearer Master Leases. Subsequent to June 30, 2022, we expanded our real estate portfolio with the addition of five skilled nursing properties and one campus property with an estimated total purchase price of $47.9 million.
As of June 30, 2022, the fair value of Standard Bearer's real estate portfolio is more than $1.0 billion. The fair value was determined by a third party independent valuation specialist and incorporated each property's rental income, capitalization rate, rental yield rate and discount rate.
In January 2022, as part of the formation of Standard Bearer, certain of our operating subsidiaries and the 67 Standard Bearer subsidiaries entered into five "triple-net" master lease agreements (collectively, the Standard Bearer Master Leases). The lease period ranges from 15 to 19 years with three five-year renewal options beyond the initial term, on the same terms and conditions. The rent structure under the Standard Bearer Master Leases includes a fixed component, subject to annual escalation equal to the lesser of (1) the percentage change in the Consumer Price Index (but not less than zero) or (2) 2.5%. In addition to rent, the operating subsidiaries are required to pay the following: (1) all impositions and taxes levied on or with respect to the leased properties (other than taxes on the income of the lessor); (2) all utilities and other services necessary or appropriate for the leased properties and the business conducted on the leased properties; (3) all insurance required in connection with the leased properties and the business conducted on the leased properties; (4) all facility maintenance and repair costs; and (5) all fees in connection with any licenses or authorizations necessary or appropriate for the leased properties and the business conducted on the leased properties. Total annual rental income under the Standard Bearer Master Lease is approximately $55.7 million. In addition, as we expand our real estate portfolio through our acquisition strategy, we anticipate that the acquired real estate will be included in Standard Bearer.
Standard Bearer has no employees. Personnel and services provided to Standard Bearer by the Service Center are pursuant to the management agreement between Standard Bearer and the Service Center. The management agreement provides for a base management fee and an incentive management fee, payable in cash, among other terms. The base management fee for each applicable period is equal to 5.0% of the total revenue of Standard Bearer. The incentive management fee is equal to 5.0% of funds from operations (FFO) and is capped at 1.0% of total revenue. In addition, operating expenses incurred by the Service Center on Standard Bearer's behalf, which includes the cost of legal, tax, consulting, accounting and other similar services rendered by the Service Center, its advisers or other third parties, are reimbursed by Standard Bearer. During the three and six months ended June 30, 2022, the Service Center management fee was $1.1 million and $2.1 million, respectively, both of which represent 6% of total Standard Bearer rental revenue.
Standard Bearer will obtain its funding through various sources including operating cash flows, access to debt arrangements and intercompany loans. The intercompany debt arrangements include mortgage loans and the Revolving Credit Facility to fund acquisitions and working capital needs. As part of the Amended Credit Agreement discussed in Note 16, Debt, the interest rates applicable to loans under the Revolving Credit Facility were amended, such that the rates are, at the Company's option, equal to either a base rate plus a margin ranging from 0.25% to 1.25% per annum or SOFR plus a margin range from 1.25% to 2.25% per annum. As of June 30, 2022, there is $36.8 million outstanding under the intercompany credit revolver. There is also an intercompany mortgage loan amount of $93.0 million which is subject to a fixed interest rate. In addition, third party debt held by the Department of Housing and Urban Development (HUD) mortgage loans and promissory notes outstanding in an aggregate amount of $158.3 million, and are included in Standard Bearer.

36

During the three months ended June 30, 2022, Standard Bearer established shareholders of its preferred shares through contributions of cash of $0.1 million. These preferred shares were fully vested at the time of the contributions by the shareholders. In addition, as part of the formation of Standard Bearer in January of 2022, we established the Standard Bearer Healthcare REIT, Inc. 2022 Omnibus Incentive Plan (Standard Bearer Equity Plan). During the three months ended June 30, 2022, Standard Bearer sold fully vested common shares from the Standard Bearer Equity Plan to shareholders for cash of $6.5 million. We did not grant any stock options nor restricted shares during the three and six months ended June 30, 2022.
Coronavirus UpdateWe are continuing to closely monitor the impact of the global COVID-19 pandemic on our business. In July 2022, the public health emergency (PHE) was extended through October 13, 2022. Our primary focus continues to be the health and safety of our patients, residents, employees and their respective families. We continue to implement measures necessary to provide the safest possible environment within our sites of service, taking into consideration the vulnerable nature of our patients and the unique exposure risks of our staff.
We continue to execute on key initiatives to rebuild occupancy lost due to the pandemic. During the second quarter of 2022, our combined Same Facilities and Transitioning Facilities occupancy increased by 2.6% compared to second quarter of 2021 and 0.9% compared to the first quarter of 2022. The improvements in occupancy were due to our operations developing innovative approaches to confront the occupancy declines, including strategic partnerships with upstream and downstream continuum partners and increasing clinical competencies to treat high-acuity patients, including those that are COVID-19 positive. Additionally, we have seen increases in hospital volumes for surgeries. Even with COVID-19 demands waning, the partnerships developed during the pandemic will continue to benefit us into the future. By strengthening existing partnerships, creating new partnerships and most importantly, demonstrating clinical capabilities and favorable outcomes, our census has continued to stabilize. We believe our operations are primed to rebuild occupancies and continue to gain additional market share as a result of relationships with acute care providers and other health care partners.
We did not receive any provider relief fund distributions (Provider Relief Fund) from the Coronavirus Aid, Relief and Economic Security Act of 2020 (the CARES Act) from the federal government during the three and six months ended June 30, 2022. To date, we have returned all Provider Relief Funds that we received and repaid all of the Medicare Accelerated and Advance Payment Program funds received.
During the three and six months ended June 30, 2022, we received an additional $27.3 million and $44.7 million in state relief funding, respectively, and recognized $24.5 million and $42.1 million as revenue, respectively. During the three and six months ended June 30, 2021, we received an additional $16.8 million and $32.4 million in state relief funding and recognized $16.7 million and $33.2 million, respectively, as revenue. See Note 3, COVID-19 Update in the Notes to the Unaudited Condensed Consolidated Financial Statements.
The CARES Act also provides for deferred payment of the employer portion of social security taxes through the end of 2020, with 50% of the deferred amount paid by December 31, 2021 and the remaining 50% payable by December 31, 2022. We recorded $48.3 million of deferred payments of social security taxes as a liability in 2020, of which $24.2 million was paid out in the fourth quarter of 2021 and the remaining liabilities will be paid in the fourth quarter of 2022.
Common Stock Repurchase ProgramOn February 9, 2022, the Board of Directors approved a stock repurchase program pursuant to which we could repurchase up to $20.0 million of our common stock under the program for a period of approximately 12 months from February 10, 2022. During the three months ended June 30, 2022, we repurchased 0.3 million shares of our common stock for $20.0 million. This repurchase program expired upon the repurchase of the fully authorized amount under the plan. On July 28, 2022, the Board of Directors approved a stock repurchase program pursuant to which we may repurchase up to $20.0 million of our common stock under the program for a period of approximately 12 months beginning August 2, 2022.

37

Facility Information
The following table sets forth the location of our operated and owned facilities by type as well as the number of beds and units located at operated and owned facilities as of June 30, 2022:
TXCAAZUTCOWAIDNEIASCWINVKSTotal
Number of operated facilities
Skilled nursing operations65 50 29 18 14 13 11 — 215 
Senior living operations— — — — — — — 11 
Campuses(1)
— — — — 25 
Number of operated beds/units
Operational skilled nursing beds8,350 5,296 4,400 1,991 1,303 1,227 984 413 368 424 100 92 601 25,549 
Senior living units505 197 718 163 725 98 21 302 31 — — — 213 2,973 
Number of owned and operated facilities
Skilled nursing properties16 — — — 56 
Senior living communities— — — — — — — — — — 
Campuses(1)
— — — — — — — — — 10 
Number of owned and operated beds/units
Owned skilled nursing beds2,012 848 1,494 684 346 204 454 88 — 424 100— 360 7,014 
Owned Senior living units439 42 315 — 461 — — 263 — — — — 129 1,649 
Number of owned and not operated facilities
Senior living properties— — — — — — — 19— 29 
(1) Campuses represent facilities that offer both skilled nursing and senior living services.
During the six months ended June 30, 2022, we expanded our operations and real estate portfolio through a combination of long-term leases and real estate purchases, with the addition of four stand-alone skilled nursing operations. Of these additions, Standard Bearer acquired the real estate of two of the stand-alone skilled nursing operations, which were leased back to Ensign affiliated entities. In addition, we added five senior living operations that were transferred from Pennant, three of which are part of campuses operated by our affiliated operating subsidiaries. These new operations added a total of 453 operational skilled nursing beds and 633 operational senior living units to be operated by our affiliated operating subsidiaries. We also invested in new ancillary services that are complementary to our existing businesses.
Subsequent to June 30, 2022, we expanded our operations through a combination of long-term leases and real estate purchases, with the addition of seven stand-alone skilled nursing operations and one campus operation. Of these additions, Standard Bearer acquired the real estate of three of these operations, which were leased back to Ensign affiliated entities. These new operations added 1,100 operational skilled nursing beds and 61 operational senior living units to be operated by our affiliated operating subsidiaries. In addition, we purchased the real estate of three skilled nursing properties which our affiliated operating subsidiaries already operated, further expanding our real estate portfolio.
For further discussion of our acquisitions, see Note 7, Standard Bearer and Note 9, Operation Expansions in the Notes to the Unaudited Condensed Consolidated Financial Statements.

38

Key Performance Indicators
We manage the fiscal aspects of our business by monitoring key performance indicators that affect our financial performance. Revenue associated with these metrics is generated based on contractually agreed-upon amounts or rate, excluding the estimates of variable consideration under the revenue recognition standard, Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) Topic 606. These indicators and their definitions include the following:
Skilled Services
Routine revenue Routine revenue is generated by the contracted daily rate charged for all contractually inclusive skilled nursing services. The inclusion of therapy and other ancillary treatments varies by payor source and by contract. Services provided outside of the routine contractual agreement are recorded separately as ancillary revenue, including Medicare Part B therapy services, and are not included in the routine revenue definition.
Skilled revenue - The amount of routine revenue generated from patients in the skilled nursing facilities who are receiving higher levels of care under Medicare, managed care, Medicaid, or other skilled reimbursement programs. The other skilled patients who are included in this population represent very high acuity patients who are receiving high levels of nursing and ancillary services which are reimbursed by payors other than Medicare or managed care. Skilled revenue excludes any revenue generated from our senior living services.
Skilled mix The amount of our skilled revenue as a percentage of our total skilled nursing routine revenue. Skilled mix (in days) represents the number of days our Medicare, managed care, or other skilled patients are receiving skilled nursing services at the skilled nursing facilities divided by the total number of days patients from all payor sources are receiving skilled nursing services at the skilled nursing facilities for any given period.
Average daily rates The routine revenue by payor source for a period at the skilled nursing facilities divided by actual patient days for that revenue source for that given period. These rates exclude additional state relief funding, which includes payments we recognized as part of The Family First Coronavirus Response Act.
Occupancy percentage (operational beds) The total number of patients occupying a bed in a skilled nursing facility as a percentage of the beds in a facility which are available for occupancy during the measurement period.
Number of facilities and operational beds The total number of skilled nursing facilities that we own or operate and the total number of operational beds associated with these facilities.
Skilled Mix Like most skilled nursing providers, we measure both patient days and revenue by payor. Medicare, managed care and other skilled patients, whom we refer to as high acuity patients, typically require a higher level of skilled nursing and rehabilitative care. Accordingly, Medicare and managed care reimbursement rates are typically higher than from other payors. In most states, Medicaid reimbursement rates are generally the lowest of all payor types. Changes in the payor mix can significantly affect our revenue and profitability.

The following table summarizes our overall skilled mix from our skilled nursing services for the periods indicated as a percentage of our total skilled nursing routine revenue and as a percentage of total skilled nursing patient days:
Three Months Ended June 30,Six Months Ended June 30,
Skilled Mix:2022202120222021
Days31.1 %30.9 %32.4 %32.6 %
Revenue50.9 %51.4 %52.6 %53.5 %
Occupancy We define occupancy derived from our skilled services as the ratio of actual patient days (one patient day equals one patient occupying one bed for one day) during any measurement period to the number of beds in facilities which are available for occupancy during the measurement period. The number of beds in a skilled nursing facility that are actually operational and available for occupancy may be less than the total official licensed bed capacity. This sometimes occurs due to the permanent dedication of bed space to alternative purposes, such as enhanced therapy treatment space or other desirable uses calculated to improve service offerings and/or operational efficiencies in a facility. In some cases, three- and four-bed wards have been reduced to two-bed rooms for resident comfort, and larger wards have been reduced to conform to changes in Medicare requirements. These beds are seldom expected to be placed back into service. We believe that reporting occupancy based on operational beds is consistent with industry practices and provides a more useful measure of actual occupancy performance from period to period.

39

The following table summarizes our overall occupancy statistics for skilled nursing operations for the periods indicated:
Three Months Ended June 30,Six Months Ended June 30,
Occupancy for skilled services:2022202120222021
Operational beds at end of period25,549 24,486 25,549 24,486 
Available patient days2,321,233 2,200,536 4,606,279 4,322,632 
Actual patient days1,745,027 1,599,707 3,440,991 3,109,307 
Occupancy percentage (based on operational beds)75.2 %72.7 %74.7 %71.9 %
Segments
We have two reportable segments: (1) skilled services, which includes the operation of skilled nursing facilities and rehabilitation therapy services and (2) Standard Bearer, which is comprised of selected properties owned by us through our captive REIT and leased to skilled nursing and senior living operations, including our own operating subsidiaries and third party operators.
We also reported an “all other” category that includes operating results from our senior living operations, mobile diagnostics, transportation, other real estate and other ancillary operations. These businesses are neither significant individually, nor in aggregate and therefore do not constitute a reportable segment. Our Chief Executive Officer, who is our chief operating decision maker, or CODM, reviews financial information at the operating segment level.
Revenue Sources

The following table sets forth our total service revenue by payor source generated by our skilled services segment and other service revenue and as a percentage of total revenue for the periods indicated (dollars in thousands):
 Three Months Ended June 30,
Skilled Services Other Service RevenueTotal Service Revenue
202220212022202120222021
Medicaid(1)
$287,827 $247,671 $6,301 $3,784 $294,128 $251,455 
Medicare190,494 170,008 — — 190,494 170,008 
Medicaid-skilled49,763 42,740 — — 49,763 42,740 
Subtotal528,084 460,419 6,301 3,784 534,385 464,203 
Managed care128,587 112,963 — — 128,587 112,963 
Private and other(2)
45,807 39,500 19,568 17,943 65,375 57,443 
TOTAL SERVICE REVENUE $702,478 $612,882 $25,869 $21,727 $728,347 $634,609 
 Three Months Ended June 30,
Skilled Services Other Service RevenueTotal Service Revenue
202220212022202120222021
Medicaid(1)
41.0 %40.4 %24.4 %17.4 %40.4 %39.6 %
Medicare27.1 27.7 — — 26.2 26.8 
Medicaid-skilled7.1 7.0 — — 6.8 6.7 
Subtotal75.2 75.1 24.4 17.4 73.4 73.1 
Managed care18.3 18.4 — — 17.7 17.8 
Private and other(2)
6.5 6.5 75.6 82.6 8.9 9.1 
TOTAL SERVICE REVENUE100.0 %100.0 %100.0 %100.0 %100.0 %100.0 %
(1) Medicaid payor includes revenue generated from senior living operations and revenue related to FMAP.
(2) Private and other payors also includes revenue from senior living operations and all payors generated in other ancillary services.
40

 Six Months Ended June 30,
Skilled ServicesOtherTotal Service Revenue
202220212022202120222021
Medicaid(1)
$549,414 $475,412 $11,062 $7,401 $560,476 $482,813 
Medicare398,905 360,311 — — 398,905 360,311 
Medicaid-skilled95,712 82,733 — — 95,712 82,733 
Subtotal1,044,031 918,456 11,062 7,401 1,055,093 925,857 
Managed care256,373 221,308 — — 256,373 221,308 
Private and other(2)
88,845 74,154 37,192 36,566 126,037 110,720 
TOTAL SERVICE REVENUE$1,389,249 $1,213,918 $48,254 $43,967 $1,437,503 $1,257,885 
 Six Months Ended June 30,
Skilled ServicesOtherTotal Service Revenue
202220212022202120222021
Medicaid(1)
39.5 %39.2 %22.9 %16.8 %39.0 %38.4 %
Medicare28.7 29.7 — — 27.7 28.6 
Medicaid-skilled6.9 6.8 — — 6.7 6.6 
Subtotal75.1 75.7 22.9 16.8 73.4 73.6 
Managed care18.5 18.2 — — 17.8 17.6 
Private and other(2)
6.4 6.1 77.1 83.2 8.8 8.8 
TOTAL SERVICE REVENUE100.0 %100.0 %100.0 %100.0 %100.0 %100.0 %
(1) Medicaid payor includes revenue generated from senior living operations and revenue related to FMAP.
(2) Private and other payors also includes revenue from senior living operations and all payors generated in other ancillary services.
Skilled Services

Within our skilled nursing operations, we generate revenue from Medicaid, private pay, managed care and Medicare payors. We believe that our skilled mix, which we define as the number of days Medicare, managed care and other skilled patients are receiving services at our skilled nursing operations divided by the total number of days patients are receiving services at our skilled nursing operations, from all payor sources (less days from senior living services) for any given period, is an important indicator of our success in attracting high-acuity patients because it represents the percentage of our patients who are reimbursed by Medicare, managed care and other skilled payors, for whom we receive higher reimbursement rates.

We are participating in supplemental payment programs in various states that provide supplemental Medicaid payments for skilled nursing facilities that are licensed to non-state government-owned entities such as city and county hospital districts. Numerous operating subsidiaries entered into transactions with various hospital districts providing for the transfer of the licenses for those skilled nursing facilities to the hospital districts. Each affected operating subsidiary agreement between the hospital district and our subsidiary is terminable by either party to fully restore the prior license status.
Standard Bearer
We generate rental revenue primarily by leasing post-acute care properties we acquired to healthcare operators under triple-net lease arrangements, whereby the tenant is solely responsible for the costs related to the property, including property taxes, insurance, and maintenance and repair costs, subject to certain exceptions. As of June 30, 2022, our real estate portfolio within Standard Bearer is comprised of 95 real estate properties. Of these properties, 67 are leased to affiliated skilled nursing facilities wholly-owned and managed by us and 29 are leased to senior living operations wholly-owned and managed by Pennant. Of the 29 real estate operations leased to Pennant, one senior living operation is located on the same real estate property as a skilled nursing facility that we own and operate. During the three and six months ended June 30, 2022, we generated rental revenues of $17.6 million and $34.8 million, respectively, of which $13.9 million and $27.3 million, respectively, was derived from affiliated wholly-owned healthcare operators, and therefore eliminated in consolidation.

41

Other

Within our senior living operations, we generate revenue primarily from private pay sources, with a portion earned from Medicaid payors or through other state-specific programs. In addition, we hold majority membership interests in our other ancillary operations. Payment for these services varies and is based upon the service provided. The payment is adjusted for an inability to obtain appropriate billing documentation or authorizations acceptable to the payor and other reasons unrelated to credit risk.
Critical Accounting Estimates

Our condensed consolidated financial statements included in this report have been prepared in accordance with accounting principles generally accepted in the United States of America (U.S. GAAP). The preparation of these financial statements requires management to make judgments, estimates and assumptions that affect the reported amounts of assets, liabilities, cash flows, revenues and expenses, and related disclosure of contingent assets and liabilities.

See Item 2., Management’s Discussion and Analysis of Financial Condition and Results of Operations, in our Annual Report on Form 10-K for the fiscal year ended December 31, 2021 for further discussion of critical accounting estimates. There were no material changes to our critical accounting policies with which the estimates are developed since December 31, 2021.
Industry Trends
The post-acute care industry has evolved to meet the growing demand for post-acute and custodial healthcare services generated by an aging population, increasing life expectancies and the trend toward shifting patient care to lower cost settings. The industry has evolved in recent years, which we believe has led to a number of favorable improvements in the industry, as described below:
Shift of Patient Care to Lower Cost Alternatives The growth of the senior population in the U.S. continues to increase healthcare costs, often faster than the available funding from government-sponsored healthcare programs. In response, federal and state governments have adopted cost-containment measures that encourage the treatment of patients in more cost-effective settings such as skilled nursing facilities, for which the staffing requirements and associated costs are often significantly lower than acute care hospitals and other post-acute care settings. As a result, skilled nursing facilities are generally serving a larger population of higher-acuity patients than in the past.
Significant Acquisition and Consolidation Opportunities The skilled nursing industry is large and highly fragmented, characterized predominantly by numerous local and regional providers. Due to the increasing demands from hospitals and insurance carriers to implement sophisticated and expensive reporting systems, we believe this fragmentation provides us with significant acquisition and consolidation opportunities.
Improving Supply and Demand Balance The number of skilled nursing facilities has declined modestly over the past several years. We expect that the supply and demand balance in the skilled nursing industry will continue to improve due to the shift of patient care to lower cost settings, an aging population and increasing life expectancies.
Increased Demand Driven by Aging Populations As seniors account for an increasing percentage of the total U.S. population, we believe the demand for skilled nursing and senior living services will continue to increase. According to the census projection released by the U.S. Census Bureau in early 2020, between 2016 and 2030, the number of individuals over 65 years old is projected to be one of the fastest growing segments of the United States population, growing from 16% to 21%. The Bureau expects this segment to increase nearly 50% to 73 million, as compared to the total U.S. population which is projected to increase by 10% over that time period. Furthermore, the generation currently retiring has accumulated less savings than prior generations, creating demand for more affordable senior housing and skilled nursing services. As a high-quality provider in lower cost settings, we believe we are well-positioned to benefit from this trend.
Transition to Value-Based Payment Models In response to rising healthcare spending in the United States, commercial, government and other payors are generally shifting away from fee-for-service payment models towards value-based models, including risk-based payment models that tie financial incentives to quality, efficiency and coordination of care. We believe that patient-centered outcomes driven reimbursement models will continue to grow in prominence. Many of our operations already receive value-based payments, and as valued-based payment systems continue to increase in prominence, it is our view that our strong clinical outcomes will be increasingly rewarded.

42

Accountable Care Organizations and Reimbursement Reform A significant goal of U.S. federal health care reform is to transform the delivery of health care by changing reimbursement to reflect and support the quality and safety of care that providers deliver, increase efficiency, and reduce growth in spending. Reimbursement models that provide financial incentives to encourage efficiency, affordability, and high-quality care have been developed and implemented by government and commercial third-party payers. The most prolific of these models, the Accountable Care Organization (ACO) model, incentivizes groups of providers to share in savings that are achieved through the coordination of care and chronic disease management of an assigned patient population.  Reimbursement methodology reform includes Value-Based Purchasing (VBP), in which a portion of provider reimbursement is redistributed based on relative performance, or improvement on designated economic, clinical quality, and patient satisfaction metrics.  In addition, the Centers for Medicare and Medicaid Services (CMS) has implemented Episode-based demonstration, voluntary and mandatory payment initiatives that bundle acute care and post-acute care reimbursement. These bundled payment models incentivize cross-continuum care coordination and include financial and performance accountability for episodes of care. These reimbursement methodologies and similar programs are likely to continue and expand, both in government and commercial health plans. Many of our operations already participate in ACOs. With our focus on quality care and strong clinical outcomes, Ensign is well-positioned to benefit from these outcome-based payment models.
We believe the post-acute industry has been and will continue to be impacted by several other trends. The use of long-term care (LTC) insurance is increasing among seniors as a means of planning for the costs of skilled nursing services. In addition, as a result of increased mobility in society, reduction of average family size, and the increased number of two-wage earner couples, more residents are looking for alternatives outside the family for their care.

GOVERNMENT REGULATION
General
Healthcare is an area of extensive and frequent regulatory change. Changes in the law or new interpretations of existing laws may have a significant impact on revenue, costs and business operations. Our independent operating subsidiaries that provide healthcare services are subject to federal, state and local laws relating to, among other things, licensure, quality and adequacy of care, physical plant requirements, life safety, personnel and operating policies. In addition, these same subsidiaries are subject to federal and state laws that govern billing and reimbursement, relationships with vendors, business relationships with physicians, and workplace protection for healthcare staff. Such laws include the Anti-Kickback Statute (AKS), the federal False Claims Act (FCA), the Stark Law, the Health Care Emergency Temporary Standard, and state corporate practice of medicine statutes.
Governmental and other authorities periodically inspect the skilled nursing facilities (SNFs), senior living facilities and outpatient rehabilitation agencies of our independent operating subsidiaries to verify continued compliance with applicable regulations and standards. The operations must pass these inspections to remain licensed under state laws and to comply with Medicare and Medicaid provider agreements. The operations can only participate in these third-party payment programs if inspections by regulatory authorities reveal that the operations are in substantial compliance with applicable state and federal requirements. In the ordinary course of business, federal or state regulatory authorities may issue notices to the operations alleging deficiencies in certain regulatory practices. These statements of deficiency may require corrective action to regain and maintain compliance. In some cases, federal or state regulators may impose other remedies including imposition of civil monetary penalties, temporary payment bans, loss of certification as a provider in the Medicare or Medicaid program, or revocation of a state operating license.
We believe that the regulatory environment surrounding the healthcare industry subjects providers to intense scrutiny. In the ordinary course of business, providers are subject to inquiries, investigations and audits by federal and state agencies related to compliance with participation and payment rules under government payment programs. These inquiries may originate from the United States Department of Health and Human Services (HHS) Office of the Inspector General (OIG), state Medicaid agencies, state Attorney Generals, local and state ombudsman offices and CMS Recovery Audit Contractors, among other agencies. In response to the inquiries, investigations and audits, federal and state agencies continue to impose citations for regulatory deficiencies and other regulatory penalties, including demands for refund of overpayments, expanded civil monetary penalties that extend over long periods of time and date back to incidents prior to surveyor visits, Medicare and Medicaid payment bans and terminations from the Medicare and Medicaid programs, which may be temporary or permanent in nature. We vigorously contest each such regulatory outcome when appropriate; however, there are significant legal and other expenses involved that consume our financial and personnel resources. Expansion of enforcement activity could adversely affect our business, financial condition or the results of operations.
43

Coronavirus
In an effort to promote efficient care delivery and to decrease the spread of COVID-19, federal, state and local regulators have implemented new regulations and waived (in some cases, temporarily) certain existing regulations, including those set forth below.
Temporary suspension of certain patient coverage criteria and documentation and care requirements - The Coronavirus Aid, Relief, and Economic Security Act of 2020 (the CARES Act) and a series of temporary waivers and guidance issued by CMS suspended various Medicare patient coverage criteria to ensure patients continue to have adequate access to care, notwithstanding the burdens placed on healthcare providers as related to the COVID-19 pandemic. Many of these regulatory waivers were issued pursuant to Section 1135 of the Social Security Act, which authorizes the HHS Secretary to temporarily waive or modify Medicare and Medicaid requirements for affected health care providers and facilities following the declaration of a PHE (Section 1135 Waivers). HHS also waived requirements specific to SNFs pursuant to its authority under Section 1812(f) of the Social Security Act (Section 1812(f) Waiver, and together with the Section 1135 Waivers, the Emergency Waivers).

Pursuant to the Emergency Waivers, CMS also authorized temporary waivers on medical review requirements, effective March 1, 2020. In addition, in March of 2020, CMS also downgraded the priority for scheduled program audits and contract-level Risk Adjustment Data Validation audits for Medicare Advantage organizations, Part D sponsors, Medicare-Medicaid Plans, and Programs of All-Inclusive Care for the Elderly organizations. Reducing the priority of those standard or scheduled audit activities allows providers, CMS and other organizations to focus on patient care, including directing audit activities toward infection control. CMS stated that this reprioritization of its audit activities would be time-limited and it would announce when normal activities would resume after the end of the PHE.
Beginning on May 7, 2021, CMS started to end certain Emergency Waivers related to the COVID-19 pandemic, beginning with waivers regarding data reporting and resident grouping, transfer, and discharge. On April 7, 2022, CMS announced the expiration of additional Emergency Waivers in place for SNF and LTC facilities, with other Emergency Waivers for other residential facilities other than hospitals and critical access hospitals, that expired on June 6, 2022.
The first group of seven (7) Emergency Waivers that expired on May 7, 2022 were: (1) waiver of the requirement that residents participate in-person during resident groups; (2) physicians’ ability to delegate tasks that otherwise would need to be personally performed by a physician within a SNF; (3) waiver of the requirement for physicians to make personal visits to patients, which the Emergency Waivers allow physicians to delegate to other clinicians; (4) waiver of the requirement for physicians and non-physician providers to conduct in-person visits to nursing home residents (and allowing those visits to be made via telemedicine as appropriate); (5) reducing LTC facilities’ requirements to develop, implement and maintain a Quality Assurance and Performance Improvement (QAPI) program that satisfies federal standards; (6) waiver of LTC facilities’ obligation to participate in discharge planning for residents ending their care at the facility; and (7) waiver of the requirement for LTC facilities to provide residents with a copy of their records within two working days of a resident’s request for those records.
The Emergency Waivers that expired on June 6, 2022 were: (1) waivers of SNF physical environment conditions for temporary use facilities (including COVID-19 treatment locations) and use of interior or non-residential space within a SNF to accommodate residents; (2) waivers of requirements for timely preventative maintenance for certain equipment, including dialysis equipment; (3) the waiver of inspection, testing and maintenance for the facilities and medical equipment used within ICFs and SNFs; (4) the waiver of inspection, testing, and maintenance for compliance with applicable life safety codes and health care facility codes for intermediate care facilities (ICFs) and SNFs; (5) the waiver of CMS’s requirement for ICFs and SNFs to have an exterior door or window in every room used for sleeping; (6) life safety code waivers of quarterly fire drills and allowing SNFs to erect temporary walls and barriers between patients; (7) waiving CMS’s minimum training requirements for paid feeding assistants in LTC facilities; (8) CMS’s waiver of its requirement for nurse aides within SNFs to receive at least 12 hours of annual in-service training; and (9) the waiver of an SNF’s normal obligation not to employ any nursing aid longer than 4 months if he or she does not satisfy federal training and certification requirements.
Select Emergency Waivers, including the three-day inpatient hospital qualifying stay, remain in effect. As patients qualify for skill-in-place for Medicare Part A stays, we could see a decrease in LTC Medicare Part B programs. There may be additional or other Emergency Waivers that will be terminated or allowed to expire, though; this expiration may occur quickly and with little public notice. Due to the prevalence of waves of COVID-19 variants in 2021 and continuing into 2022, it is unclear when the remaining Emergency Waivers will expire, or whether previously expired Emergency Waivers will be reinstated, as CMS has not announced the expiration of additional Emergency Waivers since its April 7, 2022 memorandum.
44

Examples of the Emergency Waivers still in effect as of July 1, 2022 include, but are not limited to the following: (1) approving temporary transfer, discharge, and cohorting of patients to ensure that facilities can separate COVID-19 negative patients from those that are positive for or have been exposed to the virus; (2) allowing SNFs to provide a skill-in-place program for Medicare beneficiaries who are residents of the SNFs that meet the skill-in-place criteria, foregoing the usual three-day qualifying hospital stay; (3) waiving the requirement for LTC facilities' directors of food and nutrition services to have specified higher education or other credentials in the areas of food service and management and safety; and (4) temporarily waiving certain documentation and reporting requirements regarding patient admission, transfer, and discharge (e.g., Patients Over Paperwork). Some States have also waived regulations to ease regulatory burdens on the healthcare industries. It remains uncertain when federal and state regulators will resume enforcement of those regulations, which remain waived or are otherwise not being enforced during the PHE. We believe these regulatory actions could contribute to changes in skilled mix, which may have been different without the existence of the Emergency Waivers.
Resuming visitation and resident rights — CMS has issued guidance to facilities throughout the PHE regarding patients’ rights to visitation. While the CMS guidance issued in March 2020 directed facilities to severely restrict visitation, CMS has subsequently provided guidance through the course of the pandemic (and most recently updated on March 10, 2022) that broadens visitation and provides guidance on visitation procedures.
Testing requirements — Beginning in April 2020, authorities in several states in which our independent operating subsidiaries are located began to mandate widespread COVID-19 testing at all nursing home and LTC facilities. This came after the Centers for Disease Control and Prevention (CDC) stated that older adults are at a higher risk for serious illness from the coronavirus and issued updated testing guidelines for nursing homes. Some of these states were also publicly reporting COVID-19 outbreaks in facilities. On July 22, 2020, CMS announced that nursing homes in states with a 5% or greater positivity rate for COVID-19 will be required to test all nursing home staff each week. On August 26, 2020, CMS issued new parameters for testing, requiring routine monthly testing of all facility staff if the facility’s county positivity rate is less than 5%; weekly testing if the county positivity rate is between 5% and 10%; and twice weekly testing if the county positivity rate exceeds 10%. On April 27, 2021, CMS again issued revised parameters for testing, specifying that the requirement for routine testing of staff applies only to those staff members that are unvaccinated - fully vaccinated staff do not have to be routinely tested.
Federal and state COVID-19 vaccination requirements — On December 11, 2020, the U.S. Food and Drug Administration (FDA) issued the first emergency use authorization (EUA) for the Pfizer-BioNTech vaccine for the prevention of COVID-19, followed by the second EUA for the use of the Moderna COVID-19 vaccine on December 28, 2020, and the third EUA for the Johnson & Johnson vaccine on February 27, 2021. Pfizer and Moderna's COVID-19 vaccines have since received full FDA approval.
On August 18, 2021, the Administration announced that CMS was developing an emergency regulation requiring all workers within Medicare and Medicaid-participating nursing homes to be vaccinated against COVID-19 as a condition of participation in the Medicare and Medicaid programs. The Administration expanded the scope of this forthcoming emergency regulation on September 9, 2021, and on the same day the Administration announced that OSHA would introduce an emergency temporary standard (ETS) requiring employers with more than 100 employees to mandate that its employees be fully vaccinated against COVID-19 or submit to weekly testing for the virus. Both CMS’s interim final rule (IFR) and OSHA’s ETS for vaccination were challenged in court and halted from enforcement in certain states.
On November 5, 2021, CMS issued the Omnibus COVID-19 Health Care Staff Vaccination IFR, requiring all eligible staff in certain Medicare and Medicaid participating health facilities to complete their one- or two-injection vaccination sequences by or before January 13, 2022. CMS's enforcement of this IFR was temporarily blocked in certain states pending appeal to the United States Supreme Court. By January 20, 2022, decisions of the United States Supreme Court and other courts affirmed CMS’s authority to enforce the IFR in all states, with the last among them, Texas, subject to a deadline of March 21, 2022 for full compliance with the IFR’s vaccination requirements. Additionally, facilities must test any staff or resident, regardless of vaccination status, who has signs or symptoms of COVID-19. In the event of a COVID-19 outbreak in the facility, all staff and residents must be tested at regular intervals until repeat testing identifies no new cases of COVID-19 infection among staff or residents for a 14-day period. Additional guidance may be issued in connection with this IFR. In addition to CMS's testing mandates, some states have imposed additional testing requirements for residents and staff, or are enforcing testing mandates under existing or expanded workplace safety regulations.

45

In addition to the IFR mandating vaccinations for health facility workers, several states where our independent operating facilities are located have issued vaccine mandates that apply to facility staff. These vaccine mandates are largely aligned with the Omnibus COVID-19 Health Care Staff Vaccination IFR. California issued an order on August 5, 2021 (and expanded on September 28, 2021), requiring adult care facilities and direct care workers to be vaccinated as well, and for all affected workers to be fully vaccinated by November 30, 2021. On February 22, 2022, California's Department of Public Health updated its directive to allow workers who had completed their primary vaccination series and contracted COVID-19 since becoming fully vaccinated to defer the receipt of a vaccine booster dose by up to 90 days after infection with COVID-19; otherwise, booster vaccine doses were required to be completed by March 1, 2022.
Reporting requirements Effective May 8, 2020, CMS published an IFR requiring SNFs to report information related to COVID-19 cases among facility residents and staff directly to the CDC National Health Safety Network no less than weekly; the reported information is made publicly available on a dedicated website. In addition, SNFs are required to inform residents, their families and representatives of confirmed or suspected COVID-19 cases in their facilities. This resident/family/representative notification is required to take place by 5:00 p.m. (local time) the next calendar day following the occurrence of: (1) a single confirmed infection of COVID-19, or (2) three or more residents or staff with new-onset of respiratory symptoms that occur within 72 hours of one another.
Effective May 21, 2021, CMS published an IFR requiring LTC facilities to report weekly COVID-19 vaccination data of both residents and staff to the CDC National Healthcare Safety Network. Facilities are also required to provide residents and staff with vaccine education and offer vaccines, when available, to residents and staff. CMS may initiate enforcement activities and assess civil monetary penalties for not meeting any of these COVID-19 related requirements.
Effective June 11, 2021, HHS revised the Post-Payment Notice of Reporting Requirements which are applicable to recipients of Provider Relief Funds. The revised requirements provide additional information on the data elements that recipients are required to report as part of the post-payment reporting process, as well as the timing of such reporting.
Effective August 23, 2021, CMS published an IFR incorporating comments on its May 21, 2021 IFR which continued the obligation for LTC and intermediate care facilities to report COVID-19 vaccination data for both residents and staff to the CDC National Healthcare Safety Network. This new IFR requires facilities to develop policies and procedures to ensure the availability of the COVID-19 vaccine to residents and staff, and to educate residents and staff concerning the benefits, risks, and potential side effects associated with the vaccine. This IFR also addresses responses to vaccination refusal by residents and staff in compliance with U.S. Equal Employment Opportunity Commission guidance. CMS may initiate enforcement activities and assess civil monetary penalties for not meeting any of these COVID-19 related reporting requirements under this IFR. We do not believe these COVID-19 related requirements will have a material impact on our condensed consolidated financial statements.
Survey Activity and Enforcement — On March 20, 2020, CMS announced the initiation of focused infection control surveys intended to assess LTC facility compliance with infection control requirements in connection with the COVID-19 pandemic. CMS prioritized infection control surveys over annual recertification and complaint surveys at the non-immediate jeopardy level, confirming its commitment to infection prevention and control in the skilled nursing industry. Effective August 17, 2020, CMS provided guidance authorizing resumption of traditional survey activity. On June 1, 2020 (and updated in January 2021), CMS introduced an enhanced enforcement program with respect to infection control deficiencies. The program contemplates more significant remedies against facilities with a prior history of infection control deficiencies and imposes more stringent penalties with deficiencies identified at a higher scope and severity. In February of 2022, CMS updated this tool to refocus its attention toward the traditional survey process while preventing the spread of COVID-19 variants, considering the IFR, and amending prior guidance to reflect patients and residents’ rights to receive visitors. The spectrum of remedies available to CMS for imposition on SNFs in connection with this enhancement includes increased monetary fines, shortened time periods to return to compliance, and other administrative penalties.
Medicare
Medicare presently accounts for approximately 28.7% of our skilled nursing services revenue year-to-date, being our second-largest payor. The Medicare program and its reimbursement rates and rules are subject to frequent change. These include statutory and regulatory changes, rate adjustments (including retroactive adjustments), administrative or executive orders and government funding restrictions, all of which may materially adversely affect the rates at which Medicare reimburses us for our services. Budget pressures often lead the federal government to reduce or place limits on reimbursement rates under Medicare. Implementation of these and other types of measures has in the past, and could in the future, result in substantial reductions in our revenue and operating margins.

46

Patient-Driven Payment Model (PDPM)
The Skilled Nursing Facility Prospective Payment System (SNF PPS) Rule became effective October 1, 2019. The SNF PPS Rule includes a new case-mix model that focuses on the patient’s condition (clinically relevant factors) and resulting care needs, rather than on the volume of care provided, to determine Medicare reimbursement. The case mix-model is called the Patient-Driven Payment Model (PDPM), which utilizes clinically relevant factors for determining Medicare payment by using International Classification of Diseases, Tenth Revision diagnosis codes and other patient characteristics as the basis for patient classification. PDPM utilizes five case-mix adjusted payment components: physician therapy, occupational therapy, speech language pathology, nursing and social services and non-therapy ancillary services. It also uses a sixth non-case mix component to cover utilization of SNFs' resources that do not vary depending on resident characteristics.
PDPM replaces the existing case-mix classification methodology, Resource Utilization Groups, Version IV. The structure of PDPM moves Medicare towards a more value-based, unified post-acute care payment system. For example, PDPM adjusts Medicare payments based on each aspect of a resident’s care, thereby more accurately addressing costs associated with medically complex patients. PDPM also removes therapy minutes as the basis for therapy payment. Finally, PDPM adjusts the SNFs' per diem payments to reflect varying costs throughout the stay, through the physician therapy, occupational therapy and non-therapy ancillary services components.
In addition, PDPM is intended to reduce paperwork requirements for performing patient assessments. Under the SNF PPS PDPM system, the payment to SNFs and nursing homes is based heavily on the patient’s condition rather than the specific services provided by each SNF. On August 4, 2021, CMS published the SNF PPS final rule for fiscal year 2022, which included a 1.2% net market basket increase in payment to SNFs, and reduced the negative impact of readmissions for providers with more than 25 stays by returning 60% of the 2% withheld by CMS regardless of that provider’s performance measures. Providers with lower volume and fewer than 25 stays will not have any adjustments made to their payment.
Skilled Nursing Facility - Quality Reporting Program (SNF QRP)
The Improving Medicare Post-Acute Care Transformation Act of 2014 (IMPACT Act) imposed new data reporting requirements for certain Post-Acute-Care (PAC) providers. The IMPACT Act requires that each SNF submit their quality measures data. Beginning with fiscal year 2018, and each subsequent year, if a SNF does not submit required quality data, their payment rates are reduced by 2.0% for each such fiscal year. Application of the 2.0% reduction may result in payment rates for a fiscal year being less than the preceding fiscal year. In addition, reporting-based reductions to the market basket increase factor will not be cumulative; they will only apply for the fiscal year involved. A SNF's MAC will issue the facility a notice of non-compliance if it does not satisfy its Quality Reporting Program reporting requirements.
Updated performance measures mandated for the SNF QRP for fiscal year 2020 were established in the final SNF PPS rule adopted on August 8, 2019 (fiscal year 2020 SNF PPS Rule). The final rule continues implementation of the SNF QRP measures to improve program interoperability, operational quality and safety. Specifically, the rule adopts a number of standardized patient assessment data elements. The SNF QRP applies to freestanding SNFs, SNFs affiliated with acute care facilities, and all non-critical access hospital swing-bed rural hospitals. The additional data elements adopted in the 2020 SNF PPS Rule were retained through the 2022 SNF PPS Rule, although the collection and reporting of this data to CMS is delayed for at least two full fiscal years after the end of the PHE.
On July 29, 2021, CMS issued a final rule for the SNF QRP that adopted two new reporting measures and updated the specifications for another measure. Starting with the FY 2023 SNF QRP, SNFs are required for the first time to report the SNF Healthcare-Associated Infections (HAI) measure, which tracks the number of infections requiring hospitalization following a medical intervention, and the COVID-19 Vaccination Coverage among Healthcare Personnel (HCP) measure, which tracks vaccination of staff in order to assess whether SNFs are taking steps to limit the spread of COVID-19. The Transfer of Healthcare (TOH) information data SNFs must report, which is included in the Patient-Post-Acute Care measurement, will be changed to exclude SNF patients discharged to their homes under the care of either a home health service or hospice. The elimination of this information will change how the TOH is used in calculating Patient-Post-Acute Care measurement, and may have an impact on our quality ratings and reimbursement from Medicare and Medicaid on a prospective basis.
Beginning in March 2020, due to the COVID-19 pandemic, CMS issued a temporary suspension of SNF QRP reporting requirements effective until June 30, 2020. This effectively gave SNFs discretion as to whether to report data from the fourth quarter (October 1, 2019 – December 31, 2019), and removed reporting requirements entirely for the first and second quarters of 2020 (January 1, 2020 – June 30, 2020). SNFs were required to resume timely quality data collection and submission of measure and patient assessment data effective June 30, 2020. In January 2022, SNF ratings based on the resumed data reporting were recalculated for publication on the SNF Care Compare website. SNF Care Compare website ratings based on SNF QRP data reporting were refreshed in April 2022.
47

In July of 2022, CMS announced revisions to calculating its five-star ratings for the Nursing Home Compare website. Under this new calculation, points are assigned to a SNF based on its performance across six measures: (1) case-mix adjusted total nurse staffing levels (including registered nurses, licensed practical nurses, and nursing aides), measured by hours per resident per day; (2) case-mix adjusted registered nurse staffing levels, measured by hours per resident per day; (3) case-mix adjusted total nurse staffing levels (including registered nurses, licensed practical nurses, and nursing aides), measured by hours per resident day on the weekend; (4) total nurse turnover, defined as the percentage of nursing staff that left the nursing home over a 12-month period; (5) registered nurse turnover, defined as the percentage of registered nursing staff that left the nursing home over a 12-month period; and (6) administrator turnover, defined as the percentage of administrators that left the nursing home over a 12-month period. These six measures will be measured on a quarterly basis.
Staff measurements are scored based on the points assigned to these six measures. For case-mix adjusted total nurse staffing and case-mix adjusted registered nurse staffing, each measure is scored on a 100-point scale in 10-point increments. For case-mix adjusted total nurse staffing on weekends, total nurse turnover, and total registered nurse turnover, each measure is scored on a 50-point scale in five-point increments. The measure of administrator turnover is measured on a 30-point scale, with points assigned based on the number of administrator departures during the measurement period. The result of these staffing measures will affect a SNF’s total five-star score reported on the Nursing Home Compare website. These changes are in addition to those previously announced in the January 2022 and April 2022 revisions, and began with the July 2022 refresh of the Nursing Home Compare website.
On July 29, 2022, CMS announced the adoption of a process measure for influenza vaccination coverage among healthcare personnel within SNFs. This measure will be determined by the percentage of SNF healthcare personnel who receive an influence vaccine any time from when it first became available through March 31 of the following year. SNFs will begin submitting this data to CMS through the CDC National Healthcare Safety Network beginning on October 1, 2022 through March 31, 2023.
Additionally, CMS revised certain SNF data reporting requirements, including the transfer of health information measures and certain patient assessment data elements, including ethnicity, preferred language, health literacy, and social isolation, until October 1, 2023.
Medicare Annual Payment Rule
CMS is required to calculate an annual Medicare market-basket update to the payment rates. On July 31, 2020, CMS issued a final rule for fiscal year 2021 that updates the Medicare payment rates and the quality programs for SNFs. Under the final rule, effective October 1, 2020, the aggregate payments to SNFs increased by 2.2% for fiscal year 2021, compared to fiscal year 2020. This estimated increase is attributable to a 2.2% market basket increase factor.
On July 29, 2021, CMS issued a final rule for fiscal year 2022 that updates the Medicare payment rates and the quality programs for SNFs. Under the final rule, effective October 1, 2021, the aggregate net market basket rate increased by 1.2% for fiscal year 2022, compared to fiscal year 2021. This increase is attributable to a 2.7% market basket increase factor with a 0.8% point reduction for forecast error adjustment and a 0.7% point reduction for multifactor productivity adjustment.
On July 29, 2022, CMS issued a final rule for fiscal year 2023 that updates the Medicare payment rates to aggregate net market basket increased by 2.7%. The increase is resulted from the 5.1% update to the payment rates, which is based on a 3.9% market basket increase plus a 1.5% point market basket error adjustment and less a 0.3% point productivity adjustment as well as a negative 2.3% as a result of the recalibrated parity adjustment. The recalibrated parity adjustment is being phased in over two years.
Sequestration of Medicare Rates

The Budget Control Act of 2011 requires a mandatory, across the board reduction in federal spending, called a sequestration. Medicare FFS claims with dates of service or dates of discharge on or after April 1, 2013 incur a 2.0% reduction in Medicare payments. All Medicare rate payments and settlements have incurred this mandatory reduction and will continue to be in place through at least 2023, unless Congress takes further action. In response to COVID-19, the CARES Act temporarily suspended the automatic 2.0% reduction of Medicare claim reimbursements for the period of May 1, 2020 through December 31, 2020. On December 27, 2020, the Consolidated Appropriations Act further suspended the 2.0% payment adjustment through March 31, 2021. On April 14, 2021, Congress extended the suspension of the 2.0% payment adjustment through December 31, 2021. On December 10, 2021, President Biden signed into law a bill to postpone the 2.0% payment adjustment through April 1, 2022; from April 1, 2022 through June 30, 2022, the 2.0% payment adjustment is reduced from 2.0% to 1.0%. To pay for the change, Congress would increase the sequester cuts by one year to fiscal year 2030.
48

Skilled Nursing Facility Value-Based Purchasing (SNF-VBP) Program

The SNF-VBP Program rewards SNFs with incentive payments based on the quality of care they provide to Medicare beneficiaries, as measured by a hospital readmissions measure. CMS annually adjusts its payment rules for SNFs using the SNF-VBP Program. Effective October 1, 2018, CMS began withholding 2.0% to fund the SNF-VBP Program incentive payment pool and will redistribute 60% of the withheld payments back to SNFs through the program. The fiscal year 2020 SNF PPS Rules estimate the economic impact of the SNF-VBP Program to be a reduction of $213.6 million in aggregate payments to SNFs during fiscal year 2020. The Rule also introduced two new quality measures to assess how health information is shared and adopted a number of standardized patient assessment data elements that assess factors such as cognitive function and mental status, special services, and social determinants of health. The fiscal year 2021 SNF PPS rule updated the deadlines for baseline period quality measure quarterly reporting and announced performance periods and standards for the fiscal year 2023 program year, but otherwise made no changes to the measures, scoring or payment policies. In the fiscal year 2022 program, CMS proposed changes to account for COVID-19 impacting readmission rates and SNF admissions during the performance periods of fiscal year 2020. These proposed changes would impact the SNF-VBP Program rate adjustment. On July 29, 2021, CMS published its final rule for the fiscal year 2022 program in the Federal Register, adopting the proposed changes for measuring the performance period and amending the data to be reported to CMS, which impacted the SNF-VBP Program rate adjustment.

On February 28, 2022, the Administration published a fact sheet stating its priorities for making changes to senior care, including potential changes to regulations affecting LTCs and SNFs. The SNF-VBP Program was identified as an area for change, with staffing levels, retention and resident experience affecting reimbursement. Following studies by CMS, proposed rules that may affect the SNF-VBP Program are expected by early 2023, with final rules to follow after a notice-and-comment period.

On July 29, 2022 final rule, CMS released the final rule electing to not apply the SNF 30-Day All-Cause Readmission Measure (SNFRM) as part of performance scoring for fiscal year 2023. CMS will still publicly report the SNFRM, but it will not affect SNF payment. The final rule for the fiscal year 2023 SNF PPS also provided for SNF-VBP program expansion beyond the use of its single, all-cause hospital readmission measure to determine payment, with the inclusion of measures in fiscal year 2026 for SNF healthcare associated infections requiring hospitalization (SNF HAI) and total nursing hours per resident day measures, and in fiscal year 2027 the discharge to community -post acute care measure for SNFs, which assesses the right of successful discharges to community from a SNF setting.
Part B Rehabilitation Requirements

Some of our revenue is paid by the Medicare Part B program under a fee schedule. Part B services are limited with a payment cap by combined speech-language pathology services (SLP), physical therapy (PT) services, and a separate annual cap for occupational therapy (OT) services. These caps were implemented under the authority of the Balanced Budget Amendments of 1997. These amounts were previously associated with the financial limitation amounts. The Bipartisan Budget Act of 2018 (BBA) repealed those caps while retaining and adding additional limitations to ensure appropriate therapy services. This policy does not limit the amount of medically necessary Medicare Part B therapy services a beneficiary may receive. The BBA establishes coding modifier requirements to obtain payments beyond the updated KX modifier thresholds, discussed below, and reaffirms the specific $3,000 claim audit threshold requirements for the Medicare Administrative Contractors. For PT and SLP combined the threshold for coding modifier requirements is $2,110 for 2021, compared to $2,080 for 2020. The KX Modifier threshold is set at $2,150 for CY 2022 with the same threshold for OT services.
Consistent with CMS’s “Patients over Paperwork” initiative, the agency has also been moving toward eliminating burdensome claims-based functional reporting requirements. Beginning in 2021, CMS rescinded 21 problematic National Correct Coding Initiative edits impacting outpatient therapy services, including services furnished under Medicare Part B primarily related to PT and OT services, removing a coding burden caused by requirements for additional documentation and claim modifier coding.

49

On December 1, 2020, CMS issued the calendar year 2021 Physician Fee Schedule (PFS) Final Rule, which reduced the conversion factor (i.e. the number by which CMS determine all current procedural terminology code payments) by 10.2%. These changes lowered the reimbursement rate for therapy Medicare Part B specialty providers by 9% for PT and OT and by 6% for SLP codes. These reductions were mitigated by the Consolidated Appropriations Act of 2021 (CAA, also referred to as The Omnibus Appropriations Law), which was signed into law on December 27, 2020. The CAA includes three components relevant to the Medicare Part B PFS. First, the CAA incorporates a rate relief of approximately 3.75% for fiscal year 2021. Additionally, the CAA incorporates a freeze to the payment for the physician add-on code for three years which would effectively create relief on the initial cuts through 2023. Finally, the relief calls for the 2% sequester to not be applied to the Medicare Part B program for the first quarter of 2021. CMS incorporated the first and second components of the CAA relief into the fiscal year 2021 PFS files which were published on January 5, 2021. While the 2021 PFS Final Rule reduced the fiscal year 2021 factor to $32.4085 (calendar year conversion factor was $36.0896), the CAA restored part of the reductions resulting in the final fiscal year 2021 conversion factor of $34.8931. This conversion factor rate does not include the 2% sequester which was suspended until April 1, 2022 and then was implemented as a 1% sequestration until June 30, 2022.
On November 19, 2021, CMS published the 2022 PFS, which required the use of new modifiers (the CO modifier) to identify and make payments at 85% of the otherwise applicable Part B payment amount for PT and OT services furnished in whole, or in part by PT and OT assistants. On December 10, 2021, President Biden signed the Protecting Medicare and American Farmers from Sequester Cuts Act into law, which restored funding for Medicare payments that was removed in the 2022 PFS. Following passage of this law, CMS announced payment changes to the 2022 PFS on December 16, 2021, which resulted in Medicare payments not being reduced from January 1, 2022 through March 31, 2022. Thereafter, FFS Medicare payments were adjusted by 1% from April 1, 2022 through June 30, 2022, and further adjusted by a total of 2% from July 1, 2022 through December 31, 2022. Under the recalculated 2022 PFS announced by CMS in December of 2021, the applicable conversion factor was reduced from the 2021 conversion factor of $34.8931 by 0.82% to $34.6062, a smaller reduction than the those found in the proposed rule or 2022 PFS.
On July 7, 2022, CMS issued a proposed rule for the calendar year 2023 PFS that would result in calendar year 2022’s 3% increase in physician fee schedule payments expiring for calendar year 2023. As a result, the proposed calendar year 2023 PFS conversion factor is $33.08, a decrease of $1.53 from the calendar year 2022 PFS conversion factor of $34.6062. A final rule setting the calendar year 2023 physician fee schedule is expected in the second half of 2022.
The Multiple Procedure Payment Reduction (MPPR) continues at a 50% reduction, which is applied to therapy procedures by reducing payments for practice expense of the second and subsequent procedures when services provided beyond one unit of one procedure are provided on the same day. The implementation of MPPR includes (1) facilities that provide Medicare Part B speech-language pathology, occupational therapy, and physical therapy services and bill under the same provider number; and (2) providers in private practice, including speech-language pathologists, who perform and bill for multiple services in a single day.
On May 27, 2020, pursuant to its authority under the Emergency Waivers, CMS added physical therapy, occupational therapy and speech-language pathology to list of approved telehealth Providers for the Medicare Part B programs provided by a SNF. Subsequently, the calendar year 2021 and 2022 PFS Final Rules added certain of these PT and OT services to the list of Medicare telehealth services on a temporary basis through at least the end of calendar year 2023. On December 31, 2020, CMS announced its 2021 update to the list of codes that describe Medicare Part B outpatient therapy services, making permanent existing and new codes introduced during the COVID-19 PHE for use under PT, OT, or SLP, including several telehealth codes as “sometimes therapy,” to permit physicians and certain non-physician practitioners to render these services outside a therapy plan of care when appropriate. “Sometimes therapy” codes will not have the MPPR applied. On November 19, 2021, CMS expanded these “sometimes therapy” codes further for the 2022 PFS, including five new codes for remote therapeutic monitoring treatment, which are broader than pre-existing monitoring codes and include measuring and evaluating adherence and response to medication and therapy. The PHE Waivers allow therapists to bill Telehealth therapy services up to the latter of, the end of calendar year 2023 or the end of the PHE.
Pursuant to the Emergency Waivers, CMS allowed for the facility to bill an originating site fee to CMS for telehealth services provided to Medicare Part B beneficiary residents of the facility when the services were provided by a physician from an alternate location, effective March 6, 2020 and ending on May 7, 2022. This Emergency Waiver for telehealth services was included within the Emergency Waivers CMS announced it was terminating within 30 days from April 7, 2022. Our Facilities have thus ceased using these telemedicine Emergency Waivers upon their termination.
On July 7, 2022, CMS proposed the calendar year 2023 Physician Fee Schedule to include a 4.4% negative adjustment to the conversion fact or in addition to the 1% negative base rate for an aggregate negative adjustment of 5.4%.

50

Programs of All-Inclusive Care for the Elderly
CMS issued a final rule on June 3, 2019, which updates the requirements for the Programs of All-Inclusive Care for the Elderly (PACE) under the Medicare and Medicaid programs. The regulation is intended to provide greater operational flexibility, remove redundancies and outdated information and codify existing programs. Such flexibility includes: (i) more lenient standards applicable to the current requirement that the PACE organization be monitored for compliance with the PACE program requirements during and after a 3-year trial period and (ii) relieving certain restrictions placed upon the interdisciplinary team that comprehensively assesses and provides for the individual needs of each PACE participant by allowing one person to fill two roles and permitting secondary participation in the PACE program. Further, non-physician primary care providers can provide certain services in place of primary care physicians. On October 21, 2021, CMS published an extension of the timeline to complete further final rulemaking for the PACE program until November 1, 2022, based on a proposed rule published on November 1, 2018, regarding policy and technical changes to Medicare Advantage, Medicare Prescription Drug Benefit, PACE, Medicaid FFS, and Medicaid managed care programs for 2020 and 2021. Based on completed studies, public comments, and the intervening COVID-19 pandemic that required CMS’s focus, CMS extended the timeline to issue a final rule regarding new policy and technical changes to the PACE program until November of 2022. The November 2018 proposed rule suggests changes to payment and appeals of disputes within the PACE program which may affect our business.
Decisions Regarding Skilled Nursing Facility Payment
Medicare reimbursement rates and rules are subject to frequent change. Historically, adjustments to reimbursement under Medicare have had a significant effect on our revenue. The federal government and state governments continue to focus on efforts to curb spending on healthcare programs such as Medicare and Medicaid. We are not able to predict the outcome of the legislative process. We also cannot predict the extent to which proposals will be adopted or, if adopted and implemented, what effect, if any, such proposals and existing new legislation will have on us. Efforts to impose reduced allowances, greater discounts and more stringent cost controls by government and other payors are expected to continue and could adversely affect our business, financial condition and results of operations.
These include statutory and regulatory changes, rate adjustments (including retroactive adjustments), administrative or executive orders and government funding restrictions, all of which may materially adversely affect the rates at which Medicare reimburses us for our services. Budget pressures often lead the federal government to reduce or place limits on reimbursement rates under Medicare. Implementation of these and other types of measures has in the past, and could in the future, result in substantial reductions in our revenue and operating margins. For a discussion of historic adjustments and recent changes to the Medicare program and related reimbursement rates, see Part I, Item 1A Risk Factors under the headings Risks Related to Our Business and Industry.
Patient Protection and Affordable Care Act
Various healthcare reform provisions became law upon enactment of the Patient Protection and Affordable Care Act and the Healthcare Education and Reconciliation Act (collectively, the ACA). The reforms contained in the ACA have affected our operating subsidiaries in some manner and are directed in large part at increased quality and cost reductions. Several of the reforms are very significant and could ultimately change the nature of our services, the methods of payment for our services and the underlying regulatory environment. These reforms include modifications to the conditions of qualification for payment, bundling of payments to cover both acute and post-acute care and the imposition of enrollment limitations on new providers. The upcoming Congressional elections in the United States and policies implemented by the current and former Presidential administration have resulted in significant changes in legislation, regulation, implementation of Medicare, Medicaid, and government policy. The 2022 midterm elections may significantly alter the current regulatory framework and impact our business and the health care industry. We continually monitor these developments so we can respond to the changing regulatory environment impacting our business.
Requirements of Participation
CMS has requirements that providers, including SNFs and other LTC facilities must meet in order to participate in the Medicare and Medicaid Programs. Some requirements can be burdensome and costly, and in recent years, CMS has modified these requirements. For example, beginning in 2016, SNFs were required to comply with emergency preparedness requirements, which requirements have since been strengthened via promulgation of additional rules.
51

Another relevant change is a 2019 final rule that removed the prohibition on the use of pre-dispute, binding arbitration agreements by LTC facilities. The rule imposed specific requirements on the use of these agreements, including requiring the use of plain language in drafting; that facilities post a notice in plain language that describes the policy on the use of agreements for binding arbitration in an area that is visible to residents and visitors; that admission to the facility not be conditioned on the signing of an arbitration agreement; and that the facility expressly inform the resident or his/her representative of the right not to sign the agreement as a condition of admission. Congress has routinely introduced, but not passed, legislation addressing the issue of arbitration agreements used by LTC facilities. While legislative action is possible in the future, federal and state regulations remain our primary source of authority over the use of pre-dispute binding arbitration agreements.
As discussed under the “Coronavirus” heading above, the Administration announced that CMS and OSHA would implement emergency rules requiring all workers within all Medicare and Medicaid-participating nursing homes, and all employees of companies with more than 100 employees, to be fully vaccinated against COVID-19. Significant litigation followed, including enforcement of both the CMS and OSHA vaccination mandates being halted by certain courts. On January 13, 2022, the United States Supreme Court held that the OSHA vaccination mandate could not be enforced against large employers, but that the CMS vaccination mandate could be enforced upon Medicare- and Medicaid-participating facilities. Those states except Texas where the CMS rule had been halted against enforcement then had to enforce the rule. On January 20, 2022, the United States District Court for the Northern District of Texas dismissed the block of the CMS's vaccination IFR in Texas. That same day, CMS became empowered to enforce the IFR in Texas and set a deadline of March 21, 2022 for full compliance with its vaccination requirements. Since CMS became empowered to enforce the IFR in Texas, there has not been any administrative or legislative action to change the applicability or enforcement of this IFR.
On June 29, 2022, CMS announced updated guidance for Phase 2 and 3 of the Requirements of Participation. These updates concern nursing home resident health and safety. CMS distributed these updates to surveyors and state agencies in order to enhance responses to resident complaints and reported incidents. This updated guidance arises directly from President Biden’s March 2022 State of the Union Address and accompanying fact sheet regarding nursing home areas of study and potential change. The guidance focuses on the following topics: (1) resident abuse and neglect (including reporting of abuse); (2) admission, transfer, and discharge; (3) mental health and substance abuse disorders; (4) nurse staffing and reporting of payrolls to evaluate staffing sufficiency; (5) residents’ rights (including visitation); (6) potential inaccurate diagnoses or assessments; (7) prescription and use of pharmaceuticals; (8) infection control and prevention; (9) arbitration of disputes between facilities and residents; (10) psychosocial outcomes and their severity; and (11) the timeliness and completion of state investigations to improve consistency in standards among various states.

On July 29, 2022, CMS updated the Medicare Requirements of Participation for LTC facilities, which includes the physical environment requirements to allow facilities to avoid unnecessary renovation expenses that could cause the closure of LTC facilities due to their expense; specifically, CMS is grandfathering certain facilities and will allow LTC facilities that were participating in Medicare before July 5, 2016 and that previously used the Fire Safety Evaluation System (FSES) to continue using the 2001 FSES mandatory values when determining compliance with applicable standards. In addition, CMS updated the Requirements of Participation to include revising existing qualification requirements for directors of food and nutrition services in LTC facilities, grandfathering directors with two or more years of experience and certain minimum training in food safety so that they may continue in that role without obtaining specific educational and certification requirements.

52

Civil and Criminal Fraud and Abuse Laws and Enforcement
Various complex federal and state laws exist which govern a wide array of referrals, relationships and arrangements, and prohibit fraud by healthcare providers. Governmental agencies are devoting increasing attention and resources to such anti-fraud efforts. The Health Insurance Portability and Accountability Act of 1996 (HIPAA), and the Balanced Budget Act of 1997 expanded the penalties for healthcare fraud. Additionally, in connection with our involvement with federal healthcare reimbursement programs, the government or those acting on its behalf may bring an action under the FCA, alleging that a healthcare provider has defrauded the government by submitting a claim for items or services not rendered as claimed, which may include coding errors, billing for services not provided, and submitting false or erroneous cost reports. The Fraud Enforcement and Recovery Act of 2009 (FERA) expanded the scope of the FCA by, among other things, creating liability for knowingly and improperly avoiding repayment of an overpayment received from the government and broadening protections for whistleblowers. The FCA clarifies that if an item or service is provided in violation of the AKS, the claim submitted for those items or services is a false claim that may be prosecuted under the FCA as a false claim. Civil monetary penalties under the FCA range from approximately $11 thousand to $23 thousand per violation and are adjusted annually for inflation. Under the qui tam or “whistleblower” provisions of the FCA, a private individual with knowledge of fraud may bring a claim on behalf of the federal government and receive a percentage of the federal government’s recovery. Due to these whistleblower incentives, lawsuits have become more frequent. Many states also have a false claim prohibition that mirrors or closely tracks the federal FCA. Federal law also provides that the OIG has the authority to exclude individuals and entities from federally funded health care programs on a number of grounds, including, but not limited to, certain types of criminal offenses, licensure revocations or suspensions, and exclusion from state or other federal healthcare programs. CMS can recover overpayments from health care providers up to five years following the year in which payment was made. On February 28, 2022, the Administration published a fact sheet regarding nursing home care, which identified the Administration’s priorities of further funding for SNF and LTC facility inspections, enhancing civil penalties on poor-performing facilities and increasing the scrutiny of companies that operate more than one facility. Proposed rules based on these directives and studies are expected by early 2023, with final rules to follow after a notice-and-comment period.
In November 2019, the OIG released a report of its investigation into overpayments to hospitals that did not comply with Medicare’s post-acute-care transfer policy. Hospitals violating this policy transferred patients to certain post-acute-care settings, such as SNFs, but claimed the higher reimbursements associated with discharges to homes. A similar OIG audit report, released in February 2019, focused on improper payments for SNF services when the Medicare three-day inpatient hospital stay requirement was not met. In 2021, the OIG released the result of an audit finding that Medicare overpaid millions of dollars of chronic care management (CCM) services. The OIG's 2021 report found that in calendar years 2017 and 2018, Medicare overpaid millions of dollars in CCM claims. These investigatory actions by OIG demonstrate its increased scrutiny into post-hospital SNF care provided to beneficiaries and may encourage additional oversight or stricter compliance standards.
On numerous occasions, CMS has indicated its intent to vigilantly monitor overall payments to SNFs, paying particular attention to facilities that have high reimbursements for ultra-high therapy, therapy resource utilization groups with higher activities of daily living scores, and long average lengths of stay. The OIG recognizes that there is a strong financial incentive for facilities to bill for higher levels of therapies, even when not needed by patients. We cannot predict the extent to which the OIG's recommendations to CMS will be implemented and, what effect, if any, such proposals would have on us. Our business model, like those of some other for-profit operators, is based in part on seeking out higher-acuity patients whom we believe are generally more profitable, and over time our overall patient mix has consistently shifted to higher-acuity in most facilities we operate. We also use specialized care-delivery software that assists our caregivers in more accurately capturing and recording services in order to, among other things, increase reimbursement to levels appropriate for the care actually delivered. These efforts may place us under greater scrutiny with the OIG, CMS, our fiscal intermediaries, recovery audit contractors and others.

53

Federal Healthcare Reform
Five-Star Quality Reporting Metrics - In 2015, CMS released a final rule addressing, among other things, implementation of certain provisions of Medicare Access and CHIP Reauthorization Act of 2015, which changed the way Medicare-participating providers are paid by implementing the Quality Payment Program (QPP). QPP created new paths for payment based on the Merit-based Incentive Payment System (MIPS) or the use of Alternative Payment Models (APM), which relied on quality data CMS gathered and evaluated using the Five-Star Quality Rating system, which includes a rating of one to five in various categories. These categories include (but are not limited to) the results of surveys conducted by state inspectors, other health inspection outcomes, staffing, spending, readmissions, and stay durations; the data collected and its weighting in determining a rating on a scale of one to five stars is subject to periodic and ongoing revision, re-balancing, and adjustment by CMS to reflect market conditions and CMS’s priorities in patient care. Since 2020, CMS’s measurement of the data reported by providers, including SNFs, has become more competitive and resulted in a reduction of four- and five-star rankings available under CMS’s Five-Star Quality Rating system.
Beginning in January 2020, CMS began displaying the ratings under this Five-Star Quality reporting system for nursing homes on its consumer-based Nursing Home Compare website. CMS also displays a consumer alert icon next to nursing homes that have been cited for incidents of abuse, neglect, or exploitation on the Nursing Home Compare website, which is updated monthly with CMS’s refresh of survey inspection results on that website.
In 2020, in response to the COVID-19 pandemic, CMS temporarily froze SNF Quality Reporting Program data, including data in the staffing and health inspection domains, on the Nursing Home Compare website to account for the then-suspended reporting and inspection obligations. After suspending inspections in early 2020, CMS announced a new and targeted inspection plan in August 2020 to focus on urgent patient safety threats and infection control, which affected the number of nursing homes inspected and the substance of those inspections. These safety inspections collected different information than traditional surveys, and as a result these survey results were not incorporated in CMS’s Five-Star Quality ratings for SNFs from March through December 2020. CMS resumed calculating nursing homes’ s health inspection ratings on January 27, 2021 and has continued to include this measure in subsequent updates.
Similarly, although staff reporting requirements were waived for the first and second quarters of 2020, this waiver ended on June 25, 2020. Thereafter, SNFs were required to report staffing data to CMS, which was incorporated into CMS’s Five-Star Quality rating beginning in January 2021. The January 2021 Five-Star Quality rating calculation reflected SNF-provided quarterly updates of most quality measures for the period between June 2019 and June 2020, reflecting the time period in which the normal reporting and inspection obligations were frozen due to COVID-19. CMS’s refreshes of the Nursing Home Compare website since January of 2021 have included these quality measures, and other new measures as discussed within this Government Regulation heading.
In January of 2022, CMS issued a bulletin stating that as of the same month, the Nursing Home Compare website would begin reporting SNF weekend staffing as well as staff tenure and other collected staffing data . Beginning in July of 2022, CMS began disclosing weekend staffing of all nurses, as well as staff turnover data for all nurses and administrators, on the Nursing Home Compare website. CMS also now incorporates this data into its Five-Star Quality ratings for SNFs and LTC facilities. This data is adjusted based on a facility's case mixture and evaluated on a quarterly basis.
Proposed Legislation Concerning Nursing Home Supervision - On August 10, 2021, the Nursing Home Improvement and Accountability Act of 2021 (Nursing Home Improvement Act) was introduced in the U.S. Senate and was intended to update federal nursing home policy to improve quality of care and oversight. The proposed legislation would reduce SNF payments for inaccurate submission of certain data and provide federal funding to carry out SNF data validation and ensure accuracy of cost report information. The Nursing Home Improvement Act also proposed staffing requirements for SNFs and other measures intended to improve transparency, accountability, and quality of care within nursing homes. If passed in its current form the bill would provide participating states with funds for up to six years in order to fund demonstrated improvements in nursing home workforce and care delivery. As of July 29, 2022, no action has been taken on this bill since its introduction to the Senate on August 10, 2021 and referral to the Senate Finance Committee that same day. A similar bill introduced in the United States House of Representatives in January of 2021, Bill No. H.R.598, was introduced and referred to the Ways and Means Committee’s Healthcare Subcommittee on February 2, 2021. As of July 29, 2022, no further action has been taken on this bill.
54

Proposed and Anticipated Administrative Action - On February 28, 2022, the Administration published a fact sheet stating its priorities for making changes to senior care, including potential changes to regulations affecting LTC and SNF facilities. The Administration’s priorities, which are to be studied throughout 2022, include transparency and public disclosure for nursing home owners and operators, and an examination of the role of private equity investment, real estate investment trusts (REITs) and other investment interests in this sector. The SNF-VBP Program was also identified as an area for change, with staffing levels, retention and resident experience affecting reimbursement. Additional enforcement authority and resources, including enhanced scrutiny of poorly performing facilities and tools for improving their performance, is another Administration priority. The Administration also seeks to improve accessibility to nurse aide training, tie Medicaid payments to staff wages and benefits, and enhance the recruitment and career paths for care workers. Finally, the Administration wishes to incorporate the lessons learned from the COVID-19 pandemic to impose new requirements for infection control, emergency preparedness and safety.
On April 11, 2022, CMS issued a proposed rule that could potentially lead to changes in the SNF-VBP Program, and setting SNF and LTC facility staffing levels. On June 29, 2022, CMS published guidance to surveyors for consistently evaluating Phase 2 and 3 Requirements of Participation for LTC facilities, addressing topics including infection control, resident safety, arbitration of disputes, nurse staffing, and mental health disorders.
Monitoring Compliance in Our Facilities 

Governmental agencies and other authorities periodically inspect our independent operating facilities to assess compliance with various standards, rules and regulations. The robust regulatory and enforcement environment continues to impact healthcare providers, especially in connection with responses to any alleged noncompliance identified in periodic surveys and other inspections by governmental authorities. Unannounced surveys or inspections generally occur at least annually and may also follow a government agency's receipt of a complaint about a facility. Facilities must pass these inspections to maintain licensure under state law, to obtain or maintain certification under the Medicare and Medicaid programs, to continue participation in the Veterans Administration program at some facilities, and to comply with provider contracts with managed care clients at many facilities. From time to time, our independent operating subsidiaries, like others in the healthcare industry, may receive notices from federal and state regulatory agencies of an alleged failure to substantially comply with applicable standards, rules or regulations. These notices may require corrective action, may impose civil monetary penalties for noncompliance, and may threaten or impose other operating restrictions on SNFs such as admission holds, provisional skilled nursing license, or increased staffing requirements. If our independent operating subsidiaries fail to comply with these directives or otherwise fail to comply substantially with licensure and certification laws, rules and regulations, the facility could lose its certification as a Medicare or Medicaid provider, or lose its license permitting operation in the State.

Facilities with otherwise acceptable regulatory histories generally are normally given an opportunity to correct deficiencies and continue their participation in the Medicare and Medicaid programs by a certain date, usually within six months; however, although where denial of payment remedies are asserted, such interim remedies go into effect much sooner. Facilities with deficiencies that immediately jeopardize patient health and safety and those that are classified as poor performing facilities, however, may not be given an opportunity to correct their deficiencies prior to the imposition of remedies and other enforcement actions. Moreover, facilities with poor regulatory histories continue to be classified by CMS as poor performing facilities notwithstanding any intervening change in ownership, unless the new owner obtains a new Medicare provider agreement instead of assuming the facility's existing agreement. However, new owners nearly always assume the existing Medicare provider agreement due to the difficulty and time delays generally associated with obtaining new Medicare certifications, especially in previously certified locations with sub-par operating histories. Accordingly, facilities that have poor regulatory histories before acquisition by our independent operating subsidiaries and that develop new deficiencies after acquisition are more likely to have sanctions imposed upon them by CMS or state regulators.

In addition, CMS has increased its focus on facilities with a history of serious or sustained quality of care problems through the special focus facility (SFF) initiative. A facility's administrators and owners are notified when it is identified as a SFF. This information is also provided to the general public. Local state survey agencies recommend to CMS that facilities be placed on special focus status. SFFs receive heightened scrutiny and more frequent regulatory surveys. Failure to improve the quality of care can result in fines and termination from participation in Medicare and Medicaid. A facility “graduates” from the program once it demonstrates significant improvements in quality of care that are continued over a defined period of time.

55

Sanctions such as denial of payment for new admissions often are scheduled to go into effect before surveyors return to verify compliance. Generally, if the surveyors confirm that the facility is in compliance upon their return, the sanctions never take effect. However, if they determine that the facility is not in compliance, the denial of payment goes into effect retroactive to the date given in the original notice. This possibility sometimes leaves affected operators, including our independent subsidiaries, with the difficult task of deciding whether to continue accepting patients after the potential denial of payment date, thus risking the retroactive denial of revenue associated with those patients' care if the operators are later found to be out of compliance, or simply refusing admissions from the potential denial of payment date until the facility is actually found to be in compliance. In the past and from time to time, some of our independent operating subsidiaries have been or will be in denial of payment status due to findings of continued regulatory deficiencies, resulting in an actual loss of the revenue associated with the Medicare and Medicaid patients admitted after the denial of payment date. Additional sanctions could ensue and, if imposed, could include various remedies up to and including decertification.
CMS has undertaken several initiatives to increase or intensify Medicaid and Medicare survey and enforcement activities, including federal oversight of state actions. CMS is taking steps to focus more survey and enforcement efforts on facilities with findings of substandard care or repeat violations of Medicaid and Medicare standards, and to identify multi-facility providers with patterns of noncompliance. CMS is also increasing its oversight of state survey agencies and requiring state agencies to use enforcement sanctions and remedies more promptly when substandard care or repeat violations are identified, to investigate complaints more promptly, and to survey facilities more consistently. On February 28, 2022, the Administration published a fact sheet regarding nursing home care, which identified the Administration’s priorities of further funding for SNF and LTC facility inspections, as well as enhanced penalties and other tools to use against non-compliant facilities. Proposed rules based on these directives and studies are expected in approximately one year, with final rules to follow a notice-and-comment period required by law. On April 11, 2022, the CMS issued a proposed rule that requested information to be used for study and potential rulemaking.
Regulations Regarding Financial Arrangements  
We are also subject to federal and state laws that regulate financial arrangement by and between healthcare providers, such as the federal and state anti-kickback laws, the Stark laws, and various state anti-referral laws.
The AKS, Section 1128B of the Social Security Act prohibits the knowing and willful offer, payment, solicitation, or receipt of any remuneration, directly or indirectly, overtly or covertly, in cash or in kind, to induce the referral of an individual, in return for recommending, or to arrange for, the referral of an individual for any item or service payable under any federal healthcare program, including Medicare or Medicaid. The OIG has issued regulations that create “safe harbors” for certain conduct and business relationships that are deemed protected under the AKS. In order to receive safe harbor protection, all of the requirements of a safe harbor must be met. The fact that a given business arrangement does not fall within one of these safe harbors, however, does not render the arrangement per se illegal. Business arrangements of healthcare service providers that fail to satisfy the applicable safe harbor criteria, if investigated, will be evaluated based upon all facts and circumstances and risk increased scrutiny and possible sanctions by enforcement authorities.
Violations of the AKS can result in criminal penalties of up to $112 thousand and ten years imprisonment. Violations of the AKS can also result in civil monetary penalties of up to $112 thousand per violation and an assessment of up to three times the total amount of remuneration offered, paid, solicited, or received. Violation of the AKS may also result in an individual's or organization's exclusion from future participation in federal healthcare programs. State Medicaid programs are required to enact an anti-kickback statute. Many states in which our independent operating subsidiaries operate have adopted or are considering similar legislative proposals, some of which extend beyond the Medicaid program, to prohibit the payment or receipt of remuneration for the referral of patients regardless of the source of payment for the care. We believe that business practices of providers and financial relationships between providers have become subject to increased scrutiny as healthcare reform efforts continue on the federal and state levels.

56

Additionally, Section 1877 of the Social Security Act, commonly known as the “Stark Law,” provides that a physician may not refer a Medicare or Medicaid patient for a “designated health service” to an entity with which the physician or an immediate family member has a financial relationship unless the financial arrangement meets an exception under the Stark Law or its regulations. Designated health services include inpatient and outpatient hospital services, PT, OT, SLP, durable medical equipment, prosthetics, orthotics and supplies, diagnostic imaging, enteral and parenteral feeding and supplies and home health services. Under the Stark Law, a “financial relationship” is defined as an ownership or investment interest or a compensation arrangement. If such a financial relationship exists and does not meet a Stark Law exception, the entity is prohibited from submitting or claiming payment under the Medicare or Medicaid programs or from collecting from the patient or other payor. Many of the compensation arrangements exceptions permit referrals if, among other things, the arrangement is set forth in a written agreement signed by the parties, the compensation to be paid is set in advance, is consistent with fair market value and is not determined in a manner that takes into account the volume or value of any referrals or other business generated between the parties. Exceptions may have other requirements. Any funds collected for an item or service resulting from a referral that violates the Stark Law are not eligible for payment by federal healthcare programs and must be repaid to Medicare or Medicaid, any other third-party payor, and the patient. Violations of the Stark Law may result in the imposition of civil monetary penalties, including, treble damages. Individuals and organizations may also be excluded from participation in federal healthcare programs for Stark Law violations. Many states have enacted healthcare provider referral laws that go beyond physician self-referrals or apply to a greater range of services than just the designated health services under the Stark Law.
Regulations Regarding Patient Record Confidentiality
Health care providers are also subject to laws and regulations enacted to protect the confidentiality of patient health information. For example, HHS has issued rules pursuant to HIPAA, including the Health Information Technology for Economic and Clinical Health (HITECH) Act which governs our use and disclosure of protected health information of patients. We have established policies and procedures to comply with HIPAA privacy and security requirements at our independent operating subsidiaries. Our independent operating subsidiaries have adopted and implemented HIPAA compliance plans, which we believe comply with the HIPAA privacy and security regulations. The HIPAA privacy and security regulations have and will continue to impose significant costs on our independent operating subsidiaries in order to comply with these standards. There are numerous other laws and legislative and regulatory initiatives at the federal and state levels addressing privacy and security concerns. Our independent operating subsidiaries are also subject to any federal or state privacy-related laws that are more restrictive than the privacy regulations issued under HIPAA. These laws vary and could impose additional penalties for privacy and security breaches. Healthcare entities are also required to afford patients with certain rights of access to their health information under HIPAA and the 21st Century Cures Act (Cures Act). The Office of Civil Rights, the agency responsible for HIPAA enforcement, has targeted investigative and enforcement efforts on violations of patients’ rights of access, including denial of access to medical records, imposing significant fines for violations largely initiated from patient complaints. The Office of the National Coordinator for Health Information Technology can also investigate and impose separate penalties for information blocking violations under the Cures Act.
Antitrust Laws 
We are also subject to federal and state antitrust laws. Enforcement of the antitrust laws against healthcare providers is common, and antitrust liability may arise in a wide variety of circumstances, including third party contracting, physician relations, joint venture, merger, affiliation and acquisition activities. In some respects, the application of federal and state antitrust laws to healthcare is still evolving, and enforcement activity by federal and state agencies appears to be increasing. At various times, healthcare providers and insurance and managed care organizations may be subject to an investigation by a governmental agency charged with the enforcement of antitrust laws, or may be subject to administrative or judicial action by a federal or state agency or a private party. Violators of the antitrust laws could be subject to criminal and civil enforcement by federal and state agencies, as well as by private litigants.
Americans with Disabilities Act
Our independent operating subsidiaries must also comply with the ADA, and similar state and local laws to the extent that the facilities are "public accommodations" as defined in those laws. The obligation to comply with the ADA and other similar laws is an ongoing obligation, and the independent operating subsidiaries continue to assess their facilities relative to ADA compliance and make appropriate modifications as needed.

57

REGULATIONS SPECIFIC TO SENIOR LIVING COMMUNITIES

As previously mentioned, senior living services revenue is primarily derived from private pay residents, with a small portion of senior living revenue (approximately 2.1% of total revenue) derived from Medicaid funds. Thus, some of the regulations discussed above applicable to Medicaid providers, also apply to senior living. However, the following provides a brief overview of the regulatory framework applicable specifically to senior living.

A majority of states provide, or are approved to provide, Medicaid payments for personal care and medical services to some residents in licensed senior living communities under waivers granted by or under Medicaid state plans approved by CMS. State Medicaid programs control costs for senior living and other home and community-based services by various means such as restrictive financial and functional eligibility standards, enrollment limits and waiting lists. Because rates paid to senior living community operators are generally lower than rates paid to SNF operators, some states use Medicaid funding of senior living services as a means of lowering the cost of services for residents who may not need the higher level of health services provided in SNFs. States that administer Medicaid programs for services in senior living communities are responsible for monitoring the services at, and physical conditions of, the participating communities. As a result of the growth of senior living in recent years, states have adopted licensing standards applicable to senior living communities. Most state licensing standards apply to senior living communities regardless of whether they accept Medicaid funding.

Since 2003, CMS has commenced a series of actions to increase its oversight of state quality assurance programs for senior living communities, and has provided guidance and technical assistance to states to improve their ability to monitor and improve the quality of services paid through Medicaid waiver programs. CMS is encouraging state Medicaid programs to expand their use of home and community-based services as alternatives to facility-based services, pursuant to provisions of the ACA, and other authorities, through the use of several programs. As noted above, the Administration issued a fact sheet regarding nursing home care priorities and reforms that it intends to seek in the coming year. The Administration’s desired changes are multi-faceted, concerning payment to facilities, staffing level requirements, training and retention of staff, standards of care offered to residents, increased transparency and public disclosure of ownership, and enhanced civil remedies and other authority to exercise upon facilities that do not satisfy CMS’s standards. Proposed rules based on these directives are expected by early 2023, with final rules to follow a notice-and-comment period required by law. On April 11, 2022, the CMS issued a proposed rule that requested information to be used for study and potential rulemaking consistent with the Administration’s February 28, 2022 fact sheet. On June 29, 2022, CMS published guidance to surveyors for consistently evaluating Phase 2 and 3 Requirements of Participation for LTC facilities, as detailed under the Requirements of Participation heading, addressing topics including infection control, resident safety, arbitration of disputes, nurse staffing and mental health disorders.
The types of laws and statutes affecting the regulatory landscape of the post-acute industry continue to expand. In addition to this changing regulatory environment, federal, state and local officials are increasingly focusing their efforts on the enforcement of these laws. In order to operate our businesses, we must comply with federal, state and local laws relating to licensure, delivery and adequacy of medical care, distribution of pharmaceuticals, equipment, personnel, operating policies, fire prevention, rate-setting, billing and reimbursement, building codes and environmental protection. Additionally, we must also adhere to anti-kickback statues, physician referral laws, the ADA, and safety and health standards set by the OSHA Administration. Changes in the law or new interpretations of existing laws may have an adverse impact on our methods and costs of doing business.

Our independent operating subsidiaries are also subject to various regulations and licensing requirements promulgated by state and local health and social service agencies and other regulatory authorities. Requirements vary from state to state and these requirements can affect, among other things, personnel education and training, patient and personnel records, services, staffing levels, monitoring of patient wellness, patient furnishings, housekeeping services, dietary requirements, emergency plans and procedures, certification and licensing of staff prior to beginning employment, and patient rights. These laws and regulations could limit our ability to expand into new markets and to expand the services provided by independent operating subsidiaries in existing markets.



58

RESULTS OF OPERATIONS
We believe we exist to dignify and transform post-acute care. We set out a strategy to achieve our goal of ensuring our patients are receiving the best possible care through our ability to acquire, integrate and improve our operations. Our results serve as a strong indicator that our strategy is working and our transformation is underway. We saw a recovery in our census starting in the first quarter of 2021 and has continued into 2022. Despite the emergence of COVID-19 variants in the first quarter of 2022, we continue to experience healthy growth in both revenue and operational earnings.
Our net revenue for the three months ended June 30, 2022 continues to be impacted by COVID-19. The Emergency Waivers issued by CMS, including a waiver of the requirement to have a three-day stay in a hospital to get Medicare coverage of a skilled nursing stay, as well as, the authorization of renewed SNF coverage without having to start a new benefit period for certain beneficiaries who recently exhausted their SNF benefits, remained in effect in the first half of 2022. In addition, we continued to receive state relief funding in selected states, which has been designed to enhance reimbursement to provide additional funding to cover COVID-19 related expenses. For the three and six months ended June 30, 2022, we recorded state relief revenue of $24.5 million and $42.1 million, respectively, which directly offset against COVID-19 related expenses we incurred in those states. See Recent Activities for further information.
Our total revenue for the quarter increased $94.0 million, or 14.7% while our diluted GAAP earning per share grew by 16.1%, from $0.87 to $1.01, compared to the second quarter in 2021. We have continued to make progress on targeted initiatives, including our foundational structure of local operations that are the centers of excellence in the communities they serve. As part of this focus, we have been able to expand our relationships with doctors, hospitals and managed care plans. Revenue from our skilled services collectively increased by 14.6%. We have refocused on operational fundamentals including identifying non-clinical areas where we can manage spending. These fundamentals coupled with the increase in occupancy and expansion to our operations resulted in a strong second quarter.
The following table sets forth details of operating results for our revenue, expenses and earnings, and their respective components, as a percentage of total revenue for the periods indicated:
Three Months Ended June 30,Six Months Ended June 30,
 2022202120222021
REVENUE:
Service revenue99.4 %99.4 %99.4 %99.4 %
Rental revenue0.6 0.6 0.6 0.6 
TOTAL REVENUE100.0 %100.0 %100.0 %100.0 %
Expenses:
Cost of services76.9 76.4 77.4 76.7 
Rent—cost of services5.1 5.4 5.0 5.4 
General and administrative expense5.3 5.8 5.4 5.5 
Depreciation and amortization2.0 2.2 2.0 2.2 
TOTAL EXPENSES89.3 89.8 89.8 89.8 
Income from operations10.7 10.2 10.2 10.2 
Other income (expense):
Interest expense(0.4)(0.3)(0.3)(0.3)
Other (expense) income(0.3)0.2 (0.2)0.1 
Other expense, net(0.7)(0.1)(0.5)(0.2)
Income before provision for income taxes10.0 10.1 9.7 10.0 
Provision for income taxes2.1 2.2 2.2 2.1 
NET INCOME7.9 7.9 7.5 7.9 
Less: net income attributable to noncontrolling interests — 0.2 — 0.1 
 Net income attributable to The Ensign Group, Inc.7.9 %7.7 %7.5 %7.8 %

59

 Three Months Ended June 30,Six Months Ended June 30,
 2022202120222021
SEGMENT INCOME(1)
(In thousands)
Skilled services$102,266 $90,010 $200,522 $178,941 
Standard Bearer(2)
$6,838 $7,906 $13,738 $15,619 
NON-GAAP FINANCIAL MEASURES:
PERFORMANCE METRICS
EBITDA $92,978 $77,491 $177,016 $154,198 
Adjusted EBITDA $96,096 $82,523 $188,825 $163,402 
FFO for Standard Bearer
$12,054 $12,154 $23,975 $24,022 
VALUATION METRICS
Adjusted EBITDAR$133,324 $261,815 
(1) Segment income represents operating results of the reportable segments excluding gain and loss on sale of assets, insurance recoveries and losses, impairment charges and provision for income taxes. Included in segment income for Standard Bearer for the three and six months ended June 30, 2022 are expenses for intercompany management fees between Standard Bearer and the Service Center and intercompany interest expense. Segment income is reconciled to the Condensed Consolidated Statement of Income in Note 8, Business Segments in Notes to Unaudited Condensed Consolidated Financial Statements of this Quarterly Report on Form 10-Q.
(2) Standard Bearer segment income includes rental revenue from Ensign affiliated tenants and related expenses.

The following discussion includes references to EBITDA, Adjusted EBITDA, Adjusted EBITDAR and Funds from Operations (FFO) which are non-GAAP financial measures (collectively, the Non-GAAP Financial Measures). Regulation G, Conditions for Use of Non-GAAP Financial Measures, and other provisions of the Securities Exchange Act of 1934, as amended (the Exchange Act), define and prescribe the conditions for use of certain non-GAAP financial information. These Non-GAAP Financial Measures are used in addition to and in conjunction with results presented in accordance with GAAP. These Non-GAAP Financial Measures should not be relied upon to the exclusion of GAAP financial measures. These Non-GAAP Financial Measures reflect an additional way of viewing aspects of our operations that, when viewed with our GAAP results and the accompanying reconciliations to corresponding GAAP financial measures, provide a more complete understanding of factors and trends affecting our business.
We believe the presentation of certain Non-GAAP Financial Measures are useful to investors and other external users of our financial statements regarding our results of operations because:

they are widely used by investors and analysts in our industry as a supplemental measure to evaluate the overall performance of companies in our industry without regard to items such as other expense, net and depreciation and amortization, which can vary substantially from company to company depending on the book value of assets, capital structure and the method by which assets were acquired; and
they help investors evaluate and compare the results of our operations from period to period by removing the impact of our capital structure and asset base from our operating results.

We use the Non-GAAP Financial Measures:

as measurements of our operating performance to assist us in comparing our operating performance on a consistent basis;
to allocate resources to enhance the financial performance of our business;
to assess the value of a potential acquisition;
to assess the value of a transformed operation's performance;
to evaluate the effectiveness of our operational strategies; and
to compare our operating performance to that of our competitors.

We use certain Non-GAAP Financial Measures to compare the operating performance of each operation. These measures are useful in this regard because they do not include such costs as other expense, income taxes, depreciation and amortization expense, which may vary from period-to-period depending upon various factors, including the method used to finance operations, the amount of debt that we have incurred, whether an operation is owned or leased, the date of acquisition of a facility or business, and the tax law of the state in which a business unit operates.

60

We also establish compensation programs and bonuses for our leaders that are partially based upon the achievement of Adjusted EBITDAR targets.

Despite the importance of these measures in analyzing our underlying business, designing incentive compensation and for our goal setting, the Non-GAAP Financial Measures have no standardized meaning defined by GAAP. Therefore, certain of our Non-GAAP Financial Measures have limitations as analytical tools, and they should not be considered in isolation, or as a substitute for analysis of our results as reported in accordance with GAAP. Some of these limitations are:

they do not reflect our current or future cash requirements for capital expenditures or contractual commitments;
they do not reflect changes in, or cash requirements for, our working capital needs;
they do not reflect the interest expense, or the cash requirements necessary to service interest or principal payments, on our debt;
they do not reflect rent expenses, which are necessary to operate our leased operations, in the case of Adjusted EBITDAR;
they do not reflect any income tax payments we may be required to make;
although depreciation and amortization are non-cash charges, the assets being depreciated and amortized will often have to be replaced in the future, and do not reflect any cash requirements for such replacements; and
other companies in our industry may calculate these measures differently than we do, which may limit their usefulness as comparative measures.

We compensate for these limitations by using them only to supplement net income on a basis prepared in accordance with GAAP in order to provide a more complete understanding of the factors and trends affecting our business.

Management strongly encourages investors to review our consolidated financial statements in their entirety and to not rely on any single financial measure. Because these Non-GAAP Financial Measures are not standardized, it may not be possible to compare these financial measures with other companies’ Non-GAAP financial measures having the same or similar names. These Non-GAAP Financial Measures should not be considered a substitute for, nor superior to, financial results and measures determined or calculated in accordance with GAAP. We strongly urge you to review the reconciliation of income from operations to the Non-GAAP Financial Measures in the table below, along with our unaudited condensed consolidated financial statements and related notes included elsewhere in this document.

We use the following Non-GAAP financial measures that we believe are useful to investors as key valuation and operating performance measures:

PERFORMANCE MEASURES:
EBITDA

We believe EBITDA is useful to investors in evaluating our operating performance because it helps investors evaluate and compare the results of our operations from period to period by removing the impact of our asset base (depreciation and amortization expense) from our operating results.

We calculate EBITDA as net income, adjusted for net losses attributable to noncontrolling interest, before (a) other expense, net, (b) provision for income taxes, and (c) depreciation and amortization.
Adjusted EBITDA

We adjust EBITDA when evaluating our performance because we believe that the exclusion of certain additional items described below provides useful supplemental information to investors regarding our ongoing operating performance, in the case of Adjusted EBITDA. We believe that the presentation of Adjusted EBITDA, when combined with EBITDA and GAAP net income attributable to The Ensign Group, Inc., is beneficial to an investor’s complete understanding of our operating performance.  


61

Adjusted EBITDA is EBITDA adjusted for non-core business items, which for the reported periods includes, to the extent applicable:

stock-based compensation expense;
legal finding;
acquisition related costs, costs incurred related to new systems implementation and other costs;
results related to operations not at full capacity; and
gain on sale of assets.
Funds from Operations (FFO)
We consider FFO to be a useful supplemental measure of the operating performance of Standard Bearer. Historical cost accounting for real estate assets in accordance with U.S. GAAP implicitly assumes that the value of real estate assets diminishes predictably over time as evidenced by the provision for depreciation. However, since real estate values have historically risen or fallen with market conditions, many real estate investors and analysts have considered presentations of operating results for real estate companies that use historical cost accounting to be insufficient. In response, the National Association of Real Estate Investment Trusts (NAREIT) created FFO as a supplemental measure of operating performance for REITs, which excludes historical cost depreciation from net income. We define (in accordance with the definition used by NAREIT) FFO to consist of Standard Bearer segment income, excluding depreciation and amortization related to real estate, gains or losses from the sale of real estate, insurance recoveries related to real estate and impairment of depreciable real estate assets.
VALUATION MEASURE:
Adjusted EBITDAR

 We use Adjusted EBITDAR as one measure in determining the value of prospective acquisitions. It is also a commonly used measure by our management, research analysts and investors, to compare the enterprise value of different companies in the healthcare industry, without regard to differences in capital structures and leasing arrangements. Adjusted EBITDAR is a financial valuation measure that is not specified in GAAP. This measure is not displayed as a performance measure as it excludes rent expense, which is a normal and recurring operating expense.

The adjustments made and previously described in the computation of Adjusted EBITDA are also made when computing Adjusted EBITDAR. We calculate Adjusted EBITDAR by excluding rent-cost of services from Adjusted EBITDA.

We believe the use of Adjusted EBITDAR allows the investor to compare operational results of companies who have operating and capital leases. A significant portion of capital lease expenditures are recorded in interest, whereas operating lease expenditures are recorded in rent expense.


62

The table below reconciles net income to EBITDA, Adjusted EBITDA and Adjusted EBITDAR for the periods presented:

Three Months Ended June 30,Six Months Ended June 30,
2022202120222021
Condensed consolidated statements of income data:
(In thousands)
Net income $57,803 $50,583 $107,891 $100,420 
Less: net (loss) income attributable to noncontrolling interests112 1,158 (140)1,789 
Add: Other expense, net5,275 513 8,159 1,406 
Provision for income taxes
15,154 13,758 31,292 26,707 
Depreciation and amortization14,858 13,795 29,534 27,454 
EBITDA$92,978 $77,491 $177,016 $154,198 
Stock-based compensation5,616 4,633 10,783 8,687 
Legal finding(a) — — 3,353 — 
Gain on sale of assets(2,567)— (2,567)(540)
Results related to operations not at full capacity— — — 584 
Acquisition related costs, new systems implementation costs and other costs(b)
69 399 240 435 
Rent related to items above— — — 38 
Adjusted EBITDA$96,096 $82,523 $188,825 $163,402 
Rent—cost of services37,228 34,455 72,990 67,911 
Less: rent related to items above— — — (38)
Adjusted rent 37,228 34,455 72,990 67,873 
Adjusted EBITDAR $133,324 $261,815 
(a) Legal finding against our non-emergent transportation subsidiary.
(b) Costs incurred to acquire operations and system implementation costs that are not capitalizable. Other costs includes legal, transactional and other costs
incurred related to the formation of Standard Bearer and other real estate related activities.


Three Months Ended June 30, 2022 Compared to the Three Months Ended June 30, 2021

The following table sets forth details of operating results for our revenue and earnings, and their respective components, by our reportable segment for the periods indicated.
Three Months Ended June 30, 2022
 Skilled servicesStandard BearerAll OtherEliminationsConsolidated
Total Revenue
702,478 17,598 30,619 (18,209)$732,486 
Total expenses, including other expense, net600,212 10,760 69,233 (18,209)661,996 
Segment income (loss)102,266 6,838 (38,614)— 70,490 
Gain from sale of real estate
2,467 
Income before provision for income taxes $72,957 
Three Months Ended June 30, 2021
 Skilled servicesStandard BearerAll OtherEliminationsConsolidated
Total Revenue
$612,882 $14,214 $25,245 $(13,805)$638,536 
Total expenses, including other expense, net522,872 6,308 58,820 (13,805)574,195 
Segment income (loss)90,010 7,906 (33,575)— 64,341 
Income before provision for income taxes$64,341 

63

Our total revenue increased $94.0 million, or 14.7%, compared to the three months ended June 30, 2021. The increase in revenue was primarily driven by an increase in patient days and occupancy from our skilled services operations, along with the impact of acquisitions. Total revenue from operations acquired on or subsequent to January 1, 2021 increased our consolidated revenue by $41.1 million during the three months ended June 30, 2022, when compared to the same period in 2021. In addition, we recorded $24.5 million of state relief revenue in the second quarter of 2022 compared to $16.7 million in the same period in 2021, which directly correlated to the additional COVID-19 related expenses incurred. All state relief revenue is included in Medicaid revenue.
Skilled Services

REVENUE

The following table presents the skilled services revenue and key performance metrics by category during the three months ended June 30, 2022 and 2021:
Three Months Ended June 30,
 20222021Change% Change
TOTAL FACILITY RESULTS: (Dollars in thousands)
Skilled services revenue$702,478 $612,882 $89,596 14.6 %
Number of facilities at period end215 206 4.4 %
Number of campuses at period end*25 25 — — %
Actual patient days1,745,027 1,599,707 145,320 9.1 %
Occupancy percentage — Operational beds75.2 %72.7 % 2.5 %
Skilled mix by nursing days31.1 %30.9 % 0.2 %
Skilled mix by nursing revenue50.9 %51.4 % (0.5)%
Three Months Ended June 30,
 20222021Change% Change
SAME FACILITY RESULTS:(1)
(Dollars in thousands)
Skilled services revenue$551,548 $511,921 $39,627 7.7 %
Number of facilities at period end167 167 — — %
Number of campuses at period end*20 20 — — %
Actual patient days1,348,252 1,315,775 32,477 2.5 %
Occupancy percentage — Operational beds75.8 %74.0 % 1.8 %
Skilled mix by nursing days32.6 %32.3 % 0.3 %
Skilled mix by nursing revenue52.6 %52.9 % (0.3)%

Three Months Ended June 30,
20222021Change% Change
TRANSITIONING FACILITY RESULTS:(2)
(Dollars in thousands)
Skilled services revenue$94,881 $80,487 $14,394 17.9 %
Number of facilities at period end27 27 — — %
Number of campuses at period end*— — %
Actual patient days248,767 226,729 22,038 9.7 %
Occupancy percentage — Operational beds74.4 %68.0 % 6.4 %
Skilled mix by nursing days26.4 %24.9 % 1.5 %
Skilled mix by nursing revenue45.0 %44.4 % 0.6 %

64

Three Months Ended June 30,
20222021Change% Change
RECENTLY ACQUIRED FACILITY RESULTS:(3)
(Dollars in thousands)
Skilled services revenue$56,049 $20,474 $35,575 NM
Number of facilities at period end21 12 NM
Number of campuses at period end*— — — NM
Actual patient days148,008 57,203 90,805 NM
Occupancy percentage — Operational beds71.2 %64.9 %NM
Skilled mix by nursing days25.2 %21.8 % NM
Skilled mix by nursing revenue44.2 %41.3 % NM
*Campus represents a facility that offers both skilled nursing and senior living services. Revenue and expenses related to skilled nursing and senior living services have been allocated and recorded in the respective operating segment. In the second quarter of 2022, we converted two skilled nursing facilities into campuses.
(1)Same Facility results represent all facilities purchased prior to January 1, 2019.
(2)Transitioning Facility results represent all facilities purchased from January 1, 2019 to December 31, 2020.
(3)Recently Acquired Facility (Acquisitions) results represent all facilities purchased on or subsequent to January 1, 2021.

Skilled services revenue increased $89.6 million, or 14.6%, compared to the three months ended June 30, 2021. Of the $89.6 million increase, the primary changes were from increases in Medicaid revenue of $47.2 million, or 16.2%, managed care revenue of $15.6 million, or 13.8%, Medicare revenue of $20.5 million, or 12.0% and private revenue of $6.3 million or 16.0%.

The increase in revenue was primarily driven by strong performance across our skilled services operations as our census continued to recover in the second quarter of 2022. Our consolidated occupancy increased by 2.5%. As COVID-19 cases declined from the same period in the previous year, there was a shift in Medicare patients to LTC patients, resulting in a decline in skilled mix revenue.

Revenue in our Same Facilities increased $39.6 million, or 7.7% due to increased occupancy and revenue per patient day. Our diligent efforts to strengthen our partnership with various managed care organizations, hospitals and the local communities we operate in, increased our occupancy by 1.8% to 75.8%. Managed care and Medicare skilled days increased by 4.1% and 4.0%, respectively, resulting in an increase in Managed Care and Medicare revenue.

Revenue generated by our Transitioning Facilities increased $14.4 million, or 17.9%, primarily due to improved occupancy growth of 6.4% to 74.4% and an increase in total patient days and skilled mix days compared to the three months ended June 30, 2021, demonstrating our ability to transition these healthcare operations toward higher acuity patients. This resulted in managed care days increasing by 26.0%, and Medicare days increasing by 8.9%.

Skilled services revenue generated by facilities purchased on or subsequent to January 1, 2021 (Recently Acquired Facilities) increased by approximately $35.6 million compared to the three months ended June 30, 2021. We acquired nine operations between July 1, 2021 and June 30, 2022 across four states.
In the future, if we acquire additional turnaround or start-up operations, we expect to see lower occupancy rates and skilled mix, and these metrics are expected to vary from period to period based upon the maturity of the facilities within our portfolio. Historically, we have generally experienced lower occupancy rates, lower skilled mix at Recently Acquired Facilities and therefore, we anticipate generally lower overall occupancy during years of growth.
65

The following table reflects the change in skilled nursing average daily revenue rates by payor source, excluding services that are not covered by the daily rate (1):
Three Months Ended June 30,
 Same FacilityTransitioningAcquisitionsTotal
 20222021202220212022202120222021
SKILLED NURSING AVERAGE DAILY REVENUE RATES:
Medicare$689.53 $685.30 $678.08 $670.99 $698.18 $717.04 $688.61 $684.33 
Managed care514.98 505.71 473.64 462.43 512.97 516.40 509.64 501.06 
Other skilled579.53 538.16 461.06 424.35 488.46 538.34 560.62 530.17 
Total skilled revenue595.65 582.66 565.76 560.31 586.80 622.36 591.41 581.11 
Medicaid261.00 249.46 251.78 232.53 249.28 245.07 258.48 246.65 
Private and other payors250.25 238.06 228.39 232.50 250.88 271.47 246.87 238.06 
Total skilled nursing revenue
$368.82 $355.86 $332.09 $314.18 $334.34 $329.34 $360.65 $349.00 
(1) These rates exclude additional Federal Medical Assistance Percentage (FMAP) and include sequestration reversal of 1% in 2022 and 2% in 2021.

Our Medicare daily rates at Same Facilities and Transitioning Facilities increased by 0.6% and 1.1%, respectively, compared to the three months ended June 30, 2021. The increase is attributable to the 1.2% net market basket increase that became effective in October 2021. This was offset by the sequestration reversal of 1% compared to 2% in 2021.

Our average Medicaid rates increased 4.8% due to state reimbursement increases and our participation in supplemental Medicaid payment programs and quality improvement programs in various states. Medicaid rates exclude the amount of state relief revenue we recorded.
Payor Sources as a Percentage of Skilled Nursing Services. We use our skilled mix as measures of the quality of reimbursements we receive at our affiliated skilled nursing facilities over various periods.

The following tables set forth our percentage of skilled nursing patient revenue and days by payor source:
 Three Months Ended June 30,
 Same FacilityTransitioningAcquisitionsTotal
 20222021202220212022202120222021
PERCENTAGE OF SKILLED NURSING REVENUE
Medicare24.3 %24.7 %24.7 %26.0 %22.9 %23.7 %24.2 %24.8 %
Managed care19.6 19.6 16.6 14.9 11.1 8.1 18.5 18.6 
Other skilled8.7 8.6 3.7 3.5 10.2 9.5 8.2 8.0 
Skilled Mix52.6 52.9 45.0 44.4 44.2 41.3 50.9 51.4 
Private and other payors7.1 6.9 7.9 8.1 6.4 5.9 7.2 7.0 
Medicaid40.3 40.2 47.1 47.5 49.4 52.8 41.9 41.6 
TOTAL SKILLED NURSING
100.0 %100.0 %100.0 %100.0 %100.0 %100.0 %100.0 %100.0 %
 Three Months Ended June 30,
 Same FacilityTransitioningAcquisitionsTotal
 20222021202220212022202120222021
PERCENTAGE OF SKILLED NURSING DAYS
Medicare13.0 %12.8 %12.1 %12.2 %10.9 %10.9 %12.7 %12.6 %
Managed care14.0 13.8 11.7 10.1 7.3 5.1 13.1 13.0 
Other skilled5.6 5.7 2.6 2.6 7.0 5.8 5.3 5.3 
Skilled Mix32.6 32.3 26.4 24.9 25.2 21.8 31.1 30.9 
Private and other payors10.5 10.4 11.5 10.9 8.5 7.2 10.5 10.3 
Medicaid56.9 57.3 62.1 64.2 66.3 71.0 58.4 58.8 
TOTAL SKILLED NURSING
100.0 %100.0 %100.0 %100.0 %100.0 %100.0 %100.0 %100.0 %

66

Cost of Services

The following table sets forth total cost of services for our Skilled services segment for the periods indicated (dollars in thousands):
 Three Months Ended June 30,Change
20222021$%
Cost of service$544,751 $472,217 $72,534 15.4 %
Revenue percentage77.5 %77.0 %0.5 %

Cost of services related to our Skilled services segment increased $72.5 million, or 15.4%, primarily due to additional costs related to new acquisitions, which accounted for $27.7 million of the increase to cost of services with additional increases due to higher staffing expenses, primarily agency. Cost of services as a percentage of revenue increased to 77.5% from 77.0%.
Standard Bearer
 Three Months Ended June 30,Change
20222021$%
(Dollars in thousands)
Rental revenue generated from third-party tenants$3,704 $3,430 $274 8.0 %
Rental revenue generated from Ensign affiliated operations13,894 10,784 3,110 28.8 
TOTAL RENTAL REVENUE
$17,598 $14,214 $3,384 23.8 %
Segment income6,838 7,906 (1,068)(13.5)
Depreciation and amortization5,216 4,248 968 22.8 
FFO
$12,054 $12,154 $(100)(0.8)%

Rental revenue. Our rental revenue, including revenue generated from our affiliated facilities, increased by $3.4 million, or 23.8%, to $17.6 million, compared to the three months ended June 30, 2021. The increase in revenue is primarily attributable to seven real estate purchases as well as annual rent increases since the three months ended June 30, 2021.

FFO. Our FFO decreased $0.1 million, or 0.8% to $12.1 million, compared to the three months ended June 30, 2021. The increase in rental revenue of $3.4 million is offset by interest expense of $1.9 million as well as management fee expense of $1.1 million associated with the intercompany agreements between Standard Bearer and the Service Center that started in January of 2022. As noted in Item 2., under Recent Activities, Ensign Group, Inc., the real estate properties and Standard Bearer entered into intercompany debt arrangements, including mortgage loans and the Revolving Credit Facility, and an intercompany management agreement with the formation of Standard Bearer in January of 2022. The additional offsets to rental revenue include increases in interest expense related to new mortgage loans held by HUD, property taxes and other expenses related to the formation of Standard Bearer.
All Other Revenue

Our other revenue increase by $5.4 million, or 21.3%, to $30.6 million, compared to the three months ended June 30, 2021. Other revenue for 2022 includes senior living revenue of $17.3 million and revenue from other ancillary services of $11.5 million and rental income of $1.8 million. The increase in other revenue is attributable to our senior living acquisitions as our senior living occupancy rate rebounds from the COVID-19 decreases.

Consolidated Financial Expenses
Rent — cost of services. Our rent — cost of services as a percentage of total revenue decreased by 0.3% to 5.1%, primarily due the growth in revenue outpacing the increase in rent expense.
General and administrative expense — General and administrative expense increased $1.6 million or 4.4%, to $38.5 million. This increase was primarily due to increases in wages and benefits due to enhanced performance and growth. General and administrative expense as a percentage of revenue decreased by 0.5% to 5.3%.
67

Depreciation and amortization — Depreciation and amortization expense increased $1.1 million, or 7.7%, to $14.9 million. This increase was primarily related to the additional depreciation and amortization incurred as a result of our newly acquired operations and capital expenditures. Depreciation and amortization decreased 0.2%, to 2.0%, as a percentage of revenue.
Other expense, net — Other expense, net as a percentage of revenue increased by 0.6% to 0.7%. Other expense primarily includes interest expense related to our debt and gain or loss on the deferred compensation investment program. During the three months ended June 30, 2022, we recorded a loss on those investments of $3.3 million compared to a gain of $0.8 million during the three months ended June 30, 2021. There is an offsetting reduction in expense split between cost of services and general and administrative expenses for both periods.
Provision for income taxes —  Our effective tax rate was 20.8% for the three months ended June 30, 2022, compared to 21.4% for the same period in 2021. The effective tax rate for both periods is driven by the impact of excess tax benefits from stock-based compensation, partially offset by non-deductible expenses including non-deductible compensation. See Note 15, Income Taxes, in the Notes to the Unaudited Condensed Consolidated Financial Statements for further discussion.

Six Months Ended June 30, 2022 Compared to the Six Months Ended June 30, 2021
The following table sets forth details of operating results for our revenue and earnings, and their respective components, by our reportable segment for the periods indicated:
Six Months Ended June 30, 2022
 Skilled servicesStandard BearerAll OtherEliminationsConsolidated
Total revenue $1,389,249 $34,791 $57,949 $(36,058)$1,445,931 
Total expenses, including other expense, net1,188,727 21,053 135,493 (36,058)1,309,215 
Segment income (loss)200,522 13,738 (77,544)— 136,716 
Gain from sale of real estate2,467 
Income before provision for income taxes $139,183 
Six Months Ended June 30, 2021
 Skilled servicesStandard BearerAll OtherEliminationsConsolidated
Total revenue $1,213,918 $28,283 $50,974 $(27,386)$1,265,789 
Total expenses, including other expense, net1,034,977 12,664 118,847 (27,386)1,139,102 
Segment income (loss)178,941 15,619 (67,873)— 126,687 
Loss from sale of real estate and impairment charges440 
Income before provision for income taxes$127,127 

Our total revenue increased $180.1 million, or 14.2%, compared to the six months ended June 30, 2021. The increase in revenue was primarily driven by an increase in patient days and occupancy from our skilled services operations, along with the impact of acquisitions. Total revenue from operations acquired on or subsequent to January 1, 2021 increased our consolidated revenue by $82.8 million during the six months ended June 30, 2022, when compared to the same period in 2021. In addition, we recorded $42.1 million of state relief revenue during the six months ended in 2022 compared to $33.2 million in 2021, which directly correlated to the additional COVID-19 related expenses incurred. All state relief revenue is included in Medicaid revenue.

68

Skilled Services Segment

Revenue

The following table presents the skilled services revenue and key performance metrics by category during the six months ended June 30, 2022 and 2021:
Six Months Ended June 30,
 20222021Change% Change
TOTAL FACILITY RESULTS:(Dollars in thousands)
Skilled services revenue$1,389,249 1,213,918 $175,331 14.4 %
Number of facilities at period end215 206 4.4 %
Number of campuses at period end*25 25 — — %
Actual patient days3,440,991 3,109,307 331,684 10.7 %
Occupancy percentage — Operational beds74.7 %71.9 % 2.8 %
Skilled mix by nursing days32.4 %32.6 % (0.2)%
Skilled mix by nursing revenue52.6 %53.5 % (0.9)%
Six Months Ended June 30,
 20222021Change% Change
SAME FACILITY RESULTS:(1)
(Dollars in thousands)
Skilled services revenue$1,096,733 $1,022,580 $74,153 7.3 %
Number of facilities at period end167 167 — — %
Number of campuses at period end*20 20 — — %
Actual patient days2,669,934 2,584,029 85,905 3.3 %
Occupancy percentage — Operational beds75.4 %73.1 % 2.3 %
Skilled mix by nursing days33.9 %33.7 % 0.2 %
Skilled mix by nursing revenue54.1 %54.6 % (0.5)%
Six Months Ended June 30,
20222021Change% Change
TRANSITIONING FACILITY RESULTS:(2)
(Dollars in thousands)
Skilled services revenue$186,677 $160,887 $25,790 16.0 %
Number of facilities at period end27 27 — — %
Number of campuses at period end*— — %
Actual patient days488,679 445,552 43,127 9.7 %
Occupancy percentage — Operational beds73.5 %67.2 % 6.3 %
Skilled mix by nursing days27.8 %26.8 % 1.0 %
Skilled mix by nursing revenue47.7 %47.1 % 0.6 %
69

Six Months Ended June 30,
20222021Change% Change
RECENTLY ACQUIRED FACILITY RESULTS:(3)
(Dollars in thousands)
Skilled services revenue$105,839 $30,451 $75,388 NM
Number of facilities at period end21 12 NM
Number of campuses at period end*— — — NM
Actual patient days282,378 79,726 202,652 NM
Occupancy percentage — Operational beds70.2 %64.4 %NM
Skilled mix by nursing days26.2 %26.7 % NM
Skilled mix by nursing revenue45.7 %49.1 % NM
*Campus represents a facility that offers both skilled nursing and senior living services. Revenue and expenses related to skilled nursing and senior living services have been allocated and recorded in the respective operating segment. In the first half of 2022, we converted three skilled nursing facilities into campuses.
(1)Same Facility results represent all facilities purchased prior to January 1, 2019.
(2)Transitioning Facility results represent all facilities purchased from January 1, 2019 to December 31, 2020.
(3)Recently Acquired Facility (Acquisitions) results represent all facilities purchased on or subsequent to January 1, 2021.

Skilled services revenue increased $175.3 million, or 14.4%, compared to the six months ended June 30, 2021. Of the $175.3 million increase, the primary changes were from increases in Medicaid custodial revenue of $74.0 million, or 15.6%, managed care revenue of $35.0 million, or 15.8% and Medicare revenue of $38.6 million, or 10.7%.

The increase in revenue was primarily driven by our consolidated occupancy increasing by 2.8%, which includes operations acquired at lower occupancy, compared to the same period in the prior year. As COVID-19 cases declined from the same period in the previous year, there was a shift in Medicare patients to LTC patients. However, strong skilled mix days were maintained due to increase in managed care and other skilled days.

Revenue in our Same Facilities increased $74.2 million, or 7.3% due to increased occupancy and increase in skilled mix days. Our diligent efforts to strengthen our partnership with various managed care organizations, hospitals, and the local communities we operate in, increased our occupancy by 2.3% to 75.4%. Managed care skilled days increased by 6.8%, resulting in an increase in managed care revenue.

Revenue generated by our Transitioning Facilities increased $25.8 million, or 16.0%, primarily due to improved occupancy growth of 6.3% to 73.5% and an increase in our total patient days and skilled mix days compared to the six months ended June 30, 2021, demonstrating our ability to transition these healthcare operations toward higher acuity patients. Managed care and Medicare days increased by 22.0% and 7.0%, respectively, resulting in an increase in managed care and Medicare revenue.

Skilled services revenue generated by facilities purchased on or subsequent to January 1, 2021 (Recently Acquired Facilities) increased by approximately $75.4 million compared to the six months ended June 30, 2021. We acquired nine operations between July 1, 2021 and June 30, 2022 across four states.
In the future, if we acquire additional facilities that are underperforming and need to be turned around or invest in start-up operations, we expect to see lower occupancy rates and skilled mix and these metrics are expected to vary from period to period based upon the maturity of the facilities within our portfolio. Historically, we have generally experienced lower occupancy rates and lower skilled mix at Recently Acquired Facilities and therefore, we anticipate generally lower overall occupancy during years of growth.
70

The following table reflects the change in skilled nursing average daily revenue rates by payor source, excluding services that are not covered by the daily rate (1):
Six Months Ended June 30,
 Same FacilityTransitioningAcquisitionsTotal
 20222021202220212022202120222021
SKILLED NURSING AVERAGE DAILY REVENUE RATES
Medicare$691.85 $687.54 $687.25 $679.73 $690.41 $755.33 $691.10 $688.12 
Managed care511.59 505.69 473.98 459.08 509.64 523.55 506.90 500.60 
Other skilled579.17 540.72 462.30 403.54 490.07 541.48 561.53 531.74 
Total skilled revenue597.07 588.07 577.72 569.60 587.31 647.77 594.06 587.15 
Medicaid260.73 250.79 246.75 234.03 246.33 243.36 257.26 247.95 
Private and other payors252.02 239.22 231.51 235.10 254.79 263.40 249.02 238.98 
Total skilled nursing revenue
$373.74 $363.44 $337.13 $324.03 $336.18 $352.74 $365.45 $357.51 
(1) These rates exclude additional Federal Medical Assistance Percentage (FMAP) and include sequestration reversal of 1% for the second quarter in 2022 and 2% for the first quarter of 2022 and the six months ended June 30, 2021.

Our Medicare daily rates at Same Facilities and Transitioning Facilities increased by 0.6% and 1.1%, respectively, compared to the six months ended June 30, 2021. The increase is attributable to the 1.2% net market basket increase that became effective in October 2021. Medicare daily rates in 2022 includes three months of sequestration reversal of 1% and three months of sequestration of reversal of 2% compared to six months of sequestration reversal of 2% in 2021.

Our average Medicaid rates increased 3.8% due to state reimbursement increases and our participation in supplemental Medicaid payment programs and quality improvement programs in various states. Medicaid rates exclude the amount of state relief revenue we recorded.
Payor Sources as a Percentage of Skilled Nursing Services. We use our skilled mix as a measure of the quality of reimbursements we receive at our affiliated skilled nursing facilities over various periods.


The following tables set forth our percentage of skilled nursing patient revenue and days by payor source:

 Six Months Ended June 30,
 Same FacilityTransitioningAcquisitionsTotal
 20222021202220212022202120222021
PERCENTAGE OF SKILLED NURSING REVENUE
Medicare25.9 %26.9 %27.9 %29.4 %24.5 %29.4 %26.1 %27.3 %
Managed care19.7 19.4 16.2 14.7 11.7 7.4 18.6 18.5 
Other skilled8.5 8.3 3.6 3.0 9.5 12.3 7.9 7.7 
Skilled mix54.1 54.6 47.7 47.1 45.7 49.1 52.6 53.5 
Private and other payors6.9 6.5 7.6 7.5 6.0 4.6 7.0 6.5 
Medicaid39.0 38.9 44.7 45.4 48.3 46.3 40.4 40.0 
TOTAL SKILLED NURSING100.0 %100.0 %100.0 %100.0 %100.0 %100.0 %100.0 %100.0 %

71

 Six Months Ended June 30,
 Same FacilityTransitioningAcquisitionsTotal
 20222021202220212022202120222021
PERCENTAGE OF SKILLED NURSING DAYS
Medicare14.0 %14.2 %13.7 %14.0 %11.9 %13.7 %13.8 %14.2 %
Managed care14.4 13.9 11.5 10.4 7.7 5.0 13.4 13.2 
Other skilled5.5 5.6 2.6 2.4 6.6 8.0 5.2 5.2 
Skilled mix33.9 33.7 27.8 26.8 26.2 26.7 32.4 32.6 
Private and other payors10.2 9.9 11.1 10.4 7.9 6.1 10.2 9.8 
Medicaid55.9 56.4 61.1 62.8 65.9 67.2 57.4 57.6 
TOTAL SKILLED NURSING100.0 %100.0 %100.0 %100.0 %100.0 %100.0 %100.0 %100.0 %

Cost of Services

The following table sets forth total cost of services for our skilled services segment for the periods indicated (dollars in thousands):
 Six Months Ended June 30,Change
20222021$%
Cost of service$1,078,925 $935,177 $143,748 15.4 %
Revenue percentage77.7 %77.0 %0.7 %

Cost of services related to our skilled services segment increased by $143.7 million, or 15.4%, due primarily to additional costs at new acquisitions, which accounted for $59.6 million of the increase to cost of services with additional increases mainly due to higher staffing expenses. Cost of services as a percentage of revenue increased to 77.7% from 77.0%.
Standard Bearer
 Six Months Ended June 30,Change
20222021$%
(Dollars in thousands)
Rental revenue generated from third-party tenants$7,472 6,908 $564 8.2 %
Rental revenue generated from Ensign affiliated operations27,319 21,375 5,944 27.8 
TOTAL RENTAL REVENUE$34,791 $28,283 $6,508 23.0 %
Segment income13,738 15,619 (1,881)(12.0)
Depreciation and amortization10,237 8,403 1,834 21.8 
FFO$23,975 $24,022 $(47)(0.2)%

Rental revenue. Our rental revenue, including revenue generated from our affiliated facilities, increased by $6.5 million, or 23.0% to $34.8 million, compared to the six months ended June 30, 2021. The increase in revenue is primarily attributable to seven real estate purchases as well as annual rent increases since the six months ended June 30, 2021.

FFO. Our FFO remained consistent at $24.0 million, for both the six months ended June 30, 2022 and 2021. The increase in rental revenue of $6.5 million is offset by interest expense of $3.8 million as well as management fee expense of $2.1 million associated with the intercompany agreements between Standard Bearer and the Service Center starting in January of 2022. As noted in Item 2., Recent Activities, the Company, the real estate properties and Standard Bearer entered into intercompany debt arrangements, including mortgage loans and the Revolving Credit Facility, and an intercompany management agreement with the formation of Standard Bearer in January of 2022. The additional offsets to rental revenue include increases in interest expense related to new mortgage loans held by HUD, and other expenses related to the formation of Standard Bearer.

72

All Other Revenue

Our other revenue increased by $7.0 million, or 13.7% to $57.9 million, compared to the six months ended June 30, 2021. Other revenue for 2022 includes senior living revenue of $30.9 million and revenue from other ancillary services of $23.3 million and rental income of $3.7 million. The increase in other revenue is attributable to our senior living acquisitions as our senior living occupancy rate rebounds from COVID-19 decreases.

Consolidated Financial Expenses
Rent — cost of services. Our rent — cost of services as a percentage of total revenue decreased by 0.4% to 5.0%, primarily due to the growth in revenue outpacing the increase in rent expense.
General and administrative expense. General and administrative expense increased $5.6 million or 7.9%, to $76.8 million. This increase was primarily due to increases in wages and benefits due to enhanced performance and growth. General and administrative expense as a percentage of revenue decreased by 0.1% to 5.4%.
Depreciation and amortization. Depreciation and amortization expense increased $2.1 million, or 7.6%, to $29.5 million. This increase was primarily related to the additional depreciation and amortization incurred as a result of our newly acquired operations. Depreciation and amortization decreased 0.2%, to 2.0%, as a percentage of revenue.
Other expense, net. Other expense, net as a percentage of revenue increased by 0.3%, to 0.5%. Other expense primarily includes interest expense related to our debt and gain or loss on the deferred compensation investments. During the six months ended June 30, 2022, we recorded a loss on those investments of $4.5 million compared to a gain of $1.1 million during the six months ended June 30, 2021. There is an offsetting reduction in expense split between cost of services and general and administrative expenses for both periods.
Provision for income taxes.  Our effective tax rate was 22.5% for the six months ended June 30, 2022, compared to 21.0% for the same period in 2021. The effective tax rate for both periods is driven by the impact of excess tax benefits from stock-based compensation, partially offset by non-deductible expenses. The higher effective tax rate reflects a decrease in tax benefit from stock-based payment awards. See Note 15, Income Taxes, in the Notes to the Unaudited Condensed Consolidated Financial Statements for further discussion.

Liquidity and Capital Resources
Our primary sources of liquidity have historically been derived from our cash flows from operations and long-term debt secured by our real property and our Revolving Credit Facility. Our liquidity as of June 30, 2022 is impacted by cash generated from strong operational performance and increased acquisition and share repurchase activities.
Historically, we have primarily financed the majority of our acquisitions through mortgages on our properties, our Revolving Credit Facility and cash generated from operations. Total capital expenditures for property and equipment were $37.1 million and $33.8 million for the six months ended June 30, 2022 and 2021, respectively. We currently have approximately $70.0 million budgeted for renovation projects for 2022. We believe our current cash balances, our cash flow from operations and the amounts available for borrowing under our Revolving Credit Facility will be sufficient to cover our operating needs for at least the next 12 months.

We may, in the future, seek to raise additional capital to fund growth, capital renovations, operations and other business activities, but such additional capital may not be available on acceptable terms, on a timely basis, or at all.

Our cash and cash equivalents as of June 30, 2022 consisted of bank term deposits, money market funds and U.S. Treasury bill related investments. In addition, as of June 30, 2022, we held debt security investments of approximately $49.1 million, which were split between AA, A and BBB rated securities. We believe our debt security investments that were in an unrealized loss position as of June 30, 2022 were not other-than-temporarily impaired, nor has any event occurred subsequent to that date that would indicate any other-than-temporary impairment.

As mentioned above, our primary sources of cash is from our ongoing operations. Our positive cash flows have supported our business and have allowed us to pay regular dividends to our stockholders. We currently anticipate that existing cash and total investments as of June 30, 2022, along with projected operating cash flows and available financing, will support our normal business operations for the foreseeable future.
73

On October 21, 2021, the Board of Directors approved a stock repurchase program pursuant to which we may repurchase up to $20.0 million of our common stock under the program for a period of approximately 12 months from October 29, 2021. During the three months ended March 31, 2022, we repurchased approximately 0.1 million shares of our common stock for $9.9 million. This repurchase program expired upon the repurchase of the fully authorized amount under the plan. On February 9, 2022, the Board of Directors approved a stock repurchase program pursuant to which we may repurchase up to $20.0 million of our common stock under the program for a period of approximately 12 months from February 10, 2022. During the three months ended June 30, 2022, we repurchased approximately 0.3 million shares of our common stock for $20.0 million. This repurchase program expired upon the repurchase of the fully authorized amount under the plan. The share repurchase programs do not obligate us to acquire any specific number of shares.
The following table presents selected data from our condensed consolidated statement of cash flows for the periods presented:
Six Months Ended June 30,
 20222021
NET CASH PROVIDED BY/(USED IN):(In thousands)
Operating activities$129,813 $108,397 
Investing activities(76,596)(40,862)
Financing activities(29,838)(105,686)
Net increase/(decrease) in cash and cash equivalents23,379 (38,151)
Cash and cash equivalents beginning of period262,201 236,562 
Cash and cash equivalents at end of period$285,580 $198,411 
Operating Activities
Cash provided by operating activities is net income adjusted for certain non-cash items and changes in operating assets and liabilities.
The $21.4 million increase in cash provided by operating activities for the six months ended June 30, 2022 compared to the same period in 2021, was primarily due to higher net income and changes in working capital. Changes in working capital were driven by timing of collections of accounts receivable and payments of accounts payable and other accrued liabilities.
Investing Activities
Investing cash flows consist primarily of capital expenditures, investment activities, insurance proceeds and cash used for acquisitions.
The $35.7 million increase in cash used in investing activities for the six months ended June 30, 2022 compared to the same period in 2021, was primarily due to an increase in cash used for expansions and capital expenditures of $41.6 million offset by cash proceeds from the sale of assets of $6.8 million.
Financing Activities
Financing cash flows consist primarily of payment of dividends to stockholders, issuance and repayment of short-term and long-term debt, payment for share repurchases, repayment of the Medicare Accelerated and Advance Payment Program funds and sale of subsidiary shares.

The $75.8 million decrease in cash used in financing activities for the six months ended June 30, 2022 compared to the same period in 2021, was primarily due to the $102.0 million of net proceeds and repayment of the Medicare Accelerated and Advance Payment Program funds in 2021, offset by $29.9 million of share repurchases as part of our stock repurchase program in 2022. Additionally, we received proceeds of $6.7 million from the sale of preferred shares and common stock of Standard Bearer offset by payment of deferred financing fees of $3.2 million associated with the entry into the Amended Credit Agreement in April 2022.
74

Credit Facility with a Lending Consortium Arranged by Truist

On April 8, 2022, we entered into the Amended Credit Agreement, which increased the amount of the revolving line of credit thereunder to $600.0 million in aggregate principal amount. The maturity date of the Revolving Credit Facility is April 8, 2027. Borrowings are supported by a lending consortium arranged by Truist. The interest rates applicable to loans under the Revolving Credit Facility are, at our option, equal to either a base rate plus a margin ranging from 0.25% to 1.25% per annum or SOFR plus a margin range from 1.25% to 2.25% per annum, based on the Consolidated Total Net Debt to Consolidated EBITDA ratio (as defined in the Amended Credit Agreement). In addition, we will pay a commitment fee on the unused portion of the commitments that will range from 0.20% to 0.40% per annum, depending on the Consolidated Total Net Debt to Consolidated EBITDA ratio.
Mortgage Loans and Promissory Notes

As of June 30, 2022, 23 of our subsidiaries have mortgage loans insured with HUD for an aggregate amount of $155.1 million, which subjects these subsidiaries to HUD oversight and periodic inspections. The mortgage loans bear effective interest rates at a range of 3.1% to 4.2%, including fixed interest rates at a range of 2.4% to 3.3% per annum. Amounts borrowed under the mortgage loans may be prepaid, subject to prepayment fees of the principal balance on the date of prepayment. For the majority of the loans, the prepayment fee is 10% during the first three years and is reduced by 3% in the fourth year of the loan, and is reduced by 1% per year for years five through ten of the loan. There is no prepayment penalty after year ten. The term of the mortgage loans are 25 to 35 years.

In addition to the HUD mortgage loans above, we have two promissory notes. The notes bear fixed interest rates of 6.3% and 5.3% per annum and the term of the notes are 10 months and 12 years, respectively. The 12 year note, which was used for an acquisition, is secured by the real property comprising the facility and the rent, issues and profits thereof, as well as all personal property used in the operation of the facility.
Operating Leases
As of June 30, 2022, 180 of our facilities are under long-term lease arrangements, of which 96 of the operations are under nine triple-net Master Leases and one stand-alone lease with CareTrust REIT, Inc. (CareTrust). The Master Leases consist of multiple leases, each with its own pool of properties, that have varying maturities and diversity in property geography. Under each master lease, our individual subsidiaries that operate those properties are the tenants and CareTrust's individual subsidiaries that own the properties subject to the Master Leases are the landlords. The rent structure under the Master Leases includes a fixed component, subject to annual escalation equal to the lesser of the percentage change in the Consumer Price Index (but not less than zero) or 2.5%. At our option, we can extend the Master Leases for two or three five-year renewal terms beyond the initial term, on the same terms and conditions. If we elect to renew the term of a Master Lease, the renewal will be effective as to all, but not less than all, of the leased property then subject to the Master Lease. Additionally, four of the 97 facilities leased from CareTrust include an option to purchase that we can exercise starting on December 1, 2024.
We also lease certain affiliated facilities and our administrative offices under non-cancelable operating leases, most of which have initial lease terms ranging from five to 20 years and is subject to annual escalation equal to the percentage change in the Consumer Price Index with a stated cap percentage. In addition, we lease certain of our equipment under non-cancelable operating leases with initial terms ranging from three to five years. Most of these leases contain renewal options, certain of which involve rent increases.
Forty-four of our affiliated facilities, excluding the facilities that are operated under the Master Leases from CareTrust, are operated under eight separate master lease arrangements. Under these master leases, a breach at a single facility could subject one or more of the other affiliated facilities covered by the same master lease to the same default risk. Failure to comply with Medicare and Medicaid provider requirements is a default under several of our leases, master lease agreements and debt financing instruments. In addition, other potential defaults related to an individual facility may cause a default of an entire master lease portfolio and could trigger cross-default provisions in our outstanding debt arrangements and other leases. With an indivisible lease, it is difficult to restructure the composition of the portfolio or economic terms of the lease without the consent of the landlord.

75

U.S. Department of Justice Civil Investigative Demand

On May 31, 2018, we received a Civil Investigative Demand (CID) from the U.S. Department of Justice stating that it is investigating to determine whether we have violated the False Claims Act and/or the Anti-Kickback Statute with respect to the relationships between certain of our skilled nursing facilities and persons who served as medical directors, advisory board participants or other referral sources. The CID covered the period from October 3, 2013 through 2018, and was limited in scope to ten of our Southern California skilled nursing facilities. In October 2018, the Department of Justice made an additional request for information covering the period of January 1, 2011 through 2018, relating to the same topic. As a general matter, our operating entities maintain policies and procedures to promote compliance with the False Claims Act, the Anti-Kickback Statute, and other applicable regulatory requirements. We have fully cooperated with the U.S. Department of Justice and promptly responded to its requests for information; in April 2020, we were advised that the U.S. Department of Justice declined to intervene in any subsequent action based on or related to the subject matter of this investigation.
Inflation

We have historically derived a substantial portion of our revenue from the Medicare program. We also derive revenue from state Medicaid and similar reimbursement programs. Payments under these programs generally provide for reimbursement levels that are adjusted for inflation annually based upon the state’s fiscal year for the Medicaid programs and in each October for the Medicare program. These adjustments may not continue in the future, and even if received, such adjustments may not reflect the actual increase in our costs for providing healthcare services.

Labor and supply expenses make up a substantial portion of our cost of services. Those expenses can be subject to increase in periods of rising inflation and when labor shortages occur in the marketplace. To date, we have generally been able to implement cost control measures or obtain increases in reimbursement sufficient to offset increases in these expenses. There can be no assurance that we will be able to anticipate fully or otherwise respond to any future inflationary pressures.
Recent Accounting Pronouncements

Except for rules and interpretive releases of the Securities and Exchange Commission (SEC) under authority of federal securities laws and a limited number of grandfathered standards, the FASB ASC is the sole source of authoritative GAAP literature recognized by the FASB and applicable to us. For any new pronouncements announced, we consider whether the new pronouncements could alter previous generally accepted accounting principles and determines whether any new or modified principles will have a material impact on our reported financial position or operations in the near term. The applicability of any standard is subject to the formal review of our financial management and certain standards are under consideration.

Recent Accounting Standards Adopted by the Company - In November 2021, the FASB issued ASU 2021-10 “Government Assistance (Topic 832): Disclosures by Business Entities about Government Assistance,” which created FASB ASC Topic 832, Government Assistance (ASC 832). ASC 832 requires business entities to disclose information about certain government assistance they receive. We adopted this standard on January 1, 2022 and determined there was no material impact on the our condensed consolidated financial statements.

Accounting Standards Recently Issued but Not Yet Adopted by the Company In February 2020, the FASB issued ASU 2020-04 "Reference Rate Reform (Topic 848)" which provides temporary, optional practical expedients and exceptions to enable a smoother transition to reference rates which are expected to replace LIBOR reference rates. Adoption of the provisions of ASU 2020-04 is optional. The amendments are effective for all entities from the beginning of the interim period that includes the issuance date of the ASU. An entity may elect to apply the amendments prospectively through December 31, 2022. On April 8, 2022, we entered into the Amended Credit Facility, which increased the revolving credit facility by $250.0 million to an aggregate principal amount of up to $600.0 million. Pursuant to the Amended Credit Agreement, we transitioned from LIBOR to SOFR as the applicable reference rate for borrowings under the Revolving Credit Facility. As part of the transition from LIBOR to SOFR reference rates, we determined there was no material impact on our condensed consolidated financial statements.


76

Item 3.     QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
Interest Rate Risk. We are exposed to risks associated with market changes in interest rates through our borrowing arrangements and investments. In particular, our Revolving Credit Facility exposes us to variability in interest payments due to changes in SOFR interest rates. We manage our exposure to this market risk by monitoring available financing alternatives. Our mortgages and promissory notes require principal and interest payments through maturity pursuant to amortization schedules.

Our mortgages generally contain provisions that allow us to make repayments earlier than the stated maturity date. In some cases, we are not allowed to make early repayment prior to a cutoff date. Where prepayment is permitted, we are generally allowed to make prepayments only at a premium which is often designed to preserve a stated yield to the note holder. These prepayment rights may afford us opportunities to mitigate the risk of refinancing our debts at maturity at higher rates by refinancing prior to maturity.
As of June 30, 2022, there was no outstanding debt under our Amended Credit Facility. We have outstanding indebtedness under mortgage loans insured with HUD and two promissory notes to third parties of $158.3 million all of which are at fixed interest rates.

On April 8, 2022, we entered into the Amended Credit Agreement, with a revolving line of credit of up to $600.0 million in aggregate principal amount. The Amended Credit Agreement amended the reference for borrowings under the Revolving Credit Facility rate from LIBOR to SOFR. We have no outstanding borrowings under our Amended Credit Facility as of July 27, 2022.

Our cash and cash equivalents as of June 30, 2022 consisted of bank term deposits, money market funds and U.S. Treasury bill related investments. In addition, as of June 30, 2022, we held debt security investments of approximately $49.1 million which were split between AA, A, and BBB rated securities. We believe our debt security investments that were in an unrealized loss position as of June 30, 2022 were not other-than-temporarily impaired, nor has any event occurred subsequent to that date that would indicate any other-than-temporary impairment. Our market risk exposure is interest income sensitivity, which is affected by changes in the general level of U.S. interest rates. The primary objective of our investment activities is to preserve principal while at the same time maximizing the income we receive from our investments without significantly increasing risk. Due to the low risk profile of our investment portfolio, an immediate 10.0% change in interest rates would not have a material effect on the fair market value of our portfolio. Accordingly, we would not expect our operating results or cash flows to be affected to any significant degree by the effect of a sudden change in market interest rates on our securities portfolio.

The above only incorporates those exposures that exist as of June 30, 2022 and does not consider those exposures or positions which could arise after that date. If we diversify our investment portfolio into securities and other investment alternatives, we may face increased risk and exposures as a result of interest risk and the securities markets in general.


Item 4. CONTROLS AND PROCEDURES
Disclosure Controls and Procedures
Under the supervision and with the participation of our management, including the Chief Executive Officer and Chief Financial Officer, we have evaluated the effectiveness of our disclosure controls and procedures (as such term is defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act as of the end of the period covered by this Quarterly Report on Form 10-Q. Based on that evaluation, the Chief Executive Officer and Chief Financial Officer have concluded that these disclosure controls and procedures are effective.
There were no changes in our internal control over financial reporting (as such term is defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) that occurred during the three months ended June 30, 2022, that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

77


PART II.


Item 1.        LEGAL PROCEEDINGS
Regulatory Matters Laws and regulations governing Medicare and Medicaid programs are complex and subject to review and interpretation. Compliance with such laws and regulations is evaluated regularly, the results of which can be subject to future governmental review and interpretation, and can include significant regulatory action with fines, penalties, and exclusion from certain governmental programs. Included in these laws and regulations are rules requiring vaccination of employees and HIPAA, the terms of which require healthcare providers (among other things) to safeguard the privacy and security of certain patient protected health information.
Cost-Containment MeasuresBoth government and private pay sources have instituted cost-containment measures designed to limit payments made to providers of healthcare services, and there can be no assurance that future measures designed to limit payments made to providers will not adversely affect us.
IndemnitiesFrom time to time, we enter into certain types of contracts that contingently require us to indemnify parties against third-party claims. These contracts primarily include (i) certain real estate leases, under which we may be required to indemnify property owners or prior facility operators for post-transfer environmental or other liabilities and other claims arising from our use of the applicable premises, (ii) operations transfer agreements, in which we agree to indemnify past operators of facilities we acquire against certain liabilities arising from the transfer of the operation and/or the operation thereof after the transfer to the Company's independent operating subsidiary, (iii) certain lending agreements, under which we may be required to indemnify the lender against various claims and liabilities, and (iv) certain agreements with our officers, directors and others, under which we may be required to indemnify such persons for liabilities arising out of the nature of their relationship to the Company. The terms of such obligations vary by contract and, in most instances, do not expressly state or include a specific or maximum dollar amount. Generally, amounts under these contracts cannot be reasonably estimated until a specific claim is asserted. Consequently, because no claims have been asserted, no liabilities have been recorded for these obligations on our balance sheets for any of the periods presented.

In connection with the Spin-Off, certain landlords required, in exchange for their consent to the transaction, that our lease guarantees remain in place for a certain period of time following the Spin-Off. These guarantees could result in significant additional liabilities and obligations for us if Pennant were to default on their obligations under their leases with respect to these properties.
U.S. Department of Justice Civil Investigative Demand — On May 31, 2018, we received a CID from the U.S. Department of Justice stating that it was investigating to determine whether there had been a violation of the False Claims Act and/or the Anti-Kickback Statute with respect to the relationships between certain of our independently operated skilled nursing facilities and persons who serve or have served as medical directors, advisory board participants or other potential referral sources. The CID covered the period from October 3, 2013 through 2018, and was limited in scope to ten of our Southern California independent operating entities. In October 2018, the Department of Justice made an additional request for information covering the period of January 1, 2011 through 2018, relating to the same topic. As a general matter, our independent operating entities have established and maintain policies and procedures to promote compliance with the False Claims Act, the Anti-Kickback Statute, and other applicable regulatory requirements. We have fully cooperated with the U.S. Department of Justice and promptly responded to its requests for information; in April 2020, we were advised that the U.S. Department of Justice declined to intervene in any subsequent action filed by a relator in connection with the subject matter of this investigation.
LitigationWe and our independent operating entities are party to various legal actions and administrative proceedings, and are subject to various claims arising in the ordinary course of business, including claims that services provided to patients by our independent operating entities have resulted in injury or death, and claims related to employment and commercial matters. Although we intend to vigorously defend against these claims, there can be no assurance that the outcomes of these matters will not have a material adverse effect on operational results and financial condition. In certain states in which we have or have had independent operating entities, insurance coverage for the risk of punitive damages arising from general and professional liability litigation may not be available due to state law and/or public policy prohibitions. There can be no assurance that our independent operating entities will not be liable for punitive damages awarded in litigation arising in states for which punitive damage insurance coverage is not available.

78

The skilled nursing and post-acute care industry is heavily regulated. As such, we and our independent operating subsidiaries are continuously subject to state and federal regulatory scrutiny, supervision and control in the ordinary course of business. Such regulatory scrutiny often includes inquiries, investigations, examinations, audits, site visits and surveys, some of which are non-routine. In addition to being subject to direct regulatory oversight from state and federal agencies, the skilled nursing and post-acute care industry is also subject to regulatory requirements which could result in civil, administrative or criminal fines, penalties or restitutionary relief, and reimbursement; authorities could also seek the suspension or exclusion of the provider or individual from participation in their programs. We believe that there has been, and will continue to be, an increase in governmental investigations of LTC providers, particularly in the area of Medicare/Medicaid false claims, as well as an increase in enforcement actions resulting from these investigations. Adverse determinations in legal proceedings or governmental investigations, whether currently asserted or arising in the future, could have a material adverse effect on our financial position, results of operations, and cash flows.

Additionally, and in 2020, the U.S. House of Representatives Select Subcommittee on the Coronavirus Crisis launched a nation-wide investigation into the COVID-19 pandemic, which included the impact of the coronavirus on residents and employees in nursing homes. In June 2020, we and our independent operating subsidiaries received a document and information request from the House Select Subcommittee. We and our independent operating subsidiaries have cooperated in responding to this inquiry. In July 2022, we and our independent operating subsidiaries received a follow up request for additional documents and information. We and our independent operating subsidiaries are cooperating in responding to this inquiry. However, it is not possible to predict the ultimate outcome of any such investigation, or whether and what other investigations or regulatory responses may result from the investigation, which could have a material adverse effect on our reputation, business, financial condition and results of operations.

In addition to the potential lawsuits and claims described above, we and our independent operating subsidiaries are also subject to potential lawsuits under the Federal False Claims Act and comparable state laws alleging submission of fraudulent claims for services to any healthcare program (such as Medicare or Medicaid) or other payor. A violation may provide the basis for exclusion from Federally funded healthcare programs. Such exclusions could have a correlative negative impact on our financial performance. Under the qui tam or "whistleblower" provisions of the False Claims Act, a private individual with knowledge of fraud or potential fraud may bring a claim on behalf of the Federal Government and receive a percentage of the Federal Government's recovery. Due to these whistleblower incentives, qui tam lawsuits have become more frequent. For example, and despite the decision of the U.S. Department of Justice to decline to participate in litigation based on the subject matter of its previously issued Civil Investigative Demand, the involved qui tam relator is continuing on with the lawsuit and pursuing claims that one or more of the Company's independent operating entities have allegedly violated the False Claims Act and/or the AKS.

In addition to the Federal False Claims Act, some states, including California, Arizona and Texas, have enacted similar whistleblower and false claims laws and regulations. Further, the Deficit Reduction Act of 2005 created incentives for states to enact anti-fraud legislation modeled on the Federal False Claims Act. As such, we and our independent operating subsidiaries could face increased scrutiny, potential liability, and legal expenses and costs based on claims under state false claims acts in markets where our independent operating subsidiaries do business.

In May 2009, Congress passed the FERA which made significant changes to the Federal False Claims Act (FCA) and expanded the types of activities subject to prosecution and whistleblower liability. Following changes by FERA, health care providers face significant penalties for the knowing retention of government overpayments, even if no false claim was involved. Health care providers can now be liable for knowingly and improperly avoiding or decreasing an obligation to pay money or property to the government. This includes the retention of any government overpayment. The government can argue, therefore, that an FCA violation can occur without any affirmative fraudulent action or statement, as long as the action or statement is knowingly improper. In addition, FERA extended protections against retaliation for whistleblowers, including protections not only for employees, but also contractors and agents. Thus, an employment relationship is generally not required in order to qualify for protection against retaliation for whistleblowing.

Healthcare litigation (including class action litigation) is common and is filed based upon a wide variety of claims and theories, and our independent operating entities are routinely subjected to varying types of claims, including class action "staffing" suits where the allegation is understaffing at the facility level. These class-action “staffing” suits have the potential to result in large jury verdicts and settlements. We expect the plaintiffs' bar to continue to be aggressive in their pursuit of these staffing and similar claims.

79

We and our independent operating subsidiaries have been, and continue to be, subject to claims, findings and legal actions that arise in the ordinary course of the various businesses, including healthcare and non-healthcare services. These claims include, but are not limited to potential claims related to patient care and treatment (professional negligence claims) as well as employment related claims. In addition, we and our independent operating subsidiaries, and others in the industry, are subject to claims and lawsuits in connection with COVID-19 and facility preparation for and/or response to the COVID-19 pandemic. While we have been able to settle or otherwise resolve these types of claims without an ongoing material adverse effect on our business, a significant increase in the number of these claims, or an increase in the amounts owing should plaintiffs be successful in their prosecution of future claims, could materially adversely affect the Company’s business, financial condition, results of operations and cash flows. In addition, these claims could impact our ability to procure insurance to cover our exposure related to the various services provided by our independent operating subsidiaries to their residents, customers and patients.
Claims and suits, including class actions, continue to be filed against our independent operating subsidiaries and other companies in the post-acute care industry. We and our independent operating entities have been subjected to, and/or are currently involved in, class action litigation alleging violations (alone or in combination) of state and federal wage and hour law as related to the alleged failure to pay wages, to timely provide and authorize meal and rest breaks, and other such similar causes of action. We do not believe that the ultimate resolution of these actions will have a material adverse effect on our business, cash flows, financial condition or results of operations.
Medicare Revenue RecoupmentsWe and our independent operating subsidiaries are subject to regulatory reviews relating to the provision of Medicare services, billings and potential overpayments resulting from reviews conducted via RAC, Program Safeguard Contractors, and Medicaid Integrity Contractors (collectively referred to as Reviews). For several months during the COVID-19 pandemic, CMS suspended its Targeted Probe and Educate Program. Beginning in August 2020, CMS resumed Targeted Probe and Educate Program activity. If an operation fails a Review and/or subsequent Reviews, the operation could then be subject to extended review or an extrapolation of the identified error rate to billings in the same time period. We anticipate that these Reviews could increase in frequency in the future. As of June 30, 2022 and since, 22 of our independent operating subsidiaries had Reviews scheduled, on appeal, or in a dispute resolution process.

80

Item 1A.        RISK FACTORS
We are providing the following summary of the risk factors contained in our Form 10-Q to enhance the readability and accessibility of our risk factor disclosures. We encourage our stockholders to carefully review the risk factors contained in this Form 10-Q in their entirety for additional information regarding the risks and uncertainties that could cause our actual results to vary materially from recent results or from our anticipated future results.

Risks Related to our Business and Industry

We face numerous risks related to the COVID-19 public health emergency (PHE), which could individually or in the aggregate have a material adverse effect on our business, financial condition, liquidity, results of operations and prospects.
Changes to reimbursement rates and rules and other aspects of Medicare and Medicaid could have a material, adverse effect on our revenues, financial condition and results of operations, including the reductions to reimbursement proposed in the 2023 calendar year physician fee schedule and changes to data reporting and measurement standards.
Our revenue could be impacted by a shift to value-based reimbursement models, such as PDPM, and changes to existing reimbursement models.
Reforms to the U.S. healthcare system, including the ACA, continue to impose new requirements upon us and may increase our costs or lower our reimbursements, which could materially impact our business.
The recent U.S. Presidential and Congressional elections and upcoming midterm elections in 2022, for which certain primary campaigns are already underway, may create significant changes to the regulatory framework, enforcements, and reimbursements.
We are subject to various government reviews, audits and investigations that could adversely affect our business, including an obligation to refund amounts previously paid to us, potential criminal charges, the imposition of fines, and/or the loss of our right to participate in Medicare and Medicaid programs.
Failure to comply with applicable laws and regulations, including state-specific mandates or proclamations regarding COVID-19, or if these laws and regulations change, could cause us to incur significant expenses and/or change our operations in order to bring our facilities and operations into compliance.
Public and government calls for increased survey and enforcement efforts toward long-term care (LTC) facilities, potential rulemaking that may result in enhanced enforcement and penalties, and new guidance for surveyors regarding the review of LTC facilities and enforcement of their Requirements of Participation, could result in increased scrutiny by state and federal survey agencies. Potential sanctions and remedies based upon alleged regulatory deficiencies could negatively affect our financial condition and results of operations.
Future cost containment initiatives undertaken by third-party payors may limit our revenue and profitability.
Changes in Medicare reimbursements, including implementation of Medicare funds sequestration, for physician and non-physician services could impact reimbursement for medical professionals, which could have a negative effect on our business, financial condition or results of operations.
We may be subject to increased investigation and enforcement activities related to HIPAA violations if we fail to adopt and maintain business procedures and systems designed to protect the privacy, security and integrity of patients’ individual health information.
Security breaches and other cyber-security incidents could violate security laws and subject us to significant liability.
If we are not fully reimbursed for all services for which each facility bills through consolidated billing, our revenue, financial condition and results of operations could be adversely affected.
Increased competition for, or a shortage of, nurses and other skilled personnel could increase our staffing and labor costs and subject us to monetary fines resulting from a failure to maintain minimum staffing requirements, or may affect reimbursement.
Annual caps and other cost-reductions for outpatient therapy services may reduce our future revenue and profitability or cause us to incur losses.
Increased scrutiny of our billing practices by the Office of the Inspector General or other regulatory authorities may result in an increase in regulatory monitoring and oversight, decreased reimbursement rates, or otherwise adversely affect our business, financial condition and results of operations.
State efforts to regulate or deregulate the healthcare services industry or the construction or expansion of healthcare facilities could impair our ability to expand our operations, or could result in increased competition.
Newly enacted legislation in the States where our independently operating entities are located may impact the volume of cases filed and the overall cost of those cases from a defense and indemnity standpoint.
Changes to federal and state employment-related laws and regulations could increase our cost of doing business.
Required regulatory approvals could delay or prohibit transfers of our healthcare operations, which could result in periods in which we are unable to receive reimbursement for such properties.
Compliance with federal and state fair housing, fire, safety, staffing, and other regulations may require us to incur unexpected expenses, which could be costly to us.
We depend largely upon reimbursement from third-party payors, and our revenue, financial condition and results of operations could be negatively impacted by any changes in the acuity mix of patients in our affiliated facilities as well as payor mix and payment methodologies.
81

We are subject to litigation that could result in significant legal costs and large settlement amounts or damage awards. Similarly, a change in the enforceability of arbitration provisions between LTC facilities and SNFs with residents or patients may affect the risks we face from claims and potential litigation.
If our regular internal investigations into the care delivery, recordkeeping and billing processes of our operating subsidiaries detect instances of noncompliance, efforts to correct such non-compliance could materially decrease our revenue.
We may be unable to complete future facility or business acquisitions at attractive prices or at all, or may elect to dispose of underperforming or non-strategic operating subsidiaries, either of which could decrease our revenue.
We may not be able to successfully integrate acquired facilities and businesses into our operations, or we may be exposed to costs, liabilities and regulatory issues that may adversely affect our operations.
If we do not achieve or maintain competitive quality of care ratings from CMS or private organizations engaged in similar monitoring activities, our business may be negatively affected.
If we are unable to obtain insurance, or if insurance becomes more costly for us to obtain, our business may be adversely affected, and our self-insurance programs may expose us to significant and unexpected costs and losses.
The geographic concentration of our affiliated facilities could leave us vulnerable to economic downturn, regulatory changes or acts of nature in those areas.
The actions of a national labor union that has pursued a negative publicity campaign criticizing our business in the past may adversely affect our revenue and our profitability.
We lease the majority of our affiliated facilities, and risks associated with leased property, could adversely affect our business, financial position or results of operations.
Failure to generate sufficient cash flow to cover required payments or meet operating covenants under our long-term debt, mortgages and long-term operating leases could result in defaults under such agreements and cross-defaults under other debt, mortgage or operating lease arrangements, which could harm our operating subsidiaries and cause us to lose facilities or experience foreclosures.
Move-in and occupancy rates may remain unpredictable even after the COVID-19 pandemic is over.
A housing downturn could decrease demand for senior living services.
As we continue to acquire and lease real estate assets, we may not be successful in identifying and consummating these transactions.
As we expand our presence in other relevant healthcare industries, we would become subject to risks in a market in which we have limited experience.
If our referral sources fail to view us as an attractive skilled nursing provider, or if our referral sources otherwise refer fewer patients, our patient base may decrease.
We may need additional capital to fund our operating subsidiaries and finance our growth, and we may not be able to obtain it on terms acceptable to us, or at all, which may limit our ability to grow.
The condition of the financial markets, including recent and expected future increases to the federal funds rate, could limit the availability of debt and equity financing sources to fund the capital and liquidity requirements of our business, as well as negatively impact or impair the value of our current portfolio of cash, cash equivalents and investments.
Delays in reimbursement may cause liquidity problems.
Compliance with the regulations of the Department of Housing and Urban Development may require us to make unanticipated expenditures which could increase our costs.
Failure to safeguard our patient trust funds may subject us to citations, fines and penalties.
We are a holding company with no operations and rely upon our multiple independent operating subsidiaries to provide us with the funds necessary to meet our financial obligations. Liabilities of any one or more of our subsidiaries could be imposed upon us or our other subsidiaries.
We may incur operational difficulties or be exposed to claims and liabilities as a result of the separation of Pennant, including if the Spin-Off is not tax-free for U.S. federal income tax purposes.
We may not achieve some or all of the anticipated benefits of the Spin-Off, which may adversely affect our business.
The Spin-Off and related transactions may expose us to potential liabilities arising out of state and federal fraudulent conveyance laws and legal distribution requirements.
Certain directors who serve on our Board of Directors also serve as directors of Pennant, and ownership of shares of Pennant common stock by our directors and executive officers may create, or appear to create, conflicts of interest.

Risks Related to Ownership of our Common Stock

We may not be able to pay or maintain dividends and the failure to do so would adversely affect our stock price.
Our amended and restated certificate of incorporation, amended and restated bylaws and Delaware law contain provisions that could discourage transactions resulting in a change in control, which may negatively affect the market price of our common stock.


82

Risks Related to Our Business and Industry
We face numerous risks related to the COVID-19 PHE, which could have a material adverse effect on our business, financial condition, liquidity, results of operations and prospects.

The extent to which the COVID-19 PHE will continue impacting our operations will depend on future developments, which are highly uncertain and cannot be predicted with confidence, including the duration of the outbreak, ongoing federal and state vaccination programs and requirements, additional or modified government actions, the severity of various variants, efficacy of vaccinations and the ongoing actions to contain the virus or treat its impact, among others. Effective on July 15, 2022, HHS's PHE was extended through at least October 13, 2022. HHS has reported it will provide at least sixty (60) days' advance notice prior to the end of the PHE. Some of the risks of COVID-19 are being mitigated as a result of the federal vaccination program, including vaccinations and vaccine booster injections of nursing facility staff and residents, but there remains uncertainty as to when the pandemic will subside and eventually end.

As discussed in Item 2., under Government Regulation, federal, state and local regulators have implemented new regulations and waived existing regulations to promote care delivery during the COVID-19 PHE. While the majority of these changes are beneficial by reducing regulatory burdens, these accommodations may also have an adverse effect through increased legal and operational costs related to compliance and monitoring. Additionally, most of the accommodations are limited in duration and tied to the PHE declaration, thus there may be significant operational change requirements on short notice. By June 30, 2022, sixteen of the Emergency Waivers relevant to SNFs and LTC facilities had expired pursuant to CMS's April 7, 2022 memorandum announcing the phased expiration of those Emergency Waivers. Also, the reinstatement of waived state and federal regulations may not occur simultaneously, requiring heightened monitoring to ensure compliance.

Other factors from the continuation of the COVID-19 pandemic that could have an adverse effect on our business, financial condition, liquidity, results of operations and prospects, include:

potential for increased government regulations and restrictions to combat COVID-19;
increased strain on employees and resources caused by different waves of COVID-19 variants with different infection and effects, affecting employee availability and capacity to work;
significantly reduced occupancy as a result of concerns of residents and their families related to COVID-19 transmissibility within LTC settings, as well as due to government-imposed orders;
increased costs and staffing requirements related to additional CDC protocols, federal and state workforce protection and related isolation procedures, including obligations to test patients and staff for COVID-19 vaccination mandates;
limitations on availability of staff due to COVID-19 related illness or exposure, or due to unwillingness to comply with vaccine mandates;
disruptions to supply chains which could negatively impact consistent and reliable delivery of personal protective equipment, sanitizing supplies, food, pharmaceuticals, utilities and other goods to our affiliated facilities, resulting in our inability to obtain on reasonable terms, or at all, personal protective equipment, sanitizing supplies, food, pharmaceuticals, utilities and other goods;
incurrence of additional expenditures to comply with COVID-19 isolation procedures, including temporary construction or purchase of additional equipment;
increased scrutiny by regulators of infection control and prevention measures, including increased reporting requirements related to suspected and confirmed COVID-19 diagnoses of residents and staff, which may result in fines or other sanctions related to non-compliance;
increased risk of litigation and related liabilities arising in connection with patient or staff illness, hospitalization and/or death;
negative impacts on our patients' ability or willingness to pay for healthcare services and our third parties' ability or willingness to pay rents; and
new regulations which will require that all of our workers be fully vaccinated against COVID-19 as a condition of participating in the Medicare and Medicaid programs.

The extent and duration of the impact of the COVID-19 pandemic on our stock price is uncertain, our stock price may be more volatile, and our ability to raise capital could be impaired.


83

Our revenue could be impacted by federal and state changes to reimbursement and other aspects of Medicare.
We derived 26.2% and 27.7% of our service revenue from the Medicare programs for the three and six months ended June 30, 2022, respectively, and 26.8% and 28.6% for the three and six months ended June 30, 2021, respectively. In addition, many other payors may use published Medicare rates as a basis for reimbursements. Accordingly, if Medicare reimbursement rates are reduced or fail to increase as quickly as our costs, if there are changes in the rules governing the Medicare program that are disadvantageous to our business or industry, or if there are delays in Medicare payments, our business and results of operations will be adversely affected.

The Medicare program and its reimbursement rates and rules are subject to frequent change. These include statutory and regulatory changes, rate adjustments (including retroactive adjustments), annual caps that limit the amount that can be paid (including deductible and coinsurance amounts) administrative or executive orders and government funding restrictions, all of which may materially adversely affect the rates at which Medicare reimburses us for our services. Budget pressures often lead the federal government to reduce or place limits on reimbursement rates under Medicare. Implementation of these and other types of measures has in the past and could in the future result in substantial reductions in our revenue and operating margins. For example, see Item 2., under Government Regulation, Sequestration of Medicare Rates.

Additionally, Medicare payments can be delayed or declined due to determinations that certain costs are not reimbursable or reasonable because either adequate or additional documentation was not provided or because certain services were not covered or considered medically necessary. Additionally, revenue from these payors can be retroactively adjusted after a new examination during the claims settlement process or as a result of post-payment audits. New legislation and regulatory proposals could impose further limitations on government payments to healthcare providers.

In addition, CMS often changes the rules governing the Medicare program, including those governing reimbursement. Changes to the Medicare program that could adversely affect our business include:
administrative or legislative changes to base rates or the bases of payment;
limits on the services or types of providers for which Medicare will provide reimbursement;
changes in methodology for patient assessment and/or determination of payment levels;
changes in staff requirements (i.e. requiring all workers to be vaccinated against COVID-19 and receive booster injections for those vaccinations) as a condition of payment or eligibility for Medicare reimbursement (See also, Item 2., under Government Regulation);
the reduction or elimination of annual rate increases, or the end of the reduced payments deferment (See also, Item 2., under Government Regulation); or
an increase in co-payments or deductibles payable by beneficiaries.
Among the important statutory changes that are being implemented by CMS are provisions of the IMPACT Act. This law imposes a stringent timeline for implementing benchmark quality measures and data metrics across post-acute care providers (long stay hospitals, inpatient rehabilitation facilities, skilled nursing facilities (SNFs), and home health agencies). The enactment also mandates specific actions to design a unified payment methodology for post-acute providers. CMS continues to promulgate regulations to implement provisions of this enactment. Depending on the final details, the costs of implementation could be significant. The failure to meet implementation requirements could expose providers to fines and payment reductions. 


84

Reductions in reimbursement rates or the scope of services being reimbursed could have a material, adverse effect on our revenue, financial condition and results of operations or even result in reimbursement rates that are insufficient to cover our operating costs. Loss of Medicare reimbursement entirely would also have a material adverse effect on our revenue. Medicare may rescind our certification and terminate its payor agreements if not all of our employees are fully vaccinated consistent with CMS's interim final rule (IFR) requiring vaccination of SNF employees, which the United States Supreme Court has allowed enforcement of as of January 13, 2022. As of January 20, 2022, CMS’s IFR requiring vaccination of SNF employees took effect in the State of Texas, with SNF staff required to be fully vaccinated or to have exemptions granted by March 21, 2022. There has been no further activity regarding this IFR since January of 2022 when CMS became empowered to enact and enforce it nationwide. Failure to comply with the CMS IFR in all states by their applicable deadlines stated by CMS may result in fines and other sanctions imposed by CMS. In addition, within California, Washington and Colorado, if our employees are not fully vaccinated as required by those states’ vaccination mandates, we could incur a deficiency that could endanger our Medicaid certification and participation status for certain locations within those states where employees have not been vaccinated. In addition, California has also required employees to receive at least one booster dose of the COVID-19 vaccine by March 1, 2022 in order to comply with its State Public Health Officer Order requiring vaccination of SNF employees. Any penalty, suspension, termination, or other sanction under any state’s Medicaid program could lead to reciprocal and commensurate penalties being imposed under the Medicare program, up to termination or rescission of our Medicare participation and payor agreements as noted above. Additionally, any delay or default by the government in making Medicare reimbursement payments could materially and adversely affect our business, financial condition and results of operations.
Reductions in Medicaid reimbursement rates or changes in the rules governing the Medicaid program could have a material, adverse effect on our revenue, financial condition and results of operations.
A significant portion of reimbursement for skilled nursing services comes from Medicaid. In fact, Medicaid is our largest source of revenue, accounting for 47.2% and 45.7% of our revenue for the three and six months ended June 30, 2022, respectively, and 46.3% and 45.0% for the three and six months ended June 30, 2021, respectively. Medicaid is a state-administered program financed by both state funds and matching federal funds. Medicaid spending has increased rapidly in recent years, becoming a significant component of state budgets, which has led both the federal government and many states to institute measures aimed at controlling the growth of Medicaid spending, and in some instances reducing aggregate Medicaid spending. Since a significant portion of our revenue is generated from our skilled nursing operating subsidiaries in California, Texas and Arizona, any budget reductions or delays in these states could adversely affect our net patient service revenue and profitability. Despite present state budget surpluses in many of the states in which we operate, we can expect continuing cost containment pressures on Medicaid outlays for SNFs, and any such decline could adversely affect our financial condition and results of operations.
The Medicaid program and its reimbursement rates and rules are subject to frequent change at both the federal and state level. These include statutory and regulatory changes, rate adjustments (including retroactive adjustments), administrative or executive orders and government funding restrictions, all of which may materially adversely affect the rates at which our services are reimbursed by state Medicaid plans. To generate funds to pay for the increasing costs of the Medicaid program, many states utilize financial arrangements commonly referred to as provider taxes. Under provider tax arrangements, states collect taxes from healthcare providers and then use the revenue to pay the providers as a Medicaid expenditure, which allows the states to then claim additional federal matching funds on the additional reimbursements. Current federal law provides for a cap on the maximum allowable provider tax as a percentage of the provider's total revenue. There can be no assurance that federal law will continue to provide matching federal funds on state Medicaid expenditures funded through provider taxes, or that the current caps on provider taxes will not be reduced. Any discontinuance or reduction in federal matching of provider tax-related Medicaid expenditures could have a significant and adverse effect on states' Medicaid expenditures, and as a result could have a material and adverse effect on our business, financial condition or results of operations.

85

Our revenue could be impacted by a shift to value-based reimbursement models, including PDPM, and changes to existing reimbursement models.

As discussed in more detail in Item 2., under Government Regulation, CMS implemented a final rule in October 2019 to replace the existing case-mix classification system, Resource Utilization Groups, Version IV, with a new case-mix classification system, PDPM, that focuses more on the clinical condition of the patient and less on the volume of services provided. CMS may make future adjustments to reimbursement levels as it continues to monitor the impact of PDPM on patient outcomes and budget neutrality. As included in the proposed rule, CMS could remove the entire parity calculated adjustment and this would cause a drastic reduction in payments. In addition, the Administration continues to study the nursing home industry and for HHS to issue proposed rules based on those studies, including changes to SNF-VBP Program, may also adversely affect our reimbursement. On April 11, 2022, the CMS issued a proposed rule that requested information to be used for study and potential rulemaking consistent with the Administration’s February 28, 2022 fact sheet. Based on surveyor guidance CMS issued on June 29, 2022, the Administration continues to act on the issues identified in its February 28, 2022 fact sheet and further regulation is expected regarding LTC and SNF reimbursement.
Reforms to the U.S. healthcare system continue to impose new requirements upon us and may increase our costs or lower our reimbursements.
The ACA included sweeping changes to how healthcare is paid for and furnished in the U.S. Applicable to our business, as discussed in greater detail in Item 2., under Government Regulation, the ACA has resulted in significant changes to our operations and reimbursement models for services we provide. CMS continues to issue rules to implement the ACA. Courts continue to interpret and apply the ACA’s provisions.

The efficacy of the ACA is the subject of much debate among members of Congress and the public. Additionally, a number of lawsuits have been filed challenging various aspects of the ACA and related regulations with inconsistent outcomes - some expand the ACA while others limit the ACA. In the event that the ACA is repealed or materially amended as a result of future challenges, particularly any elements of the ACA that are beneficial to our business or that cause changes in the health insurance industry, including reimbursement and coverage by private, Medicare or Medicaid payers, our business, operating results and financial condition could be harmed. Thus, the future impact of the ACA on our business is difficult to predict and its continued uncertain future may negatively impact our business. However, any material changes to the ACA or its implementing regulations may negatively impact our operations.

Similarly, the proposed Nursing Home Improvement Act may have an impact on our business due to the proposed two percent decrease in payments to SNFs, as well as the staffing and reporting requirements contained within the bill. This bill primarily creates penalties such as reduced reimbursement and monetary penalties for submitting inaccurate cost reports or staffing data. If passed in its current form, however, this bill would provide participating states with a temporary enhanced federal Medicaid match to fund improvements in nursing home workforce and care. This match would last six years, and states would be responsible for showing CMS that Medicaid reimbursement increases were used to increase worker wages and yield new training resources and opportunities for nursing home staff. While it is difficult to determine whether the Nursing Home Improvement Act will be amended prior to adoption, or even passed into law, if passed, this bill may negatively impact our business, with the scope and nature of its consequences unknown. However, based on recent statements by the Administration in its February 28, 2022 fact sheet and President Biden’s March 1, 2022 State of the Union Address, HHS and CMS are being instructed to study the nursing home industry, specifically with regard to staffing levels, and the Administration has called for greater oversight of LTC and SNF facilities—including greater penalties for non-compliance with federal laws and regulations. On April 11, 2022, the CMS issued a proposed rule that requested information to be used for study and potential rulemaking consistent with the Administration’s February 28, 2022 fact sheet. Based upon this activity, HHS and CMS are expected to issue new rules that may subject our business to greater oversight, increase penalties that the Government may seek to impose upon us, and impose additional conditions and measurements to the reimbursement we receive from Medicare and Medicaid. On June 29, 2022, CMS published guidance to surveyors for consistently evaluating Phase 2 and 3 Requirements of Participation for LTC facilities, addressing topics including infection control, resident safety, arbitration of disputes, nurse staffing and mental health disorders. On July 29, 2022, CMS requested additional information that is expected to be used in creating additional regulations regarding staffing and operations in the future. These anticipated regulations, consistent with the Administration’s prior statements, may affect our business, its operations, and its profitability.

We cannot predict what effect future reforms to the U.S. healthcare system will have on our business, including the demand for our services or the amount of reimbursement available for those services. However, it is possible these new laws may lower reimbursement or increase the cost of doing business and adversely affect our business.

86

The results of recent U.S. Presidential and Congressional elections, and upcoming midterm elections in 2022, for which certain primary campaigns are already underway, may create significant changes to regulatory framework, enforcements and reimbursements.

The most recent Presidential and Congressional elections in the United States and upcoming midterm elections in 2022, could result in significant changes in, and uncertainty with respect to, legislation, regulation, implementation or repeal of laws and rules related to government health programs, including Medicare and Medicaid. Democratic proposals for Medicare for All or significant expansion of Medicare, could significantly impact our business and the healthcare industry if implemented. Further, if proposed policies specific to nursing facilities are implemented, these may result in significant regulatory changes, increased survey frequency and scope, and increased penalties for non-compliance.

We continually monitor these developments in order to respond to the changing regulatory environment impacting our business. While it is not possible to predict whether and when any such changes will occur, specific proposals discussed during and after the election, including a repeal or material amendment of the ACA, could harm our business, operating results and financial condition. If we are slow or unable to adapt to any such changes, our business, operating results and financial condition could be adversely affected.
Our business may be materially impacted if certain aspects of the ACA are amended, repealed, or successfully challenged.

A number of lawsuits have been filed challenging various aspects of the ACA and related regulations. In addition, the efficacy of the ACA is the subject of much debate among members of Congress and the public. Cases challenging the ACA or related rules have had inconsistent outcomes - some expand the ACA while others limit the ACA. Thus, the future impact of the ACA on our business is difficult to predict. The uncertainty as to the future of the ACA may negatively impact our business, as will any material changes to the ACA.

Presidential and Congressional elections in the United States and the upcoming midterm elections of 2022 could result in significant changes to, and uncertainty with respect to, legislation, regulation, implementation or repeal of the ACA, and other federal health program policy that could significantly impact our business and the healthcare industry. In the event that legal challenges are successful or the ACA is repealed or materially amended, particularly any elements of the ACA that are beneficial to our business or that cause changes in the health insurance industry, including reimbursement and coverage by private, Medicare or Medicaid payers, our business, operating results and financial condition could be harmed. While it is not possible to predict whether and when any such changes will occur, specific proposals discussed during and after the election, including a repeal or material amendment of the ACA, could harm our business, operating results and financial condition. In addition, even if the ACA is not amended or repealed, the President and the executive branch of the federal government, as well as CMS and HHS have a significant impact on the implementation of the provisions of the ACA, and a new administration could make changes impacting the implementation and enforcement of the ACA, which could harm our business, operating results and financial condition. If we are slow or unable to adapt to any such changes, our business, operating results and financial condition could be adversely affected.
We are subject to various government reviews, audits and investigations that could adversely affect our business, including an obligation to refund amounts previously paid to us, potential criminal charges, the imposition of fines, and/or the loss of our right to participate in Medicare and Medicaid programs.

As a result of our participation in the Medicaid and Medicare programs, we are subject to various governmental reviews, audits and investigations to verify our compliance with these programs and applicable laws and regulations. We are subject to regulatory reviews relating to Medicare services, billings and potential overpayments resulting from Recovery Audit Contractors, Zone Program Integrity Contractors, Program Safeguard Contractors, Unified Program Integrity Contractors, Supplemental Medical Review Contractors and Medicaid Integrity Contractors programs, (collectively referred to as Reviews), in which third party firms engaged by CMS conduct extensive reviews of claims data and medical and other records to identify potential improper payments under the Medicare programs. As discussed above, the Administration has called for HHS and CMS to increase the scrutiny of these audits and has requested those agencies adopt rules that would impose greater penalties upon non-compliant LTC and SNF operators and CMS issued its first proposed rule seeking information regarding these priorities on April 11, 2022.


87

On June 29, 2022, CMS announced updated guidance for Phase 2 and 3 of the requirements of participation. The guidance updates the following topics: (1) resident abuse and neglect (including reporting of abuse); (2) admission, transfer, and discharge; (3) mental health and substance abuse disorders; (4) nurse staffing and reporting of payrolls to evaluate staffing sufficiency; (5) residents’ rights (including visitation); (6) potential inaccurate diagnoses or assessments; (7) prescription and use of pharmaceuticals; (8) infection control and prevention; (9) arbitration of disputes between facilities and residents; (10) psychosocial outcomes and their severity; and (11) the timeliness and completion of state investigations to improve consistency in standards among various states. CMS’s new guidance could result in more aggressive and stringent surveys, and potential fines, penalties, sanctions, or administrative actions taken against our operating subsidiaries or affiliated facilities.

Private pay sources also reserve the right to conduct audits. We believe that billing and reimbursement errors and disagreements are common in our industry. We are regularly engaged in reviews, audits and appeals of our claims for reimbursement due to the subjectivities inherent in the process related to patient diagnosis and care, record keeping, claims processing and other aspects of the patient service and reimbursement processes, and the errors and disagreements those subjectivities can produce. An adverse review, audit or investigation could result in:

an obligation to refund amounts previously paid to us pursuant to the Medicare or Medicaid programs or from private payors, in amounts that could be material to our business;
state or federal agencies imposing fines, penalties and other sanctions on us;
temporary or permanent loss of our right to participate in the Medicare or Medicaid programs or one or more private payor networks;
an increase in private litigation against us; and
damage to our reputation in various markets.
In 2004, our Medicare administrative contractors began to conduct selected reviews of claims previously submitted by and paid to some of our affiliated facilities. While we have always been subject to post-payment audits and reviews, more intensive “probe reviews” appear to be a permanent procedure with our fiscal intermediaries. All findings of overpayment from CMS contractors are eligible for appeal through the CMS defined continuum. With the exception of rare findings of overpayment related to objective errors in Medicare payment methodology or claims processing, we utilize all defenses reasonably available to us to demonstrate that the services provided meet all clinical and regulatory requirements for reimbursement.

In cases where claim and documentation review by any CMS contractor results in repeated poor performance, an operation can be subjected to protracted oversight. This oversight may include repeat education and re-probe, extended pre-payment review, referral to recovery audit or integrity contractors, or extrapolation of an error rate to other reimbursement outside of specifically reviewed claims. Sustained failure to demonstrate improvement towards meeting all claim filing and documentation requirements could ultimately lead to Medicare decertification. As of June 30, 2022 and since, 22 of our independent operating subsidiaries had reviews scheduled, on appeal, or in a dispute resolution process, either pre- or post-payment. We anticipate that these reviews could increase in frequency in the future.

Additionally, both federal and state government agencies have heightened and coordinated civil and criminal enforcement efforts as part of numerous ongoing investigations of healthcare companies and, in particular, SNFs. The focus of these investigations includes, among other things:
cost reporting and billing practices;
quality of care;
financial relationships with referral sources; and
medical necessity of services provided.

88

On May 31, 2018, we received a Civil Investigative Demand (CID) from the DOJ stating that it is investigating our company to determine whether we have violated the FCA or the Anti-Kickback Statute with respect to the relationships between certain of our SNFs and persons who served as medical directors, advisory board participants or other referral sources. The CID covered the period from October 3, 2013 through 2018 and was limited in scope to ten of our Southern California SNFs. In October 2018, the Department of Justice made an additional request for information covering the period of January 1, 2011 through 2018, relating to the same topic. As a general matter, our operating entities maintain policies and procedures to promote compliance with the FCA, the Anti-Kickback Statute, and other applicable regulatory requirements. We are fully cooperating with the U.S. Department of Justice. In April 2020, the Company was advised that the U.S. Department of Justice declined to intervene in any subsequent action filed by a relator in connection with the subject matter of this investigation.

If we should agree to a settlement of, claims or obligations under federal Medicare statutes, the federal FCA, or similar state and federal statutes and related regulations, our business, financial condition and results of operations and cash flows could be materially and adversely affected, and our stock price could be adversely impacted. Among other things, any settlement or litigation could involve the payment of substantial sums to settle any alleged civil violations and may also include our assumption of specific procedural and financial obligations going forward under a corporate integrity agreement or other arrangement with the government.

If the government or court were to conclude that errors and deficiencies constitute criminal violations, concluded that such errors and deficiencies resulted in the submission of false claims to federal healthcare programs, or if it were to discover other problems in addition to the ones identified by the probe reviews that rose to actionable levels, we and certain of our officers might face potential criminal charges and civil claims, administrative sanctions and penalties for amounts that could be material to our business, results of operations and financial condition. In addition, we or some of the key personnel of our operating subsidiaries could be temporarily or permanently excluded from future participation in state and federal healthcare reimbursement programs such as Medicaid and Medicare.

If any of our affiliated facilities is decertified or loses its licenses, our revenue, financial condition or results of operations would be adversely affected. In addition, the report of such issues at any of our affiliated facilities could harm our reputation for quality care and lead to a reduction in the patient referrals of our operating subsidiaries and ultimately a reduction in occupancy at these facilities. Also, responding to auditing and enforcement efforts diverts material time, resources and attention from our management team and our staff, and could have a materially detrimental impact on our results of operations during and after any such investigation or proceedings, regardless of whether we prevail on the underlying claim.
We are subject to extensive and complex laws and government regulations. If we are not operating in compliance with these laws and regulations or if these laws and regulations change, we could be required to make significant expenditures or change our operations in order to bring our facilities and operations into compliance.
 
We, along with other companies in the healthcare industry, are required to comply with extensive and complex laws and regulations at the federal, state and local government levels relating to, among other things:

licensure and certification;
adequacy and quality of healthcare services;
qualifications and vaccination (including boosting) of healthcare and support personnel;
quality of medical equipment;
confidentiality, maintenance and security issues associated with medical records and claims processing;
relationships with physicians and other referral sources and recipients;
constraints on protective contractual provisions with patients and third-party payors;
operating policies and procedures;
addition of facilities and services; and
billing for services.


89

The laws and regulations governing our operations, along with the terms of participation in various government programs, regulate how we do business, the services we offer, and our interactions with patients and other healthcare providers. These laws and regulations are subject to frequent change. As noted above, the Administration has called upon HHS and CMS to study and propose new rules regarding staffing requirements and reimbursement for the nursing home industry, including tying reimbursement to staffing levels, salary, benefits, and retention and CMS issued its first proposed rule seeking information regarding these priorities on April 11, 2022. The guidance CMS published on June 29, 2022 to surveyors addressed topics including infection control, resident safety, arbitration of disputes, nurse staffing, and mental health disorders. This new guidance could result in enhanced scrutiny by state surveyors and a potential increase in fines, penalties, sanctions, or administrative actions against our independent operating subsidiaries or affiliated facilities.

We believe that such regulations may increase in the future and we cannot predict the ultimate content, timing or impact on us of any healthcare reform legislation. Changes in existing laws or regulations, or the enactment of new laws or regulations, could negatively impact our business. If we fail to comply with these applicable laws and regulations, we could suffer civil or criminal penalties and other detrimental consequences, including denial of reimbursement, imposition of fines, temporary suspension of admission of new patients, suspension or decertification from the Medicaid and Medicare programs, restrictions on our ability to acquire new facilities or expand or operate existing facilities, the loss of our licenses to operate and the loss of our ability to participate in federal and state reimbursement programs. Additionally, in the future, different interpretations or enforcement of these laws and regulations could subject our current or past practices to allegations of impropriety or illegality or could require us to make changes in our facilities, equipment, personnel, services, capital expenditure programs and operating expenses.

As discussed in greater detail in Item 2., under Government Regulation, we are subject to federal and state laws intended to prevent healthcare fraud and abuse, including the federal FCA, state false claims acts, the illegal remuneration provisions of the Social Security Act, the AKS, state anti-kickback laws, the Civil Monetary Penalties Law and the federal “Stark” Law. Among other things, these laws prohibit kickbacks, bribes and rebates, as well as other direct and indirect payments or fee-splitting arrangements that are designed to induce the referral of patients to a particular provider for medical products or services payable by any federal healthcare program and prohibit presenting a false or misleading claim for payment under a federal or state program. They also prohibit some physician self-referrals. Possible sanctions for violation of any of these restrictions or prohibitions include loss of eligibility to participate in federal and state reimbursement programs and civil and criminal penalties. If we fail to comply, even inadvertently, with any of these requirements, we could be required to alter our operations, refund payments to the government, enter into a corporate integrity agreement, deferred prosecution or similar agreements with state or federal government agencies, and become subject to significant civil and criminal penalties.

These anti-fraud and abuse laws and regulations are complex, and we do not always have the benefit of significant regulatory or judicial interpretation of these laws and regulations. While we do not believe we are in violation of these prohibitions, we cannot assure you that governmental officials charged with the responsibility for enforcing these prohibitions will not assert that we are violating the provisions of such laws and regulations. Our company is currently aware of an investigation by the DOJ related to allegations some of our California facilities may have violated the FCA or the AKS with respect to the relationships between certain of our SNFs and persons who served as medical directors, advisory board participants or other referral sources. While our operating entities maintain policies and procedures to promote compliance with the FCA, the AKS, and other applicable regulatory requirements, we cannot predict when the investigation will be resolved, the outcome of the investigation or its potential impact on our company.

We are unable to predict the future course of federal, state and local regulation or legislation, including Medicare and Medicaid statutes and regulations related to fraud and abuse, the intensity of federal and state enforcement actions or the extent and size of any potential sanctions, fines or penalties. Changes in the regulatory framework, our failure to obtain or renew required regulatory approvals or licenses or to comply with applicable regulatory requirements, the suspension or revocation of our licenses or our disqualification from participation in federal and state reimbursement programs, or the imposition of other enforcement sanctions, fines or penalties could have a material adverse effect upon our business, financial condition or results of operations. Furthermore, should we lose licenses or certifications for a number of our facilities or other businesses as a result of regulatory action or legal proceedings, we could be deemed to be in default under some of our agreements, including agreements governing outstanding indebtedness.

90

Public and government calls for increased survey and enforcement efforts toward LTC facilities, and potential rulemaking that may result in enhanced enforcement and penalties, could result in increased scrutiny by state and federal survey agencies. In addition, potential sanctions and remedies based upon alleged regulatory deficiencies could negatively affect our financial condition and results of operations.

As CMS turns its attention to enhancing enforcement activities towards LTC facilities, as discussed in Item 2., under Government Regulation, state survey agencies will have more accountability for their survey and enforcement efforts.

As discussed in Item 2., under Government Regulation, from time to time in the ordinary course of business, we receive deficiency reports from state and federal regulatory bodies resulting from such inspections or surveys. The focus of these deficiency reports tends to vary from year to year and state to state. Although most inspection deficiencies are resolved through an agreed-upon plan of corrective action, the reviewing agency typically has the authority to take further action against a licensed or certified facility, which could result in the imposition of fines, imposition of a license to a conditional or provisional status, suspension or revocation of a license, suspension or denial of payment for new admissions, loss of certification as a provider under state or federal healthcare programs, or imposition of other sanctions, including criminal penalties. In the past, we have experienced inspection deficiencies that have resulted in the imposition of a provisional license and could experience these results in the future.

Furthermore, in some states, citation of one affiliated facility could negatively impact other affiliated facilities in the same state. Revocation of a license at a given facility could therefore impair our ability to obtain new licenses or to renew, or maintain, existing licenses at other facilities, which may also trigger defaults or cross-defaults under our leases and our credit arrangements, or adversely affect our ability to operate or obtain financing in the future. If state or federal regulators were to determine, formally or otherwise, that one facility's regulatory history ought to impact another of our existing or prospective facilities, this could also increase costs, result in increased scrutiny by state and federal survey agencies, and even impact our expansion plans. Therefore, our failure to comply with applicable legal and regulatory requirements in any single facility could negatively impact our financial condition and overall of operations results.

From time to time, we have opted to voluntarily stop accepting new patients pending completion of a new state survey, in order to avoid possible denial of payment for new admissions during the deficiency cure period, or simply to avoid straining staff and other resources while retraining staff, upgrading operating systems or making other operational improvements. If we elect to voluntary close any operations in the future or to opt to stop accepting new patients pending completion of a state or federal survey, it could negatively impact our financial condition and results of operation.

We have received notices of potential sanctions and remedies based upon alleged regulatory deficiencies from time to time, and such sanctions have been imposed on some of our affiliated facilities. We have had affiliated facilities placed on special focus facility status in the past, continue to have some facilities on this status currently and other operating subsidiaries may be identified for such status in the future. We currently have no facilities placed on special focus facility status.
Future cost containment initiatives undertaken by private third-party payors may limit our revenue and profitability.

Our non-Medicare and non-Medicaid revenue and profitability are affected by continuing efforts of third-party payors to maintain or reduce costs of healthcare by lowering payment rates, narrowing the scope of covered services, increasing case management review of services and negotiating pricing. In addition, sustained unfavorable economic conditions may affect the number of patients enrolled in managed care programs and the profitability of managed care companies, which could result in reduced payment rates. There can be no assurance that third party payors will make timely payments for our services, or that we will continue to maintain our current payor or revenue mix. We are continuing our efforts to develop our non-Medicare and non-Medicaid sources of revenue and any changes in payment levels from current or future third-party payors could have a material adverse effect on our business and consolidated financial condition, results of operations and cash flows.

91

Changes in Medicare reimbursements for physician and non-physician services could impact reimbursement for medical professionals.

As discussed in greater detail in Item 2., under Government Regulation, MACRA revised the payment system for physician and non-physician services. Section 1 of that law, the sustainable growth rate repeal and Medicare Provider Payment Modernization will impact payment provisions for medical professional services. That enactment also extended for two years provisions that permit an exceptions process from therapy caps imposed on Medicare Part B outpatient therapy. There was a combined cap for PT and SLP and a separate cap for OT services that apply subject to certain exceptions. On February 9, 2018, the BBA was signed into law, which provides for the repeal of all therapy caps retroactively to January 1, 2018. The law also reduced the monetary threshold that triggers a manual medical review (MMR), in certain instances (from $3,700 to $3,000). The reduction in the MMR threshold will likely result in increased number of reviews, which could in turn have a negative effect on our business, financial condition or results of operations. 
We may be subject to increased investigation and enforcement activities related to HIPAA violations.

We are required to comply with numerous legislative and regulatory requirements at the federal and state levels addressing patient privacy and security of health information, as discussed in greater detail in Item 2., under Government Regulation. HIPAA, as amended by the HITECH Act, requires us to adopt and maintain business procedures and systems designed to protect the privacy, security and integrity of patients' individual health information. States also have laws that apply to the privacy of healthcare information. We must comply with these state privacy laws to the extent that they are more protective of healthcare information or provide additional protections not afforded by HIPAA. If we fail to comply with these state and federal laws, we could be subject to criminal penalties, civil sanctions, litigation, and be forced to modify our policies and procedures. Additionally, if a breach under HIPAA or other privacy laws were to occur, remediation efforts could be costly and damage to our reputation could occur.

In addition to breaches of protected patient information, under HIPAA and the 21st Century Cures Act (Cures Act), healthcare entities are also required to afford patients with certain rights of access to their health information. Recently, the Office of Civil Rights, the agency responsible for HIPAA enforcement, has targeted investigative and enforcement efforts on violations of patients’ rights of access, imposing significant fines for violations largely initiated from patient complaints. If we fail to comply with our obligations under HIPAA, we could face significant fines. Likewise, if we fail to comply with our obligations under the Cures Act, we could face fines from the Office of the National Coordinator for Health Information Technology, the agency responsible for Cures Act enforcement.
Security breaches and other cyber-security incidents could violate security laws and subject us to significant liability.

Healthcare businesses are increasingly the target of cyberattacks whereby hackers disrupt business operations or obtain protected health information, often demanding large ransoms. Our business is dependent on the proper functioning and availability of our computer systems and networks. While we have taken steps to protect the safety and security of our information systems and the patient health information and other data maintained within those systems, we cannot assure you that our safety and security measures and disaster recovery plan will prevent damage, interruption or breach of our information systems and operations. Because the techniques used to obtain unauthorized access, disable or degrade service, or sabotage systems change frequently and may be difficult to detect, we may be unable to anticipate these techniques or implement adequate preventive measures. In addition, hardware, software or applications we develop or procure from third parties may contain defects in design or manufacture or other problems that could unexpectedly compromise the security of our information systems. Unauthorized parties may attempt to gain access to our systems or facilities, or those of third parties with whom we do business, through fraud or other forms of deceiving our employees or contractors.

On occasion, we have acquired additional information systems through our business acquisitions, and these acquired systems may expose us to risk. We also license certain third-party software to support our operations and information systems. Our inability, or the inability of third-party software providers, to continue to maintain and upgrade our information systems and software could disrupt or reduce the efficiency of our operations. In addition, costs and potential problems and interruptions associated with the implementation of new or upgraded systems and technology or with maintenance or adequate support of existing systems also could disrupt or reduce the efficiency of our operations.

92

A cyber-attack or other incident that bypasses our information systems security could cause a security breach which may lead to a material disruption to our information systems infrastructure or business and may involve a significant loss of business or patient health information. If a cyber-attack or other unauthorized attempt to access our systems or facilities were to be successful, it could result in the theft, destructions, loss, misappropriation or release of confidential information or intellectual property, and could cause operational or business delays that may materially impact our ability to provide various healthcare services. Any successful cyber-attack or other unauthorized attempt to access our systems or facilities also could result in negative publicity which could damage our reputation or brand with our patients, referral sources, payors or other third parties and could subject us to a number of adverse consequences, the vast majority of which are not insurable, including but not limited to disruptions in our operations, regulatory and other civil and criminal penalties, fines, investigations and enforcement actions (including, but not limited to, those arising from the SEC, Federal Trade Commission, Office of Civil Rights, the OIG or state attorneys general), fines, private litigation with those affected by the data breach, loss of customers, disputes with payors and increased operating expense, which either individually or in the aggregate could have a material adverse effect on our business, financial position, results of operations and liquidity.
We may not be fully reimbursed for all services for which each facility bills through consolidated billing, which could adversely affect our revenue, financial condition and results of operations.

SNFs are required to perform consolidated billing for certain items and services furnished to patients and residents. The consolidated billing requirement essentially confers on the SNF itself the Medicare billing responsibility for the entire package of care that its patients receive in these situations. The BBA also affected SNF payments by requiring that post-hospitalization skilled nursing services be “bundled” into the hospital's diagnostic related group (DRG) payment in certain circumstances. Where this rule applies, the hospital and the SNF must, in effect, divide the payment which otherwise would have been paid to the hospital alone for the patient's treatment, and no additional funds are paid by Medicare for skilled nursing care of the patient. Although this provision applies to a limited number of DRGs, it has a negative effect on SNF utilization and payments, either because hospitals are finding it difficult to place patients in SNFs which will not be paid as before or because hospitals are reluctant to discharge the patients to SNFs and lose part of their payment. This bundling requirement could be extended to more DRGs in the future, which would accentuate the negative impact on SNF utilization and payments. We may not be fully reimbursed for all services for which each facility bills through consolidated billing, which could adversely affect our revenue, financial condition and results of operations.
Increased competition for, or a shortage of, nurses and other skilled personnel could increase our staffing and labor costs and subject us to monetary fines.

Our success depends upon our ability to retain and attract nurses and other skilled personnel, such as Certified Nurse Assistants, social workers and speech, physical and occupational therapists. Our success also depends upon our ability to retain and attract skilled management personnel who are responsible for the day-to-day operations of each of our affiliated facilities. Each facility has a facility leader responsible for the overall day-to-day operations of the facility, including quality of care, social services and financial performance. Depending upon the size of the facility, each facility leader is supported by facility staff that is directly responsible for day-to-day care of the patients and marketing and community outreach programs. Other key positions supporting each facility may include individuals responsible for physical, occupational and speech therapy, food service and maintenance. We compete with various healthcare service providers, including other skilled nursing providers, in retaining and attracting qualified and skilled personnel.

93

We operate one or more affiliated SNFs in the states of Arizona, California, Colorado, Idaho, Iowa, Kansas, Nebraska, Nevada, South Carolina, Texas, Utah, Washington and Wisconsin. With the exception of Utah, which follows federal regulations, each of these states has established minimum staffing requirements for facilities operating in that state. Failure to comply with these requirements can, among other things, jeopardize a facility's compliance with the conditions of participation under relevant state and federal healthcare programs. In addition, if a facility is determined to be out of compliance with these requirements, it may be subject to a notice of deficiency, a citation, or a significant fine or litigation risk. Deficiencies (depending on the level) may also result in the suspension of patient admissions and the termination of Medicaid participation, or the suspension, revocation or non-renewal of the SNF's license. If the federal or state governments were to issue regulations which materially change the way compliance with the minimum staffing standard is calculated or enforced, our labor costs could increase and the current shortage of healthcare workers could impact us more significantly, including the increased scrutiny on staffing at the state and federal levels as a result of the COVID-19 virus. The broader labor market where we compete is in a unique state of disequilibrium where the needs of businesses such as ours outstrip the supply of available and willing workers. There is additional upward pressure on wages from different industries, some of which compete with us for labor and others that do not, which makes it difficult to make significant hourly wage and salary increases due to the fixed nature of our reimbursement under insurance contracts as well as Medicare and Medicaid, in addition to our increasing variable costs. Due to the limited supply of qualified applicants who seek or are willing to accept employment, these broader concerns, as well as those specific to both forthcoming federal COVID-19 vaccination mandates and existing state mandates, may increase our labor costs or lead to potential staffing shortages, reduced operations to comply with applicable laws and regulations, or difficulty complying with those laws and regulations at current operational levels.

Federal laws and regulations may increase our costs of maintaining qualified nursing and skilled personnel, or make it more difficult for us to attract or retain qualified nurses and skilled staff members. The proposed Nursing Home Improvement Act, if passed into law in substantially the same form as the proposed bill, may increase our responsibility to provide nursing coverage and the costs associated with that increased coverage. The Administration’s February 28, 2022 fact sheet regarding the nursing home industry demonstrates its desire to have HHS and CMS study staffing level requirements and to tie Medicare and Medicaid reimbursement to the salary, benefits, and retention of staff. On July 29, 2022, CMS requested information regarding LTC staffing level requirements. On June 29, 2022, CMS published guidance to surveyors addressing topics that specifically include nurse staffing and collection of payroll data to evaluate appropriate staffing levels. These requirements may also increase our operating costs and require additional compensation to be paid to employees in the form of wages and benefits. We are monitoring our facilities for potential effects from CMS's IFR requiring employees of Medicare and Medicaid-participating medical facilities to be vaccinated, which may cause disruption to our affiliated facilities’ nursing staff and may additionally disrupt our operations if affected personnel decline to be vaccinated and replacement staffing cannot be located. On November 5, 2021, CMS issued the IFR discussed under Item 2, Government Regulations, requiring all eligible staff to receive their first dose of a two-dose primary vaccination series by December 5, 2021 and the second dose of a two-dose primary vaccination series by January 4, 2022. CMS’s enforcement of this IFR was temporarily blocked in certain states pending appeal to the United States Supreme Court. On January 13, 2022, the United States Supreme Court entered an order allowing CMS’s enforcement of the IFR and its vaccination requirements by March 15, 2022 for our operating subsidiaries in Arizona, Idaho, Iowa, Kansas, Nebraska, South Carolina and Utah and by February 28, 2022 for all of our other operating subsidiaries except those in Texas (which, as discussed below, is now subject to the IFR).

Similar state-level requirements in the states where our affiliated SNFs operate, whether such requirements are passed by statute, regulation, or executive order, may result in a shortage or inability to obtain nurses and skilled staff. As noted above, California, Washington, and Colorado have all mandated vaccinations for workers in health care facilities that include nursing homes. These administrative mandates precede, may be more restrictive than and are not likely to be preempted by CMS's IFR. On October 11, 2021, Texas issued an executive order banning the practice of mandating vaccination, including by private employers. On January 20, 2022, the United States District Court for the Northern District of Texas dismissed the State of Texas’s lawsuit against CMS’s enforcement of the IFR’s vaccine mandate upon the request of the State of Texas. The District Court’s dismissal of the Texas's lawsuit ended the court’s injunction against CMS’s enforcement of the IFR's vaccine mandate in Texas. Since January 20, 2022, CMS has been empowered to enforce the IFR in Texas and required compliance with its vaccination requirements by March 21, 2022.


94

Increased competition for, or a shortage of, nurses or other trained personnel, or general ongoing inflationary pressures may require that we enhance our pay and benefits packages to compete effectively for such personnel. We may not be able to offset such added costs by increasing the rates we charge to the patients of our operating subsidiaries. Turnover rates and the magnitude of the shortage of nurses or other trained personnel vary substantially from facility to facility. An increase in costs associated with, or a shortage of, skilled nurses, could negatively impact our business. In addition, if we fail to attract and retain qualified and skilled personnel, our ability to conduct our business operations effectively could be harmed. Additionally, turnover in nursing staff, particularly among registered nurses, may adversely affect us and the ratings of the facilities we operate under the new five-star measurement formulation used by the Nursing Home Compare website beginning in July of 2022.
Annual caps and other cost-reductions for outpatient therapy services may reduce our future revenue and profitability or cause us to incur losses.

As discussed in detail in Item 2., under Government Regulation, sub-heading Part B Rehabilitation Requirements, several government actions have been taken in recent years to try and contain the costs of rehabilitation therapy services provided under Medicare Part B, including the MPPR, institution of annual caps, mandatory medical reviews for annual claims beyond a certain monetary threshold, and a reduction in reimbursement rates for therapy assistant claim modifiers. Of specific concern is CMS's decision to lower Medicare Part B reimbursement rates for outpatient therapy services by 9%, beginning in January 1, 2021. Such cost-containment measures and ongoing payment changes could have an adverse effect on our revenue.
The Office of the Inspector General or other regulatory authorities may choose to more closely scrutinize billing practices in areas where we operate or propose to expand, which could result in an increase in regulatory monitoring and oversight, decreased reimbursement rates, or otherwise adversely affect our business, financial condition and results of operations.

As discussed in greater detail in Item 2., under Government Regulation, Civil and Criminal Fraud and Abuse Laws and Enforcement, the OIG regularly conducts investigations regarding certain payment or compliance issues within various healthcare sectors. Following these investigation, the OIG publishes reports, in part, to educate involved stakeholders and signal future enforcement focus. Reports published in 2019 and 2020 demonstrate the OIG’s increased scrutiny on post-hospital SNF care and continues to identify SNF compliance as an issue in its 2021 and 2022 semi-annual reports to Congress. This may impact the SNF industry by motivating additional reviews and stricter compliance in the areas outlined in the recent reports, expending material time and resources. Recent publications and statements by the Administration have also called for greater scrutiny of SNF and LTC facilities, and calling for more authorities to impose penalties and other remedies on facilities that violate federal laws and regulations.

Additionally, OIG reports published in 2010 and 2015 show the OIG’s concerns related to the billing practices of SNFs based on Medicare Part A claims and financial incentives for facilities to bill for higher levels of therapies, even when not needed by patients. In its fiscal year 2014 work plan, and again in 2017, OIG specifically stated that it will continue to study and report on questionable Part A and Part B billing practices amongst SNFs. Recently, in its 2021 work plan, OIG stated it will evaluate whether payments to SNFs under PDPM complied with Medicare requirements. OIG’s 2022 work plan states it will use a series of audits to confirm compliance with COVID-19 vaccination requirements for LTC facility staff and will study nursing home emergency preparedness—particularly with managing resident care and collaborating with other health care providers. The study findings of nursing home emergency preparedness will be used to develop a key performance indicator to track challenges faced by nursing homes over time. On May 19, 2022, the OIG updated its Nursing Homes webpage, stating its key goals for nursing home oversight were (1) to protect residents from fraud, abuse and neglect, and to promote quality of resident care; (2) promote emergency preparedness and response efforts; and (3) to strengthen frontline oversight. Each of these priorities could signal an increased focus on compliance with the Requirements of Participation and other laws and regulations applicable to SNF and LTC facilities.

Our business model, like those of some other for-profit operators, is based in part on seeking out higher-acuity patients whom we believe are generally more profitable, and over time our overall patient mix has consistently shifted to higher-acuity and higher-resource utilization patients in most facilities we operate. We also use specialized care-delivery software that assists our caregivers in more accurately capturing and recording activities of daily living services, among other things. These efforts may place us under greater scrutiny with the OIG, CMS, our fiscal intermediaries, recovery audit contractors and others.

95

State efforts to regulate or deregulate the healthcare services industry or the construction or expansion of healthcare facilities could impair our ability to expand our operations, or could result in increased competition.

Some states require healthcare providers, including SNFs, to obtain prior approval, known as a certificate of need, for: (i) the purchase, construction or expansion of healthcare facilities; (ii) capital expenditures exceeding a prescribed amount; or (iii) changes in services or bed capacity.

In addition, other states that do not require certificates of need have effectively barred the expansion of existing facilities and the establishment of new ones by placing partial or complete moratoria on the number of new Medicaid beds they will certify in certain areas or in the entire state. Other states have established such stringent development standards and approval procedures for constructing new healthcare facilities that the construction of new facilities, or the expansion or renovation of existing facilities, may become cost-prohibitive or extremely time-consuming. In addition, some states require the approval of the state Attorney General for acquisition of a facility being operated by a non-profit organization.

Our ability to acquire or construct new facilities or expand or provide new services at existing facilities would be adversely affected if we are unable to obtain the necessary approvals, if there are changes in the standards applicable to those approvals, or if we experience delays and increased expenses associated with obtaining those approvals. We may not be able to obtain licensure, certificate of need approval, Medicaid certification, state Attorney General approval or other necessary approvals for future expansion projects. Conversely, the elimination or reduction of state regulations that limit the construction, expansion or renovation of new or existing facilities could result in increased competition to us or result in overbuilding of facilities in some of our markets. If overbuilding in the skilled nursing industry in the markets in which we operate were to occur, it could reduce the occupancy rates of existing facilities and, in some cases, might reduce the private rates that we charge for our services.

Newly enacted legislation in the States where our independently operating entities are located may impact the volume of cases filed and the overall cost of those cases from a defense and indemnity standpoint.

For example, AB 35 in the State of California was recently signed into law, which increases the cap of noneconomic damages awarded to plaintiffs who are successful in medical malpractice litigation. The cap increases from $250K to $350K beginning on January 1, 2023, with incremental increases over the following 10 years until the cap reaches a maximum of $750K. In wrongful death cases, the cap increases from $250K to $500K on January 1, 2023, with incremental increases over the following 10 years until the cap reaches a maximum of $1M.
Changes to federal and state employment-related laws and regulations could increase our cost of doing business.

Our operating subsidiaries are subject to a variety of federal and state employment-related laws and regulations, including, but not limited to, the U.S. Fair Labor Standards Act which governs such matters as minimum wages, overtime and other working conditions, the ADA and similar state laws that provide civil rights protections to individuals with disabilities in the context of employment, public accommodations and other areas, the National Labor Relations Act, regulations of the EEOC, regulations of the Office of Civil Rights, regulations of state Attorneys General, family leave mandates and a variety of similar laws enacted by the federal and state governments that govern these and other employment law matters. On November 5, 2021, OSHA issued an ETS requiring employers with more than 100 employees to have employees who were not fully vaccinated to complete weekly testing to prove they were not infected with COVID-19 to remain in the workforce, which the United States Supreme Court blocked enforcement of on January 13, 2022 after nationwide litigation over the ETS. The uncertain environment regarding these mandates and potential attempts to enforce similar mandates in 2022 is one we are monitoring, as it represents a risk of uncertainty to the Company that may result in limitations on staff availability, disruption caused by staff departure, potential claims under the ADA and other laws and potential government sanctions which could cause disruptions to the operations of our subsidiaries, limit our ability to grow and otherwise adversely affect our business and financial results. Furthermore, the Administration has requested HHS and CMS study and issue proposed rules regarding the sustainability of care-based careers, including improving access to training, increasing the attractiveness of compensation in care-based positions, and improving the retention and career progression of care workers. The Administration has sought proposed rules that tie some of these issues, such as wages and retention, to Medicare reimbursement for facilities. Rising operating costs due to labor shortages, greater compensation and incentives required to attract and retain qualified personnel and higher-than-usual inflation on items including energy, utilities, food and other goods used in our facilities and the costs for transporting these items could increase our cost and decrease our profits.
96


The compliance costs associated with these laws and evolving regulations could be substantial. For example, all of our affiliated facilities are required to comply with the ADA. The ADA has separate compliance requirements for “public accommodations” and “commercial properties,” but generally requires that buildings be made accessible to people with disabilities. Compliance with ADA requirements could require removal of access barriers and non-compliance could result in imposition of government fines or an award of damages to private litigants. Further legislation may impose additional burdens or restrictions with respect to access by disabled persons. In addition, federal proposals to introduce a system of mandated health insurance and flexible work time and other similar initiatives could, if implemented, adversely affect our operations. We also may be subject to employee-related claims such as wrongful discharge, discrimination or violation of equal employment law. While we are insured for these types of claims, we could be subject to damages that are not covered by our insurance policies or that exceed our insurance limits, and we may be required to pay such damages directly, which would negatively impact our cash flow from operations.
Required regulatory approvals could delay or prohibit transfers of our healthcare operations, which could result in periods in which we are unable to receive reimbursement for such properties.

The operations of our operating subsidiaries must be licensed under applicable state law and, depending upon the type of operation, certified or approved as providers under the Medicare and/or Medicaid programs. In the process of acquiring or transferring operating assets, our operations must receive change of ownership approvals from state licensing agencies, Medicare and Medicaid as well as third party payors. The Administration has requested HHS and CMS issue proposed rules that may increase the scrutiny placed on companies that operate, directly or indirectly, multiple SNF and LTC facilities, and may subject our licensing and approval process to additional scrutiny or delays if such proposals are codified into regulations. If there are any delays in receiving regulatory approvals from the applicable federal, state or local government agencies, or the inability to receive such approvals, such delays could result in delayed or lost reimbursement related to periods of service prior to the receipt of such approvals, which could negatively impact our cash position.

Compliance with federal and state fair housing, fire, safety and other regulations may require us to make unanticipated expenditures, which could be costly to us.

We must comply with the federal Fair Housing Act and similar state laws, which prohibit us from discriminating against individuals if it would cause such individuals to face barriers in gaining residency in any of our affiliated facilities. Additionally, the Fair Housing Act and other similar state laws require that we advertise our services in such a way that we promote diversity and not limit it. We may be required, among other things, to change our marketing techniques to comply with these requirements.

In addition, we are required to operate our affiliated facilities in compliance with applicable fire and safety regulations, building codes and other land use regulations and food licensing or certification requirements as they may be adopted by governmental agencies and bodies from time to time. Like other healthcare facilities, our affiliated SNFs are subject to periodic surveys or inspections by governmental authorities to assess and assure compliance with regulatory requirements. Surveys occur on a regular (often annual or biannual) schedule, and special surveys may result from a specific complaint filed by a patient, a family member or one of our competitors. We may be required to make substantial capital expenditures to comply with these requirements.
We depend largely upon reimbursement from third-party payors, and our revenue, financial condition and results of operations could be negatively impacted by any changes in the acuity mix of patients in our affiliated facilities as well as payor mix and payment methodologies.

Our revenue is affected by the percentage of the patients of our operating subsidiaries who require a high level of skilled nursing and rehabilitative care, whom we refer to as high acuity patients, and by our mix of payment sources. Changes in the acuity level of patients we attract, as well as our payor mix among Medicaid, Medicare, private payors and managed care companies, significantly affect our profitability because we generally receive higher reimbursement rates for high acuity patients and because the payors reimburse us at different rates. For both the three and six months ended June 30, 2022, 73.4% of our revenue was provided by government payors that reimburse us at predetermined rates. If our labor or other operating costs increase, we will be unable to recover such increased costs from government payors. Accordingly, if we fail to maintain our proportion of high acuity patients or if there is any significant increase in the percentage of the patients of our operating subsidiaries for whom we receive Medicaid reimbursement, our results of operations may be adversely affected.

97

Initiatives undertaken by major insurers and managed care companies to contain healthcare costs may adversely affect our business. Among other initiatives, these payors attempt to control healthcare costs by contracting with healthcare providers to obtain services on a discounted basis. We believe that this trend will continue and may limit reimbursements for healthcare services. If insurers or managed care companies from whom we receive substantial payments were to reduce the amounts they pay for services, we may lose patients if we choose not to renew our contracts with these insurers at lower rates.

On November 5, 2021, CMS issued the IFR discussed under Item 2, Government Regulations, subheading Coronavirus requiring all eligible staff to be fully vaccinated against COVID-19. CMS’s enforcement of this IFR was temporarily blocked in certain states pending appeal to the United States Supreme Court. On January 13, 2022, the United States Supreme Court entered an order allowing CMS’s enforcement of the IFR and its vaccination requirements by March 15, 2022 for our operating subsidiaries in Arizona, Idaho, Iowa, Kansas, Nebraska, South Carolina and Utah and by February 28, 2022 for all of our other operating subsidiaries except those in Texas. Since January 20, 2022, CMS has been empowered to enforce the IFR in Texas and required compliance with its vaccination requirements by March 21, 2022.

The IFR and its enforcement by CMS may cause disruption to our affiliated facilities’ nursing staff and may further disrupt our operations if affected personnel decline to be vaccinated and replacement staff cannot be located. In the event we or our affiliated facilities do not comply with this requirement, our Medicare and Medicaid agreements could be terminated and the termination of those agreements may lead to other payors terminating their agreements with us or our affiliated facilities and operating subsidiaries. CMS terminating Medicare or Medicaid participation agreements and the loss of the payment agreements with private payors as a result of CMS terminating Medicare or Medicaid participation agreements with our affiliated facilities and operating subsidiaries would materially and adversely affect our business, financial condition and results of operations.

In addition to the IFR, the Administration has requested HHS and CMS conduct studies about additional requirements pertaining to staffing, data reporting, employee compensation and retention, and resident experience that may result in a reduction of our revenue from Medicare and Medicaid. CMS issued its first proposed rule seeking information regarding these priorities on April 11, 2022. These study results may result in additional conditions of participation within those programs.
We are subject to litigation that could result in significant legal costs and large settlement amounts or damage awards.

The skilled nursing business involves a significant risk of liability given the age and health of the patients and residents of our operating subsidiaries and the services we provide. The industry has experienced an increased trend in the number and severity of litigation claims, due in part to the number of large verdicts, including large punitive damage awards. These claims are filed based upon a wide variety of claims and theories, including deficiencies under conditions of participation under certain state and federal healthcare programs. Plaintiffs' attorneys have become increasingly more aggressive in their pursuit of claims against healthcare providers, including skilled nursing providers, employing a wide variety of advertising and solicitation activities to generate more claims. The defense of lawsuits has in the past, and may in the future, result in significant legal costs, regardless of the outcome. Additionally, increases to the frequency and/or severity of losses from such claims and suits may result in increased liability insurance premiums or a decline in available insurance coverage levels, which could materially and adversely affect our business, financial condition and results of operations.

We have in the past been subject to class action litigation involving claims of violations of various regulatory requirements. While we have been able to settle these claims without an ongoing material adverse effect on our business, future claims could be brought that may materially affect our business, financial condition and results of operations. Other claims and suits, including class actions, continue to be filed against us and other companies in our industry. For example, there has been a general increase in the number of wage and hour class action claims filed in several of the jurisdictions where we are present. Allegations typically include claimed failures to permit or properly compensate for meal and rest periods, or failure to pay for time worked. If there were a significant increase in the number of these claims against us or an increase in amounts owing should plaintiffs be successful in their prosecution of these claims, this could have a material adverse effect to our business, financial condition, results of operations and cash flows.


98

Beyond our skilled nursing business, we engage in numerous ancillary businesses through one or more of our subsidiaries. These ancillary businesses generally support and provide services complementary to our operations, including but not limited to non-emergent ground transportation for patients and residents of our facilities. Our ancillary businesses may also be the subject of claims, lawsuits, and regulatory oversight that are specific to the particular services they offer. Noncompliance with the laws and regulations that may apply to our ancillary businesses may result in fines, penalties, and civil claims paid by our affected independent subsidiaries. Specific to our non-emergent ground transportation business, the drivers employed by this business may be subject to additional state-specific regulations regarding working time allowed to be spent driving, waiting time, and break or rest periods, and violations of these rules may lead to regulatory fines, penalties, or claims to be paid to individual drivers, in addition to the general employment risks described above.

Our ancillary businesses also are susceptible to general liability claims based on facts and circumstances that are specific to their activities and operations. In the case of our non-emergent ground transportation business, this liability likely exists in the form of automobile-involved accidents, which may involve property, individuals, or other automobiles. The defense of automobile accident and general liability lawsuits relating to our ancillary businesses in the past, and may in the future, result in significant legal costs, regardless of the outcome. As our ancillary businesses grow, the independent subsidiaries may be subject to increased frequency and/or severity of losses from such claims and suits which may result in increased liability insurance premiums for those businesses or a decline in available insurance coverage levels, which could materially and adversely affect our business, financial condition and results of operations.

In addition, we contract with a variety of landlords, lenders, vendors, suppliers, consultants and other individuals and businesses. These contracts typically contain covenants and default provisions. If the other party to one or more of our contracts were to allege that we have violated the contract terms, we could be subject to civil liabilities which could have a material adverse effect on our financial condition and results of operations.

If litigation is instituted against one or more of our subsidiaries, a successful plaintiff might attempt to hold us or another subsidiary liable for the alleged wrongdoing of the subsidiary principally targeted by the litigation. If a court in such litigation decided to disregard the corporate form, the resulting judgment could increase our liability and adversely affect our financial condition and results of operations.

Congress has repeatedly considered, without passage, a bill that would require, among other things, that agreements to arbitrate nursing home disputes be made after the dispute has arisen rather than before prospective patients move in, to prevent nursing home operators and prospective patients from mutually entering into a pre-admission pre-dispute arbitration agreement. This bill, known as the Fairness in Nursing Home Arbitration Act, was introduced in the House of Representatives as a H.R. 5326 in 2019 and H.R. 2812 in 2021; neither bill made it out of the committees to which it was referred for discussion to be voted on by the entire House of Representatives. We use arbitration agreements, which have generally been favored by the courts, to streamline the dispute resolution process and reduce our exposure to legal fees and excessive jury awards. CMS has identified these arbitration agreements as an area for further review and on June 29, 2022 issued guidance to state surveyors regarding arbitration agreements and their requirements under federal regulations. If we are not able to secure pre-admission arbitration agreements, our litigation exposure and costs of defense in patient liability actions could increase, our liability insurance premiums could increase, and our business may be adversely affected.
We conduct regular internal investigations into the care delivery, recordkeeping and billing processes of our operating subsidiaries. These reviews sometimes detect instances of noncompliance which we attempt to correct, which can decrease our revenue.

As an operator of healthcare facilities, we have a program to help us comply with various requirements of federal and private healthcare programs. Our compliance program includes, among other things, (i) policies and procedures modeled after applicable laws, regulations, government manuals and industry practices and customs that govern the clinical, reimbursement and operational aspects of our subsidiaries; (ii) training about our compliance process for all of the employees of our operating subsidiaries, our directors and officers, and training about Medicare and Medicaid laws, fraud and abuse prevention, clinical standards and practices, and claim submission and reimbursement policies and procedures for appropriate employees; and (iii) internal controls that monitor, for example, the accuracy of claims, reimbursement submissions, cost reports and source documents, provision of patient care, services, and supplies as required by applicable standards and laws, accuracy of clinical assessment and treatment documentation, and implementation of judicial and regulatory requirements (i.e., background checks, licensing and training).

From time to time our systems and controls highlight potential compliance issues, which we investigate as they arise. Historically, we have, and would continue to do so in the future, initiated internal inquiries into possible recordkeeping and related irregularities at our affiliated SNFs, which were detected by our internal compliance team in the course of its ongoing reviews.
99

Through these internal inquiries, we have identified potential deficiencies in the assessment of and recordkeeping for small subsets of patients. We have also identified and, at the conclusion of such investigations, assisted in implementing, targeted improvements in the assessment and recordkeeping practices to make them consistent with the existing standards and policies applicable to our affiliated SNFs in these areas. We continue to monitor the measures implemented for effectiveness and perform follow-up reviews to ensure compliance. Consistent with healthcare industry accounting practices, we record any charge for refunded payments against revenue in the period in which the claim adjustment becomes known.

If additional reviews result in identification and quantification of additional amounts to be refunded, we will accrue additional liabilities for claim costs and interest, and repay any amounts due in normal course. Furthermore, failure to refund overpayments within required time frames (as described in greater detail above) could result in FCA liability. If future investigations ultimately result in findings of significant billing and reimbursement noncompliance which could require us to record significant additional provisions or remit payments, our business, financial condition and results of operations could be materially and adversely affected and our stock price could decline.
We may be unable to complete future facility or business acquisitions at attractive prices or at all, which may adversely affect our revenue; we may also elect to dispose of underperforming or non-strategic operating subsidiaries, which would also decrease our revenue.

To date, our revenue growth has been significantly impacted by our acquisition of new facilities and businesses. Subject to general market conditions and the availability of essential resources and leadership within our company, we continue to seek both single-and multi-facility acquisition and business acquisition opportunities that are consistent with our geographic, financial and operating objectives.

We face competition for the acquisition of facilities and businesses and expect this competition to increase. Based upon factors such as our ability to identify suitable acquisition candidates, future regulations affecting the ability to purchase facilities, the purchase price of the facilities, increasing interest rates for debt-financed purchases, prevailing market conditions, the availability of leadership to manage new facilities and our own willingness to take on new operations, the rate at which we have historically acquired facilities has fluctuated significantly. In the future, we anticipate the rate at which we may acquire facilities will continue to fluctuate, which may affect our revenue.

We have also historically acquired a few facilities, which were or have proven to be non-strategic or less desirable, and we may consider disposing of such facilities or exchanging them for facilities which are more desirable, either because they were included in larger, indivisible groups of facilities or under other circumstances. To the extent we dispose of such a facility without simultaneously acquiring a facility in exchange, our revenue may decrease.
We may not be able to successfully integrate acquired facilities and businesses into our operations, and we may not achieve the benefits we expect from any of our facility acquisitions.

We may not be able to successfully or efficiently integrate new acquisitions of facilities and businesses with our existing operating subsidiaries, culture and systems. The process of integrating acquisitions into our existing operations may result in unforeseen operating difficulties, divert management's attention from existing operations, or require an unexpected commitment of staff and financial resources, and may ultimately be unsuccessful. Existing operations available for acquisition frequently serve or target different markets than those that we currently serve. We also may determine that renovations of acquired facilities and changes in staff and operating management personnel are necessary to successfully integrate those acquisitions into our existing operations. We may not be able to recover the costs incurred to reposition or renovate newly operating subsidiaries. The financial benefits we expect to realize from many of our acquisitions are largely dependent upon our ability to improve clinical performance, overcome regulatory deficiencies, rehabilitate or improve the reputation of the operations in the community, increase and maintain occupancy, control costs, and in some cases change the patient acuity mix. If we are unable to accomplish any of these objectives at the operating subsidiaries we acquire, we will not realize the anticipated benefits and we may experience lower than anticipated profits, or even losses.
100

During the six months ended June 30, 2022, we expanded our operations through a combination of long-term leases and real estate purchases, with the addition of four stand-alone skilled nursing operations. In addition, we added five senior living operations that were transferred from Pennant, three of which are part of campuses operated by our affiliated operating subsidiaries. This growth has placed and will continue to place significant demands on our current management resources. Our ability to manage our growth effectively and to successfully integrate new acquisitions into our existing business will require us to continue to expand our operational, financial and management information systems and to continue to retain, attract, train, motivate and manage key employees, including facility-level leaders and our local directors of nursing. We may not be successful in attracting qualified individuals necessary for future acquisitions to be successful, and our management team may expend significant time and energy working to attract qualified personnel to manage facilities we may acquire in the future. Also, the newly acquired facilities may require us to spend significant time improving services that have historically been substandard, and if we are unable to improve such facilities quickly enough, we may be subject to litigation and/or loss of licensure or certification. If we are not able to successfully overcome these and other integration challenges, we may not achieve the benefits we expect from any of our acquisitions, and our business may suffer.
In undertaking acquisitions, we may be adversely impacted by costs, liabilities and regulatory issues that may adversely affect our operations.

In undertaking acquisitions, we also may be adversely impacted by unforeseen liabilities attributable to the prior providers who operated those facilities, against whom we may have little or no recourse. Many facilities we have historically acquired were underperforming financially and had clinical and regulatory issues prior to and at the time of acquisition. Even where we have improved operating subsidiaries and patient care at affiliated facilities that we have acquired, we still may face post-acquisition regulatory issues related to pre-acquisition events. These may include, without limitation, payment recoupment related to our predecessors' prior noncompliance, the imposition of fines, penalties, operational restrictions or special regulatory status. Further, we may incur post-acquisition compliance risk due to the difficulty or impossibility of immediately or quickly bringing non-compliant facilities into full compliance. Diligence materials pertaining to acquisition targets, especially the underperforming facilities that often represent the greatest opportunity for return, are often inadequate, inaccurate or impossible to obtain, sometimes requiring us to make acquisition decisions with incomplete information. Despite our due diligence procedures, facilities that we have acquired or may acquire in the future may generate unexpectedly low returns, may cause us to incur substantial losses, may require unexpected levels of management time, expenditures or other resources, or may otherwise not meet a risk profile that our investors find acceptable.

In addition, we might encounter unanticipated difficulties and expenditures relating to any of the acquired facilities, including contingent liabilities. For example, when we acquire a facility, we generally assume the facility's existing Medicare provider number for purposes of billing Medicare for services. If CMS later determines that the prior owner of the facility had received overpayments from Medicare for the period of time during which it operated the facility, or had incurred fines in connection with the operation of the facility, CMS could hold us liable for repayment of the overpayments or fines. We may be unable to improve every facility that we acquire. In addition, operation of these facilities may divert management time and attention from other operations and priorities, negatively impact cash flows, result in adverse or unanticipated accounting charges, or otherwise damage other areas of our company if they are not timely and adequately improved.

We also incur regulatory risk in acquiring certain facilities due to the licensing, certification and other regulatory requirements affecting our right to operate the acquired facilities. For example, in order to acquire facilities on a predictable schedule, or to acquire declining operations quickly to prevent further pre-acquisition declines, we frequently acquire such facilities prior to receiving license approval or provider certification. Anticipated future regulations may cause delays in acquiring the required licenses and certifications, if it is possible to do so at all. We operate such facilities as the interim manager for the outgoing licensee, assuming financial responsibility, among other obligations for the facility. To the extent that we may be unable or delayed in obtaining a license, we may need to operate the facility under a management agreement from the prior operator. Any inability in obtaining consent from the prior operator of a target acquisition to utilizing its license in this manner could impact our ability to acquire additional facilities. If we were subsequently denied licensure or certification for any reason, we might not realize the expected benefits of the acquisition and would likely incur unanticipated costs and other challenges which could cause our business to suffer.

101

If we do not achieve or maintain competitive quality of care ratings from CMS or private organizations engaged in similar monitoring activities, our business may be negatively affected.

CMS, as well as certain private organizations engaged in similar monitoring activities, provides comparative public data, rating every SNF operating in each state based upon quality-of-care indicators. CMS’s system is the Five-Star Quality Rating System, introduced in 2008, to help consumers, their families and caregivers compare nursing homes more easily. The Five-Star Quality Rating System gives each nursing home a rating of between one and five stars in various categories, and the ratings are available on a consumer-facing website, Nursing Home Compare. In cases of acquisitions, the previous operator's clinical ratings are included in our overall Five-Star Quality Rating. Over the years, the Five-Star Quality Rating System has been modified, with the most recent changes being implemented in 2018 and 2019. Additionally, as a result of the COVID-19 pandemic and CMS’s suspension or modification of certain inspection and reporting requirements, the data used to calculate the star ratings of facilities was interrupted. CMS temporarily froze certain data on the Nursing Home Compare website through January 2021, and recalculated its Five Star Quality ratings with modified data used to calculate the nursing home's rating. Other data related to quality reporting measures, including new or worsened pressure-related injuries and discharges to home, are not presently factored into CMS's star calculations. This data is reflected on the Nursing Home Compare website based on the recalculation in January of 2022. The temporary adjustments due to COVID-19 could impact facilities that might have less favorable Five-Star Ratings from being able to demonstrate improvements on the public-facing website through mid-2022. The Administration has indicated that it wishes to collect more data to be reported on the Nursing Home Compare website, and to make the reported data more readily accessible and understandable for consumers. CMS guidance issued in June 2022 signaled extensive and scrutinizing enforcement of regulations by surveyor which may result in adverse findings that could reduce the Five Star Quality ratings of our facilities reported on the Nursing Home Compare website. The enhanced collection and reporting of this data on the Nursing Home Compare website may lead to more scrutiny in the marketplace and may adversely affect our scoring depending on the data to be reported and the manner in which it is displayed on the Nursing Home Compare website. For more information on these changes and proposed future alterations, see Item 2., under Government Regulation.

CMS continues to increase quality measure thresholds, making it more difficult to achieve upward ratings. CMS acknowledges that some facilities may see a decline in their overall five-star rating absent any new inspection information. This change could further affect star ratings across the industry. Additionally, on the Nursing Home Compare website, CMS recently began displaying a consumer alert icon next to nursing homes that have been cited on inspection reports for incidents of abuse, neglect, or exploitation. In July of 2022, CMS updated the scoring measures used for SNFs to include six dimensions of staffing and turnover, which may affect the rating of our facilities on the Nursing Home Compare website. CMS’s expanded evaluation and measurement of staffing and turnover, including measures of all nurses, registered nurses, and administrators, may adversely affect the scoring and evaluation of our facilities under CMS’s Five-Star Quality Rating System. See Item 2., under Government Regulation.

Providing quality patient care is the cornerstone of our business. We believe that hospitals, physicians and other referral sources refer patients to us in large part because of our reputation for delivering quality care. If we should fail to achieve our internal rating goals or fail to exceed the national average rating on the Five-Star Quality Rating System, including due to nursing and administrative staffing and turnover, or have facilities displaying a consumer alert icon for incidents of abuse, neglect, or exploitation, it may affect our ability to generate referrals, which could have a material adverse effect upon our business and consolidated financial condition, results of operations and cash flows.
If we are unable to obtain insurance, or if insurance becomes more costly for us to obtain, our business may be adversely affected.

It may become more difficult and costly for us to obtain coverage for resident care liabilities and other risks, including property, automobile and casualty insurance. For example, the following circumstances may adversely affect our ability to obtain insurance at favorable rates:

we experience higher-than-expected professional liability, property and casualty, or other types of claims or losses;
we receive survey deficiencies or citations of higher-than-normal scope or severity;
we acquire especially troubled operations or facilities that present unattractive risks to current or prospective insurers;
insurers tighten underwriting standards applicable to us or our industry; or
insurers or reinsurers are unable or unwilling to insure us or the industry at historical premiums and coverage levels.


102

If any of these potential circumstances were to occur, our insurance carriers may require us to significantly increase our self-insured retention levels or pay substantially higher premiums for the same or reduced coverage for insurance, including workers compensation, property and casualty, automobile, employment practices liability, directors and officers liability, employee healthcare and general and professional liability coverages.

In some states, the law prohibits or limits insurance coverage for the risk of punitive damages arising from professional liability and general liability claims or litigation. Coverage for punitive damages is also excluded under some insurance policies. As a result, we may be liable for punitive damage awards in these states that either are not covered or are in excess of our insurance policy limits. Claims against us, regardless of their merit or eventual outcome, also could inhibit our ability to attract patients or expand our business and could require our management to devote time to matters unrelated to the day-to-day operation of our business.

With few exceptions, workers' compensation and employee health insurance costs have also increased markedly in recent years. To partially offset these increases, we have increased the amounts of our self-insured retention and deductibles in connection with general and professional liability claims. We also have implemented a self-insurance program for workers compensation in all states, except Washington, and elected non-subscriber status for workers' compensation in Texas. In Washington, the insurance coverage is financed through premiums paid by the employers and employees. Due to the nature of our business and the residents we serve, including the risk of claims from residents as well as potential governmental action, it may be difficult to complete the underwriting process and obtain insurance at commercially reasonable rates. If we are unable to obtain insurance, or if insurance becomes more costly for us to obtain, or if the coverage levels we can economically obtain decline, our business may be adversely affected.
Our self-insurance programs may expose us to significant and unexpected costs and losses.

We have maintained general and professional liability insurance since 2002 and workers' compensation insurance since 2005 through a wholly-owned captive insurance subsidiary to insure our self-insurance reimbursements and deductibles as part of a continually evolving overall risk management strategy. We establish the insurance loss reserves based on an estimation process that uses information obtained from both company-specific and industry data. The estimation process requires us to continuously monitor and evaluate the life cycle of the claims. Using data obtained from this monitoring and our assumptions about emerging trends, we, along with an independent actuary, develop information about the size of ultimate claims based on our historical experience and other available industry information. The most significant assumptions used in the estimation process include determining the trend in costs, the expected cost of claims incurred but not reported and the expected costs to settle or pay damages with respect to unpaid claims. It is possible, however, that the actual liabilities may exceed our estimates of loss. We may also experience an unexpectedly large number of successful claims or claims that result in costs or liability significantly in excess of our projections. For these and other reasons, our self-insurance reserves could prove to be inadequate, resulting in liabilities in excess of our available insurance and self-insurance. If a successful claim is made against us and it is not covered by our insurance or exceeds the insurance policy limits, our business may be negatively and materially impacted.

Further, because our self-insurance reimbursements under our general and professional liability and workers compensation programs applies on a per claim basis, there is no limit to the maximum number of claims or the total amount for which we could incur liability in any policy period.

We also self-insure our employee health benefits. With respect to our health benefits self-insurance, our reserves and premiums are computed based on a mix of company specific and general industry data that is not specific to our own company. Even with a combination of limited company-specific loss data and general industry data, our loss reserves are based on actuarial estimates that may not correlate to actual loss experience in the future. Therefore, our reserves may prove to be insufficient and we may be exposed to significant and unexpected losses.

The frequency and magnitude of claims and legal costs may increase due to the COVID-19 pandemic or our related response efforts.

103

The geographic concentration of our affiliated facilities could leave us vulnerable to an economic downturn, regulatory changes or acts of nature in those areas.

Our affiliated facilities located in Arizona, California, and Texas account for the majority of our total revenue. As a result of this concentration, the conditions of local economies, changes in governmental rules, regulations and reimbursement rates or criteria, changes in demographics, state funding, acts of nature and other factors that may result in a decrease in demand and/or reimbursement for skilled nursing services in these states could have a disproportionately adverse effect on our revenue, costs and results of operations. Moreover, since over 21% of our affiliated facilities are located in California, we are particularly susceptible to revenue loss, cost increase or damage caused by natural disasters such as electrical power shortages, fires, earthquakes or mudslides.

In addition, our affiliated facilities in Iowa, Nebraska, Kansas, South Carolina, Washington and Texas are more susceptible to revenue loss, cost increases or damage caused by natural disasters including hurricanes, tornadoes and flooding. These acts of nature may cause disruption to us, the employees of our operating subsidiaries and our affiliated facilities, which could have an adverse impact on the patients of our operating subsidiaries and our business. In order to provide care for the patients of our operating subsidiaries, we are dependent on consistent and reliable delivery of food, pharmaceuticals, utilities and other goods to our affiliated facilities, and the availability of employees to provide services at our affiliated facilities. If the delivery of goods or the ability of employees to reach our affiliated facilities were interrupted in any material respect due to a natural disaster or other reasons, it would have a significant impact on our affiliated facilities and our business. Furthermore, the impact, or impending threat, of a natural disaster may require that we evacuate one or more facilities, which would be costly and would involve risks, including potentially fatal risks, for the patients. The impact of disasters and similar events is inherently uncertain. Such events could harm the patients and employees of our operating subsidiaries, severely damage or destroy one or more of our affiliated facilities, harm our business, reputation and financial performance, or otherwise cause our business to suffer in ways that we currently cannot predict.
The actions of a national labor union that has pursued a negative publicity campaign criticizing our business in the past may adversely affect our revenue and our profitability.

We continue to maintain our right to inform the employees of our operating subsidiaries about our views of the potential impact of unionization upon the workplace generally and upon individual employees. With one exception, to our knowledge the staff at our affiliated facilities that have been approached to unionize have uniformly rejected union organizing efforts. Forthcoming proposed rules from HHS and CMS, which, based on the Administration's statements, are anticipated within the next year, may increase the likelihood of employee unionization. If employees decide to unionize, our cost of doing business could increase, and we could experience contract delays, difficulty in adapting to a changing regulatory and economic environment, cultural conflicts between unionized and non-unionized employees, strikes and work stoppages, and we may conclude that affected facilities or operations would be uneconomical to continue operating.
Because we lease the majority of our affiliated facilities, we are subject to risks associated with leased real property, including risks relating to lease termination, lease extensions and special charges, any of which could adversely affect our business, financial position or results of operations.

As of June 30, 2022, we leased 180 of our 251 affiliated facilities. Most of our leases are triple-net leases, which means that, in addition to rent, we are required to pay for the costs related to the property (including property taxes, insurance, and maintenance and repair costs). We are responsible for paying these costs notwithstanding the fact that some of the benefits associated with paying these costs accrue to the landlords as owners of the associated facilities.

Each lease provides that the landlord may terminate the lease for a variety of reasons, including the default in any payment of rent, taxes or other payment obligations or the breach of any other covenant or agreement in the lease. Termination of a lease could result in a default under our debt agreements and could adversely affect our business, financial position or results of operations. There can be no assurance that we will be able to comply with all of our obligations under the leases in the future.

104

Failure to generate sufficient cash flow to cover required payments or meet operating covenants under our long-term debt, mortgages and long-term operating leases could result in defaults under such agreements and cross-defaults under other debt, mortgage or operating lease arrangements, which could harm our operating subsidiaries and cause us to lose facilities or experience foreclosures.

Our Amended Credit Agreement provides for a Revolving Credit Facility with borrowing capacity of up to $600.0 million in aggregate principal amount. As of July 27, 2022, we have no outstanding borrowings under our Revolving Credit Facility. Twenty-three of our subsidiaries have mortgage loans insured with Department of Housing and Urban Development (HUD) for an aggregate amount of $155.1 million, which subjects these subsidiaries to HUD oversight and periodic inspections. The terms of the mortgage loans range from 25- to 35-years.

We also have two outstanding promissory notes with an aggregate principal amount of approximately $3.2 million as of June 30, 2022. The term of the notes are 10 months and 12 years. Because this mortgage loan is insured with HUD, our borrower subsidiary under the loan is subject to HUD oversight and periodic inspections.

In addition, we had $2.0 billion of future operating lease obligations as of June 30, 2022. We intend to continue financing our operating subsidiaries through mortgage financing, long-term operating leases and other types of financing, including borrowings under our lines of credit and future credit facilities we may obtain.

We may not generate sufficient cash flow from operations to cover required interest, principal and lease payments. In addition, our outstanding Amended Credit Agreement and mortgage loans contain restrictive covenants and require us to maintain or satisfy specified coverage tests on a consolidated basis and on a facility or facilities basis. These restrictions and operating covenants include, among other things, requirements with respect to occupancy, debt service coverage, project yield, net leverage ratios, minimum interest coverage ratios and minimum asset coverage ratios. These restrictions may interfere with our ability to obtain additional advances under our Revolving Credit Facility or to obtain new financing or to engage in other business activities, which may inhibit our ability to grow our business and increase revenue.

From time to time, the financial performance of one or more of our mortgaged facilities may not comply with the required operating covenants under the terms of the mortgage. Any non-payment, noncompliance or other default under our financing arrangements could, subject to cure provisions, cause the lender to foreclose upon the facility or facilities securing such indebtedness or, in the case of a lease, cause the lessor to terminate the lease, each with a consequent loss of revenue and asset value to us or a loss of property. Furthermore, in many cases, indebtedness is secured by both a mortgage on one or more facilities, and a guaranty by us. In the event of a default under one of these scenarios, the lender could avoid judicial procedures required to foreclose on real property by declaring all amounts outstanding under the guaranty immediately due and payable, and requiring us to fulfill our obligations to make such payments. If any of these scenarios were to occur, our financial condition would be adversely affected. For tax purposes, a foreclosure on any of our properties would be treated as a sale of the property for a price equal to the outstanding balance of the debt secured by the mortgage. If the outstanding balance of the debt secured by the mortgage exceeds our tax basis in the property, we would recognize taxable income on foreclosure, but would not receive any cash proceeds, which would negatively impact our earnings and cash position. Further, because our mortgages and operating leases generally contain cross-default and cross-collateralization provisions, a default by us related to one facility could affect a significant number of other facilities and their corresponding financing arrangements and operating leases.

Because our term loans, promissory notes, bonds, mortgages and lease obligations are fixed expenses and secured by specific assets, and because our revolving loan obligations are secured by virtually all of our assets, if reimbursement rates, patient acuity mix or occupancy levels decline, or if for any reason we are unable to meet our loan or lease obligations, we may not be able to cover our costs and some or all of our assets may become at risk. Our ability to make payments of principal and interest on our indebtedness and to make lease payments on our operating leases depends upon our future performance, which will be subject to general economic conditions, industry cycles and financial, business and other factors affecting our operating subsidiaries, many of which are beyond our control. If we are unable to generate sufficient cash flow from operations in the future to service our debt or to make lease payments on our operating leases, we may be required, among other things, to seek additional financing in the debt or equity markets, refinance or restructure all or a portion of our indebtedness, sell selected assets, reduce or delay planned capital expenditures or delay or abandon desirable acquisitions. Such measures might not be sufficient to enable us to service our debt or to make lease payments on our operating leases. The failure to make required payments on our debt or operating leases or the delay or abandonment of our planned growth strategy could result in an adverse effect on our future ability to generate revenue and sustain profitability. In addition, any such financing, refinancing or sale of assets might not be available on terms that are economically favorable to us, or at all.

105

Move-in and occupancy rates may remain unpredictable even after the COVID-19 pandemic is over.

Occupancy levels at SNFs are likely to remain vulnerable to the effects of COVID-19 even after the pandemic is over. Facilities experiencing decreases in move-in rates in 2021 cite resident or family member concerns as the basis for such decreases. These and other similar concerns may continue to impact our ability to attract new residents and our ability to retain existing residents.
A housing downturn could decrease demand for senior living services.
Seniors often use the proceeds of home sales to fund their admission to senior living facilities. A downturn in the housing markets, including reductions in sales prices caused by increasing mortgage interest rates, could adversely affect seniors’ ability to afford our resident fees and entrance fees. If national or local housing markets enter a persistent decline, our occupancy rates, revenues, results of operations and cash flow could be negatively impacted.
As we continue to acquire and lease real estate assets, we may not be successful in identifying and consummating these transactions.

As part of, and subsequent to, the Spin-Off, we lease 29 of our properties to Pennant’s senior living operations. In the future, we might expand our leasing property portfolio to additional Pennant operations or other unaffiliated tenants. We have very limited control over the success or failure of our tenants’ and operators’ businesses and, at any time, a tenant or operator may experience a downturn in its business that weakens its financial condition. If that happens, the tenant or operator may fail to make its payments to us when due. Although our lease agreements give us the right to exercise certain remedies in the event of default on the obligations owing to us, we may determine not to do so if we believe that enforcement of our rights would be more detrimental to our business than seeking alternative approaches.

An important part of our business strategy is to continue to expand and diversify our real estate portfolio through accretive acquisition and investment opportunities in healthcare properties. Our execution of this strategy by successfully identifying, securing and consummating beneficial transactions is made more challenging by increased competition and can be affected by many factors, including our relationships with current and prospective tenants, our ability to obtain debt and equity capital at costs comparable to or better than our competitors and our ability to negotiate favorable terms with property owners seeking to sell and other contractual counterparties. Our competitors for these opportunities include healthcare REITs, real estate partnerships, healthcare providers, healthcare lenders and other investors, including developers, banks, insurance companies, pension funds, government-sponsored entities and private equity firms, some of whom may have greater financial resources and lower costs of capital than we do. Potential regulations may affect the ability of these entities, as well as ourselves, to compete for these opportunities or enter into transactions for real estate related to our business. If we are unsuccessful at identifying and capitalizing on investment or acquisition opportunities, our growth and profitability in our real estate investment portfolio may be adversely affected.

Investments in and acquisitions of healthcare properties entail risks associated with real estate investments generally, including risks that the investment will not achieve expected returns, that the cost estimates for necessary property improvements will prove inaccurate or that the tenant or operator will fail to meet performance expectations. Income from properties and yields from investments in our properties may be affected by many factors, including changes in governmental regulation (such as licensing and government payment), general or local economic conditions (such as fluctuations in interest rates, senior savings, and employment conditions), the available local supply of and demand for improved real estate, a reduction in rental income as the result of an inability to maintain occupancy levels, natural disasters (such as hurricanes, earthquakes and floods) or similar factors. Furthermore, healthcare properties are often highly customized, and the development or redevelopment of such properties may require costly tenant-specific improvements. As a result, we cannot assure you that we will achieve the economic benefit we expect from acquisition or investment opportunities.
As we expand our presence in other relevant healthcare industries, we would become subject to risks in a market in which we have limited experience.

The majority of our affiliated facilities have historically been SNFs. As we expand our presence in other relevant healthcare industries, our existing overall business model will continue to change and expose our company to risks in markets in which we have limited experience. We expect that we will have to adjust certain elements of our existing business model, which could have an adverse effect on our business.

106

If our referral sources fail to view us as an attractive skilled nursing provider, or if our referral sources otherwise refer fewer patients, our patient base may decrease.

We rely significantly on appropriate referrals from physicians, hospitals and other healthcare providers in the communities in which we deliver our services to attract appropriate residents and patients to our affiliated facilities. Our referral sources are not obligated to refer business to us and may refer business to other healthcare providers. We believe many of our referral sources refer business to us as a result of the quality of our patient care and our efforts to establish and build a relationship with our referral sources. If we lose, or fail to maintain, existing relationships with our referral resources, fail to develop new relationships, or if we are perceived by our referral sources as not providing high quality patient care, our occupancy rate and the quality of our patient mix could suffer. In addition, if any of our referral sources have a reduction in patients whom they can refer due to a decrease in their business, our occupancy rate and the quality of our patient mix could suffer.
We may need additional capital to fund our operating subsidiaries and finance our growth, and we may not be able to obtain it on terms acceptable to us, or at all, which may limit our ability to grow.

Our ability to maintain and enhance our operating subsidiaries and equipment in a suitable condition to meet regulatory standards, operate efficiently and remain competitive in our markets requires us to commit substantial resources to continued investment in our affiliated facilities and equipment. We are sometimes more aggressive than our competitors in capital spending to address issues that arise in connection with aging and obsolete facilities and equipment. In addition, continued expansion of our business through the acquisition of existing facilities, expansion of our existing facilities and construction of new facilities may require additional capital, particularly if we were to accelerate our acquisition and expansion plans. Financing may not be available to us or may be available to us only on terms that are not favorable, including being subject to interest rates that are higher than those enjoyed in the recent past. In addition, some of our outstanding indebtedness and long-term leases restrict, among other things, our ability to incur additional debt. If we are unable to raise additional funds or obtain additional funds on terms acceptable to us, we may have to delay or abandon some or all of our growth strategies. Further, if additional funds are raised through the issuance of additional equity securities, the percentage ownership of our stockholders would be diluted. Any newly issued equity securities may have rights, preferences or privileges senior to those of our common stock.
The condition of the financial markets, including volatility and deterioration in the capital and credit markets, could limit the availability of debt and equity financing sources to fund the capital and liquidity requirements of our business, as well as negatively impact or impair the value of our current portfolio of cash, cash equivalents and investments, including U.S. Treasury securities and U.S.-backed investments.

Our cash, cash equivalents and investments are held in a variety of interest-bearing instruments, including U.S. treasury securities. As a result of the uncertain domestic and global political, credit and financial market conditions, including an increase in the Consumer Price Index of seven percent in 2021, which has continued at a comparable rate for the first six months of 2022 and is expected to continue for the foreseeable future in 2022, investments in these types of financial instruments pose risks arising from liquidity and credit concerns. Given that future deterioration in the U.S. and global credit and financial markets is a possibility, no assurance can be made that losses or significant deterioration in the fair value of our cash, cash equivalents, or investments will not occur. Uncertainty surrounding the trading market for U.S. government securities or impairment of the U.S. government's ability to satisfy its obligations under such treasury securities could impact the liquidity or valuation of our current portfolio of cash, cash equivalents, and investments, a substantial portion of which were invested in U.S. treasury securities. Further, continued domestic and international political uncertainty, along with credit, and financial market uncertainty, may make it difficult for us to liquidate our investments prior to their maturity without incurring a loss, which would have a material adverse effect on our consolidated financial position, results of operations or cash flows.

We may need additional capital if a substantial acquisition or other growth opportunity becomes available or if unexpected events occur or opportunities arise. U.S. capital markets can be volatile. We cannot assure you that additional capital will be available or available on terms acceptable to us. If capital is not available, we may not be able to fund internal or external business expansion or respond to competitive pressures or other market conditions.

107

Delays in reimbursement may cause liquidity problems.

If we experience problems with our billing information systems or if issues arise with Medicare, Medicaid or other payors, we may encounter delays in our payment cycle. From time to time, we have experienced such delays as a result of government payors instituting planned reimbursement delays for budget balancing purposes or as a result of prepayment reviews.

Some states in which we operate are operating with budget deficits or could have budget deficit in the future, which may delay reimbursement in a manner that would adversely affect our liquidity. In addition, from time to time, procedural issues require us to resubmit or appeal claims before payment is remitted, which contributes to our aged receivables. Unanticipated delays in receiving reimbursement from state programs due to changes in their policies or billing or audit procedures may adversely impact our liquidity and working capital.
Compliance with the regulations of the Department of Housing and Urban Development may require us to make unanticipated expenditures which could increase our costs.

Twenty-three of our affiliated facilities are currently subject to regulatory agreements with HUD that give the Commissioner of HUD broad authority to require us to be replaced as the operator of those facilities in the event that the Commissioner determines there are operational deficiencies at such facilities under HUD regulations. Compliance with HUD's requirements can often be difficult because these requirements are not always consistent with the requirements of other federal and state agencies. Appealing a failed inspection can be costly and time-consuming and, if we do not successfully remediate the failed inspection, we could be precluded from obtaining HUD financing in the future or we may encounter limitations or prohibitions on our operation of HUD-insured facilities.
If we fail to safeguard the monies held in our patient trust funds, we will be required to reimburse such monies, and we may be subject to citations, fines and penalties.

Each of our affiliated facilities is required by federal law to maintain a patient trust fund to safeguard certain assets of their residents and patients. If any money held in a patient trust fund is misappropriated, we are required to reimburse the patient trust fund for the amount of money that was misappropriated. If any monies held in our patient trust funds are misappropriated in the future and are unrecoverable, we will be required to reimburse such monies, and we may be subject to citations, fines and penalties pursuant to federal and state laws.
We are a holding company with no operations and rely upon our multiple independent operating subsidiaries to provide us with the funds necessary to meet our financial obligations. Liabilities of any one or more of our subsidiaries could be imposed upon us or our other subsidiaries.

We are a holding company with no direct operating assets, employees or revenue. Each of our affiliated facilities is operated through a separate, wholly-owned, independent subsidiary, which has its own management, employees and assets. Our principal assets are the equity interests we directly or indirectly hold in our multiple operating and real estate holding subsidiaries. As a result, we are dependent upon distributions from our subsidiaries to generate the funds necessary to meet our financial obligations and pay dividends. Our subsidiaries are legally distinct from us and have no obligation to make funds available to us. The ability of our subsidiaries to make distributions to us will depend substantially on their respective operating results and will be subject to restrictions under, among other things, the laws of their jurisdiction of organization, which may limit the amount of funds available for distribution to investors or stockholders, agreements of those subsidiaries, the terms of our financing arrangements and the terms of any future financing arrangements of our subsidiaries.
We may incur operational difficulties or be exposed to claims and liabilities as a result of the separation of Pennant.

On October 1, 2019, we distributed all of the outstanding shares of The Pennant Group, Inc. or Pennant, common stock to stockholders in connection with the separation of our home health and hospice business and substantially all of our senior living operations into a separate publicly traded company, or the Spin-Off. In connection with the Spin-Off, we entered into a separation agreement and various other agreements, including a tax matters agreement, an employee matters agreement and transition services agreements. These agreements govern the separation and distribution and the relationship between us and Pennant going forward, including with respect to potential tax-related losses associated with the separation and distribution. They also provide for the performance of services by each company for the benefit of the other for a period of time.


108

The separation agreement provides for indemnification obligations designed to make Pennant financially responsible for many liabilities that may exist relating to its business activities, whether incurred prior to or after the distribution, including any pending or future litigation, but we cannot guarantee that Pennant will be able to satisfy its indemnification obligations. It is also possible that a court would disregard the allocation agreed to between us and Pennant and require us to assume responsibility for obligations allocated to Pennant. Third parties could also seek to hold us responsible for any of these liabilities or obligations, and the indemnity rights we have under the separation agreement may not be sufficient to fully cover all of these liabilities and obligations. Even if we are successful in obtaining indemnification, we may have to bear costs temporarily. In addition, our indemnity obligations to Pennant, including those related to assets or liabilities allocated to us, may be significant. In addition, certain landlords required, in exchange for their consent to the Spin-Off, that our lease guarantees remain in place for a certain period of time following the Spin-Off. These guarantees could result in significant additional liabilities and obligations for us if Pennant were to default on their obligations under their leases with respect to these properties. These risks could negatively affect our business, financial condition or results of operations.

The separation of Pennant continues to involve a number of additional risks, including, among other things, the potential that management’s and our employees’ attention will be significantly diverted by the provision of skilled services or that we may incur other operational challenges or difficulties as a result of the separation. Certain of the agreements described above provide for the performance of services by each company for the benefit of the other for a period of time. If Pennant is unable to satisfy its obligations under these agreements, we could incur losses and may not have sufficient resources available for such services. These arrangements could also lead to disputes over rights to certain shared property and over the allocation of costs and revenues for products and operations. Our inability to effectively manage the transition activities and related events could adversely affect our business, financial condition or results of operations.
If our Spin-Off fails to qualify as generally tax-free for U.S. federal income tax purposes, we and our stockholders could be subject to significant tax liabilities.

The Spin-Off is intended to qualify for tax-free treatment to us and our stockholders for U.S. federal income tax purposes. Accordingly, completion of the transaction was conditioned upon, among other things, our receipt of opinions from outside tax advisors that the distributions would qualify as a transaction that is intended to be tax-free to both us and our stockholders for U.S. federal income tax purposes under Sections 355 and 368(a)(1)(D) of the Internal Revenue Code. The opinions were based on and relied on, among other things, certain facts and assumptions, as well as certain representations, statements and undertakings, including those relating to the past and future conduct. If any of these facts, assumptions, representations, statements or undertakings is, or becomes, inaccurate or incomplete, or if any of the parties breach any of their respective covenants relating to the transactions, the tax opinions may be invalid. Moreover, the opinions are not binding on the IRS or any courts. Accordingly, notwithstanding receipt of the opinion, the IRS could determine that the distribution and certain related transactions should be treated as taxable transactions for U.S. federal income tax purposes.

If the Spin-Off fails to qualify as a transaction that is generally tax-free under Sections 355 and 368(a)(1)(D) of the Internal Revenue Code, in general, for U.S. federal income tax purposes, we would recognize taxable gain with respect to the distributed securities and our stockholders who received securities in such distribution would be subject to tax as if they had received a taxable distribution equal to the fair market value of such shares.

We also have obligations to provide indemnification to a number of parties as a result of the transaction. Any indemnity obligations for tax issues or other liabilities related to the Spin-Off, could be significant and could adversely impact our business.
Certain directors who serve on our Board of Directors also serve as directors of Pennant, and ownership of shares of Pennant common stock by our directors and executive officers may create, or appear to create, conflicts of interest.

Certain of our directors who serve on our Board of Directors also serve on the board of directors of Pennant. This may create, or appear to create, conflicts of interest when our, or Pennant's management and directors face decisions that could have different implications for us and Pennant, including the resolution of any dispute regarding the terms of the agreements governing the Spin-Off and the relationship between us and Pennant after the Spin-Off or any other commercial agreements entered into in the future between us and the spun-off business and the allocation of such directors’ time between us and Pennant.

All of our executive officers and some of our non-employee directors own shares of the common stock of Pennant. The continued ownership of such common stock by our directors and executive officers following the Spin-Off creates, or may create, the appearance of a conflict of interest when these directors and executive officers are faced with decisions that could have different implications for us and Pennant.
109

Risks Related to Ownership of our Common Stock
We may not be able to pay or maintain dividends and the failure to do so would adversely affect our stock price.

Our ability to pay and maintain cash dividends is based on many factors, including our ability to make and finance acquisitions, our ability to negotiate favorable lease and other contractual terms, anticipated operating cost levels, the level of demand for our beds, the rates we charge and actual results that may vary substantially from estimates. Some of the factors are beyond our control and a change in any such factor could affect our ability to pay or maintain dividends. The Amended Credit Agreement restricts our ability to pay dividends to stockholders if we receive notice that we are in default under this agreement. The failure to pay or maintain dividends could adversely affect our stock price.
Our amended and restated certificate of incorporation, amended and restated bylaws and Delaware law contain provisions that could discourage transactions resulting in a change in control, which may negatively affect the market price of our common stock.

Our amended and restated certificate of incorporation and our amended and restated bylaws contain provisions that may enable our Board of Directors to resist a change in control. These provisions may discourage, delay or prevent a change in the ownership of our company or a change in our management, even if doing so might be beneficial to our stockholders. In addition, these provisions could limit the price that investors would be willing to pay in the future for shares of our common stock. Such provisions set forth in our amended and restated certificate of incorporation or our amended and restated bylaws include:

our Board of Directors is authorized, without prior stockholder approval, to create and issue preferred stock, commonly referred to as “blank check” preferred stock, with rights senior to those of common stock;
advance notice requirements for stockholders to nominate individuals to serve on our Board of Directors or to submit proposals that can be acted upon at stockholder meetings;
our Board of Directors is classified so not all members of our board are elected at one time, which may make it more difficult for a person who acquires control of a majority of our outstanding voting stock to replace our directors;
stockholder action by written consent is limited;
special meetings of the stockholders are permitted to be called only by the chairman of our Board of Directors, our chief executive officer or by a majority of our Board of Directors;
stockholders are not permitted to cumulate their votes for the election of directors;
newly created directorships resulting from an increase in the authorized number of directors or vacancies on our Board of Directors are filled only by majority vote of the remaining directors;
our Board of Directors is expressly authorized to make, alter or repeal our bylaws; and
stockholders are permitted to amend our bylaws only upon receiving the affirmative vote of at least a majority of our outstanding common stock.
We are also subject to the anti-takeover provisions of Section 203 of the General Corporation Law of the State of Delaware. Under these provisions, if anyone becomes an “interested stockholder,” we may not enter into a “business combination” with that person for three years without special approval, which could discourage a third party from making a takeover offer and could delay or prevent a change of control. For purposes of Section 203, “interested stockholder” means, generally, someone owning more than 15% or more of our outstanding voting stock or an affiliate of ours that owned 15% or more of our outstanding voting stock during the past three years, subject to certain exceptions as described in Section 203.

These and other provisions in our amended and restated certificate of incorporation, amended and restated bylaws and Delaware law could discourage acquisition proposals and make it more difficult or expensive for stockholders or potential acquirers to obtain control of our Board of Directors or initiate actions that are opposed by our then-current Board of Directors, including delaying or impeding a merger, tender offer or proxy contest involving us. Any delay or prevention of a change of control transaction or changes in our Board of Directors could cause the market price of our common stock to decline.
110

Item 2.      UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

Issuer Repurchases of Equity Securities

A summary of the repurchase activity for the three months ended June 30, 2022 (dollars in millions, except per share amounts):

PeriodTotal Number of Shares RepurchasedAverage Price Per ShareTotal Number of Shares Purchased as Part of Publicly Announced Plans or ProgramsApproximate Dollar Value of Shares that May Yet Be Purchased Under the Plans or Programs
April 1 to April 30, 2022— $— — $— 
May 1 to May 31, 2022(1)
42,574 $75.70 42,574 $16.8 
June 1 to June 30, 2022(1)
228,146 $73.54 228,146 $— 
(1) These purchases were effectuated through a Rule 10b5-1 trading plan adopted by the Company on February 9, 2022.

Stock Repurchase Programs

As approved by the Board of Directors on October 21, 2021, we entered into a stock repurchase program pursuant to which we may repurchase up to $20.0 million of our common stock under the program for a period of approximately 12 months from October 29, 2021. Under this program, we are authorized to repurchase our issued and outstanding common shares from time to time in open-market and privately negotiated transactions and block trades in accordance with federal securities laws. During the three months ended March 31, 2022, we repurchased 0.1 million shares of our common stock for $9.9 million. During the fourth quarter of 2021, we repurchased 0.1 million shares of our common stock for $10.1 million. This repurchase program expired upon the repurchase of the fully authorized amount under the plan.

On February 9, 2022, the Board of Directors approved a stock repurchase program pursuant to which we may repurchase up to $20.0 million of our common stock under the program for a period of approximately 12 months from February 10, 2022. During the three months ended June 30, 2022, we repurchased 0.3 million shares of our common stock for $20.0 million. This repurchase program expired upon the repurchase of the fully authorized amount under the plan.

On July 28, 2022, the Board of Directors approved a stock repurchase program pursuant to which we may repurchase up to $20.0 million of our common stock under the program for a period of approximately 12 months beginning August 2, 2022.
111


Item 6.        EXHIBITS

EXHIBIT INDEX
ExhibitDescription
Fifth Amended and Restated Certificate of Incorporation of The Ensign Group, Inc., filed with the Delaware Secretary of State on November 15, 2007 (attached as Exhibit 3.1 to the Company’s Quarterly Report on Form 10-Q (File No. 001-33757) filed with the SEC on December 21, 2007)
Certificate of Amendment to the Fifth Amended and Restated Certificate of Incorporation of The Ensign Group, Inc., filed with the Delaware Secretary of State on February 4, 2020 (attached as Exhibit 3.2 to the Company’s Annual Report on Form 10-K (File No. 001-33757) filed with the SEC on February 5, 2020)
Amendment to the Amended and Restated Bylaws, dated August 5, 2014 (attached as Exhibit 3.2 to the Company’s Current Report on Form 8-K (File No. 001-33757) filed with the SEC on August 8, 2014)
Amended and Restated Bylaws of The Ensign Group, Inc. (attached as Exhibit 3.2 to the Company’s Quarterly Report on Form 10-Q (File No. 001-33757) filed with the SEC on December 21, 2007)
Second Amendment to Third Amended and Restated Credit Agreement, dated as of April 8, 2022, by and among The Ensign Group, Inc. and Truist Bank, as administrative agent, and the lenders party thereto (attached as Exhibit 10.1 to the Company's Current Report on Form 10-Q (File No. 001-33757) filed with the SEC on April 12, 2022).
Certification of Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
Certification of Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
Certification of Chief Executive Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
Certification of Chief Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
101.INSXBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.
101.SCHInline XBRL Taxonomy Extension Schema Document
101.CALInline XBRL Taxonomy Extension Calculation Linkbase Document
101.DEFInline XBRL Taxonomy Extension Definition Linkbase Document
101.LABInline XBRL Taxonomy Extension Label Linkbase Document
101.PREInline XBRL Taxonomy Extension Presentation Linkbase Document
104.0Cover Page Interactive Data File - the cover page XBRL tags are embedded within the Inline XBRL document.

112

SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
 THE ENSIGN GROUP, INC.
August 1, 2022BY: /s/ SUZANNE D. SNAPPER  
  Suzanne D. Snapper 
  Chief Financial Officer, Executive Vice President and Director (Principal Financial Officer and Accounting Officer and Duly Authorized Officer) 

 



 

113
EX-31.1 2 ensgq22022ex311.htm EX-31.1 Document

EXHIBIT 31.1

I, Barry R. Port, certify that:

1.I have reviewed this Quarterly Report on Form 10-Q of The Ensign Group, Inc.;
2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal controls over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
(a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
(b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external reporting purposes in accordance with generally accepted accounting principles;
(c)Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
(d)Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
5.The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
(a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
(b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: August 1, 2022
     
 /s/ Barry R. Port   
 Name:  Barry R. Port 
 Title:  Chief Executive Officer and Director (principal executive officer) 



EX-31.2 3 ensgq22022ex312.htm EX-31.2 Document

EXHIBIT 31.2

I, Suzanne D. Snapper, certify that:

1.I have reviewed this Quarterly Report on Form 10-Q of The Ensign Group, Inc.;
2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal controls over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
(a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
(b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external reporting purposes in accordance with generally accepted accounting principles;
(c)Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
(d)Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
5.The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
(a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
(b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.


Date: August 1, 2022
    
 /s/ Suzanne D. Snapper   
 Name: Suzanne D. Snapper  
 Title:  Chief Financial Officer, Executive Vice President and Director (principal financial officer and accounting officer and duly authorized officer) 


EX-32.1 4 ensgq22022ex321.htm EX-32.1 Document

EXHIBIT 32.1
CERTIFICATION PURSUANT TO
18 U.S.C. §1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of The Ensign Group, Inc. (the Company) on Form 10-Q for the period ended June 30, 2022, as filed with the Securities and Exchange Commission on the date hereof (the Report), I, Barry R. Port, Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to my knowledge:
 1 The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
 
 2 The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
     
 /s/ Barry R. Port 
 Name:  Barry R. Port  
 Title:  
Chief Executive Officer and Director (principal executive officer) 
 
 
 
August 1, 2022
 

A signed original of this written statement required by 18 U.S.C. Section 1350 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.


EX-32.2 5 ensgq22022ex322.htm EX-32.2 Document

EXHIBIT 32.2

CERTIFICATION PURSUANT TO
18 U.S.C. §1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of The Ensign Group, Inc. (the Company) on Form 10-Q for the period ended June 30, 2022, as filed with the Securities and Exchange Commission on the date hereof (the Report), I, Suzanne D. Snapper, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to my knowledge:
 1 The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
 
 2 The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
     
 /s/ Suzanne D. Snapper   
 Name:  Suzanne D. Snapper  
 Title:  Chief Financial Officer, Executive Vice President and Director (principal financial officer and accounting officer and duly authorized officer) 
 
 
August 1, 2022
 

A signed original of this written statement required by 18 U.S.C. Section 1350 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.

 


EX-101.SCH 6 ensg-20220630.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0001001 - Document - Cover Page link:presentationLink link:calculationLink link:definitionLink 1001002 - Statement - UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS link:presentationLink link:calculationLink link:definitionLink 1002003 - Statement - UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 1003004 - Statement - UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF INCOME link:presentationLink link:calculationLink link:definitionLink 1004005 - Statement - UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY link:presentationLink link:calculationLink link:definitionLink 1005006 - Statement - UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 1006007 - Statement - UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS link:presentationLink link:calculationLink link:definitionLink 2101101 - Disclosure - Description of Business link:presentationLink link:calculationLink link:definitionLink 2402401 - Disclosure - Description of Business (Details) link:presentationLink link:calculationLink link:definitionLink 2103102 - Disclosure - Summary of Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 2204201 - Disclosure - Summary of Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 2405402 - Disclosure - Summary of Significant Accounting Policies - Property and Equipment (Details) link:presentationLink link:calculationLink link:definitionLink 2406403 - Disclosure - Summary of Significant Accounting Policies - Leases and Leasehold Improvements (Details) link:presentationLink link:calculationLink link:definitionLink 2407404 - Disclosure - Summary of Significant Accounting Policies - Impairment of Long-Lived Assets (Details) link:presentationLink link:calculationLink link:definitionLink 2408405 - Disclosure - Summary of Significant Accounting Policies - Intangible Assets and Goodwill (Details) link:presentationLink link:calculationLink link:definitionLink 2409406 - Disclosure - Summary of Significant Accounting Policies - Self-Insurance (Details) link:presentationLink link:calculationLink link:definitionLink 2410407 - Disclosure - Summary of Significant Accounting Policies - Recent Accounting Pronouncements (Details) link:presentationLink link:calculationLink link:definitionLink 2111103 - Disclosure - COVID-19 Update link:presentationLink link:calculationLink link:definitionLink 2412408 - Disclosure - COVID-19 Update (Details) link:presentationLink link:calculationLink link:definitionLink 2113104 - Disclosure - Revenue and Accounts Receivable link:presentationLink link:calculationLink link:definitionLink 2314301 - Disclosure - Revenue and Accounts Receivable (Tables) link:presentationLink link:calculationLink link:definitionLink 2415409 - Disclosure - Revenue and Accounts Receivable - Revenue from Medicare and Medicaid Programs (Details) link:presentationLink link:calculationLink link:definitionLink 2416410 - Disclosure - Revenue and Accounts Receivable - Disaggregation of Revenue (Details) link:presentationLink link:calculationLink link:definitionLink 2417411 - Disclosure - Revenue and Accounts Receivable - Accounts Receivable (Details) link:presentationLink link:calculationLink link:definitionLink 2118105 - Disclosure - Computation of Net Income Per Common Share link:presentationLink link:calculationLink link:definitionLink 2319302 - Disclosure - Computation of Net Income Per Common Share (Tables) link:presentationLink link:calculationLink link:definitionLink 2420412 - Disclosure - Computation of Net Income Per Common Share (Details) link:presentationLink link:calculationLink link:definitionLink 2121106 - Disclosure - Fair Value Measurements link:presentationLink link:calculationLink link:definitionLink 2422413 - Disclosure - Fair Value Measurements - Schedule of Fair Value, of Assets and Liabilities Measured on Recurring Basis (Details) link:presentationLink link:calculationLink link:definitionLink 2423414 - Disclosure - Fair Value Measurements - Investments (Details) link:presentationLink link:calculationLink link:definitionLink 2124107 - Disclosure - Standard Bearer link:presentationLink link:calculationLink link:definitionLink 2425415 - Disclosure - Standard Bearer (Details) link:presentationLink link:calculationLink link:definitionLink 2126108 - Disclosure - Business Segments link:presentationLink link:calculationLink link:definitionLink 2327303 - Disclosure - Business Segments (Tables) link:presentationLink link:calculationLink link:definitionLink 2428416 - Disclosure - Business Segments - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2429417 - Disclosure - Business Segments - Schedule of Segment Reporting Information, by Segment (Details) link:presentationLink link:calculationLink link:definitionLink 2430418 - Disclosure - Business Segments - Revenue by Segment (Details) link:presentationLink link:calculationLink link:definitionLink 2131109 - Disclosure - Operation Expansions link:presentationLink link:calculationLink link:definitionLink 2432419 - Disclosure - Operation Expansions (Details) link:presentationLink link:calculationLink link:definitionLink 2133110 - Disclosure - Property and Equipment — Net link:presentationLink link:calculationLink link:definitionLink 2334304 - Disclosure - Property and Equipment — Net (Tables) link:presentationLink link:calculationLink link:definitionLink 2435420 - Disclosure - Property and Equipment — Net (Details) link:presentationLink link:calculationLink link:definitionLink 2436421 - Disclosure - Property and Equipment — Net - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2137111 - Disclosure - Intangible Assets — Net link:presentationLink link:calculationLink link:definitionLink 2338305 - Disclosure - Intangible Assets — Net (Tables) link:presentationLink link:calculationLink link:definitionLink 2439422 - Disclosure - Intangible Assets — Net - Schedule of Finite Lived Intangible Assets (Details) link:presentationLink link:calculationLink link:definitionLink 2440423 - Disclosure - Intangible Assets — Net - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2441424 - Disclosure - Intangible Assets — Net - Future Amortization (Details) link:presentationLink link:calculationLink link:definitionLink 2142112 - Disclosure - Goodwill and Other Indefinite-Lived Intangible Assets link:presentationLink link:calculationLink link:definitionLink 2343306 - Disclosure - Goodwill and Other Indefinite-Lived Intangible Assets (Tables) link:presentationLink link:calculationLink link:definitionLink 2444425 - Disclosure - Goodwill and Other Indefinite-Lived Intangible Assets - Goodwill Rollforward (Details) link:presentationLink link:calculationLink link:definitionLink 2445426 - Disclosure - Goodwill and Other Indefinite-Lived Intangible Assets - Indefinite-Lived Intangible Assets (Details) link:presentationLink link:calculationLink link:definitionLink 2146113 - Disclosure - Restricted and Other Assets link:presentationLink link:calculationLink link:definitionLink 2347307 - Disclosure - Restricted and Other Assets (Tables) link:presentationLink link:calculationLink link:definitionLink 2448427 - Disclosure - Restricted and Other Assets (Details) link:presentationLink link:calculationLink link:definitionLink 2449428 - Disclosure - Restricted and Other Assets - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2150114 - Disclosure - Other Accrued Liabilities link:presentationLink link:calculationLink link:definitionLink 2351308 - Disclosure - Other Accrued Liabilities (Tables) link:presentationLink link:calculationLink link:definitionLink 2452429 - Disclosure - Other Accrued Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 2153115 - Disclosure - Income Taxes link:presentationLink link:calculationLink link:definitionLink 2454430 - Disclosure - Income Taxes - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2155116 - Disclosure - Debt link:presentationLink link:calculationLink link:definitionLink 2356309 - Disclosure - Debt (Tables) link:presentationLink link:calculationLink link:definitionLink 2457431 - Disclosure - Debt - Schedule of Long-term Debt (Details) link:presentationLink link:calculationLink link:definitionLink 2458432 - Disclosure - Debt - Credit Facility with a Lending Consortium Arranged by SunTrust (Details) link:presentationLink link:calculationLink link:definitionLink 2459433 - Disclosure - Debt - Mortgage Loans and Promissory Notes and Off-Balance Sheet Arrangements (Details) link:presentationLink link:calculationLink link:definitionLink 2160117 - Disclosure - Options and Awards link:presentationLink link:calculationLink link:definitionLink 2361310 - Disclosure - Options and Awards (Tables) link:presentationLink link:calculationLink link:definitionLink 2462434 - Disclosure - Options and Awards - Stock Options, Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2463435 - Disclosure - Options and Awards - Valuation Assumptions (Details) link:presentationLink link:calculationLink link:definitionLink 2464436 - Disclosure - Options and Awards - Exercise Price and Fair Value (Details) link:presentationLink link:calculationLink link:definitionLink 2465437 - Disclosure - Options and Awards - Options Outstanding Rollforward (Details) link:presentationLink link:calculationLink link:definitionLink 2466438 - Disclosure - Options and Awards - Options Outstanding by Exercise Price (Details) link:presentationLink link:calculationLink link:definitionLink 2467439 - Disclosure - Options and Awards - Intrinsic Values (Details) link:presentationLink link:calculationLink link:definitionLink 2468440 - Disclosure - Options and Awards - Restricted Stock Awards, Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2469441 - Disclosure - Options and Awards - Restricted Award Rollforward (Details) link:presentationLink link:calculationLink link:definitionLink 2470442 - Disclosure - Options and Awards - Long-Term Incentive Plan (Details) link:presentationLink link:calculationLink link:definitionLink 2471443 - Disclosure - Options and Awards - Compensation Expense (Details) link:presentationLink link:calculationLink link:definitionLink 2172118 - Disclosure - Leases link:presentationLink link:calculationLink link:definitionLink 2373311 - Disclosure - Leases (Tables) link:presentationLink link:calculationLink link:definitionLink 2474444 - Disclosure - Leases - Lessee Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2475445 - Disclosure - Leases - Lessee Lease Cost (Details) link:presentationLink link:calculationLink link:definitionLink 2476446 - Disclosure - Leases - Lessee Future Minimum Lease Payments (Details) link:presentationLink link:calculationLink link:definitionLink 2476446 - Disclosure - Leases - Lessee Future Minimum Lease Payments (Details) link:presentationLink link:calculationLink link:definitionLink 2477447 - Disclosure - Leases - Lessor Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2478448 - Disclosure - Leases - Lessor Rental Income (Details) link:presentationLink link:calculationLink link:definitionLink 2479449 - Disclosure - Leases - Lessor Future Minimum Lease Payments Receivable (Details) link:presentationLink link:calculationLink link:definitionLink 2180119 - Disclosure - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 2481450 - Disclosure - Commitments and Contingencies (Details) link:presentationLink link:calculationLink link:definitionLink 2182120 - Disclosure - Common Stock Repurchase Program link:presentationLink link:calculationLink link:definitionLink 2483451 - Disclosure - Common Stock Repurchase Program (Details) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 7 ensg-20220630_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 8 ensg-20220630_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 9 ensg-20220630_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Transitional and skilled service facilities Skilled Service Facilities Skilled Service Facilities Business Acquisition [Axis] Business Acquisition [Axis] All States Except Colorado All States Except Colorado [Member] All States Except Colorado [Domain] Operating lease, lease income Operating Lease, Lease Income Total Medicare and Medicaid Total Medicaid and Medicare Medicaid and Medicare [Member] Total revenue from Medicaid and Medicare [Member] Increase (Decrease) in Stockholders' Equity [Roll Forward] Increase (Decrease) in Stockholders' Equity [Roll Forward] TOTAL LEASE PAYMENTS Lessee, Operating Lease, Liability, to be Paid NET INCOME Net income Net Income (Loss), Including Portion Attributable to Noncontrolling Interest Provision for doubtful accounts Accounts Receivable, Credit Loss Expense (Reversal) Other third-party Third Party Tenants [Member] Third Party Tenants [Member] Cash held in trust for patients Cash Held in Trust for Residents Cash held in trust for residents reflects monies received from, or on behalf of, residents. Maintaining a trust account for residents is a regulatory requirement and, while the trust assets offset the liability, the Company assumes a fiduciary responsibility for these funds. Deferred tax assets Deferred Income Tax Assets, Net Mortgage loans and promissory notes Long-term debt, gross Long-Term Debt, Gross 2016 Exercise Price Range Five [Member] Exercise Price Range Five [Member] Entity Address, Postal Zip Code Entity Address, Postal Zip Code Property, Plant and Equipment [Abstract] Property, Plant and Equipment [Abstract] Gain (loss) on deferral investment Gain (Loss) on Investments Proceeds from issuance of preferred shares Proceeds from Issuance of Convertible Preferred Stock Debt Instrument [Axis] Debt Instrument [Axis] All Other Other Segments [Member] Property and equipment Property, Plant and Equipment, Gross Management fees, as a percentage of funds from operations Property Management Fee, Percent Fee of Funds from Operations Property Management Fee, Percent Fee of Funds from Operations Income Tax Disclosure [Abstract] Income Tax Disclosure [Abstract] Line of credit facility, maximum borrowing capacity Line of Credit Facility, Maximum Borrowing Capacity October 21, 2021 Repurchase Program October 21, 2021 Repurchase Program [Member] October 21, 2021 Repurchase Program February 9, 2022 Repurchase Program February 9, 2022 Repurchase Program [Member] February 9, 2022 Repurchase Program Total net debt ratio, maximum after increase election Total Net Debt Ratio, Maximum After Increase Election Total Net Debt Ratio, Maximum After Increase Election Standard Bearer Standard Bearer [Text Block] Standard Bearer Health Liability Insurance Health Liability Insurance [Member] Health Liability Insurance [Member] Prepayment penalty reduced rate during the fourth year Prepayment Penalty Reduced Rate During The Fourth Year Percentage that the prepayment penalty percentage is reduced during the fourth year. Fair Value of Financial Instruments Fair Value of Financial Instruments, Policy [Policy Text Block] Management fees Management Fee Expense Number of installments Share-based Compensation Arrangement By Share-based Payment Award, Number Of Installments Share-based Compensation Arrangement By Share-based Payment Award, Number Of Installments Deferred compensation plan investments Deferred Compensation Plan Assets Skilled Nursing Operations Skilled Nursing Operations [Member] Skilled Nursing Operations Financial Instruments [Domain] Financial Instruments [Domain] Interest rate margin Debt Instrument, Basis Spread on Variable Rate Other restricted assets Payments for (Proceeds from) Other Investing Activities Statistical Measurement [Domain] Statistical Measurement [Domain] Indefinite-lived Intangible Assets, Major Class Name [Domain] Indefinite-Lived Intangible Assets, Major Class Name [Domain] Operating leases of lessee, contingent rentals, basis spread on variable rate Lessee, Operating Lease, Discount Rate Exercised (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period Schedule of Indefinite-Lived Intangible Assets [Table] Schedule of Indefinite-Lived Intangible Assets [Table] Issuance of restricted stock, net of forfeitures (in shares) Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures Operating lease, weighted average discount rate, percent Operating Lease, Weighted Average Discount Rate, Percent Debt instrument, interest rate, stated percentage Debt Instrument, Interest Rate, Stated Percentage Share-based Payment Arrangement [Abstract] Share-Based Payment Arrangement [Abstract] Liability for Claims and Claims Adjustment Expense [Table] Liability for Claims and Claims Adjustment Expense [Table] Additional paid-in capital Additional Paid in Capital, Common Stock Accounts receivable Accounts Receivable, before Allowance for Credit Loss Real Estate Properties [Domain] Real Estate Properties [Domain] Accrued dividends declared Dividends payable Dividends Payable Income taxes Income Taxes Paid Repurchase of common stock (Note 20) Repurchase of common stock, value Treasury Stock, Value, Acquired, Cost Method Net income attributable to The Ensign Group, Inc. Net income attributable to the Ensign Group, Inc. Net Income (Loss) Attributable to Parent Lessee, Lease, Description [Table] Lessee, Lease, Description [Table] Weighted Average Volatility Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Weighted Average Volatility Rate Antidilutive securities excluded from computation of earnings per share, amount (in shares) Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Subsequent Event Type [Axis] Subsequent Event Type [Axis] Year Lessee, Operating Lease, Liability, to be Paid [Abstract] Share Repurchase Program [Domain] Share Repurchase Program [Domain] Thereafter Lessee, Operating Lease, Liability, to be Paid, after Year Five Facilities under master lease arrangement Facilities Under Master Lease Arrangement Facilities operated under two separate three-facility master lease arrangements. Under these master leases, a breach at a single facility could subject one or more of the other facilities covered by the same master lease to the same default risk. Share-based Payment Arrangement, Option, Exercise Price Range Share-Based Payment Arrangement, Option, Exercise Price Range [Table Text Block] Equity Component [Domain] Equity Component [Domain] Amended Master Lease Amended Master Lease [Member] Amended Master Lease Assembled occupancy Assembled Occupancy Acquired [Member] Assembled occupancy acquired [Member] Subsequent Event Type [Domain] Subsequent Event Type [Domain] Acquired Finite-Lived Intangible Assets [Line Items] Acquired Finite-Lived Intangible Assets [Line Items] Ownership [Axis] Ownership [Axis] Number outstanding (in shares) Share-Based Payment Arrangement, Option, Exercise Price Range, Shares Outstanding LEASES Lessee, Operating Leases [Text Block] Award vesting rights, percentage Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage Payments of deferred financing costs Payments of deferred financing costs Payments of Financing Costs Payor [Axis] Payor [Axis] Payor [Axis] Lessee, Lease, Description [Line Items] Lessee, Lease, Description [Line Items] Plan Name [Axis] Plan Name [Axis] Lease Arrangement [Axis] Lease Arrangement [Axis] Information by group of related lease arrangements. Promissory Note, 5.3% Promissory Note, 5.3% [Member] Promissory Note, 5.3% SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION Supplemental Cash Flow Information [Abstract] Lease Contractual Term [Domain] Lease Contractual Term [Domain] Plan Name [Domain] Plan Name [Domain] Blanket Aggregate Blanket Aggregate [Member] Blanket Aggregate [Member] 2022 (remainder) Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year Goodwill [Line Items] Goodwill [Line Items] Statement of Cash Flows [Abstract] Statement of Cash Flows [Abstract] Entity Address, State or Province Entity Address, State or Province Fair Value, Inputs, Level 1 Fair Value, Inputs, Level 1 [Member] Operating Entity [Axis] Operating Entity [Axis] Operating Entity [Axis] Share-based compensation, options outstanding, weighted average remaining contractual term Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term Award Type [Axis] Award Type [Axis] SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Basis of Presentation and Significant Accounting Policies [Text Block] NET CASH PROVIDED BY OPERATING ACTIVITIES Net Cash Provided by (Used in) Operating Activities Deferred compensation liability Increase (Decrease) in Deferred Compensation Lease liabilities—current Less: current lease liabilities Operating Lease, Liability, Current Accounts, Notes, Loans and Financing Receivable [Line Items] Accounts, Notes, Loans and Financing Receivable [Line Items] Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table] Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table] Promissory Note, 5.0% Promissory Note, 5.0% [Member] Promissory Note, 5.0% Expense: Costs and Expenses [Abstract] Lender Name [Axis] Lender Name [Axis] COVID-19 UPDATE Unusual or Infrequent Items, or Both, Disclosure [Text Block] Noncontrolling Interest Noncontrolling Interest [Policy Text Block] The noncontrolling interest in a subsidiary initially recognized at estimated fair value on the acquisition date and is presented within total equity in the Company's condensed consolidated balance sheets. Legal Entity [Axis] Legal Entity [Axis] Long-term debt—less current maturities Long-Term Debt, Excluding Current Maturities TOTAL LIABILITIES Liabilities The Pennant Group, Inc. Pennant The Pennant Group, Inc. [Member] The Pennant Group, Inc. Operating lease, weighted average remaining lease term Operating Lease, Weighted Average Remaining Lease Term Grant date intrinsic value (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Grant Date Intrinsic Value Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Geographical [Axis] Geographical [Axis] Cash flows from investing activities: Net Cash Provided by (Used in) Investing Activities [Abstract] Issuance of common stock to employees and directors resulting from the exercise of stock options Stock Issued During Period, Value, New Issues Aggregate intrinsic value of options that vested in period Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Vested Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Fair Value Hierarchy and NAV [Domain] Fair Value Hierarchy and NAV [Domain] Deferred payment of social security taxes, current Liabilities, Deferred Tax Payments Under CARES Act, Current Liabilities, Deferred Tax Payments Under CARES Act, Current Revolving credit facility with Truist Revolving Credit Facility [Member] Schedule of Property and Equipment Property, Plant and Equipment [Table Text Block] Service and Rental Revenue Recognition Revenue from Contract with Customer [Policy Text Block] Document Type Document Type Weighted Average Exercise Price Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract] SOFR Secured Overnight Financing Rate (SOFR) Overnight Index Swap Rate [Member] Self-Insurance Retention Per Claim Self-insurance retention per claim [Member] Self-insurance retention per claim [Member] Property, plant and equipment, useful life Property, Plant and Equipment, Useful Life Non-Vested Restricted Awards Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward] Concentration Risk Benchmark [Domain] Concentration Risk Benchmark [Domain] Cash paid during the period for: Additional Cash Flow Elements and Supplemental Cash Flow Information [Abstract] Letter of credit increase Line of Credit Facility, Increase (Decrease), Net Forfeited (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period Finite-Lived Intangible Assets, Major Class Name [Domain] Finite-Lived Intangible Assets, Major Class Name [Domain] Restructuring Type [Axis] Restructuring Type [Axis] Nonvested at beginning of period (in dollars per share) Nonvested at end of period (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value DEBT Debt Disclosure [Text Block] Segments [Axis] Segments [Axis] Asset Acquisition [Axis] Asset Acquisition [Axis] Product and Service [Domain] Product and Service [Domain] Entity Shell Company Entity Shell Company Deferred income taxes Deferred Income Tax Expense (Benefit) General and Professional Liability Professional Malpractice Liability Insurance [Member] Exercise Price Range [Axis] Exercise Price Range [Axis] Concentration Risk [Table] Concentration Risk [Table] 2023 Lessee, Operating Lease, Liability, to be Paid, Year One Cost of Sales and General and Administrative Expense Cost of Sales and General and Administrative Expense [Member] Primary financial statement caption encompassing cost of services and general and administrative expense Rent - cost of services Rent, Cost Of Services [Member] Rent, Cost Of Servcies[Member] Financial Instrument [Axis] Financial Instrument [Axis] Consolidation Items [Domain] Consolidation Items [Domain] Subsequent Event Subsequent Event [Member] Revenue Benchmark Revenue Benchmark [Member] Non-employee directors Share-Based Payment Arrangement, Nonemployee [Member] Document Period End Date Document Period End Date 2027 Lessor, Operating Lease, Payment to be Received, Year Five Other long-term liabilities Increase (Decrease) in Other Deferred Liability Share-based Payment Arrangement, Option, Exercise Price Range [Line Items] Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items] Lessor, Lease, Description [Table] Lessor, Lease, Description [Table] TOTAL ASSETS Assets Skilled Services Skilled Services Segment [Member] Skilled Services Segment Debt Disclosure [Abstract] Debt Disclosure [Abstract] NET INCOME PER SHARE ATTRIBUTABLE TO THE ENSIGN GROUP INC. Earnings Per Share [Abstract] Accounts Receivable Accounts Receivable [Policy Text Block] Income Statement Location [Axis] Income Statement Location [Axis] Number of real estate properties leased with an option to purchase Number of Real Estate Properties Leased with an Option to Purchase Number of Real Estate Properties Leased with an Option to Purchase Schedule of Held-to-maturity Securities [Line Items] Schedule of Held-to-Maturity Securities [Line Items] Schedule of Restructuring and Related Costs [Table] Schedule of Restructuring and Related Costs [Table] Current maturities of long-term debt Less: current maturities Amount outstanding, current Long-Term Debt, Current Maturities 2027 Lessee, Operating Lease, Liability, to be Paid, Year Five Exercised (in dollars per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price NET CASH USED IN FINANCING ACTIVITIES Net Cash Provided by (Used in) Financing Activities Accounting Policies [Abstract] Accounting Policies [Abstract] Stock repurchase program, authorized amount Stock Repurchase Program, Authorized Amount Accrued wages and related liabilities (Note 3) Employee-related Liabilities, Current Variable lease, cost Variable Lease, Cost Income before provision for income taxes Income before provision for income taxes Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Ensign Group, Inc. stockholders' equity: Stockholders' Equity Attributable to Parent [Abstract] Prepaid expenses and other current assets Prepaid Expense and Other Assets, Current Segments [Domain] Segments [Domain] Debt security investments classified as held to maturity and carried at amortized cost Debt Securities, Held-to-Maturity, Amortized Cost, before Allowance for Credit Loss Lessor, Lease, Description [Line Items] Lessor, Lease, Description [Line Items] Schedule of Goodwill [Table] Schedule of Goodwill [Table] Amortization of deferred financing fees Amortization of Debt Issuance Costs and Discounts Asset Acquisition Asset Acquisition [Member] These acquisitions were classified as asset acquisitions in accordance with ASC 805. COMPUTATION OF NET INCOME PER COMMON SHARE Earnings Per Share [Text Block] Customer [Axis] Customer [Axis] Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] Long-term debt, threshold for EBITDA ratio increase election Long-Term Debt, Threshold For EBITDA Ratio Increase Election Long-Term Debt, Threshold For EBITDA Ratio Increase Election Self-Insurance Liability Reserve Estimate, Policy [Policy Text Block] Disposal Group, Disposed of by Sale, Not Discontinued Operations Disposal Group, Disposed of by Sale, Not Discontinued Operations [Member] Acquisition of noncontrolling interest shares Noncontrolling Interest, Decrease from Redemptions or Purchase of Interests Operating lease obligations Increase (Decrease) in Operating Lease Liability Award Type [Domain] Award Type [Domain] Grantee Status [Axis] Grantee Status [Axis] Third Parties Third Parties [Member] Third Parties Share-based compensation, nonvested awards, cost not yet recognized, period for recognition Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition Schedule of Finite-Lived Intangible Assets Schedule of Finite-Lived Intangible Assets [Table Text Block] Operational skilled nursing beds Operational Skilled Nursing Beds Number of skilled nursing beds available for use at a skilled nursing facility Payments to acquire businesses, gross Payments to Acquire Businesses, Gross Rental revenue Rental [Member] Rental Entity Registrant Name Entity Registrant Name Issuance of common stock to employees and directors resulting from the exercise of stock options (in shares) Stock Issued During Period, Shares, New Issues Mortgages Mortgages [Member] Weighted Average Dividend Yield Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate Exercise price, upper range limit (in dollars per share) Share-Based Payment Arrangement, Option, Exercise Price Range, Upper Range Limit Customer relationships Customer Relationships [Member] Entity Address, City or Town Entity Address, City or Town Leases [Abstract] Leases [Abstract] Real Estate Properties [Line Items] Real Estate Properties [Line Items] Issuance of restricted stock, net of forfeitures Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures Total equity Balance at beginning of period Balance at end of period Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest Various Landlords Various Landlords [Member] Various Landlords[Member] Revenue, FMAP payments received Revenue Recognition, Family First Coronavirus Response Act, Revenue Recognized Revenue Recognition, Family First Coronavirus Response Act, Revenue Recognized Minimum Minimum [Member] Non-controlling interest Stockholders' Equity Attributable to Noncontrolling Interest Statement of Financial Position [Abstract] Statement of Financial Position [Abstract] Entity Emerging Growth Company Entity Emerging Growth Company Common stock, par value (usd per share) Common Stock, Par or Stated Value Per Share Variable lease costs Cost of Services [Member] Cost of Services 2026 Lessor, Operating Lease, Payment to be Received, Year Four Repayments of CARES Act Provider Relief Fund and Medicare Advance Payment Program (Note 3) Repayments of CARES Act Provider Relief Fund and Medicare Advance Payment Program (Note 3) Coronavirus Aid, Relief, and Economic Security (“CARES”) Funds Repaid Coronavirus Aid, Relief, and Economic Security (“CARES”) Funds, Repayment Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Disclosure [Abstract] Less: debt issuance costs, net Debt Issuance Costs, Net Schedule of Segment Reporting Information, by Segment [Table] Schedule of Segment Reporting Information, by Segment [Table] FAIR VALUE MEASUREMENTS Fair Value Disclosures [Text Block] RESTRICTED AND OTHER ASSETS Other Assets Disclosure [Text Block] Trading Symbol Trading Symbol Entity File Number Entity File Number INTANGIBLE ASSETS — NET Intangible Assets Disclosure [Text Block] Standard Bearer Standard Bearer Healthcare REIT, Inc. [Member] Standard Bearer Healthcare REIT, Inc. Workers' Compensation Workers' Compensation Insurance [Member] 2020 Exercise Price Range Nine [Member] Exercise Price Range Nine [Member] Common stock in treasury, at cost (in shares) Balance at beginning of period (in shares) Balance at end of period (in shares) Treasury Stock, Common, Shares Forfeited (in shares) Stock Issued During Period, Shares, Restricted Stock Award, Forfeited 2026 Finite-Lived Intangible Asset, Expected Amortization, Year Four Equipment Equipment [Member] Insurance Type and Tier Identifier [Axis] Insurance Type and Tier Identifier [Axis] Disposal Group Classification [Axis] Disposal Group Classification [Axis] Granted (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period Effective income tax rate Effective Income Tax Rate Reconciliation, Percent Schedule of Earnings Per Share, Diluted, by Common Class, Including Two Class Method Schedule of Earnings Per Share, Diluted, by Common Class, Including Two Class Method [Table Text Block] Coronavirus Aid, Relief, and Economic Security (“CARES”) funds received and returned Coronavirus Aid, Relief, and Economic Security (“CARES”) Funds Received And Returned Coronavirus Aid, Relief, and Economic Security (“CARES”) Funds Received And Returned Twenty Three Subsidiaries Twenty Three Subsidiaries [Member] Twenty Three Subsidiaries Concentration Risk Benchmark [Axis] Concentration Risk Benchmark [Axis] Number of options vested (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number Estimates and Assumptions Use of Estimates, Policy [Policy Text Block] Operation Expansions Business Combination Disclosure [Text Block] Cash and cash equivalents, fair value disclosure Cash and Cash Equivalents, Fair Value Disclosure Other (expense) income: Other Nonoperating Income (Expense) [Abstract] Parent Company Parent Company [Member] Accounts payable Increase (Decrease) in Accounts Payable Concentration risk Percentage of Revenue Concentration Risk, Percentage Escrow deposits Payments for (Proceeds from) Deposits on Real Estate Acquisitions Cash surrender value of life insurance policy premiums Life Insurance, Corporate or Bank Owned, Change in Value INCOME TAXES Income Tax Disclosure [Text Block] Medicare Medicare [Member] Revenue from Medicare [Member] Purchase of property and equipment Payments To Acquire Property And Equipment Payments To Acquire Property And Equipment Credit Facility [Domain] Credit Facility [Domain] Amortization of intangible assets Amortization of Intangible Assets Schedule of Goodwill Schedule of Goodwill [Table Text Block] Interest Interest Paid, Excluding Capitalized Interest, Operating Activities Basic (in dollars per share) Basic net income per common share (in dollars per share) Earnings Per Share, Basic 2025 Lessee, Operating Lease, Liability, to be Paid, Year Three Award requisite service period Share-Based Compensation Arrangement by Share-Based Payment Award, Award Requisite Service Period Other Service Revenue All Other Corporate, Non-Segment [Member] Per Occurence Per Occurence [Member] Per Occurence [Member] Non-controlling interest distribution Payments to Noncontrolling Interests Share-based compensation, restricted awards, exercise price (in dollars per share) Share-based Compensation, Restricted Awards, Exercise Price Share-based Compensation, Restricted Awards, Exercise Price 2022 Exercise Price Range Eleven [Member] Exercise Price Range Eleven Concentration Risk Type [Domain] Concentration Risk Type [Domain] Counterparty Name [Domain] Counterparty Name [Domain] Schedule of Accounts, Notes, Loans and Financing Receivable [Table] Schedule of Accounts, Notes, Loans and Financing Receivable [Table] Treasury Stock Treasury Stock [Member] Indefinite-lived Intangible Assets [Axis] Indefinite-Lived Intangible Assets [Axis] Total Ensign Group, Inc. stockholders' equity Stockholders' Equity Attributable to Parent Cash and cash equivalents beginning of period Cash and cash equivalents end of period Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations Forfeited (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value Lease Contractual Term [Axis] Lease Contractual Term [Axis] Ownership [Domain] Ownership [Domain] Entity Interactive Data Current Entity Interactive Data Current 2023 Lessor, Operating Lease, Payment to be Received, Year One Accumulated Amortization Finite-Lived Intangible Assets, Accumulated Amortization Fair Value, by Balance Sheet Grouping [Table] Fair Value, by Balance Sheet Grouping [Table] FMAP payments received Family First Coronavirus Response Act, Payments Received Family First Coronavirus Response Act, Payments Received Property, Plant and Equipment [Table] Schedule of Property, Plant and Equipment [Table] Property, Plant and Equipment [Table] Change in operating assets and liabilities Increase (Decrease) in Operating Capital [Abstract] 2025 Finite-Lived Intangible Asset, Expected Amortization, Year Three Standard Bearer Master Leases Standard Bearer Master Leases [Member] Standard Bearer Master Leases NUMERATOR: Net Income (Loss) Attributable to Parent [Abstract] Expected to vest Share-based Compensation Arrangement by Share-based Payment Award, Options, Expected to Vest, Outstanding, Aggregate Intrinsic Value Share-based Compensation Arrangement by Share-based Payment Award, Options, Expected to Vest, Outstanding, Aggregate Intrinsic Value Business Combination Business Combination [Member] These acquisitions were classified as business acquisitions in accordance with ASC 805. Dividends paid Payments of Dividends Retained Earnings Retained Earnings [Member] Segment Reporting Information [Line Items] Segment Reporting Information [Line Items] Incentive Management Fee Management Service, Incentive [Member] 2025 Lessor, Operating Lease, Payment to be Received, Year Three Common Stock Common Stock [Member] Schedule of Stock-Based Compensation Expense Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block] Total net debt ratio, minimum Total Net Debt Ratio, Minimum Total Net Debt Ratio, Minimum Schedule of Operating Lease Expenses Lease, Cost [Table Text Block] Transitional and skilled services and senior living campuses Skilled Services And Senior Living Campuses Transitional and Skilled Services and Assistant and Independent Living Campuses Number of reportable segments Number of Reportable Segments Repurchase of shares of common stock (Note 20) Payments for Repurchase of Common Stock Number of shares available for grant (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant Schedule of Nonvested Restricted Stock Units Activity Schedule of Nonvested Restricted Stock Units Activity [Table Text Block] Income Taxes Income Tax, Policy [Policy Text Block] Statement [Table] Statement [Table] Vested (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value Debt instrument, interest rate, effective percentage Debt Instrument, Interest Rate, Effective Percentage Lessee, operating lease, renewal term Lessee, Operating Lease, Renewal Term Document Quarterly Report Document Quarterly Report Share-based compensation, options expected to vest, number (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Expected to Vest, Number As of the balance sheet date, the number of shares which are expected to vest into stock options outstanding can be converted under the option plan. Furniture and fixtures Furniture and Fixtures [Member] Current assets: Assets, Current [Abstract] Long-term lease liabilities—less current portion LONG-TERM OPERATING LEASE LIABILITIES Operating Lease, Liability, Noncurrent Statistical Measurement [Axis] Statistical Measurement [Axis] Asset Acquisition [Domain] Asset Acquisition [Domain] Repurchase of common stock (Note 20) (in shares) Repurchase of common stock (in shares) Treasury Stock, Shares, Acquired Line of Credit Facility, Lender [Domain] Line of Credit Facility, Lender [Domain] Other indefinite-lived intangibles Indefinite-Lived Intangible Assets (Excluding Goodwill) Leasehold improvements Leasehold Improvements [Member] Grantee Status [Domain] Grantee Status [Domain] Per Facility Per Facility [Member] Per Facility [Member] Retained earnings Retained Earnings (Accumulated Deficit) Disposal Group Name [Axis] Disposal Group Name [Axis] Accounts receivable—less allowance for doubtful accounts of $7,827 and $11,213 at June 30, 2022 and December 31, 2021, respectively ACCOUNTS RECEIVABLE, NET Accounts Receivable, after Allowance for Credit Loss, Current Schedule of Finite-Lived Intangible Assets [Table] Schedule of Finite-Lived Intangible Assets [Table] Equity Components [Axis] Equity Components [Axis] Weighted average exercise price of options vested (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price Number of stand-alone leases Lessee, Operating Lease, Number Of Leases Lessee, Operating Lease, Number Of Leases Number of promissory notes Debt Instruments, Number Of Instruments Debt Instruments, Number Of Instruments Colorado COLORADO Document Fiscal Year Focus Document Fiscal Year Focus Cash flows from operating activities: Net Cash Provided by (Used in) Operating Activities [Abstract] Statement [Line Items] Statement [Line Items] Intercompany Elimination Consolidation, Eliminations [Member] Nonvested at beginning of period (in shares) Nonvested at end of period (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number Indefinite-lived Intangible Assets [Line Items] Indefinite-Lived Intangible Assets [Line Items] Segment income (loss) Segment Income (Loss) Segment Income (Loss) Other expense, net Nonoperating Income (Expense) Other long-term liabilities Deferred rent and other long-term liabilities Rental expense in excess of actual rental payments and other long-term liabilities Variable Rate [Domain] Variable Rate [Domain] Gross Carrying Amount Finite-Lived Intangible Assets, Gross Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Axis] California CALIFORNIA Skilled nursing, assisted living and independent living facilities Skilled Nursing, Senior Living and Independent Living Facilities Skilled Nursing, Senior Living and Independent Living Facilities Schedule of Rental Income from Third-Party Sources Operating Lease, Lease Income [Table Text Block] Right-of-use assets Operating Lease, Right-of-Use Asset Impairment of Long-Lived Assets Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block] Schedule of Earnings Per Share, Basic, by Common Class, Including Two Class Method Schedule of Earnings Per Share, Basic, by Common Class, Including Two Class Method [Table Text Block] Rent expense Operating Lease, Expense Type of Restructuring [Domain] Type of Restructuring [Domain] Document Transition Report Document Transition Report Local Phone Number Local Phone Number Income from operations Operating Income (Loss) Recent Accounting Pronouncements New Accounting Pronouncements, Policy [Policy Text Block] Prepaid expenses and other assets Increase (Decrease) in Prepaid Expense and Other Assets Common stock, shares outstanding (in shares) Balance at beginning of period (in shares) Balance at end of period (in shares) Common Stock, Shares, Outstanding Schedule of Real Estate Properties [Table] Schedule of Real Estate Properties [Table] Service revenue Service [Member] Goodwill Balance at beginning of period Balance at end of period Goodwill Mortgage loans and promissory notes Collateralized Debt Obligations [Member] Goodwill and intangible asset impairment Goodwill and Intangible Asset Impairment Prepaid income taxes Prepaid Taxes Property, Plant and Equipment, Type [Axis] Long-Lived Tangible Asset [Axis] Notes payable Notes Payable Noncontrolling interest attributable to subsidiary equity plan Noncontrolling Interest, Increase from Subsidiary Equity Issuance Adjustments to reconcile net income to net cash provided by operating activities: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] GOODWILL AND OTHER INDEFINITE-LIVED INTANGIBLE ASSETS Goodwill and Intangible Assets Disclosure [Text Block] Provision for income taxes Income Tax Expense (Benefit) Geographical [Domain] Geographical [Domain] Property and Equipment Property, Plant and Equipment, Policy [Policy Text Block] Restricted and other assets RESTRICTED AND OTHER ASSETS Other Restricted Assets, Noncurrent 2026 Lessee, Operating Lease, Liability, to be Paid, Year Four Cash proceeds from the sale of assets Proceeds from Sales of Assets, Investing Activities Income Statement [Abstract] Income Statement [Abstract] Options granted (in shares) Options Granted (in shares) Granted (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross Impairment of long lived assets Impairment, Long-Lived Asset, Held-for-Use Additional Paid-In Capital Additional Paid-in Capital [Member] Document Fiscal Period Focus Document Fiscal Period Focus Intrinsic value of options exercised in period Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value Cost of services Cost of Goods and Services Sold Gain on sale of assets Profit (Loss) from Real Estate Operations Diluted (in shares) Adjusted weighted average common shares outstanding (in shares) Weighted Average Number of Shares Outstanding, Diluted Debt issuance costs, net Debt Issuance Costs, Line of Credit Arrangements, Net Less: accumulated depreciation Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Expected Life Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term Buildings and improvements Building and Building Improvements [Member] Real Estate Property Ownership [Axis] Real Estate Property Ownership [Axis] Accounts Receivable Accounts Receivable [Member] Amortization of deferred rent Deferred Rent Adjustment Adjustment to deferred rent arising from the difference between rent expense recognized and rental payments made in the current period. Base Rate Base Rate [Member] Common stock: $0.001 par value; 100,000 shares authorized; 58,646 and 55,278 shares issued and outstanding at June 30, 2022, respectively, and 58,134 and 55,190 shares issued and outstanding at December 31, 2021, respectively Common Stock, Value, Issued Debt Instrument, Name [Domain] Debt Instrument, Name [Domain] Business Acquisition, Acquiree [Domain] Business Acquisition, Acquiree [Domain] 2015 Exercise Price Range Four [Member] Exercise Price Range Four [Member] Granted (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value Health care facilities Number Of Health Care Facilities Number Of Health Care Facilities Operating Segments Operating Segments [Member] Insurance Coverage Limit Type [Axis] Insurance Coverage Limit Type [Axis] Insurance Coverage Limit Type [Axis] Vested Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value Non-cash leasing arrangement Non-Cash Lease Expense Non-Cash Lease Expense Deferred payment of social security taxes, noncurrent Liabilities, Deferred Tax Payments Under CARES Act, Noncurrent Liabilities, Deferred Tax Payments Under CARES Act, Noncurrent Net income (loss) attributable to noncontrolling interests Net Income (Loss) Attributable to Noncontrolling Interest Less: Net Income (Loss) Attributable to Noncontrolling Interest [Abstract] COMMITMENTS AND CONTINGENCIES Commitments and Contingencies Disclosure [Text Block] Current liabilities: Liabilities, Current [Abstract] Issuance of common stock upon exercise of options Proceeds from Stock Options Exercised Proceeds from debt (Note 16) Proceeds from Issuance of Long-Term Debt Payments to acquire business and asset acquisitions Payments To Acquire Business And Asset Acquisitions Cash paid to acquire acquisitions. Common stock, shares issued (in shares) Common Stock, Shares, Issued Concentration Risk [Line Items] Concentration Risk [Line Items] Resident advances Contract with Customer, Liability, Current Accrued self-insurance liabilities—current Self Insurance Reserve, Current Unapplied state relief funds Accrued Liabilities, State Relief Contract Liabilities Accrued Liabilities, State Relief Contract Liabilities Escrow deposits Deposits Assets, Noncurrent Accrued capital expenditures Capital Expenditures Incurred but Not yet Paid Income Statement Location [Domain] Income Statement Location [Domain] Amendment Flag Amendment Flag Finite-lived intangible asset, useful life Finite-Lived Intangible Asset, Useful Life NET CASH USED IN INVESTING ACTIVITIES Net Cash Provided by (Used in) Investing Activities Operating lease expense Operating Lease, Cost Repayment of Medicare Accelerated and Advance Payment Program Repayment Of Funds Received From The Medicare Accelerated and Advance Payment Program, CARES Act Repayment Of Funds Received From The Medicare Accelerated and Advance Payment Program, CARES Act Number of real estate skilled nursing properties acquired Number Of Properties Acquired Number Of Properties Acquired Number of operations transferred from third parties Number of Living Operations Transferred From Third-Parties Number of Living Operations Transferred From Third-Parties Medicaid Medicaid [Member] Revenue from Medicaid for custodial services [Member] Additions Goodwill, Acquired During Period Schedule of Segment Reporting Information, by Segment Schedule of Segment Reporting Information, by Segment [Table Text Block] Construction in progress Construction in Progress [Member] Entity Current Reporting Status Entity Current Reporting Status Goodwill and Intangible Assets Disclosure [Abstract] Goodwill and Intangible Assets Disclosure [Abstract] Share-based compensation, nonvested awards (in shares) Employee Service Share-based Compensation, Nonvested Awards Employee Service Share-based Compensation, Nonvested Awards Intangible Assets and Goodwill Goodwill and Intangible Assets, Policy [Policy Text Block] Campus Operation Campus Operation [Member] Campus Operation Accrued wages and related liabilities Increase (Decrease) in Employee Related Liabilities Malpractice loss contingency, accrual, undiscounted Malpractice Loss Contingency, Accrual, Undiscounted Prepaid income taxes Increase (Decrease) in Prepaid Taxes Deposits with landlords Security Deposit Depreciation and amortization Depreciation, Depletion and Amortization Disaggregation of Revenue [Table] Disaggregation of Revenue [Table] Line of credit facility, unused capacity, commitment fee percentage Line of Credit Facility, Unused Capacity, Commitment Fee Percentage Fair value adjustment, lease liability and right-of-use assets Liabilities, Fair Value Adjustment Liability for Claims and Claims Adjustment Expense [Line Items] Liability for Claims and Claims Adjustment Expense [Line Items] Thereafter Finite-Lived Intangible Asset, Expected Amortization, after Year Five 2022 (remainder) Lessor, Operating Lease, Payment to be Received, Remainder of Fiscal Year Debt Instrument, pre-payment fee reduction, term Debt Instrument, Pre-Payment Fee Reduction, Term Debt Instrument, Pre-Payment Fee Reduction, Term Lessee, operating lease, term of contract Lessee, Operating Lease, Term of Contract Counterparty Name [Axis] Counterparty Name [Axis] Balance at beginning of period, (in shares) Balance at end of period, (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number Non-California Non-California [Member] Non-California [Domain] Total net debt ratio, maximum Total Net Debt Ratio, Maximum Total Net Debt Ratio, Maximum Black-Scholes Fair Value Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Fair Value Fair value determined using a black-scholes model for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range Lessee leasing arrangements, operating leases, number of renewal terms Lessee Leasing Arrangements, Operating Leases, Number Of Renewal Terms Lessee Leasing Arrangements, Operating Leases, Number Of Renewal Terms Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Basis of Presentation Basis of Accounting, Policy [Policy Text Block] Property and equipment, net PROPERTY AND EQUIPMENT, NET Property, Plant and Equipment, Net Lease liabilities Operating Lease, Payments Payments on debt (Note 16) Repayments of Long-Term Debt Schedule of Finite-Lived Intangible Assets, Future Amortization Expense Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block] Standard Bearer Equity Plan Standard Bearer Equity Plan [Member] Standard Bearer Equity Plan Stock Options Stock-based compensation expense related to stock options Share-Based Payment Arrangement, Option [Member] Quality assurance fee Quality Assurance Fee Quality assurance fee represents amounts payable to California, Utah, Idaho, Washington, Colorado, Iowa, and Nebraska in respect of a mandated fee based on resident days Common stock in treasury, at cost, 3,368 and 2,944 shares at June 30, 2022 and December 31, 2021, respectively (Note 20) Treasury Stock, Value Mortgage loans and promissory notes Notes Payable Other Payables Notes Payable, Other Payables [Member] Dividends declared Dividends Private and other Private and other payors Private Pay and Other [Member] Revenue from self-pay and Other payors [Member] Allowance for doubtful accounts Less: allowance for doubtful accounts Accounts Receivable, Allowance for Credit Loss, Current Master lease agreements Master Lease Agreements Master Lease agreements Other (expense) income Other Nonoperating Income (Expense) Self insurance reserve Self Insurance Reserve Property taxes Accrual for Taxes Other than Income Taxes General Liability General Liability [Member] Common stock, shares authorized (in shares) Common Stock, Shares Authorized 2014 Exercise Price Range Three [Member] Exercise Price Range Three [Member] Lease Arrangement [Domain] Lease Arrangement [Domain] Lease Arrangement Maximum Maximum [Member] Two Acquisitions Concentrated in Property, Plant And Equipment Two Acquisitions Concentrated In Property, Plant And Equipment [Member] Two Acquisitions Concentrated In Property, Plant And Equipment Non-cash financing and investing activity Other Noncash Investing and Financing Items [Abstract] Schedule of Other Indefinite-lived Intangible Assets by Major Class Schedule of Acquired Indefinite-Lived Intangible Assets by Major Class [Table Text Block] Schedule of Business Acquisitions, by Acquisition [Table] Schedule of Business Acquisitions, by Acquisition [Table] Base Management Fee Management Service, Base [Member] Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value Total current assets Assets, Current Intangible Assets, Net (Excluding Goodwill) [Abstract] Intangible Assets, Net (Excluding Goodwill) [Abstract] Business Acquisition [Line Items] Business Acquisition [Line Items] Entity Small Business Entity Small Business Operating lease, variable lease income Operating Lease, Variable Lease Income COMMON STOCK REPURCHASE PROGRAM Stockholders' Equity Note Disclosure [Text Block] Dividends per share (in dollars per share) Common Stock, Dividends, Per Share, Declared Intangible assets, net Net Finite-Lived Intangible Assets, Net Net income Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest Number of operating subsidiaries Number Of Operating Subsidiaries Number Of operating subsidiaries entered into mortgage loans that are insured with HUD. Deferral investment expense (income) Investment Expense (Income) Investment Expense (Income) Distribution to noncontrolling interest holder Noncontrolling Interest, Decrease from Distributions to Noncontrolling Interest Holders Share-based compensation, nonvested awards, cost not yet recognized Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount Debt Security, Corporate, US Debt Security, Corporate, US [Member] 2021 Exercise Price Range Ten [Member] Exercise Price Range Ten [Member] Number of Options Outstanding Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward] PROPERTY AND EQUIPMENT— Net Property, Plant and Equipment Disclosure [Text Block] Remaining Company Remaining Company [Member] The Ensign Group, Inc. Management fees, as a percentage of total revenues Property Management Fee, Percent Fee of Total Revenues Property Management Fee, Percent Fee of Total Revenues Unusual or Infrequent Items, or Both [Abstract] Outstanding Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value Other States, Except California, Texas and Washington Other states, except California, Texas and Washington [Member] Other states, except California, Texas and Washington Schedule of Aggregate Intrinsic Value of Options Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable [Table Text Block] Property, Plant and Equipment, Type [Domain] Long-Lived Tangible Asset [Domain] Number of real estate properties Number of Real Estate Properties Accounts receivable Increase (Decrease) in Accounts Receivable Title of 12(b) Security Title of 12(b) Security DESCRIPTION OF BUSINESS Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block] Prepayment penalty reduced rate for the fifth through tenth years Prepayment Penalty Reduced Rate For The Fifth Through Tenth Years Percentage that the prepayment penalty percentage is reduced for the fifth through tenth years. Maturities of investments Proceeds from Sale, Maturity and Collection of Investments Operational senior living units Operational Senior Living Units Operational Assisted Living and Independent Living Units Investments—current Short-Term Investments TOTAL EXPENSES Costs and Expenses Class of Treasury Stock [Table] Class of Treasury Stock [Table] Payables and Accruals [Abstract] Payables and Accruals [Abstract] Number of businesses acquired subject to lease amendment Number of Businesses Acquired Subject To Lease Amendment Number of Businesses Acquired Subject To Lease Amendment Schedule of Acquired Finite-Lived Intangible Asset by Major Class [Table] Schedule of Acquired Finite-Lived Intangible Asset by Major Class [Table] Medicaid — skilled Medicaid-skilled [Member] Revenue from Medicaid for skilled services [Member] Business Combination and Asset Acquisition [Abstract] Debt Instrument [Line Items] Debt Instrument [Line Items] Purchase Option Purchase Option [Member] Purchase Option Proceeds from CARES Act Provider Relief Fund and Medicare Advance Payment Program (Note 3) Proceeds From CARES Act Provider Relief Funds And Medicare Advance Payment Program Proceeds From CARES Act Provider Relief Funds And Medicare Advance Payment Program PRESENT VALUE OF TOTAL LEASE LIABILITIES Operating Lease, Liability BUSINESS SEGMENTS Segment Reporting Disclosure [Text Block] Lessor, operating lease, term of contract Lessor, Operating Lease, Term of Contract Medicare Accelerated and Advance Payment Medicare Accelerated And Advance Payment, CARES ACT Medicare Accelerated And Advance Payment, CARES ACT Stock-Based Compensation Share-Based Payment Arrangement [Policy Text Block] Conversion to reduce shares availability Share-based Compensation Arrangement by Share-based Payment Award, Options, Conversion To Reduce Shares Availability Share-based Compensation Arrangement by Share-based Payment Award, Options, Conversion To Reduce Shares Availability 2024 Finite-Lived Intangible Asset, Expected Amortization, Year Two July 2022 Repurchase Program July 2022 Repurchase Program [Member] July 2022 Repurchase Program TOTAL Lessor, Operating Lease, Payments to be Received Cash, uninsured amount Cash, Uninsured Amount Total Management Fee Management Service, Total [Member] Management Service, Total LIABILITIES AND EQUITY Liabilities and Equity [Abstract] Proceeds from sale of subsidiary shares (Note 7) Proceeds From Sale Of Common Stock Associated With Subsidiary Equity Plans Proceeds From Sale Of Common Stock Associated With Subsidiary Equity Plans Weighted Average Exercise Price (in dollars per share) Granted (in dollars per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Senior living facility Senior Living Facility Sale of a senior living facility Segment Reporting, Revenue Reconciling Item [Line Items] Segment Reporting, Revenue Reconciling Item [Line Items] Forfeited (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price WEIGHTED AVERAGE COMMON SHARES OUTSTANDING DENOMINATOR: Weighted Average Number of Shares Outstanding, Diluted [Abstract] Insurance subsidiary deposits and investments Insurance Subsidiary Deposits And Investments Captive insurance subsidiary cash and equivalents designated to support long-term insurance subsidiary liabilities and debt security investments held to maturity. Accounts payable Accounts Payable, Current Number of businesses acquired Number of Businesses Acquired Number of master lease arrangements Number of Lease Arrangements Number of Lease Arrangements Debt Securities, Held-to-maturity [Table] Debt Securities, Held-to-Maturity [Table] Write-off of deferred financing fees Write off of Deferred Debt Issuance Cost 2013 Exercise Price Range Two [Member] Exercise Price Range Two [Member] Number of real estate properties leased Number of Real Estate Properties Leased Number of Real Estate Properties Leased Entity Filer Category Entity Filer Category Proceeds from issuance of common stock Proceeds from Issuance of Common Stock Basic (in shares) Weighted average shares outstanding for basic net income per share (in shares) Weighted Average Number of Shares Outstanding, Basic Truist Truist Bank [Member] Truist Bank [Member] Asset acquisition, purchase price Asset Acquisition, Consideration Transferred TOTAL Share-Based Payment Arrangement, Expense Commitments and contingencies (Notes 16, 18 and 19) Commitments and Contingencies Security Exchange Name Security Exchange Name Balance at beginning of period (in dollars per share) Balance at end of period (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price Gain on sale of assets Gain (Loss) on Disposition of Assets Weighted Average Life (Years) Acquired Finite-Lived Intangible Assets, Weighted Average Useful Life Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] Reconciliation of Revenue from Segments to Consolidated Reconciliation of Revenue from Segments to Consolidated [Table Text Block] Operating Entity [Domain] Operating Entity [Domain] [Domain] for Operating Entity [Axis] Letters of credit outstanding, pledged amount Letters of Credit Outstanding, Amount Restricted Stock Awards Stock-based compensation expense related to restricted stock awards Restricted Stock [Member] Loss-Sensitive Limit Per Claim Loss-Sensitive limit per claim [Member] [Member] Loss-Sensitive limit per claim Property, Plant and Equipment [Line Items] Property, Plant and Equipment [Line Items] General and administrative expense General and Administrative Expense [Member] TOTAL REVENUE Revenue TOTAL REVENUE Revenue from Contract with Customer, Excluding Assessed Tax Income taxes payable Increase (Decrease) in Income Taxes Payable Purchase of non-controlling interest Purchases of Non-Controlling Interest Purchases of Non-Controlling Interest Cover page. Cover [Abstract] Schedule of Long-term Debt Instruments [Table] Schedule of Long-Term Debt Instruments [Table] Leases and Leasehold Improvements Lessee, Leases [Policy Text Block] Insurance Coverage Limit Type [Domain] Insurance Coverage Limit Type [Domain] Insurance Coverage Limit Type [Domain] Stock options vested and exercisable (in shares) Share-Based Payment Arrangement, Option, Exercise Price Range, Shares Exercisable Long-term debt—less current maturities Long Term Debt, net of Current Maturities and Debt Discount Long Term Debt, net of Current Maturities and Debt Discount Managed care Managed Care [Member] Revenue from managed care payors [Member] Payor [Domain] Payor [Domain] Payor [Domain] OPTIONS AND AWARDS Share-Based Payment Arrangement [Text Block] Stop-Loss Insurance Limit Per Claim Stop-Loss Insurance limit per claim [Member] Stop-Loss Insurance limit per claim[Member] REVENUE AND ACCOUNTS RECEIVABLE Revenue from Contract with Customer [Text Block] Segment Reporting [Abstract] Segment Reporting [Abstract] Stock repurchase program, period in force Stock Repurchase Program, Period in Force 2024 Lessor, Operating Lease, Payment to be Received, Year Two Non-Controlling Interest Noncontrolling Interest [Member] Weighted Average Risk-Free Rate Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate Repurchase of shares of common stock to satisfy tax withholding obligations Payment, Tax Withholding, Share-Based Payment Arrangement TOTAL LIABILITIES AND EQUITY Liabilities and Equity Senior living facilities Senior Living Facilities Number of Assisted and Independent Living Facilities Debt instrument, term Debt Instrument, Term Health Health Insurance Product Line [Member] Long-term Debt, Type [Axis] Long-Term Debt, Type [Axis] Goodwill [Roll Forward] Goodwill [Roll Forward] Land Land [Member] Plus: incremental shares from assumed conversion (in shares) Incremental Common Shares Attributable to Dilutive Effect of Share-Based Payment Arrangements Organization, Consolidation and Presentation of Financial Statements [Abstract] Organization, Consolidation and Presentation of Financial Statements [Abstract] Schedule of Common Stock Outstanding Roll Forward Schedule of Common Stock Outstanding Roll Forward [Table Text Block] 2019 LTI Plan 2019 LTI Plan [Member] 2019 LTI Plan [Member] Disposal Group Name [Domain] Disposal Group Name [Domain] Cash payments for business acquisitions (Note 9) Payments to Acquire Businesses, Net of Cash Acquired Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items] Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] Fair Value, Inputs, Level 2 Fair Value, Inputs, Level 2 [Member] Purchases of investments Payments to Acquire Investments Current Fiscal Year End Date Current Fiscal Year End Date Rent—cost of services Rent Cost Of Services Rent cost of services OTHER ACCRUED LIABILITIES Accounts Payable and Accrued Liabilities Disclosure [Text Block] Less: present value adjustment Lessee, Operating Lease, Liability, Undiscounted Excess Amount Finite-Lived Intangible Assets [Line Items] Finite-Lived Intangible Assets [Line Items] Diluted (in dollars per share) Diluted net income per common share (in dollars per share) Earnings Per Share, Diluted Proceeds from sale of real estate Proceeds from Sale of Property, Plant, and Equipment Owned Properties Wholly Owned Properties [Member] Award vesting period Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period Gains on sales property, plant and equipment Gain (Loss) on Disposition of Property Plant Equipment Schedule of Restricted and Other Assets Schedule of Other Assets [Table Text Block] Employee stock award compensation APIC, Share-Based Payment Arrangement, Increase for Cost Recognition Reconciliation of Revenue from Segments to Consolidated [Table] Reconciliation of Revenue from Segments to Consolidated [Table] Consolidation Items [Axis] Consolidation Items [Axis] Exercise Price Range [Domain] Exercise Price Range [Domain] Concentration Risk Type [Axis] Concentration Risk Type [Axis] Total current liabilities Liabilities, Current 2024 Lessee, Operating Lease, Liability, to be Paid, Year Two Cash from insurance proceeds Proceeds from Insurance Settlement, Investing Activities Schedule of Accounts, Notes, Loans and Financing Receivable Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block] Customer Concentration Risk Customer Concentration Risk [Member] Restructuring Cost and Reserve [Line Items] Restructuring Cost and Reserve [Line Items] Thereafter Lessor, Operating Lease, Payment to be Received, after Year Five Medicare and Medicaid licenses Medicare and Medicaid Licenses [Member] Medicare licenses for home health and hospice segment and all other segment. Schedule of Annual Rental Income Lessor, Operating Lease, Payment to be Received, Fiscal Year Maturity [Table Text Block] Senior Living Facilities Senior Living Facilities [Member] Assisted Living Facilities [Member] Share Repurchase Program [Axis] Share Repurchase Program [Axis] 2019 Exercise Price Range Eight [Member] Exercise Price Range Eight [Member] Expiration period Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period Equity, Class of Treasury Stock [Line Items] Equity, Class of Treasury Stock [Line Items] Schedule of Future Minimum Lease Payments Lessee, Operating Lease, Liability, Maturity [Table Text Block] Exercise price, lower range limit (in dollars per share) Share-Based Payment Arrangement, Option, Exercise Price Range, Lower Range Limit Spinoff Spinoff [Member] Entity Address, Address Line One Entity Address, Address Line One Third-Party Payor 524292 Third Party Administration of Insurance and Pension Funds [Member] Share-based Payment Arrangement, Option, Exercise Price Range [Table] Share-Based Payment Arrangement, Option, Exercise Price Range [Table] Standard Bearer Standard Bearer Segment [Member] Standard Bearer Segment Product and Service [Axis] Product and Service [Axis] Prepayment penalty reduced rate during first three years Prepayment Penalty Reduced Rate During First Three Years Percentage that the prepayment penalty percentage is reduced during the first three years. Senior Living Operations Senior Living Operations [Member] Senior Living Operations Fair Value Disclosures [Abstract] Fair Value Disclosures [Abstract] Interest expense Interest expense Interest Expense CareTrust REIT CareTrust REIT [Member] CareTrust REIT [Member] Facility trade name Trade name Trade Names [Member] Credit Facility [Axis] Credit Facility [Axis] Schedule of Other Accrued Liabilities Schedule of Accrued Liabilities [Table Text Block] Long-term insurance losses recoverable asset Estimated Insurance Recoveries Schedule of Long-term Debt Schedule of Long-Term Debt Instruments [Table Text Block] EQUITY Equity [Abstract] Total deferred payment of social security taxes Liabilities, Deferred Tax Payments Under CARES Act Liabilities, Deferred Tax Payments Under CARES Act Vested (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract] Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract] Entity Tax Identification Number Entity Tax Identification Number Number of shares authorized (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized Schedule of Weighted Average Grant Date Fair Value and Exercise Price of Options Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value [Table Text Block] Accrued self-insurance liabilities—less current portion Self Insurance Reserve, Noncurrent Cash payments for asset acquisitions (Note 9) Purchase price Payments To Acquire Asset Acquisitions Cash paid to acquire acquisitions. Reclassifications Reclassification, Comparability Adjustment [Policy Text Block] Remaining Contractual Life (Years) Share-Based Payment Arrangement, Option, Exercise Price Range, Exercisable, Weighted Average Remaining Contractual Term 2018 Exercise Price Range Seven [Member] Exercise Price Range Seven [Member] Disaggregation of Revenue Disaggregation of Revenue [Table Text Block] Refunds payable Resident Refunds Payable Resident refunds payable includes amounts due to residents for overpayments and duplicate payments Revenue from Contract with Customer [Abstract] Revenue from Contract with Customer [Abstract] 2022 (remainder) Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year Stock-based compensation expense related to stock options and restricted stock awards to non-employee directors Stock awards [Member] Stock awards [Member] 2017 Exercise Price Range Six [Member] Exercise Price Range Six [Member] Shares of common stock used to satisfy tax withholding obligations (in shares) Share-Based Payment Arrangement, Shares Withheld for Tax Withholding Obligation Type and Tier Identifier [Domain] Type and Tier Identifier [Domain] Two Acquisitions Concentrated In Goodwill Two Acquisitions Concentrated In Goodwill [Member] Two Acquisitions Concentrated In Goodwill Net increase (decrease) in cash and cash equivalents Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Lessee, operating lease, term extension Lessee, Operating Lease, Term Extension Lessee, Operating Lease, Term Extension 2027 Finite-Lived Intangible Asset, Expected Amortization, Year Five Entity Central Index Key Entity Central Index Key Year Finite-Lived Intangible Assets, Net, Amortization Expense, Fiscal Year Maturity [Abstract] Weighted Average Grant Date Fair Value Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract] Capital improvement reserves with landlords and lenders Other Restricted Assets Finite-Lived Intangible Assets by Major Class [Axis] Finite-Lived Intangible Assets by Major Class [Axis] Shares of common stock used to satisfy tax withholding obligations Share-Based Payment Arrangement, Decrease for Tax Withholding Obligation Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table] Other than options, conversion to reduce shares availability Share-based Compensation Arrangement By Share-based Payment Award, Other Than Options, Conversion To Reduce Shares Availability Share-based Compensation Arrangement By Share-based Payment Award, Other Than Options, Conversion To Reduce Shares Availability Accrued self-insurance liabilities Increase (Decrease) in Self Insurance Reserve Other accrued liabilities OTHER ACCRUED LIABILITIES Other Accrued Liabilities, Current Entity [Domain] Entity [Domain] City Area Code City Area Code Legal finding accrued Accrued Professional Fees, Current General and administrative expense General and Administrative Expense ASSETS Assets [Abstract] Facilities under Medicare probe reviews Facilities Under Medicare Probe Reviews Facilities under Medicare Probe reviews relating to Medicare services, billings and potential overpayments Long-term Debt, Type [Domain] Long-Term Debt, Type [Domain] Depreciation and amortization Depreciation And Amortization [Member] Depreciation And Amortization [Member] Statement of Stockholders' Equity [Abstract] Statement of Stockholders' Equity [Abstract] Notes Payable to Banks Notes Payable to Banks [Member] Owned Properties Owned Properties [Member] Owned Properties Aggregate Deductible Aggregate Deductible [Member] Aggregate Deductible [Member] Cash flows from financing activities: Net Cash Provided by (Used in) Financing Activities [Abstract] Stock-based compensation Share-Based Payment Arrangement, Noncash Expense Weighted Average Fair Value of Options (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value Deferred compensation plan investments Cash Surrender Value of Life Insurance Variable Rate [Axis] Variable Rate [Axis] Other Other Liabilities, Noncurrent LEASES Lessor, Operating Leases [Text Block] Third Party Tenants Under Triple Net Lease Arrangements Third Party Tenants Under Triple Net Lease Arrangements [Member] Third Party Tenants Under Triple Net Lease Arrangements 2012 Exercise Price Range One [Member] Exercise Price Range One [Member] Disposal Group Classification [Domain] Disposal Group Classification [Domain] Other accrued liabilities Increase (Decrease) in Other Operating Liabilities Loss on insurance claims, legal finding and asset disposals Gain (Loss) On Insurance Claims And Disposal Of Assets Gain (Loss) On Insurance Claims And Disposal Of Assets Disaggregation of Revenue [Line Items] Disaggregation of Revenue [Line Items] 2023 Finite-Lived Intangible Asset, Expected Amortization, Year One TEXAS TEXAS Right-of-use assets obtained in exchange for new and modified operating lease obligations Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 2022 Plan 2022 Plan [Member] 2022 Plan Less: net (loss) income attributable to noncontrolling interests Income (Loss) from Continuing Operations, Net of Tax, Attributable to Noncontrolling Interest Customer [Domain] Customer [Domain] Affiliated Facility, Master Lease One Affiliated Facility, Master Lease One [Member] Affiliated Facility, Master Lease One EX-101.PRE 10 ensg-20220630_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT GRAPHIC 11 ensg-20220630_g1.jpg GRAPHIC begin 644 ensg-20220630_g1.jpg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htm IDEA: XBRL DOCUMENT v3.22.2
Cover Page - shares
6 Months Ended
Jun. 30, 2022
Jul. 27, 2022
Cover [Abstract]    
Document Type 10-Q  
Document Quarterly Report true  
Document Period End Date Jun. 30, 2022  
Document Transition Report false  
Entity File Number 001-33757  
Entity Registrant Name ENSIGN GROUP, INC  
Entity Incorporation, State or Country Code DE  
Entity Tax Identification Number 33-0861263  
Entity Address, Address Line One 29222 Rancho Viejo Road, Suite 127  
Entity Address, City or Town San Juan Capistrano  
Entity Address, State or Province CA  
Entity Address, Postal Zip Code 92675  
City Area Code 949  
Local Phone Number 487-9500  
Title of 12(b) Security Common Stock, par value $0.001 per share  
Trading Symbol ENSG  
Security Exchange Name NASDAQ  
Entity Current Reporting Status Yes  
Entity Interactive Data Current Yes  
Entity Filer Category Large Accelerated Filer  
Entity Small Business false  
Entity Emerging Growth Company false  
Entity Shell Company false  
Entity Common Stock, Shares Outstanding   55,289,903
Entity Central Index Key 0001125376  
Document Fiscal Year Focus 2022  
Document Fiscal Period Focus Q2  
Amendment Flag false  
Current Fiscal Year End Date --12-31  
XML 13 R2.htm IDEA: XBRL DOCUMENT v3.22.2
UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)
$ in Thousands
Jun. 30, 2022
Dec. 31, 2021
Current assets:    
Cash and cash equivalents $ 285,580 $ 262,201
Accounts receivable—less allowance for doubtful accounts of $7,827 and $11,213 at June 30, 2022 and December 31, 2021, respectively 339,001 328,731
Investments—current 8,991 13,763
Prepaid income taxes 16,336 5,452
Prepaid expenses and other current assets 32,774 29,562
Total current assets 682,682 639,709
Property and equipment, net 908,228 888,434
Right-of-use assets 1,305,009 1,138,872
Insurance subsidiary deposits and investments 40,077 36,567
Escrow deposits 15,571 0
Deferred tax assets 32,883 33,147
Restricted and other assets 57,010 47,046
Intangible assets, net 2,535 2,652
Goodwill 76,869 60,469
Other indefinite-lived intangibles 3,807 3,727
TOTAL ASSETS 3,124,671 2,850,623
Current liabilities:    
Accounts payable 60,414 58,116
Accrued wages and related liabilities (Note 3) 273,276 278,770
Lease liabilities—current 58,769 52,181
Accrued self-insurance liabilities—current 49,728 40,831
Other accrued liabilities 85,793 89,410
Current maturities of long-term debt 3,944 3,760
Total current liabilities 531,924 523,068
Long-term debt—less current maturities 151,105 152,883
Long-term lease liabilities—less current portion 1,216,335 1,056,515
Accrued self-insurance liabilities—less current portion 76,793 69,308
Other long-term liabilities 27,821 27,135
TOTAL LIABILITIES 2,003,978 1,828,909
Commitments and contingencies (Notes 16, 18 and 19)
Ensign Group, Inc. stockholders' equity:    
Common stock: $0.001 par value; 100,000 shares authorized; 58,646 and 55,278 shares issued and outstanding at June 30, 2022, respectively, and 58,134 and 55,190 shares issued and outstanding at December 31, 2021, respectively 58 58
Additional paid-in capital 398,793 369,760
Retained earnings 835,941 733,992
Common stock in treasury, at cost, 3,368 and 2,944 shares at June 30, 2022 and December 31, 2021, respectively (Note 20) (114,626) (83,042)
Total Ensign Group, Inc. stockholders' equity 1,120,166 1,020,768
Non-controlling interest 527 946
Total equity 1,120,693 1,021,714
TOTAL LIABILITIES AND EQUITY $ 3,124,671 $ 2,850,623
XML 14 R3.htm IDEA: XBRL DOCUMENT v3.22.2
UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - USD ($)
$ in Thousands
Jun. 30, 2022
Dec. 31, 2021
Statement of Financial Position [Abstract]    
Allowance for doubtful accounts $ 7,827 $ 11,213
Common stock, par value (usd per share) $ 0.001 $ 0.001
Common stock, shares authorized (in shares) 100,000,000 100,000,000
Common stock, shares issued (in shares) 58,646,000 58,134,000
Common stock, shares outstanding (in shares) 55,278,000 55,190,000
Common stock in treasury, at cost (in shares) 3,368,000 2,944,000
XML 15 R4.htm IDEA: XBRL DOCUMENT v3.22.2
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF INCOME - USD ($)
shares in Thousands, $ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2022
Jun. 30, 2021
Jun. 30, 2022
Jun. 30, 2021
TOTAL REVENUE $ 732,486 $ 638,536 $ 1,445,931 $ 1,265,789
Expense:        
Cost of services 563,641 488,524 1,119,282 970,710
Rent—cost of services 37,228 34,455 72,990 67,911
General and administrative expense 38,527 36,908 76,783 71,181
Depreciation and amortization 14,858 13,795 29,534 27,454
TOTAL EXPENSES 654,254 573,682 1,298,589 1,137,256
Income from operations 78,232 64,854 147,342 128,533
Other (expense) income:        
Interest expense (2,688) (1,634) (4,756) (3,275)
Other (expense) income (2,587) 1,121 (3,403) 1,869
Other expense, net (5,275) (513) (8,159) (1,406)
Income before provision for income taxes 72,957 64,341 139,183 127,127
Provision for income taxes 15,154 13,758 31,292 26,707
NET INCOME 57,803 50,583 107,891 100,420
Less:        
Net income (loss) attributable to noncontrolling interests 112 1,158 (140) 1,789
Net income attributable to The Ensign Group, Inc. $ 57,691 $ 49,425 $ 108,031 $ 98,631
NET INCOME PER SHARE ATTRIBUTABLE TO THE ENSIGN GROUP INC.        
Basic (in dollars per share) $ 1.05 $ 0.91 $ 1.97 $ 1.82
Diluted (in dollars per share) $ 1.01 $ 0.87 $ 1.90 $ 1.73
WEIGHTED AVERAGE COMMON SHARES OUTSTANDING        
Basic (in shares) 54,906 54,468 54,788 54,331
Diluted (in shares) 56,853 56,997 56,862 56,945
Service revenue        
TOTAL REVENUE $ 728,347 $ 634,609 $ 1,437,503 $ 1,257,885
Rental revenue        
TOTAL REVENUE $ 4,139 $ 3,927 $ 8,428 $ 7,904
XML 16 R5.htm IDEA: XBRL DOCUMENT v3.22.2
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY - USD ($)
shares in Thousands, $ in Thousands
Total
Common Stock
Additional Paid-In Capital
Retained Earnings
Treasury Stock
Non-Controlling Interest
Balance at beginning of period (in shares) at Dec. 31, 2020   54,626        
Balance at beginning of period at Dec. 31, 2020 $ 818,227 $ 58 $ 338,177 $ 551,055 $ (71,213) $ 150
Balance at beginning of period (in shares) at Dec. 31, 2020         2,791  
Increase (Decrease) in Stockholders' Equity [Roll Forward]            
Issuance of common stock to employees and directors resulting from the exercise of stock options (in shares)   246        
Issuance of common stock to employees and directors resulting from the exercise of stock options 3,880   3,880      
Issuance of restricted stock, net of forfeitures (in shares)   81        
Issuance of restricted stock, net of forfeitures 3,725   3,725      
Shares of common stock used to satisfy tax withholding obligations (9)       $ (9)  
Dividends declared (2,886)     (2,886)    
Employee stock award compensation 4,054   4,054      
Net income (loss) attributable to noncontrolling interests 631         631
Distribution to noncontrolling interest holder (1,248)         (1,248)
Net income attributable to the Ensign Group, Inc. 49,206     49,206    
Balance at end of period (in shares) at Mar. 31, 2021   54,953        
Balance at end of period at Mar. 31, 2021 875,580 $ 58 349,836 597,375 $ (71,222) (467)
Balance at end of period (in shares) at Mar. 31, 2021         2,791  
Balance at beginning of period (in shares) at Dec. 31, 2020   54,626        
Balance at beginning of period at Dec. 31, 2020 818,227 $ 58 338,177 551,055 $ (71,213) 150
Balance at beginning of period (in shares) at Dec. 31, 2020         2,791  
Increase (Decrease) in Stockholders' Equity [Roll Forward]            
Net income (loss) attributable to noncontrolling interests 1,789          
Net income attributable to the Ensign Group, Inc. 98,631          
Balance at end of period (in shares) at Jun. 30, 2021   55,130        
Balance at end of period at Jun. 30, 2021 928,643 $ 58 357,451 643,906 $ (72,822) 50
Balance at end of period (in shares) at Jun. 30, 2021         2,811  
Balance at beginning of period (in shares) at Mar. 31, 2021   54,953        
Balance at beginning of period at Mar. 31, 2021 875,580 $ 58 349,836 597,375 $ (71,222) (467)
Balance at beginning of period (in shares) at Mar. 31, 2021         2,791  
Increase (Decrease) in Stockholders' Equity [Roll Forward]            
Issuance of common stock to employees and directors resulting from the exercise of stock options (in shares)   148        
Issuance of common stock to employees and directors resulting from the exercise of stock options 2,982   2,982      
Issuance of restricted stock, net of forfeitures (in shares)   49        
Shares of common stock used to satisfy tax withholding obligations (in shares)   (20)     (20)  
Shares of common stock used to satisfy tax withholding obligations (1,600)       $ (1,600)  
Dividends declared (2,894)     (2,894)    
Employee stock award compensation 4,633   4,633      
Net income (loss) attributable to noncontrolling interests 1,158         1,158
Distribution to noncontrolling interest holder (641)         (641)
Net income attributable to the Ensign Group, Inc. 49,425     49,425    
Balance at end of period (in shares) at Jun. 30, 2021   55,130        
Balance at end of period at Jun. 30, 2021 $ 928,643 $ 58 357,451 643,906 $ (72,822) 50
Balance at end of period (in shares) at Jun. 30, 2021         2,811  
Balance at beginning of period (in shares) at Dec. 31, 2021 55,190 55,190        
Balance at beginning of period at Dec. 31, 2021 $ 1,021,714 $ 58 369,760 733,992 $ (83,042) 946
Balance at beginning of period (in shares) at Dec. 31, 2021 2,944       2,944  
Increase (Decrease) in Stockholders' Equity [Roll Forward]            
Issuance of common stock to employees and directors resulting from the exercise of stock options (in shares)   147        
Issuance of common stock to employees and directors resulting from the exercise of stock options $ 2,768   2,768      
Issuance of restricted stock, net of forfeitures (in shares)   104        
Issuance of restricted stock, net of forfeitures 5,241   5,241      
Shares of common stock used to satisfy tax withholding obligations (15)       $ (15)  
Dividends declared (3,042)     (3,042)    
Employee stock award compensation 5,167   5,167      
Repurchase of common stock (Note 20) (in shares)   (133)     (133)  
Repurchase of common stock (Note 20) (9,882)       $ (9,882)  
Acquisition of noncontrolling interest shares (26)   245     (271)
Net income (loss) attributable to noncontrolling interests (252)         (252)
Net income attributable to the Ensign Group, Inc. 50,340     50,340    
Balance at end of period (in shares) at Mar. 31, 2022   55,308        
Balance at end of period at Mar. 31, 2022 $ 1,072,013 $ 58 383,181 781,290 $ (92,939) 423
Balance at end of period (in shares) at Mar. 31, 2022         3,077  
Balance at beginning of period (in shares) at Dec. 31, 2021 55,190 55,190        
Balance at beginning of period at Dec. 31, 2021 $ 1,021,714 $ 58 369,760 733,992 $ (83,042) 946
Balance at beginning of period (in shares) at Dec. 31, 2021 2,944       2,944  
Increase (Decrease) in Stockholders' Equity [Roll Forward]            
Net income (loss) attributable to noncontrolling interests $ (140)          
Net income attributable to the Ensign Group, Inc. $ 108,031          
Balance at end of period (in shares) at Jun. 30, 2022 55,278 55,278        
Balance at end of period at Jun. 30, 2022 $ 1,120,693 $ 58 398,793 835,941 $ (114,626) 527
Balance at end of period (in shares) at Jun. 30, 2022 3,368       3,368  
Balance at beginning of period (in shares) at Mar. 31, 2022   55,308        
Balance at beginning of period at Mar. 31, 2022 $ 1,072,013 $ 58 383,181 781,290 $ (92,939) 423
Balance at beginning of period (in shares) at Mar. 31, 2022         3,077  
Increase (Decrease) in Stockholders' Equity [Roll Forward]            
Issuance of common stock to employees and directors resulting from the exercise of stock options (in shares)   223        
Issuance of common stock to employees and directors resulting from the exercise of stock options 3,303   3,303      
Issuance of restricted stock, net of forfeitures (in shares)   38        
Shares of common stock used to satisfy tax withholding obligations (in shares)   (20)     (20)  
Shares of common stock used to satisfy tax withholding obligations (1,687)       $ (1,687)  
Dividends declared (3,040)     (3,040)    
Employee stock award compensation 5,616   5,616      
Repurchase of common stock (Note 20) (in shares)   (271)     (271)  
Repurchase of common stock (Note 20) (20,000)       $ (20,000)  
Noncontrolling interest attributable to subsidiary equity plan 6,693   6,693      
Net income (loss) attributable to noncontrolling interests 112         112
Distribution to noncontrolling interest holder (8)         (8)
Net income attributable to the Ensign Group, Inc. $ 57,691     57,691    
Balance at end of period (in shares) at Jun. 30, 2022 55,278 55,278        
Balance at end of period at Jun. 30, 2022 $ 1,120,693 $ 58 $ 398,793 $ 835,941 $ (114,626) $ 527
Balance at end of period (in shares) at Jun. 30, 2022 3,368       3,368  
XML 17 R6.htm IDEA: XBRL DOCUMENT v3.22.2
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (Parenthetical) - $ / shares
3 Months Ended
Jun. 30, 2022
Mar. 31, 2022
Jun. 30, 2021
Mar. 31, 2021
Statement of Stockholders' Equity [Abstract]        
Dividends per share (in dollars per share) $ 0.0550 $ 0.0550 $ 0.0525 $ 0.0525
XML 18 R7.htm IDEA: XBRL DOCUMENT v3.22.2
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)
$ in Thousands
6 Months Ended
Jun. 30, 2022
Jun. 30, 2021
Cash flows from operating activities:    
Net income $ 107,891 $ 100,420
Adjustments to reconcile net income to net cash provided by operating activities:    
Depreciation and amortization 29,534 27,454
Amortization of deferred financing fees 505 420
Non-cash leasing arrangement 240 221
Write-off of deferred financing fees 566 0
Deferred income taxes 264 27
Provision for doubtful accounts 2,169 1,899
Stock-based compensation 10,783 8,687
Gain on sale of assets (2,567) (540)
Loss on insurance claims, legal finding and asset disposals 4,474 745
Change in operating assets and liabilities    
Accounts receivable (12,852) (15,928)
Prepaid income taxes (10,884) (7,590)
Prepaid expenses and other assets (3,996) (9,476)
Cash surrender value of life insurance policy premiums (5,621) (8,861)
Deferred compensation liability 5,617 8,930
Operating lease obligations (547) (131)
Accounts payable 2,197 7,725
Accrued wages and related liabilities (5,162) (9,063)
Income taxes payable 0 (136)
Other accrued liabilities (7,471) (1,966)
Accrued self-insurance liabilities 14,696 5,717
Other long-term liabilities (23) (157)
NET CASH PROVIDED BY OPERATING ACTIVITIES 129,813 108,397
Cash flows from investing activities:    
Purchase of property and equipment (37,082) (33,795)
Cash payments for business acquisitions (Note 9) (16,400) (6,000)
Cash payments for asset acquisitions (Note 9) (17,492) (5,183)
Escrow deposits (15,571) 0
Cash from insurance proceeds 653 6,705
Cash proceeds from the sale of assets 7,665 877
Purchases of investments (3,518) (23,706)
Maturities of investments 4,780 20,399
Other restricted assets 369 (159)
NET CASH USED IN INVESTING ACTIVITIES (76,596) (40,862)
Cash flows from financing activities:    
Proceeds from debt (Note 16) 211 224
Payments on debt (Note 16) (1,921) (1,497)
Issuance of common stock upon exercise of options 6,071 6,862
Repurchase of shares of common stock to satisfy tax withholding obligations (1,702) (1,609)
Repurchase of shares of common stock (Note 20) (29,882) 0
Dividends paid (6,077) (5,754)
Proceeds from sale of subsidiary shares (Note 7) 6,693 0
Non-controlling interest distribution (8) (1,889)
Purchase of non-controlling interest (26) 0
Payments of deferred financing costs (3,197) 0
Proceeds from CARES Act Provider Relief Fund and Medicare Advance Payment Program (Note 3) 0 11,538
Repayments of CARES Act Provider Relief Fund and Medicare Advance Payment Program (Note 3) 0 (113,561)
NET CASH USED IN FINANCING ACTIVITIES (29,838) (105,686)
Net increase (decrease) in cash and cash equivalents 23,379 (38,151)
Cash and cash equivalents beginning of period 262,201 236,562
Cash and cash equivalents end of period 285,580 198,411
Cash paid during the period for:    
Interest 3,950 2,836
Income taxes 41,905 34,540
Lease liabilities 72,919 67,539
Non-cash financing and investing activity    
Accrued capital expenditures 3,800 3,600
Accrued dividends declared 3,040 2,894
Right-of-use assets obtained in exchange for new and modified operating lease obligations $ 194,342 $ 112,192
XML 19 R8.htm IDEA: XBRL DOCUMENT v3.22.2
Description of Business
6 Months Ended
Jun. 30, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
DESCRIPTION OF BUSINESS DESCRIPTION OF BUSINESS
The Company — The Ensign Group, Inc. (collectively, Ensign or the Company), is a holding company with no direct operating assets, employees or revenue. The Company, through its operating subsidiaries, is a provider of health care services across the post-acute care continuum, engaged in the ownership, acquisition, development and leasing of skilled nursing, senior living and other healthcare-related properties and other ancillary businesses. As of June 30, 2022, the Company operated 251 facilities and other ancillary operations located in Arizona, California, Colorado, Idaho, Iowa, Kansas, Nebraska, Nevada, South Carolina, Texas, Utah, Washington and Wisconsin. The Company's operating subsidiaries have a collective capacity of approximately 25,500 operational skilled nursing beds and 3,000 senior living units. As of June 30, 2022, the Company operated 180 facilities under long-term lease arrangements, and had options to purchase 11 of those 180 facilities. The Company's real estate portfolio includes 100 owned real estate properties, which included 71 facilities operated and managed by the Company, 29 senior living operations leased to and operated by The Pennant Group, Inc. (Pennant) as part of the spin-off transaction that occurred in October 2019 (Spin-Off), and the Service Center location. Of those 29 senior living operations, one is located on the same real estate property as a skilled nursing facility that the Company owns and operates.
Certain of the Company’s wholly-owned independent subsidiaries, collectively referred to as the Service Center, provide specific accounting, payroll, human resources, information technology, legal, risk management and other centralized services to the other operating subsidiaries through contractual relationships with such subsidiaries. The Company also has a wholly-owned captive insurance subsidiary that provides some claims-made coverage to the Company’s operating subsidiaries for general and professional liabilities, as well as coverage for certain workers’ compensation insurance liabilities.
In January of 2022, the Company formed a captive real estate investment trust (REIT), which owns and manages its real estate business, called Standard Bearer Healthcare REIT, Inc. (Standard Bearer). The Company expects the REIT structure will provide it with an efficient vehicle for future acquisitions of properties that could be operated by Ensign affiliates or other third parties. Refer to Note 7, Standard Bearer for additional information on Standard Bearer.
Each of the Company's affiliated operations are operated by separate, wholly-owned, independent subsidiaries that have their own management, employees and assets. References herein to the consolidated “Company” and “its” assets and activities in this Quarterly Report is not meant to imply, nor should it be construed as meaning that The Ensign Group, Inc. has direct operating assets, employees or revenue, or that any of the subsidiaries, are operated by The Ensign Group, Inc.
Other Information The accompanying condensed consolidated financial statements as of June 30, 2022 and for the three and six months ended June 30, 2022 and 2021 (collectively, the Interim Financial Statements) are unaudited. Certain information and note disclosures normally included in annual consolidated financial statements have been condensed or omitted, as permitted under applicable rules and regulations. Readers of the Interim Financial Statements should refer to the Company’s audited consolidated financial statements and notes thereto for the year ended December 31, 2021 which are included in the Company’s Annual Report on Form 10-K, File No. 001-33757 (the Annual Report) filed with the Securities and Exchange Commission (SEC). Management believes that the Interim Financial Statements reflect all adjustments which are of a normal and recurring nature necessary to present fairly the Company’s financial position and results of operations in all material respects. The results of operations presented in the Interim Financial Statements are not necessarily representative of operations for the entire year.
XML 20 R9.htm IDEA: XBRL DOCUMENT v3.22.2
Summary of Significant Accounting Policies
6 Months Ended
Jun. 30, 2022
Accounting Policies [Abstract]  
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES SUMMARY OF SIGNIFICANT ACCOUNTING POLICIESBasis of Presentation The accompanying Interim Financial Statements have been prepared in accordance with accounting principles generally accepted in the United States (GAAP). The Company is the sole member or stockholder of various consolidated limited liability companies and corporations established to operate various acquired skilled nursing operations, senior living operations and related ancillary services. All intercompany transactions and balances have been eliminated in consolidation. The Company presents noncontrolling interests within the equity section of its condensed consolidated balance sheets and the amount of consolidated net income that is attributable to The Ensign Group, Inc. and the noncontrolling interest in its condensed consolidated statements of income.
The condensed consolidated financial statements include the accounts of all entities controlled by the Company through its ownership of a majority voting interest. Additionally, the accounts of any variable interest entities (VIEs) where the Company is subject to a majority of the risk of loss from the VIE's activities are entitled to receive a majority of the entity's residual returns, or both. The Company assesses the requirements related to the consolidation of VIEs, including a qualitative assessment of power and economics that considers which entity has the power to direct the activities that "most significantly impacts" the VIE's economic performance and has the obligation to absorb losses of, or the right to receive benefits that could be potentially significant to, the VIE. On October 1, 2021, the Company deconsolidated its VIE, which was not material, as this entity no longer met the requirements for consolidation. As of June 30, 2022 and December 31, 2021, the Company had no VIEs.
ReclassificationsPrior period results reflect reclassifications, for comparative purposes, related to the change in the Company's segment structure as a result of the formation of Standard Bearer. Refer to Note 8, Business Segments, for additional information related to segments.
Estimates and Assumptions The preparation of the Interim Financial Statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the Interim Financial Statements and the reported amounts of revenue and expenses during the reporting periods. The most significant estimates in the Company’s Interim Financial Statements relate to revenue, acquired property and equipment, intangible assets and goodwill, right-of-use assets, impairment of long-lived assets, lease liabilities, general and professional liabilities, workers' compensation and healthcare claims included in accrued self-insurance liabilities, and income taxes. Actual results could differ from those estimates.
Fair Value of Financial InstrumentsThe Company’s financial instruments consist principally of cash and cash equivalents, debt security investments, accounts receivable, insurance subsidiary deposits, accounts payable and borrowings. The Company believes all of the financial instruments’ recorded values approximate fair values because of their nature or respective short durations. Contracts insuring the lives of certain employees who are eligible to participate in non-qualified deferred compensation plans are held in a rabbi trust. Cash surrender value of the contracts is based on funds that shadow the investment allocations specified by participants in the deferred compensation plan. The fair value of the investment funds is derived using Level 2 inputs. See Note 6, Fair Value Measurements.
Service Revenue RecognitionThe Company recognizes revenue in accordance with Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) Topic 606, Revenue from Contracts with Customers (ASC 606). See Note 4, Revenue and Accounts Receivable.
Rental Revenue Recognition The Company recognizes rental revenue for operating leases on a straight-line basis over the lease term when collectability of all minimum lease payments is probable in accordance with FASB ASC Topic 842, Leases (ASC 842). See Note 4, Revenue and Accounts Receivable.
Accounts Receivable Accounts receivable consist primarily of amounts due from Medicare and Medicaid programs, other government programs, managed care health plans and private payor sources, net of estimates for variable consideration.
Property and Equipment Property and equipment are initially recorded at their historical cost. Repairs and maintenance are expensed as incurred. Depreciation is computed using the straight-line method over the estimated useful lives of the depreciable assets (ranging from three to 59 years). Leasehold improvements are amortized on a straight-line basis over the shorter of their estimated useful lives or the remaining lease term.
Leases and Leasehold Improvements The Company leases skilled nursing facilities, senior living facilities and commercial office space. The Company determines if an arrangement is a lease at the inception of each lease. Leases commencing prior to the ASC 842 adoption date were classified as operating lease under historical guidance. As the Company has elected the package of practical expedients allowing it to not reassess lease classification, these leases are classified as operating leases under ASC 842 as well. For leases commencing subsequent to the ASC 842 adoption date, the Company performs an evaluation to determine whether the lease should be classified as an operating or finance lease at the inception of the lease. As of June 30, 2022, the Company does not have any leases that are classified as finance leases. Rights and obligations of operating leases are included as right-of-use assets, current lease liabilities and long-term lease liabilities on the Company's condensed consolidated balance sheets. As the Company's leases do not provide an implicit rate, the Company uses its incremental borrowing rate based on the information available at lease commencement date in determining the present value of future lease payments. The Company utilized a third-party valuation specialist to assist in estimating the incremental borrowing rate.
The Company records rent expense for operating leases on a straight-line basis over the term of the lease. The lease term used for straight-line rent expense is calculated from the date the Company is given control of the leased premises through the end of the lease term. Renewals are not assumed in the determination of the lease term unless they are deemed to be reasonably assured at the inception of the lease. The lease term used for this evaluation also provides the basis for establishing depreciable lives for buildings subject to lease and leasehold improvements.
The Company's real estate leases generally have initial lease terms of ten years or more and typically include one or more options to renew, with renewal terms that generally extend the lease term for an additional ten to 15 years. Exercise of the renewal options is generally subject to the satisfaction of certain conditions which vary by contract and generally follow payment terms that are consistent with those in place during the initial term. The Company reassesses the renewal option using a "reasonably certain" threshold, which is understood to be a high threshold. For leases where the Company is reasonably certain to exercise its renewal option, the option periods are included within the lease term and, therefore, the measurement of the right-of-use asset and lease liability. The Company's leases generally contain annual escalation clauses that are either fixed or variable in nature, some of which are dependent upon published indices. The Company recognizes lease expense for leases with an initial term of 12 months or less on a straight-line basis over the lease term. These leases are not recorded on the condensed consolidated balance sheets. Certain of the Company's lease agreements include rental payments that are adjusted periodically for inflation. The lease agreements do not contain any material residual value guarantees or material restrictive covenants. The Company does not have material subleases.
Impairment of Long-Lived Assets The Company reviews the carrying value of long-lived assets that are held and used in the Company’s operating subsidiaries for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of these assets is determined based upon expected undiscounted future net cash flows from the operating subsidiaries to which the assets relate, utilizing management’s best estimate, appropriate assumptions, and projections at the time. If the carrying value is determined to be unrecoverable from future operating cash flows, the asset is deemed impaired and an impairment loss would be recognized to the extent the carrying value exceeded the estimated fair value of the asset. The Company estimates the fair value of assets based on the estimated future discounted cash flows of the asset. Management has evaluated its long-lived assets and determined there was no impairment during the three and six months ended June 30, 2022 and 2021.
Intangible Assets and Goodwill Definite-lived intangible assets consist primarily of patient base, facility trade names and customer relationships. Patient base is amortized over a period of four to eight months, depending on the classification of the patients and the level of occupancy in a new acquisition on the acquisition date. Trade names at affiliated facilities are amortized over 30 years and customer relationships are amortized over a period of up to 20 years.
The Company's indefinite-lived intangible assets consist of trade names, and Medicare and Medicaid licenses. The Company tests indefinite-lived intangible assets for impairment on an annual basis or more frequently if events or changes in circumstances indicate that the carrying amount of the intangible asset may not be recoverable.
Goodwill represents the excess of the purchase price over the fair value of identifiable net assets acquired in business combinations. Goodwill is subject to annual testing for impairment. In addition, goodwill is tested for impairment if events occur or circumstances indicate that its carrying value may not be recoverable. The Company performs its annual test for impairment during the fourth quarter of each year. The Company did not identify any goodwill or intangible asset impairment during the three and six months ended June 30, 2022 and 2021.
Self-Insurance — The Company is partially self-insured for general and professional liability claims up to a base amount per claim (the self-insured retention) with an aggregate, one-time deductible above this limit. Losses beyond these amounts are insured through third-party policies with coverage limits per claim, per location and on an aggregate basis for the Company. The combined self-insured retention is $500 per claim, subject to an additional one-time deductible of $1,000 for California affiliated operations and a separate, one-time, deductible of $1,250 for non-California operations. For all affiliated operations, except those located in Colorado, the third-party coverage above these limits is $1,000 per claim, $3,000 per operation, with a $5,000 blanket aggregate limit and an additional state-specific aggregate where required by state law. In Colorado, the third-party coverage above these limits is $1,000 per claim and $3,000 per operation, which is independent of the aforementioned blanket aggregate limits that apply outside of Colorado.
The majority of the self-insured retention and deductible limits for general and professional liabilities and workers' compensation liabilities are self-insured through the captive insurance subsidiary, the related assets and liabilities of which are included in the accompanying condensed consolidated balance sheets. The captive insurance subsidiary is subject to certain statutory requirements as an insurance provider.
The Company’s policy is to accrue amounts equal to the actuarial estimated costs to settle open claims of insureds, as well as an estimate of the cost of insured claims that have been incurred but not reported. The Company develops information about the size of the ultimate claims based on historical experience, current industry information and actuarial analysis, and evaluates the estimates for claim loss exposure on a quarterly basis. The Company uses actuarial valuations to estimate the liability based on historical experience and industry information. Accrued general liability and professional malpractice liabilities on an undiscounted basis, net of anticipated insurance recoveries, were $76,145 and $66,158 as of June 30, 2022 and December 31, 2021, respectively.
The Company’s operating subsidiaries are self-insured for workers’ compensation liabilities in California. To protect itself against loss exposure in California with this policy, the Company has purchased individual specific excess insurance coverage that insures individual claims that exceed $625 per occurrence. In Texas, the operating subsidiaries have elected non-subscriber status for workers’ compensation claims and the Company has purchased individual stop-loss coverage that insures individual claims that exceed $750 per occurrence. The Company’s operating subsidiaries in all other states, with the exception of Washington, are under a loss sensitive plan that insures individual claims that exceed $350 per occurrence. In the state of Washington, the Company is self insured and has purchased individual specific excess insurance coverage that insures individual claims that exceed $500 per occurrence. For all of the self insured plans and retention, the Company accrues amounts equal to the estimated costs to settle open claims, as well as an estimate of the cost of claims that have been incurred but not reported. The Company uses actuarial valuations to estimate the liability based on historical experience and industry information. Accrued workers’ compensation liabilities are recorded on an undiscounted basis in the accompanying condensed consolidated balance sheets and were $28,365 and $27,335 as of June 30, 2022 and December 31, 2021, respectively.
In addition, the Company has recorded an asset and equal liability of $8,440 and $6,755 as of June 30, 2022 and December 31, 2021, respectively, in order to present the ultimate costs of malpractice and workers' compensation claims and the anticipated insurance recoveries on a gross basis. See Note 13, Restricted and Other Assets.
The Company self-funds medical (including prescription drugs) and dental healthcare benefits to the majority of its employees. The Company is fully liable for all financial and legal aspects of these benefit plans. To protect itself against loss exposure with this policy, the Company has purchased individual stop-loss insurance coverage that insures individual claims that exceed $525 for each covered person for fiscal year 2022. The Company’s accrued liability under these plans recorded on an undiscounted basis in the accompanying condensed consolidated balance sheets was $13,571 and $9,891 as of June 30, 2022 and December 31, 2021, respectively.
The Company believes that adequate provision has been made in the Interim Financial Statements for liabilities that may arise out of patient care, workers’ compensation, healthcare benefits and related services provided to date. The amount of the Company’s reserves was determined based on an estimation process that uses information obtained from both company-specific and industry data. This estimation process requires the Company to continuously monitor and evaluate the life cycle of the claims. Using data obtained from this monitoring and the Company’s assumptions about emerging trends, the Company, with the assistance of an independent actuary, develops information about the size of ultimate claims based on the Company’s historical experience and other available industry information. The most significant assumptions used in the estimation process include determining the trend in costs, the expected cost of claims incurred but not reported and the expected costs to settle or pay damage awards with respect to unpaid claims. The self-insured liabilities are based upon estimates, and while management believes that the estimates of loss are reasonable, the ultimate liability may be in excess of or less than the recorded amounts. Due to the inherent volatility of actuarially determined loss estimates, it is reasonably possible that the Company could experience changes in estimated losses that could be material to net income. If the Company’s actual liabilities exceed its estimates of losses, its future earnings, cash flows and financial condition would be adversely affected.
Income Taxes — Deferred tax assets and liabilities are established for temporary differences between the financial reporting basis and the tax basis of the Company’s assets and liabilities at tax rates in effect when such temporary differences are expected to reverse. The Company generally expects to fully utilize its deferred tax assets; however, when necessary, the Company records a valuation allowance to reduce its net deferred tax assets to the amount that is more likely than not to be realized.
In determining the need for a valuation allowance or the need for and magnitude of liabilities for uncertain tax positions, the Company makes certain estimates and assumptions. These estimates and assumptions are based on, among other things, knowledge of operations, markets, historical trends and likely future changes and, when appropriate, the opinions of advisors with knowledge and expertise in certain fields. Due to certain risks associated with the Company’s estimates and assumptions, actual results could differ.
Noncontrolling Interest The noncontrolling interest in a subsidiary is initially recognized at estimated fair value on the acquisition date and is presented within total equity in the Company's condensed consolidated balance sheets. The Company presents the noncontrolling interest and the amount of consolidated net income attributable to The Ensign Group, Inc. in its condensed consolidated statements of income. Net income per share is calculated based on net income attributable to The Ensign Group, Inc.'s stockholders. The carrying amount of the noncontrolling interest is adjusted based on an allocation of subsidiary earnings based on ownership interest.
Stock-Based CompensationThe Company measures and recognizes compensation expense for all stock-based payment awards made to employees and directors including employee stock options based on estimated fair values, ratably over the requisite service period of the award. Net income has been reduced as a result of the recognition of the fair value of all stock options and restricted stock awards issued, the amount of which is contingent upon the number of future grants and other variables.
Recent Accounting Pronouncements Except for rules and interpretive releases of the Securities and Exchange Commission (SEC) under authority of federal securities laws and a limited number of grandfathered standards, the FASB ASC is the sole source of authoritative GAAP literature recognized by the FASB and applicable to the Company. For any new pronouncements announced, the Company considers whether the new pronouncements could alter previous generally accepted accounting principles and determines whether any new or modified principles will have a material impact on the Company's reported financial position or operations in the near term. The applicability of any standard is subject to the formal review of the Company's financial management and certain standards are under consideration.

Recent Accounting Standards Adopted by the Company In November 2021, the FASB issued ASU 2021-10 “Government Assistance (Topic 832): Disclosures by Business Entities about Government Assistance,” which created FASB ASC Topic 832, Government Assistance (ASC 832). ASC 832 requires business entities to disclose information about certain government assistance they receive. The Company adopted this standard on January 1, 2022 and determined there was no material impact on the Company's condensed consolidated financial statements.
Accounting Standards Recently Issued but Not Yet Adopted by the Company In February 2020, the FASB issued ASU 2020-04 "Reference Rate Reform (Topic 848)," which provides temporary, optional practical expedients and exceptions to enable a smoother transition to reference rates which are expected to replace London Interbank Offered Rate (LIBOR) reference rates. Adoption of the provisions of ASU 2020-04 is optional. The amendments are effective for all entities from the beginning of the interim period that includes the issuance date of the ASU. An entity may elect to apply the amendments prospectively through December 31, 2022. During the quarter ended June 30, 2022, the Company and its subsidiaries including Standard Bearer, entered into the Second Amendment to Third Amended and Restated Credit Agreement (such agreement, the Amended Credit Agreement, and the revolving credit facility thereunder, the Revolving Credit Facility), which increased the Revolving Credit Facility by $250,000 to an aggregate principal amount of up to $600,000. Pursuant to the Amended Credit Agreement, the Company transitioned from LIBOR to the Secured Overnight Financing Rate (SOFR) as the applicable reference rate for borrowings under the Revolving Credit Facility and determined there was no resulting material impact on the Company's condensed consolidated financial statements.
XML 21 R10.htm IDEA: XBRL DOCUMENT v3.22.2
COVID-19 Update
6 Months Ended
Jun. 30, 2022
Unusual or Infrequent Items, or Both [Abstract]  
COVID-19 UPDATE COVID-19 UPDATE
The COVID-19 pandemic has continued to impact the Company's affiliated operations. In prior years, as part of the Coronavirus Aid, Relief, and Economic Security Act of 2020 (the CARES Act), the Company received cash distributions of relief fund payments (Provider Relief Funds) and funds authorized by U.S. Department of Health and Human Services (HHS) to be used to protect residents of nursing homes and long-term care (LTC) facilities from the impact of COVID-19. During the three and six months ended June 30, 2022, the Company did not receive Provider Relief Funds. During the three and six months ended June 30, 2021, the Company received and returned $2,399 and $11,538, respectively, in Provider Relief Funds. The Company may continue to receive additional funding in future periods.

In fiscal year 2020, the Company applied for and received $105,255 through the Medicare Accelerated and Advance Payment Program under the CARES Act. The purpose of the program is to assist in providing needed liquidity to care delivery providers. The Company repaid $3,232 of the funds in 2020. In March 2021, the Company repaid the remaining funds of $102,023.
The Family First Coronavirus Response Act was signed into law in 2020 to provide a temporary 6.2% increase to the Federal Medical Assistance Percentage (FMAP) effective January 1, 2020. The law permits states to retroactively change their state's Medicaid program rates effective as of January 1, 2020. The law provides discretion to each state and specifies the funds are to be used to reimburse the recipient for healthcare related expenses that are attributable to COVID-19 and associated with providing patient care. In addition, increases in Medicaid rates can come from other areas of the state's budget outside of FMAP funding. Revenues from these additional payments are recognized in accordance with ASC 606, subject to variable consideration constraints. In certain operations where the Company received additional payments that exceeded expenses incurred related to COVID-19, the Company characterized such payments as variable revenue that required additional consideration and accordingly, the amount of state relief revenue recognized is limited to the actual COVID-19 related expenses incurred. As of June 30, 2022 and December 31, 2021, the Company had $4,356 and $1,781 in unapplied state relief funds, respectively. During the three and six months ended June 30, 2022, the Company received an additional $27,345 and $44,662 in state relief funding and recognized $24,489 and $42,088, respectively, as revenue. During the three and six months ended June 30, 2021, the Company received an additional $16,776 and $32,421 in state relief funding and recognized $16,692 and $33,157, respectively, as revenue.

The CARES Act also provides for deferred payment of the employer portion of social security taxes through the end of 2020, with 50% of the deferred amount due by December 31, 2021 and the remaining 50% due by December 31, 2022. The Company recorded $48,309 of deferred payments of social security taxes as a liability during 2020. The Company paid $24,154 during the year ended December 31, 2021 and the remaining short-term balance of $24,155 is included in accrued wages and related liabilities within the condensed consolidated balance sheets as of June 30, 2022.
XML 22 R11.htm IDEA: XBRL DOCUMENT v3.22.2
Revenue and Accounts Receivable
6 Months Ended
Jun. 30, 2022
Revenue from Contract with Customer [Abstract]  
REVENUE AND ACCOUNTS RECEIVABLE REVENUE AND ACCOUNTS RECEIVABLE
Service Revenue

The Company's service revenue is derived primarily from providing healthcare services to its patients. Revenue is recognized when services are provided to the patients at the amount that reflects the consideration to which the Company expects to be entitled from patients and third-party payors, including Medicaid, Medicare and insurers (private and Medicare replacement plans), in exchange for providing patient care. The healthcare services in skilled patient contracts include routine services in exchange for a contractual agreed-upon amount or rate. Routine services are treated as a single performance obligation satisfied over time as services are rendered. As such, patient care services represent a bundle of services that are not capable of being distinct. Additionally, there may be ancillary services which are not included in the daily rates for routine services, but instead are treated as separate performance obligations satisfied at a point in time, if and when those services are rendered.

Revenue recognized from healthcare services are adjusted for estimates of variable consideration to arrive at the transaction price. The Company determines the transaction price based on contractually agreed-upon amounts or rate on a per day basis, adjusted for estimates of variable consideration. The Company uses the expected value method in determining the variable component that should be used to arrive at the transaction price, using contractual agreements and historical reimbursement experience within each payor type. The amount of variable consideration which is included in the transaction price may be constrained, and is included in net revenue only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized will not occur in a future period. If actual amounts of consideration ultimately received differ from the Company’s estimates, the Company adjusts these estimates, which would affect net revenue in the period such variances become known.

Revenue from the Medicare and Medicaid programs accounted for 73.4% of all service revenue for both the three and six months ended June 30, 2022 and 73.1% and 73.6% for the three and six months ended June 30, 2021, respectively. Settlements with Medicare and Medicaid payors for retroactive adjustments due to audits and reviews are considered variable consideration and are included in the determination of the estimated transaction price. These settlements are estimated based on the terms of the payment agreement with the payor, correspondence from the payor and the Company’s historical settlement activity. Consistent with healthcare industry practices, any changes to these revenue estimates are recorded in the period the change or adjustment becomes known based on the final settlement. The Company recorded adjustments to revenue which were not material to the Company's revenue for the three and six months ended June 30, 2022 and 2021.
Rental Revenue

The Company's rental revenues are primarily generated by leasing healthcare-related properties through triple-net lease arrangements, under which the tenant is solely responsible for the costs related to the property. Revenue is recognized on a straight-line basis over the lease term if it has been deemed probable of collection. The Company has elected the single component practical expedient, which allows a lessor, by class of underlying asset, not to allocate the total consideration to the lease and non-lease components based on their relative stand-alone selling prices where certain criteria are met.

Tenant reimbursements related to property taxes and insurance are neither considered lease nor non-lease components under the new lease standards. Lessee payments for taxes and insurance paid directly to a third party, on behalf of the Company, are excluded from variable lease payments and rental revenue in the Company’s condensed consolidated statements of income. Otherwise, tenant reimbursements for taxes and insurance that are paid by the Company directly to a third party are classified as additional rental revenue and expense and recognized by the Company on a gross basis.
Disaggregation of Revenue
The Company disaggregates revenue from contracts with its patients by payors. The Company determines that disaggregating revenue into these categories achieves the disclosure objectives to depict how the nature, amount, timing and uncertainty of revenue and cash flows are affected by economic factors.
Revenue by Payor

The Company’s revenue is derived primarily from providing healthcare services to patients and is recognized on the date services are provided at amounts billable to individual patients, adjusted for estimates for variable consideration. For patients under reimbursement arrangements with third-party payors, including Medicaid, Medicare and private insurers, revenue is recorded based on contractually agreed-upon amounts or rates, adjusted for estimates for variable consideration, on a per patient, daily basis or as services are performed.
Service revenue for the three and six months ended June 30, 2022 and 2021 is summarized in the following tables:
 Three Months Ended June 30,
20222021
Revenue% of RevenueRevenue% of Revenue
Medicaid(1)
$294,128 40.4 %$251,455 39.6 %
Medicare190,494 26.2 170,008 26.8 
Medicaid — skilled49,763 6.8 42,740 6.7 
Total Medicaid and Medicare534,385 73.4 464,203 73.1 
Managed care128,587 17.7 112,963 17.8 
Private and other(2)
65,375 8.9 57,443 9.1 
SERVICE REVENUE$728,347 100.0 %$634,609 100.0 %
(1) Medicaid payor includes revenue for senior living operations and revenue related to FMAP.
(2) Private and other payors also includes revenue from senior living operations and all payors generated in other ancillary services.
 Six Months Ended June 30,
20222021
Revenue% of RevenueRevenue% of Revenue
Medicaid(1)
$560,476 39.0 %$482,813 38.4 %
Medicare398,905 27.7 360,311 28.6 
Medicaid — skilled95,712 6.7 82,733 6.6 
Total Medicaid and Medicare1,055,093 73.4 925,857 73.6 
Managed care256,373 17.8 221,308 17.6 
Private and other(2)
126,037 8.8 110,720 8.8 
SERVICE REVENUE$1,437,503 100.0 %$1,257,885 100.0 %
(1) Medicaid payor includes revenue for senior living operations and revenue related to FMAP.
(2) Private and other payors also includes revenue from senior living operations and all payors generated in other ancillary services.
In addition to the service revenue above, the Company's rental revenue derived from triple-net lease arrangements with third parties was $4,139 and $8,428, respectively, for the three and six months ended June 30, 2022 and $3,927 and $7,904, respectively, for the three and six months ended June 30, 2021.
Balance Sheet Impact

Included in the Company’s condensed consolidated balance sheets are contract balances, comprised of billed accounts receivable and unbilled receivables, which are the result of the timing of revenue recognition, billings and cash collections, as well as, contract liabilities, which primarily represent payments the Company receives in advance of services provided. The Company had no material contract liabilities and contract assets as of June 30, 2022 and December 31, 2021, or activity during the three and six months ended June 30, 2022 and 2021.

Accounts receivable as of June 30, 2022 and December 31, 2021, is summarized in the following table:
June 30, 2022December 31, 2021
Medicaid$125,348 $123,647 
Managed care86,995 79,722 
Medicare58,067 59,797 
Private and other payors76,418 76,778 
 346,828 339,944 
Less: allowance for doubtful accounts(7,827)(11,213)
ACCOUNTS RECEIVABLE, NET$339,001 $328,731 
Practical Expedients and Exemptions
As the Company’s contracts with its patients have an original duration of one year or less, the Company uses the practical expedient applicable to its contracts and does not consider the time value of money. Further, because of the short duration of these contracts, the Company has not disclosed the transaction price for the remaining performance obligations as of the end of each reporting period or when the Company expects to recognize this revenue. In addition, the Company has applied the practical expedient provided by ASC 340, Other Assets and Deferred Costs, and all incremental customer contract acquisition costs are expensed as they are incurred because the amortization period would have been one year or less.
XML 23 R12.htm IDEA: XBRL DOCUMENT v3.22.2
Computation of Net Income Per Common Share
6 Months Ended
Jun. 30, 2022
Earnings Per Share [Abstract]  
COMPUTATION OF NET INCOME PER COMMON SHARE COMPUTATION OF NET INCOME PER COMMON SHARE
Basic net income per share is computed by dividing income from operations attributable to stockholders of The Ensign Group, Inc. by the weighted average number of outstanding common shares for the period. The computation of diluted net income per share is similar to the computation of basic net income per share, except that the denominator is increased to include the number of additional common shares that would have been outstanding if the dilutive potential common shares had been issued.

A reconciliation of the numerator and denominator used in the calculation of basic net income per common share follows:

Three Months Ended June 30,Six Months Ended June 30,
 2022202120222021
NUMERATOR:  
Net income$57,803 $50,583 $107,891 $100,420 
Less: net (loss) income attributable to noncontrolling interests 112 1,158 (140)1,789 
Net income attributable to The Ensign Group, Inc. $57,691 $49,425 $108,031 $98,631 
DENOMINATOR: 
Weighted average shares outstanding for basic net income per share54,906 54,468 54,788 54,331 
Basic net income per common share:$1.05 $0.91 $1.97 $1.82 
A reconciliation of the numerator and denominator used in the calculation of diluted net income per common share follows:

Three Months Ended June 30,Six Months Ended June 30,
 2022202120222021
NUMERATOR:  
Net income $57,803 $50,583 $107,891 $100,420 
Less: net (loss) income attributable to noncontrolling interests112 1,158 (140)1,789 
Net income attributable to The Ensign Group, Inc. $57,691 $49,425 $108,031 $98,631 
DENOMINATOR:  
Weighted average common shares outstanding54,906 54,468 54,788 54,331 
Plus: incremental shares from assumed conversion (1)
1,947 2,529 2,074 2,614 
Adjusted weighted average common shares outstanding56,853 56,997 56,862 56,945 
Diluted net income per common share:$1.01 $0.87 $1.90 $1.73 
(1) Options outstanding which are anti-dilutive and therefore not factored into the weighted average common shares amount above were 789 and 697 for the three and six months ended June 30, 2022, respectively, and 167 and 80 for the three and six months ended June 30, 2021, respectively.
XML 24 R13.htm IDEA: XBRL DOCUMENT v3.22.2
Fair Value Measurements
6 Months Ended
Jun. 30, 2022
Fair Value Disclosures [Abstract]  
FAIR VALUE MEASUREMENTS FAIR VALUE MEASUREMENTS
Fair value measurements are based on a three-tier hierarchy that prioritizes the inputs used to measure fair value. These tiers include: Level 1, defined as observable inputs such as quoted market prices in active markets; Level 2, defined as inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly; and Level 3, defined as unobservable inputs for which little or no market data exists, therefore requiring an entity to develop its own assumptions.

The fair value of cash and cash equivalents of $285,580 and $262,201 as of June 30, 2022 and December 31, 2021, respectively, is derived using Level 1 inputs. The Company's other financial assets include contracts insuring the lives of certain employees who are eligible to participate in non-qualified deferred compensation plans which are held in a rabbi trust. The cash surrender value of these contracts is based on funds that shadow the investment allocations specified by participants in the deferred compensation plan. As of June 30, 2022, and December 31, 2021, the fair value of the investment funds of $23,151 and $17,530, respectively, is derived using Level 2 inputs. The investment funds are included in restricted and other assets in the condensed consolidated balance sheets. See Note 13, Restricted and Other Assets.

The Company's non-financial assets, which includes goodwill, intangible assets, property and equipment and right-of-use assets, are not required to be measured at fair value on a recurring basis. However, on a periodic basis, or whenever events or changes in circumstances indicate that their carrying value may not be recoverable, the Company assesses its long-lived assets for impairment. When impairment has occurred, such long-lived assets are written down to fair value.
Debt Security Investments - Held to Maturity

As of June 30, 2022 and December 31, 2021, the Company had approximately $49,068 and $50,330, respectively, in debt security investments which were classified as held to maturity and carried at amortized cost. The carrying value of the debt securities approximates fair value based on Level 1 inputs. The Company has the intent and ability to hold these debt securities to maturity. Further, as of June 30, 2022, the debt security investments were held in AA, A and BBB rated debt securities.

The Company believes its debt security investments and investment funds that were in an unrealized loss position as of June 30, 2022 were not other-than-temporarily impaired, nor has any event occurred subsequent to that date that would indicate any other-than-temporary impairment.
XML 25 R14.htm IDEA: XBRL DOCUMENT v3.22.2
Standard Bearer
6 Months Ended
Jun. 30, 2022
Segment Reporting [Abstract]  
Standard Bearer STANDARD BEARER
Standard Bearer's real estate portfolio consists of 95 of the Company's 100 owned real estate properties, of which 67 are operated and managed by the Company and 29 are leased to and operated by Pennant. Of those 29 senior living operations, one is located on the same real estate property as a skilled nursing facility that the Company owns and operates. Standard Bearer intends to qualify and elect to be taxed as a REIT, for U.S. federal income tax purposes, commencing with its taxable year ending December 31, 2022. During the six months ended June 30, 2022, Standard Bearer acquired the real estate of two skilled nursing facilities for a purchase price of $17,412, both of which are operated and managed by Ensign's affiliated operations. Refer to Note 9, Operation Expansions for additional information.
Subsequent to June 30, 2022, Standard Bearer expanded its real estate portfolio with the addition of five skilled nursing properties and one campus property for a total purchase price of $47,900.
As part of the formation of Standard Bearer, certain of the Company's operating subsidiaries, Standard Bearer and Standard Bearer's subsidiaries entered into several agreements that include leasing, management services and debt arrangements between the operations. As these intercompany arrangements were entered into when Standard Bearer was formed in January 2022, the transactions related to these agreements are reflected in Standard Bearer's segment income during three and six months ended June 30, 2022. All intercompany transactions have been eliminated in consolidation. Refer to Note 8, Business Segments, for additional information related to these intercompany eliminations as well as Standard Bearer as a reportable segment.
Intercompany master lease agreements
Certain of the Company's operating subsidiaries and the 67 Standard Bearer subsidiaries entered into five "triple-net" master lease agreements (collectively, the Standard Bearer Master Leases) in January 2022. The lease periods range from 15 to 19 years with three five-year renewal options beyond the initial term, on the same terms and conditions. The rent structure under the Standard Bearer Master Leases includes a fixed component, subject to annual escalation equal to the lesser of (1) the percentage change in the Consumer Price Index (but not less than zero) or (2) 2.5%. In addition to rent, the operating subsidiaries are required to pay the following: (1) all impositions and taxes levied on or with respect to the leased properties; (2) all utilities and other services necessary or appropriate for the leased properties and the business conducted on the leased properties; (3) all insurance required in connection with the leased properties and the business conducted on the leased properties; (4) all facility maintenance and repair costs; and (5) all fees in connection with any licenses or authorizations necessary or appropriate for the leased properties and the business conducted on the leased properties. The two real estate properties acquired during six months ended June 30, 2022 were added to the Standard Bearer Master Leases. Rental revenue generated from Ensign affiliated operations was $13,894 and $27,319, respectively, for the three and six months ended June 30, 2022 and $10,784 and $21,375, respectively, for the three and six months ended June 30, 2021.
Intercompany management agreement
Standard Bearer has no employees. The Service Center provides personnel and services to Standard Bearer pursuant to the management agreement between Standard Bearer and the Service Center. The management agreement provides for a base management fee that is equal to 5% of total rental revenue and an incentive management fee that is equal to 5% of funds from operations (FFO) and is capped at 1% of total rental revenue. Management fee generated between Standard Bearer and the Service Center for the three and six months ended June 30, 2022 was $1,056 and $2,078, respectively, both of which represent 6% of total Standard Bearer rental revenue. No management fees were recorded in 2021, which was prior to the formation of Standard Bearer.
Intercompany debt arrangements

Standard Bearer obtains its funding through various sources including operating cash flows, access to debt arrangements and intercompany loans. The intercompany debt arrangements include mortgage loans and the Revolving Credit Facility to fund acquisitions and working capital needs. The interest rate under the Amended Credit Agreement is a base rate plus a margin ranging from 0.25% to 1.25% per annum or SOFR plus a margin range from 1.25% to 2.25% per annum.

In addition, as the Department of Housing and Urban Development (HUD) mortgage loans and promissory notes are entered into by real estate subsidiaries of Standard Bearer, the interest expense incurred from these debts are included in Standard Bearer's segment income. Refer to Note 16, Debt, for additional information related to these debts.
Equity Instrument Denominated in the Shares of a Subsidiary
As part of the formation of Standard Bearer in January of 2022, the Company established the Standard Bearer Healthcare REIT, Inc. 2022 Omnibus Incentive Plan (Standard Bearer Equity Plan). The Company may grant stock options and restricted stock awards under the Standard Bearer Equity Plan to employees and management of Ensign's affiliated subsidiaries. These awards generally vest over a period of five years or upon the occurrence of certain prescribed events. The value of the stock options and restricted stock awards is tied to the value of the common stock of Standard Bearer, which is determined based on an independent valuation of Standard Bearer. The awards can be put to the Company at various prescribed dates, which in no event is earlier than six months after vesting of the restricted awards or exercise of the stock options. The Company can also call the awards, generally upon employee termination. During the three months ended June 30, 2022, Standard Bearer sold fully vested common shares from the Standard Bearer Equity Plan to shareholders for cash of $6,544. During the three and six months ended June 30, 2022, the Company did not grant any stock options nor restricted shares under the Standard Bearer Equity Plan.
During the three months ended June 30, 2022, Standard Bearer established shareholders of its preferred shares through contributions of cash of $149. These preferred shares were fully vested at the time of the contributions by the shareholders.
XML 26 R15.htm IDEA: XBRL DOCUMENT v3.22.2
Business Segments
6 Months Ended
Jun. 30, 2022
Segment Reporting [Abstract]  
BUSINESS SEGMENTS BUSINESS SEGMENTS
In conjunction with the formation Standard Bearer in January 2022, the Company's Chief Executive Officer, who is its chief operating decision maker, or CODM, began reviewing the results of Standard Bearer instead of all real estate properties. Accordingly, the Company revised its former real estate segment to include only real estate properties that are part of Standard Bearer. This change in organizational structure demonstrates that Standard Bearer's real estate is a core part of the Company's expansion of its real estate investment strategy. As of the first quarter of 2022, the Company has two reportable segments: (1) skilled services, which includes the operation of skilled nursing facilities and rehabilitation therapy services and (2) Standard Bearer, which is comprised of selected real estate properties owned by Standard Bearer and leased to skilled nursing and senior living operators. Segment information for prior periods has been recast to reflect the change of the Company’s segment structure.

As of June 30, 2022, the skilled services segment includes 215 skilled nursing operations and 25 campus operations that provide both skilled nursing and rehabilitative care services and senior living services. The Company's Standard Bearer segment consists of 95 owned real estate properties. These properties include 67 operations the Company operated and managed and 29 senior living operations that are leased to and operated by third parties. Of the 29 real estate operations leased to third parties, one senior living operation is located on the same real estate property as a skilled nursing facility that the Company owns and operates.

The Company also reports an “All Other” category that includes results from its senior living operations, which includes eleven stand-alone senior living operations and the senior living operations at 25 campus operations that provide both skilled nursing and rehabilitative care services and senior living services. In addition, the "All Other" category includes mobile diagnostics, medical transportation, other real estate and other ancillary operations. Services included in the “All Other” category are insignificant individually, and therefore do not constitute a reportable segment.

The Company’s reportable segments are significant operating segments that offer differentiated services. The Company's CODM reviews financial information for each operating segment to evaluate performance and allocate capital resources. This structure reflects its current operational and financial management and provides the best structure to maximize the quality of care and investment strategy provided, while maintaining financial discipline. The Company's CODM does not review assets by segment in his resource allocation and therefore assets by segment are not disclosed below.

The accounting policies of the reportable segments are the same as those described in Note 2, Summary of Significant Accounting Policies. Intercompany revenue is eliminated in consolidation, along with corresponding intercompany expenses. Segment income and loss is defined as profit or loss from operations before provision for income taxes, excluding gain or loss from sale of real estate, insurance recoveries and impairment charges from operations. Included in segment income for Standard Bearer is expense for intercompany services provided by the Service Center as described in Note 7, Standard Bearer, as it is part of the CODM financial information.
The following tables set forth financial information for the segments:
 Three Months Ended June 30, 2022
 Skilled ServicesStandard Bearer
All Other(1)
Intercompany EliminationTotal
Service revenue(2)
$702,478 $— $28,787 $(2,918)$728,347 
Rental revenue(3)
— 17,598 1,832 (15,291)4,139 
TOTAL REVENUE$702,478 $17,598 $30,619 $(18,209)$732,486 
Segment income (loss)102,266 6,838 (38,614)— 70,490 
Gain on sale of assets2,467 
Income before provision for income taxes $72,957 
Depreciation and amortization8,113 5,216 1,529 — 14,858 
Interest expense(4)
$— $3,743 $889 $(1,944)$2,688 
(1) All other primarily includes all ancillary operations, stand-alone senior living operations and the Service Center.
(2) Intercompany service revenue represents service revenue generated by ancillary operations provided to the Company's affiliated wholly-owned healthcare facilities and management service revenue generated by the Service Center with Standard Bearer. Intercompany service revenue is eliminated in consolidation along with corresponding intercompany cost of service.
(3) Intercompany rental revenue represents rental income generated by both Standard Bearer and other real estate properties with the Company's affiliated wholly-owned healthcare facilities. Intercompany rental revenue is eliminated in consolidation along with corresponding intercompany rent expense.
(4) Included in interest expense in Standard Bearer is interest expense incurred from intercompany debt arrangements between Standard Bearer and The Ensign Group, Inc. The intercompany interest expense is eliminated in the "Intercompany Elimination" column.

 Three Months Ended June 30, 2021
 Skilled ServicesStandard Bearer
All Other(1)
Intercompany EliminationTotal
Service revenue(2)
$612,882 $— $23,428 $(1,701)$634,609 
Rental revenue(3)
— 14,214 1,817 (12,104)3,927 
TOTAL REVENUE$612,882 $14,214 $25,245 $(13,805)$638,536 
Segment income (loss)90,010 7,906 (33,575)— 64,341 
Income before provision for income taxes $64,341 
Depreciation and amortization7,703 4,248 1,844 — 13,795 
Interest expense$— $1,634 $— $1,634 
(1) All other primarily includes all ancillary operations, stand-alone senior living operations and the Service Center.
(2) Intercompany service revenue represents service revenue generated by ancillary operations provided to the Company's affiliated wholly-owned healthcare facilities. Intercompany service revenue is eliminated in consolidation along with corresponding intercompany cost of service.
(3) Intercompany rental revenue represents rental income generated by both Standard Bearer and other real estate properties with the Company's affiliated wholly-owned healthcare facilities. Intercompany rental revenue is eliminated in consolidation along with corresponding intercompany rent expense.

 Six Months Ended June 30, 2022
 Skilled ServicesStandard Bearer
All Other(1)
Intercompany EliminationTotal
Service revenue(2)
$1,389,249 $— $54,254 $(6,000)$1,437,503 
Rental revenue(3)
— 34,791 3,695 (30,058)8,428 
TOTAL REVENUE$1,389,249 $34,791 $57,949 $(36,058)$1,445,931 
Segment income (loss)200,522 13,738 (77,544)— 136,716 
Gain on sale of assets2,467 
Income before provision for income taxes$139,183 
Depreciation and amortization16,014 10,237 3,283 — 29,534 
Interest expense(4)
$— $7,305 $1,247 $(3,796)$4,756 
(1) All other primarily includes all ancillary operations, stand-alone senior living operations and the Service Center.
(2) Intercompany service revenue represents service revenue generated by ancillary operations provided to the Company's affiliated wholly-owned healthcare facilities and management service revenue generated by the Service Center with Standard Bearer. Intercompany service revenue is eliminated in consolidation along with corresponding intercompany cost of service.
(3) Intercompany rental revenue represents rental income generated by both Standard Bearer and other real estate properties with the Company's affiliated wholly-owned healthcare facilities. Intercompany rental revenue is eliminated in consolidation along with corresponding intercompany rent expense.
(4) Included in interest expense in Standard Bearer is interest expense incurred from intercompany debt arrangements between Standard Bearer and The Ensign Group, Inc. The intercompany interest expense is eliminated in the "Intercompany Elimination" column.
 Six Months Ended June 30, 2021
 Skilled ServicesStandard Bearer
All Other(1)
Intercompany EliminationTotal
Service revenue(2)
$1,213,918 $— $47,347 $(3,380)$1,257,885 
Rental revenue(3)
— 28,283 3,627 (24,006)7,904 
TOTAL REVENUE$1,213,918 $28,283 $50,974 $(27,386)$1,265,789 
Segment income (loss)178,941 15,619 (67,873)— 126,687 
Gain on sale of assets440 
Income before provision for income taxes$127,127 
Depreciation and amortization15,178 8,403 3,873 — 27,454 
Interest expense$— $3,275 $— $— $3,275 
(1) All other primarily includes all ancillary operations, stand-alone senior living operations and the Service Center.
(2) Intercompany service revenue represents service revenue generated by ancillary operations provided to the Company's affiliated wholly-owned healthcare facilities. Intercompany service revenue is eliminated in consolidation along with corresponding intercompany cost of service.
(3) Intercompany rental revenue represents rental income generated by both Standard Bearer and other real estate properties with the Company's affiliated wholly-owned healthcare facilities. Intercompany rental revenue is eliminated in consolidation along with corresponding intercompany rent expense.
Service revenue by major payor source were as follows:
 Three Months Ended June 30, 2022
 Skilled ServicesAll OtherTotal Service RevenueRevenue %
Medicaid(1)
$287,827 $6,301 $294,128 40.4 %
Medicare190,494 — 190,494 26.2 
Medicaid-skilled49,763 — 49,763 6.8 
Subtotal528,084 6,301 534,385 73.4 
Managed care128,587 — 128,587 17.7 
Private and other(2)
45,807 19,568 65,375 8.9 
TOTAL SERVICE REVENUE$702,478 $25,869 $728,347 100.0 %
(1) Medicaid payor includes revenue generated from senior living operations and revenue related to FMAP.
(2) Private and other payors also includes revenue from senior living operations and all payors generated in other ancillary services.

 Three Months Ended June 30, 2021
 Skilled ServicesAll OtherTotal Service RevenueRevenue %
Medicaid(1)
$247,671 $3,784 $251,455 39.6 %
Medicare170,008 — 170,008 26.8 
Medicaid-skilled42,740 — 42,740 6.7 
Subtotal460,419 3,784 464,203 73.1 
Managed care112,963 — 112,963 17.8 
Private and other(2)
39,500 17,943 57,443 9.1 
TOTAL SERVICE REVENUE$612,882 $21,727 $634,609 100.0 %
(1) Medicaid payor includes revenue generated from senior living operations and revenue related to FMAP.
(2) Private and other payors also includes revenue from senior living operations and all payors generated in other ancillary services.
 Six Months Ended June 30, 2022
 Skilled ServicesOther Service Revenue Total Service RevenueRevenue %
Medicaid(1)
$549,414 $11,062 $560,476 39.0 %
Medicare398,905 — 398,905 27.7 
Medicaid-skilled95,712 — 95,712 6.7 
Subtotal1,044,031 11,062 1,055,093 73.4 
Managed care256,373 — 256,373 17.8 
Private and other(2)
88,845 37,192 126,037 8.8 
TOTAL SERVICE REVENUE$1,389,249 $48,254 $1,437,503 100.0 %
(1) Medicaid payor includes revenue generated from senior living operations and revenue related to FMAP.
(2) Private and other payors also includes revenue from senior living operations and all payors generated in other ancillary services.

 Six Months Ended June 30, 2021
 Skilled ServicesOther Service Revenue Total Service RevenueRevenue %
Medicaid(1)
$475,412 $7,401 $482,813 38.4 %
Medicare360,311 — 360,311 28.6 
Medicaid-skilled82,733 — 82,733 6.6 
Subtotal918,456 7,401 925,857 73.6 
Managed care221,308 — 221,308 17.6 
Private and other(2)
74,154 36,566 110,720 8.8 
TOTAL SERVICE REVENUE$1,213,918 $43,967 $1,257,885 100.0 %
(1) Medicaid payor includes revenue generated from senior living operations and revenue related to FMAP.
(2) Private and other payors also includes revenue from senior living operations and all payors generated in other ancillary services.
In addition to the service revenue above, the Company's rental revenue derived from triple-net lease arrangements with third parties is $4,139 and $8,428, respectively, for the three and six months ended June 30, 2022 and $3,927 and $7,904, respectively, for the three and six months ended June 30, 2021. This revenue is included in both Standard Bearer and the all other category.
XML 27 R16.htm IDEA: XBRL DOCUMENT v3.22.2
Operation Expansions
6 Months Ended
Jun. 30, 2022
Business Combination and Asset Acquisition [Abstract]  
Operation Expansions OPERATION EXPANSIONS
The Company's subsidiaries expansion focus is to purchase or lease operations that are complementary to the current affiliated operations, accretive to the business, or otherwise advance the Company's strategy. The results of all operating subsidiaries are included in the Interim Financial Statements subsequent to the date of acquisition. Acquisitions are accounted for using the acquisition method of accounting. The Company's affiliated operations also enter into long-term leases that may include options to purchase the facilities. As a result, from time to time, a real estate affiliated subsidiary will acquire the property of facilities that have previously been operated under third-party leases.
FASB ASC Topic 805, Clarifying the Definition of a Business (ASC 805) defined the definition of a business to assist entities with evaluating when a set of transferred assets and activities is deemed to be a business. Determining whether a transferred set constitutes a business is important because the accounting for a business combination differs from that of an asset acquisition. The definition of a business also affects the accounting for dispositions. When substantially all of the fair value of assets acquired is concentrated in a single asset, or a group of similar assets, the assets acquired would not represent a business and business combination accounting would not be required.
2022 Expansions
During the six months ended June 30, 2022, the Company expanded its operations through a combination of long-term leases and real estate purchases, with the addition of four stand-alone skilled nursing operations. Of these additions, Standard Bearer acquired the real estate of two of the stand-alone skilled nursing operations, which were leased back to Ensign affiliated entities. Refer to Note 7, Standard Bearer, for additional information on the purchase of real estate properties. In addition, the Company added five senior living operations that were transferred from Pennant, three of which are part of campuses operated by the Company's affiliated operating subsidiaries. These new operations added a total of 453 operational skilled nursing beds and 633 operational senior living units to be operated by the Company's affiliated operating subsidiaries. The Company also invested in new ancillary services that are complementary to its existing businesses. The aggregate purchase price for these expansions during the six months ended June 30, 2022 was $33,892.
In connection with the new operations made through long-term leases, the Company did not acquire any material assets or assume any liabilities other than the tenant's post-assumption rights and obligations under the long-term lease. The Company entered into a separate operations transfer agreement with the prior operator as part of each transaction.
The aggregate purchase price for the transactions that were classified as asset acquisitions during the six months ended June 30, 2022 was $17,492, consisting of real estate properties and indefinite-lived intangible assets. The remaining aggregate purchase price for transactions during the six months ended June 30, 2022 is concentrated in goodwill of $16,400 and accordingly, the transactions were classified as business combinations.
Subsequent to June 30, 2022, the Company expanded its operations through a combination of long-term leases and real estate purchases, with the addition of seven stand-alone skilled nursing operations and one campus operation. Of these additions, Standard Bearer acquired the real estate of three of these operations, which were leased back to Ensign affiliated entities. These new operations added 1,100 operational skilled nursing beds and 61 operational senior living units to be operated by the Company's affiliated operating subsidiaries. In addition, the Company purchased the real estate at three skilled nursing properties that the Company was already operating, further expanding the Company's real estate portfolio. The aggregate purchase price for these expansions was $47,900.
2021 Expansions
During the six months ended June 30, 2021, the Company expanded its operations through a combination of long-term leases and a real estate purchase, with the addition of twelve stand-alone skilled nursing operations. Of these additions, one is related to the purchase of real estate property, further expanding the Company's real estate portfolio. These new operations added a total of 1,263 operational skilled nursing beds operated by the Company's affiliated operating subsidiaries. The aggregate purchase price for these acquisitions during the six months ended June 30, 2021 was $11,183.
In connection with the new operations made through long-term leases, the Company did not acquire any material assets or assume any liabilities other than the tenant's post-assumption rights and obligations under the long-term lease. The Company entered into a separate operations transfer agreement with the prior operator as part of each transaction.
The fair value of assets for nine of the acquisitions was concentrated in property and equipment and as such, these transactions were classified as asset acquisitions. The aggregate purchase price for the asset acquisitions during the six months ended June 30, 2021 was $5,183. The fair value of assets for the remaining four additions was concentrated in goodwill of $6,000 and as such, the transaction was classified as a business combination.
The Company’s acquisition strategy has been focused on identifying both opportunistic and strategic acquisitions within its target markets that offer strong opportunities for return. The operations added by the Company are frequently underperforming financially and can have regulatory and clinical challenges to overcome. Financial information, especially with underperforming operations, is often inadequate, inaccurate or unavailable. Consequently, the Company believes that prior operating results are not a meaningful representation of the Company’s current operating results or indicative of the integration potential of its newly acquired operating subsidiaries. The assets added during the six months ended June 30, 2022 were not material operations to the Company individually or in the aggregate. Accordingly, pro forma financial information is not presented. These additions have been included in the June 30, 2022 condensed consolidated balance sheets of the Company, and the operating results have been included in the condensed consolidated statements of operations of the Company since the date the Company gained effective control.
XML 28 R17.htm IDEA: XBRL DOCUMENT v3.22.2
Property and Equipment — Net
6 Months Ended
Jun. 30, 2022
Property, Plant and Equipment [Abstract]  
PROPERTY AND EQUIPMENT— Net PROPERTY AND EQUIPMENT - NET
Property and equipment, net consists of the following:
June 30, 2022December 31, 2021
Land$121,381 $121,164 
Buildings and improvements669,215 646,221 
Leasehold improvements145,522 140,012 
Equipment279,231 262,246 
Furniture and fixtures4,373 4,305 
Construction in progress11,000 10,253 
 1,230,722 1,184,201 
Less: accumulated depreciation(322,494)(295,767)
PROPERTY AND EQUIPMENT, NET$908,228 $888,434 
The Company completed the sale of assets for a sale price of $7,707 and recorded a gain of $2,567 within the Company's condensed consolidated statement of income as cost of services during the three months ended June 30, 2022. See also Note 7, Standard Bearer and Note 9, Operation Expansions for information on acquisitions during the six months ended June 30, 2022.
XML 29 R18.htm IDEA: XBRL DOCUMENT v3.22.2
Intangible Assets — Net
6 Months Ended
Jun. 30, 2022
Intangible Assets, Net (Excluding Goodwill) [Abstract]  
INTANGIBLE ASSETS — NET INTANGIBLE ASSETS - NET
 June 30, 2022December 31, 2021
Weighted Average Life (Years)
Gross Carrying AmountAccumulated AmortizationGross Carrying AmountAccumulated Amortization
Intangible AssetsNetNet
Assembled occupancy0.4$196 $(196)$— $68 $(68)$— 
Facility trade name30.0733 (403)330 733 (391)342 
Customer relationships18.44,582 (2,377)2,205 4,582 (2,272)2,310 
TOTAL $5,511 $(2,976)$2,535 $5,383 $(2,731)$2,652 

During the three and six months ended June 30, 2022, amortization expense was $418 and $822, respectively, of which $288 and $577 was related to the amortization of right-of-use assets, respectively. Amortization expense was $363 and $724, respectively, of which $290 and $580 was related to the amortization of right-of-use assets for the three and six months ended June 30, 2021, respectively.

Estimated amortization expense for each of the years ending December 31 is as follows:
YearAmount
2022 (remainder)$117 
2023234 
2024234 
2025234 
2026234 
2027234 
Thereafter1,248 
 $2,535 
XML 30 R19.htm IDEA: XBRL DOCUMENT v3.22.2
Goodwill and Other Indefinite-Lived Intangible Assets
6 Months Ended
Jun. 30, 2022
Goodwill and Intangible Assets Disclosure [Abstract]  
GOODWILL AND OTHER INDEFINITE-LIVED INTANGIBLE ASSETS GOODWILL AND OTHER INDEFINITE-LIVED INTANGIBLE ASSETS
The Company tests goodwill during the fourth quarter of each year or more often if events or circumstances indicate there may be impairment. The Company performs its analysis for each reporting unit that constitutes a business for which discrete financial information is produced and reviewed by operating segment management and provides services that are distinct from the other components of the operating segment, in accordance with the provisions of FASB ASC Topic 350, Intangibles—Goodwill and Other (ASC 350). This guidance provides the option to first assess qualitative factors to determine whether it is more likely than not that the fair value of a reporting unit is less than its carrying value. If, based on a review of qualitative factors, it is more likely than not that the fair value of a reporting unit is less than its carrying value, the Company performs a goodwill impairment test by comparing the carrying value of each reporting unit to its respective fair value. The Company determines the estimated fair value of each reporting unit using a discounted cash flow analysis. The fair value of the reporting unit is the implied fair value of goodwill. In the event a reporting unit's carrying value exceeds its fair value, an impairment loss will be recognized. An impairment loss is measured by the difference between the carrying value of the reporting unit and its fair value.
The Company anticipates that the majority of total goodwill recognized will be fully deductible for tax purposes as of June 30, 2022.

Provided that goodwill corresponds to the acquisition of a business and not merely the acquisition of real estate property, the Company's Standard Bearer segment appropriately does not carry a goodwill balance. The following table represents activity in goodwill by skilled service segment and "all other" category as of and for the six months ended June 30, 2022:
Goodwill
 Skilled ServicesAll OtherTotal
January 1, 2022$51,486 $8,983 $60,469 
Additions16,400 — 16,400 
June 30, 2022$67,886 $8,983 $76,869 

Other indefinite-lived intangible assets consist of the following:
June 30, 2022December 31, 2021
Trade name$889 $889 
Medicare and Medicaid licenses2,918 2,838 
TOTAL$3,807 $3,727 
XML 31 R20.htm IDEA: XBRL DOCUMENT v3.22.2
Restricted and Other Assets
6 Months Ended
Jun. 30, 2022
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]  
RESTRICTED AND OTHER ASSETS RESTRICTED AND OTHER ASSETS
Restricted and other assets consist of the following:
June 30, 2022December 31, 2021
Debt issuance costs, net$4,195 $1,953 
Long-term insurance losses recoverable asset8,440 6,755 
Deposits with landlords14,725 13,705 
Capital improvement reserves with landlords and lenders6,499 7,103 
Deferred compensation plan investments23,151 17,530 
RESTRICTED AND OTHER ASSETS$57,010 $47,046 

Included in restricted and other assets as of June 30, 2022 and December 31, 2021 are anticipated insurance recoveries related to the Company's workers' compensation liabilities and general and professional liability reserves that are recorded on a gross rather than net basis in accordance with GAAP.
The Company implemented a non-qualified deferred compensation plan (the DCP) that was effective in 2019 for certain employees and was expanded to other employees in 2020. The DCP allows for the employee deferrals to be deposited into a rabbi trust and these funds are generally invested in individual variable life insurance contracts owned by the Company that are specifically designed to fund the deferrals. The cash surrender value of the insurance contracts is based on funds that shadow the investment allocations specified by participants in the deferred compensation plan.

For the three and six months ended June 30, 2022, the Company recorded a loss on these investments of $3,313 and $4,515, respectively, which is included in other (expense) income, net. During the same periods, the Company recorded an offsetting reduction in expense of $3,300 and $4,511, respectively, allocated between cost of services and general and administrative expenses.
For the three and six months ended June 30, 2021, the Company recorded a gain on the deferral investment of $751 and $1,057, respectively, which is included in other (expense) income, net. During the same periods, the Company recorded an offsetting expense of $780 and $1,131, respectively, allocated between cost of services and general and administrative expenses.
XML 32 R21.htm IDEA: XBRL DOCUMENT v3.22.2
Other Accrued Liabilities
6 Months Ended
Jun. 30, 2022
Payables and Accruals [Abstract]  
OTHER ACCRUED LIABILITIES OTHER ACCRUED LIABILITIES
Other accrued liabilities consists of the following:
June 30, 2022December 31, 2021
Quality assurance fee$6,669 $6,474 
Refunds payable36,912 34,814 
Resident advances6,273 9,337 
Unapplied state relief funds4,356 1,781 
Cash held in trust for patients5,757 6,430 
Dividends payable3,040 3,035 
Property taxes7,670 9,124 
Legal finding accrued3,626 — 
Other11,490 18,415 
OTHER ACCRUED LIABILITIES$85,793 $89,410 

Quality assurance fee represents the aggregate of amounts payable to Arizona, California, Colorado, Idaho, Iowa, Kansas, Nebraska, Nevada, Utah, Washington and Wisconsin as a result of a mandated fee based on patient days or licensed beds. Refunds payable includes payables related to overpayments, duplicate payments and credit balances from various payor sources. Resident advances occur when the Company receives payments in advance of services provided. Resident deposits include refundable deposits to patients. Cash held in trust for patients reflects monies received from or on behalf of patients. Maintaining a trust account for patients is a regulatory requirement and, while the trust assets offset the liabilities, the Company assumes a fiduciary responsibility for these funds. The cash balance related to this liability is included in other current assets in the condensed consolidated balance sheets.
XML 33 R22.htm IDEA: XBRL DOCUMENT v3.22.2
Income Taxes
6 Months Ended
Jun. 30, 2022
Income Tax Disclosure [Abstract]  
INCOME TAXES INCOME TAXES
The Company recorded income tax expense of $31,292 and $26,707 during the six months ended June 30, 2022 and 2021, respectively, or 22.5% of earnings before income taxes for the six months ended June 30, 2022, compared to 21.0% for the six months ended June 30, 2021. The effective tax rate for both periods is driven by the impact of excess tax benefits from stock-based compensation, offset by non-deductible expenses including non-deductible compensation.

The Company is not currently under examination by any major income tax jurisdiction. During 2022, the statutes of limitations will lapse on the Company's 2018 Federal tax year and certain 2017 and 2018 state tax years. The Company does not believe the Federal or state statute lapses or any other event will significantly impact the balance of unrecognized tax benefits in the next twelve months. The net balance of unrecognized tax benefits was not material to the Interim Financial Statements for the six months ended June 30, 2022 and 2021.
XML 34 R23.htm IDEA: XBRL DOCUMENT v3.22.2
Debt
6 Months Ended
Jun. 30, 2022
Debt Disclosure [Abstract]  
DEBT DEBT
Debt consists of the following:
June 30, 2022December 31, 2021
Mortgage loans and promissory notes$158,258 $159,967 
Less: current maturities(3,944)(3,760)
Less: debt issuance costs, net(3,209)(3,324)
LONG-TERM DEBT LESS CURRENT MATURITIES$151,105 $152,883 
Credit Facility with a Lending Consortium Arranged by Truist

The Company maintains a revolving credit facility between the Company and its subsidiaries, including Standard Bearer as co-borrowers, and Truist Securities (Truist) (the Revolving Credit Facility). Borrowings are supported by a lending consortium arranged by Truist. On April 8, 2022, the Company and its subsidiaries, including Standard Bearer, entered into the Amended Credit Agreement, which amended the Revolving Credit Facility to increase the revolving line of credit from $350,000 to $600,000 in aggregate principal amount. The Amended Credit Agreement also extended the maturity date of the Revolving Credit Facility to April 8, 2027 and modified the reference rate from LIBOR to SOFR. The interest rates applicable to loans under the Amended Credit Facility are, at the Company's option, equal to either a base rate plus a margin ranging from 0.25% to 1.25% per annum or SOFR plus a margin range from 1.25% to 2.25% per annum, based on the Consolidated Total Net Debt to Consolidated EBITDA ratio (as defined in the agreement). In addition, the Company and its subsidiaries, including Standard Bearer, will pay a commitment fee on the unused portion of the commitments that will range from 0.20% to 0.40% per annum, depending on the Consolidated Total Net Debt to Consolidated EBITDA ratio. Except as set forth in the Amended Credit Facility, all other terms and conditions of the Credit Facility remained in full force and effect as described below. As part of the entry into the Amended Credit Agreement, deferred financing costs of $566 were written off and additional deferred financing costs of $3,197 were capitalized during the three months ended June 30, 2022.

Borrowings made under the Revolving Credit Facility are guaranteed, jointly and severally, by certain of the Company’s wholly-owned subsidiaries, and are secured by a pledge of stock of the Company's material operating subsidiaries as well as a first lien on substantially all of their personal property. The Amended Credit Agreement contains customary covenants that, among other things, restrict, subject to certain exceptions, the ability of the Company and its operating subsidiaries to grant liens on their assets, incur indebtedness, sell assets, make investments, engage in acquisitions, mergers or consolidations, amend certain material agreements and pay certain dividends and other restricted payments. Under the Amended Credit Agreement, the Company must comply with financial maintenance covenants to be tested quarterly, consisting of (i) a maximum consolidated total net debt to consolidated EBITDA ratio (which shall not be greater than 3.00:1.00; provided that if the aggregate consideration for approved acquisitions in a six month period is greater than $50,000, then the ratio can be increased at the election of the Company with notice to the administrative agent to 3.50:1.00 for the first fiscal quarter and the immediately following three fiscal quarters), and (ii) a minimum interest/rent coverage ratio (which cannot be less than 1.50:1.00). As of June 30, 2022, and July 27, 2022, there was no outstanding debt under the Revolving Credit Facility. The Company was in compliance with all loan covenants as of June 30, 2022.
Mortgage Loans and Promissory Notes

As of June 30, 2022, the Company's operating subsidiaries had $158,258 outstanding under the mortgage loans and notes, of which $3,944 is classified as short-term and the remaining $154,314 is classified as long-term. The Company was in compliance with all loan covenants as of June 30, 2022.

As of June 30, 2022, 23 of the Company's subsidiaries have mortgage loans insured with HUD in the aggregate amount of $155,074, which subjects these subsidiaries to HUD oversight and periodic inspections. The mortgage loans bear effective interest rates in a range of 3.1% to 4.2%, including fixed interest rates in a range of 2.4% to 3.3% per annum. In addition to the interest rate, we incur other fees for HUD placement, including but not limited to audit fees. Amounts borrowed under the mortgage loans may be prepaid, subject to prepayment fees based on the principal balance on the date of prepayment. For the majority of the loans, during the first three years, the prepayment fee is 10.0% and is reduced by 3.0% in the fourth year of the loan, and reduced by 1.0% per year for years five through ten of the loan. There is no prepayment penalty after year ten. The terms for all the mortgage loans are 25 to 35 years.
In addition to the HUD mortgage loans above, the Company has two promissory notes. The notes bear fixed interest rates of 6.3% and 5.3% per annum and the term of the notes are 10 months and 12 years, respectively. The 12 year note which was used for an acquisition is secured by the real property comprising the facility and the rent, issues and profits thereof, as well as all personal property used in the operation of the facility.

Based on Level 2, the carrying value of the Company's long-term debt is considered to approximate the fair value of such debt for all periods presented based upon the interest rates that the Company believes it can currently obtain for similar debt.
Off-Balance Sheet Arrangements

As of June 30, 2022, the Company had approximately $6,710 of borrowing capacity under the Revolving Credit Facility pledged as collateral to secure outstanding letters of credit.
XML 35 R24.htm IDEA: XBRL DOCUMENT v3.22.2
Options and Awards
6 Months Ended
Jun. 30, 2022
Share-Based Payment Arrangement [Abstract]  
OPTIONS AND AWARDS OPTIONS AND AWARDS
Stock-based compensation expense consists of stock-based payment awards made to employees and directors, including employee stock options and restricted stock awards, based on estimated fair values. As stock-based compensation expense recognized in the Company’s condensed consolidated statements of income for the three and six months ended June 30, 2022 and 2021 was based on awards ultimately expected to vest, it has been reduced for estimated forfeitures. The Company estimates forfeitures at the time of grant and, if necessary, revises the estimate in subsequent periods if actual forfeitures differ.
The Company has an option plan, the 2022 Omnibus Incentive Plan (the 2022 Plan), which was approved by the Company's stockholders on May 26, 2022, and replaced the Company's prior option plan, the 2017 Omnibus Incentive Plan (the 2017 Plan). The total number of shares available for issuance under the 2022 Plan was 3,268 as of June 30, 2022.

2022 Omnibus Incentive Plan - During the second quarter of 2022, the Company's shareholders approved the 2022 Plan. Including the shares rolled over from the 2017 Plan, the 2022 Plan provides for the issuance of 3,452 shares of common stock. The number of shares available to be issued under the 2022 Plan will be reduced by (i) one share for each share that relates to an option or stock appreciation right award and (ii) two shares for each share which relates to an award other than a stock option or stock appreciation right award (a full-value award). Non-employee director options, to the extent granted, will vest and become exercisable in three equal annual installments, or the length of the term if less than three years, on the completion of each year of service measured from the grant date. All other options generally vest over five years at 20% per year on the anniversary of the grant date. Options expire ten years from the date of grant. As of June 30, 2022, there were approximately 3,268 unissued shares of common stock available for issuance under this plan. The Company retired the 2017 Plan as a result of the approval of the 2022 Plan.
The Company uses the Black-Scholes option-pricing model to recognize the value of stock-based compensation expense for stock option awards. Determining the appropriate fair-value model and calculating the fair value of stock option awards at the grant date requires judgment, including estimating stock price volatility, expected option life, and forfeiture rates. The fair-value of the restricted stock awards at the grant date is based on the market price on the grant date, adjusted for forfeiture rates. The Company develops estimates based on historical data and market information, which can change significantly over time.
Stock Options
The Company granted 154 and 318 stock options from the available plans during the three and six months ended June 30, 2022, respectively. The Company used the following assumptions for stock options granted during the three months ended June 30, 2022 and 2021:
Grant YearOptions GrantedWeighted Average Risk-Free RateExpected LifeWeighted Average VolatilityWeighted Average Dividend Yield
20221542.7%6.1 years42.1%0.3%
20212091.0%6.3 years42.3%0.3%
The Company used the following assumptions for stock options granted during the six months ended June 30, 2022 and 2021:
Grant YearOptions GrantedWeighted Average Risk-Free RateExpected LifeWeighted Average VolatilityWeighted Average Dividend Yield
20223182.3%6.1 years42.2%0.3%
20213450.9%6.3 years42.2%0.2%
For the six months ended June 30, 2022 and 2021, the following represents the exercise price and fair value displayed at grant date for stock option grants:
Grant YearGrantedWeighted Average Exercise PriceWeighted Average Fair Value of Options
2022318$80.18 $34.29 
2021345$82.77 $33.86 
The weighted average exercise price equaled the weighted average fair value of common stock on the grant date for all options granted during the periods ended June 30, 2022 and 2021 and therefore, the intrinsic value was $0 at the date of grant.
The following table represents the employee stock option activity during the six months ended June 30, 2022:
Number of Options OutstandingWeighted Average
Exercise Price
Number of
Options Vested
Weighted Average Exercise Price of Options Vested
January 1, 20224,038 $36.60 2,183 $21.02 
Granted318 80.18 — — 
Forfeited(68)57.40 — — 
Exercised(370)16.40 — — 
June 30, 20223,918 $41.69 2,151 $25.53 
The following summary information reflects stock options outstanding, vested and related details as of June 30, 2022:
Stock Options OutstandingStock Options Vested
 
Number OutstandingBlack-Scholes Fair ValueRemaining Contractual Life (Years)Vested and Exercisable
Year of GrantExercise Price
2012$5.56-$6.7510 $32 010 
20136.76-9.74125 476 1125 
20148.94-16.05457 2,204 2457 
201518.20-21.39246 1,910 3246 
201615.93-16.86233 1,377 4233 
201715.80-19.41267 1,583 5236 
201822.49-32.71496 4,806 6326 
201941.07-45.76615 9,651 7292 
202044.84-59.49569 11,205 8162 
202173.47-83.64586 19,222 964 
2022$79.79$80.60314 10,782 10— 
TOTAL 3,918 $63,248  2,151 
The aggregate intrinsic value of options outstanding, vested and expected to vest as of June 30, 2022 and December 31, 2021 is as follows:
OptionsJune 30, 2022December 31, 2021
Outstanding$130,564 $191,242 
Vested103,713 137,382 
Expected to vest24,561 48,548 
The intrinsic value is calculated as the difference between the market value of the underlying common stock and the exercise price of the options. The aggregate intrinsic value of options that vested during the six months ended June 30, 2022 and 2021 was $10,409 and $17,618, respectively. The total intrinsic value of options exercised during the six months ended June 30, 2022 and 2021 was $25,642 and $26,715, respectively.
Restricted Stock Awards
The Company granted 46 and 158 restricted stock awards from the available plans during the three and six months ended June 30, 2022, respectively. The Company granted 54 and 144 restricted stock awards during the three and six months ended June 30, 2021, respectively. All awards were granted at an issue price of $0 and generally vest over five years. The fair value per share of restricted awards granted during the six months ended June 30, 2022 and 2021 ranged from $73.17 to $83.93 and $82.20 to $93.31, respectively. The fair value per share includes quarterly stock awards to non-employee directors.
A summary of the status of the Company's non-vested restricted stock awards as of June 30, 2022 and changes during the six months ended June 30, 2022 is presented below:
Non-Vested Restricted AwardsWeighted Average Grant Date Fair Value
Non-vested at January 1, 2022549 $52.16 
Granted158 77.06 
Vested(199)54.74 
Forfeited(16)55.86 
Non-vested at June 30, 2022492 $59.01 
During the three and six months ended June 30, 2022, respectively, the Company granted 5 and 9 automatic quarterly stock awards to non-employee directors for their service on the Company's board of directors from the 2017 Plan. The fair value per share of these stock awards ranged from $77.39 to $83.93 based on the market price on the grant date.
Long-Term Incentive Plan
On August 27, 2019, the Board approved the Long-Term Incentive Plan (the 2019 LTI Plan). The 2019 LTI Plan provides that certain employees of the Company who assisted in the consummation of the Spin-Off transaction are granted shares of restricted stock upon the successful completion of the Spin-Off. The 2019 LTI Plan provides for the issuance of 500 shares of Pennant restricted stock. The shares are vested over five years at 20% per year on the anniversary of the grant date. If a recipient is terminated or voluntarily leaves the Company, all shares subject to restriction or not yet vested shall be entirely forfeited. The total stock-based compensation related to the 2019 LTI Plan was approximately $195 and $390 for the three and six months ended June 30, 2022, respectively, compared to $202 and $403 for the three and six months ended June 30, 2021, respectively.
Stock-based compensation expense recognized for the Company's equity incentive plans and long-term incentive plan for the three and six months ended June 30, 2022 and 2021 was as follows:

Three Months Ended June 30,Six Months Ended June 30,
 2022202120222021
Stock-based compensation expense related to stock options$2,786 $2,026 $5,306 $3,759 
Stock-based compensation expense related to restricted stock awards2,456 2,076 4,758 3,914 
Stock-based compensation expense related to stock options and restricted stock awards to non-employee directors374 531 719 1,014 
TOTAL$5,616 $4,633 $10,783 $8,687 

In future periods, the Company expects to recognize approximately $39,110 and $28,748 in stock-based compensation expense for unvested options and unvested restricted stock awards, respectively, that were outstanding as of June 30, 2022. Future stock-based compensation expense will be recognized over 3.7 and 3.4 weighted average years for unvested options and restricted stock awards, respectively. There were 1,767 unvested and outstanding options as of June 30, 2022, of which 1,669 shares are expected to vest. The weighted average contractual life for options outstanding, vested and expected to vest as of June 30, 2022 was 6.0 years.
XML 36 R25.htm IDEA: XBRL DOCUMENT v3.22.2
Leases
6 Months Ended
Jun. 30, 2022
Leases [Abstract]  
LEASES LEASES
The Company leases from CareTrust REIT, Inc. (CareTrust) real property associated with 97 affiliated skilled nursing and senior living facilities used in the Company’s operations, 96 of which are under nine “triple-net” master lease agreements (collectively, the Master Leases), which range in terms from 13 to 20 years. At the Company’s option, the Master Leases may be extended for two or three five-year renewal terms beyond the initial term, on the same terms and conditions. The extension of the term of any of the Master Leases is subject to the following conditions: (1) no event of default under any of the Master Leases having occurred and being continuing; and (2) the tenants providing timely notice of their intent to renew. The term of the Master Leases is subject to termination prior to the expiration of the then current term upon default by the tenants in their obligations, if not cured within any applicable cure periods set forth in the Master Leases. If the Company elects to renew the term of a Master Lease, the renewal will be effective to all, but not less than all, of the leased property then subject to the Master Lease. Additionally, four of the 97 facilities leased from CareTrust include an option to purchase that the Company can exercise starting on December 1, 2024.
The Company does not have the ability to terminate the obligations under a Master Lease prior to its expiration without CareTrust’s consent. If a Master Lease is terminated prior to its expiration other than with CareTrust’s consent, the Company may be liable for damages and incur charges such as continued payment of rent through the end of the lease term as well as maintenance and repair costs for the leased property.
The rent structure under the Master Leases includes a fixed component, subject to annual escalation equal to the lesser of (1) the percentage change in the Consumer Price Index (but not less than zero) or (2) 2.5%. In addition to rent, the Company is required to pay the following: (1) all impositions and taxes levied on or with respect to the leased properties (other than taxes on the income of the lessor); (2) all utilities and other services necessary or appropriate for the leased properties and the business conducted on the leased properties; (3) all insurance required in connection with the leased properties and the business conducted on the leased properties; (4) all facility maintenance and repair costs; and (5) all fees in connection with any licenses or authorizations necessary or appropriate for the leased properties and the business conducted on the leased properties. The terms and conditions of the one stand-alone lease are substantially the same as those for the master leases described above. Total rent expense under the Master Leases was approximately $16,007 and $31,652 for the three and six months ended June 30, 2022, respectively, and $14,419 and $28,499 for the three and six months ended June 30, 2021, respectively.
Among other things, under the Master Leases, the Company must maintain compliance with specified financial covenants measured on a quarterly basis, including a portfolio coverage ratio and a minimum rent coverage ratio. The Master Leases also include certain reporting, legal and authorization requirements. The Company is in compliance with requirements of the Master Leases as of June 30, 2022.
In connection with the Spin-Off, the Company guaranteed certain leases of Pennant based on the underlying terms of the leases. The Company does not consider these guarantees to be probable and the likelihood of Pennant defaulting is remote, and therefore no liabilities have been accrued.
The Company also leases certain affiliated operations and certain administrative offices under non-cancelable operating leases, most of which have initial lease terms ranging from five to 20 years. The Company has entered into multiple lease agreements with various landlords to operate newly constructed state-of-the-art, full-service healthcare resorts. The term of each lease is 15 years with two five-year renewal options and is subject to annual escalation equal to the percentage change in the Consumer Price Index with a stated cap percentage. In addition, the Company leases certain of its equipment under non-cancelable operating leases with initial terms ranging from three to five years. Most of these leases contain renewal options, certain of which involve rent increases. Total rent expense for continuing operations inclusive of straight-line rent adjustments and rent associated with the Master Leases noted above, was $37,251 and $73,036 for the three and six months ended June 30, 2022, respectively, and $34,476 and $67,952 for the three and six months ended June 30, 2021, respectively.
Forty-four of the Company’s affiliated facilities, excluding the facilities that are operated under the Master Leases with CareTrust, are operated under eight separate master lease arrangements. In the first quarter of 2022, the Company added an operation and extended the term for one of the master leases to 14 remaining years. As a result, the lease liabilities and right-of-use assets increased by $120,349 to reflect the new lease obligations. Under these master leases, a breach at a single facility could subject one or more of the other facilities covered by the same master lease to the same default risk. Failure to comply with Medicare and Medicaid provider requirements is a default under several of the Company’s leases, master lease agreements and debt financing instruments. In addition, other potential defaults related to an individual facility may cause a default of an entire master lease portfolio and could trigger cross-default provisions in the Company’s outstanding debt arrangements and other leases. With an indivisible lease, it is difficult to restructure the composition of the portfolio or economic terms of the lease without the consent of the landlord.

The components of operating lease expense are as follows:
Three Months Ended June 30,Six Months Ended June 30,
2022202120222021
Rent - cost of services(1)
$37,228 $34,455 $72,990 $67,911 
General and administrative expense23 21 46 41 
Depreciation and amortization(2)
288 290 577 580 
Variable lease costs(3)
3,772 3,694 9,135 7,137 
$41,311 $38,460 $82,748 $75,669 
(1)Rent- cost of services includes deferred rent expense adjustments of $116 and $240 for the three and six months ended June 30, 2022, respectively and $109 and $221 for the three and six months ended June 30, 2021, respectively. Additionally, rent- cost of services includes other variable lease costs such as CPI increases and short-term leases of $1,302 and $2,239 for the three and six months ended June 30, 2022, respectively, and $832 and $1,416 for the three and six months ended June 30, 2021, respectively.
(2)Depreciation and amortization is related to the amortization of favorable and direct lease costs.
(3)Variable lease costs, including property taxes and insurance, are classified in cost of services in the Company's condensed consolidated statements of income.

Future minimum lease payments for all leases as of June 30, 2022 are as follows:
YearAmount
2022 (remainder)$71,530 
2023141,887 
2024141,296 
2025141,187 
2026141,082 
2027140,564 
Thereafter1,254,424 
TOTAL LEASE PAYMENTS2,031,970 
Less: present value adjustment (756,866)
PRESENT VALUE OF TOTAL LEASE LIABILITIES1,275,104 
Less: current lease liabilities(58,769)
LONG-TERM OPERATING LEASE LIABILITIES$1,216,335 
Operating lease liabilities are based on the net present value of the remaining lease payments over the remaining lease term. In determining the present value of lease payments, the Company used its incremental borrowing rate based on the information available at the lease commencement date. As of June 30, 2022, the weighted average remaining lease term is 15.1 years and the weighted average discount rate used to determine the operating lease liabilities is 6.8%.
Subsequent to June 30, 2022, the Company expanded its operations through long-term lease arrangements with the addition of five stand-alone skilled nursing operations, four of which are part of an amended separate master lease agreement, adding a total of 779 operational skilled nursing beds operated by the Company's affiliated operating subsidiaries. The term of the amended separate master lease agreement was extended to 20 remaining years. The aggregate impact to the fair value of lease liabilities and right-of-use assets related to both the new long-term lease arrangement and the amended separate master lease agreement is estimated to be approximately $70,614. Additionally, Standard Bearer acquired the real estate of three skilled nursing operations, which were previously under long-term lease arrangements. The aggregate reduction in the fair value of lease liabilities and right-of-use assets related to this acquisition is estimated to be approximately $10,080.
Lessor Activities

In connection with the Spin-Off, Ensign affiliates retained ownership of the real estate at 29 senior living operations that were contributed to Pennant. Between October 2019 and June 30, 2022, the Company transferred three additional senior living operations to Pennant. During the three months ended June 30, 2022, the Company completed the sale of real estate associated with two of the senior living operations operated by Pennant and also transferred one senior living operation operated by Pennant back to Ensign affiliates. As of June 30, 2022, Ensign affiliates retained ownership of the real estate for these 29 senior living communities. All of these properties are leased to Pennant on a triple-net basis, whereas the respective Pennant affiliates are responsible for all costs at the properties including: (1) all impositions and taxes levied on or with respect to the leased properties (other than taxes on the income of the lessor); (2) all utilities and other services necessary or appropriate for the leased properties and the business conducted on the leased properties; (3) all insurance required in connection with the leased properties and the business conducted on the leased properties; (4) all facility maintenance and repair costs; and (5) all fees in connection with any licenses or authorizations necessary or appropriate for the leased properties and the business conducted on the leased properties. The initial terms range between 14 to 16 years.

Total rental income from all third-party sources for the three and six months ended June 30, 2022 and 2021 is as follows:

Three Months Ended June 30,Six Months Ended June 30,
2022202120222021
Pennant(1)
$3,690 $3,440 $7,505 $6,928 
Other third-party449 487 923 976 
$4,139 $3,927 $8,428 $7,904 
(1) Pennant rental income includes variable rent such as property taxes of $327 and $657 during the three and six months ended June 30, 2022 and $266 and $580 for the three and six months ended June 30, 2021.

Future annual rental income for all leases as of June 30, 2022 were as follows:
Year
Amount(1)
2022 (remainder)$8,098 
202315,820 
202415,373 
202515,032 
202614,821 
202714,821 
Thereafter77,369 
TOTAL$161,334 
(1) Annual rental income includes base rents and variable rental income pursuant to existing leases as of June 30, 2022.
LEASES LEASES
The Company leases from CareTrust REIT, Inc. (CareTrust) real property associated with 97 affiliated skilled nursing and senior living facilities used in the Company’s operations, 96 of which are under nine “triple-net” master lease agreements (collectively, the Master Leases), which range in terms from 13 to 20 years. At the Company’s option, the Master Leases may be extended for two or three five-year renewal terms beyond the initial term, on the same terms and conditions. The extension of the term of any of the Master Leases is subject to the following conditions: (1) no event of default under any of the Master Leases having occurred and being continuing; and (2) the tenants providing timely notice of their intent to renew. The term of the Master Leases is subject to termination prior to the expiration of the then current term upon default by the tenants in their obligations, if not cured within any applicable cure periods set forth in the Master Leases. If the Company elects to renew the term of a Master Lease, the renewal will be effective to all, but not less than all, of the leased property then subject to the Master Lease. Additionally, four of the 97 facilities leased from CareTrust include an option to purchase that the Company can exercise starting on December 1, 2024.
The Company does not have the ability to terminate the obligations under a Master Lease prior to its expiration without CareTrust’s consent. If a Master Lease is terminated prior to its expiration other than with CareTrust’s consent, the Company may be liable for damages and incur charges such as continued payment of rent through the end of the lease term as well as maintenance and repair costs for the leased property.
The rent structure under the Master Leases includes a fixed component, subject to annual escalation equal to the lesser of (1) the percentage change in the Consumer Price Index (but not less than zero) or (2) 2.5%. In addition to rent, the Company is required to pay the following: (1) all impositions and taxes levied on or with respect to the leased properties (other than taxes on the income of the lessor); (2) all utilities and other services necessary or appropriate for the leased properties and the business conducted on the leased properties; (3) all insurance required in connection with the leased properties and the business conducted on the leased properties; (4) all facility maintenance and repair costs; and (5) all fees in connection with any licenses or authorizations necessary or appropriate for the leased properties and the business conducted on the leased properties. The terms and conditions of the one stand-alone lease are substantially the same as those for the master leases described above. Total rent expense under the Master Leases was approximately $16,007 and $31,652 for the three and six months ended June 30, 2022, respectively, and $14,419 and $28,499 for the three and six months ended June 30, 2021, respectively.
Among other things, under the Master Leases, the Company must maintain compliance with specified financial covenants measured on a quarterly basis, including a portfolio coverage ratio and a minimum rent coverage ratio. The Master Leases also include certain reporting, legal and authorization requirements. The Company is in compliance with requirements of the Master Leases as of June 30, 2022.
In connection with the Spin-Off, the Company guaranteed certain leases of Pennant based on the underlying terms of the leases. The Company does not consider these guarantees to be probable and the likelihood of Pennant defaulting is remote, and therefore no liabilities have been accrued.
The Company also leases certain affiliated operations and certain administrative offices under non-cancelable operating leases, most of which have initial lease terms ranging from five to 20 years. The Company has entered into multiple lease agreements with various landlords to operate newly constructed state-of-the-art, full-service healthcare resorts. The term of each lease is 15 years with two five-year renewal options and is subject to annual escalation equal to the percentage change in the Consumer Price Index with a stated cap percentage. In addition, the Company leases certain of its equipment under non-cancelable operating leases with initial terms ranging from three to five years. Most of these leases contain renewal options, certain of which involve rent increases. Total rent expense for continuing operations inclusive of straight-line rent adjustments and rent associated with the Master Leases noted above, was $37,251 and $73,036 for the three and six months ended June 30, 2022, respectively, and $34,476 and $67,952 for the three and six months ended June 30, 2021, respectively.
Forty-four of the Company’s affiliated facilities, excluding the facilities that are operated under the Master Leases with CareTrust, are operated under eight separate master lease arrangements. In the first quarter of 2022, the Company added an operation and extended the term for one of the master leases to 14 remaining years. As a result, the lease liabilities and right-of-use assets increased by $120,349 to reflect the new lease obligations. Under these master leases, a breach at a single facility could subject one or more of the other facilities covered by the same master lease to the same default risk. Failure to comply with Medicare and Medicaid provider requirements is a default under several of the Company’s leases, master lease agreements and debt financing instruments. In addition, other potential defaults related to an individual facility may cause a default of an entire master lease portfolio and could trigger cross-default provisions in the Company’s outstanding debt arrangements and other leases. With an indivisible lease, it is difficult to restructure the composition of the portfolio or economic terms of the lease without the consent of the landlord.

The components of operating lease expense are as follows:
Three Months Ended June 30,Six Months Ended June 30,
2022202120222021
Rent - cost of services(1)
$37,228 $34,455 $72,990 $67,911 
General and administrative expense23 21 46 41 
Depreciation and amortization(2)
288 290 577 580 
Variable lease costs(3)
3,772 3,694 9,135 7,137 
$41,311 $38,460 $82,748 $75,669 
(1)Rent- cost of services includes deferred rent expense adjustments of $116 and $240 for the three and six months ended June 30, 2022, respectively and $109 and $221 for the three and six months ended June 30, 2021, respectively. Additionally, rent- cost of services includes other variable lease costs such as CPI increases and short-term leases of $1,302 and $2,239 for the three and six months ended June 30, 2022, respectively, and $832 and $1,416 for the three and six months ended June 30, 2021, respectively.
(2)Depreciation and amortization is related to the amortization of favorable and direct lease costs.
(3)Variable lease costs, including property taxes and insurance, are classified in cost of services in the Company's condensed consolidated statements of income.

Future minimum lease payments for all leases as of June 30, 2022 are as follows:
YearAmount
2022 (remainder)$71,530 
2023141,887 
2024141,296 
2025141,187 
2026141,082 
2027140,564 
Thereafter1,254,424 
TOTAL LEASE PAYMENTS2,031,970 
Less: present value adjustment (756,866)
PRESENT VALUE OF TOTAL LEASE LIABILITIES1,275,104 
Less: current lease liabilities(58,769)
LONG-TERM OPERATING LEASE LIABILITIES$1,216,335 
Operating lease liabilities are based on the net present value of the remaining lease payments over the remaining lease term. In determining the present value of lease payments, the Company used its incremental borrowing rate based on the information available at the lease commencement date. As of June 30, 2022, the weighted average remaining lease term is 15.1 years and the weighted average discount rate used to determine the operating lease liabilities is 6.8%.
Subsequent to June 30, 2022, the Company expanded its operations through long-term lease arrangements with the addition of five stand-alone skilled nursing operations, four of which are part of an amended separate master lease agreement, adding a total of 779 operational skilled nursing beds operated by the Company's affiliated operating subsidiaries. The term of the amended separate master lease agreement was extended to 20 remaining years. The aggregate impact to the fair value of lease liabilities and right-of-use assets related to both the new long-term lease arrangement and the amended separate master lease agreement is estimated to be approximately $70,614. Additionally, Standard Bearer acquired the real estate of three skilled nursing operations, which were previously under long-term lease arrangements. The aggregate reduction in the fair value of lease liabilities and right-of-use assets related to this acquisition is estimated to be approximately $10,080.
Lessor Activities

In connection with the Spin-Off, Ensign affiliates retained ownership of the real estate at 29 senior living operations that were contributed to Pennant. Between October 2019 and June 30, 2022, the Company transferred three additional senior living operations to Pennant. During the three months ended June 30, 2022, the Company completed the sale of real estate associated with two of the senior living operations operated by Pennant and also transferred one senior living operation operated by Pennant back to Ensign affiliates. As of June 30, 2022, Ensign affiliates retained ownership of the real estate for these 29 senior living communities. All of these properties are leased to Pennant on a triple-net basis, whereas the respective Pennant affiliates are responsible for all costs at the properties including: (1) all impositions and taxes levied on or with respect to the leased properties (other than taxes on the income of the lessor); (2) all utilities and other services necessary or appropriate for the leased properties and the business conducted on the leased properties; (3) all insurance required in connection with the leased properties and the business conducted on the leased properties; (4) all facility maintenance and repair costs; and (5) all fees in connection with any licenses or authorizations necessary or appropriate for the leased properties and the business conducted on the leased properties. The initial terms range between 14 to 16 years.

Total rental income from all third-party sources for the three and six months ended June 30, 2022 and 2021 is as follows:

Three Months Ended June 30,Six Months Ended June 30,
2022202120222021
Pennant(1)
$3,690 $3,440 $7,505 $6,928 
Other third-party449 487 923 976 
$4,139 $3,927 $8,428 $7,904 
(1) Pennant rental income includes variable rent such as property taxes of $327 and $657 during the three and six months ended June 30, 2022 and $266 and $580 for the three and six months ended June 30, 2021.

Future annual rental income for all leases as of June 30, 2022 were as follows:
Year
Amount(1)
2022 (remainder)$8,098 
202315,820 
202415,373 
202515,032 
202614,821 
202714,821 
Thereafter77,369 
TOTAL$161,334 
(1) Annual rental income includes base rents and variable rental income pursuant to existing leases as of June 30, 2022.
XML 37 R26.htm IDEA: XBRL DOCUMENT v3.22.2
Commitments and Contingencies
6 Months Ended
Jun. 30, 2022
Commitments and Contingencies Disclosure [Abstract]  
COMMITMENTS AND CONTINGENCIES COMMITMENTS AND CONTINGENCIES
Regulatory Matters Laws and regulations governing Medicare and Medicaid programs are complex and subject to review and interpretation. Compliance with such laws and regulations is evaluated regularly, the results of which can be subject to future governmental review and interpretation, and can include significant regulatory action including fines, penalties, and exclusion from certain governmental programs. Included in these laws and regulations is monitoring performed by the Office of Civil Rights which covers the Health Insurance Portability and Accountability Act of 1996, the terms of which require healthcare providers (among other things) to safeguard the privacy and security of certain patient protected health information.
Cost-Containment Measures Both government and private pay sources have instituted cost-containment measures designed to limit payments made to providers of healthcare services, and there can be no assurance that future measures designed to limit payments made to providers will not adversely affect the Company.
Indemnities From time to time, the Company enters into certain types of contracts that contingently require the Company to indemnify parties against third-party claims. These contracts primarily include (i) certain real estate leases, under which the Company may be required to indemnify property owners or prior facility operators for post-transfer environmental obligations or other liabilities and other claims arising from the Company’s use of the applicable premises, (ii) operations transfer agreements, in which the Company agrees to indemnify past operators of facilities the Company acquires against certain liabilities arising from the transfer of the operation and/or the operation thereof after the transfer to the Company's independent operating subsidiary, (iii) certain lending agreements, under which the Company may be required to indemnify the lender against various claims and liabilities, and (iv) certain agreements with the Company’s officers, directors and others, under which the Company may be required to indemnify such persons for liabilities arising out of the nature of their relationship to the Company. The terms of such obligations vary by contract and, in most instances, do not expressly state or include a specific or maximum dollar amount. Generally, amounts under these contracts cannot be reasonably estimated until a specific claim is asserted. Consequently, because no claims have been asserted, no liabilities have been recorded for these obligations on the Company’s condensed consolidated balance sheets for any of the periods presented.

In connection with the Spin-Off, certain landlords required, in exchange for their consent to the transaction, that the Company's lease guarantees remain in place for a certain period of time following the Spin-Off. These guarantees could result in significant additional liabilities and obligations for the Company if Pennant were to default on their obligations under their leases with respect to these properties.

U.S. Department of Justice Civil Investigative DemandOn May 31, 2018, the Company received a Civil Investigative Demand (CID) from the U.S. Department of Justice stating that it was investigating whether there had been a violation of the False Claims Act and/or the Anti-Kickback Statute with respect to relationships between certain of the Company’s independently operated skilled nursing facilities and persons who serve or have served as medical directors, advisory board participants or other potential referral sources. The CID covered the period from October 3, 2013 through 2018, and was limited in scope to ten of the Company’s Southern California independent operating entities. In October 2018, the Department of Justice made an additional request for information covering the period of January 1, 2011 through 2018, relating to the same topic. As a general matter, the Company’s independent operating entities have established and maintain policies and procedures to promote compliance with the False Claims Act, the Anti-Kickback Statute, and other applicable regulatory requirements. The Company fully cooperated with the U.S. Department of Justice and promptly responded to its requests for information; in April 2020, the Company was advised that the U.S. Department of Justice declined to intervene in any subsequent action filed by a relator in connection with the subject matter of this investigation.
U.S. House of Representatives Select Subcommittee Request In 2020, the U.S. House of Representatives Select Subcommittee on the Coronavirus Crisis launched a nation-wide investigation into the COVID-19 pandemic, which included the impact of the coronavirus on residents and employees in nursing homes. In June 2020, the Company received a document and information request from the House Select Subcommittee in connection with its investigation. The Company has cooperated in responding to this inquiry. In July 2022, the Company received a follow up request for additional documents and information. The Company is cooperating in responding to this inquiry. However, it is not possible to predict the ultimate outcome of any such investigation or whether and what other investigations or regulatory responses may result from the investigation, which could have a material adverse effect on our reputation, business, financial condition, and results of operations.
Litigation — The skilled nursing business involves a significant risk of liability given the age and health of the patients and residents served by the Company's independent operating subsidiaries. The Company, its independent operating subsidiaries, and others in the industry are subject to an increasing number of claims and lawsuits, including professional liability claims, alleging that services provided have resulted in personal injury, elder abuse, wrongful death or other related claims. In addition, the Company, its independent operating subsidiaries, and others in the industry are subject to claims and lawsuits in connection with COVID-19 and a facility's preparation for and/or response to COVID-19. The defense of these lawsuits may result in significant legal costs, regardless of the outcome, and can result in large settlement amounts or damage awards.

In addition to the potential lawsuits and claims described above, the Company and its independent operating subsidiaries are also subject to potential lawsuits under the Federal False Claims Act and comparable state laws alleging submission of fraudulent claims for services to any healthcare program (such as Medicare or Medicaid) or other payor. A violation may provide the basis for exclusion from Federally-funded healthcare programs. Such exclusions could have a correlative negative impact on the Company’s financial performance. Under the qui tam or "whistleblower" provisions of the False Claims Act, a private individual with knowledge of fraud or potential fraud may bring a claim on behalf of the Federal Government and receive a percentage of the Federal Government's recovery. Due to these whistleblower incentives, qui tam lawsuits have become more frequent. For example, and despite the decision of the U.S. Department of Justice to decline to participate in litigation based on the subject matter of its previously issued Civil Investigative Demand, the involved qui tam relator has continued on with the lawsuit and is pursuing claims that the Company and certain of its independent operating subsidiaries have allegedly violated the False Claims Act and/or the Anti-Kickback Statute (AKS).
In addition to the Federal False Claims Act, some states, including California, Arizona and Texas, have enacted similar whistleblower and false claims laws and regulations. Further, the Deficit Reduction Act of 2005 created incentives for states to enact anti-fraud legislation modeled on the Federal False Claims Act. As such, the Company and its independent operating subsidiaries could face increased scrutiny, potential liability and legal expenses and costs based on claims under state false claims acts in markets in which its independent operating subsidiaries do business.
In May 2009, Congress passed the Fraud Enforcement and Recovery Act (FERA) which made significant changes to the Federal False Claims Act and expanded the types of activities subject to prosecution and whistleblower liability. Following changes by FERA, health care providers face significant penalties for the knowing retention of government overpayments, even if no false claim was involved. Health care providers can now be liable for knowingly and improperly avoiding or decreasing an obligation to pay money or property to the government. This includes the retention of any government overpayment. The government can argue, therefore, that a Federal False Claims Act violation can occur without any affirmative fraudulent action or statement, as long as the action or statement is knowingly improper. In addition, FERA extended protections against retaliation for whistleblowers, including protections not only for employees, but also contractors and agents. Thus, an employment relationship is generally not required in order to qualify for protection against retaliation for whistleblowing.
Healthcare litigation (including class action litigation) is common and is filed based upon a wide variety of claims and theories, and the Company's independent operating subsidiaries are routinely subjected to varying types of claims, including class action "staffing" suits where the allegation is understaffing at the facility level. These class-action “staffing” suits have the potential to result in large jury verdicts and settlements, and may result in significant legal costs. The Company expects the plaintiffs' bar to continue to be aggressive in their pursuit of these staffing and similar claims. While the Company has been able to settle these claims without an ongoing material adverse effect on its business, future claims could be brought that may materially affect its business, financial condition and results of operations.
Other claims and suits, including class actions, continue to be filed against the Company and other companies in its industry. The Company and its independent operating subsidiaries have been subjected to, and are currently involved in, class action litigation alleging violations (alone or in combination) of state and federal wage and hour laws as related to the alleged failure to pay wages, to timely provide and authorize meal and rest breaks, and related causes of action. The Company does not believe that the ultimate resolution of these actions will have an ongoing material adverse effect on the Company’s business, cash flows, financial condition or results of operations.
The Company and its independent operating subsidiaries have been, and continue to be, subject to claims, findings and legal actions that arise in the ordinary course of the various businesses, including healthcare and non-healthcare services. These claims include, but are not limited to, potential claims filed by residents, customers, patients and responsible parties related to patient care and treatment (professional negligence claims); to non-care based activities of certain of the subsidiaries; and to employment related claims filed by current or former employees. A significant increase in the number of these claims, or an increase in the amounts owing should plaintiffs be successful in their prosecution of these claims, could materially adversely affect the Company’s business, financial condition, results of operations and cash flows. In addition, these claims could impact the Company's ability to procure insurance to cover its exposure related to the various services provided by its independent operating subsidiaries to their residents, customers and patients.
The Company and its independent subsidiaries are also subject to requests for information and investigations by other State and Federal governmental entities (e.g., offices of the attorney general and offices of the inspector general). The Company cannot predict or provide any assurance as to the possible outcome of any inquiry, investigation or litigation. If any such inquiry, investigation or litigation were to proceed, and the Company and its independent operating subsidiaries are subjected to, alleged to be liable for, or agree to a settlement of, claims or obligations under Federal Medicare statutes, the Federal False Claims Act, or similar state and federal statutes and related regulations, or if the Company or its independent operating subsidiaries are alleged or found to be liable on theories of general or professional negligence or wage and hour violations, the Company's business, financial condition and results of operations and cash flows could be materially and adversely affected and its stock price could be adversely impacted. Among other things, any settlement or litigation could involve the payment of substantial sums to settle any alleged violations, and may also include the assumption of specific procedural and financial obligations by the Company or its independent operating subsidiaries under a corporate integrity agreement and/or other such arrangement.
Medicare Revenue Recoupments The Company's independent operating entities are subject to regulatory reviews relating to the provision of Medicare services, billings and potential overpayments as a result of Recovery Audit Contractors (RAC), Program Safeguard Contractors, and Medicaid Integrity Contractors programs (collectively referred to as Reviews). For several months during the COVID-19 pandemic, the Centers for Medicare and Medicaid Services (CMS) suspended its Targeted Probe and Educate Program. Beginning in August 2020, CMS resumed Targeted Probe and Educate Program activity. If an operation fails a Review and/or subsequent Reviews, the operation could then be subject to extended review or an extrapolation of the identified error rate to billings in the same time period. The Company anticipates that these Reviews could increase in frequency in the future. As of June 30, 2022 and since, 22 of the Company's independent operating subsidiaries had Reviews scheduled, on appeal, or in a dispute resolution process.
Concentrations
Credit Risk — The Company has significant accounts receivable balances, the collectability of which is dependent on the availability of funds from certain governmental programs, primarily Medicare and Medicaid. These receivables represent the only significant concentration of credit risk for the Company. The Company does not believe there are significant credit risks associated with these governmental programs. The Company believes that an appropriate allowance has been recorded for the possibility of these receivables proving uncollectible, and continually monitors and adjusts these allowances as necessary. The Company’s receivables from Medicare and Medicaid payor programs accounted for 52.9% and 54.0% of its total accounts receivable as of June 30, 2022 and December 31, 2021, respectively. Revenue from reimbursement under the Medicare and Medicaid programs accounted for 73.4% of the Company's revenue for both the three and six months ended June 30, 2022, and 73.1% and 73.6% for the three and six months ended June 30, 2021, respectively.
Cash in Excess of FDIC Limits — The Company currently has bank deposits with financial institutions in the U.S. that exceed FDIC insurance limits. FDIC insurance provides protection for bank deposits up to $250. In addition, the Company has uninsured bank deposits with a financial institution outside the U.S. As of July 27, 2022, the Company had approximately $567 in uninsured cash deposits. All uninsured bank deposits are held at high quality credit institutions.
XML 38 R27.htm IDEA: XBRL DOCUMENT v3.22.2
Common Stock Repurchase Program
6 Months Ended
Jun. 30, 2022
Equity [Abstract]  
COMMON STOCK REPURCHASE PROGRAM COMMON STOCK REPURCHASE PROGRAMOn February 9, 2022, the Board of Directors approved the Company to enter into a stock repurchase program pursuant to which the Company could repurchase up to $20,000 of its common stock under the program for a period of approximately 12 months from February 10, 2022. Under this program, the Company was authorized to repurchase its issued and outstanding common shares from time to time in open-market and privately negotiated transactions and block trades in accordance with federal securities laws. During the three months ended June 30, 2022, the Company repurchased 271 shares of its common stock for $20,000. This repurchase program expired upon the repurchase of the fully authorized amount under the plan.
As approved by the Board of Directors on October 21, 2021, the Company entered into a stock repurchase program pursuant to which the Company could repurchase up to $20,000 of its common stock under the program for a period of approximately 12 months that started on October 29, 2021. Under this program, the Company was authorized to repurchase its issued and outstanding common shares from time to time in open-market and privately negotiated transactions and block trades in accordance with federal securities laws. During the three months ended March 31, 2022, the Company repurchased 133 shares of its common stock for $9,882. During the fourth quarter of 2021, the Company repurchased 132 shares of its common stock for $10,118. This repurchase program expired upon the repurchase of the fully authorized amount under the plan.

On July 28, 2022, the Board of Directors approved the Company to enter into a stock repurchase program pursuant to which the Company may repurchase up to $20,000 of its common stock under the program for a period of approximately 12 months from August 2, 2022. Under this program, the Company is authorized to repurchase its issued and outstanding common shares from time to time in open-market and privately negotiated transactions and block trades in accordance with federal securities laws.
XML 39 R28.htm IDEA: XBRL DOCUMENT v3.22.2
Summary of Significant Accounting Policies (Policies)
6 Months Ended
Jun. 30, 2022
Accounting Policies [Abstract]  
Basis of Presentation Basis of Presentation The accompanying Interim Financial Statements have been prepared in accordance with accounting principles generally accepted in the United States (GAAP). The Company is the sole member or stockholder of various consolidated limited liability companies and corporations established to operate various acquired skilled nursing operations, senior living operations and related ancillary services. All intercompany transactions and balances have been eliminated in consolidation. The Company presents noncontrolling interests within the equity section of its condensed consolidated balance sheets and the amount of consolidated net income that is attributable to The Ensign Group, Inc. and the noncontrolling interest in its condensed consolidated statements of income.The condensed consolidated financial statements include the accounts of all entities controlled by the Company through its ownership of a majority voting interest. Additionally, the accounts of any variable interest entities (VIEs) where the Company is subject to a majority of the risk of loss from the VIE's activities are entitled to receive a majority of the entity's residual returns, or both. The Company assesses the requirements related to the consolidation of VIEs, including a qualitative assessment of power and economics that considers which entity has the power to direct the activities that "most significantly impacts" the VIE's economic performance and has the obligation to absorb losses of, or the right to receive benefits that could be potentially significant to, the VIE. On October 1, 2021, the Company deconsolidated its VIE, which was not material, as this entity no longer met the requirements for consolidation. As of June 30, 2022 and December 31, 2021, the Company had no VIEs.
Reclassifications ReclassificationsPrior period results reflect reclassifications, for comparative purposes, related to the change in the Company's segment structure as a result of the formation of Standard Bearer.
Estimates and Assumptions Estimates and Assumptions The preparation of the Interim Financial Statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the Interim Financial Statements and the reported amounts of revenue and expenses during the reporting periods. The most significant estimates in the Company’s Interim Financial Statements relate to revenue, acquired property and equipment, intangible assets and goodwill, right-of-use assets, impairment of long-lived assets, lease liabilities, general and professional liabilities, workers' compensation and healthcare claims included in accrued self-insurance liabilities, and income taxes. Actual results could differ from those estimates.
Fair Value of Financial Instruments Fair Value of Financial InstrumentsThe Company’s financial instruments consist principally of cash and cash equivalents, debt security investments, accounts receivable, insurance subsidiary deposits, accounts payable and borrowings. The Company believes all of the financial instruments’ recorded values approximate fair values because of their nature or respective short durations. Contracts insuring the lives of certain employees who are eligible to participate in non-qualified deferred compensation plans are held in a rabbi trust. Cash surrender value of the contracts is based on funds that shadow the investment allocations specified by participants in the deferred compensation plan. The fair value of the investment funds is derived using Level 2 inputs.
Service and Rental Revenue Recognition Service Revenue RecognitionThe Company recognizes revenue in accordance with Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) Topic 606, Revenue from Contracts with Customers (ASC 606).Rental Revenue Recognition The Company recognizes rental revenue for operating leases on a straight-line basis over the lease term when collectability of all minimum lease payments is probable in accordance with FASB ASC Topic 842, Leases (ASC 842).
Accounts Receivable Accounts Receivable Accounts receivable consist primarily of amounts due from Medicare and Medicaid programs, other government programs, managed care health plans and private payor sources, net of estimates for variable consideration.
Property and Equipment Property and Equipment Property and equipment are initially recorded at their historical cost. Repairs and maintenance are expensed as incurred. Depreciation is computed using the straight-line method over the estimated useful lives of the depreciable assets (ranging from three to 59 years). Leasehold improvements are amortized on a straight-line basis over the shorter of their estimated useful lives or the remaining lease term.
Leases and Leasehold Improvements Leases and Leasehold Improvements The Company leases skilled nursing facilities, senior living facilities and commercial office space. The Company determines if an arrangement is a lease at the inception of each lease. Leases commencing prior to the ASC 842 adoption date were classified as operating lease under historical guidance. As the Company has elected the package of practical expedients allowing it to not reassess lease classification, these leases are classified as operating leases under ASC 842 as well. For leases commencing subsequent to the ASC 842 adoption date, the Company performs an evaluation to determine whether the lease should be classified as an operating or finance lease at the inception of the lease. As of June 30, 2022, the Company does not have any leases that are classified as finance leases. Rights and obligations of operating leases are included as right-of-use assets, current lease liabilities and long-term lease liabilities on the Company's condensed consolidated balance sheets. As the Company's leases do not provide an implicit rate, the Company uses its incremental borrowing rate based on the information available at lease commencement date in determining the present value of future lease payments. The Company utilized a third-party valuation specialist to assist in estimating the incremental borrowing rate.The Company records rent expense for operating leases on a straight-line basis over the term of the lease. The lease term used for straight-line rent expense is calculated from the date the Company is given control of the leased premises through the end of the lease term. Renewals are not assumed in the determination of the lease term unless they are deemed to be reasonably assured at the inception of the lease. The lease term used for this evaluation also provides the basis for establishing depreciable lives for buildings subject to lease and leasehold improvements.The Company's real estate leases generally have initial lease terms of ten years or more and typically include one or more options to renew, with renewal terms that generally extend the lease term for an additional ten to 15 years. Exercise of the renewal options is generally subject to the satisfaction of certain conditions which vary by contract and generally follow payment terms that are consistent with those in place during the initial term. The Company reassesses the renewal option using a "reasonably certain" threshold, which is understood to be a high threshold. For leases where the Company is reasonably certain to exercise its renewal option, the option periods are included within the lease term and, therefore, the measurement of the right-of-use asset and lease liability. The Company's leases generally contain annual escalation clauses that are either fixed or variable in nature, some of which are dependent upon published indices. The Company recognizes lease expense for leases with an initial term of 12 months or less on a straight-line basis over the lease term. These leases are not recorded on the condensed consolidated balance sheets. Certain of the Company's lease agreements include rental payments that are adjusted periodically for inflation. The lease agreements do not contain any material residual value guarantees or material restrictive covenants. The Company does not have material subleases.
Impairment of Long-Lived Assets Impairment of Long-Lived Assets The Company reviews the carrying value of long-lived assets that are held and used in the Company’s operating subsidiaries for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of these assets is determined based upon expected undiscounted future net cash flows from the operating subsidiaries to which the assets relate, utilizing management’s best estimate, appropriate assumptions, and projections at the time. If the carrying value is determined to be unrecoverable from future operating cash flows, the asset is deemed impaired and an impairment loss would be recognized to the extent the carrying value exceeded the estimated fair value of the asset. The Company estimates the fair value of assets based on the estimated future discounted cash flows of the asset.
Intangible Assets and Goodwill
Intangible Assets and Goodwill Definite-lived intangible assets consist primarily of patient base, facility trade names and customer relationships. Patient base is amortized over a period of four to eight months, depending on the classification of the patients and the level of occupancy in a new acquisition on the acquisition date. Trade names at affiliated facilities are amortized over 30 years and customer relationships are amortized over a period of up to 20 years.
The Company's indefinite-lived intangible assets consist of trade names, and Medicare and Medicaid licenses. The Company tests indefinite-lived intangible assets for impairment on an annual basis or more frequently if events or changes in circumstances indicate that the carrying amount of the intangible asset may not be recoverable.
Goodwill represents the excess of the purchase price over the fair value of identifiable net assets acquired in business combinations. Goodwill is subject to annual testing for impairment. In addition, goodwill is tested for impairment if events occur or circumstances indicate that its carrying value may not be recoverable. The Company performs its annual test for impairment during the fourth quarter of each year.
Self-Insurance
Self-Insurance — The Company is partially self-insured for general and professional liability claims up to a base amount per claim (the self-insured retention) with an aggregate, one-time deductible above this limit. Losses beyond these amounts are insured through third-party policies with coverage limits per claim, per location and on an aggregate basis for the Company. The combined self-insured retention is $500 per claim, subject to an additional one-time deductible of $1,000 for California affiliated operations and a separate, one-time, deductible of $1,250 for non-California operations. For all affiliated operations, except those located in Colorado, the third-party coverage above these limits is $1,000 per claim, $3,000 per operation, with a $5,000 blanket aggregate limit and an additional state-specific aggregate where required by state law. In Colorado, the third-party coverage above these limits is $1,000 per claim and $3,000 per operation, which is independent of the aforementioned blanket aggregate limits that apply outside of Colorado.
The majority of the self-insured retention and deductible limits for general and professional liabilities and workers' compensation liabilities are self-insured through the captive insurance subsidiary, the related assets and liabilities of which are included in the accompanying condensed consolidated balance sheets. The captive insurance subsidiary is subject to certain statutory requirements as an insurance provider.
The Company’s policy is to accrue amounts equal to the actuarial estimated costs to settle open claims of insureds, as well as an estimate of the cost of insured claims that have been incurred but not reported. The Company develops information about the size of the ultimate claims based on historical experience, current industry information and actuarial analysis, and evaluates the estimates for claim loss exposure on a quarterly basis. The Company uses actuarial valuations to estimate the liability based on historical experience and industry information. Accrued general liability and professional malpractice liabilities on an undiscounted basis, net of anticipated insurance recoveries, were $76,145 and $66,158 as of June 30, 2022 and December 31, 2021, respectively.
The Company’s operating subsidiaries are self-insured for workers’ compensation liabilities in California. To protect itself against loss exposure in California with this policy, the Company has purchased individual specific excess insurance coverage that insures individual claims that exceed $625 per occurrence. In Texas, the operating subsidiaries have elected non-subscriber status for workers’ compensation claims and the Company has purchased individual stop-loss coverage that insures individual claims that exceed $750 per occurrence. The Company’s operating subsidiaries in all other states, with the exception of Washington, are under a loss sensitive plan that insures individual claims that exceed $350 per occurrence. In the state of Washington, the Company is self insured and has purchased individual specific excess insurance coverage that insures individual claims that exceed $500 per occurrence. For all of the self insured plans and retention, the Company accrues amounts equal to the estimated costs to settle open claims, as well as an estimate of the cost of claims that have been incurred but not reported. The Company uses actuarial valuations to estimate the liability based on historical experience and industry information. Accrued workers’ compensation liabilities are recorded on an undiscounted basis in the accompanying condensed consolidated balance sheets and were $28,365 and $27,335 as of June 30, 2022 and December 31, 2021, respectively.
In addition, the Company has recorded an asset and equal liability of $8,440 and $6,755 as of June 30, 2022 and December 31, 2021, respectively, in order to present the ultimate costs of malpractice and workers' compensation claims and the anticipated insurance recoveries on a gross basis. See Note 13, Restricted and Other Assets.
The Company self-funds medical (including prescription drugs) and dental healthcare benefits to the majority of its employees. The Company is fully liable for all financial and legal aspects of these benefit plans. To protect itself against loss exposure with this policy, the Company has purchased individual stop-loss insurance coverage that insures individual claims that exceed $525 for each covered person for fiscal year 2022. The Company’s accrued liability under these plans recorded on an undiscounted basis in the accompanying condensed consolidated balance sheets was $13,571 and $9,891 as of June 30, 2022 and December 31, 2021, respectively.
The Company believes that adequate provision has been made in the Interim Financial Statements for liabilities that may arise out of patient care, workers’ compensation, healthcare benefits and related services provided to date. The amount of the Company’s reserves was determined based on an estimation process that uses information obtained from both company-specific and industry data. This estimation process requires the Company to continuously monitor and evaluate the life cycle of the claims. Using data obtained from this monitoring and the Company’s assumptions about emerging trends, the Company, with the assistance of an independent actuary, develops information about the size of ultimate claims based on the Company’s historical experience and other available industry information. The most significant assumptions used in the estimation process include determining the trend in costs, the expected cost of claims incurred but not reported and the expected costs to settle or pay damage awards with respect to unpaid claims. The self-insured liabilities are based upon estimates, and while management believes that the estimates of loss are reasonable, the ultimate liability may be in excess of or less than the recorded amounts. Due to the inherent volatility of actuarially determined loss estimates, it is reasonably possible that the Company could experience changes in estimated losses that could be material to net income. If the Company’s actual liabilities exceed its estimates of losses, its future earnings, cash flows and financial condition would be adversely affected.
Income Taxes
Income Taxes — Deferred tax assets and liabilities are established for temporary differences between the financial reporting basis and the tax basis of the Company’s assets and liabilities at tax rates in effect when such temporary differences are expected to reverse. The Company generally expects to fully utilize its deferred tax assets; however, when necessary, the Company records a valuation allowance to reduce its net deferred tax assets to the amount that is more likely than not to be realized.
In determining the need for a valuation allowance or the need for and magnitude of liabilities for uncertain tax positions, the Company makes certain estimates and assumptions. These estimates and assumptions are based on, among other things, knowledge of operations, markets, historical trends and likely future changes and, when appropriate, the opinions of advisors with knowledge and expertise in certain fields. Due to certain risks associated with the Company’s estimates and assumptions, actual results could differ.
Noncontrolling Interest Noncontrolling Interest The noncontrolling interest in a subsidiary is initially recognized at estimated fair value on the acquisition date and is presented within total equity in the Company's condensed consolidated balance sheets. The Company presents the noncontrolling interest and the amount of consolidated net income attributable to The Ensign Group, Inc. in its condensed consolidated statements of income. Net income per share is calculated based on net income attributable to The Ensign Group, Inc.'s stockholders. The carrying amount of the noncontrolling interest is adjusted based on an allocation of subsidiary earnings based on ownership interest.
Stock-Based Compensation Stock-Based CompensationThe Company measures and recognizes compensation expense for all stock-based payment awards made to employees and directors including employee stock options based on estimated fair values, ratably over the requisite service period of the award. Net income has been reduced as a result of the recognition of the fair value of all stock options and restricted stock awards issued, the amount of which is contingent upon the number of future grants and other variables.
Recent Accounting Pronouncements
Recent Accounting Pronouncements Except for rules and interpretive releases of the Securities and Exchange Commission (SEC) under authority of federal securities laws and a limited number of grandfathered standards, the FASB ASC is the sole source of authoritative GAAP literature recognized by the FASB and applicable to the Company. For any new pronouncements announced, the Company considers whether the new pronouncements could alter previous generally accepted accounting principles and determines whether any new or modified principles will have a material impact on the Company's reported financial position or operations in the near term. The applicability of any standard is subject to the formal review of the Company's financial management and certain standards are under consideration.

Recent Accounting Standards Adopted by the Company In November 2021, the FASB issued ASU 2021-10 “Government Assistance (Topic 832): Disclosures by Business Entities about Government Assistance,” which created FASB ASC Topic 832, Government Assistance (ASC 832). ASC 832 requires business entities to disclose information about certain government assistance they receive. The Company adopted this standard on January 1, 2022 and determined there was no material impact on the Company's condensed consolidated financial statements.
Accounting Standards Recently Issued but Not Yet Adopted by the Company In February 2020, the FASB issued ASU 2020-04 "Reference Rate Reform (Topic 848)," which provides temporary, optional practical expedients and exceptions to enable a smoother transition to reference rates which are expected to replace London Interbank Offered Rate (LIBOR) reference rates. Adoption of the provisions of ASU 2020-04 is optional. The amendments are effective for all entities from the beginning of the interim period that includes the issuance date of the ASU. An entity may elect to apply the amendments prospectively through December 31, 2022. During the quarter ended June 30, 2022, the Company and its subsidiaries including Standard Bearer, entered into the Second Amendment to Third Amended and Restated Credit Agreement (such agreement, the Amended Credit Agreement, and the revolving credit facility thereunder, the Revolving Credit Facility), which increased the Revolving Credit Facility by $250,000 to an aggregate principal amount of up to $600,000. Pursuant to the Amended Credit Agreement, the Company transitioned from LIBOR to the Secured Overnight Financing Rate (SOFR) as the applicable reference rate for borrowings under the Revolving Credit Facility and determined there was no resulting material impact on the Company's condensed consolidated financial statements.
XML 40 R29.htm IDEA: XBRL DOCUMENT v3.22.2
Revenue and Accounts Receivable (Tables)
6 Months Ended
Jun. 30, 2022
Revenue from Contract with Customer [Abstract]  
Disaggregation of Revenue
Service revenue for the three and six months ended June 30, 2022 and 2021 is summarized in the following tables:
 Three Months Ended June 30,
20222021
Revenue% of RevenueRevenue% of Revenue
Medicaid(1)
$294,128 40.4 %$251,455 39.6 %
Medicare190,494 26.2 170,008 26.8 
Medicaid — skilled49,763 6.8 42,740 6.7 
Total Medicaid and Medicare534,385 73.4 464,203 73.1 
Managed care128,587 17.7 112,963 17.8 
Private and other(2)
65,375 8.9 57,443 9.1 
SERVICE REVENUE$728,347 100.0 %$634,609 100.0 %
(1) Medicaid payor includes revenue for senior living operations and revenue related to FMAP.
(2) Private and other payors also includes revenue from senior living operations and all payors generated in other ancillary services.
 Six Months Ended June 30,
20222021
Revenue% of RevenueRevenue% of Revenue
Medicaid(1)
$560,476 39.0 %$482,813 38.4 %
Medicare398,905 27.7 360,311 28.6 
Medicaid — skilled95,712 6.7 82,733 6.6 
Total Medicaid and Medicare1,055,093 73.4 925,857 73.6 
Managed care256,373 17.8 221,308 17.6 
Private and other(2)
126,037 8.8 110,720 8.8 
SERVICE REVENUE$1,437,503 100.0 %$1,257,885 100.0 %
(1) Medicaid payor includes revenue for senior living operations and revenue related to FMAP.
(2) Private and other payors also includes revenue from senior living operations and all payors generated in other ancillary services.
Schedule of Accounts, Notes, Loans and Financing Receivable
Accounts receivable as of June 30, 2022 and December 31, 2021, is summarized in the following table:
June 30, 2022December 31, 2021
Medicaid$125,348 $123,647 
Managed care86,995 79,722 
Medicare58,067 59,797 
Private and other payors76,418 76,778 
 346,828 339,944 
Less: allowance for doubtful accounts(7,827)(11,213)
ACCOUNTS RECEIVABLE, NET$339,001 $328,731 
XML 41 R30.htm IDEA: XBRL DOCUMENT v3.22.2
Computation of Net Income Per Common Share (Tables)
6 Months Ended
Jun. 30, 2022
Earnings Per Share [Abstract]  
Schedule of Earnings Per Share, Basic, by Common Class, Including Two Class Method
A reconciliation of the numerator and denominator used in the calculation of basic net income per common share follows:

Three Months Ended June 30,Six Months Ended June 30,
 2022202120222021
NUMERATOR:  
Net income$57,803 $50,583 $107,891 $100,420 
Less: net (loss) income attributable to noncontrolling interests 112 1,158 (140)1,789 
Net income attributable to The Ensign Group, Inc. $57,691 $49,425 $108,031 $98,631 
DENOMINATOR: 
Weighted average shares outstanding for basic net income per share54,906 54,468 54,788 54,331 
Basic net income per common share:$1.05 $0.91 $1.97 $1.82 
Schedule of Earnings Per Share, Diluted, by Common Class, Including Two Class Method
A reconciliation of the numerator and denominator used in the calculation of diluted net income per common share follows:

Three Months Ended June 30,Six Months Ended June 30,
 2022202120222021
NUMERATOR:  
Net income $57,803 $50,583 $107,891 $100,420 
Less: net (loss) income attributable to noncontrolling interests112 1,158 (140)1,789 
Net income attributable to The Ensign Group, Inc. $57,691 $49,425 $108,031 $98,631 
DENOMINATOR:  
Weighted average common shares outstanding54,906 54,468 54,788 54,331 
Plus: incremental shares from assumed conversion (1)
1,947 2,529 2,074 2,614 
Adjusted weighted average common shares outstanding56,853 56,997 56,862 56,945 
Diluted net income per common share:$1.01 $0.87 $1.90 $1.73 
(1) Options outstanding which are anti-dilutive and therefore not factored into the weighted average common shares amount above were 789 and 697 for the three and six months ended June 30, 2022, respectively, and 167 and 80 for the three and six months ended June 30, 2021, respectively.
XML 42 R31.htm IDEA: XBRL DOCUMENT v3.22.2
Business Segments (Tables)
6 Months Ended
Jun. 30, 2022
Segment Reporting [Abstract]  
Schedule of Segment Reporting Information, by Segment
The following tables set forth financial information for the segments:
 Three Months Ended June 30, 2022
 Skilled ServicesStandard Bearer
All Other(1)
Intercompany EliminationTotal
Service revenue(2)
$702,478 $— $28,787 $(2,918)$728,347 
Rental revenue(3)
— 17,598 1,832 (15,291)4,139 
TOTAL REVENUE$702,478 $17,598 $30,619 $(18,209)$732,486 
Segment income (loss)102,266 6,838 (38,614)— 70,490 
Gain on sale of assets2,467 
Income before provision for income taxes $72,957 
Depreciation and amortization8,113 5,216 1,529 — 14,858 
Interest expense(4)
$— $3,743 $889 $(1,944)$2,688 
(1) All other primarily includes all ancillary operations, stand-alone senior living operations and the Service Center.
(2) Intercompany service revenue represents service revenue generated by ancillary operations provided to the Company's affiliated wholly-owned healthcare facilities and management service revenue generated by the Service Center with Standard Bearer. Intercompany service revenue is eliminated in consolidation along with corresponding intercompany cost of service.
(3) Intercompany rental revenue represents rental income generated by both Standard Bearer and other real estate properties with the Company's affiliated wholly-owned healthcare facilities. Intercompany rental revenue is eliminated in consolidation along with corresponding intercompany rent expense.
(4) Included in interest expense in Standard Bearer is interest expense incurred from intercompany debt arrangements between Standard Bearer and The Ensign Group, Inc. The intercompany interest expense is eliminated in the "Intercompany Elimination" column.

 Three Months Ended June 30, 2021
 Skilled ServicesStandard Bearer
All Other(1)
Intercompany EliminationTotal
Service revenue(2)
$612,882 $— $23,428 $(1,701)$634,609 
Rental revenue(3)
— 14,214 1,817 (12,104)3,927 
TOTAL REVENUE$612,882 $14,214 $25,245 $(13,805)$638,536 
Segment income (loss)90,010 7,906 (33,575)— 64,341 
Income before provision for income taxes $64,341 
Depreciation and amortization7,703 4,248 1,844 — 13,795 
Interest expense$— $1,634 $— $1,634 
(1) All other primarily includes all ancillary operations, stand-alone senior living operations and the Service Center.
(2) Intercompany service revenue represents service revenue generated by ancillary operations provided to the Company's affiliated wholly-owned healthcare facilities. Intercompany service revenue is eliminated in consolidation along with corresponding intercompany cost of service.
(3) Intercompany rental revenue represents rental income generated by both Standard Bearer and other real estate properties with the Company's affiliated wholly-owned healthcare facilities. Intercompany rental revenue is eliminated in consolidation along with corresponding intercompany rent expense.

 Six Months Ended June 30, 2022
 Skilled ServicesStandard Bearer
All Other(1)
Intercompany EliminationTotal
Service revenue(2)
$1,389,249 $— $54,254 $(6,000)$1,437,503 
Rental revenue(3)
— 34,791 3,695 (30,058)8,428 
TOTAL REVENUE$1,389,249 $34,791 $57,949 $(36,058)$1,445,931 
Segment income (loss)200,522 13,738 (77,544)— 136,716 
Gain on sale of assets2,467 
Income before provision for income taxes$139,183 
Depreciation and amortization16,014 10,237 3,283 — 29,534 
Interest expense(4)
$— $7,305 $1,247 $(3,796)$4,756 
(1) All other primarily includes all ancillary operations, stand-alone senior living operations and the Service Center.
(2) Intercompany service revenue represents service revenue generated by ancillary operations provided to the Company's affiliated wholly-owned healthcare facilities and management service revenue generated by the Service Center with Standard Bearer. Intercompany service revenue is eliminated in consolidation along with corresponding intercompany cost of service.
(3) Intercompany rental revenue represents rental income generated by both Standard Bearer and other real estate properties with the Company's affiliated wholly-owned healthcare facilities. Intercompany rental revenue is eliminated in consolidation along with corresponding intercompany rent expense.
(4) Included in interest expense in Standard Bearer is interest expense incurred from intercompany debt arrangements between Standard Bearer and The Ensign Group, Inc. The intercompany interest expense is eliminated in the "Intercompany Elimination" column.
 Six Months Ended June 30, 2021
 Skilled ServicesStandard Bearer
All Other(1)
Intercompany EliminationTotal
Service revenue(2)
$1,213,918 $— $47,347 $(3,380)$1,257,885 
Rental revenue(3)
— 28,283 3,627 (24,006)7,904 
TOTAL REVENUE$1,213,918 $28,283 $50,974 $(27,386)$1,265,789 
Segment income (loss)178,941 15,619 (67,873)— 126,687 
Gain on sale of assets440 
Income before provision for income taxes$127,127 
Depreciation and amortization15,178 8,403 3,873 — 27,454 
Interest expense$— $3,275 $— $— $3,275 
(1) All other primarily includes all ancillary operations, stand-alone senior living operations and the Service Center.
(2) Intercompany service revenue represents service revenue generated by ancillary operations provided to the Company's affiliated wholly-owned healthcare facilities. Intercompany service revenue is eliminated in consolidation along with corresponding intercompany cost of service.
(3) Intercompany rental revenue represents rental income generated by both Standard Bearer and other real estate properties with the Company's affiliated wholly-owned healthcare facilities. Intercompany rental revenue is eliminated in consolidation along with corresponding intercompany rent expense.
Reconciliation of Revenue from Segments to Consolidated
Service revenue by major payor source were as follows:
 Three Months Ended June 30, 2022
 Skilled ServicesAll OtherTotal Service RevenueRevenue %
Medicaid(1)
$287,827 $6,301 $294,128 40.4 %
Medicare190,494 — 190,494 26.2 
Medicaid-skilled49,763 — 49,763 6.8 
Subtotal528,084 6,301 534,385 73.4 
Managed care128,587 — 128,587 17.7 
Private and other(2)
45,807 19,568 65,375 8.9 
TOTAL SERVICE REVENUE$702,478 $25,869 $728,347 100.0 %
(1) Medicaid payor includes revenue generated from senior living operations and revenue related to FMAP.
(2) Private and other payors also includes revenue from senior living operations and all payors generated in other ancillary services.

 Three Months Ended June 30, 2021
 Skilled ServicesAll OtherTotal Service RevenueRevenue %
Medicaid(1)
$247,671 $3,784 $251,455 39.6 %
Medicare170,008 — 170,008 26.8 
Medicaid-skilled42,740 — 42,740 6.7 
Subtotal460,419 3,784 464,203 73.1 
Managed care112,963 — 112,963 17.8 
Private and other(2)
39,500 17,943 57,443 9.1 
TOTAL SERVICE REVENUE$612,882 $21,727 $634,609 100.0 %
(1) Medicaid payor includes revenue generated from senior living operations and revenue related to FMAP.
(2) Private and other payors also includes revenue from senior living operations and all payors generated in other ancillary services.
 Six Months Ended June 30, 2022
 Skilled ServicesOther Service Revenue Total Service RevenueRevenue %
Medicaid(1)
$549,414 $11,062 $560,476 39.0 %
Medicare398,905 — 398,905 27.7 
Medicaid-skilled95,712 — 95,712 6.7 
Subtotal1,044,031 11,062 1,055,093 73.4 
Managed care256,373 — 256,373 17.8 
Private and other(2)
88,845 37,192 126,037 8.8 
TOTAL SERVICE REVENUE$1,389,249 $48,254 $1,437,503 100.0 %
(1) Medicaid payor includes revenue generated from senior living operations and revenue related to FMAP.
(2) Private and other payors also includes revenue from senior living operations and all payors generated in other ancillary services.

 Six Months Ended June 30, 2021
 Skilled ServicesOther Service Revenue Total Service RevenueRevenue %
Medicaid(1)
$475,412 $7,401 $482,813 38.4 %
Medicare360,311 — 360,311 28.6 
Medicaid-skilled82,733 — 82,733 6.6 
Subtotal918,456 7,401 925,857 73.6 
Managed care221,308 — 221,308 17.6 
Private and other(2)
74,154 36,566 110,720 8.8 
TOTAL SERVICE REVENUE$1,213,918 $43,967 $1,257,885 100.0 %
(1) Medicaid payor includes revenue generated from senior living operations and revenue related to FMAP.
(2) Private and other payors also includes revenue from senior living operations and all payors generated in other ancillary services.
XML 43 R32.htm IDEA: XBRL DOCUMENT v3.22.2
Property and Equipment — Net (Tables)
6 Months Ended
Jun. 30, 2022
Property, Plant and Equipment [Abstract]  
Schedule of Property and Equipment Property and equipment, net consists of the following:
June 30, 2022December 31, 2021
Land$121,381 $121,164 
Buildings and improvements669,215 646,221 
Leasehold improvements145,522 140,012 
Equipment279,231 262,246 
Furniture and fixtures4,373 4,305 
Construction in progress11,000 10,253 
 1,230,722 1,184,201 
Less: accumulated depreciation(322,494)(295,767)
PROPERTY AND EQUIPMENT, NET$908,228 $888,434 
XML 44 R33.htm IDEA: XBRL DOCUMENT v3.22.2
Intangible Assets — Net (Tables)
6 Months Ended
Jun. 30, 2022
Intangible Assets, Net (Excluding Goodwill) [Abstract]  
Schedule of Finite-Lived Intangible Assets
 June 30, 2022December 31, 2021
Weighted Average Life (Years)
Gross Carrying AmountAccumulated AmortizationGross Carrying AmountAccumulated Amortization
Intangible AssetsNetNet
Assembled occupancy0.4$196 $(196)$— $68 $(68)$— 
Facility trade name30.0733 (403)330 733 (391)342 
Customer relationships18.44,582 (2,377)2,205 4,582 (2,272)2,310 
TOTAL $5,511 $(2,976)$2,535 $5,383 $(2,731)$2,652 
Schedule of Finite-Lived Intangible Assets, Future Amortization Expense Estimated amortization expense for each of the years ending December 31 is as follows:
YearAmount
2022 (remainder)$117 
2023234 
2024234 
2025234 
2026234 
2027234 
Thereafter1,248 
 $2,535 
XML 45 R34.htm IDEA: XBRL DOCUMENT v3.22.2
Goodwill and Other Indefinite-Lived Intangible Assets (Tables)
6 Months Ended
Jun. 30, 2022
Goodwill and Intangible Assets Disclosure [Abstract]  
Schedule of Goodwill The following table represents activity in goodwill by skilled service segment and "all other" category as of and for the six months ended June 30, 2022:
Goodwill
 Skilled ServicesAll OtherTotal
January 1, 2022$51,486 $8,983 $60,469 
Additions16,400 — 16,400 
June 30, 2022$67,886 $8,983 $76,869 
Schedule of Other Indefinite-lived Intangible Assets by Major Class
Other indefinite-lived intangible assets consist of the following:
June 30, 2022December 31, 2021
Trade name$889 $889 
Medicare and Medicaid licenses2,918 2,838 
TOTAL$3,807 $3,727 
XML 46 R35.htm IDEA: XBRL DOCUMENT v3.22.2
Restricted and Other Assets (Tables)
6 Months Ended
Jun. 30, 2022
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]  
Schedule of Restricted and Other Assets Restricted and other assets consist of the following:
June 30, 2022December 31, 2021
Debt issuance costs, net$4,195 $1,953 
Long-term insurance losses recoverable asset8,440 6,755 
Deposits with landlords14,725 13,705 
Capital improvement reserves with landlords and lenders6,499 7,103 
Deferred compensation plan investments23,151 17,530 
RESTRICTED AND OTHER ASSETS$57,010 $47,046 
XML 47 R36.htm IDEA: XBRL DOCUMENT v3.22.2
Other Accrued Liabilities (Tables)
6 Months Ended
Jun. 30, 2022
Payables and Accruals [Abstract]  
Schedule of Other Accrued Liabilities Other accrued liabilities consists of the following:
June 30, 2022December 31, 2021
Quality assurance fee$6,669 $6,474 
Refunds payable36,912 34,814 
Resident advances6,273 9,337 
Unapplied state relief funds4,356 1,781 
Cash held in trust for patients5,757 6,430 
Dividends payable3,040 3,035 
Property taxes7,670 9,124 
Legal finding accrued3,626 — 
Other11,490 18,415 
OTHER ACCRUED LIABILITIES$85,793 $89,410 
XML 48 R37.htm IDEA: XBRL DOCUMENT v3.22.2
Debt (Tables)
6 Months Ended
Jun. 30, 2022
Debt Disclosure [Abstract]  
Schedule of Long-term Debt
Debt consists of the following:
June 30, 2022December 31, 2021
Mortgage loans and promissory notes$158,258 $159,967 
Less: current maturities(3,944)(3,760)
Less: debt issuance costs, net(3,209)(3,324)
LONG-TERM DEBT LESS CURRENT MATURITIES$151,105 $152,883 
XML 49 R38.htm IDEA: XBRL DOCUMENT v3.22.2
Options and Awards (Tables)
6 Months Ended
Jun. 30, 2022
Share-Based Payment Arrangement [Abstract]  
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions The Company used the following assumptions for stock options granted during the three months ended June 30, 2022 and 2021:
Grant YearOptions GrantedWeighted Average Risk-Free RateExpected LifeWeighted Average VolatilityWeighted Average Dividend Yield
20221542.7%6.1 years42.1%0.3%
20212091.0%6.3 years42.3%0.3%
The Company used the following assumptions for stock options granted during the six months ended June 30, 2022 and 2021:
Grant YearOptions GrantedWeighted Average Risk-Free RateExpected LifeWeighted Average VolatilityWeighted Average Dividend Yield
20223182.3%6.1 years42.2%0.3%
20213450.9%6.3 years42.2%0.2%
Schedule of Weighted Average Grant Date Fair Value and Exercise Price of Options
For the six months ended June 30, 2022 and 2021, the following represents the exercise price and fair value displayed at grant date for stock option grants:
Grant YearGrantedWeighted Average Exercise PriceWeighted Average Fair Value of Options
2022318$80.18 $34.29 
2021345$82.77 $33.86 
The weighted average exercise price equaled the weighted average fair value of common stock on the grant date for all options granted during the periods ended June 30, 2022 and 2021 and therefore, the intrinsic value was $0 at the date of grant.
Schedule of Common Stock Outstanding Roll Forward
The following table represents the employee stock option activity during the six months ended June 30, 2022:
Number of Options OutstandingWeighted Average
Exercise Price
Number of
Options Vested
Weighted Average Exercise Price of Options Vested
January 1, 20224,038 $36.60 2,183 $21.02 
Granted318 80.18 — — 
Forfeited(68)57.40 — — 
Exercised(370)16.40 — — 
June 30, 20223,918 $41.69 2,151 $25.53 
Share-based Payment Arrangement, Option, Exercise Price Range
The following summary information reflects stock options outstanding, vested and related details as of June 30, 2022:
Stock Options OutstandingStock Options Vested
 
Number OutstandingBlack-Scholes Fair ValueRemaining Contractual Life (Years)Vested and Exercisable
Year of GrantExercise Price
2012$5.56-$6.7510 $32 010 
20136.76-9.74125 476 1125 
20148.94-16.05457 2,204 2457 
201518.20-21.39246 1,910 3246 
201615.93-16.86233 1,377 4233 
201715.80-19.41267 1,583 5236 
201822.49-32.71496 4,806 6326 
201941.07-45.76615 9,651 7292 
202044.84-59.49569 11,205 8162 
202173.47-83.64586 19,222 964 
2022$79.79$80.60314 10,782 10— 
TOTAL 3,918 $63,248  2,151 
Schedule of Aggregate Intrinsic Value of Options
The aggregate intrinsic value of options outstanding, vested and expected to vest as of June 30, 2022 and December 31, 2021 is as follows:
OptionsJune 30, 2022December 31, 2021
Outstanding$130,564 $191,242 
Vested103,713 137,382 
Expected to vest24,561 48,548 
Schedule of Nonvested Restricted Stock Units Activity
A summary of the status of the Company's non-vested restricted stock awards as of June 30, 2022 and changes during the six months ended June 30, 2022 is presented below:
Non-Vested Restricted AwardsWeighted Average Grant Date Fair Value
Non-vested at January 1, 2022549 $52.16 
Granted158 77.06 
Vested(199)54.74 
Forfeited(16)55.86 
Non-vested at June 30, 2022492 $59.01 
Schedule of Stock-Based Compensation Expense
Stock-based compensation expense recognized for the Company's equity incentive plans and long-term incentive plan for the three and six months ended June 30, 2022 and 2021 was as follows:

Three Months Ended June 30,Six Months Ended June 30,
 2022202120222021
Stock-based compensation expense related to stock options$2,786 $2,026 $5,306 $3,759 
Stock-based compensation expense related to restricted stock awards2,456 2,076 4,758 3,914 
Stock-based compensation expense related to stock options and restricted stock awards to non-employee directors374 531 719 1,014 
TOTAL$5,616 $4,633 $10,783 $8,687 
XML 50 R39.htm IDEA: XBRL DOCUMENT v3.22.2
Leases (Tables)
6 Months Ended
Jun. 30, 2022
Leases [Abstract]  
Schedule of Operating Lease Expenses
The components of operating lease expense are as follows:
Three Months Ended June 30,Six Months Ended June 30,
2022202120222021
Rent - cost of services(1)
$37,228 $34,455 $72,990 $67,911 
General and administrative expense23 21 46 41 
Depreciation and amortization(2)
288 290 577 580 
Variable lease costs(3)
3,772 3,694 9,135 7,137 
$41,311 $38,460 $82,748 $75,669 
(1)Rent- cost of services includes deferred rent expense adjustments of $116 and $240 for the three and six months ended June 30, 2022, respectively and $109 and $221 for the three and six months ended June 30, 2021, respectively. Additionally, rent- cost of services includes other variable lease costs such as CPI increases and short-term leases of $1,302 and $2,239 for the three and six months ended June 30, 2022, respectively, and $832 and $1,416 for the three and six months ended June 30, 2021, respectively.
(2)Depreciation and amortization is related to the amortization of favorable and direct lease costs.
(3)Variable lease costs, including property taxes and insurance, are classified in cost of services in the Company's condensed consolidated statements of income.
Schedule of Future Minimum Lease Payments
Future minimum lease payments for all leases as of June 30, 2022 are as follows:
YearAmount
2022 (remainder)$71,530 
2023141,887 
2024141,296 
2025141,187 
2026141,082 
2027140,564 
Thereafter1,254,424 
TOTAL LEASE PAYMENTS2,031,970 
Less: present value adjustment (756,866)
PRESENT VALUE OF TOTAL LEASE LIABILITIES1,275,104 
Less: current lease liabilities(58,769)
LONG-TERM OPERATING LEASE LIABILITIES$1,216,335 
Schedule of Rental Income from Third-Party Sources
Total rental income from all third-party sources for the three and six months ended June 30, 2022 and 2021 is as follows:

Three Months Ended June 30,Six Months Ended June 30,
2022202120222021
Pennant(1)
$3,690 $3,440 $7,505 $6,928 
Other third-party449 487 923 976 
$4,139 $3,927 $8,428 $7,904 
(1) Pennant rental income includes variable rent such as property taxes of $327 and $657 during the three and six months ended June 30, 2022 and $266 and $580 for the three and six months ended June 30, 2021.
Schedule of Annual Rental Income
Future annual rental income for all leases as of June 30, 2022 were as follows:
Year
Amount(1)
2022 (remainder)$8,098 
202315,820 
202415,373 
202515,032 
202614,821 
202714,821 
Thereafter77,369 
TOTAL$161,334 
(1) Annual rental income includes base rents and variable rental income pursuant to existing leases as of June 30, 2022.
XML 51 R40.htm IDEA: XBRL DOCUMENT v3.22.2
Description of Business (Details)
seniorLivingUnit in Thousands
Jun. 30, 2022
facility
Jun. 30, 2022
bed
Jun. 30, 2022
seniorLivingUnit
Jun. 30, 2022
seniorLivingCommunity
Jun. 30, 2022
operation
Jun. 30, 2021
bed
Oct. 31, 2019
operation
Restructuring Cost and Reserve [Line Items]              
Health care facilities 251            
Operational skilled nursing beds | bed   25,500          
Operational senior living units | seniorLivingUnit     3        
Number of real estate properties leased 180            
Number of real estate properties leased with an option to purchase 11            
Number of real estate properties 100            
Skilled Nursing Operations              
Restructuring Cost and Reserve [Line Items]              
Operational skilled nursing beds | bed   453       1,263  
Owned Properties              
Restructuring Cost and Reserve [Line Items]              
Number of real estate properties 71            
Spinoff | Senior Living Facilities              
Restructuring Cost and Reserve [Line Items]              
Number of real estate properties | operation         1    
Spinoff | Senior Living Facilities | The Pennant Group, Inc.              
Restructuring Cost and Reserve [Line Items]              
Number of real estate properties       29 3   29
XML 52 R41.htm IDEA: XBRL DOCUMENT v3.22.2
Summary of Significant Accounting Policies - Property and Equipment (Details)
6 Months Ended
Jun. 30, 2022
Minimum  
Property, Plant and Equipment [Line Items]  
Property, plant and equipment, useful life 3 years
Maximum  
Property, Plant and Equipment [Line Items]  
Property, plant and equipment, useful life 59 years
XML 53 R42.htm IDEA: XBRL DOCUMENT v3.22.2
Summary of Significant Accounting Policies - Leases and Leasehold Improvements (Details)
Jun. 30, 2022
Real Estate Properties [Line Items]  
Lessee, operating lease, term of contract 10 years
Minimum  
Real Estate Properties [Line Items]  
Lessee, operating lease, renewal term 10 years
Maximum  
Real Estate Properties [Line Items]  
Lessee, operating lease, renewal term 15 years
XML 54 R43.htm IDEA: XBRL DOCUMENT v3.22.2
Summary of Significant Accounting Policies - Impairment of Long-Lived Assets (Details) - USD ($)
3 Months Ended 6 Months Ended
Jun. 30, 2022
Jun. 30, 2021
Jun. 30, 2022
Jun. 30, 2021
Accounting Policies [Abstract]        
Impairment of long lived assets $ 0 $ 0 $ 0 $ 0
XML 55 R44.htm IDEA: XBRL DOCUMENT v3.22.2
Summary of Significant Accounting Policies - Intangible Assets and Goodwill (Details) - USD ($)
3 Months Ended 6 Months Ended
Jun. 30, 2022
Jun. 30, 2021
Jun. 30, 2022
Jun. 30, 2021
Finite-Lived Intangible Assets [Line Items]        
Goodwill and intangible asset impairment $ 0 $ 0 $ 0 $ 0
Facility trade name        
Finite-Lived Intangible Assets [Line Items]        
Finite-lived intangible asset, useful life     30 years  
Customer relationships        
Finite-Lived Intangible Assets [Line Items]        
Finite-lived intangible asset, useful life     20 years  
Minimum | Assembled occupancy        
Finite-Lived Intangible Assets [Line Items]        
Finite-lived intangible asset, useful life     4 months  
Maximum | Assembled occupancy        
Finite-Lived Intangible Assets [Line Items]        
Finite-lived intangible asset, useful life     8 months  
XML 56 R45.htm IDEA: XBRL DOCUMENT v3.22.2
Summary of Significant Accounting Policies - Self-Insurance (Details) - USD ($)
$ in Thousands
Jun. 30, 2022
Dec. 31, 2021
Liability for Claims and Claims Adjustment Expense [Line Items]    
Long-term insurance losses recoverable asset $ 8,440 $ 6,755
General and Professional Liability    
Liability for Claims and Claims Adjustment Expense [Line Items]    
Malpractice loss contingency, accrual, undiscounted 76,145 66,158
Workers' Compensation    
Liability for Claims and Claims Adjustment Expense [Line Items]    
Self insurance reserve 28,365 27,335
Health    
Liability for Claims and Claims Adjustment Expense [Line Items]    
Self insurance reserve 13,571 $ 9,891
Workers' Compensation    
Liability for Claims and Claims Adjustment Expense [Line Items]    
Self insurance reserve 625  
Workers' Compensation | TEXAS    
Liability for Claims and Claims Adjustment Expense [Line Items]    
Self insurance reserve 750  
Self-Insurance Retention Per Claim | General Liability    
Liability for Claims and Claims Adjustment Expense [Line Items]    
Self insurance reserve 500  
Loss-Sensitive Limit Per Claim | Workers' Compensation | Other States, Except California, Texas and Washington    
Liability for Claims and Claims Adjustment Expense [Line Items]    
Self insurance reserve 350  
Stop-Loss Insurance Limit Per Claim | Health Liability Insurance    
Liability for Claims and Claims Adjustment Expense [Line Items]    
Self insurance reserve 525  
Parent Company | Self-Insurance Retention Per Claim | General Liability    
Liability for Claims and Claims Adjustment Expense [Line Items]    
Self insurance reserve 500  
Parent Company | Aggregate Deductible | General Liability | California    
Liability for Claims and Claims Adjustment Expense [Line Items]    
Self insurance reserve 1,000  
Parent Company | Aggregate Deductible | General Liability | Non-California    
Liability for Claims and Claims Adjustment Expense [Line Items]    
Self insurance reserve 1,250  
Third-Party Payor | Per Occurence | General Liability | All States Except Colorado    
Liability for Claims and Claims Adjustment Expense [Line Items]    
Self insurance reserve 1,000  
Third-Party Payor | Per Occurence | General Liability | Colorado    
Liability for Claims and Claims Adjustment Expense [Line Items]    
Self insurance reserve 1,000  
Third-Party Payor | Per Facility | General Liability | All States Except Colorado    
Liability for Claims and Claims Adjustment Expense [Line Items]    
Self insurance reserve 3,000  
Third-Party Payor | Per Facility | General Liability | Colorado    
Liability for Claims and Claims Adjustment Expense [Line Items]    
Self insurance reserve 3,000  
Third-Party Payor | Blanket Aggregate | General Liability | All States Except Colorado    
Liability for Claims and Claims Adjustment Expense [Line Items]    
Self insurance reserve $ 5,000  
XML 57 R46.htm IDEA: XBRL DOCUMENT v3.22.2
Summary of Significant Accounting Policies - Recent Accounting Pronouncements (Details) - Revolving credit facility with Truist - Truist - USD ($)
3 Months Ended
Jun. 30, 2022
Apr. 08, 2022
Oct. 01, 2019
Debt Instrument [Line Items]      
Letter of credit increase $ 250,000,000    
Line of credit facility, maximum borrowing capacity   $ 600,000,000 $ 350,000,000
XML 58 R47.htm IDEA: XBRL DOCUMENT v3.22.2
COVID-19 Update (Details) - USD ($)
$ in Thousands
1 Months Ended 3 Months Ended 6 Months Ended 12 Months Ended
Mar. 31, 2021
Jun. 30, 2022
Jun. 30, 2021
Jun. 30, 2022
Jun. 30, 2021
Dec. 31, 2020
Dec. 31, 2021
Unusual or Infrequent Items, or Both [Abstract]              
Coronavirus Aid, Relief, and Economic Security (“CARES”) funds received and returned   $ 0 $ 2,399 $ 0 $ 11,538    
Repayments of CARES Act Provider Relief Fund and Medicare Advance Payment Program (Note 3)       0 113,561    
Medicare Accelerated and Advance Payment           $ 105,255  
Repayment of Medicare Accelerated and Advance Payment Program $ 102,023         3,232  
Unapplied state relief funds   4,356   4,356     $ 1,781
FMAP payments received   27,345 16,776 44,662 32,421    
Revenue, FMAP payments received   24,489 $ 16,692 42,088 $ 33,157    
Total deferred payment of social security taxes           $ 48,309  
Deferred payment of social security taxes, current             $ 24,154
Deferred payment of social security taxes, noncurrent   $ 24,155   $ 24,155      
XML 59 R48.htm IDEA: XBRL DOCUMENT v3.22.2
Revenue and Accounts Receivable - Revenue from Medicare and Medicaid Programs (Details)
3 Months Ended 6 Months Ended
Jun. 30, 2022
Jun. 30, 2021
Jun. 30, 2022
Jun. 30, 2021
Customer Concentration Risk | Revenue Benchmark | Total Medicare and Medicaid        
Disaggregation of Revenue [Line Items]        
Concentration risk 73.40% 73.10% 73.40% 73.60%
XML 60 R49.htm IDEA: XBRL DOCUMENT v3.22.2
Revenue and Accounts Receivable - Disaggregation of Revenue (Details) - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2022
Jun. 30, 2021
Jun. 30, 2022
Jun. 30, 2021
Disaggregation of Revenue [Line Items]        
Revenue $ 732,486 $ 638,536 $ 1,445,931 $ 1,265,789
Service revenue        
Disaggregation of Revenue [Line Items]        
Revenue 728,347 634,609 1,437,503 1,257,885
Rental revenue        
Disaggregation of Revenue [Line Items]        
Revenue $ 4,139 $ 3,927 $ 8,428 $ 7,904
Customer Concentration Risk | Revenue Benchmark | Service revenue        
Disaggregation of Revenue [Line Items]        
Percentage of Revenue 100.00% 100.00% 100.00% 100.00%
Medicaid | Service revenue        
Disaggregation of Revenue [Line Items]        
Revenue $ 294,128 $ 251,455 $ 560,476 $ 482,813
Medicaid | Customer Concentration Risk | Revenue Benchmark | Service revenue        
Disaggregation of Revenue [Line Items]        
Percentage of Revenue 40.40% 39.60% 39.00% 38.40%
Medicare | Service revenue        
Disaggregation of Revenue [Line Items]        
Revenue $ 190,494 $ 170,008 $ 398,905 $ 360,311
Medicare | Customer Concentration Risk | Revenue Benchmark | Service revenue        
Disaggregation of Revenue [Line Items]        
Percentage of Revenue 26.20% 26.80% 27.70% 28.60%
Medicaid — skilled | Service revenue        
Disaggregation of Revenue [Line Items]        
Revenue $ 49,763 $ 42,740 $ 95,712 $ 82,733
Medicaid — skilled | Customer Concentration Risk | Revenue Benchmark | Service revenue        
Disaggregation of Revenue [Line Items]        
Percentage of Revenue 6.80% 6.70% 6.70% 6.60%
Total Medicaid and Medicare | Service revenue        
Disaggregation of Revenue [Line Items]        
Revenue $ 534,385 $ 464,203 $ 1,055,093 $ 925,857
Total Medicaid and Medicare | Customer Concentration Risk | Revenue Benchmark        
Disaggregation of Revenue [Line Items]        
Percentage of Revenue 73.40% 73.10% 73.40% 73.60%
Total Medicaid and Medicare | Customer Concentration Risk | Revenue Benchmark | Service revenue        
Disaggregation of Revenue [Line Items]        
Percentage of Revenue 73.40% 73.10% 73.40% 73.60%
Managed care | Service revenue        
Disaggregation of Revenue [Line Items]        
Revenue $ 128,587 $ 112,963 $ 256,373 $ 221,308
Managed care | Customer Concentration Risk | Revenue Benchmark | Service revenue        
Disaggregation of Revenue [Line Items]        
Percentage of Revenue 17.70% 17.80% 17.80% 17.60%
Private and other | Service revenue        
Disaggregation of Revenue [Line Items]        
Revenue $ 65,375 $ 57,443 $ 126,037 $ 110,720
Private and other | Customer Concentration Risk | Revenue Benchmark | Service revenue        
Disaggregation of Revenue [Line Items]        
Percentage of Revenue 8.90% 9.10% 8.80% 8.80%
XML 61 R50.htm IDEA: XBRL DOCUMENT v3.22.2
Revenue and Accounts Receivable - Accounts Receivable (Details) - USD ($)
$ in Thousands
Jun. 30, 2022
Dec. 31, 2021
Accounts, Notes, Loans and Financing Receivable [Line Items]    
Accounts receivable $ 346,828 $ 339,944
Less: allowance for doubtful accounts (7,827) (11,213)
ACCOUNTS RECEIVABLE, NET 339,001 328,731
Medicaid    
Accounts, Notes, Loans and Financing Receivable [Line Items]    
Accounts receivable 125,348 123,647
Managed care    
Accounts, Notes, Loans and Financing Receivable [Line Items]    
Accounts receivable 86,995 79,722
Medicare    
Accounts, Notes, Loans and Financing Receivable [Line Items]    
Accounts receivable 58,067 59,797
Private and other payors    
Accounts, Notes, Loans and Financing Receivable [Line Items]    
Accounts receivable $ 76,418 $ 76,778
XML 62 R51.htm IDEA: XBRL DOCUMENT v3.22.2
Computation of Net Income Per Common Share (Details) - USD ($)
$ / shares in Units, shares in Thousands, $ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2022
Mar. 31, 2022
Jun. 30, 2021
Mar. 31, 2021
Jun. 30, 2022
Jun. 30, 2021
NUMERATOR:            
Net income $ 57,803   $ 50,583   $ 107,891 $ 100,420
Less: net (loss) income attributable to noncontrolling interests 112   1,158   (140) 1,789
Net income attributable to The Ensign Group, Inc. $ 57,691 $ 50,340 $ 49,425 $ 49,206 $ 108,031 $ 98,631
DENOMINATOR:            
Weighted average shares outstanding for basic net income per share (in shares) 54,906   54,468   54,788 54,331
Basic net income per common share (in dollars per share) $ 1.05   $ 0.91   $ 1.97 $ 1.82
Plus: incremental shares from assumed conversion (in shares) 1,947   2,529   2,074 2,614
Adjusted weighted average common shares outstanding (in shares) 56,853   56,997   56,862 56,945
Diluted net income per common share (in dollars per share) $ 1.01   $ 0.87   $ 1.90 $ 1.73
Antidilutive securities excluded from computation of earnings per share, amount (in shares) 789   167   697 80
XML 63 R52.htm IDEA: XBRL DOCUMENT v3.22.2
Fair Value Measurements - Schedule of Fair Value, of Assets and Liabilities Measured on Recurring Basis (Details) - USD ($)
$ in Thousands
Jun. 30, 2022
Dec. 31, 2021
Fair Value, Inputs, Level 1    
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]    
Cash and cash equivalents, fair value disclosure $ 285,580 $ 262,201
Fair Value, Inputs, Level 2    
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]    
Deferred compensation plan investments $ 23,151 $ 17,530
XML 64 R53.htm IDEA: XBRL DOCUMENT v3.22.2
Fair Value Measurements - Investments (Details) - USD ($)
$ in Thousands
Jun. 30, 2022
Dec. 31, 2021
Debt Security, Corporate, US    
Schedule of Held-to-maturity Securities [Line Items]    
Debt security investments classified as held to maturity and carried at amortized cost $ 49,068 $ 50,330
XML 65 R54.htm IDEA: XBRL DOCUMENT v3.22.2
Standard Bearer (Details)
$ in Thousands
1 Months Ended 3 Months Ended 6 Months Ended
Apr. 08, 2022
Aug. 01, 2022
USD ($)
campusProperty
skilledNursingProperty
Jan. 31, 2022
lease
renewal
Jun. 30, 2022
USD ($)
facility
operation
Jun. 30, 2021
USD ($)
Jun. 30, 2022
USD ($)
facility
operation
Jun. 30, 2021
USD ($)
Segment Reporting Information [Line Items]              
Number of real estate properties | facility       100   100  
Purchase price           $ 17,492 $ 5,183
Number of master lease arrangements | lease     5        
Lessee, operating lease, term of contract       10 years   10 years  
Operating lease, lease income       $ 4,139 $ 3,927 $ 8,428 7,904
Proceeds from sale of subsidiary shares (Note 7)           6,693 0
Standard Bearer Equity Plan              
Segment Reporting Information [Line Items]              
Award vesting period     5 years        
Proceeds from issuance of common stock           $ 6,544  
Proceeds from issuance of preferred shares       $ 149      
Minimum              
Segment Reporting Information [Line Items]              
Lessee, operating lease, renewal term       10 years   10 years  
Minimum | Revolving credit facility with Truist | Truist | Base Rate              
Segment Reporting Information [Line Items]              
Interest rate margin 0.25%            
Maximum              
Segment Reporting Information [Line Items]              
Lessee, operating lease, renewal term       15 years   15 years  
Maximum | Revolving credit facility with Truist | Truist | Base Rate              
Segment Reporting Information [Line Items]              
Interest rate margin 1.25%            
Standard Bearer Master Leases              
Segment Reporting Information [Line Items]              
Lessee leasing arrangements, operating leases, number of renewal terms | renewal     3        
Lessee, operating lease, renewal term     5 years        
Operating leases of lessee, contingent rentals, basis spread on variable rate     2.50%        
Operating lease, lease income       $ 13,894 $ 10,784 $ 27,319 $ 21,375
Standard Bearer Master Leases | Base Management Fee              
Segment Reporting Information [Line Items]              
Management fees, as a percentage of total revenues     5.00%        
Management fees       $ 1,056   $ 2,078  
Standard Bearer Master Leases | Incentive Management Fee              
Segment Reporting Information [Line Items]              
Management fees, as a percentage of total revenues     1.00%        
Management fees, as a percentage of funds from operations     5.00%        
Standard Bearer Master Leases | Total Management Fee              
Segment Reporting Information [Line Items]              
Management fees, as a percentage of total revenues       6.00%   6.00%  
Standard Bearer Master Leases | Minimum              
Segment Reporting Information [Line Items]              
Lessee, operating lease, term of contract       15 years   15 years  
Standard Bearer Master Leases | Maximum              
Segment Reporting Information [Line Items]              
Lessee, operating lease, term of contract       19 years   19 years  
Campus Operation | Subsequent Event              
Segment Reporting Information [Line Items]              
Number of businesses acquired | campusProperty   1          
Owned Properties              
Segment Reporting Information [Line Items]              
Number of real estate properties | facility       71   71  
Standard Bearer              
Segment Reporting Information [Line Items]              
Number of real estate properties | facility       95   95  
Standard Bearer | Owned Properties              
Segment Reporting Information [Line Items]              
Number of businesses acquired | facility           2  
Purchase price           $ 17,412  
Standard Bearer | Owned Properties | Subsequent Event              
Segment Reporting Information [Line Items]              
Number of businesses acquired | skilledNursingProperty   5          
Purchase price   $ 47,900          
Standard Bearer | Owned Properties              
Segment Reporting Information [Line Items]              
Number of real estate properties | operation       67   67  
XML 66 R55.htm IDEA: XBRL DOCUMENT v3.22.2
Business Segments - Narrative (Details)
$ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2022
USD ($)
facility
operation
Jun. 30, 2021
USD ($)
Jun. 30, 2022
USD ($)
facility
operation
segment
Jun. 30, 2021
USD ($)
Segment Reporting Information [Line Items]        
Number of reportable segments | segment     2  
Transitional and skilled service facilities 215   215  
Transitional and skilled services and senior living campuses 25   25  
Number of real estate properties 100   100  
Senior living facilities 11   11  
TOTAL REVENUE | $ $ 732,486 $ 638,536 $ 1,445,931 $ 1,265,789
Rental revenue        
Segment Reporting Information [Line Items]        
TOTAL REVENUE | $ $ 4,139 $ 3,927 $ 8,428 $ 7,904
Owned Properties        
Segment Reporting Information [Line Items]        
Number of real estate properties 71   71  
Standard Bearer        
Segment Reporting Information [Line Items]        
Number of real estate properties 95   95  
Standard Bearer | Remaining Company | Skilled Nursing Operations | Spinoff        
Segment Reporting Information [Line Items]        
Number of real estate properties | operation 1   1  
Standard Bearer | Third Parties        
Segment Reporting Information [Line Items]        
Number of real estate properties | operation 29   29  
Standard Bearer | Owned Properties        
Segment Reporting Information [Line Items]        
Number of real estate properties | operation 67   67  
XML 67 R56.htm IDEA: XBRL DOCUMENT v3.22.2
Business Segments - Schedule of Segment Reporting Information, by Segment (Details) - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2022
Jun. 30, 2021
Jun. 30, 2022
Jun. 30, 2021
Segment Reporting Information [Line Items]        
TOTAL REVENUE $ 732,486 $ 638,536 $ 1,445,931 $ 1,265,789
Segment income (loss) 70,490 64,341 136,716 126,687
Gain on sale of assets 2,467   2,467 440
Income before provision for income taxes 72,957 64,341 139,183 127,127
Depreciation and amortization 14,858 13,795 29,534 27,454
Interest expense 2,688 1,634 4,756 3,275
Service revenue        
Segment Reporting Information [Line Items]        
TOTAL REVENUE 728,347 634,609 1,437,503 1,257,885
Rental revenue        
Segment Reporting Information [Line Items]        
TOTAL REVENUE 4,139 3,927 8,428 7,904
Operating Segments | Skilled Services        
Segment Reporting Information [Line Items]        
TOTAL REVENUE 702,478 612,882 1,389,249 1,213,918
Segment income (loss) 102,266 90,010 200,522 178,941
Depreciation and amortization 8,113 7,703 16,014 15,178
Interest expense 0 0 0 0
Operating Segments | Skilled Services | Service revenue        
Segment Reporting Information [Line Items]        
TOTAL REVENUE 702,478 612,882 1,389,249 1,213,918
Operating Segments | Skilled Services | Rental revenue        
Segment Reporting Information [Line Items]        
TOTAL REVENUE 0 0 0 0
Operating Segments | Standard Bearer        
Segment Reporting Information [Line Items]        
TOTAL REVENUE 17,598 14,214 34,791 28,283
Segment income (loss) 6,838 7,906 13,738 15,619
Depreciation and amortization 5,216 4,248 10,237 8,403
Interest expense 3,743 1,634 7,305 3,275
Operating Segments | Standard Bearer | Service revenue        
Segment Reporting Information [Line Items]        
TOTAL REVENUE 0 0 0 0
Operating Segments | Standard Bearer | Rental revenue        
Segment Reporting Information [Line Items]        
TOTAL REVENUE 17,598 14,214 34,791 28,283
Operating Segments | All Other        
Segment Reporting Information [Line Items]        
TOTAL REVENUE 30,619 25,245 57,949 50,974
Segment income (loss) (38,614) (33,575) (77,544) (67,873)
Depreciation and amortization 1,529 1,844 3,283 3,873
Interest expense 889 1,247 0
Operating Segments | All Other | Service revenue        
Segment Reporting Information [Line Items]        
TOTAL REVENUE 28,787 23,428 54,254 47,347
Operating Segments | All Other | Rental revenue        
Segment Reporting Information [Line Items]        
TOTAL REVENUE 1,832 1,817 3,695 3,627
Intercompany Elimination        
Segment Reporting Information [Line Items]        
TOTAL REVENUE (18,209) (13,805) (36,058) (27,386)
Segment income (loss) 0   0 0
Depreciation and amortization 0 0 0 0
Interest expense (1,944) 0 (3,796) 0
Intercompany Elimination | Service revenue        
Segment Reporting Information [Line Items]        
TOTAL REVENUE (2,918) (1,701) (6,000) (3,380)
Intercompany Elimination | Rental revenue        
Segment Reporting Information [Line Items]        
TOTAL REVENUE $ (15,291) $ (12,104) $ (30,058) $ (24,006)
XML 68 R57.htm IDEA: XBRL DOCUMENT v3.22.2
Business Segments - Revenue by Segment (Details) - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2022
Jun. 30, 2021
Jun. 30, 2022
Jun. 30, 2021
Segment Reporting, Revenue Reconciling Item [Line Items]        
TOTAL REVENUE $ 732,486 $ 638,536 $ 1,445,931 $ 1,265,789
Service revenue        
Segment Reporting, Revenue Reconciling Item [Line Items]        
TOTAL REVENUE 728,347 634,609 1,437,503 1,257,885
Rental revenue        
Segment Reporting, Revenue Reconciling Item [Line Items]        
TOTAL REVENUE $ 4,139 $ 3,927 $ 8,428 $ 7,904
Revenue Benchmark | Customer Concentration Risk | Service revenue        
Segment Reporting, Revenue Reconciling Item [Line Items]        
Concentration risk 100.00% 100.00% 100.00% 100.00%
Total Medicaid and Medicare | Service revenue        
Segment Reporting, Revenue Reconciling Item [Line Items]        
TOTAL REVENUE $ 534,385 $ 464,203 $ 1,055,093 $ 925,857
Total Medicaid and Medicare | Revenue Benchmark | Customer Concentration Risk        
Segment Reporting, Revenue Reconciling Item [Line Items]        
Concentration risk 73.40% 73.10% 73.40% 73.60%
Total Medicaid and Medicare | Revenue Benchmark | Customer Concentration Risk | Service revenue        
Segment Reporting, Revenue Reconciling Item [Line Items]        
Concentration risk 73.40% 73.10% 73.40% 73.60%
Medicaid | Service revenue        
Segment Reporting, Revenue Reconciling Item [Line Items]        
TOTAL REVENUE $ 294,128 $ 251,455 $ 560,476 $ 482,813
Medicaid | Revenue Benchmark | Customer Concentration Risk | Service revenue        
Segment Reporting, Revenue Reconciling Item [Line Items]        
Concentration risk 40.40% 39.60% 39.00% 38.40%
Medicare | Service revenue        
Segment Reporting, Revenue Reconciling Item [Line Items]        
TOTAL REVENUE $ 190,494 $ 170,008 $ 398,905 $ 360,311
Medicare | Revenue Benchmark | Customer Concentration Risk | Service revenue        
Segment Reporting, Revenue Reconciling Item [Line Items]        
Concentration risk 26.20% 26.80% 27.70% 28.60%
Medicaid — skilled | Service revenue        
Segment Reporting, Revenue Reconciling Item [Line Items]        
TOTAL REVENUE $ 49,763 $ 42,740 $ 95,712 $ 82,733
Medicaid — skilled | Revenue Benchmark | Customer Concentration Risk | Service revenue        
Segment Reporting, Revenue Reconciling Item [Line Items]        
Concentration risk 6.80% 6.70% 6.70% 6.60%
Managed care | Service revenue        
Segment Reporting, Revenue Reconciling Item [Line Items]        
TOTAL REVENUE $ 128,587 $ 112,963 $ 256,373 $ 221,308
Managed care | Revenue Benchmark | Customer Concentration Risk | Service revenue        
Segment Reporting, Revenue Reconciling Item [Line Items]        
Concentration risk 17.70% 17.80% 17.80% 17.60%
Private and other | Service revenue        
Segment Reporting, Revenue Reconciling Item [Line Items]        
TOTAL REVENUE $ 65,375 $ 57,443 $ 126,037 $ 110,720
Private and other | Revenue Benchmark | Customer Concentration Risk | Service revenue        
Segment Reporting, Revenue Reconciling Item [Line Items]        
Concentration risk 8.90% 9.10% 8.80% 8.80%
Operating Segments | Skilled Services        
Segment Reporting, Revenue Reconciling Item [Line Items]        
TOTAL REVENUE $ 702,478 $ 612,882 $ 1,389,249 $ 1,213,918
Operating Segments | Skilled Services | Service revenue        
Segment Reporting, Revenue Reconciling Item [Line Items]        
TOTAL REVENUE 702,478 612,882 1,389,249 1,213,918
Operating Segments | Skilled Services | Rental revenue        
Segment Reporting, Revenue Reconciling Item [Line Items]        
TOTAL REVENUE 0 0 0 0
Operating Segments | Total Medicaid and Medicare | Skilled Services | Service revenue        
Segment Reporting, Revenue Reconciling Item [Line Items]        
TOTAL REVENUE 528,084 460,419 1,044,031 918,456
Operating Segments | Medicaid | Skilled Services | Service revenue        
Segment Reporting, Revenue Reconciling Item [Line Items]        
TOTAL REVENUE 287,827 247,671 549,414 475,412
Operating Segments | Medicare | Skilled Services | Service revenue        
Segment Reporting, Revenue Reconciling Item [Line Items]        
TOTAL REVENUE 190,494 170,008 398,905 360,311
Operating Segments | Medicaid — skilled | Skilled Services | Service revenue        
Segment Reporting, Revenue Reconciling Item [Line Items]        
TOTAL REVENUE 49,763 42,740 95,712 82,733
Operating Segments | Managed care | Skilled Services | Service revenue        
Segment Reporting, Revenue Reconciling Item [Line Items]        
TOTAL REVENUE 128,587 112,963 256,373 221,308
Operating Segments | Private and other | Skilled Services | Service revenue        
Segment Reporting, Revenue Reconciling Item [Line Items]        
TOTAL REVENUE 45,807 39,500 88,845 74,154
Other Service Revenue | Service revenue        
Segment Reporting, Revenue Reconciling Item [Line Items]        
TOTAL REVENUE 25,869 21,727 48,254 43,967
Other Service Revenue | Total Medicaid and Medicare | Service revenue        
Segment Reporting, Revenue Reconciling Item [Line Items]        
TOTAL REVENUE 6,301 3,784 11,062 7,401
Other Service Revenue | Medicaid | Service revenue        
Segment Reporting, Revenue Reconciling Item [Line Items]        
TOTAL REVENUE 6,301 3,784 11,062 7,401
Other Service Revenue | Medicare | Service revenue        
Segment Reporting, Revenue Reconciling Item [Line Items]        
TOTAL REVENUE 0 0 0 0
Other Service Revenue | Medicaid — skilled | Service revenue        
Segment Reporting, Revenue Reconciling Item [Line Items]        
TOTAL REVENUE 0 0 0 0
Other Service Revenue | Managed care | Service revenue        
Segment Reporting, Revenue Reconciling Item [Line Items]        
TOTAL REVENUE 0 0 0 0
Other Service Revenue | Private and other | Service revenue        
Segment Reporting, Revenue Reconciling Item [Line Items]        
TOTAL REVENUE 19,568 17,943 37,192 36,566
Intercompany Elimination        
Segment Reporting, Revenue Reconciling Item [Line Items]        
TOTAL REVENUE (18,209) (13,805) (36,058) (27,386)
Intercompany Elimination | Service revenue        
Segment Reporting, Revenue Reconciling Item [Line Items]        
TOTAL REVENUE (2,918) (1,701) (6,000) (3,380)
Intercompany Elimination | Rental revenue        
Segment Reporting, Revenue Reconciling Item [Line Items]        
TOTAL REVENUE $ (15,291) $ (12,104) $ (30,058) $ (24,006)
XML 69 R58.htm IDEA: XBRL DOCUMENT v3.22.2
Operation Expansions (Details)
seniorLivingUnit in Thousands, $ in Thousands
1 Months Ended 6 Months Ended
Aug. 01, 2022
USD ($)
facility
bed
Aug. 01, 2022
facility
skilledNursingProperty
bed
Aug. 01, 2022
facility
operation
bed
Aug. 01, 2022
facility
campusProperty
bed
Aug. 01, 2022
facility
realEstateProperty
bed
Jun. 30, 2022
USD ($)
operation
facility
bed
seniorLivingUnit
Jun. 30, 2021
USD ($)
bed
Jun. 30, 2021
bed
facility
Jun. 30, 2021
bed
operation
Business Acquisition [Line Items]                  
Operational skilled nursing beds | bed           25,500      
Operational senior living units | seniorLivingUnit           3      
Payments to acquire business and asset acquisitions           $ 33,892      
Additions           16,400      
Purchase price           17,492 $ 5,183    
Payments to acquire businesses, gross             6,000    
Two Acquisitions Concentrated in Property, Plant And Equipment                  
Business Acquisition [Line Items]                  
Asset acquisition, purchase price           $ 17,492      
Asset Acquisition                  
Business Acquisition [Line Items]                  
Asset acquisition, purchase price             $ 11,183    
Skilled Nursing Operations | Subsequent Event                  
Business Acquisition [Line Items]                  
Operational skilled nursing beds | bed 1,100 1,100 1,100 1,100 1,100        
Asset acquisition, purchase price $ 47,900                
Skilled Nursing Operations                  
Business Acquisition [Line Items]                  
Number of businesses acquired           4   1 12
Operational skilled nursing beds | bed           453 1,263 1,263 1,263
Skilled Nursing Operations | Subsequent Event                  
Business Acquisition [Line Items]                  
Number of businesses acquired     7   3        
Owned Properties | Standard Bearer                  
Business Acquisition [Line Items]                  
Number of businesses acquired | facility           2      
Purchase price           $ 17,412      
Owned Properties | Standard Bearer | Subsequent Event                  
Business Acquisition [Line Items]                  
Number of businesses acquired | skilledNursingProperty   5              
Purchase price $ 47,900                
Senior Living Facilities                  
Business Acquisition [Line Items]                  
Number of businesses acquired | operation           5      
Number of operations transferred from third parties | operation           3      
Operational senior living units | facility           633      
Senior Living Facilities | Subsequent Event                  
Business Acquisition [Line Items]                  
Operational senior living units | facility 61 61 61 61 61        
Two Acquisitions Concentrated In Goodwill                  
Business Acquisition [Line Items]                  
Additions           $ 16,400      
Campus Operation | Subsequent Event                  
Business Acquisition [Line Items]                  
Number of businesses acquired | campusProperty       1          
Number of real estate skilled nursing properties acquired | skilledNursingProperty   3              
Asset Acquisition                  
Business Acquisition [Line Items]                  
Number of businesses acquired | operation                 9
Business Combination                  
Business Acquisition [Line Items]                  
Number of businesses acquired | operation                 4
XML 70 R59.htm IDEA: XBRL DOCUMENT v3.22.2
Property and Equipment — Net (Details) - USD ($)
$ in Thousands
Jun. 30, 2022
Dec. 31, 2021
Property, Plant and Equipment [Line Items]    
Property and equipment $ 1,230,722 $ 1,184,201
Less: accumulated depreciation (322,494) (295,767)
PROPERTY AND EQUIPMENT, NET 908,228 888,434
Land    
Property, Plant and Equipment [Line Items]    
Property and equipment 121,381 121,164
Buildings and improvements    
Property, Plant and Equipment [Line Items]    
Property and equipment 669,215 646,221
Leasehold improvements    
Property, Plant and Equipment [Line Items]    
Property and equipment 145,522 140,012
Equipment    
Property, Plant and Equipment [Line Items]    
Property and equipment 279,231 262,246
Furniture and fixtures    
Property, Plant and Equipment [Line Items]    
Property and equipment 4,373 4,305
Construction in progress    
Property, Plant and Equipment [Line Items]    
Property and equipment $ 11,000 $ 10,253
XML 71 R60.htm IDEA: XBRL DOCUMENT v3.22.2
Property and Equipment — Net - Narrative (Details) - Senior Living Operations - Disposal Group, Disposed of by Sale, Not Discontinued Operations
$ in Thousands
3 Months Ended
Jun. 30, 2022
USD ($)
facility
Property, Plant and Equipment [Line Items]  
Senior living facility | facility 2
Proceeds from sale of real estate $ 7,707
Gains on sales property, plant and equipment $ 2,567
XML 72 R61.htm IDEA: XBRL DOCUMENT v3.22.2
Intangible Assets — Net - Schedule of Finite Lived Intangible Assets (Details) - USD ($)
$ in Thousands
6 Months Ended
Jun. 30, 2022
Dec. 31, 2021
Acquired Finite-Lived Intangible Assets [Line Items]    
Gross Carrying Amount $ 5,511 $ 5,383
Accumulated Amortization (2,976) (2,731)
Net $ 2,535 2,652
Assembled occupancy    
Acquired Finite-Lived Intangible Assets [Line Items]    
Weighted Average Life (Years) 4 months 24 days  
Gross Carrying Amount $ 196 68
Accumulated Amortization (196) (68)
Net $ 0 0
Facility trade name    
Acquired Finite-Lived Intangible Assets [Line Items]    
Weighted Average Life (Years) 30 years  
Gross Carrying Amount $ 733 733
Accumulated Amortization (403) (391)
Net $ 330 342
Customer relationships    
Acquired Finite-Lived Intangible Assets [Line Items]    
Weighted Average Life (Years) 18 years 4 months 24 days  
Gross Carrying Amount $ 4,582 4,582
Accumulated Amortization (2,377) (2,272)
Net $ 2,205 $ 2,310
XML 73 R62.htm IDEA: XBRL DOCUMENT v3.22.2
Intangible Assets — Net - Narrative (Details) - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2022
Jun. 30, 2021
Jun. 30, 2022
Jun. 30, 2021
Finite-Lived Intangible Assets [Line Items]        
Amortization of intangible assets $ 418 $ 363 $ 822 $ 724
Operating lease expense 41,311 38,460 82,748 75,669
Depreciation and amortization        
Finite-Lived Intangible Assets [Line Items]        
Operating lease expense $ 288 $ 290 $ 577 $ 580
XML 74 R63.htm IDEA: XBRL DOCUMENT v3.22.2
Intangible Assets — Net - Future Amortization (Details) - USD ($)
$ in Thousands
Jun. 30, 2022
Dec. 31, 2021
Year    
2022 (remainder) $ 117  
2023 234  
2024 234  
2025 234  
2026 234  
2027 234  
Thereafter 1,248  
Net $ 2,535 $ 2,652
XML 75 R64.htm IDEA: XBRL DOCUMENT v3.22.2
Goodwill and Other Indefinite-Lived Intangible Assets - Goodwill Rollforward (Details)
$ in Thousands
6 Months Ended
Jun. 30, 2022
USD ($)
Goodwill [Roll Forward]  
Balance at beginning of period $ 60,469
Additions 16,400
Balance at end of period 76,869
Operating Segments | Skilled Services  
Goodwill [Roll Forward]  
Balance at beginning of period 51,486
Additions 16,400
Balance at end of period 67,886
All Other  
Goodwill [Roll Forward]  
Balance at beginning of period 8,983
Additions 0
Balance at end of period $ 8,983
XML 76 R65.htm IDEA: XBRL DOCUMENT v3.22.2
Goodwill and Other Indefinite-Lived Intangible Assets - Indefinite-Lived Intangible Assets (Details) - USD ($)
$ in Thousands
Jun. 30, 2022
Dec. 31, 2021
Indefinite-lived Intangible Assets [Line Items]    
Other indefinite-lived intangibles $ 3,807 $ 3,727
Trade name    
Indefinite-lived Intangible Assets [Line Items]    
Other indefinite-lived intangibles 889 889
Medicare and Medicaid licenses    
Indefinite-lived Intangible Assets [Line Items]    
Other indefinite-lived intangibles $ 2,918 $ 2,838
XML 77 R66.htm IDEA: XBRL DOCUMENT v3.22.2
Restricted and Other Assets (Details) - USD ($)
$ in Thousands
Jun. 30, 2022
Dec. 31, 2021
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]    
Debt issuance costs, net $ 4,195 $ 1,953
Long-term insurance losses recoverable asset 8,440 6,755
Deposits with landlords 14,725 13,705
Capital improvement reserves with landlords and lenders 6,499 7,103
Deferred compensation plan investments 23,151 17,530
RESTRICTED AND OTHER ASSETS $ 57,010 $ 47,046
XML 78 R67.htm IDEA: XBRL DOCUMENT v3.22.2
Restricted and Other Assets - Narrative (Details) - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2022
Jun. 30, 2021
Jun. 30, 2022
Jun. 30, 2021
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]        
Gain (loss) on deferral investment $ (3,313) $ 751 $ (4,515) $ 1,057
Deferral investment expense (income) $ (3,300) $ 780 $ 4,511 $ 1,131
XML 79 R68.htm IDEA: XBRL DOCUMENT v3.22.2
Other Accrued Liabilities (Details) - USD ($)
$ in Thousands
Jun. 30, 2022
Dec. 31, 2021
Jun. 30, 2021
Payables and Accruals [Abstract]      
Quality assurance fee $ 6,669 $ 6,474  
Refunds payable 36,912 34,814  
Resident advances 6,273 9,337  
Unapplied state relief funds 4,356 1,781  
Cash held in trust for patients 5,757 6,430  
Dividends payable 3,040 3,035 $ 2,894
Property taxes 7,670 9,124  
Legal finding accrued 3,626 0  
Other 11,490 18,415  
OTHER ACCRUED LIABILITIES $ 85,793 $ 89,410  
XML 80 R69.htm IDEA: XBRL DOCUMENT v3.22.2
Income Taxes - Narrative (Details) - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2022
Jun. 30, 2021
Jun. 30, 2022
Jun. 30, 2021
Income Tax Disclosure [Abstract]        
Provision for income taxes $ 15,154 $ 13,758 $ 31,292 $ 26,707
Effective income tax rate     22.50% 21.00%
XML 81 R70.htm IDEA: XBRL DOCUMENT v3.22.2
Debt - Schedule of Long-term Debt (Details) - USD ($)
$ in Thousands
Jun. 30, 2022
Dec. 31, 2021
Debt Instrument [Line Items]    
Less: current maturities $ (3,944) $ (3,760)
Less: debt issuance costs, net (3,209) (3,324)
Long-term debt—less current maturities 151,105 152,883
Mortgage loans and promissory notes | Mortgage loans and promissory notes    
Debt Instrument [Line Items]    
Mortgage loans and promissory notes $ 158,258 $ 159,967
XML 82 R71.htm IDEA: XBRL DOCUMENT v3.22.2
Debt - Credit Facility with a Lending Consortium Arranged by SunTrust (Details)
6 Months Ended
Apr. 08, 2022
USD ($)
Jun. 30, 2022
USD ($)
Jun. 30, 2021
USD ($)
Jul. 27, 2022
USD ($)
Oct. 01, 2019
USD ($)
Debt Instrument [Line Items]          
Write-off of deferred financing fees   $ 566,000 $ 0    
Payments of deferred financing costs   3,197,000 $ 0    
Truist | Revolving credit facility with Truist          
Debt Instrument [Line Items]          
Line of credit facility, maximum borrowing capacity $ 600,000,000       $ 350,000,000
Total net debt ratio, maximum         3.00
Long-term debt, threshold for EBITDA ratio increase election         $ 50,000,000
Total net debt ratio, maximum after increase election         3.50
Total net debt ratio, minimum         1.50
Long-term debt, gross   $ 0      
Truist | Revolving credit facility with Truist | Subsequent Event          
Debt Instrument [Line Items]          
Long-term debt, gross       $ 0  
Truist | Revolving credit facility with Truist | Minimum          
Debt Instrument [Line Items]          
Line of credit facility, unused capacity, commitment fee percentage 0.20%        
Truist | Revolving credit facility with Truist | Maximum          
Debt Instrument [Line Items]          
Line of credit facility, unused capacity, commitment fee percentage 0.40%        
Truist | Revolving credit facility with Truist | Base Rate | Minimum          
Debt Instrument [Line Items]          
Interest rate margin 0.25%        
Truist | Revolving credit facility with Truist | Base Rate | Maximum          
Debt Instrument [Line Items]          
Interest rate margin 1.25%        
Truist | Revolving credit facility with Truist | SOFR | Minimum          
Debt Instrument [Line Items]          
Interest rate margin 1.25%        
Truist | Revolving credit facility with Truist | SOFR | Maximum          
Debt Instrument [Line Items]          
Interest rate margin 2.25%        
XML 83 R72.htm IDEA: XBRL DOCUMENT v3.22.2
Debt - Mortgage Loans and Promissory Notes and Off-Balance Sheet Arrangements (Details)
$ in Thousands
6 Months Ended
Jun. 30, 2022
USD ($)
subsidiary
promissoryNote
Dec. 31, 2021
USD ($)
Debt Instrument [Line Items]    
Amount outstanding, current $ 3,944 $ 3,760
Letters of credit outstanding, pledged amount $ 6,710  
Mortgage loans and promissory notes    
Debt Instrument [Line Items]    
Number of promissory notes | promissoryNote 2  
Mortgage loans and promissory notes | Notes Payable Other Payables    
Debt Instrument [Line Items]    
Long-term debt, gross $ 158,258 $ 159,967
Long-term debt—less current maturities $ 154,314  
Mortgage loans and promissory notes | Mortgages    
Debt Instrument [Line Items]    
Prepayment penalty reduced rate during first three years 10.00%  
Prepayment penalty reduced rate during the fourth year 3.00%  
Prepayment penalty reduced rate for the fifth through tenth years 1.00%  
Mortgage loans and promissory notes | Mortgages | Twenty Three Subsidiaries    
Debt Instrument [Line Items]    
Number of operating subsidiaries | subsidiary 23  
Notes payable $ 155,074  
Mortgage loans and promissory notes | Mortgages | Minimum    
Debt Instrument [Line Items]    
Debt Instrument, pre-payment fee reduction, term 5 years  
Debt instrument, term 25 years  
Mortgage loans and promissory notes | Mortgages | Maximum    
Debt Instrument [Line Items]    
Debt Instrument, pre-payment fee reduction, term 10 years  
Debt instrument, term 35 years  
Mortgage loans and promissory notes | Notes Payable to Banks | Minimum    
Debt Instrument [Line Items]    
Debt instrument, interest rate, effective percentage 3.10%  
Debt instrument, interest rate, stated percentage 2.40%  
Mortgage loans and promissory notes | Notes Payable to Banks | Maximum    
Debt Instrument [Line Items]    
Debt instrument, interest rate, effective percentage 4.20%  
Debt instrument, interest rate, stated percentage 3.30%  
Mortgage loans and promissory notes | Promissory Note, 5.3%    
Debt Instrument [Line Items]    
Debt instrument, interest rate, stated percentage 5.30%  
Debt instrument, term 12 years  
Mortgage loans and promissory notes | Promissory Note, 5.0%    
Debt Instrument [Line Items]    
Debt instrument, interest rate, stated percentage 6.30%  
Debt instrument, term 10 months  
XML 84 R73.htm IDEA: XBRL DOCUMENT v3.22.2
Options and Awards - Stock Options, Narrative (Details)
shares in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2022
shares
Jun. 30, 2021
shares
Jun. 30, 2022
installment
$ / shares
shares
Jun. 30, 2021
$ / shares
shares
Dec. 31, 2017
shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]          
Options granted (in shares) 154 209 318 345  
Grant date intrinsic value (in dollars per share) | $ / shares     $ 0 $ 0  
2022 Plan          
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]          
Number of shares available for grant (in shares) 3,268   3,268    
Number of shares authorized (in shares)         3,452
Conversion to reduce shares availability     1    
Other than options, conversion to reduce shares availability     2    
Award vesting period     5 years    
Award vesting rights, percentage     20.00%    
Expiration period     10 years    
2022 Plan | Non-employee directors          
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]          
Number of installments | installment     3    
Award requisite service period     3 years    
XML 85 R74.htm IDEA: XBRL DOCUMENT v3.22.2
Options and Awards - Valuation Assumptions (Details) - shares
shares in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2022
Jun. 30, 2021
Jun. 30, 2022
Jun. 30, 2021
Share-Based Payment Arrangement [Abstract]        
Options Granted (in shares) 154 209 318 345
Weighted Average Risk-Free Rate 2.70% 1.00% 2.30% 0.90%
Expected Life 6 years 1 month 6 days 6 years 3 months 18 days 6 years 1 month 6 days 6 years 3 months 18 days
Weighted Average Volatility 42.10% 42.30% 42.20% 42.20%
Weighted Average Dividend Yield 0.30% 0.30% 0.30% 0.20%
XML 86 R75.htm IDEA: XBRL DOCUMENT v3.22.2
Options and Awards - Exercise Price and Fair Value (Details) - $ / shares
shares in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2022
Jun. 30, 2021
Jun. 30, 2022
Jun. 30, 2021
Share-Based Payment Arrangement [Abstract]        
Granted (in shares) 154 209 318 345
Weighted Average Exercise Price (in dollars per share)     $ 80.18 $ 82.77
Weighted Average Fair Value of Options (in dollars per share)     $ 34.29 $ 33.86
XML 87 R76.htm IDEA: XBRL DOCUMENT v3.22.2
Options and Awards - Options Outstanding Rollforward (Details) - $ / shares
shares in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2022
Jun. 30, 2021
Jun. 30, 2022
Jun. 30, 2021
Dec. 31, 2021
Number of Options Outstanding          
Balance at beginning of period, (in shares)     4,038    
Granted (in shares) 154 209 318 345  
Forfeited (in shares)     (68)    
Exercised (in shares)     (370)    
Balance at end of period, (in shares) 3,918   3,918    
Weighted Average Exercise Price          
Balance at beginning of period (in dollars per share)     $ 36.60    
Granted (in dollars per share)     80.18 $ 82.77  
Forfeited (in dollars per share)     57.40    
Exercised (in dollars per share)     16.40    
Balance at end of period (in dollars per share) $ 41.69   $ 41.69    
Number of options vested (in shares) 2,151   2,151   2,183
Weighted average exercise price of options vested (in dollars per share) $ 25.53   $ 25.53   $ 21.02
XML 88 R77.htm IDEA: XBRL DOCUMENT v3.22.2
Options and Awards - Options Outstanding by Exercise Price (Details)
$ / shares in Units, shares in Thousands, $ in Thousands
6 Months Ended
Jun. 30, 2022
USD ($)
$ / shares
shares
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]  
Number outstanding (in shares) 3,918
Black-Scholes Fair Value | $ $ 63,248
Stock options vested and exercisable (in shares) 2,151
2012  
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]  
Exercise price, lower range limit (in dollars per share) | $ / shares $ 5.56
Exercise price, upper range limit (in dollars per share) | $ / shares $ 6.75
Number outstanding (in shares) 10
Black-Scholes Fair Value | $ $ 32
Remaining Contractual Life (Years) 0 years
Stock options vested and exercisable (in shares) 10
2013  
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]  
Exercise price, lower range limit (in dollars per share) | $ / shares $ 6.76
Exercise price, upper range limit (in dollars per share) | $ / shares $ 9.74
Number outstanding (in shares) 125
Black-Scholes Fair Value | $ $ 476
Remaining Contractual Life (Years) 1 year
Stock options vested and exercisable (in shares) 125
2014  
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]  
Exercise price, lower range limit (in dollars per share) | $ / shares $ 8.94
Exercise price, upper range limit (in dollars per share) | $ / shares $ 16.05
Number outstanding (in shares) 457
Black-Scholes Fair Value | $ $ 2,204
Remaining Contractual Life (Years) 2 years
Stock options vested and exercisable (in shares) 457
2015  
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]  
Exercise price, lower range limit (in dollars per share) | $ / shares $ 18.20
Exercise price, upper range limit (in dollars per share) | $ / shares $ 21.39
Number outstanding (in shares) 246
Black-Scholes Fair Value | $ $ 1,910
Remaining Contractual Life (Years) 3 years
Stock options vested and exercisable (in shares) 246
2016  
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]  
Exercise price, lower range limit (in dollars per share) | $ / shares $ 15.93
Exercise price, upper range limit (in dollars per share) | $ / shares $ 16.86
Number outstanding (in shares) 233
Black-Scholes Fair Value | $ $ 1,377
Remaining Contractual Life (Years) 4 years
Stock options vested and exercisable (in shares) 233
2017  
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]  
Exercise price, lower range limit (in dollars per share) | $ / shares $ 15.80
Exercise price, upper range limit (in dollars per share) | $ / shares $ 19.41
Number outstanding (in shares) 267
Black-Scholes Fair Value | $ $ 1,583
Remaining Contractual Life (Years) 5 years
Stock options vested and exercisable (in shares) 236
2018  
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]  
Exercise price, lower range limit (in dollars per share) | $ / shares $ 22.49
Exercise price, upper range limit (in dollars per share) | $ / shares $ 32.71
Number outstanding (in shares) 496
Black-Scholes Fair Value | $ $ 4,806
Remaining Contractual Life (Years) 6 years
Stock options vested and exercisable (in shares) 326
2019  
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]  
Exercise price, lower range limit (in dollars per share) | $ / shares $ 41.07
Exercise price, upper range limit (in dollars per share) | $ / shares $ 45.76
Number outstanding (in shares) 615
Black-Scholes Fair Value | $ $ 9,651
Remaining Contractual Life (Years) 7 years
Stock options vested and exercisable (in shares) 292
2020  
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]  
Exercise price, lower range limit (in dollars per share) | $ / shares $ 44.84
Exercise price, upper range limit (in dollars per share) | $ / shares $ 59.49
Number outstanding (in shares) 569
Black-Scholes Fair Value | $ $ 11,205
Remaining Contractual Life (Years) 8 years
Stock options vested and exercisable (in shares) 162
2021  
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]  
Exercise price, lower range limit (in dollars per share) | $ / shares $ 73.47
Exercise price, upper range limit (in dollars per share) | $ / shares $ 83.64
Number outstanding (in shares) 586
Black-Scholes Fair Value | $ $ 19,222
Remaining Contractual Life (Years) 9 years
Stock options vested and exercisable (in shares) 64
2022  
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]  
Exercise price, lower range limit (in dollars per share) | $ / shares $ 79.79
Exercise price, upper range limit (in dollars per share) | $ / shares $ 80.60
Number outstanding (in shares) 314
Black-Scholes Fair Value | $ $ 10,782
Remaining Contractual Life (Years) 10 years
Stock options vested and exercisable (in shares) 0
XML 89 R78.htm IDEA: XBRL DOCUMENT v3.22.2
Options and Awards - Intrinsic Values (Details) - USD ($)
$ in Thousands
6 Months Ended
Jun. 30, 2022
Jun. 30, 2021
Dec. 31, 2021
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Outstanding $ 130,564   $ 191,242
Vested 103,713   137,382
Expected to vest 24,561   $ 48,548
Intrinsic value of options exercised in period 25,642 $ 26,715  
Stock Options      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Aggregate intrinsic value of options that vested in period $ 10,409 $ 17,618  
XML 90 R79.htm IDEA: XBRL DOCUMENT v3.22.2
Options and Awards - Restricted Stock Awards, Narrative (Details) - $ / shares
shares in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2022
Jun. 30, 2021
Jun. 30, 2022
Jun. 30, 2021
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Share-based compensation, restricted awards, exercise price (in dollars per share)     $ 0  
Restricted Stock Awards        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Granted (in shares) 46 54 158 144
Award vesting period     5 years  
Granted (in dollars per share)     $ 77.06  
Restricted Stock Awards | Non-employee directors        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Granted (in shares) 5   9  
Restricted Stock Awards | Minimum        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Granted (in dollars per share)     $ 73.17 $ 82.20
Restricted Stock Awards | Minimum | Non-employee directors        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Granted (in dollars per share)     77.39  
Restricted Stock Awards | Maximum        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Granted (in dollars per share)     83.93 $ 93.31
Restricted Stock Awards | Maximum | Non-employee directors        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Granted (in dollars per share)     $ 83.93  
XML 91 R80.htm IDEA: XBRL DOCUMENT v3.22.2
Options and Awards - Restricted Award Rollforward (Details) - Restricted Stock Awards - $ / shares
shares in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2022
Jun. 30, 2021
Jun. 30, 2022
Jun. 30, 2021
Non-Vested Restricted Awards        
Nonvested at beginning of period (in shares)     549  
Granted (in shares) 46 54 158 144
Vested (in shares)     (199)  
Forfeited (in shares)     (16)  
Nonvested at end of period (in shares) 492   492  
Weighted Average Grant Date Fair Value        
Nonvested at beginning of period (in dollars per share)     $ 52.16  
Granted (in dollars per share)     77.06  
Vested (in dollars per share)     54.74  
Forfeited (in dollars per share)     55.86  
Nonvested at end of period (in dollars per share) $ 59.01   $ 59.01  
XML 92 R81.htm IDEA: XBRL DOCUMENT v3.22.2
Options and Awards - Long-Term Incentive Plan (Details) - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended
Aug. 27, 2019
Jun. 30, 2022
Jun. 30, 2021
Jun. 30, 2022
Jun. 30, 2021
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]          
TOTAL   $ 5,616 $ 4,633 $ 10,783 $ 8,687
Spinoff | 2019 LTI Plan          
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]          
Number of shares authorized (in shares) 500,000        
Award vesting period 5 years        
Award vesting rights, percentage 20.00%        
TOTAL   $ 195 $ 202 $ 390 $ 403
XML 93 R82.htm IDEA: XBRL DOCUMENT v3.22.2
Options and Awards - Compensation Expense (Details) - USD ($)
shares in Thousands, $ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2022
Jun. 30, 2021
Jun. 30, 2022
Jun. 30, 2021
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]        
TOTAL $ 5,616 $ 4,633 $ 10,783 $ 8,687
Share-based compensation, options outstanding, weighted average remaining contractual term     6 years  
Stock-based compensation expense related to stock options        
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]        
TOTAL 2,786 2,026 $ 5,306 3,759
Share-based compensation, nonvested awards, cost not yet recognized $ 39,110   $ 39,110  
Share-based compensation, nonvested awards, cost not yet recognized, period for recognition     3 years 8 months 12 days  
Share-based compensation, nonvested awards (in shares) 1,767   1,767  
Share-based compensation, options expected to vest, number (in shares) 1,669   1,669  
Stock-based compensation expense related to restricted stock awards        
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]        
TOTAL $ 2,456 2,076 $ 4,758 3,914
Share-based compensation, nonvested awards, cost not yet recognized 28,748   $ 28,748  
Share-based compensation, nonvested awards, cost not yet recognized, period for recognition     3 years 4 months 24 days  
Stock-based compensation expense related to stock options and restricted stock awards to non-employee directors        
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]        
TOTAL $ 374 $ 531 $ 719 $ 1,014
XML 94 R83.htm IDEA: XBRL DOCUMENT v3.22.2
Leases - Lessee Narrative (Details)
$ in Thousands
1 Months Ended 3 Months Ended 6 Months Ended
Aug. 01, 2022
USD ($)
bed
Aug. 01, 2022
bed
operation
Aug. 01, 2022
bed
realEstateProperty
Aug. 01, 2022
bed
repurchaseProgram
Jun. 30, 2022
USD ($)
facility
agreement
renewal
bed
Mar. 31, 2022
USD ($)
Jun. 30, 2021
USD ($)
bed
Jun. 30, 2022
USD ($)
facility
operation
agreement
renewal
bed
lease
Jun. 30, 2021
USD ($)
bed
Jun. 30, 2021
bed
facility
Jun. 30, 2021
bed
operation
Lessee, Lease, Description [Line Items]                      
Master lease agreements | agreement         8     8      
Lessee, operating lease, term of contract         10 years     10 years      
Facilities under master lease arrangement | facility         44     44      
Right-of-use assets obtained in exchange for new and modified operating lease obligations               $ 194,342 $ 112,192    
Operating lease, weighted average remaining lease term         15 years 1 month 6 days     15 years 1 month 6 days      
Operating lease, weighted average discount rate, percent         6.80%     6.80%      
Operational skilled nursing beds | bed         25,500     25,500      
Number of real estate properties | facility         100     100      
Subsequent Event                      
Lessee, Lease, Description [Line Items]                      
Fair value adjustment, lease liability and right-of-use assets $ 10,080                    
Skilled Nursing Operations                      
Lessee, Lease, Description [Line Items]                      
Number of businesses acquired               4   1 12
Operational skilled nursing beds | bed         453   1,263 453 1,263 1,263 1,263
Skilled Nursing Operations | Subsequent Event                      
Lessee, Lease, Description [Line Items]                      
Number of businesses acquired   7 3                
Cost of Sales and General and Administrative Expense                      
Lessee, Lease, Description [Line Items]                      
Rent expense         $ 37,251   $ 34,476 $ 73,036 $ 67,952    
Minimum                      
Lessee, Lease, Description [Line Items]                      
Lessee, operating lease, renewal term         10 years     10 years      
Maximum                      
Lessee, Lease, Description [Line Items]                      
Lessee, operating lease, renewal term         15 years     15 years      
Affiliated Facility, Master Lease One                      
Lessee, Lease, Description [Line Items]                      
Lessee, operating lease, term extension           14 years          
Right-of-use assets obtained in exchange for new and modified operating lease obligations           $ 120,349          
Amended Master Lease | Subsequent Event                      
Lessee, Lease, Description [Line Items]                      
Lessee, operating lease, term extension 20 years 20 years 20 years 20 years              
Right-of-use assets obtained in exchange for new and modified operating lease obligations $ 70,614                    
Operational skilled nursing beds | bed 779 779 779 779              
Amended Master Lease | Skilled Nursing Operations | Subsequent Event                      
Lessee, Lease, Description [Line Items]                      
Number of businesses acquired | operation   5                  
Number of businesses acquired subject to lease amendment | repurchaseProgram       4              
CareTrust REIT                      
Lessee, Lease, Description [Line Items]                      
Skilled nursing, assisted living and independent living facilities | facility         97     97      
Master lease agreements | agreement         9     9      
Lessee, operating lease, renewal term         5 years     5 years      
Operating leases of lessee, contingent rentals, basis spread on variable rate         2.50%     2.50%      
Number of stand-alone leases | lease               1      
Rent expense         $ 16,007   $ 14,419 $ 31,652 $ 28,499    
CareTrust REIT | Minimum                      
Lessee, Lease, Description [Line Items]                      
Lessee, operating lease, term of contract         13 years     13 years      
Lessee leasing arrangements, operating leases, number of renewal terms | renewal         2     2      
CareTrust REIT | Maximum                      
Lessee, Lease, Description [Line Items]                      
Lessee, operating lease, term of contract         20 years     20 years      
Lessee leasing arrangements, operating leases, number of renewal terms | renewal         3     3      
CareTrust REIT | Third Party Tenants Under Triple Net Lease Arrangements                      
Lessee, Lease, Description [Line Items]                      
Skilled nursing, assisted living and independent living facilities | facility         96     96      
CareTrust REIT | Purchase Option                      
Lessee, Lease, Description [Line Items]                      
Skilled nursing, assisted living and independent living facilities | facility         4     4      
Various Landlords                      
Lessee, Lease, Description [Line Items]                      
Lessee, operating lease, term of contract         15 years     15 years      
Lessee leasing arrangements, operating leases, number of renewal terms | renewal         2     2      
Lessee, operating lease, renewal term         5 years     5 years      
Various Landlords | Minimum                      
Lessee, Lease, Description [Line Items]                      
Lessee, operating lease, term of contract         5 years     5 years      
Various Landlords | Minimum | Equipment                      
Lessee, Lease, Description [Line Items]                      
Lessee, operating lease, term of contract         3 years     3 years      
Various Landlords | Maximum                      
Lessee, Lease, Description [Line Items]                      
Lessee, operating lease, term of contract         20 years     20 years      
Various Landlords | Maximum | Equipment                      
Lessee, Lease, Description [Line Items]                      
Lessee, operating lease, term of contract         5 years     5 years      
XML 95 R84.htm IDEA: XBRL DOCUMENT v3.22.2
Leases - Lessee Lease Cost (Details) - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2022
Jun. 30, 2021
Jun. 30, 2022
Jun. 30, 2021
Lessee, Lease, Description [Line Items]        
Operating lease expense $ 41,311 $ 38,460 $ 82,748 $ 75,669
Amortization of deferred rent 116 109 240 221
Rent - cost of services        
Lessee, Lease, Description [Line Items]        
Operating lease expense 37,228 34,455 72,990 67,911
Variable lease, cost 1,302 832 2,239 1,416
General and administrative expense        
Lessee, Lease, Description [Line Items]        
Operating lease expense 23 21 46 41
Depreciation and amortization        
Lessee, Lease, Description [Line Items]        
Operating lease expense 288 290 577 580
Variable lease costs        
Lessee, Lease, Description [Line Items]        
Variable lease, cost $ 3,772 $ 3,694 $ 9,135 $ 7,137
XML 96 R85.htm IDEA: XBRL DOCUMENT v3.22.2
Leases - Lessee Future Minimum Lease Payments (Details) - USD ($)
$ in Thousands
Jun. 30, 2022
Dec. 31, 2021
Year    
2022 (remainder) $ 71,530  
2023 141,887  
2024 141,296  
2025 141,187  
2026 141,082  
2027 140,564  
Thereafter 1,254,424  
TOTAL LEASE PAYMENTS 2,031,970  
Less: present value adjustment (756,866)  
PRESENT VALUE OF TOTAL LEASE LIABILITIES 1,275,104  
Less: current lease liabilities (58,769) $ (52,181)
LONG-TERM OPERATING LEASE LIABILITIES $ 1,216,335 $ 1,056,515
XML 97 R86.htm IDEA: XBRL DOCUMENT v3.22.2
Leases - Lessor Narrative (Details)
3 Months Ended
Jun. 30, 2022
facility
Jun. 30, 2022
seniorLivingCommunity
Jun. 30, 2022
operation
Oct. 31, 2019
operation
Oct. 01, 2019
Lessor, Lease, Description [Line Items]          
Number of real estate properties 100        
Disposal Group, Disposed of by Sale, Not Discontinued Operations | Senior Living Operations          
Lessor, Lease, Description [Line Items]          
Senior living facility 2        
Spinoff | Minimum          
Lessor, Lease, Description [Line Items]          
Lessor, operating lease, term of contract         14 years
Spinoff | Maximum          
Lessor, Lease, Description [Line Items]          
Lessor, operating lease, term of contract         16 years
Spinoff | Senior Living Facilities          
Lessor, Lease, Description [Line Items]          
Number of real estate properties | operation     1    
The Pennant Group, Inc. | Spinoff | Senior Living Facilities          
Lessor, Lease, Description [Line Items]          
Number of real estate properties   29 3 29  
XML 98 R87.htm IDEA: XBRL DOCUMENT v3.22.2
Leases - Lessor Rental Income (Details) - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2022
Jun. 30, 2021
Jun. 30, 2022
Jun. 30, 2021
Lessor, Lease, Description [Line Items]        
Operating lease, lease income $ 4,139 $ 3,927 $ 8,428 $ 7,904
Pennant        
Lessor, Lease, Description [Line Items]        
Operating lease, variable lease income 327 266 657 580
Pennant        
Lessor, Lease, Description [Line Items]        
Operating lease, lease income 3,690 3,440 7,505 6,928
Other third-party        
Lessor, Lease, Description [Line Items]        
Operating lease, lease income $ 449 $ 487 $ 923 $ 976
XML 99 R88.htm IDEA: XBRL DOCUMENT v3.22.2
Leases - Lessor Future Minimum Lease Payments Receivable (Details)
$ in Thousands
Jun. 30, 2022
USD ($)
Leases [Abstract]  
2022 (remainder) $ 8,098
2023 15,820
2024 15,373
2025 15,032
2026 14,821
2027 14,821
Thereafter 77,369
TOTAL $ 161,334
XML 100 R89.htm IDEA: XBRL DOCUMENT v3.22.2
Commitments and Contingencies (Details)
$ in Thousands
3 Months Ended 6 Months Ended 12 Months Ended
Jun. 30, 2022
facility
Jun. 30, 2021
Jun. 30, 2022
facility
Jun. 30, 2021
Dec. 31, 2021
Jul. 27, 2022
USD ($)
Concentration Risk [Line Items]            
Facilities under Medicare probe reviews | facility 22   22      
Subsequent Event            
Concentration Risk [Line Items]            
Cash, uninsured amount | $           $ 567
Customer Concentration Risk | Total Medicaid and Medicare | Accounts Receivable            
Concentration Risk [Line Items]            
Concentration risk     52.90%   54.00%  
Customer Concentration Risk | Total Medicaid and Medicare | Revenue Benchmark            
Concentration Risk [Line Items]            
Concentration risk 73.40% 73.10% 73.40% 73.60%    
XML 101 R90.htm IDEA: XBRL DOCUMENT v3.22.2
Common Stock Repurchase Program (Details) - USD ($)
shares in Thousands
3 Months Ended
Jul. 28, 2022
Feb. 09, 2022
Oct. 21, 2021
Jun. 30, 2022
Mar. 31, 2022
Dec. 31, 2021
Equity, Class of Treasury Stock [Line Items]            
Repurchase of common stock, value       $ 20,000,000 $ 9,882,000  
February 9, 2022 Repurchase Program            
Equity, Class of Treasury Stock [Line Items]            
Stock repurchase program, authorized amount   $ 20,000,000        
Stock repurchase program, period in force   12 months        
October 21, 2021 Repurchase Program            
Equity, Class of Treasury Stock [Line Items]            
Stock repurchase program, authorized amount     $ 20,000,000      
Stock repurchase program, period in force     12 months      
Repurchase of common stock (in shares)       271 133 132
Repurchase of common stock, value       $ 20,000,000 $ 9,882,000 $ 10,118,000
July 2022 Repurchase Program | Subsequent Event            
Equity, Class of Treasury Stock [Line Items]            
Stock repurchase program, authorized amount $ 20,000,000          
Stock repurchase program, period in force 12 months          
XML 102 ensg-20220630_htm.xml IDEA: XBRL DOCUMENT 0001125376 2022-01-01 2022-06-30 0001125376 2022-07-27 0001125376 2022-06-30 0001125376 2021-12-31 0001125376 us-gaap:ServiceMember 2022-04-01 2022-06-30 0001125376 us-gaap:ServiceMember 2021-04-01 2021-06-30 0001125376 us-gaap:ServiceMember 2022-01-01 2022-06-30 0001125376 us-gaap:ServiceMember 2021-01-01 2021-06-30 0001125376 ensg:RentalMember 2022-04-01 2022-06-30 0001125376 ensg:RentalMember 2021-04-01 2021-06-30 0001125376 ensg:RentalMember 2022-01-01 2022-06-30 0001125376 ensg:RentalMember 2021-01-01 2021-06-30 0001125376 2022-04-01 2022-06-30 0001125376 2021-04-01 2021-06-30 0001125376 2021-01-01 2021-06-30 0001125376 us-gaap:CommonStockMember 2021-12-31 0001125376 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0001125376 us-gaap:RetainedEarningsMember 2021-12-31 0001125376 us-gaap:TreasuryStockMember 2021-12-31 0001125376 us-gaap:NoncontrollingInterestMember 2021-12-31 0001125376 us-gaap:CommonStockMember 2022-01-01 2022-03-31 0001125376 us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-03-31 0001125376 2022-01-01 2022-03-31 0001125376 us-gaap:TreasuryStockMember 2022-01-01 2022-03-31 0001125376 us-gaap:RetainedEarningsMember 2022-01-01 2022-03-31 0001125376 us-gaap:NoncontrollingInterestMember 2022-01-01 2022-03-31 0001125376 us-gaap:CommonStockMember 2022-03-31 0001125376 us-gaap:AdditionalPaidInCapitalMember 2022-03-31 0001125376 us-gaap:RetainedEarningsMember 2022-03-31 0001125376 us-gaap:TreasuryStockMember 2022-03-31 0001125376 us-gaap:NoncontrollingInterestMember 2022-03-31 0001125376 2022-03-31 0001125376 us-gaap:CommonStockMember 2022-04-01 2022-06-30 0001125376 us-gaap:AdditionalPaidInCapitalMember 2022-04-01 2022-06-30 0001125376 us-gaap:TreasuryStockMember 2022-04-01 2022-06-30 0001125376 us-gaap:RetainedEarningsMember 2022-04-01 2022-06-30 0001125376 us-gaap:NoncontrollingInterestMember 2022-04-01 2022-06-30 0001125376 us-gaap:CommonStockMember 2022-06-30 0001125376 us-gaap:AdditionalPaidInCapitalMember 2022-06-30 0001125376 us-gaap:RetainedEarningsMember 2022-06-30 0001125376 us-gaap:TreasuryStockMember 2022-06-30 0001125376 us-gaap:NoncontrollingInterestMember 2022-06-30 0001125376 us-gaap:CommonStockMember 2020-12-31 0001125376 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0001125376 us-gaap:RetainedEarningsMember 2020-12-31 0001125376 us-gaap:TreasuryStockMember 2020-12-31 0001125376 us-gaap:NoncontrollingInterestMember 2020-12-31 0001125376 2020-12-31 0001125376 us-gaap:CommonStockMember 2021-01-01 2021-03-31 0001125376 us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-03-31 0001125376 2021-01-01 2021-03-31 0001125376 us-gaap:TreasuryStockMember 2021-01-01 2021-03-31 0001125376 us-gaap:RetainedEarningsMember 2021-01-01 2021-03-31 0001125376 us-gaap:NoncontrollingInterestMember 2021-01-01 2021-03-31 0001125376 us-gaap:CommonStockMember 2021-03-31 0001125376 us-gaap:AdditionalPaidInCapitalMember 2021-03-31 0001125376 us-gaap:RetainedEarningsMember 2021-03-31 0001125376 us-gaap:TreasuryStockMember 2021-03-31 0001125376 us-gaap:NoncontrollingInterestMember 2021-03-31 0001125376 2021-03-31 0001125376 us-gaap:CommonStockMember 2021-04-01 2021-06-30 0001125376 us-gaap:AdditionalPaidInCapitalMember 2021-04-01 2021-06-30 0001125376 us-gaap:TreasuryStockMember 2021-04-01 2021-06-30 0001125376 us-gaap:RetainedEarningsMember 2021-04-01 2021-06-30 0001125376 us-gaap:NoncontrollingInterestMember 2021-04-01 2021-06-30 0001125376 us-gaap:CommonStockMember 2021-06-30 0001125376 us-gaap:AdditionalPaidInCapitalMember 2021-06-30 0001125376 us-gaap:RetainedEarningsMember 2021-06-30 0001125376 us-gaap:TreasuryStockMember 2021-06-30 0001125376 us-gaap:NoncontrollingInterestMember 2021-06-30 0001125376 2021-06-30 0001125376 us-gaap:WhollyOwnedPropertiesMember 2022-06-30 0001125376 ensg:SeniorLivingFacilitiesMember us-gaap:SpinoffMember ensg:ThePennantGroupInc.Member 2022-06-30 0001125376 ensg:RemainingCompanyMember ensg:SkilledNursingOperationsMember us-gaap:SpinoffMember ensg:StandardBearerHealthcareREITIncMember 2022-06-30 0001125376 srt:MinimumMember 2022-01-01 2022-06-30 0001125376 srt:MaximumMember 2022-01-01 2022-06-30 0001125376 srt:MinimumMember 2022-06-30 0001125376 srt:MaximumMember 2022-06-30 0001125376 srt:MinimumMember ensg:AssembledOccupancyAcquiredMember 2022-01-01 2022-06-30 0001125376 srt:MaximumMember ensg:AssembledOccupancyAcquiredMember 2022-01-01 2022-06-30 0001125376 us-gaap:TradeNamesMember 2022-01-01 2022-06-30 0001125376 us-gaap:CustomerRelationshipsMember 2022-01-01 2022-06-30 0001125376 us-gaap:GeneralLiabilityMember ensg:SelfInsuranceRetentionPerClaimMember srt:ParentCompanyMember 2022-06-30 0001125376 us-gaap:GeneralLiabilityMember stpr:CA ensg:AggregateDeductibleMember srt:ParentCompanyMember 2022-06-30 0001125376 us-gaap:GeneralLiabilityMember ensg:NonCaliforniaMember ensg:AggregateDeductibleMember srt:ParentCompanyMember 2022-06-30 0001125376 us-gaap:GeneralLiabilityMember ensg:AllStatesExceptColoradoMember ensg:PerOccurenceMember naics:ZZ524292 2022-06-30 0001125376 us-gaap:GeneralLiabilityMember ensg:AllStatesExceptColoradoMember ensg:PerFacilityMember naics:ZZ524292 2022-06-30 0001125376 us-gaap:GeneralLiabilityMember ensg:AllStatesExceptColoradoMember ensg:BlanketAggregateMember naics:ZZ524292 2022-06-30 0001125376 us-gaap:GeneralLiabilityMember stpr:CO ensg:PerOccurenceMember naics:ZZ524292 2022-06-30 0001125376 us-gaap:GeneralLiabilityMember stpr:CO ensg:PerFacilityMember naics:ZZ524292 2022-06-30 0001125376 us-gaap:ProfessionalMalpracticeLiabilityMember 2022-06-30 0001125376 us-gaap:ProfessionalMalpracticeLiabilityMember 2021-12-31 0001125376 us-gaap:WorkersCompensationInsuranceMember 2022-06-30 0001125376 us-gaap:WorkersCompensationInsuranceMember stpr:TX 2022-06-30 0001125376 us-gaap:WorkersCompensationInsuranceMember ensg:OtherStatesExceptCaliforniaTexasAndWashingtonMember ensg:LossSensitivelimitperclaimMemberMember 2022-06-30 0001125376 us-gaap:GeneralLiabilityMember ensg:SelfInsuranceRetentionPerClaimMember 2022-06-30 0001125376 us-gaap:WorkersCompensationInsuranceMember 2022-06-30 0001125376 us-gaap:WorkersCompensationInsuranceMember 2021-12-31 0001125376 ensg:HealthLiabilityInsuranceMember ensg:StopLossInsuranceLimitPerClaimMember 2022-06-30 0001125376 us-gaap:HealthInsuranceProductLineMember 2022-06-30 0001125376 us-gaap:HealthInsuranceProductLineMember 2021-12-31 0001125376 us-gaap:RevolvingCreditFacilityMember ensg:TruistBankMember 2022-04-01 2022-06-30 0001125376 us-gaap:RevolvingCreditFacilityMember ensg:TruistBankMember 2022-04-08 0001125376 2020-01-01 2020-12-31 0001125376 2021-03-01 2021-03-31 0001125376 ensg:MedicaidAndMedicareMember us-gaap:ServiceMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2022-04-01 2022-06-30 0001125376 ensg:MedicaidAndMedicareMember us-gaap:ServiceMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2022-01-01 2022-06-30 0001125376 ensg:MedicaidAndMedicareMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2021-04-01 2021-06-30 0001125376 ensg:MedicaidAndMedicareMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2021-01-01 2021-06-30 0001125376 ensg:MedicaidMember us-gaap:ServiceMember 2022-04-01 2022-06-30 0001125376 ensg:MedicaidMember us-gaap:ServiceMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2022-04-01 2022-06-30 0001125376 ensg:MedicaidMember us-gaap:ServiceMember 2021-04-01 2021-06-30 0001125376 ensg:MedicaidMember us-gaap:ServiceMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2021-04-01 2021-06-30 0001125376 ensg:MedicareMember us-gaap:ServiceMember 2022-04-01 2022-06-30 0001125376 ensg:MedicareMember us-gaap:ServiceMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2022-04-01 2022-06-30 0001125376 ensg:MedicareMember us-gaap:ServiceMember 2021-04-01 2021-06-30 0001125376 ensg:MedicareMember us-gaap:ServiceMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2021-04-01 2021-06-30 0001125376 ensg:MedicaidSkilledMember us-gaap:ServiceMember 2022-04-01 2022-06-30 0001125376 ensg:MedicaidSkilledMember us-gaap:ServiceMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2022-04-01 2022-06-30 0001125376 ensg:MedicaidSkilledMember us-gaap:ServiceMember 2021-04-01 2021-06-30 0001125376 ensg:MedicaidSkilledMember us-gaap:ServiceMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2021-04-01 2021-06-30 0001125376 ensg:MedicaidAndMedicareMember us-gaap:ServiceMember 2022-04-01 2022-06-30 0001125376 ensg:MedicaidAndMedicareMember us-gaap:ServiceMember 2021-04-01 2021-06-30 0001125376 ensg:MedicaidAndMedicareMember us-gaap:ServiceMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2021-04-01 2021-06-30 0001125376 ensg:ManagedCareMember us-gaap:ServiceMember 2022-04-01 2022-06-30 0001125376 ensg:ManagedCareMember us-gaap:ServiceMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2022-04-01 2022-06-30 0001125376 ensg:ManagedCareMember us-gaap:ServiceMember 2021-04-01 2021-06-30 0001125376 ensg:ManagedCareMember us-gaap:ServiceMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2021-04-01 2021-06-30 0001125376 ensg:PrivatePayAndOtherMember us-gaap:ServiceMember 2022-04-01 2022-06-30 0001125376 ensg:PrivatePayAndOtherMember us-gaap:ServiceMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2022-04-01 2022-06-30 0001125376 ensg:PrivatePayAndOtherMember us-gaap:ServiceMember 2021-04-01 2021-06-30 0001125376 ensg:PrivatePayAndOtherMember us-gaap:ServiceMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2021-04-01 2021-06-30 0001125376 us-gaap:ServiceMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2022-04-01 2022-06-30 0001125376 us-gaap:ServiceMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2021-04-01 2021-06-30 0001125376 ensg:MedicaidMember us-gaap:ServiceMember 2022-01-01 2022-06-30 0001125376 ensg:MedicaidMember us-gaap:ServiceMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2022-01-01 2022-06-30 0001125376 ensg:MedicaidMember us-gaap:ServiceMember 2021-01-01 2021-06-30 0001125376 ensg:MedicaidMember us-gaap:ServiceMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2021-01-01 2021-06-30 0001125376 ensg:MedicareMember us-gaap:ServiceMember 2022-01-01 2022-06-30 0001125376 ensg:MedicareMember us-gaap:ServiceMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2022-01-01 2022-06-30 0001125376 ensg:MedicareMember us-gaap:ServiceMember 2021-01-01 2021-06-30 0001125376 ensg:MedicareMember us-gaap:ServiceMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2021-01-01 2021-06-30 0001125376 ensg:MedicaidSkilledMember us-gaap:ServiceMember 2022-01-01 2022-06-30 0001125376 ensg:MedicaidSkilledMember us-gaap:ServiceMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2022-01-01 2022-06-30 0001125376 ensg:MedicaidSkilledMember us-gaap:ServiceMember 2021-01-01 2021-06-30 0001125376 ensg:MedicaidSkilledMember us-gaap:ServiceMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2021-01-01 2021-06-30 0001125376 ensg:MedicaidAndMedicareMember us-gaap:ServiceMember 2022-01-01 2022-06-30 0001125376 ensg:MedicaidAndMedicareMember us-gaap:ServiceMember 2021-01-01 2021-06-30 0001125376 ensg:MedicaidAndMedicareMember us-gaap:ServiceMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2021-01-01 2021-06-30 0001125376 ensg:ManagedCareMember us-gaap:ServiceMember 2022-01-01 2022-06-30 0001125376 ensg:ManagedCareMember us-gaap:ServiceMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2022-01-01 2022-06-30 0001125376 ensg:ManagedCareMember us-gaap:ServiceMember 2021-01-01 2021-06-30 0001125376 ensg:ManagedCareMember us-gaap:ServiceMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2021-01-01 2021-06-30 0001125376 ensg:PrivatePayAndOtherMember us-gaap:ServiceMember 2022-01-01 2022-06-30 0001125376 ensg:PrivatePayAndOtherMember us-gaap:ServiceMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2022-01-01 2022-06-30 0001125376 ensg:PrivatePayAndOtherMember us-gaap:ServiceMember 2021-01-01 2021-06-30 0001125376 ensg:PrivatePayAndOtherMember us-gaap:ServiceMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2021-01-01 2021-06-30 0001125376 us-gaap:ServiceMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2022-01-01 2022-06-30 0001125376 us-gaap:ServiceMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2021-01-01 2021-06-30 0001125376 ensg:MedicaidMember 2022-06-30 0001125376 ensg:MedicaidMember 2021-12-31 0001125376 ensg:ManagedCareMember 2022-06-30 0001125376 ensg:ManagedCareMember 2021-12-31 0001125376 ensg:MedicareMember 2022-06-30 0001125376 ensg:MedicareMember 2021-12-31 0001125376 ensg:PrivatePayAndOtherMember 2022-06-30 0001125376 ensg:PrivatePayAndOtherMember 2021-12-31 0001125376 us-gaap:FairValueInputsLevel1Member 2022-06-30 0001125376 us-gaap:FairValueInputsLevel1Member 2021-12-31 0001125376 us-gaap:FairValueInputsLevel2Member 2022-06-30 0001125376 us-gaap:FairValueInputsLevel2Member 2021-12-31 0001125376 us-gaap:DomesticCorporateDebtSecuritiesMember 2022-06-30 0001125376 us-gaap:DomesticCorporateDebtSecuritiesMember 2021-12-31 0001125376 ensg:StandardBearerHealthcareREITIncMember 2022-06-30 0001125376 us-gaap:WhollyOwnedPropertiesMember ensg:StandardBearerHealthcareREITIncMember 2022-06-30 0001125376 ensg:ThirdPartiesMember ensg:StandardBearerHealthcareREITIncMember 2022-06-30 0001125376 ensg:OwnedPropertiesMember ensg:StandardBearerHealthcareREITIncMember 2022-01-01 2022-06-30 0001125376 ensg:OwnedPropertiesMember us-gaap:SubsequentEventMember ensg:StandardBearerHealthcareREITIncMember 2022-07-01 2022-08-01 0001125376 ensg:CampusOperationMember us-gaap:SubsequentEventMember 2022-07-01 2022-08-01 0001125376 2022-01-01 2022-01-31 0001125376 srt:MinimumMember ensg:StandardBearerMasterLeasesMember 2022-06-30 0001125376 srt:MaximumMember ensg:StandardBearerMasterLeasesMember 2022-06-30 0001125376 ensg:StandardBearerMasterLeasesMember 2022-01-31 0001125376 ensg:StandardBearerMasterLeasesMember 2022-04-01 2022-06-30 0001125376 ensg:StandardBearerMasterLeasesMember 2022-01-01 2022-06-30 0001125376 ensg:StandardBearerMasterLeasesMember 2021-04-01 2021-06-30 0001125376 ensg:StandardBearerMasterLeasesMember 2021-01-01 2021-06-30 0001125376 us-gaap:ManagementServiceBaseMember ensg:StandardBearerMasterLeasesMember 2022-01-01 2022-01-31 0001125376 us-gaap:ManagementServiceIncentiveMember ensg:StandardBearerMasterLeasesMember 2022-01-01 2022-01-31 0001125376 us-gaap:ManagementServiceBaseMember ensg:StandardBearerMasterLeasesMember 2022-04-01 2022-06-30 0001125376 us-gaap:ManagementServiceBaseMember ensg:StandardBearerMasterLeasesMember 2022-01-01 2022-06-30 0001125376 ensg:ManagementServiceTotalMember ensg:StandardBearerMasterLeasesMember 2022-04-01 2022-06-30 0001125376 ensg:ManagementServiceTotalMember ensg:StandardBearerMasterLeasesMember 2022-01-01 2022-06-30 0001125376 srt:MinimumMember us-gaap:RevolvingCreditFacilityMember ensg:TruistBankMember us-gaap:BaseRateMember 2022-04-08 2022-04-08 0001125376 srt:MaximumMember us-gaap:RevolvingCreditFacilityMember ensg:TruistBankMember us-gaap:BaseRateMember 2022-04-08 2022-04-08 0001125376 srt:MinimumMember us-gaap:RevolvingCreditFacilityMember ensg:TruistBankMember us-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember 2022-04-08 2022-04-08 0001125376 srt:MaximumMember us-gaap:RevolvingCreditFacilityMember ensg:TruistBankMember us-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember 2022-04-08 2022-04-08 0001125376 ensg:StandardBearerEquityPlanMember 2022-01-01 2022-01-31 0001125376 ensg:StandardBearerEquityPlanMember 2022-01-01 2022-06-30 0001125376 ensg:StandardBearerEquityPlanMember 2022-04-01 2022-06-30 0001125376 us-gaap:OperatingSegmentsMember us-gaap:ServiceMember ensg:SkilledServicesSegmentMember 2022-04-01 2022-06-30 0001125376 us-gaap:OperatingSegmentsMember us-gaap:ServiceMember ensg:StandardBearerSegmentMember 2022-04-01 2022-06-30 0001125376 us-gaap:OperatingSegmentsMember us-gaap:ServiceMember us-gaap:AllOtherSegmentsMember 2022-04-01 2022-06-30 0001125376 srt:ConsolidationEliminationsMember us-gaap:ServiceMember 2022-04-01 2022-06-30 0001125376 us-gaap:OperatingSegmentsMember ensg:RentalMember ensg:SkilledServicesSegmentMember 2022-04-01 2022-06-30 0001125376 us-gaap:OperatingSegmentsMember ensg:RentalMember ensg:StandardBearerSegmentMember 2022-04-01 2022-06-30 0001125376 us-gaap:OperatingSegmentsMember ensg:RentalMember us-gaap:AllOtherSegmentsMember 2022-04-01 2022-06-30 0001125376 srt:ConsolidationEliminationsMember ensg:RentalMember 2022-04-01 2022-06-30 0001125376 us-gaap:OperatingSegmentsMember ensg:SkilledServicesSegmentMember 2022-04-01 2022-06-30 0001125376 us-gaap:OperatingSegmentsMember ensg:StandardBearerSegmentMember 2022-04-01 2022-06-30 0001125376 us-gaap:OperatingSegmentsMember us-gaap:AllOtherSegmentsMember 2022-04-01 2022-06-30 0001125376 srt:ConsolidationEliminationsMember 2022-04-01 2022-06-30 0001125376 us-gaap:OperatingSegmentsMember us-gaap:ServiceMember ensg:SkilledServicesSegmentMember 2021-04-01 2021-06-30 0001125376 us-gaap:OperatingSegmentsMember us-gaap:ServiceMember ensg:StandardBearerSegmentMember 2021-04-01 2021-06-30 0001125376 us-gaap:OperatingSegmentsMember us-gaap:ServiceMember us-gaap:AllOtherSegmentsMember 2021-04-01 2021-06-30 0001125376 srt:ConsolidationEliminationsMember us-gaap:ServiceMember 2021-04-01 2021-06-30 0001125376 us-gaap:OperatingSegmentsMember ensg:RentalMember ensg:SkilledServicesSegmentMember 2021-04-01 2021-06-30 0001125376 us-gaap:OperatingSegmentsMember ensg:RentalMember ensg:StandardBearerSegmentMember 2021-04-01 2021-06-30 0001125376 us-gaap:OperatingSegmentsMember ensg:RentalMember us-gaap:AllOtherSegmentsMember 2021-04-01 2021-06-30 0001125376 srt:ConsolidationEliminationsMember ensg:RentalMember 2021-04-01 2021-06-30 0001125376 us-gaap:OperatingSegmentsMember ensg:SkilledServicesSegmentMember 2021-04-01 2021-06-30 0001125376 us-gaap:OperatingSegmentsMember ensg:StandardBearerSegmentMember 2021-04-01 2021-06-30 0001125376 us-gaap:OperatingSegmentsMember us-gaap:AllOtherSegmentsMember 2021-04-01 2021-06-30 0001125376 srt:ConsolidationEliminationsMember 2021-04-01 2021-06-30 0001125376 srt:ConsolidationEliminationsMember 2021-01-01 2021-06-30 0001125376 us-gaap:OperatingSegmentsMember us-gaap:ServiceMember ensg:SkilledServicesSegmentMember 2022-01-01 2022-06-30 0001125376 us-gaap:OperatingSegmentsMember us-gaap:ServiceMember ensg:StandardBearerSegmentMember 2022-01-01 2022-06-30 0001125376 us-gaap:OperatingSegmentsMember us-gaap:ServiceMember us-gaap:AllOtherSegmentsMember 2022-01-01 2022-06-30 0001125376 srt:ConsolidationEliminationsMember us-gaap:ServiceMember 2022-01-01 2022-06-30 0001125376 us-gaap:OperatingSegmentsMember ensg:RentalMember ensg:SkilledServicesSegmentMember 2022-01-01 2022-06-30 0001125376 us-gaap:OperatingSegmentsMember ensg:RentalMember ensg:StandardBearerSegmentMember 2022-01-01 2022-06-30 0001125376 us-gaap:OperatingSegmentsMember ensg:RentalMember us-gaap:AllOtherSegmentsMember 2022-01-01 2022-06-30 0001125376 srt:ConsolidationEliminationsMember ensg:RentalMember 2022-01-01 2022-06-30 0001125376 us-gaap:OperatingSegmentsMember ensg:SkilledServicesSegmentMember 2022-01-01 2022-06-30 0001125376 us-gaap:OperatingSegmentsMember ensg:StandardBearerSegmentMember 2022-01-01 2022-06-30 0001125376 us-gaap:OperatingSegmentsMember us-gaap:AllOtherSegmentsMember 2022-01-01 2022-06-30 0001125376 srt:ConsolidationEliminationsMember 2022-01-01 2022-06-30 0001125376 us-gaap:OperatingSegmentsMember us-gaap:ServiceMember ensg:SkilledServicesSegmentMember 2021-01-01 2021-06-30 0001125376 us-gaap:OperatingSegmentsMember us-gaap:ServiceMember ensg:StandardBearerSegmentMember 2021-01-01 2021-06-30 0001125376 us-gaap:OperatingSegmentsMember us-gaap:ServiceMember us-gaap:AllOtherSegmentsMember 2021-01-01 2021-06-30 0001125376 srt:ConsolidationEliminationsMember us-gaap:ServiceMember 2021-01-01 2021-06-30 0001125376 us-gaap:OperatingSegmentsMember ensg:RentalMember ensg:SkilledServicesSegmentMember 2021-01-01 2021-06-30 0001125376 us-gaap:OperatingSegmentsMember ensg:RentalMember ensg:StandardBearerSegmentMember 2021-01-01 2021-06-30 0001125376 us-gaap:OperatingSegmentsMember ensg:RentalMember us-gaap:AllOtherSegmentsMember 2021-01-01 2021-06-30 0001125376 srt:ConsolidationEliminationsMember ensg:RentalMember 2021-01-01 2021-06-30 0001125376 us-gaap:OperatingSegmentsMember ensg:SkilledServicesSegmentMember 2021-01-01 2021-06-30 0001125376 us-gaap:OperatingSegmentsMember ensg:StandardBearerSegmentMember 2021-01-01 2021-06-30 0001125376 us-gaap:OperatingSegmentsMember us-gaap:AllOtherSegmentsMember 2021-01-01 2021-06-30 0001125376 us-gaap:OperatingSegmentsMember ensg:MedicaidMember us-gaap:ServiceMember ensg:SkilledServicesSegmentMember 2022-04-01 2022-06-30 0001125376 us-gaap:CorporateNonSegmentMember ensg:MedicaidMember us-gaap:ServiceMember 2022-04-01 2022-06-30 0001125376 us-gaap:OperatingSegmentsMember ensg:MedicareMember us-gaap:ServiceMember ensg:SkilledServicesSegmentMember 2022-04-01 2022-06-30 0001125376 us-gaap:CorporateNonSegmentMember ensg:MedicareMember us-gaap:ServiceMember 2022-04-01 2022-06-30 0001125376 us-gaap:OperatingSegmentsMember ensg:MedicaidSkilledMember us-gaap:ServiceMember ensg:SkilledServicesSegmentMember 2022-04-01 2022-06-30 0001125376 us-gaap:CorporateNonSegmentMember ensg:MedicaidSkilledMember us-gaap:ServiceMember 2022-04-01 2022-06-30 0001125376 us-gaap:OperatingSegmentsMember ensg:MedicaidAndMedicareMember us-gaap:ServiceMember ensg:SkilledServicesSegmentMember 2022-04-01 2022-06-30 0001125376 us-gaap:CorporateNonSegmentMember ensg:MedicaidAndMedicareMember us-gaap:ServiceMember 2022-04-01 2022-06-30 0001125376 us-gaap:OperatingSegmentsMember ensg:ManagedCareMember us-gaap:ServiceMember ensg:SkilledServicesSegmentMember 2022-04-01 2022-06-30 0001125376 us-gaap:CorporateNonSegmentMember ensg:ManagedCareMember us-gaap:ServiceMember 2022-04-01 2022-06-30 0001125376 us-gaap:OperatingSegmentsMember ensg:PrivatePayAndOtherMember us-gaap:ServiceMember ensg:SkilledServicesSegmentMember 2022-04-01 2022-06-30 0001125376 us-gaap:CorporateNonSegmentMember ensg:PrivatePayAndOtherMember us-gaap:ServiceMember 2022-04-01 2022-06-30 0001125376 us-gaap:CorporateNonSegmentMember us-gaap:ServiceMember 2022-04-01 2022-06-30 0001125376 us-gaap:OperatingSegmentsMember ensg:MedicaidMember us-gaap:ServiceMember ensg:SkilledServicesSegmentMember 2021-04-01 2021-06-30 0001125376 us-gaap:CorporateNonSegmentMember ensg:MedicaidMember us-gaap:ServiceMember 2021-04-01 2021-06-30 0001125376 us-gaap:OperatingSegmentsMember ensg:MedicareMember us-gaap:ServiceMember ensg:SkilledServicesSegmentMember 2021-04-01 2021-06-30 0001125376 us-gaap:CorporateNonSegmentMember ensg:MedicareMember us-gaap:ServiceMember 2021-04-01 2021-06-30 0001125376 us-gaap:OperatingSegmentsMember ensg:MedicaidSkilledMember us-gaap:ServiceMember ensg:SkilledServicesSegmentMember 2021-04-01 2021-06-30 0001125376 us-gaap:CorporateNonSegmentMember ensg:MedicaidSkilledMember us-gaap:ServiceMember 2021-04-01 2021-06-30 0001125376 us-gaap:OperatingSegmentsMember ensg:MedicaidAndMedicareMember us-gaap:ServiceMember ensg:SkilledServicesSegmentMember 2021-04-01 2021-06-30 0001125376 us-gaap:CorporateNonSegmentMember ensg:MedicaidAndMedicareMember us-gaap:ServiceMember 2021-04-01 2021-06-30 0001125376 us-gaap:OperatingSegmentsMember ensg:ManagedCareMember us-gaap:ServiceMember ensg:SkilledServicesSegmentMember 2021-04-01 2021-06-30 0001125376 us-gaap:CorporateNonSegmentMember ensg:ManagedCareMember us-gaap:ServiceMember 2021-04-01 2021-06-30 0001125376 us-gaap:OperatingSegmentsMember ensg:PrivatePayAndOtherMember us-gaap:ServiceMember ensg:SkilledServicesSegmentMember 2021-04-01 2021-06-30 0001125376 us-gaap:CorporateNonSegmentMember ensg:PrivatePayAndOtherMember us-gaap:ServiceMember 2021-04-01 2021-06-30 0001125376 us-gaap:CorporateNonSegmentMember us-gaap:ServiceMember 2021-04-01 2021-06-30 0001125376 us-gaap:OperatingSegmentsMember ensg:MedicaidMember us-gaap:ServiceMember ensg:SkilledServicesSegmentMember 2022-01-01 2022-06-30 0001125376 us-gaap:CorporateNonSegmentMember ensg:MedicaidMember us-gaap:ServiceMember 2022-01-01 2022-06-30 0001125376 us-gaap:OperatingSegmentsMember ensg:MedicareMember us-gaap:ServiceMember ensg:SkilledServicesSegmentMember 2022-01-01 2022-06-30 0001125376 us-gaap:CorporateNonSegmentMember ensg:MedicareMember us-gaap:ServiceMember 2022-01-01 2022-06-30 0001125376 us-gaap:OperatingSegmentsMember ensg:MedicaidSkilledMember us-gaap:ServiceMember ensg:SkilledServicesSegmentMember 2022-01-01 2022-06-30 0001125376 us-gaap:CorporateNonSegmentMember ensg:MedicaidSkilledMember us-gaap:ServiceMember 2022-01-01 2022-06-30 0001125376 us-gaap:OperatingSegmentsMember ensg:MedicaidAndMedicareMember us-gaap:ServiceMember ensg:SkilledServicesSegmentMember 2022-01-01 2022-06-30 0001125376 us-gaap:CorporateNonSegmentMember ensg:MedicaidAndMedicareMember us-gaap:ServiceMember 2022-01-01 2022-06-30 0001125376 us-gaap:OperatingSegmentsMember ensg:ManagedCareMember us-gaap:ServiceMember ensg:SkilledServicesSegmentMember 2022-01-01 2022-06-30 0001125376 us-gaap:CorporateNonSegmentMember ensg:ManagedCareMember us-gaap:ServiceMember 2022-01-01 2022-06-30 0001125376 us-gaap:OperatingSegmentsMember ensg:PrivatePayAndOtherMember us-gaap:ServiceMember ensg:SkilledServicesSegmentMember 2022-01-01 2022-06-30 0001125376 us-gaap:CorporateNonSegmentMember ensg:PrivatePayAndOtherMember us-gaap:ServiceMember 2022-01-01 2022-06-30 0001125376 us-gaap:CorporateNonSegmentMember us-gaap:ServiceMember 2022-01-01 2022-06-30 0001125376 us-gaap:OperatingSegmentsMember ensg:MedicaidMember us-gaap:ServiceMember ensg:SkilledServicesSegmentMember 2021-01-01 2021-06-30 0001125376 us-gaap:CorporateNonSegmentMember ensg:MedicaidMember us-gaap:ServiceMember 2021-01-01 2021-06-30 0001125376 us-gaap:OperatingSegmentsMember ensg:MedicareMember us-gaap:ServiceMember ensg:SkilledServicesSegmentMember 2021-01-01 2021-06-30 0001125376 us-gaap:CorporateNonSegmentMember ensg:MedicareMember us-gaap:ServiceMember 2021-01-01 2021-06-30 0001125376 us-gaap:OperatingSegmentsMember ensg:MedicaidSkilledMember us-gaap:ServiceMember ensg:SkilledServicesSegmentMember 2021-01-01 2021-06-30 0001125376 us-gaap:CorporateNonSegmentMember ensg:MedicaidSkilledMember us-gaap:ServiceMember 2021-01-01 2021-06-30 0001125376 us-gaap:OperatingSegmentsMember ensg:MedicaidAndMedicareMember us-gaap:ServiceMember ensg:SkilledServicesSegmentMember 2021-01-01 2021-06-30 0001125376 us-gaap:CorporateNonSegmentMember ensg:MedicaidAndMedicareMember us-gaap:ServiceMember 2021-01-01 2021-06-30 0001125376 us-gaap:OperatingSegmentsMember ensg:ManagedCareMember us-gaap:ServiceMember ensg:SkilledServicesSegmentMember 2021-01-01 2021-06-30 0001125376 us-gaap:CorporateNonSegmentMember ensg:ManagedCareMember us-gaap:ServiceMember 2021-01-01 2021-06-30 0001125376 us-gaap:OperatingSegmentsMember ensg:PrivatePayAndOtherMember us-gaap:ServiceMember ensg:SkilledServicesSegmentMember 2021-01-01 2021-06-30 0001125376 us-gaap:CorporateNonSegmentMember ensg:PrivatePayAndOtherMember us-gaap:ServiceMember 2021-01-01 2021-06-30 0001125376 us-gaap:CorporateNonSegmentMember us-gaap:ServiceMember 2021-01-01 2021-06-30 0001125376 ensg:SkilledNursingOperationsMember 2022-01-01 2022-06-30 0001125376 ensg:SeniorLivingFacilitiesMember 2022-01-01 2022-06-30 0001125376 ensg:SkilledNursingOperationsMember 2022-06-30 0001125376 ensg:SeniorLivingFacilitiesMember 2022-06-30 0001125376 ensg:TwoAcquisitionsConcentratedInPropertyPlantAndEquipmentMember 2022-01-01 2022-06-30 0001125376 ensg:TwoAcquisitionsConcentratedInGoodwillMember 2022-01-01 2022-06-30 0001125376 ensg:SkilledNursingOperationsMember us-gaap:SubsequentEventMember 2022-07-01 2022-08-01 0001125376 ensg:SkilledNursingOperationsMember us-gaap:SubsequentEventMember 2022-08-01 0001125376 ensg:SeniorLivingFacilitiesMember us-gaap:SubsequentEventMember 2022-08-01 0001125376 ensg:SkilledNursingOperationsMember us-gaap:SubsequentEventMember 2022-07-01 2022-08-01 0001125376 ensg:SkilledNursingOperationsMember 2021-01-01 2021-06-30 0001125376 ensg:SkilledNursingOperationsMember 2021-06-30 0001125376 ensg:AssetAcquisitionMember 2021-01-01 2021-06-30 0001125376 ensg:AssetAcquisitionMember 2021-01-01 2021-06-30 0001125376 ensg:BusinessCombinationMember 2021-01-01 2021-06-30 0001125376 us-gaap:LandMember 2022-06-30 0001125376 us-gaap:LandMember 2021-12-31 0001125376 us-gaap:BuildingAndBuildingImprovementsMember 2022-06-30 0001125376 us-gaap:BuildingAndBuildingImprovementsMember 2021-12-31 0001125376 us-gaap:LeaseholdImprovementsMember 2022-06-30 0001125376 us-gaap:LeaseholdImprovementsMember 2021-12-31 0001125376 us-gaap:EquipmentMember 2022-06-30 0001125376 us-gaap:EquipmentMember 2021-12-31 0001125376 us-gaap:FurnitureAndFixturesMember 2022-06-30 0001125376 us-gaap:FurnitureAndFixturesMember 2021-12-31 0001125376 us-gaap:ConstructionInProgressMember 2022-06-30 0001125376 us-gaap:ConstructionInProgressMember 2021-12-31 0001125376 us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember ensg:SeniorLivingOperationsMember 2022-04-01 2022-06-30 0001125376 ensg:AssembledOccupancyAcquiredMember 2022-01-01 2022-06-30 0001125376 ensg:AssembledOccupancyAcquiredMember 2022-06-30 0001125376 ensg:AssembledOccupancyAcquiredMember 2021-12-31 0001125376 us-gaap:TradeNamesMember 2022-06-30 0001125376 us-gaap:TradeNamesMember 2021-12-31 0001125376 us-gaap:CustomerRelationshipsMember 2022-06-30 0001125376 us-gaap:CustomerRelationshipsMember 2021-12-31 0001125376 ensg:DepreciationAndAmortizationMember 2022-04-01 2022-06-30 0001125376 ensg:DepreciationAndAmortizationMember 2022-01-01 2022-06-30 0001125376 ensg:DepreciationAndAmortizationMember 2021-04-01 2021-06-30 0001125376 ensg:DepreciationAndAmortizationMember 2021-01-01 2021-06-30 0001125376 us-gaap:OperatingSegmentsMember ensg:SkilledServicesSegmentMember 2021-12-31 0001125376 us-gaap:CorporateNonSegmentMember 2021-12-31 0001125376 us-gaap:CorporateNonSegmentMember 2022-01-01 2022-06-30 0001125376 us-gaap:OperatingSegmentsMember ensg:SkilledServicesSegmentMember 2022-06-30 0001125376 us-gaap:CorporateNonSegmentMember 2022-06-30 0001125376 us-gaap:TradeNamesMember 2022-06-30 0001125376 us-gaap:TradeNamesMember 2021-12-31 0001125376 ensg:MedicareandMedicaidLicensesMember 2022-06-30 0001125376 ensg:MedicareandMedicaidLicensesMember 2021-12-31 0001125376 us-gaap:NotesPayableOtherPayablesMember us-gaap:CollateralizedDebtObligationsMember 2022-06-30 0001125376 us-gaap:NotesPayableOtherPayablesMember us-gaap:CollateralizedDebtObligationsMember 2021-12-31 0001125376 us-gaap:RevolvingCreditFacilityMember ensg:TruistBankMember 2019-10-01 0001125376 srt:MinimumMember us-gaap:RevolvingCreditFacilityMember ensg:TruistBankMember 2022-04-08 2022-04-08 0001125376 srt:MaximumMember us-gaap:RevolvingCreditFacilityMember ensg:TruistBankMember 2022-04-08 2022-04-08 0001125376 us-gaap:RevolvingCreditFacilityMember ensg:TruistBankMember 2022-06-30 0001125376 us-gaap:RevolvingCreditFacilityMember ensg:TruistBankMember us-gaap:SubsequentEventMember 2022-07-27 0001125376 us-gaap:MortgagesMember us-gaap:CollateralizedDebtObligationsMember ensg:TwentyThreeSubsidiariesMember 2022-06-30 0001125376 srt:MinimumMember us-gaap:NotesPayableToBanksMember us-gaap:CollateralizedDebtObligationsMember 2022-06-30 0001125376 srt:MaximumMember us-gaap:NotesPayableToBanksMember us-gaap:CollateralizedDebtObligationsMember 2022-06-30 0001125376 us-gaap:MortgagesMember us-gaap:CollateralizedDebtObligationsMember 2022-06-30 0001125376 srt:MinimumMember us-gaap:MortgagesMember us-gaap:CollateralizedDebtObligationsMember 2022-01-01 2022-06-30 0001125376 srt:MaximumMember us-gaap:MortgagesMember us-gaap:CollateralizedDebtObligationsMember 2022-01-01 2022-06-30 0001125376 us-gaap:CollateralizedDebtObligationsMember 2022-01-01 2022-06-30 0001125376 ensg:PromissoryNote50Member us-gaap:CollateralizedDebtObligationsMember 2022-06-30 0001125376 ensg:PromissoryNote53Member us-gaap:CollateralizedDebtObligationsMember 2022-06-30 0001125376 ensg:PromissoryNote50Member us-gaap:CollateralizedDebtObligationsMember 2022-01-01 2022-06-30 0001125376 ensg:PromissoryNote53Member us-gaap:CollateralizedDebtObligationsMember 2022-01-01 2022-06-30 0001125376 ensg:A2022PlanMember 2022-06-30 0001125376 ensg:A2022PlanMember 2017-12-31 0001125376 ensg:A2022PlanMember 2022-01-01 2022-06-30 0001125376 us-gaap:ShareBasedPaymentArrangementNonemployeeMember ensg:A2022PlanMember 2022-01-01 2022-06-30 0001125376 ensg:ExercisePriceRangeOneMember 2022-01-01 2022-06-30 0001125376 ensg:ExercisePriceRangeOneMember 2022-06-30 0001125376 ensg:ExercisePriceRangeTwoMember 2022-01-01 2022-06-30 0001125376 ensg:ExercisePriceRangeTwoMember 2022-06-30 0001125376 ensg:ExercisePriceRangeThreeMember 2022-01-01 2022-06-30 0001125376 ensg:ExercisePriceRangeThreeMember 2022-06-30 0001125376 ensg:ExercisePriceRangeFourMember 2022-01-01 2022-06-30 0001125376 ensg:ExercisePriceRangeFourMember 2022-06-30 0001125376 ensg:ExercisePriceRangeFiveMember 2022-01-01 2022-06-30 0001125376 ensg:ExercisePriceRangeFiveMember 2022-06-30 0001125376 ensg:ExercisePriceRangeSixMember 2022-01-01 2022-06-30 0001125376 ensg:ExercisePriceRangeSixMember 2022-06-30 0001125376 ensg:ExercisePriceRangeSevenMember 2022-01-01 2022-06-30 0001125376 ensg:ExercisePriceRangeSevenMember 2022-06-30 0001125376 ensg:ExercisePriceRangeEightMember 2022-01-01 2022-06-30 0001125376 ensg:ExercisePriceRangeEightMember 2022-06-30 0001125376 ensg:ExercisePriceRangeNineMember 2022-01-01 2022-06-30 0001125376 ensg:ExercisePriceRangeNineMember 2022-06-30 0001125376 ensg:ExercisePriceRangeTenMember 2022-01-01 2022-06-30 0001125376 ensg:ExercisePriceRangeTenMember 2022-06-30 0001125376 ensg:ExercisePriceRangeElevenMember 2022-01-01 2022-06-30 0001125376 ensg:ExercisePriceRangeElevenMember 2022-06-30 0001125376 us-gaap:EmployeeStockOptionMember 2022-01-01 2022-06-30 0001125376 us-gaap:EmployeeStockOptionMember 2021-01-01 2021-06-30 0001125376 us-gaap:RestrictedStockMember 2022-04-01 2022-06-30 0001125376 us-gaap:RestrictedStockMember 2022-01-01 2022-06-30 0001125376 us-gaap:RestrictedStockMember 2021-04-01 2021-06-30 0001125376 us-gaap:RestrictedStockMember 2021-01-01 2021-06-30 0001125376 srt:MinimumMember us-gaap:RestrictedStockMember 2022-01-01 2022-06-30 0001125376 srt:MaximumMember us-gaap:RestrictedStockMember 2022-01-01 2022-06-30 0001125376 srt:MinimumMember us-gaap:RestrictedStockMember 2021-01-01 2021-06-30 0001125376 srt:MaximumMember us-gaap:RestrictedStockMember 2021-01-01 2021-06-30 0001125376 us-gaap:RestrictedStockMember 2021-12-31 0001125376 us-gaap:RestrictedStockMember 2022-06-30 0001125376 us-gaap:RestrictedStockMember us-gaap:ShareBasedPaymentArrangementNonemployeeMember 2022-04-01 2022-06-30 0001125376 us-gaap:RestrictedStockMember us-gaap:ShareBasedPaymentArrangementNonemployeeMember 2022-01-01 2022-06-30 0001125376 srt:MinimumMember us-gaap:RestrictedStockMember us-gaap:ShareBasedPaymentArrangementNonemployeeMember 2022-01-01 2022-06-30 0001125376 srt:MaximumMember us-gaap:RestrictedStockMember us-gaap:ShareBasedPaymentArrangementNonemployeeMember 2022-01-01 2022-06-30 0001125376 ensg:A2019LTIPlanMember us-gaap:SpinoffMember 2019-08-27 0001125376 ensg:A2019LTIPlanMember us-gaap:SpinoffMember 2019-08-27 2019-08-27 0001125376 ensg:A2019LTIPlanMember us-gaap:SpinoffMember 2022-04-01 2022-06-30 0001125376 ensg:A2019LTIPlanMember us-gaap:SpinoffMember 2022-01-01 2022-06-30 0001125376 ensg:A2019LTIPlanMember us-gaap:SpinoffMember 2021-04-01 2021-06-30 0001125376 ensg:A2019LTIPlanMember us-gaap:SpinoffMember 2021-01-01 2021-06-30 0001125376 us-gaap:EmployeeStockOptionMember 2022-04-01 2022-06-30 0001125376 us-gaap:EmployeeStockOptionMember 2021-04-01 2021-06-30 0001125376 ensg:StockAwardsMember 2022-04-01 2022-06-30 0001125376 ensg:StockAwardsMember 2021-04-01 2021-06-30 0001125376 ensg:StockAwardsMember 2022-01-01 2022-06-30 0001125376 ensg:StockAwardsMember 2021-01-01 2021-06-30 0001125376 us-gaap:EmployeeStockOptionMember 2022-06-30 0001125376 ensg:CareTrustREITMember 2022-06-30 0001125376 ensg:CareTrustREITMember ensg:ThirdPartyTenantsUnderTripleNetLeaseArrangementsMember 2022-06-30 0001125376 ensg:CareTrustREITMember srt:MinimumMember 2022-06-30 0001125376 ensg:CareTrustREITMember srt:MaximumMember 2022-06-30 0001125376 ensg:CareTrustREITMember ensg:PurchaseOptionMember 2022-06-30 0001125376 ensg:CareTrustREITMember 2022-01-01 2022-06-30 0001125376 ensg:CareTrustREITMember 2022-04-01 2022-06-30 0001125376 ensg:CareTrustREITMember 2021-04-01 2021-06-30 0001125376 ensg:CareTrustREITMember 2021-01-01 2021-06-30 0001125376 ensg:VariousLandlordsMember srt:MinimumMember 2022-06-30 0001125376 ensg:VariousLandlordsMember srt:MaximumMember 2022-06-30 0001125376 ensg:VariousLandlordsMember 2022-06-30 0001125376 ensg:VariousLandlordsMember srt:MinimumMember us-gaap:EquipmentMember 2022-06-30 0001125376 ensg:VariousLandlordsMember srt:MaximumMember us-gaap:EquipmentMember 2022-06-30 0001125376 ensg:CostofSalesandGeneralandAdministrativeExpenseMember 2022-04-01 2022-06-30 0001125376 ensg:CostofSalesandGeneralandAdministrativeExpenseMember 2022-01-01 2022-06-30 0001125376 ensg:CostofSalesandGeneralandAdministrativeExpenseMember 2021-04-01 2021-06-30 0001125376 ensg:CostofSalesandGeneralandAdministrativeExpenseMember 2021-01-01 2021-06-30 0001125376 ensg:AffiliatedFacilityMasterLeaseOneMember 2022-03-31 0001125376 ensg:AffiliatedFacilityMasterLeaseOneMember 2022-01-01 2022-03-31 0001125376 ensg:RentCostOfServicesMember 2022-04-01 2022-06-30 0001125376 ensg:RentCostOfServicesMember 2021-04-01 2021-06-30 0001125376 ensg:RentCostOfServicesMember 2022-01-01 2022-06-30 0001125376 ensg:RentCostOfServicesMember 2021-01-01 2021-06-30 0001125376 us-gaap:GeneralAndAdministrativeExpenseMember 2022-04-01 2022-06-30 0001125376 us-gaap:GeneralAndAdministrativeExpenseMember 2021-04-01 2021-06-30 0001125376 us-gaap:GeneralAndAdministrativeExpenseMember 2022-01-01 2022-06-30 0001125376 us-gaap:GeneralAndAdministrativeExpenseMember 2021-01-01 2021-06-30 0001125376 ensg:CostOfServicesMember 2022-04-01 2022-06-30 0001125376 ensg:CostOfServicesMember 2021-04-01 2021-06-30 0001125376 ensg:CostOfServicesMember 2022-01-01 2022-06-30 0001125376 ensg:CostOfServicesMember 2021-01-01 2021-06-30 0001125376 ensg:SkilledNursingOperationsMember us-gaap:SubsequentEventMember ensg:AmendedMasterLeaseMember 2022-07-01 2022-08-01 0001125376 us-gaap:SubsequentEventMember ensg:AmendedMasterLeaseMember 2022-08-01 0001125376 us-gaap:SubsequentEventMember ensg:AmendedMasterLeaseMember 2022-07-01 2022-08-01 0001125376 us-gaap:SubsequentEventMember 2022-07-01 2022-08-01 0001125376 ensg:SeniorLivingFacilitiesMember us-gaap:SpinoffMember ensg:ThePennantGroupInc.Member 2019-10-31 0001125376 ensg:SeniorLivingFacilitiesMember us-gaap:SpinoffMember 2022-06-30 0001125376 srt:MinimumMember us-gaap:SpinoffMember 2019-10-01 0001125376 srt:MaximumMember us-gaap:SpinoffMember 2019-10-01 0001125376 ensg:ThePennantGroupInc.Member 2022-04-01 2022-06-30 0001125376 ensg:ThePennantGroupInc.Member 2021-04-01 2021-06-30 0001125376 ensg:ThePennantGroupInc.Member 2022-01-01 2022-06-30 0001125376 ensg:ThePennantGroupInc.Member 2021-01-01 2021-06-30 0001125376 ensg:ThirdPartyTenantsMember 2022-04-01 2022-06-30 0001125376 ensg:ThirdPartyTenantsMember 2021-04-01 2021-06-30 0001125376 ensg:ThirdPartyTenantsMember 2022-01-01 2022-06-30 0001125376 ensg:ThirdPartyTenantsMember 2021-01-01 2021-06-30 0001125376 ensg:ThePennantGroupInc.Member 2022-04-01 2022-06-30 0001125376 ensg:ThePennantGroupInc.Member 2022-01-01 2022-06-30 0001125376 ensg:ThePennantGroupInc.Member 2021-04-01 2021-06-30 0001125376 ensg:ThePennantGroupInc.Member 2021-01-01 2021-06-30 0001125376 ensg:MedicaidAndMedicareMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2022-01-01 2022-06-30 0001125376 ensg:MedicaidAndMedicareMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2021-01-01 2021-12-31 0001125376 ensg:MedicaidAndMedicareMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2022-01-01 2022-06-30 0001125376 ensg:MedicaidAndMedicareMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2022-04-01 2022-06-30 0001125376 us-gaap:SubsequentEventMember 2022-07-27 0001125376 ensg:February92022RepurchaseProgramMember 2022-02-09 0001125376 ensg:February92022RepurchaseProgramMember 2022-02-09 2022-02-09 0001125376 ensg:October212021RepurchaseProgramMember 2022-04-01 2022-06-30 0001125376 ensg:October212021RepurchaseProgramMember 2021-10-21 0001125376 ensg:October212021RepurchaseProgramMember 2021-10-21 2021-10-21 0001125376 ensg:October212021RepurchaseProgramMember 2022-01-01 2022-03-31 0001125376 ensg:October212021RepurchaseProgramMember 2021-10-01 2021-12-31 0001125376 ensg:July2022RepurchaseProgramMember us-gaap:SubsequentEventMember 2022-07-28 0001125376 ensg:July2022RepurchaseProgramMember us-gaap:SubsequentEventMember 2022-07-28 2022-07-28 shares iso4217:USD iso4217:USD shares ensg:facility ensg:bed ensg:seniorLivingUnit ensg:seniorLivingCommunity ensg:operation pure ensg:skilledNursingProperty ensg:campusProperty ensg:lease ensg:renewal ensg:segment ensg:realEstateProperty ensg:subsidiary ensg:promissoryNote ensg:installment ensg:agreement ensg:repurchaseProgram 0001125376 2022 Q2 false --12-31 P3Y0M0D P10Y P4M0D P5Y0M P10Y0M P10Y0M P5Y0M P3Y0M 10-Q true 2022-06-30 false 001-33757 ENSIGN GROUP, INC DE 33-0861263 29222 Rancho Viejo Road, Suite 127 San Juan Capistrano CA 92675 949 487-9500 Common Stock, par value $0.001 per share ENSG NASDAQ Yes Yes Large Accelerated Filer false false false 55289903 285580000 262201000 7827000 11213000 339001000 328731000 8991000 13763000 16336000 5452000 32774000 29562000 682682000 639709000 908228000 888434000 1305009000 1138872000 40077000 36567000 15571000 0 32883000 33147000 57010000 47046000 2535000 2652000 76869000 60469000 3807000 3727000 3124671000 2850623000 60414000 58116000 273276000 278770000 58769000 52181000 49728000 40831000 85793000 89410000 3944000 3760000 531924000 523068000 151105000 152883000 1216335000 1056515000 76793000 69308000 27821000 27135000 2003978000 1828909000 0.001 0.001 100000000 100000000 58646000 55278000 58134000 55190000 58000 58000 398793000 369760000 835941000 733992000 3368000 2944000 114626000 83042000 1120166000 1020768000 527000 946000 1120693000 1021714000 3124671000 2850623000 728347000 634609000 1437503000 1257885000 4139000 3927000 8428000 7904000 732486000 638536000 1445931000 1265789000 563641000 488524000 1119282000 970710000 37228000 34455000 72990000 67911000 38527000 36908000 76783000 71181000 14858000 13795000 29534000 27454000 654254000 573682000 1298589000 1137256000 78232000 64854000 147342000 128533000 2688000 1634000 4756000 3275000 -2587000 1121000 -3403000 1869000 -5275000 -513000 -8159000 -1406000 72957000 64341000 139183000 127127000 15154000 13758000 31292000 26707000 57803000 50583000 107891000 100420000 112000 1158000 -140000 1789000 57691000 49425000 108031000 98631000 1.05 0.91 1.97 1.82 1.01 0.87 1.90 1.73 54906000 54468000 54788000 54331000 56853000 56997000 56862000 56945000 55190000 58000 369760000 733992000 2944000 -83042000 946000 1021714000 147000 2768000 2768000 104000 5241000 5241000 15000 15000 0.0550 3042000 3042000 5167000 5167000 133000 133000 9882000 9882000 -245000 271000 26000 -252000 -252000 50340000 50340000 55308000 58000 383181000 781290000 3077000 -92939000 423000 1072013000 223000 3303000 3303000 38000 20000 20000 1687000 1687000 0.0550 3040000 3040000 5616000 5616000 271000 271000 20000000 20000000 6693000 6693000 112000 112000 8000 8000 57691000 57691000 55278000 58000 398793000 835941000 3368000 -114626000 527000 1120693000 54626000 58000 338177000 551055000 2791000 -71213000 150000 818227000 246000 3880000 3880000 81000 3725000 3725000 9000 9000 0.0525 2886000 2886000 4054000 4054000 631000 631000 1248000 1248000 49206000 49206000 54953000 58000 349836000 597375000 2791000 -71222000 -467000 875580000 148000 2982000 2982000 49000 20000 20000 1600000 1600000 0.0525 2894000 2894000 4633000 4633000 1158000 1158000 641000 641000 49425000 49425000 55130000 58000 357451000 643906000 2811000 -72822000 50000 928643000 107891000 100420000 29534000 27454000 505000 420000 240000 221000 566000 0 264000 27000 2169000 1899000 10783000 8687000 2567000 540000 -4474000 -745000 12852000 15928000 10884000 7590000 3996000 9476000 5621000 8861000 5617000 8930000 -547000 -131000 2197000 7725000 -5162000 -9063000 0 -136000 -7471000 -1966000 14696000 5717000 -23000 -157000 129813000 108397000 37082000 33795000 16400000 6000000 17492000 5183000 15571000 0 653000 6705000 7665000 877000 3518000 23706000 4780000 20399000 -369000 159000 -76596000 -40862000 211000 224000 1921000 1497000 6071000 6862000 1702000 1609000 29882000 0 6077000 5754000 6693000 0 8000 1889000 26000 0 3197000 0 0 11538000 0 113561000 -29838000 -105686000 23379000 -38151000 262201000 236562000 285580000 198411000 3950000 2836000 41905000 34540000 72919000 67539000 3800000 3600000 3040000 2894000 194342000 112192000 DESCRIPTION OF BUSINESS<div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The Company</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> — </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Ensign Group, Inc. (collectively, Ensign or the Company), is a holding company with no direct operating assets, employees or revenue. The Company, through its operating subsidiaries, is a provider of health care services across the post-acute care continuum, engaged in the ownership, acquisition, development and leasing of skilled nursing, senior living and other healthcare-related properties and other ancillary businesses. As of June 30, 2022, the Company operated 251 facilities and other ancillary operations located in Arizona, California, Colorado, Idaho, Iowa, Kansas, Nebraska, Nevada, South Carolina, Texas, Utah, Washington and Wisconsin. The Company's operating subsidiaries have a collective capacity of approximately 25,500 operational skilled nursing beds and 3,000 senior living units. As of June 30, 2022, the Company operated 180 facilities under long-term lease arrangements, and had options to purchase 11 of those 180 facilities. The Company's real estate portfolio includes 100 owned real estate properties, which included 71 facilities operated and managed by the Company, 29 senior living operations leased to and operated by The Pennant Group, Inc. (Pennant) as part of the spin-off transaction that occurred in October 2019 (Spin-Off), and the Service Center location. Of those 29 senior living operations, one is located on the same real estate property as a skilled nursing facility that the Company owns and operates. </span></div><div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain of the Company’s wholly-owned independent subsidiaries, collectively referred to as the Service Center, provide specific accounting, payroll, human resources, information technology, legal, risk management and other centralized services to the other operating subsidiaries through contractual relationships with such subsidiaries. The Company also has a wholly-owned captive insurance subsidiary that provides some claims-made coverage to the Company’s operating subsidiaries for general and professional liabilities, as well as coverage for certain workers’ compensation insurance liabilities.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January of 2022, the Company formed a captive real estate investment trust (REIT), which owns and manages its real estate business, called Standard Bearer Healthcare REIT, Inc. (Standard Bearer). The Company expects the REIT structure will provide it with an efficient vehicle for future acquisitions of properties that could be operated by Ensign affiliates or other third parties. Refer to Note 7, </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Standard Bearer </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for additional information on Standard Bearer.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each of the Company's affiliated operations are operated by separate, wholly-owned, independent subsidiaries that have their own management, employees and assets. References herein to the consolidated “Company” and “its” assets and activities in this Quarterly Report is not meant to imply, nor should it be construed as meaning that The Ensign Group, Inc. has direct operating assets, employees or revenue, or that any of the subsidiaries, are operated by The Ensign Group, Inc.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Information</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> —</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The accompanying condensed consolidated financial statements as of June 30, 2022 and for the three and six months ended June 30, 2022 and 2021 (collectively, the Interim Financial Statements) are unaudited. Certain information and note disclosures normally included in annual consolidated financial statements have been condensed or omitted, as permitted under applicable rules and regulations. Readers of the Interim Financial Statements should refer to the Company’s audited consolidated financial statements and notes thereto for the year ended December 31, 2021 which are included in the Company’s Annual Report on Form 10-K, File No. 001-33757 (the Annual Report) filed with the Securities and Exchange Commission (SEC). Management believes that the Interim Financial Statements reflect all adjustments which are of a normal and recurring nature necessary to present fairly the Company’s financial position and results of operations in all material respects. The results of operations presented in the Interim Financial Statements are not necessarily representative of operations for the entire year.</span></div> 251 25500 3000 180 11 180 100 71 29 29 1 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES<span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> —</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The accompanying Interim Financial Statements have been prepared in accordance with accounting principles generally accepted in the United States (GAAP). The Company is the sole member or stockholder of various consolidated limited liability companies and corporations established to operate various acquired skilled nursing operations, senior living operations and related ancillary services. All intercompany transactions and balances have been eliminated in consolidation. The Company presents noncontrolling interests within the equity section of its condensed consolidated balance sheets and the amount of consolidated net income that is attributable to The Ensign Group, Inc. and the noncontrolling interest in its condensed consolidated statements of income.</span><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The condensed consolidated financial statements include the accounts of all entities controlled by the Company through its ownership of a majority voting interest. Additionally, the accounts of any variable interest entities (VIEs) where the Company is subject to a majority of the risk of loss from the VIE's activities are entitled to receive a majority of the entity's residual returns, or both. The Company assesses the requirements related to the consolidation of VIEs, including a qualitative assessment of power and economics that considers which entity has the power to direct the activities that "most significantly impacts" the VIE's economic performance and has the obligation to absorb losses of, or the right to receive benefits that could be potentially significant to, the VIE. On October 1, 2021, the Company deconsolidated its VIE, which was not material, as this entity no longer met the requirements for consolidation. As of June 30, 2022 and December 31, 2021, the Company had no VIEs. </span></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Reclassifications</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> — </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior period results reflect reclassifications, for comparative purposes, related to the change in the Company's segment structure as a result of the formation of Standard Bearer. Refer to Note 8, </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Business Segments</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, for additional information related to segments. </span></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Estimates and Assumptions</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> —</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The preparation of the Interim Financial Statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the Interim Financial Statements and the reported amounts of revenue and expenses during the reporting periods. The most significant estimates in the Company’s Interim Financial Statements relate to revenue, acquired property and equipment, intangible assets and goodwill, right-of-use assets, impairment of long-lived assets, lease liabilities, general and professional liabilities, workers' compensation and healthcare claims included in accrued self-insurance liabilities, and income taxes. Actual results could differ from those estimates.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value of Financial Instruments</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> —</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s financial instruments consist principally of cash and cash equivalents, debt security investments, accounts receivable, insurance subsidiary deposits, accounts payable and borrowings. The Company believes all of the financial instruments’ recorded values approximate fair values because of their nature or respective short durations. Contracts insuring the lives of certain employees who are eligible to participate in non-qualified deferred compensation plans are held in a rabbi trust. Cash surrender value of the contracts is based on funds that shadow the investment allocations specified by participants in the deferred compensation plan. The fair value of the investment funds is derived using Level 2 inputs. See Note 6,</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Fair Value Measurements.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Service Revenue Recognition</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> — </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes revenue in accordance with Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) Topic 606, </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(ASC 606). </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 4,</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Revenue and Accounts Receivable.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Rental Revenue Recognition</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> —</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company recognizes rental revenue for operating leases on a straight-line basis over the lease term when collectability of all minimum lease payments is probable in accordance with FASB ASC Topic 842, </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (ASC 842). See Note 4,</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Revenue and Accounts Receivable.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accounts Receivable </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">—</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Accounts receivable consist primarily of amounts due from Medicare and Medicaid programs, other government programs, managed care health plans and private payor sources, net of estimates for variable consideration.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property and Equipment</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> —</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Property and equipment are initially recorded at their historical cost. Repairs and maintenance are expensed as incurred. Depreciation is computed using the straight-line method over the estimated useful lives of the depreciable assets (ranging from <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjM2YTQ4YjE0Mzg2NDRlY2E5NDlhYmUxZGY1NTg0NTZhL3NlYzozNmE0OGIxNDM4NjQ0ZWNhOTQ5YWJlMWRmNTU4NDU2YV82MS9mcmFnOjQ5ZTkwZDZhNDRiMjQzZTI5MzFmNzdlYmJhZDkzNDlkL3RleHRyZWdpb246NDllOTBkNmE0NGIyNDNlMjkzMWY3N2ViYmFkOTM0OWRfNDYxMA_a81d5b1f-786e-462b-9155-a5f439062ef8">three</span> to 59 years). Leasehold improvements are amortized on a straight-line basis over the shorter of their estimated useful lives or the remaining lease term. </span></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases and Leasehold Improvements</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">—</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company leases skilled nursing facilities, senior living facilities and commercial office space.</span><span style="color:#ff0000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determines if an arrangement is a lease at the inception of each lease. Leases commencing prior to the ASC 842 adoption date were classified as operating lease under historical guidance. As the Company has elected the package of practical expedients allowing it to not reassess lease classification, these leases are classified as operating leases under ASC 842 as well. For leases commencing subsequent to the ASC 842 adoption date, the Company performs an evaluation to determine whether the lease should be classified as an operating or finance lease at the inception of the lease. As of June 30, 2022, the Company does not have any leases that are classified as finance leases. Rights and obligations of operating leases are included as right-of-use assets, current lease liabilities and long-term lease liabilities on the Company's condensed consolidated balance sheets. As the Company's leases do not provide an implicit rate, the Company uses its incremental borrowing rate based on the information available at lease commencement date in determining the present value of future lease payments. The Company utilized a third-party valuation specialist to assist in estimating the incremental borrowing rate.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company records rent expense for operating leases on a straight-line basis over the term of the lease. The lease term used for straight-line rent expense is calculated from the date the Company is given control of the leased premises through the end of the lease term. Renewals are not assumed in the determination of the lease term unless they are deemed to be reasonably assured at the inception of the lease. The lease term used for this evaluation also provides the basis for establishing depreciable lives for buildings subject to lease and leasehold improvements.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's real estate leases generally have initial lease terms of ten years or more and typically include one or more options to renew, with renewal terms that generally extend the lease term for an additional <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjM2YTQ4YjE0Mzg2NDRlY2E5NDlhYmUxZGY1NTg0NTZhL3NlYzozNmE0OGIxNDM4NjQ0ZWNhOTQ5YWJlMWRmNTU4NDU2YV82MS9mcmFnOjQ5ZTkwZDZhNDRiMjQzZTI5MzFmNzdlYmJhZDkzNDlkL3RleHRyZWdpb246NDllOTBkNmE0NGIyNDNlMjkzMWY3N2ViYmFkOTM0OWRfNjg5Ng_460f93ff-8b39-4d0b-85c3-bfff4577a24e">ten</span> to 15 years. Exercise of the renewal options is generally subject to the satisfaction of certain conditions which vary by contract and generally follow payment terms that are consistent with those in place during the initial term. The Company reassesses the renewal option using a "reasonably certain" threshold, which is understood to be a high threshold. For leases where the Company is reasonably certain to exercise its renewal option, the option periods are included within the lease term and, therefore, the measurement of the right-of-use asset and lease liability. The Company's leases generally contain annual escalation clauses that are either fixed or variable in nature, some of which are dependent upon published indices. The Company recognizes lease expense for leases with an initial term of 12 months or less on a straight-line basis over the lease term. These leases are not recorded on the condensed consolidated balance sheets. Certain of the Company's lease agreements include rental payments that are adjusted periodically for inflation. The lease agreements do not contain any material residual value guarantees or material restrictive covenants. The Company does not have material subleases. </span></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Impairment of Long-Lived Assets </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">— </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company reviews the carrying value of long-lived assets that are held and used in the Company’s operating subsidiaries for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of these assets is determined based upon expected undiscounted future net cash flows from the operating subsidiaries to which the assets relate, utilizing management’s best estimate, appropriate assumptions, and projections at the time. If the carrying value is determined to be unrecoverable from future operating cash flows, the asset is deemed impaired and an impairment loss would be recognized to the extent the carrying value exceeded the estimated fair value of the asset. The Company estimates the fair value of assets based on the estimated future discounted cash flows of the asset. Management has evaluated its long-lived assets and determined there was no impairment during the three and six months ended June 30, 2022 and 2021. </span></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Intangible Assets and Goodwill</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> —</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Definite-lived intangible assets consist primarily of patient base, facility trade names and customer relationships. Patient base is amortized over a period of <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjM2YTQ4YjE0Mzg2NDRlY2E5NDlhYmUxZGY1NTg0NTZhL3NlYzozNmE0OGIxNDM4NjQ0ZWNhOTQ5YWJlMWRmNTU4NDU2YV82MS9mcmFnOjQ5ZTkwZDZhNDRiMjQzZTI5MzFmNzdlYmJhZDkzNDlkL3RleHRyZWdpb246NDllOTBkNmE0NGIyNDNlMjkzMWY3N2ViYmFkOTM0OWRfOTI5OQ_dea5be0e-fac6-4da5-b203-ebeeaf11a40e">four</span> to eight months, depending on the classification of the patients and the level of occupancy in a new acquisition on the acquisition date. Trade names at affiliated facilities are amortized over 30 years and customer relationships are amortized over a period of up to 20 years.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's indefinite-lived intangible assets consist of trade names, and Medicare and Medicaid licenses. The Company tests indefinite-lived intangible assets for impairment on an annual basis or more frequently if events or changes in circumstances indicate that the carrying amount of the intangible asset may not be recoverable. </span></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill represents the excess of the purchase price over the fair value of identifiable net assets acquired in business combinations. Goodwill is subject to annual testing for impairment. In addition, goodwill is tested for impairment if events occur or circumstances indicate that its carrying value may not be recoverable. The Company performs its annual test for impairment during the fourth quarter of each year. The Company did not identify any goodwill or intangible asset impairment during the three and six months ended June 30, 2022 and 2021. </span></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Self-Insurance</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> — The Company is partially self-insured for general and professional liability claims up to a base amount per claim (the self-insured retention) with an aggregate, one-time deductible above this limit. Losses beyond these amounts are insured through third-party policies with coverage limits per claim, per location and on an aggregate basis for the Company. The combined self-insured retention is $500 per claim, subject to an additional one-time deductible of $1,000 for California affiliated operations and a separate, one-time, deductible of $1,250 for non-California operations. For all affiliated operations, except those located in Colorado, the third-party coverage above these limits is $1,000 per claim, $3,000 per operation, with a $5,000 blanket aggregate limit and an additional state-specific aggregate where required by state law. In Colorado, the third-party coverage above these limits is $1,000 per claim and $3,000 per operation, which is independent of the aforementioned blanket aggregate limits that apply outside of Colorado. </span></div><div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The majority of the self-insured retention and deductible limits for general and professional liabilities and workers' compensation liabilities are self-insured through the captive insurance subsidiary, the related assets and liabilities of which are included in the accompanying condensed consolidated balance sheets. The captive insurance subsidiary is subject to certain statutory requirements as an insurance provider. </span></div><div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s policy is to accrue amounts equal to the actuarial estimated costs to settle open claims of insureds, as well as an estimate of the cost of insured claims that have been incurred but not reported. The Company develops information about the size of the ultimate claims based on historical experience, current industry information and actuarial analysis, and evaluates the estimates for claim loss exposure on a quarterly basis. The Company uses actuarial valuations to estimate the liability based on historical experience and industry information. Accrued general liability and professional malpractice liabilities on an undiscounted basis, net of anticipated insurance recoveries, were $76,145 and $66,158 as of June 30, 2022 and December 31, 2021, respectively. </span></div><div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s operating subsidiaries are self-insured for workers’ compensation liabilities in California. To protect itself against loss exposure in California with this policy, the Company has purchased individual specific excess insurance coverage that insures individual claims that exceed $625 per occurrence. In Texas, the operating subsidiaries have elected non-subscriber status for workers’ compensation claims and the Company has purchased individual stop-loss coverage that insures individual claims that exceed $750 per occurrence. The Company’s operating subsidiaries in all other states, with the exception of Washington, are under a loss sensitive plan that insures individual claims that exceed $350 per occurrence. In the state of Washington, the Company is self insured and has purchased individual specific excess insurance coverage that insures individual claims that exceed $500 per occurrence. For all of the self insured plans and retention, the Company accrues amounts equal to the estimated costs to settle open claims, as well as an estimate of the cost of claims that have been incurred but not reported. The Company uses actuarial valuations to estimate the liability based on historical experience and industry information. Accrued workers’ compensation liabilities are recorded on an undiscounted basis in the accompanying condensed consolidated balance sheets and were $28,365 and $27,335 as of June 30, 2022 and December 31, 2021, respectively.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the Company has recorded an asset and equal liability of $8,440 and $6,755 as of June 30, 2022 and December 31, 2021, respectively, in order to present the ultimate costs of malpractice and workers' compensation claims and the anticipated insurance recoveries on a gross basis. See Note 13, </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Restricted and Other Assets.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company self-funds medical (including prescription drugs) and dental healthcare benefits to the majority of its employees. The Company is fully liable for all financial and legal aspects of these benefit plans. To protect itself against loss exposure with this policy, the Company has purchased individual stop-loss insurance coverage that insures individual claims that exceed $525 for each covered person for fiscal year 2022. The Company’s accrued liability under these plans recorded on an undiscounted basis in the accompanying condensed consolidated balance sheets was $13,571 and $9,891 as of June 30, 2022 and December 31, 2021, respectively.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company believes that adequate provision has been made in the Interim Financial Statements for liabilities that may arise out of patient care, workers’ compensation, healthcare benefits and related services provided to date. The amount of the Company’s reserves was determined based on an estimation process that uses information obtained from both company-specific and industry data. This estimation process requires the Company to continuously monitor and evaluate the life cycle of the claims. Using data obtained from this monitoring and the Company’s assumptions about emerging trends, the Company, with the assistance of an independent actuary, develops information about the size of ultimate claims based on the Company’s historical experience and other available industry information. The most significant assumptions used in the estimation process include determining the trend in costs, the expected cost of claims incurred but not reported and the expected costs to settle or pay damage awards with respect to unpaid claims. The self-insured liabilities are based upon estimates, and while management believes that the estimates of loss are reasonable, the ultimate liability may be in excess of or less than the recorded amounts. Due to the inherent volatility of actuarially determined loss estimates, it is reasonably possible that the Company could experience changes in estimated losses that could be material to net income. If the Company’s actual liabilities exceed its estimates of losses, its future earnings, cash flows and financial condition would be adversely affected.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> — Deferred tax assets and liabilities are established for temporary differences between the financial reporting basis and the tax basis of the Company’s assets and liabilities at tax rates in effect when such temporary differences are expected to reverse. The Company generally expects to fully utilize its deferred tax assets; however, when necessary, the Company records a valuation allowance to reduce its net deferred tax assets to the amount that is more likely than not to be realized. </span></div><div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In determining the need for a valuation allowance or the need for and magnitude of liabilities for uncertain tax positions, the Company makes certain estimates and assumptions. These estimates and assumptions are based on, among other things, knowledge of operations, markets, historical trends and likely future changes and, when appropriate, the opinions of advisors with knowledge and expertise in certain fields. Due to certain risks associated with the Company’s estimates and assumptions, actual results could differ.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Noncontrolling Interest </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">— </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The noncontrolling interest in a subsidiary is initially recognized at estimated fair value on the acquisition date and is presented within total equity in the Company's condensed consolidated balance sheets. The Company presents the noncontrolling interest and the amount of consolidated net income attributable to The Ensign Group, Inc. in its condensed consolidated statements of income. Net income per share is calculated based on net income attributable to The Ensign Group, Inc.'s stockholders. The carrying amount of the noncontrolling interest is adjusted based on an allocation of subsidiary earnings based on ownership interest. </span></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-Based Compensation</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> — </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company measures and recognizes compensation expense for all stock-based payment awards made to employees and directors including employee stock options based on estimated fair values, ratably over the requisite service period of the award. Net income has been reduced as a result of the recognition of the fair value of all stock options and restricted stock awards issued, the amount of which is contingent upon the number of future grants and other variables.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Accounting Pronouncements</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> —</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Except for rules and interpretive releases of the Securities and Exchange Commission (SEC) under authority of federal securities laws and a limited number of grandfathered standards, the FASB ASC is the sole source of authoritative GAAP literature recognized by the FASB and applicable to the Company. For any new pronouncements announced, the Company considers whether the new pronouncements could alter previous generally accepted accounting principles and determines whether any new or modified principles will have a material impact on the Company's reported financial position or operations in the near term. The applicability of any standard is subject to the formal review of the Company's financial management and certain standards are under consideration.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Accounting Standards Adopted by the Company </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">—</span><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2021, the FASB issued ASU 2021-10 “</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Government Assistance (Topic 832): Disclosures by Business Entities about Government Assistance,</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">” which created FASB ASC Topic 832, </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Government Assistance </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(ASC 832)</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">. </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ASC 832 requires business entities to disclose information about certain government assistance they receive.</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company adopted this standard on January 1, 2022 and determined there was no material impact on the Company's condensed consolidated financial statements. </span></div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accounting Standards Recently Issued but Not Yet Adopted by the Company </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">— </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2020, the FASB issued ASU 2020-04</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> "Reference Rate Reform (Topic 848),"</span> which provides temporary, optional practical expedients and exceptions to enable a smoother transition to reference rates which are expected to replace London Interbank Offered Rate (LIBOR) reference rates. Adoption of the provisions of ASU 2020-04 is optional. The amendments are effective for all entities from the beginning of the interim period that includes the issuance date of the ASU. An entity may elect to apply the amendments prospectively through December 31, 2022. During the quarter ended June 30, 2022, the Company and its subsidiaries including Standard Bearer, entered into the Second Amendment to Third Amended and Restated Credit Agreement (such agreement, the Amended Credit Agreement, and the revolving credit facility thereunder, the Revolving Credit Facility), which increased the Revolving Credit Facility by $250,000 to an aggregate principal amount of up to $600,000. Pursuant to the Amended Credit Agreement, the Company transitioned from LIBOR to the Secured Overnight Financing Rate (SOFR) as the applicable reference rate for borrowings under the Revolving Credit Facility and determined there was no resulting material impact on the Company's condensed consolidated financial statements. <span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> —</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The accompanying Interim Financial Statements have been prepared in accordance with accounting principles generally accepted in the United States (GAAP). The Company is the sole member or stockholder of various consolidated limited liability companies and corporations established to operate various acquired skilled nursing operations, senior living operations and related ancillary services. All intercompany transactions and balances have been eliminated in consolidation. The Company presents noncontrolling interests within the equity section of its condensed consolidated balance sheets and the amount of consolidated net income that is attributable to The Ensign Group, Inc. and the noncontrolling interest in its condensed consolidated statements of income.</span>The condensed consolidated financial statements include the accounts of all entities controlled by the Company through its ownership of a majority voting interest. Additionally, the accounts of any variable interest entities (VIEs) where the Company is subject to a majority of the risk of loss from the VIE's activities are entitled to receive a majority of the entity's residual returns, or both. The Company assesses the requirements related to the consolidation of VIEs, including a qualitative assessment of power and economics that considers which entity has the power to direct the activities that "most significantly impacts" the VIE's economic performance and has the obligation to absorb losses of, or the right to receive benefits that could be potentially significant to, the VIE. On October 1, 2021, the Company deconsolidated its VIE, which was not material, as this entity no longer met the requirements for consolidation. As of June 30, 2022 and December 31, 2021, the Company had no VIEs. <span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Reclassifications</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> — </span>Prior period results reflect reclassifications, for comparative purposes, related to the change in the Company's segment structure as a result of the formation of Standard Bearer. <span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Estimates and Assumptions</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> —</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The preparation of the Interim Financial Statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the Interim Financial Statements and the reported amounts of revenue and expenses during the reporting periods. The most significant estimates in the Company’s Interim Financial Statements relate to revenue, acquired property and equipment, intangible assets and goodwill, right-of-use assets, impairment of long-lived assets, lease liabilities, general and professional liabilities, workers' compensation and healthcare claims included in accrued self-insurance liabilities, and income taxes. Actual results could differ from those estimates.</span> <span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value of Financial Instruments</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> —</span>The Company’s financial instruments consist principally of cash and cash equivalents, debt security investments, accounts receivable, insurance subsidiary deposits, accounts payable and borrowings. The Company believes all of the financial instruments’ recorded values approximate fair values because of their nature or respective short durations. Contracts insuring the lives of certain employees who are eligible to participate in non-qualified deferred compensation plans are held in a rabbi trust. Cash surrender value of the contracts is based on funds that shadow the investment allocations specified by participants in the deferred compensation plan. The fair value of the investment funds is derived using Level 2 inputs. <span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Service Revenue Recognition</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> — </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes revenue in accordance with Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) Topic 606, </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers </span>(ASC 606).<span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Rental Revenue Recognition</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> —</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company recognizes rental revenue for operating leases on a straight-line basis over the lease term when collectability of all minimum lease payments is probable in accordance with FASB ASC Topic 842, </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases</span> (ASC 842). <span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accounts Receivable </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">—</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Accounts receivable consist primarily of amounts due from Medicare and Medicaid programs, other government programs, managed care health plans and private payor sources, net of estimates for variable consideration.</span> <span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property and Equipment</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> —</span> Property and equipment are initially recorded at their historical cost. Repairs and maintenance are expensed as incurred. Depreciation is computed using the straight-line method over the estimated useful lives of the depreciable assets (ranging from <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjM2YTQ4YjE0Mzg2NDRlY2E5NDlhYmUxZGY1NTg0NTZhL3NlYzozNmE0OGIxNDM4NjQ0ZWNhOTQ5YWJlMWRmNTU4NDU2YV82MS9mcmFnOjQ5ZTkwZDZhNDRiMjQzZTI5MzFmNzdlYmJhZDkzNDlkL3RleHRyZWdpb246NDllOTBkNmE0NGIyNDNlMjkzMWY3N2ViYmFkOTM0OWRfNDYxMA_a81d5b1f-786e-462b-9155-a5f439062ef8">three</span> to 59 years). Leasehold improvements are amortized on a straight-line basis over the shorter of their estimated useful lives or the remaining lease term. P59Y <span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases and Leasehold Improvements</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">—</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company leases skilled nursing facilities, senior living facilities and commercial office space.</span><span style="color:#ff0000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determines if an arrangement is a lease at the inception of each lease. Leases commencing prior to the ASC 842 adoption date were classified as operating lease under historical guidance. As the Company has elected the package of practical expedients allowing it to not reassess lease classification, these leases are classified as operating leases under ASC 842 as well. For leases commencing subsequent to the ASC 842 adoption date, the Company performs an evaluation to determine whether the lease should be classified as an operating or finance lease at the inception of the lease. As of June 30, 2022, the Company does not have any leases that are classified as finance leases. Rights and obligations of operating leases are included as right-of-use assets, current lease liabilities and long-term lease liabilities on the Company's condensed consolidated balance sheets. As the Company's leases do not provide an implicit rate, the Company uses its incremental borrowing rate based on the information available at lease commencement date in determining the present value of future lease payments. The Company utilized a third-party valuation specialist to assist in estimating the incremental borrowing rate.</span>The Company records rent expense for operating leases on a straight-line basis over the term of the lease. The lease term used for straight-line rent expense is calculated from the date the Company is given control of the leased premises through the end of the lease term. Renewals are not assumed in the determination of the lease term unless they are deemed to be reasonably assured at the inception of the lease. The lease term used for this evaluation also provides the basis for establishing depreciable lives for buildings subject to lease and leasehold improvements.The Company's real estate leases generally have initial lease terms of ten years or more and typically include one or more options to renew, with renewal terms that generally extend the lease term for an additional <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjM2YTQ4YjE0Mzg2NDRlY2E5NDlhYmUxZGY1NTg0NTZhL3NlYzozNmE0OGIxNDM4NjQ0ZWNhOTQ5YWJlMWRmNTU4NDU2YV82MS9mcmFnOjQ5ZTkwZDZhNDRiMjQzZTI5MzFmNzdlYmJhZDkzNDlkL3RleHRyZWdpb246NDllOTBkNmE0NGIyNDNlMjkzMWY3N2ViYmFkOTM0OWRfNjg5Ng_460f93ff-8b39-4d0b-85c3-bfff4577a24e">ten</span> to 15 years. Exercise of the renewal options is generally subject to the satisfaction of certain conditions which vary by contract and generally follow payment terms that are consistent with those in place during the initial term. The Company reassesses the renewal option using a "reasonably certain" threshold, which is understood to be a high threshold. For leases where the Company is reasonably certain to exercise its renewal option, the option periods are included within the lease term and, therefore, the measurement of the right-of-use asset and lease liability. The Company's leases generally contain annual escalation clauses that are either fixed or variable in nature, some of which are dependent upon published indices. The Company recognizes lease expense for leases with an initial term of 12 months or less on a straight-line basis over the lease term. These leases are not recorded on the condensed consolidated balance sheets. Certain of the Company's lease agreements include rental payments that are adjusted periodically for inflation. The lease agreements do not contain any material residual value guarantees or material restrictive covenants. The Company does not have material subleases. P10Y P15Y <span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Impairment of Long-Lived Assets </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">— </span>The Company reviews the carrying value of long-lived assets that are held and used in the Company’s operating subsidiaries for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of these assets is determined based upon expected undiscounted future net cash flows from the operating subsidiaries to which the assets relate, utilizing management’s best estimate, appropriate assumptions, and projections at the time. If the carrying value is determined to be unrecoverable from future operating cash flows, the asset is deemed impaired and an impairment loss would be recognized to the extent the carrying value exceeded the estimated fair value of the asset. The Company estimates the fair value of assets based on the estimated future discounted cash flows of the asset. 0 0 0 0 <div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Intangible Assets and Goodwill</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> —</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Definite-lived intangible assets consist primarily of patient base, facility trade names and customer relationships. Patient base is amortized over a period of <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjM2YTQ4YjE0Mzg2NDRlY2E5NDlhYmUxZGY1NTg0NTZhL3NlYzozNmE0OGIxNDM4NjQ0ZWNhOTQ5YWJlMWRmNTU4NDU2YV82MS9mcmFnOjQ5ZTkwZDZhNDRiMjQzZTI5MzFmNzdlYmJhZDkzNDlkL3RleHRyZWdpb246NDllOTBkNmE0NGIyNDNlMjkzMWY3N2ViYmFkOTM0OWRfOTI5OQ_dea5be0e-fac6-4da5-b203-ebeeaf11a40e">four</span> to eight months, depending on the classification of the patients and the level of occupancy in a new acquisition on the acquisition date. Trade names at affiliated facilities are amortized over 30 years and customer relationships are amortized over a period of up to 20 years.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's indefinite-lived intangible assets consist of trade names, and Medicare and Medicaid licenses. The Company tests indefinite-lived intangible assets for impairment on an annual basis or more frequently if events or changes in circumstances indicate that the carrying amount of the intangible asset may not be recoverable. </span></div>Goodwill represents the excess of the purchase price over the fair value of identifiable net assets acquired in business combinations. Goodwill is subject to annual testing for impairment. In addition, goodwill is tested for impairment if events occur or circumstances indicate that its carrying value may not be recoverable. The Company performs its annual test for impairment during the fourth quarter of each year. P8M P30Y P20Y 0 0 0 0 <div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Self-Insurance</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> — The Company is partially self-insured for general and professional liability claims up to a base amount per claim (the self-insured retention) with an aggregate, one-time deductible above this limit. Losses beyond these amounts are insured through third-party policies with coverage limits per claim, per location and on an aggregate basis for the Company. The combined self-insured retention is $500 per claim, subject to an additional one-time deductible of $1,000 for California affiliated operations and a separate, one-time, deductible of $1,250 for non-California operations. For all affiliated operations, except those located in Colorado, the third-party coverage above these limits is $1,000 per claim, $3,000 per operation, with a $5,000 blanket aggregate limit and an additional state-specific aggregate where required by state law. In Colorado, the third-party coverage above these limits is $1,000 per claim and $3,000 per operation, which is independent of the aforementioned blanket aggregate limits that apply outside of Colorado. </span></div><div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The majority of the self-insured retention and deductible limits for general and professional liabilities and workers' compensation liabilities are self-insured through the captive insurance subsidiary, the related assets and liabilities of which are included in the accompanying condensed consolidated balance sheets. The captive insurance subsidiary is subject to certain statutory requirements as an insurance provider. </span></div><div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s policy is to accrue amounts equal to the actuarial estimated costs to settle open claims of insureds, as well as an estimate of the cost of insured claims that have been incurred but not reported. The Company develops information about the size of the ultimate claims based on historical experience, current industry information and actuarial analysis, and evaluates the estimates for claim loss exposure on a quarterly basis. The Company uses actuarial valuations to estimate the liability based on historical experience and industry information. Accrued general liability and professional malpractice liabilities on an undiscounted basis, net of anticipated insurance recoveries, were $76,145 and $66,158 as of June 30, 2022 and December 31, 2021, respectively. </span></div><div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s operating subsidiaries are self-insured for workers’ compensation liabilities in California. To protect itself against loss exposure in California with this policy, the Company has purchased individual specific excess insurance coverage that insures individual claims that exceed $625 per occurrence. In Texas, the operating subsidiaries have elected non-subscriber status for workers’ compensation claims and the Company has purchased individual stop-loss coverage that insures individual claims that exceed $750 per occurrence. The Company’s operating subsidiaries in all other states, with the exception of Washington, are under a loss sensitive plan that insures individual claims that exceed $350 per occurrence. In the state of Washington, the Company is self insured and has purchased individual specific excess insurance coverage that insures individual claims that exceed $500 per occurrence. For all of the self insured plans and retention, the Company accrues amounts equal to the estimated costs to settle open claims, as well as an estimate of the cost of claims that have been incurred but not reported. The Company uses actuarial valuations to estimate the liability based on historical experience and industry information. Accrued workers’ compensation liabilities are recorded on an undiscounted basis in the accompanying condensed consolidated balance sheets and were $28,365 and $27,335 as of June 30, 2022 and December 31, 2021, respectively.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the Company has recorded an asset and equal liability of $8,440 and $6,755 as of June 30, 2022 and December 31, 2021, respectively, in order to present the ultimate costs of malpractice and workers' compensation claims and the anticipated insurance recoveries on a gross basis. See Note 13, </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Restricted and Other Assets.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company self-funds medical (including prescription drugs) and dental healthcare benefits to the majority of its employees. The Company is fully liable for all financial and legal aspects of these benefit plans. To protect itself against loss exposure with this policy, the Company has purchased individual stop-loss insurance coverage that insures individual claims that exceed $525 for each covered person for fiscal year 2022. The Company’s accrued liability under these plans recorded on an undiscounted basis in the accompanying condensed consolidated balance sheets was $13,571 and $9,891 as of June 30, 2022 and December 31, 2021, respectively.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company believes that adequate provision has been made in the Interim Financial Statements for liabilities that may arise out of patient care, workers’ compensation, healthcare benefits and related services provided to date. The amount of the Company’s reserves was determined based on an estimation process that uses information obtained from both company-specific and industry data. This estimation process requires the Company to continuously monitor and evaluate the life cycle of the claims. Using data obtained from this monitoring and the Company’s assumptions about emerging trends, the Company, with the assistance of an independent actuary, develops information about the size of ultimate claims based on the Company’s historical experience and other available industry information. The most significant assumptions used in the estimation process include determining the trend in costs, the expected cost of claims incurred but not reported and the expected costs to settle or pay damage awards with respect to unpaid claims. The self-insured liabilities are based upon estimates, and while management believes that the estimates of loss are reasonable, the ultimate liability may be in excess of or less than the recorded amounts. Due to the inherent volatility of actuarially determined loss estimates, it is reasonably possible that the Company could experience changes in estimated losses that could be material to net income. If the Company’s actual liabilities exceed its estimates of losses, its future earnings, cash flows and financial condition would be adversely affected.</span></div> 500000 1000000 1250000 1000000 3000000 5000000 1000000 3000000 76145000 66158000 625000 750000 350000 500000 28365000 27335000 8440000 6755000 525000 13571000 9891000 <div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> — Deferred tax assets and liabilities are established for temporary differences between the financial reporting basis and the tax basis of the Company’s assets and liabilities at tax rates in effect when such temporary differences are expected to reverse. The Company generally expects to fully utilize its deferred tax assets; however, when necessary, the Company records a valuation allowance to reduce its net deferred tax assets to the amount that is more likely than not to be realized. </span></div><div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In determining the need for a valuation allowance or the need for and magnitude of liabilities for uncertain tax positions, the Company makes certain estimates and assumptions. These estimates and assumptions are based on, among other things, knowledge of operations, markets, historical trends and likely future changes and, when appropriate, the opinions of advisors with knowledge and expertise in certain fields. Due to certain risks associated with the Company’s estimates and assumptions, actual results could differ.</span></div> <span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Noncontrolling Interest </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">— </span>The noncontrolling interest in a subsidiary is initially recognized at estimated fair value on the acquisition date and is presented within total equity in the Company's condensed consolidated balance sheets. The Company presents the noncontrolling interest and the amount of consolidated net income attributable to The Ensign Group, Inc. in its condensed consolidated statements of income. Net income per share is calculated based on net income attributable to The Ensign Group, Inc.'s stockholders. The carrying amount of the noncontrolling interest is adjusted based on an allocation of subsidiary earnings based on ownership interest. <span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-Based Compensation</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> — </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company measures and recognizes compensation expense for all stock-based payment awards made to employees and directors including employee stock options based on estimated fair values, ratably over the requisite service period of the award. Net income has been reduced as a result of the recognition of the fair value of all stock options and restricted stock awards issued, the amount of which is contingent upon the number of future grants and other variables.</span> <div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Accounting Pronouncements</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> —</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Except for rules and interpretive releases of the Securities and Exchange Commission (SEC) under authority of federal securities laws and a limited number of grandfathered standards, the FASB ASC is the sole source of authoritative GAAP literature recognized by the FASB and applicable to the Company. For any new pronouncements announced, the Company considers whether the new pronouncements could alter previous generally accepted accounting principles and determines whether any new or modified principles will have a material impact on the Company's reported financial position or operations in the near term. The applicability of any standard is subject to the formal review of the Company's financial management and certain standards are under consideration.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Accounting Standards Adopted by the Company </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">—</span><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2021, the FASB issued ASU 2021-10 “</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Government Assistance (Topic 832): Disclosures by Business Entities about Government Assistance,</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">” which created FASB ASC Topic 832, </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Government Assistance </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(ASC 832)</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">. </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ASC 832 requires business entities to disclose information about certain government assistance they receive.</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company adopted this standard on January 1, 2022 and determined there was no material impact on the Company's condensed consolidated financial statements. </span></div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accounting Standards Recently Issued but Not Yet Adopted by the Company </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">— </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2020, the FASB issued ASU 2020-04</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> "Reference Rate Reform (Topic 848),"</span> which provides temporary, optional practical expedients and exceptions to enable a smoother transition to reference rates which are expected to replace London Interbank Offered Rate (LIBOR) reference rates. Adoption of the provisions of ASU 2020-04 is optional. The amendments are effective for all entities from the beginning of the interim period that includes the issuance date of the ASU. An entity may elect to apply the amendments prospectively through December 31, 2022. During the quarter ended June 30, 2022, the Company and its subsidiaries including Standard Bearer, entered into the Second Amendment to Third Amended and Restated Credit Agreement (such agreement, the Amended Credit Agreement, and the revolving credit facility thereunder, the Revolving Credit Facility), which increased the Revolving Credit Facility by $250,000 to an aggregate principal amount of up to $600,000. Pursuant to the Amended Credit Agreement, the Company transitioned from LIBOR to the Secured Overnight Financing Rate (SOFR) as the applicable reference rate for borrowings under the Revolving Credit Facility and determined there was no resulting material impact on the Company's condensed consolidated financial statements. 250000000 600000000 COVID-19 UPDATE<div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The COVID-19 pandemic has continued to impact the Company's affiliated operations. In prior years, as part of the Coronavirus Aid, Relief, and Economic Security Act of 2020 (the CARES Act), the Company received cash distributions of relief fund payments (Provider Relief Funds) and funds authorized by </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S. Department of Health and Human Services (HHS)</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to be used to protect residents of nursing homes and long-term care (LTC) facilities from the impact of COVID-19</span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three and six months ended June 30, 2022, the Company did not receive Provider Relief Funds. During the three and six months ended June 30, 2021, the Company received and returned $2,399 and $11,538, respectively, in Provider Relief Funds. The Company may continue to receive additional funding in future periods. </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In fiscal year 2020, the Company applied for and received $105,255 through the Medicare Accelerated and Advance Payment Program under the CARES Act. The purpose of the program is to assist in providing needed liquidity to care delivery providers. The Company repaid $3,232 of the funds in 2020. In March 2021, the Company repaid the remaining funds of $102,023. </span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Family First Coronavirus Response Act was signed into law in 2020 to provide a temporary 6.2% increase to the Federal Medical Assistance Percentage (FMAP) effective January 1, 2020. The law permits states to retroactively change their state's Medicaid program rates effective as of January 1, 2020. The law provides discretion to each state and specifies the funds are to be used to reimburse the recipient for healthcare related expenses that are attributable to COVID-19 and associated with providing patient care. In addition, increases in Medicaid rates can come from other areas of the state's budget outside of FMAP funding. Revenues from these additional payments are recognized in accordance with ASC 606, subject to variable consideration constraints. In certain operations where the Company received additional payments that exceeded expenses incurred related to COVID-19, the Company characterized such payments as variable revenue that required additional consideration and accordingly, the amount of state relief revenue recognized is limited to the actual COVID-19 related expenses incurred. As of June 30, 2022 and December 31, 2021, the Company had $4,356 and $1,781 in unapplied state relief funds, respectively. During the three and six months ended June 30, 2022, the Company received an additional $27,345 and $44,662 in state relief funding and recognized $24,489 and $42,088, respectively, as revenue. During the three and six months ended June 30, 2021, the Company received an additional $16,776 and $32,421 in state relief funding and recognized $16,692 and $33,157, respectively, as revenue. </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The CARES Act also provides for deferred payment of the employer portion of social security taxes through the end of 2020, with 50% of the deferred amount due by December 31, 2021 and the remaining 50% due by December 31, 2022. The Company recorded $48,309 of deferred payments of social security taxes as a liability during 2020. The Company paid $24,154 during the year ended December 31, 2021 and the remaining short-term balance of $24,155 is included in accrued wages and related liabilities within the condensed consolidated balance sheets as of June 30, 2022.</span></div> 0 0 2399000 11538000 105255000 3232000 102023000 4356000 1781000 27345000 44662000 24489000 42088000 16776000 32421000 16692000 33157000 48309000 24154000 24155000 REVENUE AND ACCOUNTS RECEIVABLE<div style="margin-top:9pt;text-align:justify"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Service Revenue </span></div><div style="text-align:justify;text-indent:24.75pt"><span><br/></span></div><div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's service revenue is derived primarily from providing healthcare services to its patients. Revenue is recognized when services are provided to the patients at the amount that reflects the consideration to which the Company expects to be entitled from patients and third-party payors, including Medicaid, Medicare and insurers (private and Medicare replacement plans), in exchange for providing patient care. The healthcare services in skilled patient contracts include routine services in exchange for a contractual agreed-upon amount or rate. Routine services are treated as a single performance obligation satisfied over time as services are rendered. As such, patient care services represent a bundle of services that are not capable of being distinct. Additionally, there may be ancillary services which are not included in the daily rates for routine services, but instead are treated as separate performance obligations satisfied at a point in time, if and when those services are rendered.</span></div><div style="text-align:justify;text-indent:24.75pt"><span><br/></span></div><div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue recognized from healthcare services are adjusted for estimates of variable consideration to arrive at the transaction price. The Company determines the transaction price based on contractually agreed-upon amounts or rate on a per day basis, adjusted for estimates of variable consideration. The Company uses the expected value method in determining the variable component that should be used to arrive at the transaction price, using contractual agreements and historical reimbursement experience within each payor type. The amount of variable consideration which is included in the transaction price may be constrained, and is included in net revenue only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized will not occur in a future period. If actual amounts of consideration ultimately received differ from the Company’s estimates, the Company adjusts these estimates, which would affect net revenue in the period such variances become known. </span></div><div style="text-align:justify;text-indent:24.75pt"><span><br/></span></div><div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue from the Medicare and Medicaid programs accounted for 73.4% of all service revenue for both the three and six months ended June 30, 2022 and 73.1% and 73.6% for the three and six months ended June 30, 2021, respectively. Settlements with Medicare and Medicaid payors for retroactive adjustments due to audits and reviews are considered variable consideration and are included in the determination of the estimated transaction price. These settlements are estimated based on the terms of the payment agreement with the payor, correspondence from the payor and the Company’s historical settlement activity. Consistent with healthcare industry practices, any changes to these revenue estimates are recorded in the period the change or adjustment becomes known based on the final settlement. The Company recorded adjustments to revenue which were not material to the Company's revenue for the three and six months ended June 30, 2022 and 2021.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Rental Revenue </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's rental revenues are primarily generated by leasing healthcare-related properties through triple-net lease arrangements, under which the tenant is solely responsible for the costs related to the property. Revenue is recognized on a straight-line basis over the lease term if it has been deemed probable of collection. The Company has elected the single component practical expedient, which allows a lessor, by class of underlying asset, not to allocate the total consideration to the lease and non-lease components based on their relative stand-alone selling prices where certain criteria are met. </span></div><div style="text-align:justify;text-indent:24.75pt"><span><br/></span></div><div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Tenant reimbursements related to property taxes and insurance are neither considered lease nor non-lease components under the new lease standards. Lessee payments for taxes and insurance paid directly to a third party, on behalf of the Company, are excluded from variable lease payments and rental revenue in the Company’s condensed consolidated statements of income. Otherwise, tenant reimbursements for taxes and insurance that are paid by the Company directly to a third party are classified as additional rental revenue and expense and recognized by the Company on a gross basis.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Disaggregation of Revenue</span></div><div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company disaggregates revenue from contracts with its patients by payors. The Company determines that disaggregating revenue into these categories achieves the disclosure objectives to depict how the nature, amount, timing and uncertainty of revenue and cash flows are affected by economic factors. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue by Payor</span></div><div style="text-align:justify;text-indent:24.75pt"><span><br/></span></div><div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s revenue is derived primarily from providing healthcare services to patients and is recognized on the date services are provided at amounts billable to individual patients, adjusted for estimates for variable consideration. For patients under reimbursement arrangements with third-party payors, including Medicaid, Medicare and private insurers, revenue is recorded based on contractually agreed-upon amounts or rates, adjusted for estimates for variable consideration, on a per patient, daily basis or as services are performed. </span></div><div style="margin-top:9.75pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Service revenue for the three and six months ended June 30, 2022 and 2021 is summarized in the following tables:</span></div><div style="margin-top:9.75pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:39.981%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.086%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="21" style="border-bottom:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Revenue</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">% of Revenue</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Revenue</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">% of Revenue</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicaid</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">294,128 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40.4 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">251,455 </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39.6 </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare</span></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">190,494 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26.2 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">170,008 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26.8 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicaid — skilled</span></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,763 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.8 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,740 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.7 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Medicaid and Medicare</span></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">534,385</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">73.4</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">464,203</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">73.1</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Managed care</span></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">128,587 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.7 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112,963 </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.8 </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Private and other</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65,375 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.9 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57,443 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.1 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">SERVICE REVENUE</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">728,347</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">100.0</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"/><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">634,609</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">100.0</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td></tr></table><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1) Medicaid payor includes revenue for senior living operations and </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">revenue related to FMAP.</span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2) </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Private and other payors also includes revenue from senior living operations and all payors generated in other ancillary services.</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:40.566%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.935%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.935%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.935%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.939%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="21" style="border-bottom:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Revenue</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">% of Revenue</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Revenue</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">% of Revenue</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicaid</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">560,476 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39.0 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">482,813 </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38.4 </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare</span></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">398,905 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27.7 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">360,311 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28.6 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicaid — skilled</span></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95,712 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.7 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82,733 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.6 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Medicaid and Medicare</span></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,055,093</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">73.4</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">925,857</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">73.6</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Managed care</span></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">256,373 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.8 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">221,308 </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.6 </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Private and other</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">126,037 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.8 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110,720 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.8 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">SERVICE REVENUE</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,437,503</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">100.0</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"/><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,257,885</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">100.0</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1) Medicaid payor includes revenue for senior living operations and </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">revenue related to FMAP.</span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2) </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Private and other payors also includes revenue from senior living operations and all payors generated in other ancillary services.</span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">In addition to the service revenue above, the Company's rental revenue derived from triple-net lease arrangements with third parties was $4,139 and $8,428, respectively, for the three and six months ended June 30, 2022 and $3,927 and $7,904, respectively, for the three and six months ended June 30, 2021.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Balance Sheet Impact</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Included in the Company’s condensed consolidated balance sheets are contract balances, comprised of billed accounts receivable and unbilled receivables, which are the result of the timing of revenue recognition, billings and cash collections, as well as, contract liabilities, which primarily represent payments the Company receives in advance of services provided. The Company had no material contract liabilities and contract assets as of June 30, 2022 and December 31, 2021, or activity during the three and six months ended June 30, 2022 and 2021.</span></div><div style="margin-top:9.75pt;text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts receivable as of June 30, 2022 and December 31, 2021, is summarized in the following table:</span></div><div style="margin-top:9.75pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:63.812%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.297%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.861%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicaid</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">125,348 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">123,647 </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Managed care</span></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86,995 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79,722 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare</span></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58,067 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59,797 </span></td><td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Private and other payors</span></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76,418 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76,778 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">346,828</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">339,944</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: allowance for doubtful accounts</span></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,827)</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,213)</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ACCOUNTS RECEIVABLE, NET</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">339,001</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"/><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">328,731</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt;text-align:justify"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Practical Expedients and Exemptions</span></div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As the Company’s contracts with its patients have an original duration of one year or less, the Company uses the practical expedient applicable to its contracts and does not consider the time value of money. Further, because of the short duration of these contracts, the Company has not disclosed the transaction price for the remaining performance obligations as of the end of each reporting period or when the Company expects to recognize this revenue. In addition, the Company has applied the practical expedient provided by ASC 340, </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Assets and Deferred Costs</span>, and all incremental customer contract acquisition costs are expensed as they are incurred because the amortization period would have been one year or less. 0.734 0.734 0.731 0.736 <div style="margin-top:9.75pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Service revenue for the three and six months ended June 30, 2022 and 2021 is summarized in the following tables:</span></div><div style="margin-top:9.75pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:39.981%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.086%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="21" style="border-bottom:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Revenue</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">% of Revenue</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Revenue</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">% of Revenue</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicaid</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">294,128 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40.4 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">251,455 </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39.6 </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare</span></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">190,494 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26.2 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">170,008 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26.8 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicaid — skilled</span></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,763 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.8 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,740 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.7 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Medicaid and Medicare</span></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">534,385</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">73.4</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">464,203</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">73.1</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Managed care</span></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">128,587 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.7 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112,963 </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.8 </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Private and other</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65,375 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.9 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57,443 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.1 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">SERVICE REVENUE</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">728,347</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">100.0</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"/><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">634,609</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">100.0</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td></tr></table><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1) Medicaid payor includes revenue for senior living operations and </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">revenue related to FMAP.</span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2) </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Private and other payors also includes revenue from senior living operations and all payors generated in other ancillary services.</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:40.566%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.935%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.935%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.935%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.939%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="21" style="border-bottom:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Revenue</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">% of Revenue</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Revenue</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">% of Revenue</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicaid</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">560,476 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39.0 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">482,813 </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38.4 </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare</span></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">398,905 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27.7 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">360,311 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28.6 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicaid — skilled</span></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95,712 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.7 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82,733 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.6 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Medicaid and Medicare</span></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,055,093</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">73.4</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">925,857</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">73.6</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Managed care</span></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">256,373 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.8 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">221,308 </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.6 </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Private and other</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">126,037 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.8 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110,720 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.8 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">SERVICE REVENUE</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,437,503</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">100.0</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"/><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,257,885</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">100.0</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1) Medicaid payor includes revenue for senior living operations and </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">revenue related to FMAP.</span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2) </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Private and other payors also includes revenue from senior living operations and all payors generated in other ancillary services.</span></div> 294128000 0.404 251455000 0.396 190494000 0.262 170008000 0.268 49763000 0.068 42740000 0.067 534385000 0.734 0.734 464203000 0.731 128587000 0.177 112963000 0.178 65375000 0.089 57443000 0.091 728347000 1.000 634609000 1.000 560476000 0.390 482813000 0.384 398905000 0.277 360311000 0.286 95712000 0.067 82733000 0.066 1055093000 0.734 925857000 0.736 256373000 0.178 221308000 0.176 126037000 0.088 110720000 0.088 1437503000 1.000 1257885000 1.000 4139000 8428000 3927000 7904000 <div style="text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts receivable as of June 30, 2022 and December 31, 2021, is summarized in the following table:</span></div><div style="margin-top:9.75pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:63.812%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.297%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.861%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicaid</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">125,348 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">123,647 </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Managed care</span></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86,995 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79,722 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare</span></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58,067 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59,797 </span></td><td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Private and other payors</span></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76,418 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76,778 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">346,828</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">339,944</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: allowance for doubtful accounts</span></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,827)</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,213)</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ACCOUNTS RECEIVABLE, NET</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">339,001</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"/><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">328,731</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 125348000 123647000 86995000 79722000 58067000 59797000 76418000 76778000 346828000 339944000 7827000 11213000 339001000 328731000 COMPUTATION OF NET INCOME PER COMMON SHARE<div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net income per share is computed by dividing income from operations attributable to stockholders of The Ensign Group, Inc. by the weighted average number of outstanding common shares for the period. The computation of diluted net income per share is similar to the computation of basic net income per share, except that the denominator is increased to include the number of additional common shares that would have been outstanding if the dilutive potential common shares had been issued.</span></div><div style="text-align:justify;text-indent:24.75pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of the numerator and denominator used in the calculation of basic net income per common share follows:</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:50.800%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.449%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.449%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.449%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.455%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">NUMERATOR:</span></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57,803 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,583 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107,891 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100,420 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: net (loss) income attributable to noncontrolling interests </span></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,158 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(140)</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,789 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net income attributable to The Ensign Group, Inc. </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">57,691</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">49,425</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">108,031</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">98,631</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">DENOMINATOR:</span></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average shares outstanding for basic net income per share</span></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54,906 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54,468 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54,788 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54,331 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Basic net income per common share:</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1.05</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"/><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">0.91</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"/><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1.97</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"/><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1.82</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of the numerator and denominator used in the calculation of diluted net income per common share follows:</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:50.946%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.449%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.449%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.449%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.455%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">NUMERATOR:</span></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income </span></td><td style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57,803 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,583 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107,891 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100,420 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: net (loss) income attributable to noncontrolling interests</span></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,158 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(140)</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,789 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net income attributable to The Ensign Group, Inc. </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">57,691</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">49,425</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">108,031</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">98,631</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">DENOMINATOR:</span></td><td colspan="3" style="background-color:#e4e9df;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#3d6702;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average common shares outstanding</span></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54,906 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54,468 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54,788 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54,331 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Plus: incremental shares from assumed conversion</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> (1)</span></div></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,947 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,529 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,074 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,614 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Adjusted weighted average common shares outstanding</span></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">56,853</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">56,997</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">56,862</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">56,945</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Diluted net income per common share:</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1.01</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"/><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">0.87</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"/><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1.90</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"/><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1.73</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1) Options outstanding which are anti-dilutive and therefore not factored into the weighted average common shares amount above were</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> 789 and 697 </span>for the three and six months ended June 30, 2022, respectively, and 167 and 80 for the three and six months ended June 30, 2021, respectively. <div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of the numerator and denominator used in the calculation of basic net income per common share follows:</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:50.800%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.449%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.449%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.449%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.455%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">NUMERATOR:</span></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57,803 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,583 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107,891 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100,420 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: net (loss) income attributable to noncontrolling interests </span></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,158 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(140)</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,789 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net income attributable to The Ensign Group, Inc. </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">57,691</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">49,425</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">108,031</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">98,631</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">DENOMINATOR:</span></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average shares outstanding for basic net income per share</span></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54,906 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54,468 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54,788 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54,331 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Basic net income per common share:</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1.05</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"/><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">0.91</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"/><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1.97</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"/><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1.82</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div> 57803000 50583000 107891000 100420000 112000 1158000 -140000 1789000 57691000 49425000 108031000 98631000 54906000 54468000 54788000 54331000 1.05 0.91 1.97 1.82 <div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of the numerator and denominator used in the calculation of diluted net income per common share follows:</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:50.946%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.449%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.449%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.449%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.455%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">NUMERATOR:</span></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income </span></td><td style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57,803 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,583 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107,891 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100,420 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: net (loss) income attributable to noncontrolling interests</span></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,158 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(140)</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,789 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net income attributable to The Ensign Group, Inc. </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">57,691</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">49,425</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">108,031</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">98,631</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">DENOMINATOR:</span></td><td colspan="3" style="background-color:#e4e9df;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#3d6702;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average common shares outstanding</span></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54,906 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54,468 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54,788 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54,331 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Plus: incremental shares from assumed conversion</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> (1)</span></div></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,947 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,529 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,074 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,614 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Adjusted weighted average common shares outstanding</span></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">56,853</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">56,997</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">56,862</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">56,945</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Diluted net income per common share:</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1.01</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"/><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">0.87</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"/><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1.90</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"/><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1.73</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1) Options outstanding which are anti-dilutive and therefore not factored into the weighted average common shares amount above were</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> 789 and 697 </span>for the three and six months ended June 30, 2022, respectively, and 167 and 80 for the three and six months ended June 30, 2021, respectively. 57803000 50583000 107891000 100420000 112000 1158000 -140000 1789000 57691000 49425000 108031000 98631000 54906000 54468000 54788000 54331000 1947000 2529000 2074000 2614000 56853000 56997000 56862000 56945000 1.01 0.87 1.90 1.73 789000 697000 167000 80000 FAIR VALUE MEASUREMENTS<div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value measurements are based on a three-tier hierarchy that prioritizes the inputs used to measure fair value. These tiers include: Level 1, defined as observable inputs such as quoted market prices in active markets; Level 2, defined as inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly; and Level 3, defined as unobservable inputs for which little or no market data exists, therefore requiring an entity to develop its own assumptions.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of cash and cash equivalents of $285,580 and $262,201 as of June 30, 2022 and December 31, 2021, respectively, is derived using Level 1 inputs. The Company's other financial assets include contracts insuring the lives of certain employees who are eligible to participate in non-qualified deferred compensation plans which are held in a rabbi trust. The cash surrender value of these contracts is based on funds that shadow the investment allocations specified by participants in the deferred compensation plan. As of June 30, 2022, and December 31, 2021, the fair value of the investment funds of $23,151 and $17,530, respectively, is derived using Level 2 inputs. The investment funds are included in restricted and other assets in the condensed consolidated balance sheets. See Note 13, </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Restricted and Other Assets.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's non-financial assets, which includes goodwill, intangible assets, property and equipment and right-of-use assets, are not required to be measured at fair value on a recurring basis. However, on a periodic basis, or whenever events or changes in circumstances indicate that their carrying value may not be recoverable, the Company assesses its long-lived assets for impairment. When impairment has occurred, such long-lived assets are written down to fair value. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Debt Security Investments - Held to Maturity</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June 30, 2022 and December 31, 2021, the Company had approximately $49,068 and $50,330, respectively, in debt security investments which were classified as held to maturity and carried at amortized cost. The carrying value of the debt securities approximates fair value based on Level 1 inputs. The Company has the intent and ability to hold these debt securities to maturity. Further, as of June 30, 2022, the debt security investments were held in AA, A and BBB r</span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ated de</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">bt securities. </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company believes its debt security investments and investment funds that were in an unrealized loss position as of June 30, 2022 were not other-than-temporarily impaired, nor has any event occurred subsequent to that date that would indicate any other-than-temporary impairment.</span></div> 285580000 262201000 23151000 17530000 49068000 50330000 STANDARD BEARER<div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Standard Bearer's real estate portfolio consists of 95 of the Company's 100 owned real estate properties, of which 67 are operated and managed by the Company and 29 are leased to and operated by Pennant. Of those 29 senior living operations, one is located on the same real estate property as a skilled nursing facility that the Company owns and operates. Standard Bearer intends to qualify and elect to be taxed as a REIT, for U.S. federal income tax purposes, commencing with its taxable year ending December 31, 2022. During the six months ended June 30, 2022, Standard Bearer acquired the real estate of two skilled nursing facilities for a purchase price of $17,412, both of which are operated and managed by Ensign's affiliated operations. Refer to Note 9, </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Operation Expansions </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for additional information.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subsequent to June 30, 2022, Standard Bearer expanded its real estate portfolio with the addition of five skilled nursing properties and one campus property for a total purchase price of $47,900. </span></div><div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of the formation of Standard Bearer, certain of the Company's operating subsidiaries, Standard Bearer and Standard Bearer's subsidiaries entered into several agreements that include leasing, management services and debt arrangements between the operations. </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As these intercompany arrangements were entered into when Standard Bearer was formed in January 2022, the transactions related to these agreements are reflected in Standard Bearer's segment income during three and six months ended June 30, 2022. All intercompany transactions have been eliminated in consolidation. Refer to Note 8, </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Business Segments</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, for additional information related to these intercompany eliminations as well as Standard Bearer as a reportable segment. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Intercompany master lease agreements</span></div><div style="margin-top:10pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain of the Company's operating subsidiaries and the 67 Standard Bearer subsidiaries entered into five "triple-net" master lease agreements (collectively, the Standard Bearer Master Leases) in January 2022. The lease periods range from 15 to 19 years with three five-year renewal options beyond the initial term, on the same terms and conditions. The rent structure under the Standard Bearer Master Leases includes a fixed component, subject to annual escalation equal to the lesser of (1) the percentage change in the Consumer Price Index (but not less than zero) or (2) 2.5%. In addition to rent, the operating subsidiaries are required to pay the following: (1) all impositions and taxes levied on or with respect to the leased properties; (2) all utilities and other services necessary or appropriate for the leased properties and the business conducted on the leased properties; (3) all insurance required in connection with the leased properties and the business conducted on the leased properties; (4) all facility maintenance and repair costs; and (5) all fees in connection with any licenses or authorizations necessary or appropriate for the leased properties and the business conducted on the leased properties. The two real estate properties acquired during six months ended June 30, 2022 were added to the Standard Bearer Master Leases. Rental revenue generated from Ensign affiliated operations was $13,894 and $27,319, respectively, for the three and six months ended June 30, 2022 and $10,784 and $21,375, respectively, for the three and six months ended June 30, 2021.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Intercompany management agreement</span></div><div style="margin-top:10pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Standard Bearer has no employees. The Service Center provides personnel and services to Standard Bearer pursuant to the management agreement between Standard Bearer and the Service Center. The management agreement provides for a base management fee that is equal to 5% of total rental revenue and an incentive management fee that is equal to 5% of funds from operations (FFO) and is capped at 1% of total rental revenue. Management fee generated between Standard Bearer and the Service Center for the three and six months ended June 30, 2022 was $1,056 and $2,078, respectively, both of which represent 6% of total Standard Bearer rental revenue. No management fees were recorded in 2021, which was prior to the formation of Standard Bearer. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Intercompany debt arrangements</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Standard Bearer obtains its funding through various sources including operating cash flows, access to debt arrangements and intercompany loans. The intercompany debt arrangements include mortgage loans and the Revolving Credit Facility to fund acquisitions and working capital needs. The interest rate under the Amended Credit Agreement is a base rate plus a margin ranging from 0.25% to 1.25% per annum or SOFR plus a margin range from 1.25% to 2.25% per annum. </span></div><div style="text-align:justify;text-indent:24.75pt"><span><br/></span></div><div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, as the Department of Housing and Urban Development (HUD) mortgage loans and promissory notes are entered into by real estate subsidiaries of Standard Bearer, the interest expense incurred from these debts are included in Standard Bearer's segment income. Refer to Note 16, </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Debt</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, for additional information related to these debts. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Equity Instrument Denominated in the Shares of a Subsidiary</span></div><div style="margin-bottom:12pt;margin-top:10pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of the formation of Standard Bearer in January of 2022, the Company established the Standard Bearer Healthcare REIT, Inc. 2022 Omnibus Incentive Plan (Standard Bearer Equity Plan). The Company may grant stock options and restricted stock awards under the Standard Bearer Equity Plan to employees and management of Ensign's affiliated subsidiaries. These awards generally vest over a period of five years or upon the occurrence of certain prescribed events. The value of the stock options and restricted stock awards is tied to the value of the common stock of Standard Bearer, which is determined based on an independent valuation of Standard Bearer. The awards can be put to the Company at various prescribed dates, which in no event is earlier than six months after vesting of the restricted awards or exercise of the stock options. The Company can also call the awards, generally upon employee termination. During the three months ended June 30, 2022, Standard Bearer sold fully vested common shares from the Standard Bearer Equity Plan to shareholders for cash of $6,544. During the three and six months ended June 30, 2022, the Company did not grant any stock options nor restricted shares under the Standard Bearer Equity Plan.</span></div><div style="margin-bottom:12pt;margin-top:10pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended June 30, 2022, Standard Bearer established shareholders of its preferred shares through contributions of cash of $149. These preferred shares were fully vested at the time of the contributions by the shareholders.</span></div> 95 100 67 29 29 1 2 17412000 5 1 47900000 67 5 P15Y P19Y 3 P5Y 0.025 2 13894000 27319000 10784000 21375000 0.05 0.05 0.01 1056000 2078000 0.06 0.06 0.0025 0.0125 0.0125 0.0225 P5Y 6544000 149000 BUSINESS SEGMENTS<div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In conjunction with the formation Standard Bearer in January 2022, the Company's Chief Executive Officer, who is its chief operating decision maker, or CODM, began reviewing the results of Standard Bearer instead of all real estate properties. Accordingly, the Company revised its former real estate segment to include only real estate properties that are part of Standard Bearer. This change in organizational structure demonstrates that Standard Bearer's real estate is a core part of the Company's expansion of its real estate investment strategy. As of the first quarter of 2022, the Company has two reportable segments: (1) skilled services, which includes the operation of skilled nursing facilities and rehabilitation therapy services and (2) Standard Bearer, which is comprised of selected real estate properties owned by Standard Bearer and leased to skilled nursing and senior living operators. Segment information for prior periods has been recast to reflect the change of the Company’s segment structure.</span></div><div style="text-align:justify;text-indent:24.75pt"><span><br/></span></div><div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June 30, 2022, the skilled services segment includes 215 skilled nursing operations and 25 campus operations that provide both skilled nursing and rehabilitative care services and senior living services. The Company's Standard Bearer segment consists of 95 owned real estate properties. These properties include 67 operations the Company operated and managed and 29 senior living operations that are leased to and operated by third parties. Of the 29 real estate operations leased to third parties, one senior living operation is located on the same real estate property as a skilled nursing facility that the Company owns and operates. </span></div><div style="text-align:justify;text-indent:24.75pt"><span><br/></span></div><div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company also reports an “All Other” category that includes results from its senior living operations, which includes eleven stand-alone senior living operations and the senior living operations at 25 campus operations that provide both skilled nursing and rehabilitative care services and senior living services. In addition, the "All Other" category includes mobile diagnostics, medical transportation, other real estate and other ancillary operations. Services included in the “All Other” category are insignificant individually, and therefore do not constitute a reportable segment.</span></div><div style="text-align:justify;text-indent:24.75pt"><span><br/></span></div><div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s reportable segments are significant operating segments that offer differentiated services. The Company's CODM reviews financial information for each operating segment to evaluate performance and allocate capital resources. This structure reflects its current operational and financial management and provides the best structure to maximize the quality of care and investment strategy provided, while maintaining financial discipline. The Company's CODM does not review assets by segment in his resource allocation and therefore assets by segment are not disclosed below.</span></div><div style="text-align:justify;text-indent:24.75pt"><span><br/></span></div><div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The accounting policies of the reportable segments are the same as those described in Note 2, </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Summary of Significant Accounting Policies</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Intercompany revenue is eliminated in consolidation, along with corresponding intercompany expenses. Segment income and loss is defined as profit or loss from operations before provision for income taxes, excluding gain or loss from sale of real estate, insurance recoveries and impairment charges from operations. Included in segment income for Standard Bearer is expense for intercompany services provided by the Service Center as described in Note 7, </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Standard Bearer</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, as it is part of the CODM financial information. </span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables set forth financial information for the segments:</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:35.742%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.204%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.603%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended June 30, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Skilled Services</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Standard Bearer</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">All Other</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Intercompany Elimination</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total </span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Service revenue</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">702,478 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,787 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,918)</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">728,347 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rental revenue</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,598 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,832 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15,291)</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,139 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">TOTAL REVENUE</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">702,478</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"/><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">17,598</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"/><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">30,619</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"/><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(18,209)</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"/><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">732,486</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Segment income (loss)</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">102,266 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,838 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(38,614)</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70,490 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain on sale of assets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,467 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Income before provision for income taxes </span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"/><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">72,957</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,113 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,216 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,529 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,858 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span></div></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,743 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">889 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,944)</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,688 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1) All other primarily includes all ancillary operations, stand-alone senior living operations and the Service Center. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2) Intercompany service revenue represents service revenue generated by ancillary operations provided to the Company's affiliated wholly-owned healthcare facilities and management service revenue generated by the Service Center with Standard Bearer. Intercompany service revenue is eliminated in consolidation along with corresponding intercompany cost of service. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(3) Intercompany rental revenue represents rental income generated by both Standard Bearer and other real estate properties with the Company's affiliated wholly-owned healthcare facilities. Intercompany rental revenue is eliminated in consolidation along with corresponding intercompany rent expense. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(4) Included in interest expense in Standard Bearer is interest expense incurred from intercompany debt arrangements between Standard Bearer and The Ensign Group, Inc. The intercompany interest expense is eliminated in the "Intercompany Elimination" column. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:35.742%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.204%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.603%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended June 30, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Skilled Services</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Standard Bearer</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">All Other</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Intercompany Elimination</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Service revenue</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">612,882 </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,428 </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,701)</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">634,609 </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rental revenue</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,214 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,817 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,104)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,927 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">TOTAL REVENUE</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">612,882</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">14,214</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">25,245</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(13,805)</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">638,536</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Segment income (loss)</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90,010 </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,906 </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(33,575)</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64,341 </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Income before provision for income taxes </span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">64,341</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,703 </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,248 </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,844 </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,795 </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,634 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,634 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1) All other primarily includes all ancillary operations, stand-alone senior living operations and the Service Center. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2) Intercompany service revenue represents service revenue generated by ancillary operations provided to the Company's affiliated wholly-owned healthcare facilities. Intercompany service revenue is eliminated in consolidation along with corresponding intercompany cost of service. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(3) Intercompany rental revenue represents rental income generated by both Standard Bearer and other real estate properties with the Company's affiliated wholly-owned healthcare facilities. Intercompany rental revenue is eliminated in consolidation along with corresponding intercompany rent expense. </span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:35.742%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.204%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.603%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="27" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended June 30, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Skilled Services</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Standard Bearer</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">All Other</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Intercompany Elimination</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total </span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Service revenue</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,389,249 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54,254 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,000)</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,437,503 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rental revenue</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,791 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,695 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(30,058)</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,428 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">TOTAL REVENUE</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,389,249</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"/><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">34,791</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"/><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">57,949</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"/><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(36,058)</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"/><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,445,931</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Segment income (loss)</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">200,522 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,738 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(77,544)</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">136,716 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain on sale of assets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,467 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Income before provision for income taxes</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"/><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">139,183</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,014 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,237 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,283 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,534 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span></div></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,305 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,247 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,796)</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,756 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1) All other primarily includes all ancillary operations, stand-alone senior living operations and the Service Center. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2) Intercompany service revenue represents service revenue generated by ancillary operations provided to the Company's affiliated wholly-owned healthcare facilities and management service revenue generated by the Service Center with Standard Bearer. Intercompany service revenue is eliminated in consolidation along with corresponding intercompany cost of service. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(3) Intercompany rental revenue represents rental income generated by both Standard Bearer and other real estate properties with the Company's affiliated wholly-owned healthcare facilities. Intercompany rental revenue is eliminated in consolidation along with corresponding intercompany rent expense. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(4) Included in interest expense in Standard Bearer is interest expense incurred from intercompany debt arrangements between Standard Bearer and The Ensign Group, Inc. The intercompany interest expense is eliminated in the "Intercompany Elimination" column. </span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:35.742%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.204%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.603%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="27" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended June 30, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Skilled Services</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Standard Bearer</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">All Other</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1)</span></div></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Intercompany Elimination</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Service revenue</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,213,918 </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,347 </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,380)</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,257,885 </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rental revenue</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,283 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,627 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(24,006)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,904 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">TOTAL REVENUE</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,213,918</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">28,283</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">50,974</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(27,386)</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,265,789</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Segment income (loss)</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">178,941 </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,619 </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(67,873)</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">126,687 </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain on sale of assets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">440 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Income before provision for income taxes</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">127,127</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,178 </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,403 </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,873 </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,454 </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,275 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,275 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1) All other primarily includes all ancillary operations, stand-alone senior living operations and the Service Center. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2) Intercompany service revenue represents service revenue generated by ancillary operations provided to the Company's affiliated wholly-owned healthcare facilities. Intercompany service revenue is eliminated in consolidation along with corresponding intercompany cost of service. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(3) Intercompany rental revenue represents rental income generated by both Standard Bearer and other real estate properties with the Company's affiliated wholly-owned healthcare facilities. Intercompany rental revenue is eliminated in consolidation along with corresponding intercompany rent expense. </span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:35.742%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.204%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.603%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Service revenue by major payor source were as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:33.549%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.548%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended June 30, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Skilled Services</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">All Other</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Service Revenue</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Revenue %</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicaid</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">287,827 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,301 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">294,128 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40.4 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">190,494 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">190,494 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26.2 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicaid-skilled</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,763 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,763 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.8 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Subtotal</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">528,084</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6,301</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">534,385</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">73.4</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Managed care</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">128,587 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">128,587 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.7 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Private and other</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,807 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,568 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65,375 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.9 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">TOTAL SERVICE REVENUE</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">702,478</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">25,869</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"/><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">728,347</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">100.0</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1) Medicaid payor includes revenue generated from senior living operations and revenue related to FMAP. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2) Private and other payors also includes revenue from senior living operations and all payors generated in other ancillary services.</span></div><div style="text-align:justify"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:33.549%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.548%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended June 30, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Skilled Services</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">All Other</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Service Revenue</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Revenue %</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicaid</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">247,671 </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,784 </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">251,455 </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39.6 </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">170,008 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">170,008 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26.8 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicaid-skilled</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,740 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,740 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.7 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Subtotal</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">460,419</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,784</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">464,203</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">73.1</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Managed care</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112,963 </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112,963 </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.8 </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Private and other</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,500 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,943 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57,443 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.1 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">TOTAL SERVICE REVENUE</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">612,882</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">21,727</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">634,609</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">100.0</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1) Medicaid payor includes revenue generated from senior living operations and revenue related to FMAP. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2) Private and other payors also includes revenue from senior living operations and all payors generated in other ancillary services.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:35.303%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.397%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:14.397%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:14.397%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.378%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended June 30, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Skilled Services</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other Service Revenue </span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Service Revenue</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Revenue %</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicaid</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">549,414 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,062 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">560,476 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39.0 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">398,905 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">398,905 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27.7 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicaid-skilled</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95,712 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95,712 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.7 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Subtotal</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,044,031</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">11,062</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,055,093</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">73.4</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Managed care</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">256,373 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">256,373 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.8 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Private and other</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88,845 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,192 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">126,037 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.8 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">TOTAL SERVICE REVENUE</span></td><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"/><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,389,249</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">48,254</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,437,503</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">100.0</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1) Medicaid payor includes revenue generated from senior living operations and revenue related to FMAP. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2) Private and other payors also includes revenue from senior living operations and all payors generated in other ancillary services.</span></div><div style="text-align:justify"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:34.718%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.379%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended June 30, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Skilled Services</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other Service Revenue </span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Service Revenue</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Revenue %</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicaid</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">475,412 </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,401 </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">482,813 </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38.4 </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">360,311 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">360,311 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28.6 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicaid-skilled</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82,733 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82,733 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.6 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Subtotal</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">918,456</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">7,401</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">925,857</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">73.6</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Managed care</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">221,308 </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">221,308 </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.6 </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Private and other</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74,154 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,566 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110,720 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.8 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">TOTAL SERVICE REVENUE</span></td><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"/><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,213,918</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">43,967</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,257,885</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">100.0</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1) Medicaid payor includes revenue generated from senior living operations and revenue related to FMAP.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2) Private and other payors also includes revenue from senior living operations and all payors generated in other ancillary services.</span></div><div style="margin-top:10pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:26.239%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.929%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:13.958%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.929%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.671%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> In addition to the service revenue above, the Company's rental revenue derived from triple-net lease arrangements with third parties is $4,139 and $8,428, respectively, for the three and six months ended June 30, 2022 and $3,927 and $7,904, respectively, for the three and six months ended June 30, 2021. This revenue is included in both Standard Bearer and the all other category.</span></div> 2 215 25 95 67 29 29 1 11 25 <div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables set forth financial information for the segments:</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:35.742%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.204%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.603%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended June 30, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Skilled Services</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Standard Bearer</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">All Other</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Intercompany Elimination</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total </span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Service revenue</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">702,478 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,787 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,918)</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">728,347 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rental revenue</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,598 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,832 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15,291)</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,139 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">TOTAL REVENUE</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">702,478</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"/><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">17,598</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"/><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">30,619</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"/><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(18,209)</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"/><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">732,486</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Segment income (loss)</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">102,266 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,838 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(38,614)</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70,490 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain on sale of assets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,467 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Income before provision for income taxes </span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"/><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">72,957</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,113 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,216 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,529 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,858 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span></div></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,743 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">889 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,944)</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,688 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1) All other primarily includes all ancillary operations, stand-alone senior living operations and the Service Center. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2) Intercompany service revenue represents service revenue generated by ancillary operations provided to the Company's affiliated wholly-owned healthcare facilities and management service revenue generated by the Service Center with Standard Bearer. Intercompany service revenue is eliminated in consolidation along with corresponding intercompany cost of service. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(3) Intercompany rental revenue represents rental income generated by both Standard Bearer and other real estate properties with the Company's affiliated wholly-owned healthcare facilities. Intercompany rental revenue is eliminated in consolidation along with corresponding intercompany rent expense. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(4) Included in interest expense in Standard Bearer is interest expense incurred from intercompany debt arrangements between Standard Bearer and The Ensign Group, Inc. The intercompany interest expense is eliminated in the "Intercompany Elimination" column. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:35.742%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.204%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.603%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended June 30, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Skilled Services</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Standard Bearer</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">All Other</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Intercompany Elimination</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Service revenue</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">612,882 </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,428 </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,701)</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">634,609 </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rental revenue</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,214 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,817 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,104)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,927 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">TOTAL REVENUE</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">612,882</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">14,214</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">25,245</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(13,805)</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">638,536</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Segment income (loss)</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90,010 </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,906 </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(33,575)</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64,341 </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Income before provision for income taxes </span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">64,341</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,703 </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,248 </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,844 </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,795 </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,634 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,634 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1) All other primarily includes all ancillary operations, stand-alone senior living operations and the Service Center. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2) Intercompany service revenue represents service revenue generated by ancillary operations provided to the Company's affiliated wholly-owned healthcare facilities. Intercompany service revenue is eliminated in consolidation along with corresponding intercompany cost of service. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(3) Intercompany rental revenue represents rental income generated by both Standard Bearer and other real estate properties with the Company's affiliated wholly-owned healthcare facilities. Intercompany rental revenue is eliminated in consolidation along with corresponding intercompany rent expense. </span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:35.742%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.204%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.603%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="27" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended June 30, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Skilled Services</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Standard Bearer</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">All Other</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Intercompany Elimination</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total </span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Service revenue</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,389,249 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54,254 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,000)</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,437,503 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rental revenue</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,791 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,695 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(30,058)</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,428 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">TOTAL REVENUE</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,389,249</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"/><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">34,791</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"/><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">57,949</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"/><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(36,058)</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"/><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,445,931</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Segment income (loss)</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">200,522 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,738 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(77,544)</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">136,716 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain on sale of assets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,467 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Income before provision for income taxes</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"/><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">139,183</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,014 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,237 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,283 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,534 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span></div></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,305 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,247 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,796)</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,756 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1) All other primarily includes all ancillary operations, stand-alone senior living operations and the Service Center. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2) Intercompany service revenue represents service revenue generated by ancillary operations provided to the Company's affiliated wholly-owned healthcare facilities and management service revenue generated by the Service Center with Standard Bearer. Intercompany service revenue is eliminated in consolidation along with corresponding intercompany cost of service. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(3) Intercompany rental revenue represents rental income generated by both Standard Bearer and other real estate properties with the Company's affiliated wholly-owned healthcare facilities. Intercompany rental revenue is eliminated in consolidation along with corresponding intercompany rent expense. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(4) Included in interest expense in Standard Bearer is interest expense incurred from intercompany debt arrangements between Standard Bearer and The Ensign Group, Inc. The intercompany interest expense is eliminated in the "Intercompany Elimination" column. </span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:35.742%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.204%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.603%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="27" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended June 30, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Skilled Services</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Standard Bearer</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">All Other</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1)</span></div></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Intercompany Elimination</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Service revenue</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,213,918 </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,347 </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,380)</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,257,885 </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rental revenue</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,283 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,627 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(24,006)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,904 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">TOTAL REVENUE</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,213,918</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">28,283</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">50,974</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(27,386)</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,265,789</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Segment income (loss)</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">178,941 </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,619 </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(67,873)</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">126,687 </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain on sale of assets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">440 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Income before provision for income taxes</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">127,127</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,178 </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,403 </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,873 </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,454 </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,275 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,275 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1) All other primarily includes all ancillary operations, stand-alone senior living operations and the Service Center. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2) Intercompany service revenue represents service revenue generated by ancillary operations provided to the Company's affiliated wholly-owned healthcare facilities. Intercompany service revenue is eliminated in consolidation along with corresponding intercompany cost of service. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(3) Intercompany rental revenue represents rental income generated by both Standard Bearer and other real estate properties with the Company's affiliated wholly-owned healthcare facilities. Intercompany rental revenue is eliminated in consolidation along with corresponding intercompany rent expense. </span></div> 702478000 0 28787000 -2918000 728347000 0 17598000 1832000 -15291000 4139000 702478000 17598000 30619000 -18209000 732486000 102266000 6838000 -38614000 0 70490000 2467000 72957000 8113000 5216000 1529000 0 14858000 0 3743000 889000 -1944000 2688000 612882000 0 23428000 -1701000 634609000 0 14214000 1817000 -12104000 3927000 612882000 14214000 25245000 -13805000 638536000 90010000 7906000 -33575000 0 64341000 64341000 7703000 4248000 1844000 0 13795000 0 1634000 0 1634000 1389249000 0 54254000 -6000000 1437503000 0 34791000 3695000 -30058000 8428000 1389249000 34791000 57949000 -36058000 1445931000 200522000 13738000 -77544000 0 136716000 2467000 139183000 16014000 10237000 3283000 0 29534000 0 7305000 1247000 -3796000 4756000 1213918000 0 47347000 -3380000 1257885000 0 28283000 3627000 -24006000 7904000 1213918000 28283000 50974000 -27386000 1265789000 178941000 15619000 -67873000 0 126687000 440000 127127000 15178000 8403000 3873000 0 27454000 0 3275000 0 0 3275000 <div style="text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Service revenue by major payor source were as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:33.549%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.548%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended June 30, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Skilled Services</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">All Other</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Service Revenue</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Revenue %</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicaid</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">287,827 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,301 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">294,128 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40.4 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">190,494 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">190,494 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26.2 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicaid-skilled</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,763 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,763 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.8 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Subtotal</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">528,084</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6,301</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">534,385</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">73.4</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Managed care</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">128,587 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">128,587 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.7 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Private and other</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,807 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,568 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65,375 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.9 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">TOTAL SERVICE REVENUE</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">702,478</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">25,869</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"/><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">728,347</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">100.0</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1) Medicaid payor includes revenue generated from senior living operations and revenue related to FMAP. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2) Private and other payors also includes revenue from senior living operations and all payors generated in other ancillary services.</span></div><div style="text-align:justify"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:33.549%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.548%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended June 30, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Skilled Services</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">All Other</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Service Revenue</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Revenue %</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicaid</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">247,671 </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,784 </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">251,455 </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39.6 </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">170,008 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">170,008 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26.8 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicaid-skilled</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,740 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,740 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.7 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Subtotal</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">460,419</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,784</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">464,203</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">73.1</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Managed care</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112,963 </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112,963 </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.8 </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Private and other</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,500 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,943 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57,443 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.1 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">TOTAL SERVICE REVENUE</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">612,882</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">21,727</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">634,609</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">100.0</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1) Medicaid payor includes revenue generated from senior living operations and revenue related to FMAP. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2) Private and other payors also includes revenue from senior living operations and all payors generated in other ancillary services.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:35.303%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.397%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:14.397%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:14.397%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.378%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended June 30, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Skilled Services</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other Service Revenue </span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Service Revenue</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Revenue %</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicaid</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">549,414 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,062 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">560,476 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39.0 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">398,905 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">398,905 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27.7 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicaid-skilled</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95,712 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95,712 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.7 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Subtotal</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,044,031</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">11,062</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,055,093</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">73.4</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Managed care</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">256,373 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">256,373 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.8 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Private and other</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88,845 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,192 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">126,037 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.8 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">TOTAL SERVICE REVENUE</span></td><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"/><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,389,249</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">48,254</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,437,503</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">100.0</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1) Medicaid payor includes revenue generated from senior living operations and revenue related to FMAP. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2) Private and other payors also includes revenue from senior living operations and all payors generated in other ancillary services.</span></div><div style="text-align:justify"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:34.718%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.379%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended June 30, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Skilled Services</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other Service Revenue </span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Service Revenue</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Revenue %</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicaid</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">475,412 </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,401 </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">482,813 </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38.4 </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">360,311 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">360,311 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28.6 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicaid-skilled</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82,733 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82,733 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.6 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Subtotal</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">918,456</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">7,401</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">925,857</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">73.6</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Managed care</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">221,308 </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">221,308 </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.6 </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Private and other</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74,154 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,566 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110,720 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.8 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">TOTAL SERVICE REVENUE</span></td><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"/><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,213,918</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">43,967</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,257,885</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">100.0</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1) Medicaid payor includes revenue generated from senior living operations and revenue related to FMAP.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2) Private and other payors also includes revenue from senior living operations and all payors generated in other ancillary services.</span></div> 287827000 6301000 294128000 0.404 190494000 0 190494000 0.262 49763000 0 49763000 0.068 528084000 6301000 534385000 0.734 128587000 0 128587000 0.177 45807000 19568000 65375000 0.089 702478000 25869000 728347000 1.000 247671000 3784000 251455000 0.396 170008000 0 170008000 0.268 42740000 0 42740000 0.067 460419000 3784000 464203000 0.731 112963000 0 112963000 0.178 39500000 17943000 57443000 0.091 612882000 21727000 634609000 1.000 549414000 11062000 560476000 0.390 398905000 0 398905000 0.277 95712000 0 95712000 0.067 1044031000 11062000 1055093000 0.734 256373000 0 256373000 0.178 88845000 37192000 126037000 0.088 1389249000 48254000 1437503000 1.000 475412000 7401000 482813000 0.384 360311000 0 360311000 0.286 82733000 0 82733000 0.066 918456000 7401000 925857000 0.736 221308000 0 221308000 0.176 74154000 36566000 110720000 0.088 1213918000 43967000 1257885000 1.000 4139000 8428000 3927000 7904000 OPERATION EXPANSIONS<div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's subsidiaries expansion focus is to purchase or lease operations that are complementary to the current affiliated operations, accretive to the business, or otherwise advance the Company's strategy. The results of all operating subsidiaries are included in the Interim Financial Statements subsequent to the date of acquisition. Acquisitions are accounted for using the acquisition method of accounting. The Company's affiliated operations also enter into long-term leases that may include options to purchase the facilities. As a result, from time to time, a real estate affiliated subsidiary will acquire the property of facilities that have previously been operated under third-party leases. </span></div><div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">FASB ASC Topic 805, </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Clarifying the Definition of a Business </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(ASC 805) defined the definition of a business to assist entities with evaluating when a set of transferred assets and activities is deemed to be a business. Determining whether a transferred set constitutes a business is important because the accounting for a business combination differs from that of an asset acquisition. The definition of a business also affects the accounting for dispositions. When substantially all of the fair value of assets acquired is concentrated in a single asset, or a group of similar assets, the assets acquired would not represent a business and business combination accounting would not be required. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2022 Expansions</span></div><div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the six months ended June 30, 2022, the Company expanded its operations through a combination of long-term leases and real estate purchases, with the addition of four stand-alone skilled nursing operations. Of these additions, Standard Bearer acquired the real estate of </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">two</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of the stand-alone skilled nursing operations, which were leased back to Ensign affiliated entities. Refer to Note 7, </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Standard Bearer, </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for additional information on the purchase of real estate properties. In addition, the Company added five senior living operations that were transferred from Pennant, three of which are part of campuses operated by the Company's affiliated operating subsidiaries. These new operations added a total of 453 operational skilled nursing beds and 633 operational senior living units to be operated by the Company's affiliated operating subsidiaries. The Company also invested in new ancillary services that are complementary to its existing businesses. </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The aggregate purchase price for these expansions during the six months ended June 30, 2022 was </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$33,892</span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </span></div><div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the new operations made through long-term leases, the Company did not acquire any material assets or assume any liabilities other than the tenant's post-assumption rights and obligations under the long-term lease. The Company entered into a separate operations transfer agreement with the prior operator as part of each transaction. </span></div><div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">aggregate </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">purchase price for the transactions that were classified as asset acquisitions </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">during the six months ended June 30, 2022 was $17,492, consisting of real estate properties and indefinite-lived intangible assets. </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The remaining aggregate purchase price for transactions during the six months ended June 30, 2022 is concentrated in goodwill of $16,400 and accordingly, the transactions were classified as business combinations. </span></div><div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subsequent to June 30, 2022, the Company expanded its operations through a combination of long-term leases and real estate purchases, with the addition of seven stand-alone skilled nursing operations and one campus operation. Of these additions, Standard Bearer acquired the real estate of three of these operations, which were leased back to Ensign affiliated entities. These new operations added 1,100 operational skilled nursing beds and 61 operational senior living units to be operated by the Company's affiliated operating subsidiaries. In addition, the Company purchased the real estate at three skilled nursing properties that the Company was already operating, further expanding the Company's real estate portfolio. The aggregate purchase price for these expansions was $47,900.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2021 Expansions</span></div><div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the six months ended June 30, 2021, </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the Company expanded its operations through a combination of long-term leases and a real estate purchase,</span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> with the addition of twelve stand-alone skilled nursing operations. </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Of these additions, one is related to the purchase of real estate property, further expanding the Company's real estate portfolio.</span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> These new operations added a total of 1,263 operational skilled nursing beds operated by the Company's affiliated operating subsidiaries.</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The aggregate purchase price for these acquisitions during the six months ended June 30, 2021 was $11,183. </span></div><div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the new operations made through long-term leases, the Company did not acquire any material assets or assume any liabilities other than the tenant's post-assumption rights and obligations under the long-term lease. The Company entered into a separate operations transfer agreement with the prior operator as part of each transaction. </span></div><div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of assets for nine of the acquisitions was concentrated in property and equipment and as such, these transactions were classified as asset acquisitions. The aggregate purchase price for the asset acquisitions during the six months ended June 30, 2021 was $5,183. The fair value of assets for the remaining four additions was concentrated in goodwill of $6,000 and as such, the transaction was classified as a business combination. </span></div><div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:62.642%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.449%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.449%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.600%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="text-align:justify;text-indent:24.75pt"><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s acquisition strategy has been focused on identifying both opportunistic and strategic acquisitions within its target markets that offer strong opportunities for return. The operations added by the Company are frequently underperforming financially and can have regulatory and clinical challenges to overcome. Financial information, especially with underperforming operations, is often inadequate, inaccurate or unavailable. Consequently, the Company believes that prior operating results are not a meaningful representation of the Company’s current operating results or indicative of the integration potential of its newly acquired operating subsidiaries. The assets added during the six months ended June 30, 2022 were not material operations to the Company individually or in the aggregate. Accordingly, pro forma financial information is not presented. These additions have been included in the June 30, 2022 </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">condensed consolidated</span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> balance sheets of the Company, and the operating results have been included in the </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">condensed consolidated</span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> statements of operations of the Company since the date the Company gained effective control.</span></div> 4 2 5 3 453 633 33892000 17492000 16400000 7 1 3 1100 61 3 47900000 12 1 1263 11183000 9 5183000 4 6000000 PROPERTY AND EQUIPMENT - NET<div style="margin-top:10pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment, net consists of the following:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:63.958%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.297%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.715%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Land</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">121,381 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">121,164 </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Buildings and improvements</span></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">669,215 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">646,221 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #edfee2;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">145,522 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">140,012 </span></td><td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equipment</span></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">279,231 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">262,246 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #edfee2;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,373 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,305 </span></td><td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Construction in progress</span></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,000 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,253 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,230,722</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,184,201</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #566b39;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: accumulated depreciation</span></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(322,494)</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(295,767)</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">PROPERTY AND EQUIPMENT, NET</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">908,228</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"/><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">888,434</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:10pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company completed the sale of assets for a sale price of $7,707 and recorded a gain of $2,567 within the Company's condensed consolidated statement of income as cost of services during the three months ended June 30, 2022. See also Note 7, </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Standard Bearer </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and Note 9, </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Operation Expansions </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for information on acquisitions during the six months ended June 30, 2022.</span></div> <span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment, net consists of the following:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:63.958%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.297%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.715%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Land</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">121,381 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">121,164 </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Buildings and improvements</span></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">669,215 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">646,221 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #edfee2;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">145,522 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">140,012 </span></td><td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equipment</span></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">279,231 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">262,246 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #edfee2;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,373 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,305 </span></td><td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Construction in progress</span></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,000 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,253 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,230,722</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,184,201</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #566b39;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: accumulated depreciation</span></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(322,494)</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(295,767)</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">PROPERTY AND EQUIPMENT, NET</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">908,228</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"/><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">888,434</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> 121381000 121164000 669215000 646221000 145522000 140012000 279231000 262246000 4373000 4305000 11000000 10253000 1230722000 1184201000 322494000 295767000 908228000 888434000 7707000 2567000 INTANGIBLE ASSETS - NET<div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:19.806%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.303%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.671%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.682%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Life (Years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #3d6702;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #3d6702;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #3d6702;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #3d6702;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #3d6702;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #3d6702;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #3d6702;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #3d6702;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #3d6702;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #3d6702;padding:0 1pt"/></tr><tr style="height:17pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Carrying Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated Amortization</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Carrying Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated Amortization</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:17pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Intangible Assets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assembled occupancy</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">196 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(196)</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68 </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(68)</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Facility trade name</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30.0</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">733 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(403)</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">330 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">733 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(391)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">342 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer relationships</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.4</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,582 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,377)</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,205 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,582 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,272)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,310 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">TOTAL</span></td><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"/><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5,511</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"/><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(2,976)</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"/><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,535</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"/><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5,383</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"/><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(2,731)</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"/><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,652</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three and six months ended June 30, 2022, amortization expense was $418 and $822, respectively, of which $288 and $577 was related to the amortization of right-of-use assets, respectively. Amortization expense was $363 and $724, respectively, of which $290 and $580 was related to the amortization of right-of-use assets for the three and six months ended June 30, 2021, respectively.</span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Estimated amortization expense for each of the years ending December 31 is as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:87.837%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.382%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.381%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022 (remainder)</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">234 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">234 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">234 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">234 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">234 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,248 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"/><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,535</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:19.806%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.303%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.671%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.682%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Life (Years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #3d6702;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #3d6702;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #3d6702;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #3d6702;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #3d6702;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #3d6702;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #3d6702;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #3d6702;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #3d6702;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #3d6702;padding:0 1pt"/></tr><tr style="height:17pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Carrying Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated Amortization</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Carrying Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated Amortization</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:17pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Intangible Assets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assembled occupancy</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">196 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(196)</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68 </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(68)</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Facility trade name</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30.0</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">733 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(403)</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">330 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">733 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(391)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">342 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer relationships</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.4</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,582 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,377)</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,205 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,582 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,272)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,310 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">TOTAL</span></td><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"/><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5,511</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"/><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(2,976)</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"/><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,535</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"/><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5,383</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"/><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(2,731)</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"/><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,652</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> P0Y4M24D 196000 196000 0 68000 68000 0 P30Y 733000 403000 330000 733000 391000 342000 P18Y4M24D 4582000 2377000 2205000 4582000 2272000 2310000 5511000 2976000 2535000 5383000 2731000 2652000 418000 822000 288000 577000 363000 724000 290000 580000 <span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Estimated amortization expense for each of the years ending December 31 is as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:87.837%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.382%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.381%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022 (remainder)</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">234 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">234 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">234 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">234 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">234 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,248 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"/><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,535</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> 117000 234000 234000 234000 234000 234000 1248000 2535000 GOODWILL AND OTHER INDEFINITE-LIVED INTANGIBLE ASSETS<div style="margin-bottom:10pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company tests goodwill during the fourth quarter of each year or more often if events or circumstances indicate there may be impairment. The Company performs its analysis for each reporting unit that constitutes a business for which discrete financial information is produced and reviewed by operating segment management and provides services that are distinct from the other components of the operating segment, in accordance with the provisions of FASB ASC Topic 350, </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Intangibles—Goodwill and Other </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(ASC 350). This guidance provides the option to first assess qualitative factors to determine whether it is more likely than not that the fair value of a reporting unit is less than its carrying value. If, based on a review of qualitative factors, it is more likely than not that the fair value of a reporting unit is less than its carrying value, the Company performs a goodwill impairment test by comparing the carrying value of each reporting unit to its respective fair value. The Company determines the estimated fair value of each reporting unit using a discounted cash flow analysis. The fair value of the reporting unit is the implied fair value of goodwill. In the event a reporting unit's carrying value exceeds its fair value, an impairment loss will be recognized. An impairment loss is measured by the difference between the carrying value of the reporting unit and its fair value. </span></div><div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company anticipates that the majority of total goodwill recognized will be fully deductible for tax purposes as of June 30, 2022. </span></div><div style="text-align:justify;text-indent:24.75pt"><span><br/></span></div><div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Provided that goodwill corresponds to the acquisition of a business and not merely the acquisition of real estate property, the Company's Standard Bearer segment appropriately does not carry a goodwill balance. The following table represents activity in goodwill by skilled service segment and "all other" category as of and for the six months ended June 30, 2022:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:53.578%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.524%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Goodwill</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Skilled Services</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">All Other</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 1, 2022</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51,486 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,983 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,469 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions</span></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,400 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,400 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30, 2022</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">67,886</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">8,983</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"/><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">76,869</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other indefinite-lived intangible assets consist of the following:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:62.788%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.590%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.592%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trade name</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">889 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">889 </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare and Medicaid licenses</span></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,918 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,838 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;text-indent:4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">TOTAL</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,807</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"/><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,727 </span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> The following table represents activity in goodwill by skilled service segment and "all other" category as of and for the six months ended June 30, 2022:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:53.578%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.524%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Goodwill</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Skilled Services</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">All Other</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 1, 2022</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51,486 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,983 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,469 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions</span></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,400 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,400 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30, 2022</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">67,886</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">8,983</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"/><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">76,869</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> 51486000 8983000 60469000 16400000 0 16400000 67886000 8983000 76869000 <div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other indefinite-lived intangible assets consist of the following:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:62.788%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.590%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.592%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trade name</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">889 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">889 </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare and Medicaid licenses</span></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,918 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,838 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;text-indent:4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">TOTAL</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,807</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"/><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,727 </span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 889000 889000 2918000 2838000 3807000 3727000 RESTRICTED AND OTHER ASSETS<div style="margin-top:10pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted and other assets consist of the following:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:62.935%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.590%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.591%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt issuance costs, net</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,195 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,953 </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term insurance losses recoverable asset</span></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,440 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,755 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deposits with landlords</span></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,725 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,705 </span></td><td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capital improvement reserves with landlords and lenders</span></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,499 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,103 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred compensation plan investments</span></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,151 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,530 </span></td><td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">RESTRICTED AND OTHER ASSETS</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">57,010</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"/><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">47,046</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Included in restricted and other assets as of June 30, 2022 and December 31, 2021 are anticipated insurance recoveries related to the Company's workers' compensation liabilities and general and professional liability reserves that are recorded on a gross rather than net basis in accordance with GAAP. </span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company implemented a non-qualified deferred compensation plan (the DCP) that was effective in 2019 for certain employees and was expanded to other employees in 2020. The DCP allows for the employee deferrals to be deposited into a rabbi trust and these funds are generally invested in individual variable life insurance contracts owned by the Company that are specifically designed to fund the deferrals. The cash surrender value of the insurance contracts is based on funds that shadow the investment allocations specified by participants in the deferred compensation plan. </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%">For the three and six months ended June 30, 2022, the Company recorded a loss on these investments of $3,313 and $4,515, respectively, which is included in other (expense) income, net. During the same periods, the Company recorded an offsetting reduction in expense of $3,300 and $4,511, respectively, allocated between cost of services and general and administrative expenses.</span></div>For the three and six months ended June 30, 2021, the Company recorded a gain on the deferral investment of $751 and $1,057, respectively, which is included in other (expense) income, net. During the same periods, the Company recorded an offsetting expense of $780 and $1,131, respectively, allocated between cost of services and general and administrative expenses. <span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted and other assets consist of the following:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:62.935%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.590%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.591%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt issuance costs, net</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,195 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,953 </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term insurance losses recoverable asset</span></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,440 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,755 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deposits with landlords</span></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,725 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,705 </span></td><td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capital improvement reserves with landlords and lenders</span></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,499 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,103 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred compensation plan investments</span></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,151 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,530 </span></td><td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">RESTRICTED AND OTHER ASSETS</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">57,010</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"/><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">47,046</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> 4195000 1953000 8440000 6755000 14725000 13705000 6499000 7103000 23151000 17530000 57010000 47046000 -3313000 -4515000 -3300000 4511000 751000 1057000 780000 1131000 OTHER ACCRUED LIABILITIES<div style="text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other accrued liabilities consists of the following:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:62.788%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.590%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.592%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Quality assurance fee</span></td><td style="background-color:#e4e9df;border-top:1pt solid #3d6702;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #3d6702;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,669 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #3d6702;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #3d6702;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #3d6702;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,474 </span></td><td style="border-top:1pt solid #3d6702;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Refunds payable</span></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,912 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,814 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Resident advances</span></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,273 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,337 </span></td><td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unapplied state relief funds</span></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,356 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,781 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash held in trust for patients</span></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,757 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,430 </span></td><td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividends payable</span></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,040 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,035 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property taxes</span></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,670 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,124 </span></td><td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Legal finding accrued</span></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,626 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,490 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,415 </span></td><td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">OTHER ACCRUED LIABILITIES</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">85,793</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"/><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">89,410</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Quality assurance fee represents the aggregate of amounts payable to Arizona, California, Colorado, Idaho, Iowa, Kansas, Nebraska, Nevada, Utah, Washington and Wisconsin as a result of a mandated fee based on patient days or licensed beds. Refunds payable includes payables related to overpayments, duplicate payments and credit balances from various payor sources. Resident advances occur when the Company receives payments in advance of services provided. Resident deposits include refundable deposits to patients. Cash held in trust for patients reflects monies received from or on behalf of patients. Maintaining a trust account for patients is a regulatory requirement and, while the trust assets offset the liabilities, the Company assumes a fiduciary responsibility for these funds. The cash balance related to this liability is included in other current assets in the condensed consolidated balance sheets.</span></div> <span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other accrued liabilities consists of the following:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:62.788%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.590%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.592%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Quality assurance fee</span></td><td style="background-color:#e4e9df;border-top:1pt solid #3d6702;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #3d6702;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,669 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #3d6702;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #3d6702;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #3d6702;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,474 </span></td><td style="border-top:1pt solid #3d6702;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Refunds payable</span></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,912 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,814 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Resident advances</span></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,273 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,337 </span></td><td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unapplied state relief funds</span></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,356 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,781 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash held in trust for patients</span></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,757 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,430 </span></td><td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividends payable</span></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,040 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,035 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property taxes</span></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,670 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,124 </span></td><td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Legal finding accrued</span></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,626 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,490 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,415 </span></td><td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">OTHER ACCRUED LIABILITIES</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">85,793</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"/><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">89,410</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> 6669000 6474000 36912000 34814000 6273000 9337000 4356000 1781000 5757000 6430000 3040000 3035000 7670000 9124000 3626000 0 11490000 18415000 85793000 89410000 INCOME TAXES<div style="margin-top:10pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recorded income tax expense of $31,292 and $26,707 during the six months ended June 30, 2022 and 2021, respectively, or 22.5% of earnings before income taxes for the six months ended June 30, 2022, compared to 21.0% for the six months ended June 30, 2021. The effective tax rate for both periods is driven by the impact of excess tax benefits from stock-based compensation, offset by non-deductible expenses including non-deductible compensation. </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Th</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">e Company is not currently under examination by any major income tax jurisdiction. During 2022, the statutes of limitations will lapse on the Company's 2018 Federal tax year and certain 2017 and 2018 state tax years. The Company does not believe the Federal or state statute lapses or any other event will significantly impact the balance of unrecognized tax benefits in the next twelve months. The net balance of unrecognized tax benefits was not material to the Interim Financial Statements for the six months ended June 30, 2022 and 2021.</span></div> 31292000 26707000 0.225 0.210 DEBT<div style="text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Debt consists of the following:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:62.788%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.590%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.592%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mortgage loans and promissory notes</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">158,258 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">159,967 </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: current maturities</span></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,944)</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,760)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: debt issuance costs, net</span></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,209)</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,324)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">LONG-TERM DEBT LESS CURRENT MATURITIES</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">151,105</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"/><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">152,883</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt;text-align:justify"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Credit Facility with a Lending Consortium Arranged by Truist </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company maintains a revolving credit facility between the Company and its subsidiaries, including Standard Bearer as co-borrowers, and Truist Securities (Truist) (the Revolving Credit Facility). Borrowings are supported by a lending consortium arranged by Truist. On April 8, 2022, the Company and its subsidiaries, including Standard Bearer, entered into the Amended Credit Agreement, which amended the Revolving Credit Facility to increase the revolving line of credit from $350,000 to $600,000 in aggregate principal amount. The Amended Credit Agreement also extended the maturity date of the Revolving Credit Facility to April 8, 2027 and modified the reference rate from LIBOR to SOFR. The interest rates applicable to loans under the Amended Credit Facility are, at the Company's option, equal to either a base rate plus a margin ranging from 0.25% to 1.25% per annum or SOFR plus a margin range from 1.25% to 2.25% per annum, based on the Consolidated Total Net Debt to Consolidated EBITDA ratio (as defined in the agreement). In addition, the Company and its subsidiaries, including Standard Bearer, will pay a commitment fee on the unused portion of the commitments that will range from 0.20% to 0.40% per annum, depending on the Consolidated Total Net Debt to Consolidated EBITDA ratio. Except as set forth in the Amended Credit Facility, all other terms and conditions of the Credit Facility remained in full force and effect as described below. As part of the entry into the Amended Credit Agreement, deferred financing costs of $566 were written off and additional deferred financing costs of $3,197 were capitalized during the three months ended June 30, 2022. </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Borrowings made under the Revolving Credit Facility are guaranteed, jointly and severally, by certain of the Company’s wholly-owned subsidiaries, and are secured by a pledge of stock of the Company's material operating subsidiaries as well as a first lien on substantially all of their personal property. The Amended Credit Agreement contains customary covenants that, among other things, restrict, subject to certain exceptions, the ability of the Company and its operating subsidiaries to grant liens on their assets, incur indebtedness, sell assets, make investments, engage in acquisitions, mergers or consolidations, amend certain material agreements and pay certain dividends and other restricted payments. Under the Amended Credit Agreement, the Company must comply with financial maintenance covenants to be tested quarterly, consisting of (i) a maximum consolidated total net debt to consolidated EBITDA ratio (which shall not be greater than 3.00:1.00; provided that if the aggregate consideration for approved acquisitions in a six month period is greater than $50,000, then the ratio can be increased at the election of the Company with notice to the administrative agent to 3.50:1.00 for the first fiscal quarter and the immediately following three fiscal quarters), and (ii) a minimum interest/rent coverage ratio (which cannot be less than 1.50:1.00). As of June 30, 2022, and July 27, 2022, there was no outstanding debt under the Revolving Credit Facility. The Company was in compliance with all loan covenants as of June 30, 2022.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Mortgage Loans and Promissory Notes</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June 30, 2022, the Company's operating subsidiaries had $158,258 outstanding under the mortgage loans and notes, of which $3,944 is classified as short-term and the remaining $154,314 is classified as long-term. The Company was in compliance with all loan covenants as of June 30, 2022. </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June 30, 2022, 23 of the Company's subsidiaries have mortgage loans insured with HUD in the aggregate amount of $155,074, which subjects these subsidiaries to HUD oversight and periodic inspections. The mortgage loans bear effective interest rates in a range of 3.1% to 4.2%, including fixed interest rates in a range of 2.4% to 3.3% per annum. In addition to the interest rate, we incur other fees for HUD placement, including but not limited to audit fees. Amounts borrowed under the mortgage loans may be prepaid, subject to prepayment fees based on the principal balance on the date of prepayment. For the majority of the loans, during the first three years, the prepayment fee is 10.0% and is reduced by 3.0% in the fourth year of the loan, and reduced by 1.0%</span><span style="color:#ff0000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">per year for years <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjM2YTQ4YjE0Mzg2NDRlY2E5NDlhYmUxZGY1NTg0NTZhL3NlYzozNmE0OGIxNDM4NjQ0ZWNhOTQ5YWJlMWRmNTU4NDU2YV8xNTQvZnJhZzpkZTY4ODRjZDA1ZTQ0ZDRlOGUxZWFiMjY4YmE0MTUyYy90ZXh0cmVnaW9uOmRlNjg4NGNkMDVlNDRkNGU4ZTFlYWIyNjhiYTQxNTJjXzQ2MDk_c6716671-daa6-459a-b033-ed201ae6a633">five</span> through <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjM2YTQ4YjE0Mzg2NDRlY2E5NDlhYmUxZGY1NTg0NTZhL3NlYzozNmE0OGIxNDM4NjQ0ZWNhOTQ5YWJlMWRmNTU4NDU2YV8xNTQvZnJhZzpkZTY4ODRjZDA1ZTQ0ZDRlOGUxZWFiMjY4YmE0MTUyYy90ZXh0cmVnaW9uOmRlNjg4NGNkMDVlNDRkNGU4ZTFlYWIyNjhiYTQxNTJjXzQ2MjA_0fa5e946-02ae-485c-8bb4-a289dfcd1e26">ten</span> of the loan. There is no prepayment penalty after year <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjM2YTQ4YjE0Mzg2NDRlY2E5NDlhYmUxZGY1NTg0NTZhL3NlYzozNmE0OGIxNDM4NjQ0ZWNhOTQ5YWJlMWRmNTU4NDU2YV8xNTQvZnJhZzpkZTY4ODRjZDA1ZTQ0ZDRlOGUxZWFiMjY4YmE0MTUyYy90ZXh0cmVnaW9uOmRlNjg4NGNkMDVlNDRkNGU4ZTFlYWIyNjhiYTQxNTJjXzQ2Nzg_dd1d9564-2373-4c5d-a1d0-f29f273591af">ten</span>. The terms for all the mortgage loans are 25 to 35 years. </span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the HUD mortgage loans above, the Company has two promissory notes. The notes bear fixed interest rates of 6.3% and 5.3% per annum and the term of the notes are 10 months and 12 years, respectively. The 12 year note which was used for an acquisition is secured by the real property comprising the facility and the rent, issues and profits thereof, as well as all personal property used in the operation of the facility. </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on Level 2, the carrying value of the Company's long-term debt is considered to approximate the fair value of such debt for all periods presented based upon the interest rates that the Company believes it can currently obtain for similar debt.</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:87.057%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.013%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:9pt;text-align:justify"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Off-Balance Sheet Arrangements</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June 30, 2022, the Company had approximately $6,710 of borrowing capacity under the Revolving Credit Facility pledged as collateral to secure outstanding letters of credit.</span></div> <div style="text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Debt consists of the following:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:62.788%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.590%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.592%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mortgage loans and promissory notes</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">158,258 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">159,967 </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: current maturities</span></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,944)</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,760)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: debt issuance costs, net</span></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,209)</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,324)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">LONG-TERM DEBT LESS CURRENT MATURITIES</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">151,105</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"/><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">152,883</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 158258000 159967000 3944000 3760000 3209000 3324000 151105000 152883000 350000000 600000000 0.0025 0.0125 0.0125 0.0225 0.0020 0.0040 566000 3197000 3.00 50000000 3.50 1.50 0 0 158258000 3944000 154314000 23 155074000 0.031 0.042 0.024 0.033 0.100 0.030 0.010 P25Y P35Y 2 0.063 0.053 P10M P12Y P12Y 6710000 OPTIONS AND AWARDS<div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation expense consists of stock-based payment awards made to employees and directors, including employee stock options and restricted stock awards, based on estimated fair values. As stock-based compensation expense recognized in the Company’s condensed consolidated statements of income for the three and six months ended June 30, 2022 and 2021 was based on awards ultimately expected to vest, it has been reduced for estimated forfeitures. The Company estimates forfeitures at the time of grant and, if necessary, revises the estimate in subsequent periods if actual forfeitures differ.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has an option plan, the 2022 Omnibus Incentive Plan (the 2022 Plan), which was approved by the Company's stockholders on May 26, 2022, and replaced the Company's prior option plan, the 2017 Omnibus Incentive Plan (the 2017 Plan). The total number of shares available for issuance under the 2022 Plan was 3,268 as of June 30, 2022.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"><span><br/></span></div><div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2022 Omnibus Incentive Plan</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - During the second quarter of 2022, the Company's shareholders approved the 2022 Plan. Including the shares rolled over from the 2017 Plan, the 2022 Plan provides for the issuance of 3,452 shares of common stock. The number of shares available to be issued under the 2022 Plan will be reduced by (i) one share for each share that relates to an option or stock appreciation right award and (ii) two shares for each share which relates to an award other than a stock option or stock appreciation right award (a full-value award). Non-employee director options, to the extent granted, will vest and become exercisable in three equal annual installments, or the length of the term if less than three years, on the completion of each year of service measured from the grant date. All other options generally vest over five years at 20% per year on the anniversary of the grant date. Options expire ten years from the date of grant. As of June 30, 2022, there were approximately 3,268 unissued shares of common stock available for issuance under this plan. The Company retired the 2017 Plan as a result of the approval of the 2022 Plan.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company uses the Black-Scholes option-pricing model to recognize the value of stock-based compensation expense for stock option awards. Determining the appropriate fair-value model and calculating the fair value of stock option awards at the grant date requires judgment, including estimating stock price volatility, expected option life, and forfeiture rates. The fair-value of the restricted stock awards at the grant date is based on the market price on the grant date, adjusted for forfeiture rates. The Company develops estimates based on historical data and market information, which can change significantly over time. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Options</span></div><div style="margin-bottom:5pt;margin-top:10pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company granted 154 and 318 stock options from the available plans during the three and six months ended June 30, 2022, respectively. The Company used the following assumptions for stock options granted during the three months ended June 30, 2022 and 2021:</span></div><div style="margin-bottom:5pt;margin-top:10pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:18.490%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.420%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.420%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.428%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Grant Year</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Options Granted</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Risk-Free Rate</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Expected Life</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Volatility</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Dividend Yield</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">154</span></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.7%</span></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.1 years</span></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42.1%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">209</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.0%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.3 years</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42.3%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:5pt;margin-top:10pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company used the following assumptions for stock options granted during the six months ended June 30, 2022 and 2021:</span></div><div style="margin-bottom:5pt;margin-top:10pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:18.490%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.420%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.420%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.428%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Grant Year</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Options Granted</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Risk-Free Rate</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Expected Life</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Volatility</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Dividend Yield</span></td></tr><tr><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">318</span></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.3%</span></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.1 years</span></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42.2%</span></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">345</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.9%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.3 years</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42.2%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2%</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the six months ended June 30, 2022 and 2021, the following represents the exercise price and fair value displayed at grant date for stock option grants:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.245%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.280%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.198%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.687%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Grant Year</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Granted</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Exercise Price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Fair Value of Options</span></td></tr><tr><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">318</span></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80.18 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34.29 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">345</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82.77 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33.86 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:12pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted average exercise price equaled the weighted average fair value of common stock on the grant date for all options granted during the periods ended June 30, 2022 and 2021 and therefore, the intrinsic value was $0 at the date of grant. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table represents the employee stock option activity during the six months ended June 30, 2022:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:24.777%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.297%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.297%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.958%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.981%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">Number of Options Outstanding</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">Weighted Average<br/>Exercise Price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">Number of<br/>Options Vested</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">Weighted Average Exercise Price of Options Vested</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">January 1, 2022</span></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,038 </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36.60 </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,183 </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.02 </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">318 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80.18 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(68)</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57.40 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(370)</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.40 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30, 2022</span></td><td colspan="2" style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,918 </span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41.69 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,151 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25.53 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following summary information reflects stock options outstanding, vested and related details as of June 30, 2022:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:31.794%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.478%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.554%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.478%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.110%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.892%"/><td style="width:0.1%"/></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="27" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Stock Options Outstanding</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Stock Options Vested</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:17pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" rowspan="2" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Number Outstanding</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" rowspan="2" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Black-Scholes Fair Value</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" rowspan="2" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Remaining Contractual Life (Years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Vested and Exercisable</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year of Grant</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Exercise Price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2012</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$5.56</span></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$6.75</span></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0</span></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2013</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#e4e9df;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.76</span></td><td colspan="3" style="background-color:#e4e9df;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="background-color:#e4e9df;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.74</span></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">125 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">476 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="3" style="background-color:#e4e9df;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1</span></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">125 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2014</span></td><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.94</span></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.05</span></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">457 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,204 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2</span></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">457 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2015</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#e4e9df;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.20</span></td><td colspan="3" style="background-color:#e4e9df;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="background-color:#e4e9df;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.39</span></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">246 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,910 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="3" style="background-color:#e4e9df;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3</span></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">246 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2016</span></td><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.93</span></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.86</span></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">233 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,377 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4</span></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">233 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2017</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#e4e9df;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.80</span></td><td colspan="3" style="background-color:#e4e9df;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="background-color:#e4e9df;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.41</span></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">267 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,583 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="3" style="background-color:#e4e9df;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5</span></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">236 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2018</span></td><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.49</span></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.71</span></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">496 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,806 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6</span></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">326 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#e4e9df;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41.07</span></td><td colspan="3" style="background-color:#e4e9df;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="background-color:#e4e9df;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45.76</span></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">615 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,651 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="3" style="background-color:#e4e9df;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7</span></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">292 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44.84</span></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59.49</span></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">569 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,205 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8</span></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">162 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#e4e9df;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73.47</span></td><td colspan="3" style="background-color:#e4e9df;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="background-color:#e4e9df;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83.64</span></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">586 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,222 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="3" style="background-color:#e4e9df;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9</span></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$79.79</span></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$80.60</span></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">314 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,782 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10</span></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">TOTAL</span></td><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,918</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"/><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">63,248</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,151</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The aggregate intrinsic value of options outstanding, vested and expected to vest as of June 30, 2022 and December 31, 2021 is as follows:</span></div><div style="margin-top:10pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.344%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.347%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Options</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130,564 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">191,242 </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">103,713 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">137,382 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected to vest</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,561 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,548 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The intrinsic value is calculated as the difference between the market value of the underlying common stock and the exercise price of the options</span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The aggregate intrinsic value of options that vested </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">during the six months ended June 30, 2022 and 2021 was</span><span style="color:#ff0090;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$10,409 and $17,618, respectively. </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total intrinsic value of options exercised </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">during the six months ended June 30, 2022 and 2021 was $25,642 and $26,715, respectively. </span><span style="color:#ff0090;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restricted Stock Awards</span></div><div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company granted</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> 46 and 158 </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">restricted stock awards from the available plans during the three and six months ended June 30, 2022, respectively. The Company granted 54 and 144 restricted stock awards during the three and six months ended June 30, 2021, respectively. All awards were granted at an issue price of $0 and generally vest over five years. The fair value per share of restricted awards granted during the </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">six months ended June 30, 2022 and 2021</span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> ranged from</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> $73.17 to $83.93</span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and $82.20 to $93.31, respectively. The fair value per share includes quarterly stock awards to non-employee directors. </span></div><div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the status of the Company's non-vested restricted stock awards as of June 30, 2022 and changes during the six months ended June 30, 2022 is presented below: </span></div><div style="margin-top:10pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:60.157%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.859%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.954%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Non-Vested Restricted Awards</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Weighted Average Grant Date Fair Value</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Non-vested at January 1, 2022</span></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">549 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52.16 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">158 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77.06 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(199)</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54.74 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16)</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55.86 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Non-vested at June 30, 2022</span></td><td colspan="2" style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">492</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59.01 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three and six months ended June 30, 2022, respectively, the Company granted</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> 5 and 9 </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">automatic quarterly stock awards to non-employee directors for their service on the Company's board of directors from the 2017 Plan. The fair value per share of these stock awards ranged from</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> $77.39 to $83.93</span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> based on the market price on the grant date. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Long-Term Incentive Plan</span></div><div style="margin-bottom:12pt;margin-top:10pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 27, 2019, the Board approved the Long-Term Incentive Plan (the 2019 LTI Plan). The 2019 LTI Plan provides that certain employees of the Company who assisted in the consummation of the Spin-Off transaction are granted shares of restricted stock upon the successful completion of the Spin-Off. The 2019 LTI Plan provides for the issuance of 500 shares of Pennant restricted stock. The shares are vested over five years at 20% per year on the anniversary of the grant date. If a recipient is terminated or voluntarily leaves the Company, all shares subject to restriction or not yet vested shall be entirely forfeited. The total stock-based compensation related to the 2019 LTI Plan was approximately $195 and $390 for the three and six months ended June 30, 2022, respectively, compared to $202 and $403 for the three and six months ended June 30, 2021, respectively.</span></div><div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation expense recognized for the Company's equity incentive plans and long-term incentive plan for the three and six months ended June 30, 2022 and 2021 was as follows:</span></div><div style="text-align:justify;text-indent:24.75pt"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:50.069%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.326%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.326%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.011%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.016%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation expense related to stock options</span></td><td style="background-color:#e4e9df;border-top:1pt solid #3d6702;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #3d6702;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,786 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #3d6702;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #3d6702;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #3d6702;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,026 </span></td><td style="border-top:1pt solid #3d6702;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#e4e9df;border-top:1pt solid #3d6702;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #3d6702;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,306 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #3d6702;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #3d6702;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #3d6702;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,759 </span></td><td style="border-top:1pt solid #3d6702;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation expense related to restricted stock awards</span></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,456 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,076 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,758 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,914 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation expense related to stock options and restricted stock awards to non-employee directors</span></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">374 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">531 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">719 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,014 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">TOTAL</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5,616</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"/><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4,633</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"/><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">10,783</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"/><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">8,687</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="text-align:justify;text-indent:24.75pt"><span><br/></span></div><div style="text-align:justify;text-indent:24.75pt"><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In future periods, the Company expects to recognize approximately</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> $39,110 and $28,748 in stock-based compensation expense for unvested options and unvested restricted stock awards, respectively, that were outstanding as of June 30, 2022. Future stock-based compensation expense will be recognized over 3.7 and 3.4 weighted average years for unvested options and restricted stock awards, respectively. There were 1,767 unvested and outstanding options as of June 30, 2022, of which 1,669 shares are expected to vest. The weighted average contractual life for options outstanding, vested and expected to vest as of June 30, 2022 was 6.0 years.</span></div> 3268000 3452000 1 2 3 P3Y P5Y 0.20 P10Y 3268000 154000 318000 The Company used the following assumptions for stock options granted during the three months ended June 30, 2022 and 2021:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:18.490%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.420%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.420%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.428%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Grant Year</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Options Granted</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Risk-Free Rate</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Expected Life</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Volatility</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Dividend Yield</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">154</span></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.7%</span></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.1 years</span></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42.1%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">209</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.0%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.3 years</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42.3%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table><div style="margin-bottom:5pt;margin-top:10pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company used the following assumptions for stock options granted during the six months ended June 30, 2022 and 2021:</span></div><div style="margin-bottom:5pt;margin-top:10pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:18.490%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.420%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.420%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.428%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Grant Year</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Options Granted</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Risk-Free Rate</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Expected Life</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Volatility</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Dividend Yield</span></td></tr><tr><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">318</span></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.3%</span></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.1 years</span></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42.2%</span></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">345</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.9%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.3 years</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42.2%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2%</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div> 154000 0.027 P6Y1M6D 0.421 0.003 209000 0.010 P6Y3M18D 0.423 0.003 318000 0.023 P6Y1M6D 0.422 0.003 345000 0.009 P6Y3M18D 0.422 0.002 <div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the six months ended June 30, 2022 and 2021, the following represents the exercise price and fair value displayed at grant date for stock option grants:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.245%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.280%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.198%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.687%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Grant Year</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Granted</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Exercise Price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Fair Value of Options</span></td></tr><tr><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">318</span></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80.18 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34.29 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">345</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82.77 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33.86 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div>The weighted average exercise price equaled the weighted average fair value of common stock on the grant date for all options granted during the periods ended June 30, 2022 and 2021 and therefore, the intrinsic value was $0 at the date of grant. 318000 80.18 34.29 345000 82.77 33.86 0 0 <div style="margin-top:12pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table represents the employee stock option activity during the six months ended June 30, 2022:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:24.777%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.297%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.297%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.958%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.981%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">Number of Options Outstanding</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">Weighted Average<br/>Exercise Price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">Number of<br/>Options Vested</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">Weighted Average Exercise Price of Options Vested</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">January 1, 2022</span></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,038 </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36.60 </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,183 </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.02 </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">318 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80.18 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(68)</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57.40 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(370)</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.40 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30, 2022</span></td><td colspan="2" style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,918 </span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41.69 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,151 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25.53 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 4038000 36.60 2183000 21.02 318000 80.18 68000 57.40 370000 16.40 3918000 41.69 2151000 25.53 <div style="text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following summary information reflects stock options outstanding, vested and related details as of June 30, 2022:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:31.794%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.478%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.554%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.478%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.110%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.892%"/><td style="width:0.1%"/></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="27" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Stock Options Outstanding</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Stock Options Vested</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:17pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" rowspan="2" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Number Outstanding</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" rowspan="2" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Black-Scholes Fair Value</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" rowspan="2" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Remaining Contractual Life (Years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Vested and Exercisable</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year of Grant</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Exercise Price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2012</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$5.56</span></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$6.75</span></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0</span></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2013</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#e4e9df;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.76</span></td><td colspan="3" style="background-color:#e4e9df;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="background-color:#e4e9df;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.74</span></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">125 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">476 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="3" style="background-color:#e4e9df;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1</span></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">125 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2014</span></td><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.94</span></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.05</span></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">457 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,204 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2</span></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">457 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2015</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#e4e9df;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.20</span></td><td colspan="3" style="background-color:#e4e9df;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="background-color:#e4e9df;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.39</span></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">246 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,910 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="3" style="background-color:#e4e9df;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3</span></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">246 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2016</span></td><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.93</span></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.86</span></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">233 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,377 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4</span></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">233 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2017</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#e4e9df;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.80</span></td><td colspan="3" style="background-color:#e4e9df;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="background-color:#e4e9df;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.41</span></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">267 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,583 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="3" style="background-color:#e4e9df;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5</span></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">236 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2018</span></td><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.49</span></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.71</span></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">496 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,806 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6</span></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">326 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#e4e9df;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41.07</span></td><td colspan="3" style="background-color:#e4e9df;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="background-color:#e4e9df;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45.76</span></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">615 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,651 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="3" style="background-color:#e4e9df;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7</span></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">292 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44.84</span></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59.49</span></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">569 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,205 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8</span></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">162 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#e4e9df;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73.47</span></td><td colspan="3" style="background-color:#e4e9df;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="background-color:#e4e9df;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83.64</span></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">586 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,222 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="3" style="background-color:#e4e9df;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9</span></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$79.79</span></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$80.60</span></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">314 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,782 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10</span></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">TOTAL</span></td><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,918</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"/><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">63,248</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,151</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 5.56 6.75 10000 32000 P0Y 10000 6.76 9.74 125000 476000 P1Y 125000 8.94 16.05 457000 2204000 P2Y 457000 18.20 21.39 246000 1910000 P3Y 246000 15.93 16.86 233000 1377000 P4Y 233000 15.80 19.41 267000 1583000 P5Y 236000 22.49 32.71 496000 4806000 P6Y 326000 41.07 45.76 615000 9651000 P7Y 292000 44.84 59.49 569000 11205000 P8Y 162000 73.47 83.64 586000 19222000 P9Y 64000 79.79 80.60 314000 10782000 P10Y 0 3918000 63248000 2151000 <div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The aggregate intrinsic value of options outstanding, vested and expected to vest as of June 30, 2022 and December 31, 2021 is as follows:</span></div><div style="margin-top:10pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.344%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.347%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Options</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130,564 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">191,242 </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">103,713 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">137,382 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected to vest</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,561 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,548 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div> 130564000 191242000 103713000 137382000 24561000 48548000 10409000 17618000 25642000 26715000 46000 158000 54000 144000 0 P5Y 73.17 83.93 82.20 93.31 <div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the status of the Company's non-vested restricted stock awards as of June 30, 2022 and changes during the six months ended June 30, 2022 is presented below: </span></div><div style="margin-top:10pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:60.157%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.859%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.954%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Non-Vested Restricted Awards</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Weighted Average Grant Date Fair Value</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Non-vested at January 1, 2022</span></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">549 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52.16 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">158 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77.06 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(199)</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54.74 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16)</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55.86 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Non-vested at June 30, 2022</span></td><td colspan="2" style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">492</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59.01 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 549000 52.16 158000 77.06 199000 54.74 16000 55.86 492000 59.01 5000 9000 77.39 83.93 500000 P5Y 0.20 195000 390000 202000 403000 <div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation expense recognized for the Company's equity incentive plans and long-term incentive plan for the three and six months ended June 30, 2022 and 2021 was as follows:</span></div><div style="text-align:justify;text-indent:24.75pt"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:50.069%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.326%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.326%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.011%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.016%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation expense related to stock options</span></td><td style="background-color:#e4e9df;border-top:1pt solid #3d6702;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #3d6702;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,786 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #3d6702;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #3d6702;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #3d6702;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,026 </span></td><td style="border-top:1pt solid #3d6702;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#e4e9df;border-top:1pt solid #3d6702;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #3d6702;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,306 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #3d6702;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #3d6702;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #3d6702;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,759 </span></td><td style="border-top:1pt solid #3d6702;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation expense related to restricted stock awards</span></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,456 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,076 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,758 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,914 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation expense related to stock options and restricted stock awards to non-employee directors</span></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">374 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">531 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">719 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,014 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">TOTAL</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5,616</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"/><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4,633</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"/><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">10,783</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"/><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">8,687</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div> 2786000 2026000 5306000 3759000 2456000 2076000 4758000 3914000 374000 531000 719000 1014000 5616000 4633000 10783000 8687000 39110000 28748000 P3Y8M12D P3Y4M24D 1767000 1669000 P6Y LEASES<div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company leases from CareTrust REIT, Inc. (CareTrust) real property associated with 97 affiliated skilled nursing and senior living facilities used in the Company’s operations, 96 of which are under nine “triple-net” master lease agreements (collectively, the Master Leases), which range in terms from 13 to 20 years. At the Company’s option, the Master Leases may be extended for two or three five-year renewal terms beyond the initial term, on the same terms and conditions. The extension of the term of any of the Master Leases is subject to the following conditions: (1) no event of default under any of the Master Leases having occurred and being continuing; and (2) the tenants providing timely notice of their intent to renew. The term of the Master Leases is subject to termination prior to the expiration of the then current term upon default by the tenants in their obligations, if not cured within any applicable cure periods set forth in the Master Leases. If the Company elects to renew the term of a Master Lease, the renewal will be effective to all, but not less than all, of the leased property then subject to the Master Lease. Additionally, four of the 97 facilities leased from CareTrust include an option to purchase that the Company can exercise starting on December 1, 2024. </span></div><div style="margin-top:10.05pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company does not have the ability to terminate the obligations under a Master Lease prior to its expiration without CareTrust’s consent. If a Master Lease is terminated prior to its expiration other than with CareTrust’s consent, the Company may be liable for damages and incur charges such as continued payment of rent through the end of the lease term as well as maintenance and repair costs for the leased property.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The rent structure under the Master Leases includes a fixed component, subject to annual escalation equal to the lesser of (1) the percentage change in the Consumer Price Index (but not less than zero) or (2) 2.5%. In addition to rent, the Company is required to pay the following: (1) all impositions and taxes levied on or with respect to the leased properties (other than taxes on the income of the lessor); (2) all utilities and other services necessary or appropriate for the leased properties and the business conducted on the leased properties; (3) all insurance required in connection with the leased properties and the business conducted on the leased properties; (4) all facility maintenance and repair costs; and (5) all fees in connection with any licenses or authorizations necessary or appropriate for the leased properties and the business conducted on the leased properties. The terms and conditions of the one stand-alone lease are substantially the same as those for the master leases described above. Total rent expense under the Master Leases was approximately $16,007 and $31,652 for the three and six months ended June 30, 2022, respectively, and $14,419 and $28,499 for the three and six months ended June 30, 2021, respectively. </span></div><div style="margin-top:10pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Among other things, under the Master Leases, the Company must maintain compliance with specified financial covenants measured on a quarterly basis, including a portfolio coverage ratio and a minimum rent coverage ratio. The Master Leases also include certain reporting, legal and authorization requirements. The Company is in compliance with requirements of the Master Leases as of June 30, 2022. </span></div><div style="margin-top:10pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Spin-Off, the Company guaranteed certain leases of Pennant based on the underlying terms of the leases. The Company does not consider these guarantees to be probable and the likelihood of Pennant defaulting is remote, and therefore no liabilities have been accrued. </span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company also leases certain affiliated operations and certain administrative offices under non-cancelable operating leases, most of which have initial lease terms ranging from <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjM2YTQ4YjE0Mzg2NDRlY2E5NDlhYmUxZGY1NTg0NTZhL3NlYzozNmE0OGIxNDM4NjQ0ZWNhOTQ5YWJlMWRmNTU4NDU2YV8xNzIvZnJhZzoxMzgwOTgxMTU1OGI0ODcxYjcwNmEyNTg4Y2Q5NjNhOS90ZXh0cmVnaW9uOjEzODA5ODExNTU4YjQ4NzFiNzA2YTI1ODhjZDk2M2E5XzM3MzQ_1eae761a-ad0c-4f56-9e34-0add274056fa">five</span> to 20 years. The Company has entered into multiple lease agreements with various landlords to operate newly constructed state-of-the-art, full-service healthcare resorts. The term of each lease is 15 years with two five-year renewal options and is subject to annual escalation equal to the percentage change in the Consumer Price Index with a stated cap percentage. In addition, the Company leases certain of its equipment under non-cancelable operating leases with initial terms ranging from <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjM2YTQ4YjE0Mzg2NDRlY2E5NDlhYmUxZGY1NTg0NTZhL3NlYzozNmE0OGIxNDM4NjQ0ZWNhOTQ5YWJlMWRmNTU4NDU2YV8xNzIvZnJhZzoxMzgwOTgxMTU1OGI0ODcxYjcwNmEyNTg4Y2Q5NjNhOS90ZXh0cmVnaW9uOjEzODA5ODExNTU4YjQ4NzFiNzA2YTI1ODhjZDk2M2E5XzQyMTU_be7ed89f-de90-4ef9-8829-8d11dad520e0">three</span> to five years. Most of these leases contain renewal options, certain of which involve rent increases. Total rent expense for continuing operations inclusive of straight-line rent adjustments and rent associated with the Master Leases noted above, was $37,251 and $73,036 for the three and six months ended June 30, 2022, respectively, and $34,476 and $67,952 for the three and six months ended June 30, 2021, respectively.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Forty-four of the Company’s affiliated facilities, excluding the facilities that are operated under the Master Leases with CareTrust, are operated under eight separate master lease arrangements. In the first quarter of 2022, the Company added an operation and extended the term for one of the master leases to 14 remaining years. As a result, the lease liabilities and right-of-use assets increased by $120,349 to reflect the new lease obligations. Under these master leases, a breach at a single facility could subject one or more of the other facilities covered by the same master lease to the same default risk. Failure to comply with Medicare and Medicaid provider requirements is a default under several of the Company’s leases, master lease agreements and debt financing instruments. In addition, other potential defaults related to an individual facility may cause a default of an entire master lease portfolio and could trigger cross-default provisions in the Company’s outstanding debt arrangements and other leases. With an indivisible lease, it is difficult to restructure the composition of the portfolio or economic terms of the lease without the consent of the landlord.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of operating lease expense are as follows:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:44.660%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.911%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.911%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.911%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.917%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rent - cost of services</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,228 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,455 </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72,990 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67,911 </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative expense</span></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">288 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">290 </span></td><td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">577 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">580 </span></td><td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Variable lease costs</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,772 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,694 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,135 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,137 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"/><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">41,311</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"/><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">38,460</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"/><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">82,748</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"/><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">75,669</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:9.11pt">Rent- cost of services includes deferred rent expense adju</span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">stments of </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$116 and $240 for the three and six months ended June 30, 2022, respectively and $109 and $221 for the three and six months ended June 30, 2021, respectively. Additionally, rent- cost of services includes other variable lease costs such as CPI increases and short-term leases of $1,302 and $2,239 for the three and six months ended June 30, 2022, respectively, and $832 and $1,416 for the three and six months ended June 30, 2021, respectively.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:9.11pt">Depreciation and amortization is related to the amortization of favorable and direct lease costs.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(3)</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:9.11pt">Variable lease costs, including property taxes and insurance, are classified in cost of services in the Company's condensed consolidated statements of income.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future minimum lease payments for all leases as of June 30, 2022 are as follows: </span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:84.718%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.352%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022 (remainder)</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#e4e9df;border-top:1pt solid #3d6702;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #3d6702;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71,530 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #3d6702;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">141,887 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">141,296 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">141,187 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">141,082 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">140,564 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,254,424 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">TOTAL LEASE PAYMENTS</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,031,970</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: present value adjustment </span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(756,866)</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">PRESENT VALUE OF TOTAL LEASE LIABILITIES</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,275,104</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: current lease liabilities</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(58,769)</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">LONG-TERM OPERATING LEASE LIABILITIES</span></td><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"/><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,216,335</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:10pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease liabilities are based on the net present value of the remaining lease payments over the remaining lease term. In determining the present value of lease payments, the Company used its incremental borrowing rate based on the information available at the lease commencement date. As of June 30, 2022, the weighted average remaining lease term is 15.1 years and the weighted average discount rate used to determine the operating lease liabilities is 6.8%. </span></div><div style="margin-top:10pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subsequent to June 30, 2022, the Company expanded its operations through long-term lease arrangements with the addition of five stand-alone skilled nursing operations, four of which are part of an amended separate master lease agreement, adding a total of 779 operational skilled nursing beds operated by the Company's affiliated operating subsidiaries. The term of the amended separate master lease agreement was extended to 20 remaining years. The aggregate impact to the fair value of lease liabilities and right-of-use assets related to both the new long-term lease arrangement and the amended separate master lease agreement is estimated to be approximately $70,614. Additionally, Standard Bearer acquired the real estate of three skilled nursing operations, which were previously under long-term lease arrangements. The aggregate reduction in the fair value of lease liabilities and right-of-use assets related to this acquisition is estimated to be approximately $10,080.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Lessor Activities</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Spin-Off, Ensign affiliates retained ownership of the real estate at 29 senior living operations that were contributed to Pennant. Between October 2019 and June 30, 2022, the Company transferred three additional senior living operations to Pennant. During the three months ended June 30, 2022, the Company completed the sale of real estate associated with two of the senior living operations operated by Pennant and also transferred one senior living operation operated by Pennant back to Ensign affiliates. As of June 30, 2022, Ensign affiliates retained ownership of the real estate for these 29 senior living communities. All of these properties are leased to Pennant on a triple-net basis, whereas the respective Pennant affiliates are responsible for all costs at the properties including: (1) all impositions and taxes levied on or with respect to the leased properties (other than taxes on the income of the lessor); (2) all utilities and other services necessary or appropriate for the leased properties and the business conducted on the leased properties; (3) all insurance required in connection with the leased properties and the business conducted on the leased properties; (4) all facility maintenance and repair costs; and (5) all fees in connection with any licenses or authorizations necessary or appropriate for the leased properties and the business conducted on the leased properties. The initial terms range between 14 to 16 years. </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total rental income from all third-party sources for the three and six months ended June 30, 2022 and 2021 is as follows:</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:44.660%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.911%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.911%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.911%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.917%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pennant</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,690 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,440 </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,505 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,928 </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other third-party</span></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">449 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">487 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">923 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">976 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"/><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4,139</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"/><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,927</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"/><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">8,428</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"/><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">7,904</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1) Pennant rental income includes variable rent such as property taxes of $327 and $657 during the three and six months ended June 30, 2022 and $266 and $580 for the three and six months ended June 30, 2021. </span></div><div style="text-align:justify;text-indent:24.75pt"><span><br/></span></div><div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future annual rental income for all leases as of June 30, 2022 were as follows:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:84.864%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.206%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022 (remainder)</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,098 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,820 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,373 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,032 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,821 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,821 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77,369 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">TOTAL</span></td><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"/><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">161,334</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div>(1) Annual rental income includes base rents and variable rental income pursuant to existing leases as of June 30, 2022. LEASES<div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company leases from CareTrust REIT, Inc. (CareTrust) real property associated with 97 affiliated skilled nursing and senior living facilities used in the Company’s operations, 96 of which are under nine “triple-net” master lease agreements (collectively, the Master Leases), which range in terms from 13 to 20 years. At the Company’s option, the Master Leases may be extended for two or three five-year renewal terms beyond the initial term, on the same terms and conditions. The extension of the term of any of the Master Leases is subject to the following conditions: (1) no event of default under any of the Master Leases having occurred and being continuing; and (2) the tenants providing timely notice of their intent to renew. The term of the Master Leases is subject to termination prior to the expiration of the then current term upon default by the tenants in their obligations, if not cured within any applicable cure periods set forth in the Master Leases. If the Company elects to renew the term of a Master Lease, the renewal will be effective to all, but not less than all, of the leased property then subject to the Master Lease. Additionally, four of the 97 facilities leased from CareTrust include an option to purchase that the Company can exercise starting on December 1, 2024. </span></div><div style="margin-top:10.05pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company does not have the ability to terminate the obligations under a Master Lease prior to its expiration without CareTrust’s consent. If a Master Lease is terminated prior to its expiration other than with CareTrust’s consent, the Company may be liable for damages and incur charges such as continued payment of rent through the end of the lease term as well as maintenance and repair costs for the leased property.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The rent structure under the Master Leases includes a fixed component, subject to annual escalation equal to the lesser of (1) the percentage change in the Consumer Price Index (but not less than zero) or (2) 2.5%. In addition to rent, the Company is required to pay the following: (1) all impositions and taxes levied on or with respect to the leased properties (other than taxes on the income of the lessor); (2) all utilities and other services necessary or appropriate for the leased properties and the business conducted on the leased properties; (3) all insurance required in connection with the leased properties and the business conducted on the leased properties; (4) all facility maintenance and repair costs; and (5) all fees in connection with any licenses or authorizations necessary or appropriate for the leased properties and the business conducted on the leased properties. The terms and conditions of the one stand-alone lease are substantially the same as those for the master leases described above. Total rent expense under the Master Leases was approximately $16,007 and $31,652 for the three and six months ended June 30, 2022, respectively, and $14,419 and $28,499 for the three and six months ended June 30, 2021, respectively. </span></div><div style="margin-top:10pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Among other things, under the Master Leases, the Company must maintain compliance with specified financial covenants measured on a quarterly basis, including a portfolio coverage ratio and a minimum rent coverage ratio. The Master Leases also include certain reporting, legal and authorization requirements. The Company is in compliance with requirements of the Master Leases as of June 30, 2022. </span></div><div style="margin-top:10pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Spin-Off, the Company guaranteed certain leases of Pennant based on the underlying terms of the leases. The Company does not consider these guarantees to be probable and the likelihood of Pennant defaulting is remote, and therefore no liabilities have been accrued. </span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company also leases certain affiliated operations and certain administrative offices under non-cancelable operating leases, most of which have initial lease terms ranging from <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjM2YTQ4YjE0Mzg2NDRlY2E5NDlhYmUxZGY1NTg0NTZhL3NlYzozNmE0OGIxNDM4NjQ0ZWNhOTQ5YWJlMWRmNTU4NDU2YV8xNzIvZnJhZzoxMzgwOTgxMTU1OGI0ODcxYjcwNmEyNTg4Y2Q5NjNhOS90ZXh0cmVnaW9uOjEzODA5ODExNTU4YjQ4NzFiNzA2YTI1ODhjZDk2M2E5XzM3MzQ_1eae761a-ad0c-4f56-9e34-0add274056fa">five</span> to 20 years. The Company has entered into multiple lease agreements with various landlords to operate newly constructed state-of-the-art, full-service healthcare resorts. The term of each lease is 15 years with two five-year renewal options and is subject to annual escalation equal to the percentage change in the Consumer Price Index with a stated cap percentage. In addition, the Company leases certain of its equipment under non-cancelable operating leases with initial terms ranging from <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjM2YTQ4YjE0Mzg2NDRlY2E5NDlhYmUxZGY1NTg0NTZhL3NlYzozNmE0OGIxNDM4NjQ0ZWNhOTQ5YWJlMWRmNTU4NDU2YV8xNzIvZnJhZzoxMzgwOTgxMTU1OGI0ODcxYjcwNmEyNTg4Y2Q5NjNhOS90ZXh0cmVnaW9uOjEzODA5ODExNTU4YjQ4NzFiNzA2YTI1ODhjZDk2M2E5XzQyMTU_be7ed89f-de90-4ef9-8829-8d11dad520e0">three</span> to five years. Most of these leases contain renewal options, certain of which involve rent increases. Total rent expense for continuing operations inclusive of straight-line rent adjustments and rent associated with the Master Leases noted above, was $37,251 and $73,036 for the three and six months ended June 30, 2022, respectively, and $34,476 and $67,952 for the three and six months ended June 30, 2021, respectively.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Forty-four of the Company’s affiliated facilities, excluding the facilities that are operated under the Master Leases with CareTrust, are operated under eight separate master lease arrangements. In the first quarter of 2022, the Company added an operation and extended the term for one of the master leases to 14 remaining years. As a result, the lease liabilities and right-of-use assets increased by $120,349 to reflect the new lease obligations. Under these master leases, a breach at a single facility could subject one or more of the other facilities covered by the same master lease to the same default risk. Failure to comply with Medicare and Medicaid provider requirements is a default under several of the Company’s leases, master lease agreements and debt financing instruments. In addition, other potential defaults related to an individual facility may cause a default of an entire master lease portfolio and could trigger cross-default provisions in the Company’s outstanding debt arrangements and other leases. With an indivisible lease, it is difficult to restructure the composition of the portfolio or economic terms of the lease without the consent of the landlord.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of operating lease expense are as follows:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:44.660%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.911%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.911%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.911%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.917%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rent - cost of services</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,228 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,455 </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72,990 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67,911 </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative expense</span></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">288 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">290 </span></td><td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">577 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">580 </span></td><td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Variable lease costs</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,772 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,694 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,135 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,137 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"/><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">41,311</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"/><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">38,460</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"/><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">82,748</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"/><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">75,669</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:9.11pt">Rent- cost of services includes deferred rent expense adju</span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">stments of </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$116 and $240 for the three and six months ended June 30, 2022, respectively and $109 and $221 for the three and six months ended June 30, 2021, respectively. Additionally, rent- cost of services includes other variable lease costs such as CPI increases and short-term leases of $1,302 and $2,239 for the three and six months ended June 30, 2022, respectively, and $832 and $1,416 for the three and six months ended June 30, 2021, respectively.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:9.11pt">Depreciation and amortization is related to the amortization of favorable and direct lease costs.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(3)</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:9.11pt">Variable lease costs, including property taxes and insurance, are classified in cost of services in the Company's condensed consolidated statements of income.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future minimum lease payments for all leases as of June 30, 2022 are as follows: </span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:84.718%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.352%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022 (remainder)</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#e4e9df;border-top:1pt solid #3d6702;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #3d6702;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71,530 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #3d6702;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">141,887 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">141,296 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">141,187 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">141,082 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">140,564 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,254,424 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">TOTAL LEASE PAYMENTS</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,031,970</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: present value adjustment </span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(756,866)</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">PRESENT VALUE OF TOTAL LEASE LIABILITIES</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,275,104</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: current lease liabilities</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(58,769)</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">LONG-TERM OPERATING LEASE LIABILITIES</span></td><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"/><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,216,335</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:10pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease liabilities are based on the net present value of the remaining lease payments over the remaining lease term. In determining the present value of lease payments, the Company used its incremental borrowing rate based on the information available at the lease commencement date. As of June 30, 2022, the weighted average remaining lease term is 15.1 years and the weighted average discount rate used to determine the operating lease liabilities is 6.8%. </span></div><div style="margin-top:10pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subsequent to June 30, 2022, the Company expanded its operations through long-term lease arrangements with the addition of five stand-alone skilled nursing operations, four of which are part of an amended separate master lease agreement, adding a total of 779 operational skilled nursing beds operated by the Company's affiliated operating subsidiaries. The term of the amended separate master lease agreement was extended to 20 remaining years. The aggregate impact to the fair value of lease liabilities and right-of-use assets related to both the new long-term lease arrangement and the amended separate master lease agreement is estimated to be approximately $70,614. Additionally, Standard Bearer acquired the real estate of three skilled nursing operations, which were previously under long-term lease arrangements. The aggregate reduction in the fair value of lease liabilities and right-of-use assets related to this acquisition is estimated to be approximately $10,080.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Lessor Activities</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Spin-Off, Ensign affiliates retained ownership of the real estate at 29 senior living operations that were contributed to Pennant. Between October 2019 and June 30, 2022, the Company transferred three additional senior living operations to Pennant. During the three months ended June 30, 2022, the Company completed the sale of real estate associated with two of the senior living operations operated by Pennant and also transferred one senior living operation operated by Pennant back to Ensign affiliates. As of June 30, 2022, Ensign affiliates retained ownership of the real estate for these 29 senior living communities. All of these properties are leased to Pennant on a triple-net basis, whereas the respective Pennant affiliates are responsible for all costs at the properties including: (1) all impositions and taxes levied on or with respect to the leased properties (other than taxes on the income of the lessor); (2) all utilities and other services necessary or appropriate for the leased properties and the business conducted on the leased properties; (3) all insurance required in connection with the leased properties and the business conducted on the leased properties; (4) all facility maintenance and repair costs; and (5) all fees in connection with any licenses or authorizations necessary or appropriate for the leased properties and the business conducted on the leased properties. The initial terms range between 14 to 16 years. </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total rental income from all third-party sources for the three and six months ended June 30, 2022 and 2021 is as follows:</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:44.660%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.911%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.911%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.911%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.917%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pennant</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,690 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,440 </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,505 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,928 </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other third-party</span></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">449 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">487 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">923 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">976 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"/><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4,139</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"/><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,927</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"/><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">8,428</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"/><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">7,904</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1) Pennant rental income includes variable rent such as property taxes of $327 and $657 during the three and six months ended June 30, 2022 and $266 and $580 for the three and six months ended June 30, 2021. </span></div><div style="text-align:justify;text-indent:24.75pt"><span><br/></span></div><div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future annual rental income for all leases as of June 30, 2022 were as follows:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:84.864%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.206%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022 (remainder)</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,098 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,820 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,373 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,032 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,821 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,821 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77,369 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">TOTAL</span></td><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"/><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">161,334</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div>(1) Annual rental income includes base rents and variable rental income pursuant to existing leases as of June 30, 2022. 97 96 9 P13Y P20Y 2 3 P5Y 4 97 0.025 1 16007000 31652000 14419000 28499000 P20Y P15Y 2 P5Y P5Y 37251000 73036000 34476000 67952000 44 8 P14Y 120349000 <div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of operating lease expense are as follows:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:44.660%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.911%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.911%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.911%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.917%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rent - cost of services</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,228 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,455 </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72,990 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67,911 </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative expense</span></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">288 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">290 </span></td><td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">577 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">580 </span></td><td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Variable lease costs</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,772 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,694 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,135 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,137 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"/><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">41,311</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"/><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">38,460</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"/><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">82,748</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"/><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">75,669</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:9.11pt">Rent- cost of services includes deferred rent expense adju</span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">stments of </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$116 and $240 for the three and six months ended June 30, 2022, respectively and $109 and $221 for the three and six months ended June 30, 2021, respectively. Additionally, rent- cost of services includes other variable lease costs such as CPI increases and short-term leases of $1,302 and $2,239 for the three and six months ended June 30, 2022, respectively, and $832 and $1,416 for the three and six months ended June 30, 2021, respectively.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:9.11pt">Depreciation and amortization is related to the amortization of favorable and direct lease costs.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(3)</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:9.11pt">Variable lease costs, including property taxes and insurance, are classified in cost of services in the Company's condensed consolidated statements of income.</span></div> 37228000 34455000 72990000 67911000 23000 21000 46000 41000 288000 290000 577000 580000 3772000 3694000 9135000 7137000 41311000 38460000 82748000 75669000 116000 240000 109000 221000 1302000 2239000 832000 1416000 <div style="text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future minimum lease payments for all leases as of June 30, 2022 are as follows: </span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:84.718%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.352%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022 (remainder)</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#e4e9df;border-top:1pt solid #3d6702;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #3d6702;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71,530 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #3d6702;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">141,887 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">141,296 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">141,187 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">141,082 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">140,564 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,254,424 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">TOTAL LEASE PAYMENTS</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,031,970</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: present value adjustment </span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(756,866)</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">PRESENT VALUE OF TOTAL LEASE LIABILITIES</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,275,104</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: current lease liabilities</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(58,769)</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">LONG-TERM OPERATING LEASE LIABILITIES</span></td><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"/><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,216,335</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 71530000 141887000 141296000 141187000 141082000 140564000 1254424000 2031970000 756866000 1275104000 58769000 1216335000 P15Y1M6D 0.068 5 4 779 P20Y 70614000 3 10080000 29 3 2 1 29 P14Y P16Y <div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total rental income from all third-party sources for the three and six months ended June 30, 2022 and 2021 is as follows:</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:44.660%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.911%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.911%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.911%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.917%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pennant</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,690 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,440 </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,505 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,928 </span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other third-party</span></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">449 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">487 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">923 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">976 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"/><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4,139</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"/><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,927</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"/><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">8,428</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"/><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">7,904</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div>(1) Pennant rental income includes variable rent such as property taxes of $327 and $657 during the three and six months ended June 30, 2022 and $266 and $580 for the three and six months ended June 30, 2021. 3690000 3440000 7505000 6928000 449000 487000 923000 976000 4139000 3927000 8428000 7904000 327000 657000 266000 580000 <div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future annual rental income for all leases as of June 30, 2022 were as follows:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:84.864%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.206%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022 (remainder)</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,098 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,820 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,373 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,032 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,821 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,821 </span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77,369 </span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">TOTAL</span></td><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"/><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">161,334</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div>(1) Annual rental income includes base rents and variable rental income pursuant to existing leases as of June 30, 2022. 8098000 15820000 15373000 15032000 14821000 14821000 77369000 161334000 COMMITMENTS AND CONTINGENCIES<div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Regulatory Matters</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> —</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Laws and regulations governing Medicare and Medicaid programs are complex and subject to review and interpretation. Compliance with such laws and regulations is evaluated regularly, the results of which can be subject to future governmental review and interpretation, and can include significant regulatory action including fines, penalties, and exclusion from certain governmental programs. Included in these laws and regulations is monitoring performed by the Office of Civil Rights which covers the Health Insurance Portability and Accountability Act of 1996, the terms of which require healthcare providers (among other things) to safeguard the privacy and security of certain patient protected health information.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cost-Containment Measures</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> —</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Both government and private pay sources have instituted cost-containment measures designed to limit payments made to providers of healthcare services, and there can be no assurance that future measures designed to limit payments made to providers will not adversely affect the Company.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Indemnities</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> —</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> From time to time, the Company enters into certain types of contracts that contingently require the Company to indemnify parties against third-party claims. These contracts primarily include (i) certain real estate leases, under which the Company may be required to indemnify property owners or prior facility operators for post-transfer environmental obligations or other liabilities and other claims arising from the Company’s use of the applicable premises, (ii) operations transfer agreements, in which the Company agrees to indemnify past operators of facilities the Company acquires against certain liabilities arising from the transfer of the operation and/or the operation thereof after the transfer to the Company's independent operating subsidiary, (iii) certain lending agreements, under which the Company may be required to indemnify the lender against various claims and liabilities, and (iv) certain agreements with the Company’s officers, directors and others, under which the Company may be required to indemnify such persons for liabilities arising out of the nature of their relationship to the Company. The terms of such obligations vary by contract and, in most instances, do not expressly state or include a specific or maximum dollar amount. Generally, amounts under these contracts cannot be reasonably estimated until a specific claim is asserted. Consequently, because no claims have been asserted, no liabilities have been recorded for these obligations on the Company’s condensed consolidated balance sheets for any of the periods presented.</span></div><div style="text-align:justify;text-indent:24.75pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Spin-Off, certain landlords required, in exchange for their consent to the transaction, that the Company's lease guarantees remain in place for a certain period of time following the Spin-Off. These guarantees could result in significant additional liabilities and obligations for the Company if Pennant were to default on their obligations under their leases with respect to these properties. </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">U.S. Department of Justice Civil Investigative Demand</span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> — </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 31, 2018, the Company received a Civil Investigative Demand (CID) from the U.S. Department of Justice stating that it was investigating whether there had been a violation of the False Claims Act and/or the Anti-Kickback Statute with respect to relationships between certain of the Company’s independently operated skilled nursing facilities and persons who serve or have served as medical directors, advisory board participants or other potential referral sources. The CID covered the period from October 3, 2013 through 2018, and was limited in scope to ten of the Company’s Southern California independent operating entities. In October 2018, the Department of Justice made an additional request for information covering the period of January 1, 2011 through 2018, relating to the same topic. As a general matter, the Company’s independent operating entities have established and maintain policies and procedures to promote compliance with the False Claims Act, the Anti-Kickback Statute, and other applicable regulatory requirements. The Company fully cooperated with the U.S. Department of Justice and promptly responded to its requests for information; in April 2020, the Company was advised that the U.S. Department of Justice declined to intervene in any subsequent action filed by a relator in connection with the subject matter of this investigation.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">U.S. House of Representatives Select Subcommittee Request</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">—</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> In 2020, the U.S. House of Representatives Select Subcommittee on the Coronavirus Crisis launched a nation-wide investigation into the COVID-19 pandemic, which included the impact of the coronavirus on residents and employees in nursing homes. In June 2020, the Company received a document and information request from the House Select Subcommittee in connection with its investigation. The Company has cooperated in responding to this inquiry. In July 2022, the Company received a follow up request for additional documents and information. The Company is cooperating in responding to this inquiry. However, it is not possible to predict the ultimate outcome of any such investigation or whether and what other investigations or regulatory responses may result from the investigation, which could have a material adverse effect on our reputation, business, financial condition, and results of operations.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Litigation</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> — The skilled nursing business involves a significant risk of liability given the age and health of the patients and residents served by the Company's independent operating subsidiaries. The Company, its independent operating subsidiaries, and others in the industry are subject to an increasing number of claims and lawsuits, including professional liability claims, alleging that services provided have resulted in personal injury, elder abuse, wrongful death or other related claims. In addition, the Company, its independent operating subsidiaries, and others in the industry are subject to claims and lawsuits in connection with COVID-19 and a facility's preparation for and/or response to COVID-19. The defense of these lawsuits may result in significant legal costs, regardless of the outcome, and can result in large settlement amounts or damage awards. </span></div><div style="text-align:justify;text-indent:24.75pt"><span><br/></span></div><div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the potential lawsuits and claims described above, the Company and its independent operating subsidiaries are also subject to potential lawsuits under the Federal False Claims Act and comparable state laws alleging submission of fraudulent claims for services to any healthcare program (such as Medicare or Medicaid) or other payor. A violation may provide the basis for exclusion from Federally-funded healthcare programs. Such exclusions could have a correlative negative impact on the Company’s financial performance. Under the </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">qui tam</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> or "whistleblower" provisions of the False Claims Act, a private individual with knowledge of fraud or potential fraud may bring a claim on behalf of the Federal Government and receive a percentage of the Federal Government's recovery. Due to these whistleblower incentives, </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">qui tam</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> lawsuits have become more frequent. For example, and despite the decision of the U.S. Department of Justice to decline to participate in litigation based on the subject matter of its previously issued Civil Investigative Demand, the involved </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">qui tam</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> relator has continued on with the lawsuit and is pursuing claims that the Company and certain of its independent operating subsidiaries have allegedly violated the False Claims Act and/or the Anti-Kickback Statute (AKS).</span></div><div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the Federal False Claims Act, some states, including California, Arizona and Texas, have enacted similar whistleblower and false claims laws and regulations. Further, the Deficit Reduction Act of 2005 created incentives for states to enact anti-fraud legislation modeled on the Federal False Claims Act. As such, the Company and its independent operating subsidiaries could face increased scrutiny, potential liability and legal expenses and costs based on claims under state false claims acts in markets in which its independent operating subsidiaries do business.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2009, Congress passed the Fraud Enforcement and Recovery Act (FERA) which made significant changes to the Federal False Claims Act and expanded the types of activities subject to prosecution and whistleblower liability. Following changes by FERA, health care providers face significant penalties for the knowing retention of government overpayments, even if no false claim was involved. Health care providers can now be liable for knowingly and improperly avoiding or decreasing an obligation to pay money or property to the government. This includes the retention of any government overpayment. The government can argue, therefore, that a Federal False Claims Act violation can occur without any affirmative fraudulent action or statement, as long as the action or statement is knowingly improper. In addition, FERA extended protections against retaliation for whistleblowers, including protections not only for employees, but also contractors and agents. Thus, an employment relationship is generally not required in order to qualify for protection against retaliation for whistleblowing.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Healthcare litigation (including class action litigation) is common and is filed based upon a wide variety of claims and theories, and the Company's independent operating subsidiaries are routinely subjected to varying types of claims, including class action "staffing" suits where the allegation is understaffing at the facility level. These class-action “staffing” suits have the potential to result in large jury verdicts and settlements, and may result in significant legal costs. The Company expects the plaintiffs' bar to continue to be aggressive in their pursuit of these staffing and similar claims. While the Company has been able to settle these claims without an ongoing material adverse effect on its business, future claims could be brought that may materially affect its business, financial condition and results of operations.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other claims and suits, including class actions, continue to be filed against the Company and other companies in its industry. The Company and its independent operating subsidiaries have been subjected to, and are currently involved in, class action litigation alleging violations (alone or in combination) of state and federal wage and hour laws as related to the alleged failure to pay wages, to timely provide and au</span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">thorize meal and rest breaks, and related causes of action. The Company does not believe that the ultimate resolution of these actions will have an ongoing material adverse effect on the Company’s business, cash flows, financial condition or results of operations. </span></div><div style="margin-top:9.75pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company and its independent operating subsidiaries have been, and continue to be, subject to claims, findings and legal actions that arise in the ordinary course of the various businesses, including healthcare and non-healthcare services. These claims include, but are not limited to, potential claims </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">filed by residents, customers, patients and responsible parties </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">related to patient care and treatment (professional negligence claims); to non-care based activities of certain of the subsidiaries; and to employment related claims filed by current or former employees. A significant increase in the number of these claims, or an increase in the amounts owing should plaintiffs be successful in their prosecution of these claims, could materially adversely affect the Company’s business, financial condition, results of operations and cash flows. In addition, these claims could impact the Company's ability to procure insurance to cover its exposure related to the various services provided by its independent operating subsidiaries to their residents, customers and patients.</span></div><div style="margin-top:9.75pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company and its independent subsidiaries are also subject to requests for information and investigations by other State and Federal governmental entities (e.g., offices of the attorney general and offices of the inspector general). The Company cannot predict or provide any assurance as to the possible outcome of any inquiry, investigation or litigation. If any such inquiry, investigation or litigation were to proceed, and the Company and its independent operating subsidiaries are subjected to, alleged to be liable for, or agree to a settlement of, claims or obligations under Federal Medicare statutes, the Federal False Claims Act, or similar state and federal statutes and related regulations, or if the Company or its independent operating subsidiaries are alleged or found to be liable on theories of general or professional negligence or wage and hour violations, the Company's business, financial condition and results of operations and cash flows could be materially and adversely affected and its stock price could be adversely impacted. Among other things, any settlement or litigation could involve the payment of substantial sums to settle any alleged violations, and may also include the assumption of specific procedural and financial obligations by the Company or its independent </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">operating </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">subsidiaries under a corporate integrity agreement and/or other such arrangement.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Medicare Revenue Recoupments</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> —</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company's independent operating entities are subject to regulatory reviews relating to the provision of Medicare services, billings and potential overpayments as a result of Recovery Audit Contractors (RAC), Program Safeguard Contractors, and Medicaid Integrity Contractors programs (collectively referred to as Reviews). For several months during the COVID-19 pandemic, the Centers for Medicare and Medicaid Services (CMS) suspended its Targeted Probe and Educate Program. Beginning in August 2020, CMS resumed Targeted Probe and Educate Program activity. If an operation fails a Review and/or subsequent Reviews, the operation could then be subject to extended review or an extrapolation of the identified error rate to billings in the same time period. The Company anticipates that these Reviews could increase in frequency in the future. As of June 30, 2022 and since, 22 of the Company's independent operating subsidiaries had Reviews scheduled, on appeal, or in a dispute resolution process. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentrations</span></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Credit Risk</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> — The Company has significant accounts receivable balances, the collectability of which is dependent on the availability of funds from certain governmental programs, primarily Medicare and Medicaid. These receivables represent the only significant concentration of credit risk for the Company. The Company does not believe there are significant credit risks associated with these governmental programs. The Company believes that an appropriate allowance has been recorded for the possibility of these receivables proving uncollectible, and continually monitors and adjusts these allowances as necessary. The Company’s receivables from Medicare and Medicaid payor programs accounted for 52.9% and 54.0% of its total accounts receivable as of June 30, 2022 and December 31, 2021, respectively. Revenue from reimbursement under the Medicare and Medicaid programs accounted for 73.4% of the Company's revenue for both the three and six months ended June 30, 2022, and 73.1% and 73.6% for the three and six months ended June 30, 2021, respectively.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash in Excess of FDIC Limits</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> — The Company currently has bank deposits with financial institutions in the U.S. that exceed FDIC insurance limits. FDIC insurance provides protection for bank deposits up to $250. In addition, the Company has uninsured bank deposits with a financial institution outside the U.S. As of July 27, 2022, the Company had approximately $567 in uninsured cash deposits. All uninsured bank deposits are held at high quality credit institutions.</span></div> 22 0.529 0.540 0.734 0.734 0.731 0.736 567000 COMMON STOCK REPURCHASE PROGRAMOn February 9, 2022, the Board of Directors approved the Company to enter into a stock repurchase program pursuant to which the Company could repurchase up to $20,000 of its common stock under the program for a period of approximately 12 months from February 10, 2022. Under this program, the Company was authorized to repurchase its issued and outstanding common shares from time to time in open-market and privately negotiated transactions and block trades in accordance with federal securities laws. During the three months ended June 30, 2022, the Company repurchased 271 shares of its common stock for $20,000. This repurchase program expired upon the repurchase of the fully authorized amount under the plan.<div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As approved by the Board of Directors on October 21, 2021, the Company entered into a stock repurchase program pursuant to which the Company could repurchase up to $20,000 of its common stock under the program for a period of approximately 12 months that started on October 29, 2021. Under this program, the Company was authorized to repurchase its issued and outstanding common shares from time to time in open-market and privately negotiated transactions and block trades in accordance with federal securities laws. During the three months ended March 31, 2022, the Company repurchased 133 shares of its common stock for $9,882. During the fourth quarter of 2021, the Company repurchased 132 shares of its common stock for $10,118. This repurchase program expired upon the repurchase of the fully authorized amount under the plan.</span></div><div style="text-align:justify;text-indent:24.75pt"><span><br/></span></div><div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 28, 2022, the Board of Directors approved the Company to enter into a stock repurchase program pursuant to which the Company may repurchase up to $20,000 of its common stock under the program for a period of approximately 12 months from August 2, 2022. Under this program, the Company is authorized to repurchase its issued and outstanding common shares from time to time in open-market and privately negotiated transactions and block trades in accordance with federal securities laws.</span></div> 20000000 P12M 271000 20000000 20000000 P12M 133000 9882000 132000 10118000 20000000 P12M EXCEL 103 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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

#G"84(?UY+@,0KE?7%WP:AR -FG;I3%JE!@D#T MJ;+4W]ID!'#__MO!:+C_SH&%,3\\O#%+2L@ZTCD.U%BH.35MI,#12&KAY&:AP_<.M.(8&QR/K$_%0W ;X+"G]?$+5:G>(I M;/F;H A\-1%47"&$[, 3\1\*YY0V]MK%NM4T'J#N K_4%O]I MBE)9B8D*QH2 A06%_$9]X ZF,F=0T^6ICCI<^AUM74Q MU31#!]N7,2B0=9 >M6^(0*";-\ZC(UQPUY_U3!KM-^9>JD-@)5*(TSMB8BXL3)$ M?H*2!VO'"E*$/#*L->,WG% (IK2.FB63PT'I4Y/-AG_8,D=_BPQ_A,LW!36&4I?%A =DW-!"T M2 @=GW; MKO]\7"#6 XV9JG_:R W!FDT?MJV'@7H[DD(T$RX"_+V?WX]7XV2 M37V'HP2/! M637%Z!FG)BK51\<#9I(P2,*J\6#(4^3N8/2J.\?.]'TXL3TO.AKLO@H,,.[, MGVNS:WH0 !4[6N@8&(8=LP?Y7.4RC0UA9]E?1 M?(A$6,B_C>T, VQ"OSL'!JH,[/> K,4A8MT4*HMA,L"0SU.$0^5D=1IFKS'= MCJ";F9KF<]+3W3$P6T=F.(CG!5Y)<>>M88!*)_@5U-(\.DV:21C>,SEHVE2'S"AS#NOVL3$\6[,^L&XNJ,G$Q"%HN;C+;#>$MS#&7G M:M6^79OI4/96F5E_;?BEL^+CJ3:8%I,T# M676^(H1C=E,>>BDG1R(($<2:>N!^#R; MO3F+=7G#OV+$%WQA:OU14^3>U_$36VWM]?40:\K'3YS%PI$H M"R_X\IQ&M/ ")8!IKR9LW5H--KY1W.N_W>8BG7S%(.Z@OO.IO[[8_ ME)R&WP=6R\.O+!_Y=0MRKV8030;[DYZPX9>+\,6;BG\MF!J/@Q)?+A2.H986 MX/G,H'CB%]J@_?GHY']02P,$% @ =X !5=\[AFF\#0 =RD !D !X M;"]W;W)K&ULS5II;]M($OTK#:\RZP TS9N2)S%@ MQ\EL!IG8L+T9#!;[@2);$B<4J;!)'_OK]U5W\Y3DV#.#Q7Z1>'175U57O3J: M;^Z+\JM8<5ZQAW66B[<'JZK:G!P?BWC%UY$PBPW/\691E.NHPFVY/!:;DD>) MG+3.CAW+"H[749H?G+Z1SZ[*TS=%765ISJ]*)NKU.BH?SWE6W+\]L ^:!]?I M,;CBBA$^+OC[WB6$2&P\4W3/&B7I(G]ZX;Z!RD[ M9)E'@K\KLE_3I%J]/9@>L(0OHCJKKHO[?W MCT_TXB(3\I?=J[&>>\#B6E3% M6D\&!^LT5__1@]9#;\+4VC/!T1,D',&B/&%G]U&9B#?'%>C2V^-8TSA7-)P]- +V2Y%7 M*\'>YPE/AO./P4_+E-,P=>X\2?#G.C>9:QG,L1SG"7IN*Z0KZ;E[Z-VLHI(? MG6/S$G85/<*F*G96EE&^Y/+Z7V=S494PD'_O$E[1]G;3)J,3G'LMY]Y3U$\OKVX_7GZ^86>?+]C9KV?7%S>[.'PI#793 M%?'7H[E42%RLX>$BDD["'^B:XR'<3E2"%0LF>H,W6GN1-!488L)953"^WF3% M(^?*CI*TA,\5I3!8FL=9G:3YLAVBR+&B9W=06U6F<07ZZJ6B;C"U)K$EJA0> MB)M%E);L+LIJ+DQV)@;,[90$K!3+//T/WJ%K5 M)>GBMI.L'2+Z0UA4*=:!J231$O9?$7]8:L%R'G,A ,L&%KM+!<;3X(82Z4[4 M<\&_U;3]&UZF!03 1'A-'66#A9)TL>#ED"42)RP'4"WKPUVOTKCE=1DM-F4Q1UT,'_L[^G?M4&LBBSAI2!5 M_Q(],B=0NV%H<\/RI,WAQ U$*GB*#B9 M-OM61V6E>%%*&"F,^&L4UNIUP)%)RV@_EH252&61963/=R"^*(LU&ZC#&$E% MA--$V:1\U>H C+F&YSL-7=S#V>!4:C.56I]0*%QFKLB!FYT*3;.,AC1N!*,Y M3%_#.K0HRJ\BV):ZK5;PE9)GTH5 O3-PP!?7J MOFA8'9%79CRDKR87X)N8IP<#H'S&PH<16]19=B3!43V#17XN\J,6>AM@;M#7 MH,6EFS]4Y-82$C@ 02J,8$B*,^<2^_@#+^-42)5+*"4(!"# VJ,\I[\T!VAF MF01-@^EMSGB^K%:T<1)]>+DFV,B -DI01>>11Q0O"@71A.095X(OE.IH@-Q] M1-@41K/FD0#:))WE*4 C\$9D /]*F4V@6?*P)ZIV0W@&I%KF6*QK5H*R/6V*&EGY!5T(_TOXO:2_[H%>HP+ZBY%-,Z6?=<'"1_([B0Z<.LU520G)F\@>PP;C%:7E2*M@'PM,S"LX@O162EQ, ME;JVCM?G0Z,7LWU/KN/:TU&RV7IEYS+D&LA8NJ#YW,R.\B1!^P=\R!ZWO$&Y MU@(1LK@GTA'<?2#2UV06[QL3_ 3;VQ[]I;76[7<7*85S,/%;RK-$\42J=\SP%0M, M6R.AYYCV*V:9[BN5!SO6C-FF14/<;HBKA_S56GQF=O[_I$,R6ZF0@0Z=O@Y= MS\?=;*1#.00_'W3@?:;LQDC'2(^ICJ6Z1Z4&,NIS#142G3JL3%(!#WH$\:CJ MP\T64,MW8J#GO?I]WRQY)9?<>O^!UO_2X&"S7:WR)FQJF?+?]4QGUJD,+V"< M(;UPS6D@C>V^(1YIXB-Y97ZC[7!K[#!H#(+R%J1*E424ENRWUJ:L>K*0I N9 M,8 @5YN7YH@"*-ACS0P5$!.KB0*C%.1VL-N51,'QGN^JU54#C[X=\SBA[%+UP&JI\CY*!(TVRM,,^P7&D$@1E8S#'L MJ8L[!]CCM*9'YJ*,178#G!_;_P\JY&',83!]S?S0]*RM00U/&.2&UFMF![M& M#??1-6;2-CW;#&;$EF\36[[INZ.MT7W2?J"D-BCU,\4(^8I.J8;,;WFB2]U, M=@H27B'@B5WUY,DHHO;W9_A&ZUGO47_<,.GKN>FYLS#:VR9A7=^B*UP+$0O=6W9(#DU'0M#8#(N=LK# M=.R=Q5QYC2%XX)LS5U$!GCBNBR$N$,:3US*QQI I4;%GIH?H%^")X<,4P88K MJ0#M'=.;88@+=+*9-PM@NU,K8 &>R"$SLA8KQ!#/)ZD"<#GGUJ+3E F>)-M2F3"4?+9/8I6?OSFR :(WY>79E(H_,!L/ MN1X]G-BA$=C372FSZI8]P0IO,?:/,N+X1N"IAQ,GP![Z8T:NNS)*09XZ"=E9 M7<#UB9+M3_=67_^K,J-A2=<[MN?M9>GE*]OCE:FEHJG)5D6S>D1-(M5]Z^R. ML@^L\'33I:MJ];93]T6UR$"B)XI>]H_G]TR>]>A>T00H"&"&VTZ @\!O:1E( M#0&B]'#FFNZ6]'LY514_PIYNLT+6@>9!,=_5@Z/CBS;$:T^E(X=:-'==BY8( M:&_<6_'O04E53HL7Z(SZ12H9I$XIG=J>R"ZBAL&>KV@OV4K55,R^((SIY0*? M.R%@,N-LS4?,FC ?Q6+09F?D8V%H(A+JM0_MV0RYF$@V0$>^A2!1VL, MY/(0*"<4'2V[WR3_8XXX:*)WCBCI //JJJ"$+7ZQ433-<6BM:706^<@:YH5L M%2_ZL[:Z[T_[%H8*/F1IZ"$AI3R=A[R@=62R3T6^/+JE/N_H<.(R9V?ULJ90 M&1HRKU%J/)<"#8X>]M)HCEQF[-/MQ_ZQR^!9=]@@(UG,2^2_>>^8;-#^Z7. &\HI(?UC0 \.N1;OEJ/5&ZTK4,9VU M+>ILU.?NK_"D4+M.4'S+ZJU^Q?.<=F3,A2+;G*" <>TM?TT[_.-"]H_C=)/2 M<0*01'5E9;H#GN^*K,ZKJ$SA#QE'%2WZNV#(\ECS)NKY[S!NU2Q6,NACD+RH MP%.;GF"\.MPA*RFI:[YHD*&?8>QM+3Z:\?.+.K!K-5!##6V*ZH\&]]3^0NQD9%G MJE.33>3]QO)87^-R7=S!O0W/U&TM0MQN;J&5IH=W]84:,D1]43R'_+ MH7_?<"WZ1Q7@SUY$>5_,=@P/%2SHAU3QA8AV5%)Y?X+K)[ZF>"+FN BGOHOJ M$*9O&U0Z)[(4I(NI$4Q#8#-;U/)80'>NAF%1E7)B>. S MP7I[G/W#TK4 M[_+6G3:W'B;AU35#=2YA>MNM1'ULN$^L9TDC\:XY2;2-, @[8D2D+V%+?->! M))ZH QG;"()9/UR,JW-S=Q,U[G5[Z%1+"O:75/Z$%8%IZ0)BUQ=6Q[V/X=:\ M7,I/_N@K'X0>]5U<^[3]JO!,?4S7#5>?)/X2E4N4I8A5"TRUS- _4$?NS4U5 M;.2G=?.B0L8G+U<\0I%. _!^4115 55? M<2A)S \ .Y5 9 >&PO=V]R:W-H965TI>7FRRO/-L_-S$ZWD.C2] M;"-3O%ED>AWF^*F7YV:C91CSI'5R'O3[X_-UJ-*35R_XV;5^]2(K\D2E\EH+ M4ZS7H=Z]EDFV?7GBGY0//JKE*J<'YZ]>;,*EO)'Y]YMKC5_G%958K65J5)8* M+1 M9C#*$L-_Q=:.]3$X*DR>K=UD<+!6J?T,[YT>&A.F_2,3 C MOGJALZW0-!K4Z N+RK/!G$II4VYRC;<*\_)7[R1$,B_.<]"B)^>1F_?:S@N. MS!N+]UF:KXRX3&,9M^>?@X>*D:!DY'7P*,%_%VE/#/J>"/I!\ B]0278@.D- M'A5,_.=B;G*-O?_O(1DMB>%A$N0/S\PFC.3+$QB\D?I.GKSZ^A_^N/_\$0:' M%8/#QZB_>G=Y<7-YE2A"F>R51E6B3JCIXLP@B#F)B_P([\3X >+@:B?F4LC[7))K" 1.D6\S01\K\"@6X.N,J$/KJ=Q"\7;Y MN=QE4"515"FTYUYX(K/J,^%:NJ&D\@B#%6NOQ_O."W*LA")I/ VE[V0,[E&; M4V40B^<_0U,D,KU?0''9EK:PIOY,G/I/19H)>0?M$B47]-P>'26_"MD8LB@J MM(8BB.FY=,1SE1;X^IR?G@9/'<=I2!L(0[Q3,8W,D0"2'5;/523=,DI#/SGQ M JY9A58!I;R?%13C5,J&AY7(;)WT\GZCK$%6*ES)5##[M!K1+S9X6RI@OFNQ M;1W LZ@LAB<(A/#9N!VSFU: MLO3$U:)ID(+SFZE4T=[YUEQKK*7-;>'$;*>+A745(A$FB2?F1P%)IE!0Q_#MU M/D>+; H=KZDCAKD!+X-JF%/:E85.T]X!%M6Q5,($_((#FO+=[ MQ&"ZU?+Q4=(9&--VKSA@'UW":RG+A2K$=;)""E1QN 84LP$&FL=60<^:GIB" M(K,I?9>8"7=K%Q&L?ZQT5BQ7UI4POVDPUB0Q?0O\19^$%]EO(LF+:;D)X3E1 M9B 9A\R'MF:WC-="3B^BO*@2Q0&?MW8#41!P[R7%RS5\EW70,-4N$0 IT @^#$QH#\$]\( !B.4V@XLB.EU3HS;P V" E4F;"WEMQ M#LX!,P.G#6R)9ANKU(?= H74%06LBS]SX:%=V(6UW:-V[I+?R$V1;+4/N&,L M!^VE9-6DM@)A1*M?70CZ:U1:9]A]\%$: ER+XFT:GX4)?7>H#!X*;Z,7!&B2 M78UD0O*'S-2,-N&<08XUD59SP@WS[ YIY#;+X9?L_8A\I(ZCOK\%;5;%O4+= M1@#BB3_V^OT)\_YDX'OC45"M:U$9HUAU+]:VK+'8#46)K(H2KW0:ARN9EC_T MAO[,?@^FWG V^ZUT_39=Y$L,758A'=X-$'%$TKUP3OF2#2YD.UH#8+#AL1W1 M$FI!86"AR!X)7T;0K,4N:]!CA$*5LD (U%@%BD/%JPC$<#1EM"\V ">(/"KC MZ9HB(:_PDHPSMP=S6()1)MTT M_-*A&?&W<[ER;M06OSG^,$H,^7EKRSDT'PH7-QN5GGU8+-H;L(3:H$U)V<9) MXJP9A*]E2JKF'D+E:+ROR8ZA+CM7,VF:(QB%E*:'+!<-==L^WL+/=61.4[E=Z#0%JL.HA!I4>P9FX MAK$,22GN65XQ[6B8:D$U[] D;BHA?VY">KI7\6JN7YT'7%F#6B@-?3C_)9%L MY&I:*: &5V/U?O!V5 5K54%0(*-0[A33CL\P-7](5H,M)"V4Y3(!+L0S&);7 M@']-(^(T2'*=98NS@@0!QN+R*=(V[\PI8 =];S"<63RT2!BK@!R5.)9D X?W MQ/=I[0\M/J%5,0=9 J_8%D$=BT36^3G*BB2N "%+JV%3NI+:QN'&_G)(LTQ6 MN:RU+PY2\8NR4M3*?.J)MZ%*"+/FF0U/.VL"[V6,0E!;?[4_5.R*8*G;D4N1 M?ML%N)$48Y-C]ELYRI%N"2T:RWE>I@4*!RGAZ]JP2G#J.6UL,BJ_R<4<)Q0^ M$C9;AM0@$"LP3T"Z@82H.N/]K@3@[H0@6GI/B762L7"#=BF'U2PQ(M*9,6QR4AA%@2>Q%;3*:0=B13&*%F?K MK(L16IWK# O!RRVIA8%Q283O;*VB P&_*A$M':[8J@'@,\FTB[A5,<,$]J)B MA8_8IHPK$\PSS*20UVS>#/?%]_*E&V6\WH[_I?,!P.!A89C,?11O&^T MI(YD&:S"->$#!P6XD)I.18 51I.)&$W[XH=0VZK6:L36E506#+S)),#?\6PH M9IX_&(D)_D[ VM#W!F -7 /'C8G9:>!-AB3'9.2-QS.6CB0_('A5;L(L);>[ M6D@UC'\N (\K]/'$]\<.- [[?Q").B#:+U$HM/:'(6BK9:,_([+UGKM#&B^[ M!F^NKZKX;EW. ,OE9YQG:HST!%O0#YP<7C#XS6#Z,$B?#AQ-'V!]_(>U0_;V MN$6J5D#D=E+S-21=A'>9KD!:C/@7Y4W-]=A8#UEQ$XS773BNT&W7QI6\%D]$ M";*KA?T,BA_L83-B_M.6@F2Q7.(9Q*S8]OQS?%36:UL R&<%1[T2\;O(;=M" MMHM#A6UR%%X_"% _45<<]4\!U^$!IQ9@(,U17)GXWFC0IS<#@ _?FTXGW,OC M'\%L3#]&_,.W;\;\HS_EJ#7!C[XW&@\I@L(2%SEW X,1@A1HW'ZXO7@G^"!% M7%_\]/[RN]L;$7A]5(NS21^8S8!!/G$!CL3<=CY^*ZX^7 M-Y@K?KAX]_VE^/"V1?C=U<7KJW=7MU>7-[0TXHK?'SK:99_Y(6(Z'4V]R7CV M5+S[\-VW9[>7']^+#]>7'R]NK[[[]@#A)T0:!>\ P>W#7FIH 3%HOU6-I#+? MD] EGQKF[>TQ8:&#(\BQ&3O$TO8O2Z3\@'Z;8ANJVM.C$AO2 .2,>::U/:1@ M3-R20*7VG)J]\@YPR[I8WLBQ,%T0BIB:(.MFT+IOFI:/+>-O0LME&7M 3/)V M?]3S+02NBJX'.:RX]L%Y89]Z9?]<1-,3? A.X$Y #; MU=G /3YBI\)&]55V:I,L739"A[B'%2GF M4)-*Q0KQMMGL*NW_"YGEQE-=1_$QXH,*B6B'2TQ9$B$%KAKG;]0;W/.,+RF= M&LEFGKEMXTKI^ 97=OJELL'\@'2YH1:[1L->CVW2]\;^H/E]1=4;B.?C_>97Y?62G?H\S -+E!6$,N]YG&T^7J5'+1G^%6*%^"IGU M%NC:K-2FCM^UFA$,@]G>@7TK-F ZY=.>K2:%XYYUS;J81_S+;6 /D1Y1@=J M0=\U0!^)1 #WJ7' V,&NRD@>X:6QZC>%+E.()? 8!FR="%*E+7-G<"9,I#VQ M:FAD[[H#G]9;Q1UEK1E>RH8:PT!J@36EY2!YF,I!(O,P^D2"/]C>(VGJ]YJ! M \%4:.U; V7((E6V[W^1E)T%/MJL#Q%T=4Q0;Y/M'M3/'N M$[-@*CZ41U:58,/A3 Q1BLU0L,TF8VJR>#ZJ>J(P M"ZCI,D7MQ1T6;X9"B%8I5VSKK6HV5&T&>P_ ]1?V"F%J)0P"=]PW'DU$O)\] MOE"Y3X*QZ]-04^FW-@ZJ"MG=,M@SA<_7QYR'CQ7(I*P#1?+4Z\^FKD8>>=.@ M[TKDD3>8#%R%/$)9&Y0%,L;X97W,WQOE\63B#<8S5\*BKAS[J"J'XI'KCZ/J M^N/H=UY_?'1>=_VQN_[877_LKC]VUQ^[ZX_=]LG_:90<"[S:?\=9/:W^F>F%_1^>]7#[GU#?AWJ)N 7-+#"UWYN,3BSV M*G_DV8;_HR? ;IZM^>M*AE #<#[19;EY0]:H/H7KZ_^!U!+ P04 " !W M@ %5]"2) ?06 !@0P &0 'AL+W=O#Q )21A3A(8@I6A_ M_3[=#8 @)=E.MO9+8LD$T.CSZ8-^M;;UK9MKW61?%V7E7A_,FV;Y\_&QR^=Z MH=S8+G6%WTQMO5 -/M:S8[>LM2IXT:(\/CLY>7Z\4*8Z>/.*O_M:M+NWY]<'H0OK@VLWE#7QR_>;54,WVCFW\L/]?X=!QW*G/;Y_2\_S /XU>N^3GC&XRL?:6/EP5KP].B"!=ZKRA'13^ M6^D+79:T$G/8??W?'?<9:*5&NU?'#8Z@!X]SO]U;V>YLSW;/LP_88.ZR=U6AB_[Z8Y 6 MZ3L+]+T]NW/#W]IJG#TY&65G)V=G=^SW)-[W">_WY'ONFUT:EY?6M;7._N]\ MXIH:2O/_N[@@ASS=?0@9TL]NJ7+]^@"6XG2]T@=O_O:7T^7+V[V47L?[%==JUG;:D: M6V^R#ZII=.VRO_WEQ[/3LY?9[VHM/*SE&1B9RV9VI>L*',T^Z,+D"IRD1^2# M*;)E;6>U6F A?I/;Q;+47_D)UT[^@*5FC<5^*S)G^M94.!(\;'C[,<2%%495 MN8:=-'.LRN=9N8L0XS*]4F6K&AU^49>;4=;,-3XZ&*W+[#1;SPUVR%65371* MP[1M2 OD.J0NJMQ/UXB_HTU,E9=M@9W,K#)37+EJ E7$0B6N2)XB)DTA##?* MX&)5V1CZD7;27_%[=GO3VBZR7-<-W&N?F,#(<78E9Q)1=#NG]S)D82L#.NC@ MI:[)HV/59,,\^30%N9I8_O33\X[(V*Y7+Z4[G;4WGXH# MR4X *;1O@W$BSO+ M86"81#6O6JYY3.X 2XC'T%E%GJ!3^+>@(Q$"G\=G-Z!!;3)GVSK'\W.UTMC; M-:9IZ;2<=LZ3G1=AYT*3HN 1W*DT<$RTCSBGA8(:X>N.&;A1PB3R*A"8UQAB MD YJ7-E,N2">9JZ:H,W?=^[:E"7VQ'T+T@)=@M/3*=L)F$\6J:H-J6&A%] O MDW#L/:EO@R!..]+_HW1-IBMV*# F&X75;)::[TH,(__KY IY<-0-S@]*DVZ& M/8R0,-W@.C43HF:*!$&Z4Q>/Z=M-EI?*D-U\85OICH$H@4L,M@]6?&B.(EU M/&6F74/"+L%'XGR+\VJOQRDI"RC#1 _(7+IO2+TE[0&+EICA,5RM3V^ $[*0T,V_?>%3L!/Z1;8_O#]V0;^76<+O& ML>-AR70TL\1>O'19Z]@)T*_4$KXV5Y.23$PO#-_YT( I0B$?&RE3LUIKUJ$1 M>:)MKO #;B@G"*>[+P[V7"#B>XMSYF4GT2"7WFV'EXO$^1M%NHDQQ[8>?,E6 MA$?5M-%U?P/2WXZ<'QS? 6Z[('OV.^!D1!!G"@-XRYQ*]*?$L_1$RJ;OTA]Z MD#9CE@LO5KBX;5V4,82>L$4\Q*%9=<1T1$@8W:4(E@-"C>4%B,A9/E&=OI=X MCM?@EB/5(>W>)3[D#D%@E6+')9],C5U].)N;Y4 F;-!==.&34OL DS84[(+! MTV584Q* UPB.2!.MJ[AF1+]-F=\] F';FO#$ MU 9B>WZFVJDNN ]LP7&XJYPM3<'43U3)88@S%!$Y*8D7+S3!V()<+TZI^"I7 M%6U0^:0M:N?-TE2/@5%&G4%!?B4(=5'56)K 3G.%.!&HA](0062F7E_8I@6) MC22V]"V;O7M&\ +HC3P6?!\=2$BB!*B72W3H@N_ -Z) -X46V#6I<4IVB#;) MKD!)9>&A*.V=0D95%(;H@XO?\N:)*/P5H^F9:?995Q7ML"8\@ O[!-5+#7FF(I@QE<_#?DJ00>!3E>52O2 M7CH$*G4)YH'L@ @^5<@C-MF34\KH3G_LXP%HGL:: MR]8ZO#BZO+H\['WT$/ M&:Y( D(&R%DK\MMQ2_QF/=<>6Q*_YJKP5I*MC!5/$U3UO2K!B NQIW-Q'R&" MG,-$'__=Y+<3E=]F-S@5N&^+E:GO&!(1_(%720V+O+ZA(,FV.,)2_\)?E_;=C;W MJD"4DX@8D4H^XW)(%"*NR"U4:F$1EU)[H3'2+$L/+!%HZ-=RM M1 R( :P3FR2' R5B^TMR"+EV,/W.+_RFJI:"C^C\Z>#6HA:T2-R34PR7ER8? M9^<09S:30 )"*/\>W:34Q(/!6^=1=6J;ZX*S!,D" M%I"W9.I)WKW+(D;[;6&4 -$$52:9L??AC$F\'GFG,&T10T% U/U(P!V6[V^R M6$JVX)84G02+-"[(SPT%^))4[AQHO*1RTTG?.9%FLH&P7ONH<0<)ALI 2'F$ MC7ER*!>/ V&0C 8'!SHW"Z\7_BMA9BVQ9_$IL+F;2P I/8?_4*( M3<*P7=S9(5O2S($04SN8*Y=: :>DK-?1=[ 2D!EM_$6@^U0VW7L1P2I9N^QY MM,31A9NZX57[I)F.,B+F'M)^M6N](D>&B(SO"?LBQW6&/ *[' I,8EY +HR" M*24 [UCWQ'Q8_JF^V#H&C47Y]9:.8C&, M@!N[5$5&"#\/5OGB2*:E-$(4M732L@TUPDGKJ-J'.#LUP&@YK2+4;+H28E*8 M[%+L'W*%4A//!YUE$DJ'T%FID7AE$>&*: M L"PEZG^:*D8H$M.V"$B!,,UO-,,<0TQ0A&S [1BQT\9E*]0776HHV?#_PO& M[6#0+B<5O3$]J&+-Z@?.X1 &14LES6-\' R,S@B+10N0FE#"Z'7-EZWYW,04 M!XD1Q,!6XTA\,&/ U)(T/M1WQ$UT]?AN%Z3F,X*_35-J<=X^*0>-A5JP_J^Q M79_M 91UH#<2R4<(TPKM\MI,R*=. '[_I8]YX/$Q2(!J+*I7':<'-.V[+TN M&!KN2DX8LT$@Y%9]V9+; D&5<<;"L,ISV:U6;=&61)R_%,DP:CI;UF90I*?^ M0W;(OABQ*?9[L"ZT>XZ2M$%M; U$FV16)&9O0GR;B2)T0.<.&B#^FN7F\;1E M'+=-!\1V0X3$E:[OIX$(!&CC4Z5]0AE P^Z*1N>E?;.$X"^ 5>0^XEG6@ 4@ M^ "AP4&S)HBGNCZ0:PD9>_)'Z&AL'D UD.X6K2K%R&XKNX9CG^DH&:X21TV0 MK[C0QNF&\C4A2^7_N2JG\5"O'[_TFQ8> A %&HD;8-Q,[U_R@^.2$#XB>%^V MNBL+]"Y-WI3H6Y'?":R).NO+2QS$%Q9RF]:"?\?9>Q:XHE:@&"[,:8D$D,D! MBC8N2"!/D7T MGXQ>%[B.6)\'S=]>TS@\__O-T4X/N<\5C3)',FGK*QWF6[>I[0K_:FCQ0R/$12<#T:^2X$M9\ M@_+LY.191L!!(GA097#S=E G"$>"-&"$Y4Q?\F2UTV:G6/HYP6D]>\[OC MA'BV*=4B/=@A'N5UBT1GAA(TAE):)2(!C_TX@JV#,JMU-'R 7U9 Z_HZPCU]%Y M77M?Q(([?/_N^OS($\&5FA0M2"78W:>BON?.^:6<')N0/#0D-90T)M>6^LRA MD310R\ATRDXT(ZU9BF+:TRZTO13 MZ.8"=Q+ -U.J]B>2#)50=EGCT-,?T$+X"6=18X*N5$KAVQ]?>H5=2&F8/JZL M8<,F0*4C!,VA?^E?[M:(#*K3>YCGR.7+>U)YB@YU.#:?#*YW")U_/ M"6Z#"!@1/BIIDD')178\0R&@XVW@ZR '(-6!IC::-=7/,S#*"*U &DF!M"(* M[ZGF,.6)JRD'MQ7.9? 5ZB.4LC8"2$.W*C0!U2P4ZEK.,OPBODBO1X=;S4(C MC(^)?4&*8G4AK=4_6PH&+\87=7*+US@>O=(T=2N5@L MO!T3^I0R'#O$=DG?9URB>RYU $6"/E8SFJ\T/+BC_8 $!W]?5/.^/3R<>8@11P]*^(LR MCD;0 8_] 02+STY>AI7\\?1EEJ"[?I[$#8]^\D69< :CI/*.\],Z(1WS+'Q0 MYM'&4;_H24FR*OI$M&./56' M/4)2_J^Y*?N3)P3QI&WD2UARK=#H%77I/ $9O4#9)51"_&/!:;*D;P>EC M'3^6PM\8*<9Z%,'UB;Z0OP$<=8WLU*!$O7CHL$4FR-VTB-D-7.L>%]'ERS$< MT%@:G+F?"* ;3$SE_0D-'C!L8FSJ(\LZ%M>H)"@@U<5BCX]\'J+#%$W9UCI$ M2EH+SOKQJ;)+F/DZ+9;" ?V;1[O*(,L&FJ'5K0LU15]4HIF "&J&)=S":@D# M$UT:O=)=^A%KL-C9EFW2$W4AD/D9,4DU'J3?N_+M3D]SY>;9%-Y]C\Y*66F7 MROZW.N,K1ST]'FV7R9@LL@"7 .O "\$5M7'!Q5"OIBKQ6PF^" MO9-A3L^[5'POY3"[!4)B*;6[I;=^4B&>?TW@#A6GTH@34JL@Q:Z8G#KV4<:U MSJVG8WF1P;J;L]/NXI.,&^>0H*-"+DM1BZR3Q_*F7OV,BP[[+0D M7T -9KA=BG:#<.1+:7T(%))/29ERR>_W'_>6:_>UEGT#K=>)PA4D"-[$D!&2D=ZH=VSC M'^KQ;#SRDWFQLJ@:P'+*I\*@ $?7_C-@^Y*G/,)#1_V[^AFTT'L3&.[CS":9 M)E8QF8XMNT%KSK?Y1MOMN2ZH0IUZ?;S[5\1Y)AY/H%&O >#^UC+[ !OXX"NX MI\IEE!1ZR+D-)<(FO M5+MXN>G-R? WW])_$%:P@VRK 4\D='/.PV4'KW&B+SL=/*5K/?S3X:C1P%U\ M)U =^*H.'Z>.DM#2P%GZ,1CB#9Q!?DOE>(I(87GWO#@WJI2<;[V/,!)%3A2C MI[?>.PK2]#W53:A<$_,;)>'8M0N7Y ZLTEX4*<="DL1^)\RCLA> C2Z6(6[$ M8=$PSN/=0L?85&/[C=QO4!A1=>ZN+&TMI?9&S_@%C#AC'*K*PC5I%]4UE<.D M6!,MY)J*5:WF"E^[E+F#M-]]7VX=_>2@M=EK]],K/&YKZ"KV:XAYGJD+SRC$RH4P+/-?RB6:B@'%Z?7QR-LL^^A783WV9)'AKU MWYNZBGQ--XIO4QWFMN07'5>:!YYH,$_\&:BZEDL?2:O%T? %C9/)BWK0C3"Q MMF/2AK_VKVE,8V-O^%+738C.AQK>4"A6IT1?*_PHHPZ8(QZ&7"A[(9K)L0:U M\J!19O]HC%BF!X> )'2TNNZ0TX'PZ&HZ'.I[;/DF["^%!&Y <.,,26QXM]+7 M.N"R\?EL,&OYL'(6C<\&8NCM82J((E*3[UXND;J,?,:LLL*X9=M/*=E145L M^DW-E^#<+PB20#HTN[+#&7#QI3@:CX/M\KB.EA_HR0![/P:PMV,):A?@@C MR5@T&[YNX)%E9'FSQ2=VUE"^M@I>;Q):QSYSYYCOWW;T!>OBC]9)E= E9+#7 MKC1IGAK4G&+^E![-DM_S9BL-."3OMXH>^GL].QO_](B??_9T?/(H]&\;VW#A M8%MEU1X+O<0CG(;*!/W9Z2B,F+/K'\<@RI36VBPF5'+@.-S-C=SW;FZ/]A=/ MQD\?;3N$.AR$1R;6][2;.6%E<25?0X@1-]F[BT@+.Y\^"C\]?Q0UX(&[;-W] M@D @3/+=U]P/!;V_O+K(?J?ZQTXHD10#61]5=4L^P#H3WHSJ %-XH5->IJVZ M:036<_V5TA(YK\MQN?)"+>C^USZWO;L9/\D&)/=5KPU M]RVV+J!V7X'2-A<&;_@:(2;0T.B+T8[!47+O;,M?N1Z(Y_[Z[/D+8D5' ,/P M0 #V+,N]U"E^Z1<1"]R;F]EXU7L76=?0NBO[^P:B%%)4JG25:WZ M!>^N9YYY9O:9]3+82G6G"T0#CU4I]# HC*FOPE"G!59,=V6-@M[D4E7,T%1M M0ETK9)EWJLHPB:++L&)$3)>(5"X.?.6YU:PPND[64 M=V[R8S8,(D<(2TR-0V#T>, IEJ4#(AKW>\S@&-(YML<'] \^=\IES31.9?D+ MSTPQ#/H!9)@S6YJEW'[$?3YO'5XJ2^U_8=O8]I( 4JN-K/;.Q*#BHGFRQWT= M6@[]Z!F'9.^0>-Y-(,_RFADV&BBY!>6L"F\AQX39E912]Y>1G1E-9 M552$D>1'PDQ5=Z$4=2*(D>0&O=\RXY_%ZS^#=W%MN=O#K>*V-(E'\ M=B['!N+B/(1KE"M=LQ2' 76"1O6 P>C;;^++Z/L7"%X<"5Z\A#Z:SF>S^6=8 M?9E/?X+ES>)V.?TX7MW 8CG_83F>G:/[MP#G C[@6EGJ27C?E+D#ID"82*8R MD#E<'"CR"^O+MSN$;D^0'9.2&X9%<&:0BK^NRN#;!-V M_+C6EEXP0>&MT88&7&R.M M&@FFB&SK<'(!_<@'NH/V.3L8[.HJ=>ZWX0T-; MX$8:3F,*J)C0S)]HVENM2U<(6LX(E[MC+I4J8R)%.DE, 3E20JP$C:E5W'"R M*ME6=^&:ID3,)6<*A7BH#+J^!>HZ/';=:0F>$LX@>1NIU0SO//\CJ-DKP:A4ZG..Y_E0:B;\$G2Y9)_Q_\ M$%1L]U4_ V.[H8L6)'_U&\#_(XUR[JX2MJZ2%:J-OS"[)"W#\IS+Z U!+ P04 " !W@ %51Q3]1,$4 \0P &0 'AL+W=O MEU-7!V]?TW6?[]K5IFT)7ZK,5KBU+:;?O5&$V;PYF!^&++WJU M;O"+X[>O:[E2-ZKYO?YLX=-Q'"77I:J<-I6P:OGFX'+VT[O9!3Y =_Q5JXWK M_"UP*0MC;O'#=?[F8(H2J4)E#0XAX=>=NE)%@2.!'/_T@Q[$.?'![M]A](^T M>%C,0CIU98J_Z;Q9OSFX.!"Y6LJV:+Z8S5^47] 9CI>9PM%/L>%[STX/1-:Z MQI3^89"@U!7_EM^\(CH/7$SW/##W#\Q);IZ(I'PO&_GVM34;8?%N& W_H*72 MTR"9KYGFG/QFZF:M1,?JESE_>>/0>0H]SS(_6X^.N O M;74D3J83,9_.YR/CG40]G-!X)WO&&UKP?U\N7&/!;OYG:,$\WNGP>.A,/[E: M9NK- 7B+4_9.';S]\Y]FY]-7(]*>1FE/QT9_^TXZ[7#//N/852/1PH>$?,(P MXL]_NIC/YJ_$U[4"I\E,6*VX];+*X9.MC26=.*%<(Q>%!D?+16,$ MH")<47%@F?VSU;AF=ZN+ GY7K76X2KX1AY@(4+$&V0I]U[]"LUE5D%2HV:) MET2CT9ER1^*R*$ AH'R_&0*LLG(R2T\O9(%*[FZ#PO55TBLSK1R>Z6NPYLUW MHC(5W-984Q0H(,T(ZW:T=7Y#%*RS0=D85$&WNB&]YH#4*N]KV$LE")Y84!Q# MEF@#^&SO[@IB$)B$*17<)1O<6=DT5B]:5+U"M:/8'R BK"KQLS5M/0&;S([B MP'L6@.L?D=(E(\;ED 1'(TYZ%IWT;-2[OJBLD,X1I-).#3GHZ!##*')OW.BQ M(T*?1Z'/1X7^X!I=DK.A4B\=1.MZK_!/'*J',(P6,E@3;N,HSK M(QU!.R10 M050 _R$/=! <*Z 3>#-:3"EO%3IO1Q+9D80,32Z78,XT-0AC++DAV2A9!-P? MK#= 18"(7+NL,*ZURELS(AO.O.\9G@7M[E&+#88]))95=ZIJ%=VCOM5HV$[D MK47+3\\0TL($)G?L]:4!AW"=4)^4XUW=BZ< <\!$)I2]L*BR], MM3H$(%5YO*%00,ZZVIZ$N$+#@S!+Y9!,PA>]NY V*NN>$?R#&MD6\9FUDD6S MSB"8"7 Y7:**LJ+-8VRS+>*'*I:'N@(K(+#KC8VC!$R3WPC+LZ8%"20 M>W_WH,'11Y9P$9=P,3K;#0=#4N@7I"H%_&(' #PT8,[[*-#CQAT8K =3(5A: MOOXOY:(##M"&?@EGG^\O'GW8OB.*Y-'?!?/+V^N7HBO MIM:9.)^>3Z*P9"]7&/& "W"8%E>4,X ]CZCIX971DV&! +:!K8"0Y&> 0+!J M@?28G!75BMD1TLD[L&3$$79(P(Y2;-8*8;O 7"R0+416X#7 4739EO[N6FX] MS#OTV 4%_B$%@^H$J,5KY>)T/A&_DF CMO9CM+4?1VW"[PAJ,%/Z#F48,JP_ M/$A4>[QFTS6D)!J@&6@Q)&2Z8 5YN,_#9O^F*$6@+2'J3 MS+FGL6- -9NF='0ZJK;/W9CQ(<2,P83S*0/%+6C65JDQB3L)]&QT(C8[FH;^ MQ*Q#7)>@^#NU%UJ_=\Q!#_:>N9N"+&46XU$_!4E7?,)3 G 0;)GE$E&1N&<_ M6\@5>C3("SX*!@JN:2'N><*%E-U[LJ\HQ*K5!!P0>EV7 MWT"J!&D=(I)BD@5KO04/04%K!%1Z&IE5KIF,%8794%Y!S+(R#?@OL@_G_-Q] M7C[!49T*VR(?$MUYV>/2 =%541R)C[AC]]3EVH4#4N5Y[EZ=37IKAAF1.N-^ M"W4'P9LC# P0]Q7!FE D8;A;$TM9["X !DEK "&7%/;4B 7$,6DWX(M?6I@Q MU''ZLN9&.=(RY;0= V?2?D^=O=F!:5&%D2W;0.J^\LD23'I/\3A8I'8PU" # MS5J+@?$^T62:CXR4@MW]ZZ9'K)\],E_>-=AG+HB;L_4A' #\XC8 .\:B%5CD MO2UO\0E-F5-FR4W!K!?&6C9F*F-@73,/8NJ*B[W$@N^D+@CK95BX-T%V>/)* MB,_!>D+RX6L*XB[PPV7;8);4C_)]9&D;T->_< -@"&WS0\@+ ;^3E;I:(3AA ME 2#Q:WGW-Y'IS#W_G4> 1NIQD!_GD!_/@K0U[ULY%?<^U\I&[DD8QF$_-$1 MAU/]!Z9Y3.(_2Q70V6C)\NUU2LLN4UKVLT_+!I?TA!KH^"QQ1>\5N+-NE$_R M[J>,@WRI!BM 9:$]3T)XHW(9N$DERQ#H/$?F[!518:UKL,;/G<P:&U+7>9^A?^6.%1B1,,DTZ;&Z7VH%74V;?=Y6&RG*/F!#I6C=S MKBAB5Q6FH)ZN6P&K1'K)P004"7$=F7]#%[,U1G>NNVB;M:5KN-((LV.@\\4Z M=#R0WE*A.!7XV!_[4@$3W1)^+10E':!:1)BC42M.E?'9>$W[!K/QZY"-#UKM M'QE@D&AA<@+8I*EDG=)_V '4]X-5AVVH)K0U 1G;FU<:F!A?%L^IKMT=W0+* M5FBO+WPU'?9RM;)J1:!O*G4(0*@ C/,6Z LI? 'J13AU7.X&WF60L8#NMX:+ M2W'J$ 9Y+B#(IEVM>U!1*O@1$"N12TY4I#."%XW9*X"6&GB7'RAJ"F>*4=7?UP$K^),T^\.8%B MZ>(":,@M.&K:+QJ1==%3,-7.#RDP ^WM/ DTJI0E 5FL^5;12$W1^+ZW[@B M$FK/HM8:\@W-0%DKI%P1E"1L#I$$N!/E&UYQX)IUC?&E;3#;Q1&"]+ZD*O\! MN0:7-/;[+!>,D\WX"1Z%&(%D#IW?9G?F3'R- UW@&+E*Q$I,(G6MIMQ-? M-/:G4,/U:U@@*[5'F'W=N'=6^$B&^_4!J7#W.MZ=048O83JTI182O&VP,%\N MIY0DC>,)LNT%SUC7)C3C T3CB[D1"6%44+_/JR26;"VFQ:$.@JO"" PW@)X: M1( :*UP,ZW2*1-K'T,Y9G)MO!R^ EC M!)G#'UM1JI?LI]P). .^&^=*= M6(@ZDF"X6T!W9C4^R527Y*OW]E6&UGFO\P4/3D/=\M92%+QO<2_Y@XR&UUXZJ M?N0%I!]?7), #YFN/=8'V_7,B$\H$$M_>'D^F9V>,=Z=P]]G%U1$V,FAZ?I[ ME?%1^,F,OH6?0,!K12TPQ7;8'U)6'/UO$%%PZSP0^6?WPQ'&KA@)85J#.FO0 MFP'[8% 7/!G\(&^%?0>X^!$'(9=MI_?8AFG;BWP5$<*S#7X/'IOC$H859WK MZ#:&&#YGIG6Y[J-=-\2G%:I\?L8!)F-GP(H2!+*OZIMT+-$>!9(?AT(3<@.\ MFEF-^T- YAY4J9DTB79]-Y2_X#%8+T>$(]KT13VW21L MHO(#_B8A]:I6#89K-#2N@$DV!X?-7Q0:L$[]AU9P,K"":PY3S$-VYF[Z M[)Y,,]@[G03^'QE9(+9=N0-G[+"+*%LJX$>>T5\,QS4W'-@>%&\*^*W3] MOX#Z8T%,6H9CFZM\+YP_G04QLR.(GU],3LX]Q,]?3DY.SIX.\=>)J-\'S+@< MI/.4E/LS^EZ,P[3F8G)Z.O5!9_+R[,D"X;&_P#FIQ!_J@WTN0D8(@W=#Z7[: MNP.*#X51IA8KB\CB:<6-4N(3A",Q.\%#5; 4G37>X_^+T(M+5'U;I6"X! MP MHJ0R32&>,Q?F4PR%X.X+\+9=N1>>^5-!LM-2L !.L=3L=LU.&H%?J[(NS%;M MUGXP;VZQ\%#P(=S2P\,RGCD3:X^\J[HX)^/&X^/Q4R-P#$/?"XL0 M>W&==(!$(R#V@4F CI=T\.!P&[9*6C+(X7 5&C:2@7.X8=4PE/XG_7PC,7T] MF9R]G+%#_3BY^''V;R%QL+&%!OH?$M8<7;GQ&1!U4.,F$2*76'?TBQAM[5G2 M06&"01H9:W> T: O3"LZ)51IV6.=7MO_;:!H>Z ME'R!F;4<#[/R%"52Z$)UP!04KVE1?$32R6C, M-,Y+IXZ+XP5.VB^3JUCFY\ M 2F1WJ*'#$P2>].Z7H/I+#6,M:9UX,ZEJ72#OMS)FGS$6X+;;+,BA5QRD2/Q M.YWOXMP[$I.K^@&I(-LGCLDC.JUPG"C"WML5G:0 ^\A=S]$[)(X/7\BX*8/I ME5@XCF\GCTU(]R:C0R+O#_;,-].)U7#P'^R!Z^JA=:FD,;"7ONIQ[\2+],7= MB:[Q>D,!LT"O.AQI+RF*&]5[LD?,+)Z>P9Z75"+;4+<0;8O'!KRWK6H\.PAF M\G6W)K5+;ECA;6T2N_/I^V:ML:\ZM53V<::?TU-?G@M\20(XXSY,^D$^@2]" MR8*@R'-G/)G%DVYVR\H7I )180)[)-ZW*D1,76&5$8\9#9[CQ+:BP".+;1<) M.*2E]6GJ5XB"8GD;K)HZCS<&*.EXC38LM M[' &>C8,8Y+; [L[Y(,@48)=7?,Z7#A>A?B'!HF'U9#804,% MKX3%LCYV%%,ZG^>C3= 7W/CXU=L?!P\B'G\X]US046NT\AO M>[MLK>KUZ],Q [ I8[&BR+V6BLZP%JK98$S$G4@J2IVS'/^*4B_#*Q!XX MW=?U"X_:T&2KN-^8FN)<"XQF6#A:1L !WV!KW4X[3GIU@F\EK&!^Z,_3R3[R M^VI[)=9F@T-.6))*H1/&2G"W+1 Q1G8.XJD3AL"?Q,K;C&=!^QZ8*=91.8"' MYGXZ=BST+1H>^3LB(=Q*QX*26@$HB]E%VDKY/1T6R9\II;M@-P L(1:V7+SO M;@W>T%:AK(PB PAH?QK350/VD;M8?][;4$Z;X\8ZSA/>4LT#@O3*1RY\QP)= M][8RFT+EW(G4/1TJ)9 KC"V=&,AAVIL'9@XMXVE"#A]\E!$S*V9BZQZ;A7F[N7TB(R2F]CW7(=N^[?P)Y MH7P$JSPAW?5O5L#0#1ID2JW#'3R:,-ZC(EU,D7B)O>G4>P36!/Y#X3TV)A,= M!R]7(>/H]'403J%@1^)3>A\I)D\,=MS\YNTS/&4[_=7^JR1&Z';N2\X:C&4' MONC5HL$A5#[I F<\?=.N^ZX)\3:"O)9??XO=5BM(N4,''$%,Z-P=?:M@EGKR M9^/-\]C:O/.RJ#65:7UWV'#0_[XAHTE^X*-R-##;%MYJZ(TO\$,J&D-:Z5O5 M>3=N%+#N=)8* Q!$HF&7FDYQQ/.;#UA.R"\ M29@V #6?+R4JG=\PX[Y^WL[8O-Y]=Y%;KLE._,225D$O-T&TPC#06I4\C@[5 MXW D2(U-@.%=N5YC!=60P7DKM<%,IJM06?&G?+)#>;FWV_7Z00>>9W2&S!YN M =7?T?N0 V]T#K_ZR:6QV%(G:>H58S;0A/!QCZGK+G?;!F3 MJ\3P0I 7QG9[/7S65V$9"47R=0>OUI1?5-NXI3L'U.3UF&S2VQ/X4GJ?*CYS M'2DZ:15UI:7#;?\62#H1Z7?:B_M>DEX=N<3NWV0=83^#WP"A^H1=Y&BH7%2* M-L20 Y;Y.UTYG$WIJ?GTE?@YO5%PF5+_Y_[MBY/YBY_$^_@NG,.YW[4.=Q3? M^&Z\TU'B/SC2A">:O?( EP$!Q#7LON9Q,I_L$X6:GT$0<23\GZGLL@BRJ" + M%I987C50G @[T7F/HE/P 'UM_9L;.V1<>M53^25:" S[BZRP(B)FG?)>)S,E MF*#"564>MN<]Q<9D5^F%UJ-A$V'S >>\YAW',L0G(-]_AXCWL/E\5 M+JX&E M3/>:S_1P>BH.OBB?SH@OF/S#1U!UM)O3BQ>3@Z%(=-SYAP98D*)_VT!04S7\ MOPWBM_%?0USR/T1(M_/_E?A-8CT+6Z>7\.CTZ"4DG9;_50-_:$Q-_QYA89K& ME/3G6@$GL7@#7%\:TX0/.$'\AQEO_Q=02P,$% @ =X !56VS^2SD! M30P !D !X;"]W;W)K&ULY5?;;ALW$/V5@=H& M-D!(O.S5L07(BH*FB%/#=MR'H@_4+B4MLEJJ)&4G_?H.N:N5'/VGRQ*Z4U MS*554UW_5I5N=3'(!E"JA=S6[D8__JRZ]02"A:YM^(7'UC:A RBVUNEUYXP, MUE73MO)KEX=')\;_0C&6R.:[X2E!F\D5S5^4VZ= MP:\5^KGQC7I0S5:!;$J8%(7>-L["C2I4]2#GM8*3.]_8T_.1PVC>9U1TR)J;(J9%7""3N%'X'G$6$\@X@.(S3$B9B1 M*(Y!Y,,$)UISHX#EE$1Y!#P9.^5T'+A&8FS M%&D@'F.(*R*$I'1(0S82))30O)_Q2>NI;^0WW/VJ*>IMJ>PS25C5 M5-C4U8/?2WP63)">#<1VAD;5R+4$I^']U>1Z&+B^7$$(@YZUU0>"^0-Y-)JL MZQW$4C7^4RNW%EPV!6X6/C%@6V7;(=RB@O\SP<4)ZBA-O+[:%$<9)QD3(+*@ MP%X+(L](3F/@?I,%>@G&@&>HRE<%E\:,X8)2FGH?]2='C<1$IB M%/I>=HQP%&J&)^'_)+PC-WWL9"[%RBV\Q"G#W1!/XI)W"YJ.6';7W M5>/C(^?]\WWH+3@:[/"CU1<&9E\82.OYO'P'WJ')>H[)$"S,XN^_>17.OH-Z M ;-7"DH))2VB+/0$2?!V>Z;K+"%YCAX*ZWUEO %^7VC47C?P ?K_(,9_ U!+ P04 " !W@ %5_9^;,Y5 SW4KU05>4&GBNN= SKS*FF02!+BI:$SV0#15XLI:J)@:7:A/H M1E%2.J&:!W$89D%-F/#F4[=WI^93V1K.!+U3H-NZ)NKCDG*YG7F1M]^X9YO* MV(U@/FW(ACY0\ZZY4[@*>BTEJZG03 I0=#WS%M%DF=K[[L+/C&[UP1RL)RLI M/]C%53GS0@N([G]@>[\<0 +R;7[PG9W-_2@:+61]4X8$=1,="-YWL7A M&',HWQ)#Y5,DM*'L;M=F)<]5)(S@F;%(>C,)3AG)F?B'KIC7$ M14BNX0;+X$H4LJ9P1Q7@:8T'#Q51%,X>R8I3?3X-#!JVXD&Q,[+LC,2O&,G@ M6@I3:;@4)2U?R@<(N$<=[U$OXY,*?VS% (:A#W$8QR?T#?LH#)V^X2OZ+HD2 M3&RT<[KS]I?%2AN%1?/K,7\[=%% MRWO!E?4"!-8CZ^JQ00^+SB'M,K26')\4/8''2E'ZHL0 "X2Z GE@SZ^3*,2M<>1FH9_$(?Q$-6*Q M@,^XU/I\+TV,46R%'$/R@)$@,$((2"%ZFPLF#,4(&@U1%$/D1VD.9U$2GN-\ ME(\/7-[< M7E_==+Z^=V\7!H<\8:(VM NP!GS$M<&<69SX_A_/29>,-/''86:'),OM,,K= M,$1;RT^E(O^?S%I3J+X%TA3 M=G[\3YO_AC:'<7[)GE/TN.,M1@#!*HK=CB%\KV"M9 U8<%@))>H6:,7U0F>1 M]7*+$EB4OV'3@/>W_P!F>&9_! MWLBQ-^]H.P[=,!HZL+>-+="71K<5*RJP!4F$8=^ZRL7^S%4[5C;V9A+/A#2P MQI\PSFW-8_9LU7_"-U++5A@@*_ED[Z(:6Q%6<8;^'7M.@H,&"FFW<6VB1K6H MI^NE^MV^$UUT#=B?U[LV]IJH#4-?.5VC:#@8X9N@NM:P6QC9N'9L)0TV=VY: M83=-E;V YVLIS7YA#?3]^?P/4$L#!!0 ( '> 56.UL;#' D ) F 9 M >&PO=V]R:W-H965TT9G 2 M( !>;,_8CI->IM?K-N>M-VD[\P19! M KN+Q;//+D">/.;%AW)F;44^SM.L/!W,JFKQ>C0JQS,[C\MAOK 9GDSS8AY7 M:!;WHW)1V'CB!\W3D6!,C>9QD@W.3OR]=\792;ZLTB2S[PI2+N?SN'BZL&G^ M>#K@@]6-Z^1^5KD;H[.317QO;VSU\^)=@=:HE3))YC8KDSPCA9V>#L[YZXO0 M]?<=WB?VL5R[)FXF=WG^P37>3$X'S!ED4SNNG(08/P_VTJ:I$P0S?FED#EJ5 M;N#Z]4KZ]W[NF,M=7-K+//U[,JEFIP,S(!,[C9=I=9T__L4V\_$&CO.T]/_) M8]TW5 ,R7I95/F\&PX)YDM6_\[5N2M_"ZNXK.3(G\D MA>L-:>["3]6/AG%)YA;EIBKP-,&XZNQB6>).69(;>P]?5R4YNHWO4EL>GXPJ MR'>]1N-&UD4M2^R1IL$=>,T=R;1=Y4279/?G'^5U9%8#&/W=-MY8F=TMSX?*Z7,1C M>SI /)2V>+"#LV^^XHI]>\!6V=HJ#TD_NT'X39:I)?F4;-O])JOC$<"FY.YI MU6/7) ZJV3V)VYDETSQ%P#I=E<<#*<$04%K-R#3)XFRG*%N-\OHBS)W*5)@B'6O5M7L&81@JHXL%F2TN.Q#'YFF@FJ-0&5]]\ M9007W^)*&*J-QL61H!$WOAON!5+#Q9F3U1"1VY]NS_]*KJ_>7_WMYZN>UF;4UV[6BD=.*3=4L,AK#=#-J':!DPS3@]8T M+\MCPB%$*$44-!J88B! =O9H1F7$R ]@7@(GE'$-EKC$2I4$@I6&R[S .XO5 ML611Y ])N5JL1ED5?X3GG0=H%&KRG04.L+@U9V83$L\=YOY=WS"4\X!@ZES! M$:&(.N](:D)3KY$M*V(_(F^4F(L\[OD^H%H&^#6F]@6-I.\AJ#+&+[-;]-PO M^J)(D"F2],G9FBXGL#/&0P>^-$4*(LI*1TV'D5IWGF,)@EF&&:/#@ M=[W\A!Q(5UBYM,[>H<=*#U[E!I@*Z\/#$>3FHWN;.?G ,0)QEVVUWQW\J]QK MOZR5_!GV3*=)FOC!CS-$W-.K_#%#8V;CM)J-$01D&D-B4B6VMGX>9TB6'BT' M#=F>)3(+@G8K(98;BWZ068L:/;> F5$S(M\GE? MX<3>520NBCBKD56",*I':[<%._>Z['"%JNP^(S\4^7)!G7E#?[LG==N"3>>X M91CL8W64/WFZG&?#Y_((_UWRB.*"&B/Z>22@4IB:QC3COEL@J6+1P3PB09_2 MY1&N,5)0SK#$ 8V$WLHCG=9F%)2"?67HE0;4L+#6:F@8[,LC$:.,,Z)IQ!0L M"6BHP\X<)9'X^*=DBF;$X4RAX9$ V5%(GS*E[.:/%!"%VYEBW;.",92> MPA.)*XPUS)1KA3&'*(T"]4M5QBCP*3?!,X3'8;^C=49%H.$1@1$KBT0$>I;/ M%\>:!BST'A#2[T\<52K7!_X*U0O]O93'+Y3Z4A[WR^.#2>7W*8[!5R#CB/>/ M6:3V1RJ>Q@+3)!4!QC\LE+.?U_S/T'CMG#]I@] M/'C,?FUAQMC/T5F!I;AN[/5YH'TK BA=MO9NOMRH#]H/*]HD3JS2//X7HF81 M/^%_F2\+/'U$-(-2FM/WSSI#[^B\S]BK>:U^_T3>VDDRCI.)IP%'GZ \X?A: MH0QUQ;F()%C*$,F&LNT/ WGDCI[7=O1-6ZBA:*6^*AO+9$2UZIBK::JA(3?+ MN\K;&(*ZF9&-8I3*8.V0Z !JW_J";D)JQ>@7@H0[4J[;7 \U>58*B*UEX.<,:&#(YP_FJ= M5Z]?RYC;-.6!=) BN^!._0B [?NWY^]JGMR>EM?HN+G,M_4^K\UQ>B.B,](E M-2^\8]2&D\K/.8#[?!"B:%":UR\*3'W>A?U@&)(@&JH>"#5VF\RLO9ZIV\(A M:QN$@FJDZ!:$=5,!-BT(I0**D?IKQ5)A2XRT"Q#R#1!R0:,U0*_: *'9 T)L M($/&W+N@2 9NSROQ$T'P/A!VYWZ"4UT'97.R^$<%X:>>G=3PVP3>)\(Q!%M) M?^S*.67*+4CH8**5PR-;QV,0H8#$[KT]&FG:PG'3%AXCU*)K7TE-+?%O?\6JD2UOJ9'M0> P =08 M !D !X;"]W;W)K&ULA55A;]LV$/TK!W4H$H"( M1$J6%==B$D2> M$):8.X\@Z?6"MUB6'HAH?-MA!H>4/O#8WJ-_[&JG6I;2XJTN_U"%VTR"+( " M5[(MW:/>?L)=/0./E^O2=D_8]KX)9K^+5]WYW 4D$4_"!"[ M -'Q[A-U+.^DD].QT5LPWIO0O-&5VD43.57[ICPY0U\5Q;GIPE!_C?L.LBY@ M_JU5#9VX@_?O,L'%!WB@:W'Q+) M%UB\C0^)Z(&MV+.=B;. /[?U%<01 Q$)<08O/E0?=WCQ_U3/8%%**OOM(?QU ML[3.T+WY^U3I/7)R&MG/TL@V,L=)0,-BT;Q@,'W_CJ?1AS.\DP/OY!SZ](EF MLVA+!+V"TQT\Q?@LYFG&;\!Q#\Z@IGN1:QI-ZZPGX38(*UW2B*MZ/0+J$Q[Z M!'>88[5$ S'O=CC\XN%^ BXXBS.^LWB:P*Q594$0MDNHJL;H%_0I+:3I-1-\ M &F2,N$QD(9QH\O_N/%DP :4E"<1B[@X:J<8$D#,0:2"B22%CZVIE6L-=KE6 MZM7;%A(6#V/_C 9P2R4ZT_8"HFJ@/&ORH2R<15$$/&)B$ ,GW(@-?5;&LX2) MR-.S=D2BD[=56TJ'!6D%G6NN9 =V$0O!DNOD$B[$]8 -T^$E+!Y_7 56+3NJIB@, "H( 9 M >&PO=V]R:W-H965TU*&Q LR1* MLIS4-N"D2=Z"ELT54$CV2BN/]^AXI6W51U]B /5BZ._+NON-] MU'FZE>JS+A$-/-=5HV=>:1,/ M"ESQMC(?Y?9GW-?C .:RTNX)VVYOQCS(6VUDO7!$8YOR8!2M"O(S\W>-XPT?B!TXK>C@-#.6R'D&^CWO5Q64_B#N&][(QI8:;IL#B M6_^ ,/9 V0'H%3L;\)>V&4$<^L!"QL[$B_O"8Q%^UW%-\]YU1:B6<-; M*8NMJ*HA_+E8:J.(0'^=.H@N3W(ZC[U4EWK#1./P]9DJ MDKZ*Y%ST^0-=TJ*E&N0*;D4C#/YT1RPOX+OR3B$_&_LT(,YUDM4 M$$?.$L$G=P\(P>()%5UKN!,KA,$?R)4>PELEM89KKM3.'O&BEFUC8)'G;=U6 MW+G54AGQ#W=W]C]N_Y[,MJ7V9]6:[ 5(;QY-AZRW-1";,#(D.!T/#:'L4HA"R.89"$\1#B>*_%%Q%I"8-K=XGI MB!16#J8NQ49#-*'TB9].& R8'V?9$)C/PO2KC67,VN(HA,=?'Q=W!"3UTRBR MN)A_D3G S$_CU*W$D[A;R>*H6QFG#,YP+.TYEOY/'//AMC6MPF^[37R:@#?:B-JUGA\GP2X)T)@"Y'EIP9H286=Y!]BX&WW$5A :N*;M%8TE M?0F6GP=^.68/%-J95J"RAQE%F37'P.+$"LE!2 _"^"!D3G@LD6;DRE"RR&?) MI&_5J88$1]]O8LK:32D-N473?S#_ E!+ P04 " !W M@ %5Q/R2JDH# "G!P &0 'AL+W=O[,B*:QMPDKVT:-"@=K2=7)O]^1 MM%6G=8Q^(7GDW7/OQ\E.Z0>S0;3PV IIIM'&VNTX24RUP9:9"[5%22]KI5MF MB=1-8K8:6>V%6I'D:5HD+>,RFDW\W;V>351G!9=XK\%T;WFNBDAZEYBU*PY4$C>MI-,_&UY>.WS/\R7%GCL[@ M/%DI]>"(=_4T2IU!*+"R#H'1]@5O4 @'1&;\M\>,>I5.\/A\0/_-^TZ^K)C! M&R7^XK7=3*,R@AK7K!/VD]K]@7M_O(&5$L:OL N\!3%7G;&JW0N3!2V786>/ M^S@<"93I"P+Y7B#W=@=%WLI;9MELHM4.M.,F-'?PKGII,HY+EY2%U?3*2<[. M?E>JWG$A@,D:/MH-:G@GR2LNN<5?/E#$:KJP3#9\)1#FQJ U\-.2$65^GB26 M;'!(2;77=QWTY2_H*^!.2;LQ\"MIJ9_+)V1[[T!^<. Z/POXOI,7,$ACR-,\ M/X,WZ ,R\'B#'PG(]Y[?,9F]>947Z]HP/P]Z'X3GTV8):M^[(:+6&@S^G;#R+?T\H=S^EV?BA?ZE")_Q_ZE -X(9LRI M$CBK]'0)!.W\6^W\JW86M%<4.&ZLL]@>E\WXF[C=8H7MBC '(2,9+#6K$21K MT<6RO-JO=UCSBE'KN;H(!*]!4)*EH3SG\556TEH.2EA^7,X_D-@@+M.1WT?Y MZ&0>DJ/AV:)N_!?AC.^D#7.TO^U_H7D8OE_9PQ=VQW3#J5@$KDDTO1A1='7X M%@)AU=:/XI6R--C]<4,_*6K'0.]KI>R!< KZOWGV/U!+ P04 " !W@ %5 MB34(0A@# !_!@ &0 'AL+W=O30^*OW1'! M?&Z$-)/@8&U['T6F.F##S(UJ4=*7G=(-L[35 M^\BT&EGM@QH1I7$\BAK&93 =>]NCGHY59P67^*C!=$W#]+\/*-1Q$B3!V;#B M^X-UAF@Z;MD>UVC_:!\U[:(!I>8-2L.5!(V[23!+[A]RY^\=_N1X-,_6X"K9 M*O71;=[4DR!VA%!@91T"H]<3SE$(!T0T/ITP@R&E"WR^/J/_YFNG6K;,X%R) MOWAM#Y/@-H :=ZP3=J6.K_%43^'P*B6,?\*Q]RW+ *K.6-6<@HE!PV7_9I]/ M?7@6 E+/NT_D62Z89=.Q5D?0SIO0W,*7ZJ.)')=N*&NKZ2NG.#M= MH;&:5Q9K8+*&#_: &F;&H#7P\X9M!9I?QI&E3,X_JDZH#SUJ^@+J"-XI:0\& MEK+&^NOXB!@.--,SS8?T*N#OG;R!+ XAC=/T"EXVE)UYO.P%O 7N4&LJ>JZ, M-2',6'ZI]+[>FSYY>SNXMV M;UI6X22@FV10/V$P_>F'9!3_>J6V?*@MOX8^7=/%K3N!H'9P9;R7:%\%ODS[ MFPS*9V!]NRI%E]=81X3,L%."-(#+_3W0/'&8)RRPPF9+<5GB+0E9MA:X,1V3 M%1*.'Y(DC?H1\C"Y*^B=A'=%!F^5W+^RJ!O@DN;BW6E"!@U)1J6>4+LSW!." MVS#/8QB%95%0AE893B2/W!Y $'>A=&T@R<,R+2#)PC(NSN<">--J B,ULG J M_;M(5[Y .O#:4([\[@[*,(DS&,Y:I1K24L.\'+442)P)QSI4 VD6)D4"21D6 M60RKY7JS>C/?+!

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how.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 105 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 106 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.2 html 487 413 1 false 129 0 false 20 false false R1.htm 0001001 - Document - Cover Page Sheet http://www.ensigngroup.net/role/CoverPage Cover Page Cover 1 false false R2.htm 1001002 - Statement - UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS Sheet http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS Statements 2 false false R3.htm 1002003 - Statement - UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) Sheet http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) Statements 3 false false R4.htm 1003004 - Statement - UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF INCOME Sheet http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF INCOME Statements 4 false false R5.htm 1004005 - Statement - UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY Sheet http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY Statements 5 false false R6.htm 1005006 - Statement - UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (Parenthetical) Sheet http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYParenthetical UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (Parenthetical) Statements 6 false false R7.htm 1006007 - Statement - UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS Sheet http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS Statements 7 false false R8.htm 2101101 - Disclosure - Description of Business Sheet http://www.ensigngroup.net/role/DescriptionofBusiness Description of Business Notes 8 false false R9.htm 2103102 - Disclosure - Summary of Significant Accounting Policies Sheet http://www.ensigngroup.net/role/SummaryofSignificantAccountingPolicies Summary of Significant Accounting Policies Notes 9 false false R10.htm 2111103 - Disclosure - COVID-19 Update Sheet http://www.ensigngroup.net/role/COVID19Update COVID-19 Update Notes 10 false false R11.htm 2113104 - Disclosure - Revenue and Accounts Receivable Sheet http://www.ensigngroup.net/role/RevenueandAccountsReceivable Revenue and Accounts Receivable Notes 11 false false R12.htm 2118105 - Disclosure - Computation of Net Income Per Common Share Sheet http://www.ensigngroup.net/role/ComputationofNetIncomePerCommonShare Computation of Net Income Per Common Share Notes 12 false false R13.htm 2121106 - Disclosure - Fair Value Measurements Sheet http://www.ensigngroup.net/role/FairValueMeasurements Fair Value Measurements Notes 13 false false R14.htm 2124107 - Disclosure - Standard Bearer Sheet http://www.ensigngroup.net/role/StandardBearer Standard Bearer Notes 14 false false R15.htm 2126108 - Disclosure - Business Segments Sheet http://www.ensigngroup.net/role/BusinessSegments Business Segments Notes 15 false false R16.htm 2131109 - Disclosure - Operation Expansions Sheet http://www.ensigngroup.net/role/OperationExpansions Operation Expansions Notes 16 false false R17.htm 2133110 - Disclosure - Property and Equipment ??? Net Sheet http://www.ensigngroup.net/role/PropertyandEquipmentNet Property and Equipment ??? Net Notes 17 false false R18.htm 2137111 - Disclosure - Intangible Assets ??? Net Sheet http://www.ensigngroup.net/role/IntangibleAssetsNet Intangible Assets ??? Net Notes 18 false false R19.htm 2142112 - Disclosure - Goodwill and Other Indefinite-Lived Intangible Assets Sheet http://www.ensigngroup.net/role/GoodwillandOtherIndefiniteLivedIntangibleAssets Goodwill and Other Indefinite-Lived Intangible Assets Notes 19 false false R20.htm 2146113 - Disclosure - Restricted and Other Assets Sheet http://www.ensigngroup.net/role/RestrictedandOtherAssets Restricted and Other Assets Notes 20 false false R21.htm 2150114 - Disclosure - Other Accrued Liabilities Sheet http://www.ensigngroup.net/role/OtherAccruedLiabilities Other Accrued Liabilities Notes 21 false false R22.htm 2153115 - Disclosure - Income Taxes Sheet http://www.ensigngroup.net/role/IncomeTaxes Income Taxes Notes 22 false false R23.htm 2155116 - Disclosure - Debt Sheet http://www.ensigngroup.net/role/Debt Debt Notes 23 false false R24.htm 2160117 - Disclosure - Options and Awards Sheet http://www.ensigngroup.net/role/OptionsandAwards Options and Awards Notes 24 false false R25.htm 2172118 - Disclosure - Leases Sheet http://www.ensigngroup.net/role/Leases Leases Notes 25 false false R26.htm 2180119 - Disclosure - Commitments and Contingencies Sheet http://www.ensigngroup.net/role/CommitmentsandContingencies Commitments and Contingencies Notes 26 false false R27.htm 2182120 - Disclosure - Common Stock Repurchase Program Sheet http://www.ensigngroup.net/role/CommonStockRepurchaseProgram Common Stock Repurchase Program Notes 27 false false R28.htm 2204201 - Disclosure - Summary of Significant Accounting Policies (Policies) Sheet http://www.ensigngroup.net/role/SummaryofSignificantAccountingPoliciesPolicies Summary of Significant Accounting Policies (Policies) Policies http://www.ensigngroup.net/role/SummaryofSignificantAccountingPolicies 28 false false R29.htm 2314301 - Disclosure - Revenue and Accounts Receivable (Tables) Sheet http://www.ensigngroup.net/role/RevenueandAccountsReceivableTables Revenue and Accounts Receivable (Tables) Tables http://www.ensigngroup.net/role/RevenueandAccountsReceivable 29 false false R30.htm 2319302 - Disclosure - Computation of Net Income Per Common Share (Tables) Sheet http://www.ensigngroup.net/role/ComputationofNetIncomePerCommonShareTables Computation of Net Income Per Common Share (Tables) Tables http://www.ensigngroup.net/role/ComputationofNetIncomePerCommonShare 30 false false R31.htm 2327303 - Disclosure - Business Segments (Tables) Sheet http://www.ensigngroup.net/role/BusinessSegmentsTables Business Segments (Tables) Tables http://www.ensigngroup.net/role/BusinessSegments 31 false false R32.htm 2334304 - Disclosure - Property and Equipment ??? Net (Tables) Sheet http://www.ensigngroup.net/role/PropertyandEquipmentNetTables Property and Equipment ??? Net (Tables) Tables http://www.ensigngroup.net/role/PropertyandEquipmentNet 32 false false R33.htm 2338305 - Disclosure - Intangible Assets ??? Net (Tables) Sheet http://www.ensigngroup.net/role/IntangibleAssetsNetTables Intangible Assets ??? Net (Tables) Tables http://www.ensigngroup.net/role/IntangibleAssetsNet 33 false false R34.htm 2343306 - Disclosure - Goodwill and Other Indefinite-Lived Intangible Assets (Tables) Sheet http://www.ensigngroup.net/role/GoodwillandOtherIndefiniteLivedIntangibleAssetsTables Goodwill and Other Indefinite-Lived Intangible Assets (Tables) Tables http://www.ensigngroup.net/role/GoodwillandOtherIndefiniteLivedIntangibleAssets 34 false false R35.htm 2347307 - Disclosure - Restricted and Other Assets (Tables) Sheet http://www.ensigngroup.net/role/RestrictedandOtherAssetsTables Restricted and Other Assets (Tables) Tables http://www.ensigngroup.net/role/RestrictedandOtherAssets 35 false false R36.htm 2351308 - Disclosure - Other Accrued Liabilities (Tables) Sheet http://www.ensigngroup.net/role/OtherAccruedLiabilitiesTables Other Accrued Liabilities (Tables) Tables http://www.ensigngroup.net/role/OtherAccruedLiabilities 36 false false R37.htm 2356309 - Disclosure - Debt (Tables) Sheet http://www.ensigngroup.net/role/DebtTables Debt (Tables) Tables http://www.ensigngroup.net/role/Debt 37 false false R38.htm 2361310 - Disclosure - Options and Awards (Tables) Sheet http://www.ensigngroup.net/role/OptionsandAwardsTables Options and Awards (Tables) Tables http://www.ensigngroup.net/role/OptionsandAwards 38 false false R39.htm 2373311 - Disclosure - Leases (Tables) Sheet http://www.ensigngroup.net/role/LeasesTables Leases (Tables) Tables http://www.ensigngroup.net/role/Leases 39 false false R40.htm 2402401 - Disclosure - Description of Business (Details) Sheet http://www.ensigngroup.net/role/DescriptionofBusinessDetails Description of Business (Details) Details http://www.ensigngroup.net/role/DescriptionofBusiness 40 false false R41.htm 2405402 - Disclosure - Summary of Significant Accounting Policies - Property and Equipment (Details) Sheet http://www.ensigngroup.net/role/SummaryofSignificantAccountingPoliciesPropertyandEquipmentDetails Summary of Significant Accounting Policies - Property and Equipment (Details) Details 41 false false R42.htm 2406403 - Disclosure - Summary of Significant Accounting Policies - Leases and Leasehold Improvements (Details) Sheet http://www.ensigngroup.net/role/SummaryofSignificantAccountingPoliciesLeasesandLeaseholdImprovementsDetails Summary of Significant Accounting Policies - Leases and Leasehold Improvements (Details) Details 42 false false R43.htm 2407404 - Disclosure - Summary of Significant Accounting Policies - Impairment of Long-Lived Assets (Details) Sheet http://www.ensigngroup.net/role/SummaryofSignificantAccountingPoliciesImpairmentofLongLivedAssetsDetails Summary of Significant Accounting Policies - Impairment of Long-Lived Assets (Details) Details 43 false false R44.htm 2408405 - Disclosure - Summary of Significant Accounting Policies - Intangible Assets and Goodwill (Details) Sheet http://www.ensigngroup.net/role/SummaryofSignificantAccountingPoliciesIntangibleAssetsandGoodwillDetails Summary of Significant Accounting Policies - Intangible Assets and Goodwill (Details) Details 44 false false R45.htm 2409406 - Disclosure - Summary of Significant Accounting Policies - Self-Insurance (Details) Sheet http://www.ensigngroup.net/role/SummaryofSignificantAccountingPoliciesSelfInsuranceDetails Summary of Significant Accounting Policies - Self-Insurance (Details) Details 45 false false R46.htm 2410407 - Disclosure - Summary of Significant Accounting Policies - Recent Accounting Pronouncements (Details) Sheet http://www.ensigngroup.net/role/SummaryofSignificantAccountingPoliciesRecentAccountingPronouncementsDetails Summary of Significant Accounting Policies - Recent Accounting Pronouncements (Details) Details 46 false false R47.htm 2412408 - Disclosure - COVID-19 Update (Details) Sheet http://www.ensigngroup.net/role/COVID19UpdateDetails COVID-19 Update (Details) Details http://www.ensigngroup.net/role/COVID19Update 47 false false R48.htm 2415409 - Disclosure - Revenue and Accounts Receivable - Revenue from Medicare and Medicaid Programs (Details) Sheet http://www.ensigngroup.net/role/RevenueandAccountsReceivableRevenuefromMedicareandMedicaidProgramsDetails Revenue and Accounts Receivable - Revenue from Medicare and Medicaid Programs (Details) Details 48 false false R49.htm 2416410 - Disclosure - Revenue and Accounts Receivable - Disaggregation of Revenue (Details) Sheet http://www.ensigngroup.net/role/RevenueandAccountsReceivableDisaggregationofRevenueDetails Revenue and Accounts Receivable - Disaggregation of Revenue (Details) Details 49 false false R50.htm 2417411 - Disclosure - Revenue and Accounts Receivable - Accounts Receivable (Details) Sheet http://www.ensigngroup.net/role/RevenueandAccountsReceivableAccountsReceivableDetails Revenue and Accounts Receivable - Accounts Receivable (Details) Details 50 false false R51.htm 2420412 - Disclosure - Computation of Net Income Per Common Share (Details) Sheet http://www.ensigngroup.net/role/ComputationofNetIncomePerCommonShareDetails Computation of Net Income Per Common Share (Details) Details http://www.ensigngroup.net/role/ComputationofNetIncomePerCommonShareTables 51 false false R52.htm 2422413 - Disclosure - Fair Value Measurements - Schedule of Fair Value, of Assets and Liabilities Measured on Recurring Basis (Details) Sheet http://www.ensigngroup.net/role/FairValueMeasurementsScheduleofFairValueofAssetsandLiabilitiesMeasuredonRecurringBasisDetails Fair Value Measurements - Schedule of Fair Value, of Assets and Liabilities Measured on Recurring Basis (Details) Details 52 false false R53.htm 2423414 - Disclosure - Fair Value Measurements - Investments (Details) Sheet http://www.ensigngroup.net/role/FairValueMeasurementsInvestmentsDetails Fair Value Measurements - Investments (Details) Details 53 false false R54.htm 2425415 - Disclosure - Standard Bearer (Details) Sheet http://www.ensigngroup.net/role/StandardBearerDetails Standard Bearer (Details) Details http://www.ensigngroup.net/role/StandardBearer 54 false false R55.htm 2428416 - Disclosure - Business Segments - Narrative (Details) Sheet http://www.ensigngroup.net/role/BusinessSegmentsNarrativeDetails Business Segments - Narrative (Details) Details 55 false false R56.htm 2429417 - Disclosure - Business Segments - Schedule of Segment Reporting Information, by Segment (Details) Sheet http://www.ensigngroup.net/role/BusinessSegmentsScheduleofSegmentReportingInformationbySegmentDetails Business Segments - Schedule of Segment Reporting Information, by Segment (Details) Details 56 false false R57.htm 2430418 - Disclosure - Business Segments - Revenue by Segment (Details) Sheet http://www.ensigngroup.net/role/BusinessSegmentsRevenuebySegmentDetails Business Segments - Revenue by Segment (Details) Details 57 false false R58.htm 2432419 - Disclosure - Operation Expansions (Details) Sheet http://www.ensigngroup.net/role/OperationExpansionsDetails Operation Expansions (Details) Details http://www.ensigngroup.net/role/OperationExpansions 58 false false R59.htm 2435420 - Disclosure - Property and Equipment ??? Net (Details) Sheet http://www.ensigngroup.net/role/PropertyandEquipmentNetDetails Property and Equipment ??? Net (Details) Details http://www.ensigngroup.net/role/PropertyandEquipmentNetTables 59 false false R60.htm 2436421 - Disclosure - Property and Equipment ??? Net - Narrative (Details) Sheet http://www.ensigngroup.net/role/PropertyandEquipmentNetNarrativeDetails Property and Equipment ??? Net - Narrative (Details) Details 60 false false R61.htm 2439422 - Disclosure - Intangible Assets ??? Net - Schedule of Finite Lived Intangible Assets (Details) Sheet http://www.ensigngroup.net/role/IntangibleAssetsNetScheduleofFiniteLivedIntangibleAssetsDetails Intangible Assets ??? Net - Schedule of Finite Lived Intangible Assets (Details) Details 61 false false R62.htm 2440423 - Disclosure - Intangible Assets ??? Net - Narrative (Details) Sheet http://www.ensigngroup.net/role/IntangibleAssetsNetNarrativeDetails Intangible Assets ??? Net - Narrative (Details) Details 62 false false R63.htm 2441424 - Disclosure - Intangible Assets ??? Net - Future Amortization (Details) Sheet http://www.ensigngroup.net/role/IntangibleAssetsNetFutureAmortizationDetails Intangible Assets ??? Net - Future Amortization (Details) Details 63 false false R64.htm 2444425 - Disclosure - Goodwill and Other Indefinite-Lived Intangible Assets - Goodwill Rollforward (Details) Sheet http://www.ensigngroup.net/role/GoodwillandOtherIndefiniteLivedIntangibleAssetsGoodwillRollforwardDetails Goodwill and Other Indefinite-Lived Intangible Assets - Goodwill Rollforward (Details) Details 64 false false R65.htm 2445426 - Disclosure - Goodwill and Other Indefinite-Lived Intangible Assets - Indefinite-Lived Intangible Assets (Details) Sheet http://www.ensigngroup.net/role/GoodwillandOtherIndefiniteLivedIntangibleAssetsIndefiniteLivedIntangibleAssetsDetails Goodwill and Other Indefinite-Lived Intangible Assets - Indefinite-Lived Intangible Assets (Details) Details 65 false false R66.htm 2448427 - Disclosure - Restricted and Other Assets (Details) Sheet http://www.ensigngroup.net/role/RestrictedandOtherAssetsDetails Restricted and Other Assets (Details) Details http://www.ensigngroup.net/role/RestrictedandOtherAssetsTables 66 false false R67.htm 2449428 - Disclosure - Restricted and Other Assets - Narrative (Details) Sheet http://www.ensigngroup.net/role/RestrictedandOtherAssetsNarrativeDetails Restricted and Other Assets - Narrative (Details) Details 67 false false R68.htm 2452429 - Disclosure - Other Accrued Liabilities (Details) Sheet http://www.ensigngroup.net/role/OtherAccruedLiabilitiesDetails Other Accrued Liabilities (Details) Details http://www.ensigngroup.net/role/OtherAccruedLiabilitiesTables 68 false false R69.htm 2454430 - Disclosure - Income Taxes - Narrative (Details) Sheet http://www.ensigngroup.net/role/IncomeTaxesNarrativeDetails Income Taxes - Narrative (Details) Details 69 false false R70.htm 2457431 - Disclosure - Debt - Schedule of Long-term Debt (Details) Sheet http://www.ensigngroup.net/role/DebtScheduleofLongtermDebtDetails Debt - Schedule of Long-term Debt (Details) Details 70 false false R71.htm 2458432 - Disclosure - Debt - Credit Facility with a Lending Consortium Arranged by SunTrust (Details) Sheet http://www.ensigngroup.net/role/DebtCreditFacilitywithaLendingConsortiumArrangedbySunTrustDetails Debt - Credit Facility with a Lending Consortium Arranged by SunTrust (Details) Details 71 false false R72.htm 2459433 - Disclosure - Debt - Mortgage Loans and Promissory Notes and Off-Balance Sheet Arrangements (Details) Notes http://www.ensigngroup.net/role/DebtMortgageLoansandPromissoryNotesandOffBalanceSheetArrangementsDetails Debt - Mortgage Loans and Promissory Notes and Off-Balance Sheet Arrangements (Details) Details 72 false false R73.htm 2462434 - Disclosure - Options and Awards - Stock Options, Narrative (Details) Sheet http://www.ensigngroup.net/role/OptionsandAwardsStockOptionsNarrativeDetails Options and Awards - Stock Options, Narrative (Details) Details 73 false false R74.htm 2463435 - Disclosure - Options and Awards - Valuation Assumptions (Details) Sheet http://www.ensigngroup.net/role/OptionsandAwardsValuationAssumptionsDetails Options and Awards - Valuation Assumptions (Details) Details 74 false false R75.htm 2464436 - Disclosure - Options and Awards - Exercise Price and Fair Value (Details) Sheet http://www.ensigngroup.net/role/OptionsandAwardsExercisePriceandFairValueDetails Options and Awards - Exercise Price and Fair Value (Details) Details 75 false false R76.htm 2465437 - Disclosure - Options and Awards - Options Outstanding Rollforward (Details) Sheet http://www.ensigngroup.net/role/OptionsandAwardsOptionsOutstandingRollforwardDetails Options and Awards - Options Outstanding Rollforward (Details) Details 76 false false R77.htm 2466438 - Disclosure - Options and Awards - Options Outstanding by Exercise Price (Details) Sheet http://www.ensigngroup.net/role/OptionsandAwardsOptionsOutstandingbyExercisePriceDetails Options and Awards - Options Outstanding by Exercise Price (Details) Details 77 false false R78.htm 2467439 - Disclosure - Options and Awards - Intrinsic Values (Details) Sheet http://www.ensigngroup.net/role/OptionsandAwardsIntrinsicValuesDetails Options and Awards - Intrinsic Values (Details) Details 78 false false R79.htm 2468440 - Disclosure - Options and Awards - Restricted Stock Awards, Narrative (Details) Sheet http://www.ensigngroup.net/role/OptionsandAwardsRestrictedStockAwardsNarrativeDetails Options and Awards - Restricted Stock Awards, Narrative (Details) Details 79 false false R80.htm 2469441 - Disclosure - Options and Awards - Restricted Award Rollforward (Details) Sheet http://www.ensigngroup.net/role/OptionsandAwardsRestrictedAwardRollforwardDetails Options and Awards - Restricted Award Rollforward (Details) Details 80 false false R81.htm 2470442 - Disclosure - Options and Awards - Long-Term Incentive Plan (Details) Sheet http://www.ensigngroup.net/role/OptionsandAwardsLongTermIncentivePlanDetails Options and Awards - Long-Term Incentive Plan (Details) Details 81 false false R82.htm 2471443 - Disclosure - Options and Awards - Compensation Expense (Details) Sheet http://www.ensigngroup.net/role/OptionsandAwardsCompensationExpenseDetails Options and Awards - Compensation Expense (Details) Details 82 false false R83.htm 2474444 - Disclosure - Leases - Lessee Narrative (Details) Sheet http://www.ensigngroup.net/role/LeasesLesseeNarrativeDetails Leases - Lessee Narrative (Details) Details 83 false false R84.htm 2475445 - Disclosure - Leases - Lessee Lease Cost (Details) Sheet http://www.ensigngroup.net/role/LeasesLesseeLeaseCostDetails Leases - Lessee Lease Cost (Details) Details 84 false false R85.htm 2476446 - Disclosure - Leases - Lessee Future Minimum Lease Payments (Details) Sheet http://www.ensigngroup.net/role/LeasesLesseeFutureMinimumLeasePaymentsDetails Leases - Lessee Future Minimum Lease Payments (Details) Details 85 false false R86.htm 2477447 - Disclosure - Leases - Lessor Narrative (Details) Sheet http://www.ensigngroup.net/role/LeasesLessorNarrativeDetails Leases - Lessor Narrative (Details) Details 86 false false R87.htm 2478448 - Disclosure - Leases - Lessor Rental Income (Details) Sheet http://www.ensigngroup.net/role/LeasesLessorRentalIncomeDetails Leases - Lessor Rental Income (Details) Details 87 false false R88.htm 2479449 - Disclosure - Leases - Lessor Future Minimum Lease Payments Receivable (Details) Sheet http://www.ensigngroup.net/role/LeasesLessorFutureMinimumLeasePaymentsReceivableDetails Leases - Lessor Future Minimum Lease Payments Receivable (Details) Details 88 false false R89.htm 2481450 - Disclosure - Commitments and Contingencies (Details) Sheet http://www.ensigngroup.net/role/CommitmentsandContingenciesDetails Commitments and Contingencies (Details) Details http://www.ensigngroup.net/role/CommitmentsandContingencies 89 false false R90.htm 2483451 - Disclosure - Common Stock Repurchase Program (Details) Sheet http://www.ensigngroup.net/role/CommonStockRepurchaseProgramDetails Common Stock Repurchase Program (Details) Details http://www.ensigngroup.net/role/CommonStockRepurchaseProgram 90 false false All Reports Book All Reports ensg-20220630.htm ensg-20220630.xsd ensg-20220630_cal.xml ensg-20220630_def.xml ensg-20220630_lab.xml ensg-20220630_pre.xml ensgq22022ex311.htm ensgq22022ex312.htm ensgq22022ex321.htm ensgq22022ex322.htm ensg-20220630_g1.jpg http://fasb.org/us-gaap/2022 http://xbrl.sec.gov/dei/2022 true true JSON 109 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "ensg-20220630.htm": { "axisCustom": 4, "axisStandard": 37, "contextCount": 487, "dts": { "calculationLink": { "local": [ "ensg-20220630_cal.xml" ] }, "definitionLink": { "local": [ "ensg-20220630_def.xml" ] }, "inline": { "local": [ "ensg-20220630.htm" ] }, "labelLink": { "local": [ "ensg-20220630_lab.xml" ] }, "presentationLink": { "local": [ "ensg-20220630_pre.xml" ] }, "schema": { "local": [ "ensg-20220630.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd", "https://xbrl.sec.gov/country/2022/country-2022.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd", "https://xbrl.sec.gov/naics/2022/naics-2022.xsd", "https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd" ] } }, "elementCount": 715, "entityCount": 1, "hidden": { "http://fasb.org/us-gaap/2022": 5, "http://www.ensigngroup.net/20220630": 3, "http://xbrl.sec.gov/dei/2022": 5, "total": 13 }, "keyCustom": 70, "keyStandard": 343, "memberCustom": 70, "memberStandard": 52, "nsprefix": "ensg", "nsuri": "http://www.ensigngroup.net/20220630", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ensg-20220630.htm", "contextRef": "i3cb824adc37b4eae96c4309acc277bcb_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "0001001 - Document - Cover Page", "role": "http://www.ensigngroup.net/role/CoverPage", "shortName": "Cover Page", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ensg-20220630.htm", "contextRef": "i3cb824adc37b4eae96c4309acc277bcb_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ensg-20220630.htm", "contextRef": "i3cb824adc37b4eae96c4309acc277bcb_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:UnusualOrInfrequentItemsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2111103 - Disclosure - COVID-19 Update", "role": "http://www.ensigngroup.net/role/COVID19Update", "shortName": "COVID-19 Update", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ensg-20220630.htm", "contextRef": "i3cb824adc37b4eae96c4309acc277bcb_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:UnusualOrInfrequentItemsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ensg-20220630.htm", "contextRef": "i3cb824adc37b4eae96c4309acc277bcb_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2113104 - Disclosure - Revenue and Accounts Receivable", "role": "http://www.ensigngroup.net/role/RevenueandAccountsReceivable", "shortName": "Revenue and Accounts Receivable", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ensg-20220630.htm", "contextRef": "i3cb824adc37b4eae96c4309acc277bcb_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ensg-20220630.htm", "contextRef": "i3cb824adc37b4eae96c4309acc277bcb_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2118105 - Disclosure - Computation of Net Income Per Common Share", "role": "http://www.ensigngroup.net/role/ComputationofNetIncomePerCommonShare", "shortName": "Computation of Net Income Per Common Share", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ensg-20220630.htm", "contextRef": "i3cb824adc37b4eae96c4309acc277bcb_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ensg-20220630.htm", "contextRef": "i3cb824adc37b4eae96c4309acc277bcb_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2121106 - Disclosure - Fair Value Measurements", "role": "http://www.ensigngroup.net/role/FairValueMeasurements", "shortName": "Fair Value Measurements", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ensg-20220630.htm", "contextRef": "i3cb824adc37b4eae96c4309acc277bcb_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ensg-20220630.htm", "contextRef": "i3cb824adc37b4eae96c4309acc277bcb_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "ensg:StandardBearerTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2124107 - Disclosure - Standard Bearer", "role": "http://www.ensigngroup.net/role/StandardBearer", "shortName": "Standard Bearer", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ensg-20220630.htm", "contextRef": "i3cb824adc37b4eae96c4309acc277bcb_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "ensg:StandardBearerTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ensg-20220630.htm", "contextRef": "i3cb824adc37b4eae96c4309acc277bcb_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2126108 - Disclosure - Business Segments", "role": "http://www.ensigngroup.net/role/BusinessSegments", "shortName": "Business Segments", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ensg-20220630.htm", "contextRef": "i3cb824adc37b4eae96c4309acc277bcb_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ensg-20220630.htm", "contextRef": "i3cb824adc37b4eae96c4309acc277bcb_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BusinessCombinationDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2131109 - Disclosure - Operation Expansions", "role": "http://www.ensigngroup.net/role/OperationExpansions", "shortName": "Operation Expansions", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ensg-20220630.htm", "contextRef": "i3cb824adc37b4eae96c4309acc277bcb_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BusinessCombinationDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ensg-20220630.htm", "contextRef": "i3cb824adc37b4eae96c4309acc277bcb_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2133110 - Disclosure - Property and Equipment \u2014 Net", "role": "http://www.ensigngroup.net/role/PropertyandEquipmentNet", "shortName": "Property and Equipment \u2014 Net", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ensg-20220630.htm", "contextRef": "i3cb824adc37b4eae96c4309acc277bcb_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ensg-20220630.htm", "contextRef": "i3cb824adc37b4eae96c4309acc277bcb_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IntangibleAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2137111 - Disclosure - Intangible Assets \u2014 Net", "role": "http://www.ensigngroup.net/role/IntangibleAssetsNet", "shortName": "Intangible Assets \u2014 Net", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ensg-20220630.htm", "contextRef": "i3cb824adc37b4eae96c4309acc277bcb_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IntangibleAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ensg-20220630.htm", "contextRef": "i3cb824adc37b4eae96c4309acc277bcb_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2142112 - Disclosure - Goodwill and Other Indefinite-Lived Intangible Assets", "role": "http://www.ensigngroup.net/role/GoodwillandOtherIndefiniteLivedIntangibleAssets", "shortName": "Goodwill and Other Indefinite-Lived Intangible Assets", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ensg-20220630.htm", "contextRef": "i3cb824adc37b4eae96c4309acc277bcb_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "ensg-20220630.htm", "contextRef": "i83961bfae89a426da695eba2aaf791c2_I20220630", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1001002 - Statement - UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS", "role": "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS", "shortName": "UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "ensg-20220630.htm", "contextRef": "i83961bfae89a426da695eba2aaf791c2_I20220630", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ensg-20220630.htm", "contextRef": "i3cb824adc37b4eae96c4309acc277bcb_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OtherAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2146113 - Disclosure - Restricted and Other Assets", "role": "http://www.ensigngroup.net/role/RestrictedandOtherAssets", "shortName": "Restricted and Other Assets", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ensg-20220630.htm", "contextRef": "i3cb824adc37b4eae96c4309acc277bcb_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OtherAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ensg-20220630.htm", "contextRef": "i3cb824adc37b4eae96c4309acc277bcb_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2150114 - Disclosure - Other Accrued Liabilities", "role": "http://www.ensigngroup.net/role/OtherAccruedLiabilities", "shortName": "Other Accrued Liabilities", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ensg-20220630.htm", "contextRef": "i3cb824adc37b4eae96c4309acc277bcb_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ensg-20220630.htm", "contextRef": "i3cb824adc37b4eae96c4309acc277bcb_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2153115 - Disclosure - Income Taxes", "role": "http://www.ensigngroup.net/role/IncomeTaxes", "shortName": "Income Taxes", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ensg-20220630.htm", "contextRef": "i3cb824adc37b4eae96c4309acc277bcb_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ensg-20220630.htm", "contextRef": "i3cb824adc37b4eae96c4309acc277bcb_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2155116 - Disclosure - Debt", "role": "http://www.ensigngroup.net/role/Debt", "shortName": "Debt", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ensg-20220630.htm", "contextRef": "i3cb824adc37b4eae96c4309acc277bcb_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ensg-20220630.htm", "contextRef": "i3cb824adc37b4eae96c4309acc277bcb_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2160117 - Disclosure - Options and Awards", "role": "http://www.ensigngroup.net/role/OptionsandAwards", "shortName": "Options and Awards", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ensg-20220630.htm", "contextRef": "i3cb824adc37b4eae96c4309acc277bcb_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "us-gaap:LesseeOperatingLeasesTextBlock", "span", "div", "body", "html" ], "baseRef": "ensg-20220630.htm", "contextRef": "i3cb824adc37b4eae96c4309acc277bcb_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OperatingLeasesOfLessorDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2172118 - Disclosure - Leases", "role": "http://www.ensigngroup.net/role/Leases", "shortName": "Leases", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "us-gaap:LesseeOperatingLeasesTextBlock", "span", "div", "body", "html" ], "baseRef": "ensg-20220630.htm", "contextRef": "i3cb824adc37b4eae96c4309acc277bcb_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OperatingLeasesOfLessorDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ensg-20220630.htm", "contextRef": "i3cb824adc37b4eae96c4309acc277bcb_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2180119 - Disclosure - Commitments and Contingencies", "role": "http://www.ensigngroup.net/role/CommitmentsandContingencies", "shortName": "Commitments and Contingencies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ensg-20220630.htm", "contextRef": "i3cb824adc37b4eae96c4309acc277bcb_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ensg-20220630.htm", "contextRef": "i3cb824adc37b4eae96c4309acc277bcb_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2182120 - Disclosure - Common Stock Repurchase Program", "role": "http://www.ensigngroup.net/role/CommonStockRepurchaseProgram", "shortName": "Common Stock Repurchase Program", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ensg-20220630.htm", "contextRef": "i3cb824adc37b4eae96c4309acc277bcb_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "ensg-20220630.htm", "contextRef": "i3cb824adc37b4eae96c4309acc277bcb_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2204201 - Disclosure - Summary of Significant Accounting Policies (Policies)", "role": "http://www.ensigngroup.net/role/SummaryofSignificantAccountingPoliciesPolicies", "shortName": "Summary of Significant Accounting Policies (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "ensg-20220630.htm", "contextRef": "i3cb824adc37b4eae96c4309acc277bcb_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "ensg-20220630.htm", "contextRef": "i3cb824adc37b4eae96c4309acc277bcb_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisaggregationOfRevenueTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2314301 - Disclosure - Revenue and Accounts Receivable (Tables)", "role": "http://www.ensigngroup.net/role/RevenueandAccountsReceivableTables", "shortName": "Revenue and Accounts Receivable (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "ensg-20220630.htm", "contextRef": "i3cb824adc37b4eae96c4309acc277bcb_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisaggregationOfRevenueTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "ensg-20220630.htm", "contextRef": "i83961bfae89a426da695eba2aaf791c2_I20220630", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1002003 - Statement - UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)", "role": "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical", "shortName": "UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "us-gaap:CommonStockParOrStatedValuePerShare", "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "ensg-20220630.htm", "contextRef": "i83961bfae89a426da695eba2aaf791c2_I20220630", "decimals": "INF", "lang": "en-US", "name": "us-gaap:CommonStockParOrStatedValuePerShare", "reportCount": 1, "unique": true, "unitRef": "usdPerShare", "xsiNil": "false" } }, "R30": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "ensg-20220630.htm", "contextRef": "i3cb824adc37b4eae96c4309acc277bcb_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicByCommonClassTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2319302 - Disclosure - Computation of Net Income Per Common Share (Tables)", "role": "http://www.ensigngroup.net/role/ComputationofNetIncomePerCommonShareTables", "shortName": "Computation of Net Income Per Common Share (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "ensg-20220630.htm", "contextRef": "i3cb824adc37b4eae96c4309acc277bcb_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicByCommonClassTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "ensg-20220630.htm", "contextRef": "i3cb824adc37b4eae96c4309acc277bcb_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2327303 - Disclosure - Business Segments (Tables)", "role": "http://www.ensigngroup.net/role/BusinessSegmentsTables", "shortName": "Business Segments (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "ensg-20220630.htm", "contextRef": "i3cb824adc37b4eae96c4309acc277bcb_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "div", "ix:continuation", "body", "html" ], "baseRef": "ensg-20220630.htm", "contextRef": "i3cb824adc37b4eae96c4309acc277bcb_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2334304 - Disclosure - Property and Equipment \u2014 Net (Tables)", "role": "http://www.ensigngroup.net/role/PropertyandEquipmentNetTables", "shortName": "Property and Equipment \u2014 Net (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "ix:continuation", "body", "html" ], "baseRef": "ensg-20220630.htm", "contextRef": "i3cb824adc37b4eae96c4309acc277bcb_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "div", "ix:continuation", "body", "html" ], "baseRef": "ensg-20220630.htm", "contextRef": "i3cb824adc37b4eae96c4309acc277bcb_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2338305 - Disclosure - Intangible Assets \u2014 Net (Tables)", "role": "http://www.ensigngroup.net/role/IntangibleAssetsNetTables", "shortName": "Intangible Assets \u2014 Net (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "ix:continuation", "body", "html" ], "baseRef": "ensg-20220630.htm", "contextRef": "i3cb824adc37b4eae96c4309acc277bcb_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "ensg-20220630.htm", "contextRef": "i3cb824adc37b4eae96c4309acc277bcb_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfGoodwillTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2343306 - Disclosure - Goodwill and Other Indefinite-Lived Intangible Assets (Tables)", "role": "http://www.ensigngroup.net/role/GoodwillandOtherIndefiniteLivedIntangibleAssetsTables", "shortName": "Goodwill and Other Indefinite-Lived Intangible Assets (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "ensg-20220630.htm", "contextRef": "i3cb824adc37b4eae96c4309acc277bcb_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfGoodwillTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "div", "ix:continuation", "body", "html" ], "baseRef": "ensg-20220630.htm", "contextRef": "i3cb824adc37b4eae96c4309acc277bcb_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfOtherAssetsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2347307 - Disclosure - Restricted and Other Assets (Tables)", "role": "http://www.ensigngroup.net/role/RestrictedandOtherAssetsTables", "shortName": "Restricted and Other Assets (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "ix:continuation", "body", "html" ], "baseRef": "ensg-20220630.htm", "contextRef": "i3cb824adc37b4eae96c4309acc277bcb_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfOtherAssetsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R36": { "firstAnchor": { "ancestors": [ "div", "ix:continuation", "body", "html" ], "baseRef": "ensg-20220630.htm", "contextRef": "i3cb824adc37b4eae96c4309acc277bcb_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2351308 - Disclosure - Other Accrued Liabilities (Tables)", "role": "http://www.ensigngroup.net/role/OtherAccruedLiabilitiesTables", "shortName": "Other Accrued Liabilities (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "ix:continuation", "body", "html" ], "baseRef": "ensg-20220630.htm", "contextRef": "i3cb824adc37b4eae96c4309acc277bcb_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R37": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "ensg-20220630.htm", "contextRef": "i3cb824adc37b4eae96c4309acc277bcb_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2356309 - Disclosure - Debt (Tables)", "role": "http://www.ensigngroup.net/role/DebtTables", "shortName": "Debt (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "ensg-20220630.htm", "contextRef": "i3cb824adc37b4eae96c4309acc277bcb_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R38": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "ensg-20220630.htm", "contextRef": "i3cb824adc37b4eae96c4309acc277bcb_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2361310 - Disclosure - Options and Awards (Tables)", "role": "http://www.ensigngroup.net/role/OptionsandAwardsTables", "shortName": "Options and Awards (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "ensg-20220630.htm", "contextRef": "i3cb824adc37b4eae96c4309acc277bcb_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R39": { "firstAnchor": { "ancestors": [ "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "ensg-20220630.htm", "contextRef": "i3cb824adc37b4eae96c4309acc277bcb_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LeaseCostTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2373311 - Disclosure - Leases (Tables)", "role": "http://www.ensigngroup.net/role/LeasesTables", "shortName": "Leases (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "ensg-20220630.htm", "contextRef": "i3cb824adc37b4eae96c4309acc277bcb_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LeaseCostTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "ensg-20220630.htm", "contextRef": "i2d4f1f58b2004ae3aa227577e5611584_D20220401-20220630", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1003004 - Statement - UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF INCOME", "role": "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME", "shortName": "UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF INCOME", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "ensg-20220630.htm", "contextRef": "i2d4f1f58b2004ae3aa227577e5611584_D20220401-20220630", "decimals": "-3", "lang": "en-US", "name": "us-gaap:CostOfGoodsAndServicesSold", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R40": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "ensg-20220630.htm", "contextRef": "i83961bfae89a426da695eba2aaf791c2_I20220630", "decimals": "0", "first": true, "lang": "en-US", "name": "ensg:NumberOfHealthCareFacilities", "reportCount": 1, "unique": true, "unitRef": "facility", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2402401 - Disclosure - Description of Business (Details)", "role": "http://www.ensigngroup.net/role/DescriptionofBusinessDetails", "shortName": "Description of Business (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "ensg-20220630.htm", "contextRef": "i83961bfae89a426da695eba2aaf791c2_I20220630", "decimals": "0", "first": true, "lang": "en-US", "name": "ensg:NumberOfHealthCareFacilities", "reportCount": 1, "unique": true, "unitRef": "facility", "xsiNil": "false" } }, "R41": { "firstAnchor": { "ancestors": [ "ix:continuation", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "ensg-20220630.htm", "contextRef": "i7e34082b0e674b5993fb91623644eaa5_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2405402 - Disclosure - Summary of Significant Accounting Policies - Property and Equipment (Details)", "role": "http://www.ensigngroup.net/role/SummaryofSignificantAccountingPoliciesPropertyandEquipmentDetails", "shortName": "Summary of Significant Accounting Policies - Property and Equipment (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "ix:continuation", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "ensg-20220630.htm", "contextRef": "i7e34082b0e674b5993fb91623644eaa5_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R42": { "firstAnchor": { "ancestors": [ "ix:continuation", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "ensg-20220630.htm", "contextRef": "i83961bfae89a426da695eba2aaf791c2_I20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeaseTermOfContract", "reportCount": 1, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2406403 - Disclosure - Summary of Significant Accounting Policies - Leases and Leasehold Improvements (Details)", "role": "http://www.ensigngroup.net/role/SummaryofSignificantAccountingPoliciesLeasesandLeaseholdImprovementsDetails", "shortName": "Summary of Significant Accounting Policies - Leases and Leasehold Improvements (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R43": { "firstAnchor": { "ancestors": [ "us-gaap:ImpairmentOfLongLivedAssetsHeldForUse", "us-gaap:ImpairmentOfLongLivedAssetsHeldForUse", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "ensg-20220630.htm", "contextRef": "i2d4f1f58b2004ae3aa227577e5611584_D20220401-20220630", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:ImpairmentOfLongLivedAssetsHeldForUse", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2407404 - Disclosure - Summary of Significant Accounting Policies - Impairment of Long-Lived Assets (Details)", "role": "http://www.ensigngroup.net/role/SummaryofSignificantAccountingPoliciesImpairmentofLongLivedAssetsDetails", "shortName": "Summary of Significant Accounting Policies - Impairment of Long-Lived Assets (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "us-gaap:ImpairmentOfLongLivedAssetsHeldForUse", "us-gaap:ImpairmentOfLongLivedAssetsHeldForUse", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "ensg-20220630.htm", "contextRef": "i2d4f1f58b2004ae3aa227577e5611584_D20220401-20220630", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:ImpairmentOfLongLivedAssetsHeldForUse", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R44": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "ensg-20220630.htm", "contextRef": "i2d4f1f58b2004ae3aa227577e5611584_D20220401-20220630", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:GoodwillAndIntangibleAssetImpairment", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2408405 - Disclosure - Summary of Significant Accounting Policies - Intangible Assets and Goodwill (Details)", "role": "http://www.ensigngroup.net/role/SummaryofSignificantAccountingPoliciesIntangibleAssetsandGoodwillDetails", "shortName": "Summary of Significant Accounting Policies - Intangible Assets and Goodwill (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "ensg-20220630.htm", "contextRef": "i2d4f1f58b2004ae3aa227577e5611584_D20220401-20220630", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:GoodwillAndIntangibleAssetImpairment", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R45": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "ensg-20220630.htm", "contextRef": "i83961bfae89a426da695eba2aaf791c2_I20220630", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:EstimatedInsuranceRecoveries", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2409406 - Disclosure - Summary of Significant Accounting Policies - Self-Insurance (Details)", "role": "http://www.ensigngroup.net/role/SummaryofSignificantAccountingPoliciesSelfInsuranceDetails", "shortName": "Summary of Significant Accounting Policies - Self-Insurance (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "ensg-20220630.htm", "contextRef": "ibd3dfa92672c4366ad947e29749807ab_I20220630", "decimals": "-3", "lang": "en-US", "name": "us-gaap:MalpracticeLossContingencyAccrualUndiscounted", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R46": { "firstAnchor": { "ancestors": [ "ix:continuation", "ix:continuation", "span", "div", "body", "html" ], "baseRef": "ensg-20220630.htm", "contextRef": "i13205ebf8b0e41249d01b4dce028a7fc_D20220401-20220630", "decimals": "-4", "first": true, "lang": "en-US", "name": "us-gaap:LineOfCreditFacilityIncreaseDecreaseForPeriodNet", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2410407 - Disclosure - Summary of Significant Accounting Policies - Recent Accounting Pronouncements (Details)", "role": "http://www.ensigngroup.net/role/SummaryofSignificantAccountingPoliciesRecentAccountingPronouncementsDetails", "shortName": "Summary of Significant Accounting Policies - Recent Accounting Pronouncements (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "ix:continuation", "ix:continuation", "span", "div", "body", "html" ], "baseRef": "ensg-20220630.htm", "contextRef": "i13205ebf8b0e41249d01b4dce028a7fc_D20220401-20220630", "decimals": "-4", "first": true, "lang": "en-US", "name": "us-gaap:LineOfCreditFacilityIncreaseDecreaseForPeriodNet", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R47": { "firstAnchor": { "ancestors": [ "ensg:CoronavirusAidReliefAndEconomicSecurityCARESFundsReceivedAndReturned", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "ensg-20220630.htm", "contextRef": "i2d4f1f58b2004ae3aa227577e5611584_D20220401-20220630", "decimals": "-3", "first": true, "lang": "en-US", "name": "ensg:CoronavirusAidReliefAndEconomicSecurityCARESFundsReceivedAndReturned", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2412408 - Disclosure - COVID-19 Update (Details)", "role": "http://www.ensigngroup.net/role/COVID19UpdateDetails", "shortName": "COVID-19 Update (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "ensg:CoronavirusAidReliefAndEconomicSecurityCARESFundsReceivedAndReturned", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "ensg-20220630.htm", "contextRef": "i2d4f1f58b2004ae3aa227577e5611584_D20220401-20220630", "decimals": "-3", "first": true, "lang": "en-US", "name": "ensg:CoronavirusAidReliefAndEconomicSecurityCARESFundsReceivedAndReturned", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R48": { "firstAnchor": { "ancestors": [ "us-gaap:ConcentrationRiskPercentage1", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "ensg-20220630.htm", "contextRef": "ic5b54ba611d44958beb34cadbf38abb2_D20220401-20220630", "decimals": "3", "first": true, "lang": "en-US", "name": "us-gaap:ConcentrationRiskPercentage1", "reportCount": 1, "unitRef": "number", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2415409 - Disclosure - Revenue and Accounts Receivable - Revenue from Medicare and Medicaid Programs (Details)", "role": "http://www.ensigngroup.net/role/RevenueandAccountsReceivableRevenuefromMedicareandMedicaidProgramsDetails", "shortName": "Revenue and Accounts Receivable - Revenue from Medicare and Medicaid Programs (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R49": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "ensg-20220630.htm", "contextRef": "i2d4f1f58b2004ae3aa227577e5611584_D20220401-20220630", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2416410 - Disclosure - Revenue and Accounts Receivable - Disaggregation of Revenue (Details)", "role": "http://www.ensigngroup.net/role/RevenueandAccountsReceivableDisaggregationofRevenueDetails", "shortName": "Revenue and Accounts Receivable - Disaggregation of Revenue (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R5": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "ensg-20220630.htm", "contextRef": "icac9ba64227048d98d25eb4e6c51f286_I20201231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:CommonStockSharesOutstanding", "reportCount": 1, "unitRef": "shares", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1004005 - Statement - UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY", "role": "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY", "shortName": "UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "ensg-20220630.htm", "contextRef": "i0f7120c2a8a74c4f94bd42f76f7efe34_D20210101-20210331", "decimals": "-3", "lang": "en-US", "name": "us-gaap:StockIssuedDuringPeriodSharesNewIssues", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R50": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ensg-20220630.htm", "contextRef": "i83961bfae89a426da695eba2aaf791c2_I20220630", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AccountsReceivableGross", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2417411 - Disclosure - Revenue and Accounts Receivable - Accounts Receivable (Details)", "role": "http://www.ensigngroup.net/role/RevenueandAccountsReceivableAccountsReceivableDetails", "shortName": "Revenue and Accounts Receivable - Accounts Receivable (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ensg-20220630.htm", "contextRef": "i83961bfae89a426da695eba2aaf791c2_I20220630", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AccountsReceivableGross", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R51": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEarningsPerShareDilutedByCommonClassTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ensg-20220630.htm", "contextRef": "i2d4f1f58b2004ae3aa227577e5611584_D20220401-20220630", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2420412 - Disclosure - Computation of Net Income Per Common Share (Details)", "role": "http://www.ensigngroup.net/role/ComputationofNetIncomePerCommonShareDetails", "shortName": "Computation of Net Income Per Common Share (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEarningsPerShareDilutedByCommonClassTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ensg-20220630.htm", "contextRef": "i2d4f1f58b2004ae3aa227577e5611584_D20220401-20220630", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R52": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "ensg-20220630.htm", "contextRef": "ife97d93618a5454cab609c3ae4bf961d_I20220630", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2422413 - Disclosure - Fair Value Measurements - Schedule of Fair Value, of Assets and Liabilities Measured on Recurring Basis (Details)", "role": "http://www.ensigngroup.net/role/FairValueMeasurementsScheduleofFairValueofAssetsandLiabilitiesMeasuredonRecurringBasisDetails", "shortName": "Fair Value Measurements - Schedule of Fair Value, of Assets and Liabilities Measured on Recurring Basis (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "ensg-20220630.htm", "contextRef": "ife97d93618a5454cab609c3ae4bf961d_I20220630", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R53": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "ensg-20220630.htm", "contextRef": "idde5a75cc8d84578b43e7bfa5d8ce085_I20220630", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:HeldToMaturitySecurities", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2423414 - Disclosure - Fair Value Measurements - Investments (Details)", "role": "http://www.ensigngroup.net/role/FairValueMeasurementsInvestmentsDetails", "shortName": "Fair Value Measurements - Investments (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "ensg-20220630.htm", "contextRef": "idde5a75cc8d84578b43e7bfa5d8ce085_I20220630", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:HeldToMaturitySecurities", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R54": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "ensg-20220630.htm", "contextRef": "i83961bfae89a426da695eba2aaf791c2_I20220630", "decimals": "-2", "first": true, "lang": "en-US", "name": "us-gaap:NumberOfRealEstateProperties", "reportCount": 1, "unitRef": "facility", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2425415 - Disclosure - Standard Bearer (Details)", "role": "http://www.ensigngroup.net/role/StandardBearerDetails", "shortName": "Standard Bearer (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "ensg-20220630.htm", "contextRef": "ibbbb2ca524434b44bb60ee51da524727_D20220101-20220131", "decimals": "INF", "lang": "en-US", "name": "ensg:NumberOfLeaseArrangements", "reportCount": 1, "unique": true, "unitRef": "lease", "xsiNil": "false" } }, "R55": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "ensg-20220630.htm", "contextRef": "i3cb824adc37b4eae96c4309acc277bcb_D20220101-20220630", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:NumberOfReportableSegments", "reportCount": 1, "unique": true, "unitRef": "segment", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2428416 - Disclosure - Business Segments - Narrative (Details)", "role": "http://www.ensigngroup.net/role/BusinessSegmentsNarrativeDetails", "shortName": "Business Segments - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "ensg-20220630.htm", "contextRef": "i3cb824adc37b4eae96c4309acc277bcb_D20220101-20220630", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:NumberOfReportableSegments", "reportCount": 1, "unique": true, "unitRef": "segment", "xsiNil": "false" } }, "R56": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "ensg-20220630.htm", "contextRef": "i2d4f1f58b2004ae3aa227577e5611584_D20220401-20220630", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2429417 - Disclosure - Business Segments - Schedule of Segment Reporting Information, by Segment (Details)", "role": "http://www.ensigngroup.net/role/BusinessSegmentsScheduleofSegmentReportingInformationbySegmentDetails", "shortName": "Business Segments - Schedule of Segment Reporting Information, by Segment (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ensg-20220630.htm", "contextRef": "i2d4f1f58b2004ae3aa227577e5611584_D20220401-20220630", "decimals": "-3", "lang": "en-US", "name": "ensg:SegmentIncomeLoss", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R57": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "ensg-20220630.htm", "contextRef": "i2d4f1f58b2004ae3aa227577e5611584_D20220401-20220630", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2430418 - Disclosure - Business Segments - Revenue by Segment (Details)", "role": "http://www.ensigngroup.net/role/BusinessSegmentsRevenuebySegmentDetails", "shortName": "Business Segments - Revenue by Segment (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ensg-20220630.htm", "contextRef": "iadfb2ab9737745df9ead2ae612b26c85_D20220401-20220630", "decimals": "-3", "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R58": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "ensg-20220630.htm", "contextRef": "i83961bfae89a426da695eba2aaf791c2_I20220630", "decimals": "-2", "first": true, "lang": "en-US", "name": "ensg:OperationalSkilledNursingBeds", "reportCount": 1, "unitRef": "bed", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2432419 - Disclosure - Operation Expansions (Details)", "role": "http://www.ensigngroup.net/role/OperationExpansionsDetails", "shortName": "Operation Expansions (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "ensg-20220630.htm", "contextRef": "i3cb824adc37b4eae96c4309acc277bcb_D20220101-20220630", "decimals": "-3", "lang": "en-US", "name": "ensg:PaymentsToAcquireBusinessAndAssetAcquisitions", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R59": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "ensg-20220630.htm", "contextRef": "i83961bfae89a426da695eba2aaf791c2_I20220630", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentGross", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2435420 - Disclosure - Property and Equipment \u2014 Net (Details)", "role": "http://www.ensigngroup.net/role/PropertyandEquipmentNetDetails", "shortName": "Property and Equipment \u2014 Net (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "ensg-20220630.htm", "contextRef": "i83961bfae89a426da695eba2aaf791c2_I20220630", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentGross", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "ensg-20220630.htm", "contextRef": "i2d4f1f58b2004ae3aa227577e5611584_D20220401-20220630", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:CommonStockDividendsPerShareDeclared", "reportCount": 1, "unique": true, "unitRef": "usdPerShare", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1005006 - Statement - UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (Parenthetical)", "role": "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYParenthetical", "shortName": "UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "ensg-20220630.htm", "contextRef": "i2d4f1f58b2004ae3aa227577e5611584_D20220401-20220630", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:CommonStockDividendsPerShareDeclared", "reportCount": 1, "unique": true, "unitRef": "usdPerShare", "xsiNil": "false" } }, "R60": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "ensg-20220630.htm", "contextRef": "ibd26b82c9d124d0e9a4d251cac22886a_D20220401-20220630", "decimals": "INF", "first": true, "lang": "en-US", "name": "ensg:SeniorLivingFacility", "reportCount": 1, "unitRef": "facility", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2436421 - Disclosure - Property and Equipment \u2014 Net - Narrative (Details)", "role": "http://www.ensigngroup.net/role/PropertyandEquipmentNetNarrativeDetails", "shortName": "Property and Equipment \u2014 Net - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "ensg-20220630.htm", "contextRef": "ibd26b82c9d124d0e9a4d251cac22886a_D20220401-20220630", "decimals": "-3", "lang": "en-US", "name": "us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R61": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "ensg-20220630.htm", "contextRef": "i83961bfae89a426da695eba2aaf791c2_I20220630", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:FiniteLivedIntangibleAssetsGross", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2439422 - Disclosure - Intangible Assets \u2014 Net - Schedule of Finite Lived Intangible Assets (Details)", "role": "http://www.ensigngroup.net/role/IntangibleAssetsNetScheduleofFiniteLivedIntangibleAssetsDetails", "shortName": "Intangible Assets \u2014 Net - Schedule of Finite Lived Intangible Assets (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "ensg-20220630.htm", "contextRef": "i83961bfae89a426da695eba2aaf791c2_I20220630", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:FiniteLivedIntangibleAssetsGross", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R62": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "ensg-20220630.htm", "contextRef": "i2d4f1f58b2004ae3aa227577e5611584_D20220401-20220630", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AmortizationOfIntangibleAssets", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2440423 - Disclosure - Intangible Assets \u2014 Net - Narrative (Details)", "role": "http://www.ensigngroup.net/role/IntangibleAssetsNetNarrativeDetails", "shortName": "Intangible Assets \u2014 Net - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "ensg-20220630.htm", "contextRef": "i2d4f1f58b2004ae3aa227577e5611584_D20220401-20220630", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AmortizationOfIntangibleAssets", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R63": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "ensg-20220630.htm", "contextRef": "i83961bfae89a426da695eba2aaf791c2_I20220630", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2441424 - Disclosure - Intangible Assets \u2014 Net - Future Amortization (Details)", "role": "http://www.ensigngroup.net/role/IntangibleAssetsNetFutureAmortizationDetails", "shortName": "Intangible Assets \u2014 Net - Future Amortization (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "ensg-20220630.htm", "contextRef": "i83961bfae89a426da695eba2aaf791c2_I20220630", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R64": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "ensg-20220630.htm", "contextRef": "i3450cd617ab24c7691f5b5f3e354f3e0_I20211231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:Goodwill", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2444425 - Disclosure - Goodwill and Other Indefinite-Lived Intangible Assets - Goodwill Rollforward (Details)", "role": "http://www.ensigngroup.net/role/GoodwillandOtherIndefiniteLivedIntangibleAssetsGoodwillRollforwardDetails", "shortName": "Goodwill and Other Indefinite-Lived Intangible Assets - Goodwill Rollforward (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "ensg-20220630.htm", "contextRef": "ia683dc64343443f1bc683f4eaa26ea8f_I20211231", "decimals": "-3", "lang": "en-US", "name": "us-gaap:Goodwill", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R65": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAcquiredIndefiniteLivedIntangibleAssetsByMajorClassTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ensg-20220630.htm", "contextRef": "i83961bfae89a426da695eba2aaf791c2_I20220630", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2445426 - Disclosure - Goodwill and Other Indefinite-Lived Intangible Assets - Indefinite-Lived Intangible Assets (Details)", "role": "http://www.ensigngroup.net/role/GoodwillandOtherIndefiniteLivedIntangibleAssetsIndefiniteLivedIntangibleAssetsDetails", "shortName": "Goodwill and Other Indefinite-Lived Intangible Assets - Indefinite-Lived Intangible Assets (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAcquiredIndefiniteLivedIntangibleAssetsByMajorClassTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ensg-20220630.htm", "contextRef": "i31403127964541a59d136de9a8aec00d_I20220630", "decimals": "-3", "lang": "en-US", "name": "us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R66": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfOtherAssetsTableTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "ensg-20220630.htm", "contextRef": "i83961bfae89a426da695eba2aaf791c2_I20220630", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:DebtIssuanceCostsLineOfCreditArrangementsNet", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2448427 - Disclosure - Restricted and Other Assets (Details)", "role": "http://www.ensigngroup.net/role/RestrictedandOtherAssetsDetails", "shortName": "Restricted and Other Assets (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfOtherAssetsTableTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "ensg-20220630.htm", "contextRef": "i83961bfae89a426da695eba2aaf791c2_I20220630", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:DebtIssuanceCostsLineOfCreditArrangementsNet", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R67": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "ensg-20220630.htm", "contextRef": "i2d4f1f58b2004ae3aa227577e5611584_D20220401-20220630", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:GainLossOnInvestments", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2449428 - Disclosure - Restricted and Other Assets - Narrative (Details)", "role": "http://www.ensigngroup.net/role/RestrictedandOtherAssetsNarrativeDetails", "shortName": "Restricted and Other Assets - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "ensg-20220630.htm", "contextRef": "i2d4f1f58b2004ae3aa227577e5611584_D20220401-20220630", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:GainLossOnInvestments", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R68": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "ensg-20220630.htm", "contextRef": "i83961bfae89a426da695eba2aaf791c2_I20220630", "decimals": "-3", "first": true, "lang": "en-US", "name": "ensg:QualityAssuranceFee", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2452429 - Disclosure - Other Accrued Liabilities (Details)", "role": "http://www.ensigngroup.net/role/OtherAccruedLiabilitiesDetails", "shortName": "Other Accrued Liabilities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "ensg-20220630.htm", "contextRef": "i83961bfae89a426da695eba2aaf791c2_I20220630", "decimals": "-3", "first": true, "lang": "en-US", "name": "ensg:QualityAssuranceFee", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R69": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "ensg-20220630.htm", "contextRef": "i2d4f1f58b2004ae3aa227577e5611584_D20220401-20220630", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxExpenseBenefit", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2454430 - Disclosure - Income Taxes - Narrative (Details)", "role": "http://www.ensigngroup.net/role/IncomeTaxesNarrativeDetails", "shortName": "Income Taxes - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "ensg-20220630.htm", "contextRef": "i3cb824adc37b4eae96c4309acc277bcb_D20220101-20220630", "decimals": "3", "lang": "en-US", "name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "ensg-20220630.htm", "contextRef": "i3cb824adc37b4eae96c4309acc277bcb_D20220101-20220630", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:ProfitLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1006007 - Statement - UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS", "role": "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS", "shortName": "UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "ensg-20220630.htm", "contextRef": "i3cb824adc37b4eae96c4309acc277bcb_D20220101-20220630", "decimals": "-3", "lang": "en-US", "name": "us-gaap:AmortizationOfFinancingCostsAndDiscounts", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R70": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "ensg-20220630.htm", "contextRef": "i83961bfae89a426da695eba2aaf791c2_I20220630", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:LongTermDebtCurrent", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2457431 - Disclosure - Debt - Schedule of Long-term Debt (Details)", "role": "http://www.ensigngroup.net/role/DebtScheduleofLongtermDebtDetails", "shortName": "Debt - Schedule of Long-term Debt (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ensg-20220630.htm", "contextRef": "i83961bfae89a426da695eba2aaf791c2_I20220630", "decimals": "-3", "lang": "en-US", "name": "us-gaap:DeferredFinanceCostsNet", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R71": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "ensg-20220630.htm", "contextRef": "i3cb824adc37b4eae96c4309acc277bcb_D20220101-20220630", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:WriteOffOfDeferredDebtIssuanceCost", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2458432 - Disclosure - Debt - Credit Facility with a Lending Consortium Arranged by SunTrust (Details)", "role": "http://www.ensigngroup.net/role/DebtCreditFacilitywithaLendingConsortiumArrangedbySunTrustDetails", "shortName": "Debt - Credit Facility with a Lending Consortium Arranged by SunTrust (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "ensg-20220630.htm", "contextRef": "icf120bb0a5774cf0a87e0e51db0bdfed_I20191001", "decimals": "INF", "lang": "en-US", "name": "ensg:TotalNetDebtRatioMaximum", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R72": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "ensg-20220630.htm", "contextRef": "i83961bfae89a426da695eba2aaf791c2_I20220630", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:LongTermDebtCurrent", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2459433 - Disclosure - Debt - Mortgage Loans and Promissory Notes and Off-Balance Sheet Arrangements (Details)", "role": "http://www.ensigngroup.net/role/DebtMortgageLoansandPromissoryNotesandOffBalanceSheetArrangementsDetails", "shortName": "Debt - Mortgage Loans and Promissory Notes and Off-Balance Sheet Arrangements (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "ensg-20220630.htm", "contextRef": "i83961bfae89a426da695eba2aaf791c2_I20220630", "decimals": "-3", "lang": "en-US", "name": "us-gaap:LettersOfCreditOutstandingAmount", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R73": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "ensg-20220630.htm", "contextRef": "i2d4f1f58b2004ae3aa227577e5611584_D20220401-20220630", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "reportCount": 1, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2462434 - Disclosure - Options and Awards - Stock Options, Narrative (Details)", "role": "http://www.ensigngroup.net/role/OptionsandAwardsStockOptionsNarrativeDetails", "shortName": "Options and Awards - Stock Options, Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "ix:continuation", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "ensg-20220630.htm", "contextRef": "i3cb824adc37b4eae96c4309acc277bcb_D20220101-20220630", "decimals": "0", "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue", "reportCount": 1, "unique": true, "unitRef": "usdPerShare", "xsiNil": "false" } }, "R74": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "ensg-20220630.htm", "contextRef": "i2d4f1f58b2004ae3aa227577e5611584_D20220401-20220630", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "reportCount": 1, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2463435 - Disclosure - Options and Awards - Valuation Assumptions (Details)", "role": "http://www.ensigngroup.net/role/OptionsandAwardsValuationAssumptionsDetails", "shortName": "Options and Awards - Valuation Assumptions (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "ensg-20220630.htm", "contextRef": "i2d4f1f58b2004ae3aa227577e5611584_D20220401-20220630", "decimals": "3", "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R75": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "ensg-20220630.htm", "contextRef": "i2d4f1f58b2004ae3aa227577e5611584_D20220401-20220630", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "reportCount": 1, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2464436 - Disclosure - Options and Awards - Exercise Price and Fair Value (Details)", "role": "http://www.ensigngroup.net/role/OptionsandAwardsExercisePriceandFairValueDetails", "shortName": "Options and Awards - Exercise Price and Fair Value (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ensg-20220630.htm", "contextRef": "i3cb824adc37b4eae96c4309acc277bcb_D20220101-20220630", "decimals": "2", "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "reportCount": 1, "unique": true, "unitRef": "usdPerShare", "xsiNil": "false" } }, "R76": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfCommonStockOutstandingRollForwardTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ensg-20220630.htm", "contextRef": "i3450cd617ab24c7691f5b5f3e354f3e0_I20211231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2465437 - Disclosure - Options and Awards - Options Outstanding Rollforward (Details)", "role": "http://www.ensigngroup.net/role/OptionsandAwardsOptionsOutstandingRollforwardDetails", "shortName": "Options and Awards - Options Outstanding Rollforward (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfCommonStockOutstandingRollForwardTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ensg-20220630.htm", "contextRef": "i3450cd617ab24c7691f5b5f3e354f3e0_I20211231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R77": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ensg-20220630.htm", "contextRef": "i83961bfae89a426da695eba2aaf791c2_I20220630", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2466438 - Disclosure - Options and Awards - Options Outstanding by Exercise Price (Details)", "role": "http://www.ensigngroup.net/role/OptionsandAwardsOptionsOutstandingbyExercisePriceDetails", "shortName": "Options and Awards - Options Outstanding by Exercise Price (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ensg-20220630.htm", "contextRef": "i83961bfae89a426da695eba2aaf791c2_I20220630", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R78": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ensg-20220630.htm", "contextRef": "i83961bfae89a426da695eba2aaf791c2_I20220630", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2467439 - Disclosure - Options and Awards - Intrinsic Values (Details)", "role": "http://www.ensigngroup.net/role/OptionsandAwardsIntrinsicValuesDetails", "shortName": "Options and Awards - Intrinsic Values (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ensg-20220630.htm", "contextRef": "i83961bfae89a426da695eba2aaf791c2_I20220630", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R79": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "ensg-20220630.htm", "contextRef": "i3cb824adc37b4eae96c4309acc277bcb_D20220101-20220630", "decimals": "0", "first": true, "lang": "en-US", "name": "ensg:SharebasedCompensationRestrictedAwardsExercisePrice", "reportCount": 1, "unique": true, "unitRef": "usdPerShare", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2468440 - Disclosure - Options and Awards - Restricted Stock Awards, Narrative (Details)", "role": "http://www.ensigngroup.net/role/OptionsandAwardsRestrictedStockAwardsNarrativeDetails", "shortName": "Options and Awards - Restricted Stock Awards, Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "ensg-20220630.htm", "contextRef": "i3cb824adc37b4eae96c4309acc277bcb_D20220101-20220630", "decimals": "0", "first": true, "lang": "en-US", "name": "ensg:SharebasedCompensationRestrictedAwardsExercisePrice", "reportCount": 1, "unique": true, "unitRef": "usdPerShare", "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ensg-20220630.htm", "contextRef": "i3cb824adc37b4eae96c4309acc277bcb_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2101101 - Disclosure - Description of Business", "role": "http://www.ensigngroup.net/role/DescriptionofBusiness", "shortName": "Description of Business", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ensg-20220630.htm", "contextRef": "i3cb824adc37b4eae96c4309acc277bcb_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R80": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ensg-20220630.htm", "contextRef": "i620a7423de4a47b58ce8112ac58b218c_I20211231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2469441 - Disclosure - Options and Awards - Restricted Award Rollforward (Details)", "role": "http://www.ensigngroup.net/role/OptionsandAwardsRestrictedAwardRollforwardDetails", "shortName": "Options and Awards - Restricted Award Rollforward (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ensg-20220630.htm", "contextRef": "i620a7423de4a47b58ce8112ac58b218c_I20211231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R81": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ensg-20220630.htm", "contextRef": "i2d4f1f58b2004ae3aa227577e5611584_D20220401-20220630", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2470442 - Disclosure - Options and Awards - Long-Term Incentive Plan (Details)", "role": "http://www.ensigngroup.net/role/OptionsandAwardsLongTermIncentivePlanDetails", "shortName": "Options and Awards - Long-Term Incentive Plan (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "ensg-20220630.htm", "contextRef": "i799d920c66bf4e98b79b9aa93a310c7d_I20190827", "decimals": "INF", "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R82": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "ix:continuation", "body", "html" ], "baseRef": "ensg-20220630.htm", "contextRef": "i2d4f1f58b2004ae3aa227577e5611584_D20220401-20220630", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2471443 - Disclosure - Options and Awards - Compensation Expense (Details)", "role": "http://www.ensigngroup.net/role/OptionsandAwardsCompensationExpenseDetails", "shortName": "Options and Awards - Compensation Expense (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "ensg-20220630.htm", "contextRef": "i3cb824adc37b4eae96c4309acc277bcb_D20220101-20220630", "decimals": null, "lang": "en-US", "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R83": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "ensg-20220630.htm", "contextRef": "i83961bfae89a426da695eba2aaf791c2_I20220630", "decimals": "INF", "first": true, "lang": "en-US", "name": "ensg:MasterLeaseAgreements", "reportCount": 1, "unitRef": "agreement", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2474444 - Disclosure - Leases - Lessee Narrative (Details)", "role": "http://www.ensigngroup.net/role/LeasesLesseeNarrativeDetails", "shortName": "Leases - Lessee Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "ensg-20220630.htm", "contextRef": "i4b40205cf54f46e2846d158963d15eac_D20220701-20220801", "decimals": "-3", "lang": "en-US", "name": "us-gaap:LiabilitiesFairValueAdjustment", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R84": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:LeaseCostTableTextBlock", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "ensg-20220630.htm", "contextRef": "i2d4f1f58b2004ae3aa227577e5611584_D20220401-20220630", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:OperatingLeaseCost", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2475445 - Disclosure - Leases - Lessee Lease Cost (Details)", "role": "http://www.ensigngroup.net/role/LeasesLesseeLeaseCostDetails", "shortName": "Leases - Lessee Lease Cost (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "us-gaap:LeaseCostTableTextBlock", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "ensg-20220630.htm", "contextRef": "i2d4f1f58b2004ae3aa227577e5611584_D20220401-20220630", "decimals": "-3", "lang": "en-US", "name": "ensg:DeferredRentAdjustment", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R85": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "ensg-20220630.htm", "contextRef": "i83961bfae89a426da695eba2aaf791c2_I20220630", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2476446 - Disclosure - Leases - Lessee Future Minimum Lease Payments (Details)", "role": "http://www.ensigngroup.net/role/LeasesLesseeFutureMinimumLeasePaymentsDetails", "shortName": "Leases - Lessee Future Minimum Lease Payments (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "ensg-20220630.htm", "contextRef": "i83961bfae89a426da695eba2aaf791c2_I20220630", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R86": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "ensg-20220630.htm", "contextRef": "i83961bfae89a426da695eba2aaf791c2_I20220630", "decimals": "-2", "first": true, "lang": "en-US", "name": "us-gaap:NumberOfRealEstateProperties", "reportCount": 1, "unitRef": "facility", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2477447 - Disclosure - Leases - Lessor Narrative (Details)", "role": "http://www.ensigngroup.net/role/LeasesLessorNarrativeDetails", "shortName": "Leases - Lessor Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "ensg-20220630.htm", "contextRef": "i776f94c50572453eae6b584fa57117d7_I20191001", "decimals": null, "lang": "en-US", "name": "us-gaap:LessorOperatingLeaseTermOfContract", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R87": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:OperatingLeaseLeaseIncomeTableTextBlock", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "ensg-20220630.htm", "contextRef": "i2d4f1f58b2004ae3aa227577e5611584_D20220401-20220630", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:OperatingLeaseLeaseIncome", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2478448 - Disclosure - Leases - Lessor Rental Income (Details)", "role": "http://www.ensigngroup.net/role/LeasesLessorRentalIncomeDetails", "shortName": "Leases - Lessor Rental Income (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "ix:continuation", "span", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "ensg-20220630.htm", "contextRef": "i645fa67ae63e48fbbbe2aa0b4ff90006_D20220401-20220630", "decimals": "-3", "lang": "en-US", "name": "us-gaap:OperatingLeaseVariableLeaseIncome", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R88": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:LessorOperatingLeasePaymentsToBeReceivedMaturityTableTextBlock", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "ensg-20220630.htm", "contextRef": "i83961bfae89a426da695eba2aaf791c2_I20220630", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:LessorOperatingLeasePaymentsToBeReceivedRemainderOfFiscalYear", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2479449 - Disclosure - Leases - Lessor Future Minimum Lease Payments Receivable (Details)", "role": "http://www.ensigngroup.net/role/LeasesLessorFutureMinimumLeasePaymentsReceivableDetails", "shortName": "Leases - Lessor Future Minimum Lease Payments Receivable (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:LessorOperatingLeasePaymentsToBeReceivedMaturityTableTextBlock", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "ensg-20220630.htm", "contextRef": "i83961bfae89a426da695eba2aaf791c2_I20220630", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:LessorOperatingLeasePaymentsToBeReceivedRemainderOfFiscalYear", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R89": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "ensg-20220630.htm", "contextRef": "i83961bfae89a426da695eba2aaf791c2_I20220630", "decimals": "INF", "first": true, "lang": "en-US", "name": "ensg:FacilitiesUnderMedicareProbeReviews", "reportCount": 1, "unitRef": "facility", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2481450 - Disclosure - Commitments and Contingencies (Details)", "role": "http://www.ensigngroup.net/role/CommitmentsandContingenciesDetails", "shortName": "Commitments and Contingencies (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "ensg-20220630.htm", "contextRef": "if8e5415b2b54475fbf3cabfc98818e55_I20220727", "decimals": "-3", "lang": "en-US", "name": "us-gaap:CashUninsuredAmount", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ensg-20220630.htm", "contextRef": "i3cb824adc37b4eae96c4309acc277bcb_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2103102 - Disclosure - Summary of Significant Accounting Policies", "role": "http://www.ensigngroup.net/role/SummaryofSignificantAccountingPolicies", "shortName": "Summary of Significant Accounting Policies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ensg-20220630.htm", "contextRef": "i3cb824adc37b4eae96c4309acc277bcb_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R90": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "ensg-20220630.htm", "contextRef": "i2d4f1f58b2004ae3aa227577e5611584_D20220401-20220630", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:TreasuryStockValueAcquiredCostMethod", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2483451 - Disclosure - Common Stock Repurchase Program (Details)", "role": "http://www.ensigngroup.net/role/CommonStockRepurchaseProgramDetails", "shortName": "Common Stock Repurchase Program (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "ix:continuation", "span", "div", "body", "html" ], "baseRef": "ensg-20220630.htm", "contextRef": "i2225c5801ea04fa6b0bba7e7698fb3e6_I20220209", "decimals": "INF", "lang": "en-US", "name": "us-gaap:StockRepurchaseProgramAuthorizedAmount1", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } } }, "segmentCount": 129, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.ensigngroup.net/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.ensigngroup.net/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]", "terseLabel": "Cover page." } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2022", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date", "terseLabel": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.ensigngroup.net/role/CoverPage" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus", "terseLabel": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.ensigngroup.net/role/CoverPage" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus", "terseLabel": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.ensigngroup.net/role/CoverPage" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.ensigngroup.net/role/CoverPage" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r685" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report", "terseLabel": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.ensigngroup.net/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r686" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report", "terseLabel": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.ensigngroup.net/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.ensigngroup.net/role/CoverPage" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.ensigngroup.net/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.ensigngroup.net/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.ensigngroup.net/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.ensigngroup.net/role/CoverPage" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r683" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.ensigngroup.net/role/CoverPage" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding", "terseLabel": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.ensigngroup.net/role/CoverPage" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status", "terseLabel": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.ensigngroup.net/role/CoverPage" ], "xbrltype": "yesNoItemType" }, "dei_EntityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains.", "label": "Entity [Domain]", "terseLabel": "Entity [Domain]" } } }, "localname": "EntityDomain", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.ensigngroup.net/role/BusinessSegmentsNarrativeDetails", "http://www.ensigngroup.net/role/DebtMortgageLoansandPromissoryNotesandOffBalanceSheetArrangementsDetails", "http://www.ensigngroup.net/role/OperationExpansionsDetails", "http://www.ensigngroup.net/role/StandardBearerDetails" ], "xbrltype": "domainItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r683" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.ensigngroup.net/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.ensigngroup.net/role/CoverPage" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r683" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category", "terseLabel": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.ensigngroup.net/role/CoverPage" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.ensigngroup.net/role/CoverPage" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r694" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current", "terseLabel": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.ensigngroup.net/role/CoverPage" ], "xbrltype": "yesNoItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r683" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.ensigngroup.net/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r683" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company", "terseLabel": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.ensigngroup.net/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r683" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business", "terseLabel": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.ensigngroup.net/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r683" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.ensigngroup.net/role/CoverPage" ], "xbrltype": "employerIdItemType" }, "dei_LegalEntityAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The set of legal entities associated with a report.", "label": "Legal Entity [Axis]", "terseLabel": "Legal Entity [Axis]" } } }, "localname": "LegalEntityAxis", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.ensigngroup.net/role/BusinessSegmentsNarrativeDetails", "http://www.ensigngroup.net/role/DebtMortgageLoansandPromissoryNotesandOffBalanceSheetArrangementsDetails", "http://www.ensigngroup.net/role/OperationExpansionsDetails", "http://www.ensigngroup.net/role/StandardBearerDetails" ], "xbrltype": "stringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.ensigngroup.net/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r682" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.ensigngroup.net/role/CoverPage" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r684" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.ensigngroup.net/role/CoverPage" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.ensigngroup.net/role/CoverPage" ], "xbrltype": "tradingSymbolItemType" }, "ensg_A2019LTIPlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "2019 LTI Plan [Member]", "label": "2019 LTI Plan [Member]", "terseLabel": "2019 LTI Plan" } } }, "localname": "A2019LTIPlanMember", "nsuri": "http://www.ensigngroup.net/20220630", "presentation": [ "http://www.ensigngroup.net/role/OptionsandAwardsLongTermIncentivePlanDetails" ], "xbrltype": "domainItemType" }, "ensg_A2022PlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "2022 Plan", "label": "2022 Plan [Member]", "terseLabel": "2022 Plan" } } }, "localname": "A2022PlanMember", "nsuri": "http://www.ensigngroup.net/20220630", "presentation": [ "http://www.ensigngroup.net/role/OptionsandAwardsStockOptionsNarrativeDetails" ], "xbrltype": "domainItemType" }, "ensg_AccruedLiabilitiesStateReliefContractLiabilities": { "auth_ref": [], "calculation": { "http://www.ensigngroup.net/role/OtherAccruedLiabilitiesDetails": { "order": 1.0, "parentTag": "us-gaap_OtherAccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accrued Liabilities, State Relief Contract Liabilities", "label": "Accrued Liabilities, State Relief Contract Liabilities", "terseLabel": "Unapplied state relief funds" } } }, "localname": "AccruedLiabilitiesStateReliefContractLiabilities", "nsuri": "http://www.ensigngroup.net/20220630", "presentation": [ "http://www.ensigngroup.net/role/COVID19UpdateDetails", "http://www.ensigngroup.net/role/OtherAccruedLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "ensg_AffiliatedFacilityMasterLeaseOneMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Affiliated Facility, Master Lease One", "label": "Affiliated Facility, Master Lease One [Member]", "terseLabel": "Affiliated Facility, Master Lease One" } } }, "localname": "AffiliatedFacilityMasterLeaseOneMember", "nsuri": "http://www.ensigngroup.net/20220630", "presentation": [ "http://www.ensigngroup.net/role/LeasesLesseeNarrativeDetails" ], "xbrltype": "domainItemType" }, "ensg_AggregateDeductibleMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Aggregate Deductible [Member]", "label": "Aggregate Deductible [Member]", "terseLabel": "Aggregate Deductible" } } }, "localname": "AggregateDeductibleMember", "nsuri": "http://www.ensigngroup.net/20220630", "presentation": [ "http://www.ensigngroup.net/role/SummaryofSignificantAccountingPoliciesSelfInsuranceDetails" ], "xbrltype": "domainItemType" }, "ensg_AllStatesExceptColoradoMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "All States Except Colorado [Domain]", "label": "All States Except Colorado [Member]", "terseLabel": "All States Except Colorado" } } }, "localname": "AllStatesExceptColoradoMember", "nsuri": "http://www.ensigngroup.net/20220630", "presentation": [ "http://www.ensigngroup.net/role/SummaryofSignificantAccountingPoliciesSelfInsuranceDetails" ], "xbrltype": "domainItemType" }, "ensg_AmendedMasterLeaseMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Amended Master Lease", "label": "Amended Master Lease [Member]", "terseLabel": "Amended Master Lease" } } }, "localname": "AmendedMasterLeaseMember", "nsuri": "http://www.ensigngroup.net/20220630", "presentation": [ "http://www.ensigngroup.net/role/LeasesLesseeNarrativeDetails" ], "xbrltype": "domainItemType" }, "ensg_AssembledOccupancyAcquiredMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Assembled occupancy acquired [Member]", "label": "Assembled Occupancy Acquired [Member]", "terseLabel": "Assembled occupancy" } } }, "localname": "AssembledOccupancyAcquiredMember", "nsuri": "http://www.ensigngroup.net/20220630", "presentation": [ "http://www.ensigngroup.net/role/IntangibleAssetsNetScheduleofFiniteLivedIntangibleAssetsDetails", "http://www.ensigngroup.net/role/SummaryofSignificantAccountingPoliciesIntangibleAssetsandGoodwillDetails" ], "xbrltype": "domainItemType" }, "ensg_AssetAcquisitionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "These acquisitions were classified as asset acquisitions in accordance with ASC 805.", "label": "Asset Acquisition [Member]", "terseLabel": "Asset Acquisition" } } }, "localname": "AssetAcquisitionMember", "nsuri": "http://www.ensigngroup.net/20220630", "presentation": [ "http://www.ensigngroup.net/role/OperationExpansionsDetails" ], "xbrltype": "domainItemType" }, "ensg_BlanketAggregateMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Blanket Aggregate [Member]", "label": "Blanket Aggregate [Member]", "terseLabel": "Blanket Aggregate" } } }, "localname": "BlanketAggregateMember", "nsuri": "http://www.ensigngroup.net/20220630", "presentation": [ "http://www.ensigngroup.net/role/SummaryofSignificantAccountingPoliciesSelfInsuranceDetails" ], "xbrltype": "domainItemType" }, "ensg_BusinessCombinationMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "These acquisitions were classified as business acquisitions in accordance with ASC 805.", "label": "Business Combination [Member]", "terseLabel": "Business Combination" } } }, "localname": "BusinessCombinationMember", "nsuri": "http://www.ensigngroup.net/20220630", "presentation": [ "http://www.ensigngroup.net/role/OperationExpansionsDetails" ], "xbrltype": "domainItemType" }, "ensg_CampusOperationMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Campus Operation", "label": "Campus Operation [Member]", "terseLabel": "Campus Operation" } } }, "localname": "CampusOperationMember", "nsuri": "http://www.ensigngroup.net/20220630", "presentation": [ "http://www.ensigngroup.net/role/OperationExpansionsDetails", "http://www.ensigngroup.net/role/StandardBearerDetails" ], "xbrltype": "domainItemType" }, "ensg_CareTrustREITMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "CareTrust REIT [Member]", "label": "CareTrust REIT [Member]", "terseLabel": "CareTrust REIT" } } }, "localname": "CareTrustREITMember", "nsuri": "http://www.ensigngroup.net/20220630", "presentation": [ "http://www.ensigngroup.net/role/LeasesLesseeNarrativeDetails" ], "xbrltype": "domainItemType" }, "ensg_CashHeldInTrustForResidents": { "auth_ref": [], "calculation": { "http://www.ensigngroup.net/role/OtherAccruedLiabilitiesDetails": { "order": 9.0, "parentTag": "us-gaap_OtherAccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Cash held in trust for residents reflects monies received from, or on behalf of, residents. Maintaining a trust account for residents is a regulatory requirement and, while the trust assets offset the liability, the Company assumes a fiduciary responsibility for these funds.", "label": "Cash Held in Trust for Residents", "terseLabel": "Cash held in trust for patients" } } }, "localname": "CashHeldInTrustForResidents", "nsuri": "http://www.ensigngroup.net/20220630", "presentation": [ "http://www.ensigngroup.net/role/OtherAccruedLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "ensg_CoronavirusAidReliefAndEconomicSecurityCARESFundsReceivedAndReturned": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Coronavirus Aid, Relief, and Economic Security (\u201cCARES\u201d) Funds Received And Returned", "label": "Coronavirus Aid, Relief, and Economic Security (\u201cCARES\u201d) Funds Received And Returned", "terseLabel": "Coronavirus Aid, Relief, and Economic Security (\u201cCARES\u201d) funds received and returned" } } }, "localname": "CoronavirusAidReliefAndEconomicSecurityCARESFundsReceivedAndReturned", "nsuri": "http://www.ensigngroup.net/20220630", "presentation": [ "http://www.ensigngroup.net/role/COVID19UpdateDetails" ], "xbrltype": "monetaryItemType" }, "ensg_CoronavirusAidReliefAndEconomicSecurityCARESFundsRepaid": { "auth_ref": [], "calculation": { "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Coronavirus Aid, Relief, and Economic Security (\u201cCARES\u201d) Funds, Repayment", "label": "Coronavirus Aid, Relief, and Economic Security (\u201cCARES\u201d) Funds Repaid", "negatedTerseLabel": "Repayments of CARES Act Provider Relief Fund and Medicare Advance Payment Program (Note 3)", "terseLabel": "Repayments of CARES Act Provider Relief Fund and Medicare Advance Payment Program (Note 3)" } } }, "localname": "CoronavirusAidReliefAndEconomicSecurityCARESFundsRepaid", "nsuri": "http://www.ensigngroup.net/20220630", "presentation": [ "http://www.ensigngroup.net/role/COVID19UpdateDetails", "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "ensg_CostOfServicesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cost of Services", "label": "Cost of Services [Member]", "terseLabel": "Variable lease costs" } } }, "localname": "CostOfServicesMember", "nsuri": "http://www.ensigngroup.net/20220630", "presentation": [ "http://www.ensigngroup.net/role/LeasesLesseeLeaseCostDetails" ], "xbrltype": "domainItemType" }, "ensg_CostofSalesandGeneralandAdministrativeExpenseMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing cost of services and general and administrative expense", "label": "Cost of Sales and General and Administrative Expense [Member]", "terseLabel": "Cost of Sales and General and Administrative Expense" } } }, "localname": "CostofSalesandGeneralandAdministrativeExpenseMember", "nsuri": "http://www.ensigngroup.net/20220630", "presentation": [ "http://www.ensigngroup.net/role/LeasesLesseeNarrativeDetails" ], "xbrltype": "domainItemType" }, "ensg_DebtInstrumentPrePaymentFeeReductionTerm": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt Instrument, Pre-Payment Fee Reduction, Term", "label": "Debt Instrument, Pre-Payment Fee Reduction, Term", "terseLabel": "Debt Instrument, pre-payment fee reduction, term" } } }, "localname": "DebtInstrumentPrePaymentFeeReductionTerm", "nsuri": "http://www.ensigngroup.net/20220630", "presentation": [ "http://www.ensigngroup.net/role/DebtMortgageLoansandPromissoryNotesandOffBalanceSheetArrangementsDetails" ], "xbrltype": "durationItemType" }, "ensg_DebtInstrumentsNumberOfInstruments": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt Instruments, Number Of Instruments", "label": "Debt Instruments, Number Of Instruments", "terseLabel": "Number of promissory notes" } } }, "localname": "DebtInstrumentsNumberOfInstruments", "nsuri": "http://www.ensigngroup.net/20220630", "presentation": [ "http://www.ensigngroup.net/role/DebtMortgageLoansandPromissoryNotesandOffBalanceSheetArrangementsDetails" ], "xbrltype": "integerItemType" }, "ensg_DeferredRentAdjustment": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Adjustment to deferred rent arising from the difference between rent expense recognized and rental payments made in the current period.", "label": "Deferred Rent Adjustment", "terseLabel": "Amortization of deferred rent" } } }, "localname": "DeferredRentAdjustment", "nsuri": "http://www.ensigngroup.net/20220630", "presentation": [ "http://www.ensigngroup.net/role/LeasesLesseeLeaseCostDetails" ], "xbrltype": "monetaryItemType" }, "ensg_DeferredRentAndOtherLongTermLiabilities": { "auth_ref": [], "calculation": { "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 5.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Rental expense in excess of actual rental payments and other long-term liabilities", "label": "Deferred rent and other long-term liabilities", "verboseLabel": "Other long-term liabilities" } } }, "localname": "DeferredRentAndOtherLongTermLiabilities", "nsuri": "http://www.ensigngroup.net/20220630", "presentation": [ "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "ensg_DepreciationAndAmortizationMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Depreciation And Amortization [Member]", "label": "Depreciation And Amortization [Member]", "terseLabel": "Depreciation and amortization" } } }, "localname": "DepreciationAndAmortizationMember", "nsuri": "http://www.ensigngroup.net/20220630", "presentation": [ "http://www.ensigngroup.net/role/IntangibleAssetsNetNarrativeDetails", "http://www.ensigngroup.net/role/LeasesLesseeLeaseCostDetails" ], "xbrltype": "domainItemType" }, "ensg_EmployeeServiceShareBasedCompensationNonvestedAwards": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Employee Service Share-based Compensation, Nonvested Awards", "label": "Employee Service Share-based Compensation, Nonvested Awards", "terseLabel": "Share-based compensation, nonvested awards (in shares)" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwards", "nsuri": "http://www.ensigngroup.net/20220630", "presentation": [ "http://www.ensigngroup.net/role/OptionsandAwardsCompensationExpenseDetails" ], "xbrltype": "sharesItemType" }, "ensg_ExercisePriceRangeEightMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Exercise Price Range Eight [Member]", "label": "Exercise Price Range Eight [Member]", "terseLabel": "2019" } } }, "localname": "ExercisePriceRangeEightMember", "nsuri": "http://www.ensigngroup.net/20220630", "presentation": [ "http://www.ensigngroup.net/role/OptionsandAwardsOptionsOutstandingbyExercisePriceDetails" ], "xbrltype": "domainItemType" }, "ensg_ExercisePriceRangeElevenMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Exercise Price Range Eleven", "label": "Exercise Price Range Eleven [Member]", "terseLabel": "2022" } } }, "localname": "ExercisePriceRangeElevenMember", "nsuri": "http://www.ensigngroup.net/20220630", "presentation": [ "http://www.ensigngroup.net/role/OptionsandAwardsOptionsOutstandingbyExercisePriceDetails" ], "xbrltype": "domainItemType" }, "ensg_ExercisePriceRangeFiveMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Exercise Price Range Five [Member]", "label": "Exercise Price Range Five [Member]", "terseLabel": "2016" } } }, "localname": "ExercisePriceRangeFiveMember", "nsuri": "http://www.ensigngroup.net/20220630", "presentation": [ "http://www.ensigngroup.net/role/OptionsandAwardsOptionsOutstandingbyExercisePriceDetails" ], "xbrltype": "domainItemType" }, "ensg_ExercisePriceRangeFourMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Exercise Price Range Four [Member]", "label": "Exercise Price Range Four [Member]", "terseLabel": "2015" } } }, "localname": "ExercisePriceRangeFourMember", "nsuri": "http://www.ensigngroup.net/20220630", "presentation": [ "http://www.ensigngroup.net/role/OptionsandAwardsOptionsOutstandingbyExercisePriceDetails" ], "xbrltype": "domainItemType" }, "ensg_ExercisePriceRangeNineMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Exercise Price Range Nine [Member]", "label": "Exercise Price Range Nine [Member]", "terseLabel": "2020" } } }, "localname": "ExercisePriceRangeNineMember", "nsuri": "http://www.ensigngroup.net/20220630", "presentation": [ "http://www.ensigngroup.net/role/OptionsandAwardsOptionsOutstandingbyExercisePriceDetails" ], "xbrltype": "domainItemType" }, "ensg_ExercisePriceRangeOneMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Exercise Price Range One [Member]", "label": "Exercise Price Range One [Member]", "terseLabel": "2012" } } }, "localname": "ExercisePriceRangeOneMember", "nsuri": "http://www.ensigngroup.net/20220630", "presentation": [ "http://www.ensigngroup.net/role/OptionsandAwardsOptionsOutstandingbyExercisePriceDetails" ], "xbrltype": "domainItemType" }, "ensg_ExercisePriceRangeSevenMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Exercise Price Range Seven [Member]", "label": "Exercise Price Range Seven [Member]", "terseLabel": "2018" } } }, "localname": "ExercisePriceRangeSevenMember", "nsuri": "http://www.ensigngroup.net/20220630", "presentation": [ "http://www.ensigngroup.net/role/OptionsandAwardsOptionsOutstandingbyExercisePriceDetails" ], "xbrltype": "domainItemType" }, "ensg_ExercisePriceRangeSixMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Exercise Price Range Six [Member]", "label": "Exercise Price Range Six [Member]", "terseLabel": "2017" } } }, "localname": "ExercisePriceRangeSixMember", "nsuri": "http://www.ensigngroup.net/20220630", "presentation": [ "http://www.ensigngroup.net/role/OptionsandAwardsOptionsOutstandingbyExercisePriceDetails" ], "xbrltype": "domainItemType" }, "ensg_ExercisePriceRangeTenMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Exercise Price Range Ten [Member]", "label": "Exercise Price Range Ten [Member]", "terseLabel": "2021" } } }, "localname": "ExercisePriceRangeTenMember", "nsuri": "http://www.ensigngroup.net/20220630", "presentation": [ "http://www.ensigngroup.net/role/OptionsandAwardsOptionsOutstandingbyExercisePriceDetails" ], "xbrltype": "domainItemType" }, "ensg_ExercisePriceRangeThreeMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Exercise Price Range Three [Member]", "label": "Exercise Price Range Three [Member]", "terseLabel": "2014" } } }, "localname": "ExercisePriceRangeThreeMember", "nsuri": "http://www.ensigngroup.net/20220630", "presentation": [ "http://www.ensigngroup.net/role/OptionsandAwardsOptionsOutstandingbyExercisePriceDetails" ], "xbrltype": "domainItemType" }, "ensg_ExercisePriceRangeTwoMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Exercise Price Range Two [Member]", "label": "Exercise Price Range Two [Member]", "terseLabel": "2013" } } }, "localname": "ExercisePriceRangeTwoMember", "nsuri": "http://www.ensigngroup.net/20220630", "presentation": [ "http://www.ensigngroup.net/role/OptionsandAwardsOptionsOutstandingbyExercisePriceDetails" ], "xbrltype": "domainItemType" }, "ensg_FacilitiesUnderMasterLeaseArrangement": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Facilities operated under two separate three-facility master lease arrangements. Under these master leases, a breach at a single facility could subject one or more of the other facilities covered by the same master lease to the same default risk.", "label": "Facilities Under Master Lease Arrangement", "terseLabel": "Facilities under master lease arrangement" } } }, "localname": "FacilitiesUnderMasterLeaseArrangement", "nsuri": "http://www.ensigngroup.net/20220630", "presentation": [ "http://www.ensigngroup.net/role/LeasesLesseeNarrativeDetails" ], "xbrltype": "integerItemType" }, "ensg_FacilitiesUnderMedicareProbeReviews": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Facilities under Medicare Probe reviews relating to Medicare services, billings and potential overpayments", "label": "Facilities Under Medicare Probe Reviews", "terseLabel": "Facilities under Medicare probe reviews" } } }, "localname": "FacilitiesUnderMedicareProbeReviews", "nsuri": "http://www.ensigngroup.net/20220630", "presentation": [ "http://www.ensigngroup.net/role/CommitmentsandContingenciesDetails" ], "xbrltype": "integerItemType" }, "ensg_FamilyFirstCoronavirusResponseActPaymentsReceived": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Family First Coronavirus Response Act, Payments Received", "label": "Family First Coronavirus Response Act, Payments Received", "terseLabel": "FMAP payments received" } } }, "localname": "FamilyFirstCoronavirusResponseActPaymentsReceived", "nsuri": "http://www.ensigngroup.net/20220630", "presentation": [ "http://www.ensigngroup.net/role/COVID19UpdateDetails" ], "xbrltype": "monetaryItemType" }, "ensg_February92022RepurchaseProgramMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "February 9, 2022 Repurchase Program", "label": "February 9, 2022 Repurchase Program [Member]", "terseLabel": "February 9, 2022 Repurchase Program" } } }, "localname": "February92022RepurchaseProgramMember", "nsuri": "http://www.ensigngroup.net/20220630", "presentation": [ "http://www.ensigngroup.net/role/CommonStockRepurchaseProgramDetails" ], "xbrltype": "domainItemType" }, "ensg_GainLossOnInsuranceClaimsAndDisposalOfAssets": { "auth_ref": [], "calculation": { "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 11.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Gain (Loss) On Insurance Claims And Disposal Of Assets", "label": "Gain (Loss) On Insurance Claims And Disposal Of Assets", "negatedLabel": "Loss on insurance claims, legal finding and asset disposals" } } }, "localname": "GainLossOnInsuranceClaimsAndDisposalOfAssets", "nsuri": "http://www.ensigngroup.net/20220630", "presentation": [ "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "ensg_HealthLiabilityInsuranceMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Health Liability Insurance [Member]", "label": "Health Liability Insurance [Member]", "terseLabel": "Health Liability Insurance" } } }, "localname": "HealthLiabilityInsuranceMember", "nsuri": "http://www.ensigngroup.net/20220630", "presentation": [ "http://www.ensigngroup.net/role/SummaryofSignificantAccountingPoliciesSelfInsuranceDetails" ], "xbrltype": "domainItemType" }, "ensg_InsuranceCoverageLimitTypeAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Insurance Coverage Limit Type [Axis]", "label": "Insurance Coverage Limit Type [Axis]", "terseLabel": "Insurance Coverage Limit Type [Axis]" } } }, "localname": "InsuranceCoverageLimitTypeAxis", "nsuri": "http://www.ensigngroup.net/20220630", "presentation": [ "http://www.ensigngroup.net/role/SummaryofSignificantAccountingPoliciesSelfInsuranceDetails" ], "xbrltype": "stringItemType" }, "ensg_InsuranceCoverageLimitTypeDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Insurance Coverage Limit Type [Domain]", "label": "Insurance Coverage Limit Type [Domain]", "terseLabel": "Insurance Coverage Limit Type [Domain]" } } }, "localname": "InsuranceCoverageLimitTypeDomain", "nsuri": "http://www.ensigngroup.net/20220630", "presentation": [ "http://www.ensigngroup.net/role/SummaryofSignificantAccountingPoliciesSelfInsuranceDetails" ], "xbrltype": "domainItemType" }, "ensg_InsuranceSubsidiaryDepositsAndInvestments": { "auth_ref": [], "calculation": { "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 4.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Captive insurance subsidiary cash and equivalents designated to support long-term insurance subsidiary liabilities and debt security investments held to maturity.", "label": "Insurance Subsidiary Deposits And Investments", "terseLabel": "Insurance subsidiary deposits and investments" } } }, "localname": "InsuranceSubsidiaryDepositsAndInvestments", "nsuri": "http://www.ensigngroup.net/20220630", "presentation": [ "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "ensg_InvestmentExpenseIncome": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Investment Expense (Income)", "label": "Investment Expense (Income)", "terseLabel": "Deferral investment expense (income)" } } }, "localname": "InvestmentExpenseIncome", "nsuri": "http://www.ensigngroup.net/20220630", "presentation": [ "http://www.ensigngroup.net/role/RestrictedandOtherAssetsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "ensg_July2022RepurchaseProgramMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "July 2022 Repurchase Program", "label": "July 2022 Repurchase Program [Member]", "terseLabel": "July 2022 Repurchase Program" } } }, "localname": "July2022RepurchaseProgramMember", "nsuri": "http://www.ensigngroup.net/20220630", "presentation": [ "http://www.ensigngroup.net/role/CommonStockRepurchaseProgramDetails" ], "xbrltype": "domainItemType" }, "ensg_LeaseArrangementAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by group of related lease arrangements.", "label": "Lease Arrangement [Axis]", "terseLabel": "Lease Arrangement [Axis]" } } }, "localname": "LeaseArrangementAxis", "nsuri": "http://www.ensigngroup.net/20220630", "presentation": [ "http://www.ensigngroup.net/role/LeasesLesseeNarrativeDetails", "http://www.ensigngroup.net/role/LeasesLessorRentalIncomeDetails", "http://www.ensigngroup.net/role/StandardBearerDetails" ], "xbrltype": "stringItemType" }, "ensg_LeaseArrangementDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Lease Arrangement", "label": "Lease Arrangement [Domain]", "terseLabel": "Lease Arrangement [Domain]" } } }, "localname": "LeaseArrangementDomain", "nsuri": "http://www.ensigngroup.net/20220630", "presentation": [ "http://www.ensigngroup.net/role/LeasesLesseeNarrativeDetails", "http://www.ensigngroup.net/role/LeasesLessorRentalIncomeDetails", "http://www.ensigngroup.net/role/StandardBearerDetails" ], "xbrltype": "domainItemType" }, "ensg_LesseeLeasingArrangementsOperatingLeasesNumberOfRenewalTerms": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Lessee Leasing Arrangements, Operating Leases, Number Of Renewal Terms", "label": "Lessee Leasing Arrangements, Operating Leases, Number Of Renewal Terms", "terseLabel": "Lessee leasing arrangements, operating leases, number of renewal terms" } } }, "localname": "LesseeLeasingArrangementsOperatingLeasesNumberOfRenewalTerms", "nsuri": "http://www.ensigngroup.net/20220630", "presentation": [ "http://www.ensigngroup.net/role/LeasesLesseeNarrativeDetails", "http://www.ensigngroup.net/role/StandardBearerDetails" ], "xbrltype": "integerItemType" }, "ensg_LesseeOperatingLeaseNumberOfLeases": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Lessee, Operating Lease, Number Of Leases", "label": "Lessee, Operating Lease, Number Of Leases", "terseLabel": "Number of stand-alone leases" } } }, "localname": "LesseeOperatingLeaseNumberOfLeases", "nsuri": "http://www.ensigngroup.net/20220630", "presentation": [ "http://www.ensigngroup.net/role/LeasesLesseeNarrativeDetails" ], "xbrltype": "integerItemType" }, "ensg_LesseeOperatingLeaseTermExtension": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Lessee, Operating Lease, Term Extension", "label": "Lessee, Operating Lease, Term Extension", "terseLabel": "Lessee, operating lease, term extension" } } }, "localname": "LesseeOperatingLeaseTermExtension", "nsuri": "http://www.ensigngroup.net/20220630", "presentation": [ "http://www.ensigngroup.net/role/LeasesLesseeNarrativeDetails" ], "xbrltype": "durationItemType" }, "ensg_LiabilitiesDeferredTaxPaymentsUnderCARESAct": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Liabilities, Deferred Tax Payments Under CARES Act", "label": "Liabilities, Deferred Tax Payments Under CARES Act", "terseLabel": "Total deferred payment of social security taxes" } } }, "localname": "LiabilitiesDeferredTaxPaymentsUnderCARESAct", "nsuri": "http://www.ensigngroup.net/20220630", "presentation": [ "http://www.ensigngroup.net/role/COVID19UpdateDetails" ], "xbrltype": "monetaryItemType" }, "ensg_LiabilitiesDeferredTaxPaymentsUnderCARESActCurrent": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Liabilities, Deferred Tax Payments Under CARES Act, Current", "label": "Liabilities, Deferred Tax Payments Under CARES Act, Current", "terseLabel": "Deferred payment of social security taxes, current" } } }, "localname": "LiabilitiesDeferredTaxPaymentsUnderCARESActCurrent", "nsuri": "http://www.ensigngroup.net/20220630", "presentation": [ "http://www.ensigngroup.net/role/COVID19UpdateDetails" ], "xbrltype": "monetaryItemType" }, "ensg_LiabilitiesDeferredTaxPaymentsUnderCARESActNoncurrent": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Liabilities, Deferred Tax Payments Under CARES Act, Noncurrent", "label": "Liabilities, Deferred Tax Payments Under CARES Act, Noncurrent", "terseLabel": "Deferred payment of social security taxes, noncurrent" } } }, "localname": "LiabilitiesDeferredTaxPaymentsUnderCARESActNoncurrent", "nsuri": "http://www.ensigngroup.net/20220630", "presentation": [ "http://www.ensigngroup.net/role/COVID19UpdateDetails" ], "xbrltype": "monetaryItemType" }, "ensg_LongTermDebtNetOfCurrentMaturitiesAndDebtDiscount": { "auth_ref": [], "calculation": { "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 2.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Long Term Debt, net of Current Maturities and Debt Discount", "label": "Long Term Debt, net of Current Maturities and Debt Discount", "terseLabel": "Long-term debt\u2014less current maturities" } } }, "localname": "LongTermDebtNetOfCurrentMaturitiesAndDebtDiscount", "nsuri": "http://www.ensigngroup.net/20220630", "presentation": [ "http://www.ensigngroup.net/role/DebtScheduleofLongtermDebtDetails", "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "ensg_LongTermDebtThresholdForEBITDARatioIncreaseElection": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Long-Term Debt, Threshold For EBITDA Ratio Increase Election", "label": "Long-Term Debt, Threshold For EBITDA Ratio Increase Election", "terseLabel": "Long-term debt, threshold for EBITDA ratio increase election" } } }, "localname": "LongTermDebtThresholdForEBITDARatioIncreaseElection", "nsuri": "http://www.ensigngroup.net/20220630", "presentation": [ "http://www.ensigngroup.net/role/DebtCreditFacilitywithaLendingConsortiumArrangedbySunTrustDetails" ], "xbrltype": "monetaryItemType" }, "ensg_LossSensitivelimitperclaimMemberMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Loss-Sensitive limit per claim", "label": "Loss-Sensitive limit per claim [Member] [Member]", "terseLabel": "Loss-Sensitive Limit Per Claim" } } }, "localname": "LossSensitivelimitperclaimMemberMember", "nsuri": "http://www.ensigngroup.net/20220630", "presentation": [ "http://www.ensigngroup.net/role/SummaryofSignificantAccountingPoliciesSelfInsuranceDetails" ], "xbrltype": "domainItemType" }, "ensg_ManagedCareMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Revenue from managed care payors [Member]", "label": "Managed Care [Member]", "terseLabel": "Managed care" } } }, "localname": "ManagedCareMember", "nsuri": "http://www.ensigngroup.net/20220630", "presentation": [ "http://www.ensigngroup.net/role/BusinessSegmentsRevenuebySegmentDetails", "http://www.ensigngroup.net/role/RevenueandAccountsReceivableAccountsReceivableDetails", "http://www.ensigngroup.net/role/RevenueandAccountsReceivableDisaggregationofRevenueDetails" ], "xbrltype": "domainItemType" }, "ensg_ManagementServiceTotalMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Management Service, Total", "label": "Management Service, Total [Member]", "terseLabel": "Total Management Fee" } } }, "localname": "ManagementServiceTotalMember", "nsuri": "http://www.ensigngroup.net/20220630", "presentation": [ "http://www.ensigngroup.net/role/StandardBearerDetails" ], "xbrltype": "domainItemType" }, "ensg_MasterLeaseAgreements": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Master Lease agreements", "label": "Master Lease Agreements", "terseLabel": "Master lease agreements" } } }, "localname": "MasterLeaseAgreements", "nsuri": "http://www.ensigngroup.net/20220630", "presentation": [ "http://www.ensigngroup.net/role/LeasesLesseeNarrativeDetails" ], "xbrltype": "integerItemType" }, "ensg_MedicaidAndMedicareMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Total revenue from Medicaid and Medicare [Member]", "label": "Medicaid and Medicare [Member]", "terseLabel": "Total Medicare and Medicaid", "verboseLabel": "Total Medicaid and Medicare" } } }, "localname": "MedicaidAndMedicareMember", "nsuri": "http://www.ensigngroup.net/20220630", "presentation": [ "http://www.ensigngroup.net/role/BusinessSegmentsRevenuebySegmentDetails", "http://www.ensigngroup.net/role/CommitmentsandContingenciesDetails", "http://www.ensigngroup.net/role/RevenueandAccountsReceivableDisaggregationofRevenueDetails", "http://www.ensigngroup.net/role/RevenueandAccountsReceivableRevenuefromMedicareandMedicaidProgramsDetails" ], "xbrltype": "domainItemType" }, "ensg_MedicaidMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Revenue from Medicaid for custodial services [Member]", "label": "Medicaid [Member]", "terseLabel": "Medicaid" } } }, "localname": "MedicaidMember", "nsuri": "http://www.ensigngroup.net/20220630", "presentation": [ "http://www.ensigngroup.net/role/BusinessSegmentsRevenuebySegmentDetails", "http://www.ensigngroup.net/role/RevenueandAccountsReceivableAccountsReceivableDetails", "http://www.ensigngroup.net/role/RevenueandAccountsReceivableDisaggregationofRevenueDetails" ], "xbrltype": "domainItemType" }, "ensg_MedicaidSkilledMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Revenue from Medicaid for skilled services [Member]", "label": "Medicaid-skilled [Member]", "terseLabel": "Medicaid \u2014 skilled" } } }, "localname": "MedicaidSkilledMember", "nsuri": "http://www.ensigngroup.net/20220630", "presentation": [ "http://www.ensigngroup.net/role/BusinessSegmentsRevenuebySegmentDetails", "http://www.ensigngroup.net/role/RevenueandAccountsReceivableDisaggregationofRevenueDetails" ], "xbrltype": "domainItemType" }, "ensg_MedicareAcceleratedAndAdvancePaymentCARESACT": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Medicare Accelerated And Advance Payment, CARES ACT", "label": "Medicare Accelerated And Advance Payment, CARES ACT", "terseLabel": "Medicare Accelerated and Advance Payment" } } }, "localname": "MedicareAcceleratedAndAdvancePaymentCARESACT", "nsuri": "http://www.ensigngroup.net/20220630", "presentation": [ "http://www.ensigngroup.net/role/COVID19UpdateDetails" ], "xbrltype": "monetaryItemType" }, "ensg_MedicareMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Revenue from Medicare [Member]", "label": "Medicare [Member]", "terseLabel": "Medicare" } } }, "localname": "MedicareMember", "nsuri": "http://www.ensigngroup.net/20220630", "presentation": [ "http://www.ensigngroup.net/role/BusinessSegmentsRevenuebySegmentDetails", "http://www.ensigngroup.net/role/RevenueandAccountsReceivableAccountsReceivableDetails", "http://www.ensigngroup.net/role/RevenueandAccountsReceivableDisaggregationofRevenueDetails" ], "xbrltype": "domainItemType" }, "ensg_MedicareandMedicaidLicensesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Medicare licenses for home health and hospice segment and all other segment.", "label": "Medicare and Medicaid Licenses [Member]", "terseLabel": "Medicare and Medicaid licenses" } } }, "localname": "MedicareandMedicaidLicensesMember", "nsuri": "http://www.ensigngroup.net/20220630", "presentation": [ "http://www.ensigngroup.net/role/GoodwillandOtherIndefiniteLivedIntangibleAssetsIndefiniteLivedIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "ensg_NonCaliforniaMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Non-California [Domain]", "label": "Non-California [Member]", "terseLabel": "Non-California" } } }, "localname": "NonCaliforniaMember", "nsuri": "http://www.ensigngroup.net/20220630", "presentation": [ "http://www.ensigngroup.net/role/SummaryofSignificantAccountingPoliciesSelfInsuranceDetails" ], "xbrltype": "domainItemType" }, "ensg_NonCashLeaseExpense": { "auth_ref": [], "calculation": { "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Non-Cash Lease Expense", "label": "Non-Cash Lease Expense", "terseLabel": "Non-cash leasing arrangement" } } }, "localname": "NonCashLeaseExpense", "nsuri": "http://www.ensigngroup.net/20220630", "presentation": [ "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "ensg_NoncontrollingInterestPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The noncontrolling interest in a subsidiary initially recognized at estimated fair value on the acquisition date and is presented within total equity in the Company's condensed consolidated balance sheets.", "label": "Noncontrolling Interest [Policy Text Block]", "terseLabel": "Noncontrolling Interest" } } }, "localname": "NoncontrollingInterestPolicyTextBlock", "nsuri": "http://www.ensigngroup.net/20220630", "presentation": [ "http://www.ensigngroup.net/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "ensg_NumberOfBusinessesAcquiredSubjectToLeaseAmendment": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of Businesses Acquired Subject To Lease Amendment", "label": "Number of Businesses Acquired Subject To Lease Amendment", "terseLabel": "Number of businesses acquired subject to lease amendment" } } }, "localname": "NumberOfBusinessesAcquiredSubjectToLeaseAmendment", "nsuri": "http://www.ensigngroup.net/20220630", "presentation": [ "http://www.ensigngroup.net/role/LeasesLesseeNarrativeDetails" ], "xbrltype": "integerItemType" }, "ensg_NumberOfHealthCareFacilities": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number Of Health Care Facilities", "label": "Number Of Health Care Facilities", "terseLabel": "Health care facilities" } } }, "localname": "NumberOfHealthCareFacilities", "nsuri": "http://www.ensigngroup.net/20220630", "presentation": [ "http://www.ensigngroup.net/role/DescriptionofBusinessDetails" ], "xbrltype": "integerItemType" }, "ensg_NumberOfLeaseArrangements": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of Lease Arrangements", "label": "Number of Lease Arrangements", "terseLabel": "Number of master lease arrangements" } } }, "localname": "NumberOfLeaseArrangements", "nsuri": "http://www.ensigngroup.net/20220630", "presentation": [ "http://www.ensigngroup.net/role/StandardBearerDetails" ], "xbrltype": "integerItemType" }, "ensg_NumberOfLivingOperationsTransferredFromThirdParties": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of Living Operations Transferred From Third-Parties", "label": "Number of Living Operations Transferred From Third-Parties", "terseLabel": "Number of operations transferred from third parties" } } }, "localname": "NumberOfLivingOperationsTransferredFromThirdParties", "nsuri": "http://www.ensigngroup.net/20220630", "presentation": [ "http://www.ensigngroup.net/role/OperationExpansionsDetails" ], "xbrltype": "integerItemType" }, "ensg_NumberOfOperatingSubsidiaries": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number Of operating subsidiaries entered into mortgage loans that are insured with HUD.", "label": "Number Of Operating Subsidiaries", "terseLabel": "Number of operating subsidiaries" } } }, "localname": "NumberOfOperatingSubsidiaries", "nsuri": "http://www.ensigngroup.net/20220630", "presentation": [ "http://www.ensigngroup.net/role/DebtMortgageLoansandPromissoryNotesandOffBalanceSheetArrangementsDetails" ], "xbrltype": "integerItemType" }, "ensg_NumberOfPropertiesAcquired": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number Of Properties Acquired", "label": "Number Of Properties Acquired", "terseLabel": "Number of real estate skilled nursing properties acquired" } } }, "localname": "NumberOfPropertiesAcquired", "nsuri": "http://www.ensigngroup.net/20220630", "presentation": [ "http://www.ensigngroup.net/role/OperationExpansionsDetails" ], "xbrltype": "integerItemType" }, "ensg_NumberOfRealEstatePropertiesLeased": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of Real Estate Properties Leased", "label": "Number of Real Estate Properties Leased", "terseLabel": "Number of real estate properties leased" } } }, "localname": "NumberOfRealEstatePropertiesLeased", "nsuri": "http://www.ensigngroup.net/20220630", "presentation": [ "http://www.ensigngroup.net/role/DescriptionofBusinessDetails" ], "xbrltype": "integerItemType" }, "ensg_NumberOfRealEstatePropertiesLeasedWithOptionToPurchase": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of Real Estate Properties Leased with an Option to Purchase", "label": "Number of Real Estate Properties Leased with an Option to Purchase", "terseLabel": "Number of real estate properties leased with an option to purchase" } } }, "localname": "NumberOfRealEstatePropertiesLeasedWithOptionToPurchase", "nsuri": "http://www.ensigngroup.net/20220630", "presentation": [ "http://www.ensigngroup.net/role/DescriptionofBusinessDetails" ], "xbrltype": "integerItemType" }, "ensg_October212021RepurchaseProgramMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "October 21, 2021 Repurchase Program", "label": "October 21, 2021 Repurchase Program [Member]", "terseLabel": "October 21, 2021 Repurchase Program" } } }, "localname": "October212021RepurchaseProgramMember", "nsuri": "http://www.ensigngroup.net/20220630", "presentation": [ "http://www.ensigngroup.net/role/CommonStockRepurchaseProgramDetails" ], "xbrltype": "domainItemType" }, "ensg_OperatingEntityAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Operating Entity [Axis]", "label": "Operating Entity [Axis]", "terseLabel": "Operating Entity [Axis]" } } }, "localname": "OperatingEntityAxis", "nsuri": "http://www.ensigngroup.net/20220630", "presentation": [ "http://www.ensigngroup.net/role/BusinessSegmentsNarrativeDetails", "http://www.ensigngroup.net/role/DescriptionofBusinessDetails", "http://www.ensigngroup.net/role/LeasesLessorNarrativeDetails", "http://www.ensigngroup.net/role/StandardBearerDetails" ], "xbrltype": "stringItemType" }, "ensg_OperatingEntityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "[Domain] for Operating Entity [Axis]", "label": "Operating Entity [Domain]", "terseLabel": "Operating Entity [Domain]" } } }, "localname": "OperatingEntityDomain", "nsuri": "http://www.ensigngroup.net/20220630", "presentation": [ "http://www.ensigngroup.net/role/BusinessSegmentsNarrativeDetails", "http://www.ensigngroup.net/role/DescriptionofBusinessDetails", "http://www.ensigngroup.net/role/LeasesLessorNarrativeDetails", "http://www.ensigngroup.net/role/StandardBearerDetails" ], "xbrltype": "domainItemType" }, "ensg_OperationalSeniorLivingUnits": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Operational Assisted Living and Independent Living Units", "label": "Operational Senior Living Units", "terseLabel": "Operational senior living units" } } }, "localname": "OperationalSeniorLivingUnits", "nsuri": "http://www.ensigngroup.net/20220630", "presentation": [ "http://www.ensigngroup.net/role/DescriptionofBusinessDetails", "http://www.ensigngroup.net/role/OperationExpansionsDetails" ], "xbrltype": "integerItemType" }, "ensg_OperationalSkilledNursingBeds": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of skilled nursing beds available for use at a skilled nursing facility", "label": "Operational Skilled Nursing Beds", "terseLabel": "Operational skilled nursing beds" } } }, "localname": "OperationalSkilledNursingBeds", "nsuri": "http://www.ensigngroup.net/20220630", "presentation": [ "http://www.ensigngroup.net/role/DescriptionofBusinessDetails", "http://www.ensigngroup.net/role/LeasesLesseeNarrativeDetails", "http://www.ensigngroup.net/role/OperationExpansionsDetails" ], "xbrltype": "integerItemType" }, "ensg_OtherStatesExceptCaliforniaTexasAndWashingtonMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Other states, except California, Texas and Washington", "label": "Other states, except California, Texas and Washington [Member]", "terseLabel": "Other States, Except California, Texas and Washington" } } }, "localname": "OtherStatesExceptCaliforniaTexasAndWashingtonMember", "nsuri": "http://www.ensigngroup.net/20220630", "presentation": [ "http://www.ensigngroup.net/role/SummaryofSignificantAccountingPoliciesSelfInsuranceDetails" ], "xbrltype": "domainItemType" }, "ensg_OwnedPropertiesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Owned Properties", "label": "Owned Properties [Member]", "terseLabel": "Owned Properties" } } }, "localname": "OwnedPropertiesMember", "nsuri": "http://www.ensigngroup.net/20220630", "presentation": [ "http://www.ensigngroup.net/role/OperationExpansionsDetails", "http://www.ensigngroup.net/role/StandardBearerDetails" ], "xbrltype": "domainItemType" }, "ensg_PaymentsToAcquireAssetAcquisitions": { "auth_ref": [], "calculation": { "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Cash paid to acquire acquisitions.", "label": "Payments To Acquire Asset Acquisitions", "negatedTerseLabel": "Cash payments for asset acquisitions (Note 9)", "terseLabel": "Purchase price" } } }, "localname": "PaymentsToAcquireAssetAcquisitions", "nsuri": "http://www.ensigngroup.net/20220630", "presentation": [ "http://www.ensigngroup.net/role/OperationExpansionsDetails", "http://www.ensigngroup.net/role/StandardBearerDetails", "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "ensg_PaymentsToAcquireBusinessAndAssetAcquisitions": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Cash paid to acquire acquisitions.", "label": "Payments To Acquire Business And Asset Acquisitions", "terseLabel": "Payments to acquire business and asset acquisitions" } } }, "localname": "PaymentsToAcquireBusinessAndAssetAcquisitions", "nsuri": "http://www.ensigngroup.net/20220630", "presentation": [ "http://www.ensigngroup.net/role/OperationExpansionsDetails" ], "xbrltype": "monetaryItemType" }, "ensg_PaymentsToAcquirePropertyAndEquipment": { "auth_ref": [], "calculation": { "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Payments To Acquire Property And Equipment", "label": "Payments To Acquire Property And Equipment", "negatedLabel": "Purchase of property and equipment" } } }, "localname": "PaymentsToAcquirePropertyAndEquipment", "nsuri": "http://www.ensigngroup.net/20220630", "presentation": [ "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "ensg_PayorAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Payor [Axis]", "label": "Payor [Axis]", "terseLabel": "Payor [Axis]" } } }, "localname": "PayorAxis", "nsuri": "http://www.ensigngroup.net/20220630", "presentation": [ "http://www.ensigngroup.net/role/SummaryofSignificantAccountingPoliciesSelfInsuranceDetails" ], "xbrltype": "stringItemType" }, "ensg_PayorDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Payor [Domain]", "label": "Payor [Domain]", "terseLabel": "Payor [Domain]" } } }, "localname": "PayorDomain", "nsuri": "http://www.ensigngroup.net/20220630", "presentation": [ "http://www.ensigngroup.net/role/SummaryofSignificantAccountingPoliciesSelfInsuranceDetails" ], "xbrltype": "domainItemType" }, "ensg_PerFacilityMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Per Facility [Member]", "label": "Per Facility [Member]", "terseLabel": "Per Facility" } } }, "localname": "PerFacilityMember", "nsuri": "http://www.ensigngroup.net/20220630", "presentation": [ "http://www.ensigngroup.net/role/SummaryofSignificantAccountingPoliciesSelfInsuranceDetails" ], "xbrltype": "domainItemType" }, "ensg_PerOccurenceMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Per Occurence [Member]", "label": "Per Occurence [Member]", "terseLabel": "Per Occurence" } } }, "localname": "PerOccurenceMember", "nsuri": "http://www.ensigngroup.net/20220630", "presentation": [ "http://www.ensigngroup.net/role/SummaryofSignificantAccountingPoliciesSelfInsuranceDetails" ], "xbrltype": "domainItemType" }, "ensg_PrepaymentPenaltyReducedRateDuringFirstThreeYears": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage that the prepayment penalty percentage is reduced during the first three years.", "label": "Prepayment Penalty Reduced Rate During First Three Years", "terseLabel": "Prepayment penalty reduced rate during first three years" } } }, "localname": "PrepaymentPenaltyReducedRateDuringFirstThreeYears", "nsuri": "http://www.ensigngroup.net/20220630", "presentation": [ "http://www.ensigngroup.net/role/DebtMortgageLoansandPromissoryNotesandOffBalanceSheetArrangementsDetails" ], "xbrltype": "percentItemType" }, "ensg_PrepaymentPenaltyReducedRateDuringTheFourthYear": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage that the prepayment penalty percentage is reduced during the fourth year.", "label": "Prepayment Penalty Reduced Rate During The Fourth Year", "terseLabel": "Prepayment penalty reduced rate during the fourth year" } } }, "localname": "PrepaymentPenaltyReducedRateDuringTheFourthYear", "nsuri": "http://www.ensigngroup.net/20220630", "presentation": [ "http://www.ensigngroup.net/role/DebtMortgageLoansandPromissoryNotesandOffBalanceSheetArrangementsDetails" ], "xbrltype": "percentItemType" }, "ensg_PrepaymentPenaltyReducedRateForTheFifthThroughTenthYears": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage that the prepayment penalty percentage is reduced for the fifth through tenth years.", "label": "Prepayment Penalty Reduced Rate For The Fifth Through Tenth Years", "terseLabel": "Prepayment penalty reduced rate for the fifth through tenth years" } } }, "localname": "PrepaymentPenaltyReducedRateForTheFifthThroughTenthYears", "nsuri": "http://www.ensigngroup.net/20220630", "presentation": [ "http://www.ensigngroup.net/role/DebtMortgageLoansandPromissoryNotesandOffBalanceSheetArrangementsDetails" ], "xbrltype": "percentItemType" }, "ensg_PrivatePayAndOtherMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Revenue from self-pay and Other payors [Member]", "label": "Private Pay and Other [Member]", "terseLabel": "Private and other payors", "verboseLabel": "Private and other" } } }, "localname": "PrivatePayAndOtherMember", "nsuri": "http://www.ensigngroup.net/20220630", "presentation": [ "http://www.ensigngroup.net/role/BusinessSegmentsRevenuebySegmentDetails", "http://www.ensigngroup.net/role/RevenueandAccountsReceivableAccountsReceivableDetails", "http://www.ensigngroup.net/role/RevenueandAccountsReceivableDisaggregationofRevenueDetails" ], "xbrltype": "domainItemType" }, "ensg_ProceedsFromCARESActProviderReliefFundsAndMedicareAdvancePaymentProgram": { "auth_ref": [], "calculation": { "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Proceeds From CARES Act Provider Relief Funds And Medicare Advance Payment Program", "label": "Proceeds From CARES Act Provider Relief Funds And Medicare Advance Payment Program", "terseLabel": "Proceeds from CARES Act Provider Relief Fund and Medicare Advance Payment Program (Note 3)" } } }, "localname": "ProceedsFromCARESActProviderReliefFundsAndMedicareAdvancePaymentProgram", "nsuri": "http://www.ensigngroup.net/20220630", "presentation": [ "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "ensg_ProceedsFromSaleOfCommonStockAssociatedWithSubsidiaryEquityPlans": { "auth_ref": [], "calculation": { "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Proceeds From Sale Of Common Stock Associated With Subsidiary Equity Plans", "label": "Proceeds From Sale Of Common Stock Associated With Subsidiary Equity Plans", "terseLabel": "Proceeds from sale of subsidiary shares (Note 7)" } } }, "localname": "ProceedsFromSaleOfCommonStockAssociatedWithSubsidiaryEquityPlans", "nsuri": "http://www.ensigngroup.net/20220630", "presentation": [ "http://www.ensigngroup.net/role/StandardBearerDetails", "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "ensg_PromissoryNote50Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Promissory Note, 5.0%", "label": "Promissory Note, 5.0% [Member]", "terseLabel": "Promissory Note, 5.0%" } } }, "localname": "PromissoryNote50Member", "nsuri": "http://www.ensigngroup.net/20220630", "presentation": [ "http://www.ensigngroup.net/role/DebtMortgageLoansandPromissoryNotesandOffBalanceSheetArrangementsDetails" ], "xbrltype": "domainItemType" }, "ensg_PromissoryNote53Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Promissory Note, 5.3%", "label": "Promissory Note, 5.3% [Member]", "terseLabel": "Promissory Note, 5.3%" } } }, "localname": "PromissoryNote53Member", "nsuri": "http://www.ensigngroup.net/20220630", "presentation": [ "http://www.ensigngroup.net/role/DebtMortgageLoansandPromissoryNotesandOffBalanceSheetArrangementsDetails" ], "xbrltype": "domainItemType" }, "ensg_PropertyManagementFeePercentFeeOfFundsFromOperations": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Property Management Fee, Percent Fee of Funds from Operations", "label": "Property Management Fee, Percent Fee of Funds from Operations", "terseLabel": "Management fees, as a percentage of funds from operations" } } }, "localname": "PropertyManagementFeePercentFeeOfFundsFromOperations", "nsuri": "http://www.ensigngroup.net/20220630", "presentation": [ "http://www.ensigngroup.net/role/StandardBearerDetails" ], "xbrltype": "percentItemType" }, "ensg_PropertyManagementFeePercentFeeOfTotalRevenues": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Property Management Fee, Percent Fee of Total Revenues", "label": "Property Management Fee, Percent Fee of Total Revenues", "terseLabel": "Management fees, as a percentage of total revenues" } } }, "localname": "PropertyManagementFeePercentFeeOfTotalRevenues", "nsuri": "http://www.ensigngroup.net/20220630", "presentation": [ "http://www.ensigngroup.net/role/StandardBearerDetails" ], "xbrltype": "percentItemType" }, "ensg_PurchaseOptionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Purchase Option", "label": "Purchase Option [Member]", "terseLabel": "Purchase Option" } } }, "localname": "PurchaseOptionMember", "nsuri": "http://www.ensigngroup.net/20220630", "presentation": [ "http://www.ensigngroup.net/role/LeasesLesseeNarrativeDetails" ], "xbrltype": "domainItemType" }, "ensg_PurchasesOfNonControllingInterest": { "auth_ref": [], "calculation": { "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 12.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Purchases of Non-Controlling Interest", "label": "Purchases of Non-Controlling Interest", "negatedLabel": "Purchase of non-controlling interest" } } }, "localname": "PurchasesOfNonControllingInterest", "nsuri": "http://www.ensigngroup.net/20220630", "presentation": [ "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "ensg_QualityAssuranceFee": { "auth_ref": [], "calculation": { "http://www.ensigngroup.net/role/OtherAccruedLiabilitiesDetails": { "order": 4.0, "parentTag": "us-gaap_OtherAccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Quality assurance fee represents amounts payable to California, Utah, Idaho, Washington, Colorado, Iowa, and Nebraska in respect of a mandated fee based on resident days", "label": "Quality Assurance Fee", "terseLabel": "Quality assurance fee" } } }, "localname": "QualityAssuranceFee", "nsuri": "http://www.ensigngroup.net/20220630", "presentation": [ "http://www.ensigngroup.net/role/OtherAccruedLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "ensg_RemainingCompanyMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The Ensign Group, Inc.", "label": "Remaining Company [Member]", "terseLabel": "Remaining Company" } } }, "localname": "RemainingCompanyMember", "nsuri": "http://www.ensigngroup.net/20220630", "presentation": [ "http://www.ensigngroup.net/role/BusinessSegmentsNarrativeDetails", "http://www.ensigngroup.net/role/DescriptionofBusinessDetails" ], "xbrltype": "domainItemType" }, "ensg_RentCostOfServices": { "auth_ref": [], "calculation": { "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME": { "order": 2.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Rent cost of services", "label": "Rent Cost Of Services", "terseLabel": "Rent\u2014cost of services" } } }, "localname": "RentCostOfServices", "nsuri": "http://www.ensigngroup.net/20220630", "presentation": [ "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME" ], "xbrltype": "monetaryItemType" }, "ensg_RentCostOfServicesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Rent, Cost Of Servcies[Member]", "label": "Rent, Cost Of Services [Member]", "terseLabel": "Rent - cost of services" } } }, "localname": "RentCostOfServicesMember", "nsuri": "http://www.ensigngroup.net/20220630", "presentation": [ "http://www.ensigngroup.net/role/LeasesLesseeLeaseCostDetails" ], "xbrltype": "domainItemType" }, "ensg_RentalMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Rental", "label": "Rental [Member]", "terseLabel": "Rental revenue" } } }, "localname": "RentalMember", "nsuri": "http://www.ensigngroup.net/20220630", "presentation": [ "http://www.ensigngroup.net/role/BusinessSegmentsNarrativeDetails", "http://www.ensigngroup.net/role/BusinessSegmentsRevenuebySegmentDetails", "http://www.ensigngroup.net/role/BusinessSegmentsScheduleofSegmentReportingInformationbySegmentDetails", "http://www.ensigngroup.net/role/RevenueandAccountsReceivableDisaggregationofRevenueDetails", "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME" ], "xbrltype": "domainItemType" }, "ensg_RepaymentOfFundsReceivedFromTheMedicareAcceleratedAndAdvancePaymentProgramCARESAct": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Repayment Of Funds Received From The Medicare Accelerated and Advance Payment Program, CARES Act", "label": "Repayment Of Funds Received From The Medicare Accelerated and Advance Payment Program, CARES Act", "terseLabel": "Repayment of Medicare Accelerated and Advance Payment Program" } } }, "localname": "RepaymentOfFundsReceivedFromTheMedicareAcceleratedAndAdvancePaymentProgramCARESAct", "nsuri": "http://www.ensigngroup.net/20220630", "presentation": [ "http://www.ensigngroup.net/role/COVID19UpdateDetails" ], "xbrltype": "monetaryItemType" }, "ensg_ResidentRefundsPayable": { "auth_ref": [], "calculation": { "http://www.ensigngroup.net/role/OtherAccruedLiabilitiesDetails": { "order": 5.0, "parentTag": "us-gaap_OtherAccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Resident refunds payable includes amounts due to residents for overpayments and duplicate payments", "label": "Resident Refunds Payable", "terseLabel": "Refunds payable" } } }, "localname": "ResidentRefundsPayable", "nsuri": "http://www.ensigngroup.net/20220630", "presentation": [ "http://www.ensigngroup.net/role/OtherAccruedLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "ensg_RevenueRecognitionFamilyFirstCoronavirusResponseActRevenueRecognized": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Revenue Recognition, Family First Coronavirus Response Act, Revenue Recognized", "label": "Revenue Recognition, Family First Coronavirus Response Act, Revenue Recognized", "terseLabel": "Revenue, FMAP payments received" } } }, "localname": "RevenueRecognitionFamilyFirstCoronavirusResponseActRevenueRecognized", "nsuri": "http://www.ensigngroup.net/20220630", "presentation": [ "http://www.ensigngroup.net/role/COVID19UpdateDetails" ], "xbrltype": "monetaryItemType" }, "ensg_SegmentIncomeLoss": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Segment Income (Loss)", "label": "Segment Income (Loss)", "terseLabel": "Segment income (loss)" } } }, "localname": "SegmentIncomeLoss", "nsuri": "http://www.ensigngroup.net/20220630", "presentation": [ "http://www.ensigngroup.net/role/BusinessSegmentsScheduleofSegmentReportingInformationbySegmentDetails" ], "xbrltype": "monetaryItemType" }, "ensg_SelfInsuranceRetentionPerClaimMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Self-insurance retention per claim [Member]", "label": "Self-insurance retention per claim [Member]", "terseLabel": "Self-Insurance Retention Per Claim" } } }, "localname": "SelfInsuranceRetentionPerClaimMember", "nsuri": "http://www.ensigngroup.net/20220630", "presentation": [ "http://www.ensigngroup.net/role/SummaryofSignificantAccountingPoliciesSelfInsuranceDetails" ], "xbrltype": "domainItemType" }, "ensg_SeniorLivingFacilities": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of Assisted and Independent Living Facilities", "label": "Senior Living Facilities", "terseLabel": "Senior living facilities" } } }, "localname": "SeniorLivingFacilities", "nsuri": "http://www.ensigngroup.net/20220630", "presentation": [ "http://www.ensigngroup.net/role/BusinessSegmentsNarrativeDetails" ], "xbrltype": "integerItemType" }, "ensg_SeniorLivingFacilitiesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Assisted Living Facilities [Member]", "label": "Senior Living Facilities [Member]", "terseLabel": "Senior Living Facilities" } } }, "localname": "SeniorLivingFacilitiesMember", "nsuri": "http://www.ensigngroup.net/20220630", "presentation": [ "http://www.ensigngroup.net/role/DescriptionofBusinessDetails", "http://www.ensigngroup.net/role/LeasesLessorNarrativeDetails", "http://www.ensigngroup.net/role/OperationExpansionsDetails" ], "xbrltype": "domainItemType" }, "ensg_SeniorLivingFacility": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Sale of a senior living facility", "label": "Senior Living Facility", "terseLabel": "Senior living facility" } } }, "localname": "SeniorLivingFacility", "nsuri": "http://www.ensigngroup.net/20220630", "presentation": [ "http://www.ensigngroup.net/role/LeasesLessorNarrativeDetails", "http://www.ensigngroup.net/role/PropertyandEquipmentNetNarrativeDetails" ], "xbrltype": "integerItemType" }, "ensg_SeniorLivingOperationsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Senior Living Operations", "label": "Senior Living Operations [Member]", "terseLabel": "Senior Living Operations" } } }, "localname": "SeniorLivingOperationsMember", "nsuri": "http://www.ensigngroup.net/20220630", "presentation": [ "http://www.ensigngroup.net/role/LeasesLessorNarrativeDetails", "http://www.ensigngroup.net/role/PropertyandEquipmentNetNarrativeDetails" ], "xbrltype": "domainItemType" }, "ensg_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfInstallments": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-based Compensation Arrangement By Share-based Payment Award, Number Of Installments", "label": "Share-based Compensation Arrangement By Share-based Payment Award, Number Of Installments", "terseLabel": "Number of installments" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfInstallments", "nsuri": "http://www.ensigngroup.net/20220630", "presentation": [ "http://www.ensigngroup.net/role/OptionsandAwardsStockOptionsNarrativeDetails" ], "xbrltype": "integerItemType" }, "ensg_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsConversionToReduceSharesAvailability": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Conversion To Reduce Shares Availability", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Conversion To Reduce Shares Availability", "terseLabel": "Conversion to reduce shares availability" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsConversionToReduceSharesAvailability", "nsuri": "http://www.ensigngroup.net/20220630", "presentation": [ "http://www.ensigngroup.net/role/OptionsandAwardsStockOptionsNarrativeDetails" ], "xbrltype": "pureItemType" }, "ensg_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "As of the balance sheet date, the number of shares which are expected to vest into stock options outstanding can be converted under the option plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Expected to Vest, Number", "terseLabel": "Share-based compensation, options expected to vest, number (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestNumber", "nsuri": "http://www.ensigngroup.net/20220630", "presentation": [ "http://www.ensigngroup.net/role/OptionsandAwardsCompensationExpenseDetails" ], "xbrltype": "sharesItemType" }, "ensg_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestOutstandingAggregateIntrinsicValue": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Expected to Vest, Outstanding, Aggregate Intrinsic Value", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Expected to Vest, Outstanding, Aggregate Intrinsic Value", "terseLabel": "Expected to vest" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestOutstandingAggregateIntrinsicValue", "nsuri": "http://www.ensigngroup.net/20220630", "presentation": [ "http://www.ensigngroup.net/role/OptionsandAwardsIntrinsicValuesDetails" ], "xbrltype": "monetaryItemType" }, "ensg_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsConversionToReduceSharesAvailability": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-based Compensation Arrangement By Share-based Payment Award, Other Than Options, Conversion To Reduce Shares Availability", "label": "Share-based Compensation Arrangement By Share-based Payment Award, Other Than Options, Conversion To Reduce Shares Availability", "terseLabel": "Other than options, conversion to reduce shares availability" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsConversionToReduceSharesAvailability", "nsuri": "http://www.ensigngroup.net/20220630", "presentation": [ "http://www.ensigngroup.net/role/OptionsandAwardsStockOptionsNarrativeDetails" ], "xbrltype": "pureItemType" }, "ensg_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeFairValue": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value determined using a black-scholes model for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range", "label": "Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Fair Value", "terseLabel": "Black-Scholes Fair Value" } } }, "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeFairValue", "nsuri": "http://www.ensigngroup.net/20220630", "presentation": [ "http://www.ensigngroup.net/role/OptionsandAwardsOptionsOutstandingbyExercisePriceDetails" ], "xbrltype": "monetaryItemType" }, "ensg_SharebasedCompensationRestrictedAwardsExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-based Compensation, Restricted Awards, Exercise Price", "label": "Share-based Compensation, Restricted Awards, Exercise Price", "terseLabel": "Share-based compensation, restricted awards, exercise price (in dollars per share)" } } }, "localname": "SharebasedCompensationRestrictedAwardsExercisePrice", "nsuri": "http://www.ensigngroup.net/20220630", "presentation": [ "http://www.ensigngroup.net/role/OptionsandAwardsRestrictedStockAwardsNarrativeDetails" ], "xbrltype": "perShareItemType" }, "ensg_SkilledNursingOperationsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Skilled Nursing Operations", "label": "Skilled Nursing Operations [Member]", "terseLabel": "Skilled Nursing Operations" } } }, "localname": "SkilledNursingOperationsMember", "nsuri": "http://www.ensigngroup.net/20220630", "presentation": [ "http://www.ensigngroup.net/role/BusinessSegmentsNarrativeDetails", "http://www.ensigngroup.net/role/DescriptionofBusinessDetails", "http://www.ensigngroup.net/role/LeasesLesseeNarrativeDetails", "http://www.ensigngroup.net/role/OperationExpansionsDetails" ], "xbrltype": "domainItemType" }, "ensg_SkilledNursingSeniorLivingAndIndependentLivingFacilities": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Skilled Nursing, Senior Living and Independent Living Facilities", "label": "Skilled Nursing, Senior Living and Independent Living Facilities", "terseLabel": "Skilled nursing, assisted living and independent living facilities" } } }, "localname": "SkilledNursingSeniorLivingAndIndependentLivingFacilities", "nsuri": "http://www.ensigngroup.net/20220630", "presentation": [ "http://www.ensigngroup.net/role/LeasesLesseeNarrativeDetails" ], "xbrltype": "integerItemType" }, "ensg_SkilledServiceFacilities": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Skilled Service Facilities", "label": "Skilled Service Facilities", "terseLabel": "Transitional and skilled service facilities" } } }, "localname": "SkilledServiceFacilities", "nsuri": "http://www.ensigngroup.net/20220630", "presentation": [ "http://www.ensigngroup.net/role/BusinessSegmentsNarrativeDetails" ], "xbrltype": "integerItemType" }, "ensg_SkilledServicesAndSeniorLivingCampuses": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Transitional and Skilled Services and Assistant and Independent Living Campuses", "label": "Skilled Services And Senior Living Campuses", "terseLabel": "Transitional and skilled services and senior living campuses" } } }, "localname": "SkilledServicesAndSeniorLivingCampuses", "nsuri": "http://www.ensigngroup.net/20220630", "presentation": [ "http://www.ensigngroup.net/role/BusinessSegmentsNarrativeDetails" ], "xbrltype": "integerItemType" }, "ensg_SkilledServicesSegmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Skilled Services Segment", "label": "Skilled Services Segment [Member]", "terseLabel": "Skilled Services" } } }, "localname": "SkilledServicesSegmentMember", "nsuri": "http://www.ensigngroup.net/20220630", "presentation": [ "http://www.ensigngroup.net/role/BusinessSegmentsRevenuebySegmentDetails", "http://www.ensigngroup.net/role/BusinessSegmentsScheduleofSegmentReportingInformationbySegmentDetails", "http://www.ensigngroup.net/role/GoodwillandOtherIndefiniteLivedIntangibleAssetsGoodwillRollforwardDetails" ], "xbrltype": "domainItemType" }, "ensg_StandardBearerEquityPlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Standard Bearer Equity Plan", "label": "Standard Bearer Equity Plan [Member]", "terseLabel": "Standard Bearer Equity Plan" } } }, "localname": "StandardBearerEquityPlanMember", "nsuri": "http://www.ensigngroup.net/20220630", "presentation": [ "http://www.ensigngroup.net/role/StandardBearerDetails" ], "xbrltype": "domainItemType" }, "ensg_StandardBearerHealthcareREITIncMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Standard Bearer Healthcare REIT, Inc.", "label": "Standard Bearer Healthcare REIT, Inc. [Member]", "terseLabel": "Standard Bearer" } } }, "localname": "StandardBearerHealthcareREITIncMember", "nsuri": "http://www.ensigngroup.net/20220630", "presentation": [ "http://www.ensigngroup.net/role/BusinessSegmentsNarrativeDetails", "http://www.ensigngroup.net/role/OperationExpansionsDetails", "http://www.ensigngroup.net/role/StandardBearerDetails" ], "xbrltype": "domainItemType" }, "ensg_StandardBearerMasterLeasesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Standard Bearer Master Leases", "label": "Standard Bearer Master Leases [Member]", "terseLabel": "Standard Bearer Master Leases" } } }, "localname": "StandardBearerMasterLeasesMember", "nsuri": "http://www.ensigngroup.net/20220630", "presentation": [ "http://www.ensigngroup.net/role/StandardBearerDetails" ], "xbrltype": "domainItemType" }, "ensg_StandardBearerSegmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Standard Bearer Segment", "label": "Standard Bearer Segment [Member]", "terseLabel": "Standard Bearer" } } }, "localname": "StandardBearerSegmentMember", "nsuri": "http://www.ensigngroup.net/20220630", "presentation": [ "http://www.ensigngroup.net/role/BusinessSegmentsScheduleofSegmentReportingInformationbySegmentDetails" ], "xbrltype": "domainItemType" }, "ensg_StandardBearerTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Standard Bearer", "label": "Standard Bearer [Text Block]", "terseLabel": "Standard Bearer" } } }, "localname": "StandardBearerTextBlock", "nsuri": "http://www.ensigngroup.net/20220630", "presentation": [ "http://www.ensigngroup.net/role/StandardBearer" ], "xbrltype": "textBlockItemType" }, "ensg_StockAwardsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Stock awards [Member]", "label": "Stock awards [Member]", "terseLabel": "Stock-based compensation expense related to stock options and restricted stock awards to non-employee directors" } } }, "localname": "StockAwardsMember", "nsuri": "http://www.ensigngroup.net/20220630", "presentation": [ "http://www.ensigngroup.net/role/OptionsandAwardsCompensationExpenseDetails" ], "xbrltype": "domainItemType" }, "ensg_StopLossInsuranceLimitPerClaimMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Stop-Loss Insurance limit per claim[Member]", "label": "Stop-Loss Insurance limit per claim [Member]", "terseLabel": "Stop-Loss Insurance Limit Per Claim" } } }, "localname": "StopLossInsuranceLimitPerClaimMember", "nsuri": "http://www.ensigngroup.net/20220630", "presentation": [ "http://www.ensigngroup.net/role/SummaryofSignificantAccountingPoliciesSelfInsuranceDetails" ], "xbrltype": "domainItemType" }, "ensg_ThePennantGroupInc.Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The Pennant Group, Inc.", "label": "The Pennant Group, Inc. [Member]", "terseLabel": "The Pennant Group, Inc.", "verboseLabel": "Pennant" } } }, "localname": "ThePennantGroupInc.Member", "nsuri": "http://www.ensigngroup.net/20220630", "presentation": [ "http://www.ensigngroup.net/role/DescriptionofBusinessDetails", "http://www.ensigngroup.net/role/LeasesLessorNarrativeDetails", "http://www.ensigngroup.net/role/LeasesLessorRentalIncomeDetails", "http://www.ensigngroup.net/role/StandardBearerDetails" ], "xbrltype": "domainItemType" }, "ensg_ThirdPartiesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Third Parties", "label": "Third Parties [Member]", "terseLabel": "Third Parties" } } }, "localname": "ThirdPartiesMember", "nsuri": "http://www.ensigngroup.net/20220630", "presentation": [ "http://www.ensigngroup.net/role/BusinessSegmentsNarrativeDetails" ], "xbrltype": "domainItemType" }, "ensg_ThirdPartyTenantsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Third Party Tenants [Member]", "label": "Third Party Tenants [Member]", "terseLabel": "Other third-party" } } }, "localname": "ThirdPartyTenantsMember", "nsuri": "http://www.ensigngroup.net/20220630", "presentation": [ "http://www.ensigngroup.net/role/LeasesLessorRentalIncomeDetails" ], "xbrltype": "domainItemType" }, "ensg_ThirdPartyTenantsUnderTripleNetLeaseArrangementsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Third Party Tenants Under Triple Net Lease Arrangements", "label": "Third Party Tenants Under Triple Net Lease Arrangements [Member]", "terseLabel": "Third Party Tenants Under Triple Net Lease Arrangements" } } }, "localname": "ThirdPartyTenantsUnderTripleNetLeaseArrangementsMember", "nsuri": "http://www.ensigngroup.net/20220630", "presentation": [ "http://www.ensigngroup.net/role/LeasesLesseeNarrativeDetails" ], "xbrltype": "domainItemType" }, "ensg_TotalNetDebtRatioMaximum": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Total Net Debt Ratio, Maximum", "label": "Total Net Debt Ratio, Maximum", "terseLabel": "Total net debt ratio, maximum" } } }, "localname": "TotalNetDebtRatioMaximum", "nsuri": "http://www.ensigngroup.net/20220630", "presentation": [ "http://www.ensigngroup.net/role/DebtCreditFacilitywithaLendingConsortiumArrangedbySunTrustDetails" ], "xbrltype": "pureItemType" }, "ensg_TotalNetDebtRatioMaximumAfterIncreaseElection": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Total Net Debt Ratio, Maximum After Increase Election", "label": "Total Net Debt Ratio, Maximum After Increase Election", "terseLabel": "Total net debt ratio, maximum after increase election" } } }, "localname": "TotalNetDebtRatioMaximumAfterIncreaseElection", "nsuri": "http://www.ensigngroup.net/20220630", "presentation": [ "http://www.ensigngroup.net/role/DebtCreditFacilitywithaLendingConsortiumArrangedbySunTrustDetails" ], "xbrltype": "pureItemType" }, "ensg_TotalNetDebtRatioMinimum": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Total Net Debt Ratio, Minimum", "label": "Total Net Debt Ratio, Minimum", "terseLabel": "Total net debt ratio, minimum" } } }, "localname": "TotalNetDebtRatioMinimum", "nsuri": "http://www.ensigngroup.net/20220630", "presentation": [ "http://www.ensigngroup.net/role/DebtCreditFacilitywithaLendingConsortiumArrangedbySunTrustDetails" ], "xbrltype": "pureItemType" }, "ensg_TruistBankMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Truist Bank [Member]", "label": "Truist Bank [Member]", "terseLabel": "Truist" } } }, "localname": "TruistBankMember", "nsuri": "http://www.ensigngroup.net/20220630", "presentation": [ "http://www.ensigngroup.net/role/DebtCreditFacilitywithaLendingConsortiumArrangedbySunTrustDetails", "http://www.ensigngroup.net/role/StandardBearerDetails", "http://www.ensigngroup.net/role/SummaryofSignificantAccountingPoliciesRecentAccountingPronouncementsDetails" ], "xbrltype": "domainItemType" }, "ensg_TwentyThreeSubsidiariesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Twenty Three Subsidiaries", "label": "Twenty Three Subsidiaries [Member]", "terseLabel": "Twenty Three Subsidiaries" } } }, "localname": "TwentyThreeSubsidiariesMember", "nsuri": "http://www.ensigngroup.net/20220630", "presentation": [ "http://www.ensigngroup.net/role/DebtMortgageLoansandPromissoryNotesandOffBalanceSheetArrangementsDetails" ], "xbrltype": "domainItemType" }, "ensg_TwoAcquisitionsConcentratedInGoodwillMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two Acquisitions Concentrated In Goodwill", "label": "Two Acquisitions Concentrated In Goodwill [Member]", "terseLabel": "Two Acquisitions Concentrated In Goodwill" } } }, "localname": "TwoAcquisitionsConcentratedInGoodwillMember", "nsuri": "http://www.ensigngroup.net/20220630", "presentation": [ "http://www.ensigngroup.net/role/OperationExpansionsDetails" ], "xbrltype": "domainItemType" }, "ensg_TwoAcquisitionsConcentratedInPropertyPlantAndEquipmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two Acquisitions Concentrated In Property, Plant And Equipment", "label": "Two Acquisitions Concentrated In Property, Plant And Equipment [Member]", "terseLabel": "Two Acquisitions Concentrated in Property, Plant And Equipment" } } }, "localname": "TwoAcquisitionsConcentratedInPropertyPlantAndEquipmentMember", "nsuri": "http://www.ensigngroup.net/20220630", "presentation": [ "http://www.ensigngroup.net/role/OperationExpansionsDetails" ], "xbrltype": "domainItemType" }, "ensg_VariousLandlordsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Various Landlords[Member]", "label": "Various Landlords [Member]", "terseLabel": "Various Landlords" } } }, "localname": "VariousLandlordsMember", "nsuri": "http://www.ensigngroup.net/20220630", "presentation": [ "http://www.ensigngroup.net/role/LeasesLesseeNarrativeDetails" ], "xbrltype": "domainItemType" }, "naics_ZZ524292": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "524292 Third Party Administration of Insurance and Pension Funds [Member]", "terseLabel": "Third-Party Payor" } } }, "localname": "ZZ524292", "nsuri": "http://xbrl.sec.gov/naics/2022", "presentation": [ "http://www.ensigngroup.net/role/SummaryofSignificantAccountingPoliciesSelfInsuranceDetails" ], "xbrltype": "domainItemType" }, "srt_ConsolidationEliminationsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Consolidation, Eliminations [Member]", "terseLabel": "Intercompany Elimination" } } }, "localname": "ConsolidationEliminationsMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.ensigngroup.net/role/BusinessSegmentsRevenuebySegmentDetails", "http://www.ensigngroup.net/role/BusinessSegmentsScheduleofSegmentReportingInformationbySegmentDetails" ], "xbrltype": "domainItemType" }, "srt_ConsolidationItemsAxis": { "auth_ref": [ "r106", "r157", "r170", "r171", "r172", "r173", "r175", "r177", "r181", "r284", "r285", "r286", "r287", "r288", "r289", "r291", "r292", "r294", "r296", "r297" ], "lang": { "en-us": { "role": { "label": "Consolidation Items [Axis]", "terseLabel": "Consolidation Items [Axis]" } } }, "localname": "ConsolidationItemsAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.ensigngroup.net/role/BusinessSegmentsRevenuebySegmentDetails", "http://www.ensigngroup.net/role/BusinessSegmentsScheduleofSegmentReportingInformationbySegmentDetails", "http://www.ensigngroup.net/role/GoodwillandOtherIndefiniteLivedIntangibleAssetsGoodwillRollforwardDetails" ], "xbrltype": "stringItemType" }, "srt_ConsolidationItemsDomain": { "auth_ref": [ "r106", "r157", "r170", "r171", "r172", "r173", "r175", "r177", "r181", "r284", "r285", "r286", "r287", "r288", "r289", "r291", "r292", "r294", "r296", "r297" ], "lang": { "en-us": { "role": { "label": "Consolidation Items [Domain]", "terseLabel": "Consolidation Items [Domain]" } } }, "localname": "ConsolidationItemsDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.ensigngroup.net/role/BusinessSegmentsRevenuebySegmentDetails", "http://www.ensigngroup.net/role/BusinessSegmentsScheduleofSegmentReportingInformationbySegmentDetails", "http://www.ensigngroup.net/role/GoodwillandOtherIndefiniteLivedIntangibleAssetsGoodwillRollforwardDetails" ], "xbrltype": "domainItemType" }, "srt_CounterpartyNameAxis": { "auth_ref": [ "r48", "r50", "r104", "r105", "r303", "r336" ], "lang": { "en-us": { "role": { "label": "Counterparty Name [Axis]", "terseLabel": "Counterparty Name [Axis]" } } }, "localname": "CounterpartyNameAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.ensigngroup.net/role/LeasesLesseeNarrativeDetails", "http://www.ensigngroup.net/role/LeasesLessorRentalIncomeDetails" ], "xbrltype": "stringItemType" }, "srt_MajorCustomersAxis": { "auth_ref": [ "r188", "r380", "r385", "r652" ], "lang": { "en-us": { "role": { "label": "Customer [Axis]", "terseLabel": "Customer [Axis]" } } }, "localname": "MajorCustomersAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.ensigngroup.net/role/BusinessSegmentsRevenuebySegmentDetails", "http://www.ensigngroup.net/role/CommitmentsandContingenciesDetails", "http://www.ensigngroup.net/role/RevenueandAccountsReceivableAccountsReceivableDetails", "http://www.ensigngroup.net/role/RevenueandAccountsReceivableDisaggregationofRevenueDetails", "http://www.ensigngroup.net/role/RevenueandAccountsReceivableRevenuefromMedicareandMedicaidProgramsDetails" ], "xbrltype": "stringItemType" }, "srt_MaximumMember": { "auth_ref": [ "r278", "r279", "r280", "r281", "r302", "r335", "r401", "r403", "r584", "r585", "r586", "r587", "r588", "r589", "r608", "r649", "r653", "r680", "r681" ], "lang": { "en-us": { "role": { "label": "Maximum [Member]", "terseLabel": "Maximum" } } }, "localname": "MaximumMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.ensigngroup.net/role/DebtCreditFacilitywithaLendingConsortiumArrangedbySunTrustDetails", "http://www.ensigngroup.net/role/DebtMortgageLoansandPromissoryNotesandOffBalanceSheetArrangementsDetails", "http://www.ensigngroup.net/role/LeasesLesseeNarrativeDetails", "http://www.ensigngroup.net/role/LeasesLessorNarrativeDetails", "http://www.ensigngroup.net/role/OptionsandAwardsRestrictedStockAwardsNarrativeDetails", "http://www.ensigngroup.net/role/StandardBearerDetails", "http://www.ensigngroup.net/role/SummaryofSignificantAccountingPoliciesIntangibleAssetsandGoodwillDetails", "http://www.ensigngroup.net/role/SummaryofSignificantAccountingPoliciesLeasesandLeaseholdImprovementsDetails", "http://www.ensigngroup.net/role/SummaryofSignificantAccountingPoliciesPropertyandEquipmentDetails" ], "xbrltype": "domainItemType" }, "srt_MinimumMember": { "auth_ref": [ "r278", "r279", "r280", "r281", "r302", "r335", "r401", "r403", "r584", "r585", "r586", "r587", "r588", "r589", "r608", "r649", "r653", "r680", "r681" ], "lang": { "en-us": { "role": { "label": "Minimum [Member]", "terseLabel": "Minimum" } } }, "localname": "MinimumMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.ensigngroup.net/role/DebtCreditFacilitywithaLendingConsortiumArrangedbySunTrustDetails", "http://www.ensigngroup.net/role/DebtMortgageLoansandPromissoryNotesandOffBalanceSheetArrangementsDetails", "http://www.ensigngroup.net/role/LeasesLesseeNarrativeDetails", "http://www.ensigngroup.net/role/LeasesLessorNarrativeDetails", "http://www.ensigngroup.net/role/OptionsandAwardsRestrictedStockAwardsNarrativeDetails", "http://www.ensigngroup.net/role/StandardBearerDetails", "http://www.ensigngroup.net/role/SummaryofSignificantAccountingPoliciesIntangibleAssetsandGoodwillDetails", "http://www.ensigngroup.net/role/SummaryofSignificantAccountingPoliciesLeasesandLeaseholdImprovementsDetails", "http://www.ensigngroup.net/role/SummaryofSignificantAccountingPoliciesPropertyandEquipmentDetails" ], "xbrltype": "domainItemType" }, "srt_NameOfMajorCustomerDomain": { "auth_ref": [ "r188", "r380", "r385", "r652" ], "lang": { "en-us": { "role": { "label": "Customer [Domain]", "terseLabel": "Customer [Domain]" } } }, "localname": "NameOfMajorCustomerDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.ensigngroup.net/role/BusinessSegmentsRevenuebySegmentDetails", "http://www.ensigngroup.net/role/CommitmentsandContingenciesDetails", "http://www.ensigngroup.net/role/RevenueandAccountsReceivableAccountsReceivableDetails", "http://www.ensigngroup.net/role/RevenueandAccountsReceivableDisaggregationofRevenueDetails", "http://www.ensigngroup.net/role/RevenueandAccountsReceivableRevenuefromMedicareandMedicaidProgramsDetails" ], "xbrltype": "domainItemType" }, "srt_OwnershipAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Ownership [Axis]", "terseLabel": "Ownership [Axis]" } } }, "localname": "OwnershipAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.ensigngroup.net/role/BusinessSegmentsNarrativeDetails", "http://www.ensigngroup.net/role/DescriptionofBusinessDetails" ], "xbrltype": "stringItemType" }, "srt_OwnershipDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Ownership [Domain]", "terseLabel": "Ownership [Domain]" } } }, "localname": "OwnershipDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.ensigngroup.net/role/BusinessSegmentsNarrativeDetails", "http://www.ensigngroup.net/role/DescriptionofBusinessDetails" ], "xbrltype": "domainItemType" }, "srt_ParentCompanyMember": { "auth_ref": [ "r106" ], "lang": { "en-us": { "role": { "label": "Parent Company [Member]", "terseLabel": "Parent Company" } } }, "localname": "ParentCompanyMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.ensigngroup.net/role/SummaryofSignificantAccountingPoliciesSelfInsuranceDetails" ], "xbrltype": "domainItemType" }, "srt_ProductOrServiceAxis": { "auth_ref": [ "r184", "r279", "r280", "r380", "r383", "r609", "r648", "r650" ], "lang": { "en-us": { "role": { "label": "Product and Service [Axis]", "terseLabel": "Product and Service [Axis]" } } }, "localname": "ProductOrServiceAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.ensigngroup.net/role/BusinessSegmentsNarrativeDetails", "http://www.ensigngroup.net/role/BusinessSegmentsRevenuebySegmentDetails", "http://www.ensigngroup.net/role/BusinessSegmentsScheduleofSegmentReportingInformationbySegmentDetails", "http://www.ensigngroup.net/role/RevenueandAccountsReceivableDisaggregationofRevenueDetails", "http://www.ensigngroup.net/role/StandardBearerDetails", "http://www.ensigngroup.net/role/SummaryofSignificantAccountingPoliciesSelfInsuranceDetails", "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME" ], "xbrltype": "stringItemType" }, "srt_ProductsAndServicesDomain": { "auth_ref": [ "r184", "r279", "r280", "r380", "r383", "r609", "r648", "r650" ], "lang": { "en-us": { "role": { "label": "Product and Service [Domain]", "terseLabel": "Product and Service [Domain]" } } }, "localname": "ProductsAndServicesDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.ensigngroup.net/role/BusinessSegmentsNarrativeDetails", "http://www.ensigngroup.net/role/BusinessSegmentsRevenuebySegmentDetails", "http://www.ensigngroup.net/role/BusinessSegmentsScheduleofSegmentReportingInformationbySegmentDetails", "http://www.ensigngroup.net/role/RevenueandAccountsReceivableDisaggregationofRevenueDetails", "http://www.ensigngroup.net/role/StandardBearerDetails", "http://www.ensigngroup.net/role/SummaryofSignificantAccountingPoliciesSelfInsuranceDetails", "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME" ], "xbrltype": "domainItemType" }, "srt_RangeAxis": { "auth_ref": [ "r266", "r278", "r279", "r280", "r281", "r302", "r335", "r391", "r401", "r403", "r438", "r439", "r440", "r584", "r585", "r586", "r587", "r588", "r589", "r608", "r649", "r653", "r680", "r681" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Axis]", "terseLabel": "Statistical Measurement [Axis]" } } }, "localname": "RangeAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.ensigngroup.net/role/DebtCreditFacilitywithaLendingConsortiumArrangedbySunTrustDetails", "http://www.ensigngroup.net/role/DebtMortgageLoansandPromissoryNotesandOffBalanceSheetArrangementsDetails", "http://www.ensigngroup.net/role/LeasesLesseeNarrativeDetails", "http://www.ensigngroup.net/role/LeasesLessorNarrativeDetails", "http://www.ensigngroup.net/role/OptionsandAwardsRestrictedStockAwardsNarrativeDetails", "http://www.ensigngroup.net/role/StandardBearerDetails", "http://www.ensigngroup.net/role/SummaryofSignificantAccountingPoliciesIntangibleAssetsandGoodwillDetails", "http://www.ensigngroup.net/role/SummaryofSignificantAccountingPoliciesLeasesandLeaseholdImprovementsDetails", "http://www.ensigngroup.net/role/SummaryofSignificantAccountingPoliciesPropertyandEquipmentDetails" ], "xbrltype": "stringItemType" }, "srt_RangeMember": { "auth_ref": [ "r266", "r278", "r279", "r280", "r281", "r302", "r335", "r391", "r401", "r403", "r438", "r439", "r440", "r584", "r585", "r586", "r587", "r588", "r589", "r608", "r649", "r653", "r680", "r681" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Domain]", "terseLabel": "Statistical Measurement [Domain]" } } }, "localname": "RangeMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.ensigngroup.net/role/DebtCreditFacilitywithaLendingConsortiumArrangedbySunTrustDetails", "http://www.ensigngroup.net/role/DebtMortgageLoansandPromissoryNotesandOffBalanceSheetArrangementsDetails", "http://www.ensigngroup.net/role/LeasesLesseeNarrativeDetails", "http://www.ensigngroup.net/role/LeasesLessorNarrativeDetails", "http://www.ensigngroup.net/role/OptionsandAwardsRestrictedStockAwardsNarrativeDetails", "http://www.ensigngroup.net/role/StandardBearerDetails", "http://www.ensigngroup.net/role/SummaryofSignificantAccountingPoliciesIntangibleAssetsandGoodwillDetails", "http://www.ensigngroup.net/role/SummaryofSignificantAccountingPoliciesLeasesandLeaseholdImprovementsDetails", "http://www.ensigngroup.net/role/SummaryofSignificantAccountingPoliciesPropertyandEquipmentDetails" ], "xbrltype": "domainItemType" }, "srt_RepurchaseAgreementCounterpartyNameDomain": { "auth_ref": [ "r49", "r50", "r104", "r105", "r303", "r336" ], "lang": { "en-us": { "role": { "label": "Counterparty Name [Domain]", "terseLabel": "Counterparty Name [Domain]" } } }, "localname": "RepurchaseAgreementCounterpartyNameDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.ensigngroup.net/role/LeasesLesseeNarrativeDetails", "http://www.ensigngroup.net/role/LeasesLessorRentalIncomeDetails" ], "xbrltype": "domainItemType" }, "srt_SegmentGeographicalDomain": { "auth_ref": [ "r185", "r186", "r380", "r384", "r651", "r671", "r672", "r673", "r674", "r675", "r676", "r677", "r678", "r679" ], "lang": { "en-us": { "role": { "label": "Geographical [Domain]", "terseLabel": "Geographical [Domain]" } } }, "localname": "SegmentGeographicalDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.ensigngroup.net/role/SummaryofSignificantAccountingPoliciesSelfInsuranceDetails" ], "xbrltype": "domainItemType" }, "srt_StatementGeographicalAxis": { "auth_ref": [ "r185", "r186", "r380", "r384", "r651", "r662", "r671", "r672", "r673", "r674", "r675", "r676", "r677", "r678", "r679" ], "lang": { "en-us": { "role": { "label": "Geographical [Axis]", "terseLabel": "Geographical [Axis]" } } }, "localname": "StatementGeographicalAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.ensigngroup.net/role/SummaryofSignificantAccountingPoliciesSelfInsuranceDetails" ], "xbrltype": "stringItemType" }, "stpr_CA": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CALIFORNIA", "terseLabel": "California" } } }, "localname": "CA", "nsuri": "http://xbrl.sec.gov/stpr/2022", "presentation": [ "http://www.ensigngroup.net/role/SummaryofSignificantAccountingPoliciesSelfInsuranceDetails" ], "xbrltype": "domainItemType" }, "stpr_CO": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "COLORADO", "terseLabel": "Colorado" } } }, "localname": "CO", "nsuri": "http://xbrl.sec.gov/stpr/2022", "presentation": [ "http://www.ensigngroup.net/role/SummaryofSignificantAccountingPoliciesSelfInsuranceDetails" ], "xbrltype": "domainItemType" }, "stpr_TX": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "TEXAS", "terseLabel": "TEXAS" } } }, "localname": "TX", "nsuri": "http://xbrl.sec.gov/stpr/2022", "presentation": [ "http://www.ensigngroup.net/role/SummaryofSignificantAccountingPoliciesSelfInsuranceDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]", "terseLabel": "Accounting Policies [Abstract]" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_AccountsNotesAndLoansReceivableLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Accounts, Notes, Loans and Financing Receivable [Line Items]", "terseLabel": "Accounts, Notes, Loans and Financing Receivable [Line Items]" } } }, "localname": "AccountsNotesAndLoansReceivableLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/RevenueandAccountsReceivableAccountsReceivableDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": { "auth_ref": [ "r34" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.", "label": "Accounts Payable and Accrued Liabilities Disclosure [Text Block]", "terseLabel": "OTHER ACCRUED LIABILITIES" } } }, "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/OtherAccruedLiabilities" ], "xbrltype": "textBlockItemType" }, "us-gaap_AccountsPayableCurrent": { "auth_ref": [ "r33", "r576" ], "calculation": { "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accounts Payable, Current", "terseLabel": "Accounts payable" } } }, "localname": "AccountsPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsReceivableGross": { "auth_ref": [ "r24", "r190" ], "calculation": { "http://www.ensigngroup.net/role/RevenueandAccountsReceivableAccountsReceivableDetails": { "order": 1.0, "parentTag": "us-gaap_AccountsReceivableNetCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business.", "label": "Accounts Receivable, before Allowance for Credit Loss", "terseLabel": "Accounts receivable" } } }, "localname": "AccountsReceivableGross", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/RevenueandAccountsReceivableAccountsReceivableDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsReceivableMember": { "auth_ref": [ "r665" ], "lang": { "en-us": { "role": { "documentation": "Due from customers or clients for goods or services that have been delivered or sold.", "label": "Accounts Receivable [Member]", "terseLabel": "Accounts Receivable" } } }, "localname": "AccountsReceivableMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/CommitmentsandContingenciesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccountsReceivableNetCurrent": { "auth_ref": [ "r190", "r191" ], "calculation": { "http://www.ensigngroup.net/role/RevenueandAccountsReceivableAccountsReceivableDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.", "label": "Accounts Receivable, after Allowance for Credit Loss, Current", "terseLabel": "Accounts receivable\u2014less allowance for doubtful accounts of $7,827 and $11,213 at June\u00a030, 2022 and December\u00a031, 2021, respectively", "totalLabel": "ACCOUNTS RECEIVABLE, NET" } } }, "localname": "AccountsReceivableNetCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/RevenueandAccountsReceivableAccountsReceivableDetails", "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrentAndNoncurrent": { "auth_ref": [ "r459", "r622", "r643" ], "calculation": { "http://www.ensigngroup.net/role/OtherAccruedLiabilitiesDetails": { "order": 7.0, "parentTag": "us-gaap_OtherAccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for real and property taxes.", "label": "Accrual for Taxes Other than Income Taxes", "terseLabel": "Property taxes" } } }, "localname": "AccrualForTaxesOtherThanIncomeTaxesCurrentAndNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/OtherAccruedLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedProfessionalFeesCurrent": { "auth_ref": [ "r38" ], "calculation": { "http://www.ensigngroup.net/role/OtherAccruedLiabilitiesDetails": { "order": 3.0, "parentTag": "us-gaap_OtherAccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Professional Fees, Current", "terseLabel": "Legal finding accrued" } } }, "localname": "AccruedProfessionalFeesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/OtherAccruedLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "auth_ref": [ "r13", "r258" ], "calculation": { "http://www.ensigngroup.net/role/PropertyandEquipmentNetDetails": { "order": 2.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.", "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment", "negatedTerseLabel": "Less: accumulated depreciation" } } }, "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/PropertyandEquipmentNetDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Acquired Finite-Lived Intangible Assets [Line Items]", "terseLabel": "Acquired Finite-Lived Intangible Assets [Line Items]" } } }, "localname": "AcquiredFiniteLivedIntangibleAssetsLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/IntangibleAssetsNetScheduleofFiniteLivedIntangibleAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife": { "auth_ref": [ "r241" ], "lang": { "en-us": { "role": { "documentation": "Weighted average amortization period of finite-lived intangible assets acquired either individually or as part of a group of assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Acquired Finite-Lived Intangible Assets, Weighted Average Useful Life", "terseLabel": "Weighted Average Life (Years)" } } }, "localname": "AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/IntangibleAssetsNetScheduleofFiniteLivedIntangibleAssetsDetails" ], "xbrltype": "durationItemType" }, "us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Additional Cash Flow Elements and Supplemental Cash Flow Information [Abstract]", "terseLabel": "Cash paid during the period for:" } } }, "localname": "AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "stringItemType" }, "us-gaap_AdditionalPaidInCapitalCommonStock": { "auth_ref": [ "r25" ], "calculation": { "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.", "label": "Additional Paid in Capital, Common Stock", "terseLabel": "Additional paid-in capital" } } }, "localname": "AdditionalPaidInCapitalCommonStock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [ "r108", "r109", "r110", "r451", "r452", "r453", "r518" ], "lang": { "en-us": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid-in Capital [Member]", "terseLabel": "Additional Paid-In Capital" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of decrease to equity for grantee's tax withholding obligation for award under share-based payment arrangement.", "label": "Share-Based Payment Arrangement, Decrease for Tax Withholding Obligation", "negatedTerseLabel": "Shares of common stock used to satisfy tax withholding obligations" } } }, "localname": "AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "auth_ref": [ "r405", "r456", "r457" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.", "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition", "terseLabel": "Employee stock award compensation" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Adjustments to reconcile net income to net cash provided by operating activities:" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "stringItemType" }, "us-gaap_AllOtherSegmentsMember": { "auth_ref": [ "r152", "r170", "r171", "r172", "r173", "r175" ], "lang": { "en-us": { "role": { "documentation": "Operating segments classified as other. Excludes intersegment elimination and reconciling items.", "label": "Other Segments [Member]", "terseLabel": "All Other" } } }, "localname": "AllOtherSegmentsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/BusinessSegmentsScheduleofSegmentReportingInformationbySegmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AllocatedShareBasedCompensationExpense": { "auth_ref": [ "r444" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.", "label": "Share-Based Payment Arrangement, Expense", "verboseLabel": "TOTAL" } } }, "localname": "AllocatedShareBasedCompensationExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/OptionsandAwardsCompensationExpenseDetails", "http://www.ensigngroup.net/role/OptionsandAwardsLongTermIncentivePlanDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent": { "auth_ref": [ "r30", "r196", "r213" ], "calculation": { "http://www.ensigngroup.net/role/RevenueandAccountsReceivableAccountsReceivableDetails": { "order": 2.0, "parentTag": "us-gaap_AccountsReceivableNetCurrent", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of allowance for credit loss on accounts receivable, classified as current.", "label": "Accounts Receivable, Allowance for Credit Loss, Current", "negatedTerseLabel": "Less: allowance for doubtful accounts", "terseLabel": "Allowance for doubtful accounts" } } }, "localname": "AllowanceForDoubtfulAccountsReceivableCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/RevenueandAccountsReceivableAccountsReceivableDetails", "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical" ], "xbrltype": "monetaryItemType" }, "us-gaap_AmortizationOfFinancingCostsAndDiscounts": { "auth_ref": [ "r88", "r322", "r331", "r332", "r543" ], "calculation": { "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.", "label": "Amortization of Debt Issuance Costs and Discounts", "terseLabel": "Amortization of deferred financing fees" } } }, "localname": "AmortizationOfFinancingCostsAndDiscounts", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_AmortizationOfIntangibleAssets": { "auth_ref": [ "r88", "r239", "r247" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.", "label": "Amortization of Intangible Assets", "terseLabel": "Amortization of intangible assets" } } }, "localname": "AmortizationOfIntangibleAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/IntangibleAssetsNetNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "auth_ref": [ "r132" ], "lang": { "en-us": { "role": { "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "terseLabel": "Antidilutive securities excluded from computation of earnings per share, amount (in shares)" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/ComputationofNetIncomePerCommonShareDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_AssetAcquisitionAxis": { "auth_ref": [ "r492" ], "lang": { "en-us": { "role": { "documentation": "Information by asset acquisition.", "label": "Asset Acquisition [Axis]", "terseLabel": "Asset Acquisition [Axis]" } } }, "localname": "AssetAcquisitionAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/OperationExpansionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AssetAcquisitionConsiderationTransferred": { "auth_ref": [ "r493", "r494", "r495", "r496" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of consideration transferred in asset acquisition. Includes, but is not limited to, cash, liability incurred by acquirer, and equity interest issued by acquirer.", "label": "Asset Acquisition, Consideration Transferred", "terseLabel": "Asset acquisition, purchase price" } } }, "localname": "AssetAcquisitionConsiderationTransferred", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/OperationExpansionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetAcquisitionDomain": { "auth_ref": [ "r492" ], "lang": { "en-us": { "role": { "documentation": "Asset acquisition.", "label": "Asset Acquisition [Domain]", "terseLabel": "Asset Acquisition [Domain]" } } }, "localname": "AssetAcquisitionDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/OperationExpansionsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_Assets": { "auth_ref": [ "r17", "r100", "r165", "r172", "r179", "r210", "r284", "r285", "r286", "r288", "r289", "r290", "r291", "r293", "r295", "r297", "r298", "r503", "r509", "r531", "r574", "r576", "r614", "r635" ], "calculation": { "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets", "totalLabel": "TOTAL ASSETS" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets [Abstract]", "terseLabel": "ASSETS" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r9", "r32", "r100", "r210", "r284", "r285", "r286", "r288", "r289", "r290", "r291", "r293", "r295", "r297", "r298", "r503", "r509", "r531", "r574", "r576" ], "calculation": { "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Current", "totalLabel": "Total current assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets, Current [Abstract]", "terseLabel": "Current assets:" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "stringItemType" }, "us-gaap_AwardTypeAxis": { "auth_ref": [ "r409", "r410", "r411", "r413", "r415", "r416", "r417", "r418", "r419", "r420", "r421", "r423", "r424", "r425", "r426", "r427", "r428", "r430", "r431", "r432", "r433", "r437", "r438", "r439", "r440", "r441" ], "lang": { "en-us": { "role": { "documentation": "Information by type of award under share-based payment arrangement.", "label": "Award Type [Axis]", "terseLabel": "Award Type [Axis]" } } }, "localname": "AwardTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/OptionsandAwardsCompensationExpenseDetails", "http://www.ensigngroup.net/role/OptionsandAwardsIntrinsicValuesDetails", "http://www.ensigngroup.net/role/OptionsandAwardsRestrictedAwardRollforwardDetails", "http://www.ensigngroup.net/role/OptionsandAwardsRestrictedStockAwardsNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BaseRateMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Minimum rate investor will accept.", "label": "Base Rate [Member]", "terseLabel": "Base Rate" } } }, "localname": "BaseRateMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/DebtCreditFacilitywithaLendingConsortiumArrangedbySunTrustDetails", "http://www.ensigngroup.net/role/StandardBearerDetails" ], "xbrltype": "domainItemType" }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).", "label": "Basis of Accounting, Policy [Policy Text Block]", "terseLabel": "Basis of Presentation" } } }, "localname": "BasisOfAccountingPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock": { "auth_ref": [ "r107" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity.", "label": "Basis of Presentation and Significant Accounting Policies [Text Block]", "terseLabel": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES" } } }, "localname": "BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/SummaryofSignificantAccountingPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_BuildingAndBuildingImprovementsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Facility held for productive use including, but not limited to, office, production, storage and distribution facilities and any addition, improvement, or renovation to the structure, for example, but not limited to, interior masonry, interior flooring, electrical, and plumbing.", "label": "Building and Building Improvements [Member]", "terseLabel": "Buildings and improvements" } } }, "localname": "BuildingAndBuildingImprovementsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/PropertyandEquipmentNetDetails" ], "xbrltype": "domainItemType" }, "us-gaap_BusinessAcquisitionAcquireeDomain": { "auth_ref": [ "r400", "r402", "r487" ], "lang": { "en-us": { "role": { "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.", "label": "Business Acquisition, Acquiree [Domain]", "terseLabel": "Business Acquisition, Acquiree [Domain]" } } }, "localname": "BusinessAcquisitionAcquireeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/BusinessSegmentsNarrativeDetails", "http://www.ensigngroup.net/role/DescriptionofBusinessDetails", "http://www.ensigngroup.net/role/LeasesLesseeNarrativeDetails", "http://www.ensigngroup.net/role/OperationExpansionsDetails", "http://www.ensigngroup.net/role/StandardBearerDetails" ], "xbrltype": "domainItemType" }, "us-gaap_BusinessAcquisitionAxis": { "auth_ref": [ "r400", "r402", "r485", "r486", "r487" ], "lang": { "en-us": { "role": { "documentation": "Information by business combination or series of individually immaterial business combinations.", "label": "Business Acquisition [Axis]", "terseLabel": "Business Acquisition [Axis]" } } }, "localname": "BusinessAcquisitionAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/BusinessSegmentsNarrativeDetails", "http://www.ensigngroup.net/role/DescriptionofBusinessDetails", "http://www.ensigngroup.net/role/LeasesLesseeNarrativeDetails", "http://www.ensigngroup.net/role/OperationExpansionsDetails", "http://www.ensigngroup.net/role/StandardBearerDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessAcquisitionLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Business Acquisition [Line Items]", "terseLabel": "Business Acquisition [Line Items]" } } }, "localname": "BusinessAcquisitionLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/OperationExpansionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessCombinationAndAssetAcquisitionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Business Combination and Asset Acquisition [Abstract]" } } }, "localname": "BusinessCombinationAndAssetAcquisitionAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_BusinessCombinationDisclosureTextBlock": { "auth_ref": [ "r488", "r497" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).", "label": "Business Combination Disclosure [Text Block]", "terseLabel": "Operation Expansions" } } }, "localname": "BusinessCombinationDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/OperationExpansions" ], "xbrltype": "textBlockItemType" }, "us-gaap_CapitalExpendituresIncurredButNotYetPaid": { "auth_ref": [ "r92", "r93", "r94" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred.", "label": "Capital Expenditures Incurred but Not yet Paid", "terseLabel": "Accrued capital expenditures" } } }, "localname": "CapitalExpendituresIncurredButNotYetPaid", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r7", "r11", "r90" ], "calculation": { "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 1.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash and Cash Equivalents, at Carrying Value", "terseLabel": "Cash and cash equivalents" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsFairValueDisclosure": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash and Cash Equivalents, Fair Value Disclosure", "terseLabel": "Cash and cash equivalents, fair value disclosure" } } }, "localname": "CashAndCashEquivalentsFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/FairValueMeasurementsScheduleofFairValueofAssetsandLiabilitiesMeasuredonRecurringBasisDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": { "auth_ref": [ "r83", "r90", "r95" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations", "periodEndLabel": "Cash and cash equivalents end of period", "periodStartLabel": "Cash and cash equivalents beginning of period" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "auth_ref": [ "r83", "r532" ], "calculation": { "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "totalLabel": "Net increase (decrease) in cash and cash equivalents" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashSurrenderValueOfLifeInsurance": { "auth_ref": [ "r16" ], "calculation": { "http://www.ensigngroup.net/role/RestrictedandOtherAssetsDetails": { "order": 5.0, "parentTag": "us-gaap_OtherRestrictedAssetsNoncurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Carrying amount as of the balance sheet date of amounts which could be received based on the terms of the insurance contract upon surrendering life policies owned by the entity.", "label": "Cash Surrender Value of Life Insurance", "terseLabel": "Deferred compensation plan investments" } } }, "localname": "CashSurrenderValueOfLifeInsurance", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/RestrictedandOtherAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashUninsuredAmount": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of cash as of the balance sheet date that is not insured by the Federal Deposit Insurance Corporation.", "label": "Cash, Uninsured Amount", "terseLabel": "Cash, uninsured amount" } } }, "localname": "CashUninsuredAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/CommitmentsandContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ClassOfTreasuryStockTable": { "auth_ref": [ "r356", "r357", "r358", "r359" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about treasury stock, including, but not limited to, average cost per share, description of share repurchase program, shares repurchased, shares held for each class of treasury stock.", "label": "Class of Treasury Stock [Table]", "terseLabel": "Class of Treasury Stock [Table]" } } }, "localname": "ClassOfTreasuryStockTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/CommonStockRepurchaseProgramDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CollateralizedDebtObligationsMember": { "auth_ref": [ "r202", "r392" ], "lang": { "en-us": { "role": { "documentation": "Securities collateralized by a pool of assets.", "label": "Collateralized Debt Obligations [Member]", "terseLabel": "Mortgage loans and promissory notes" } } }, "localname": "CollateralizedDebtObligationsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/DebtMortgageLoansandPromissoryNotesandOffBalanceSheetArrangementsDetails", "http://www.ensigngroup.net/role/DebtScheduleofLongtermDebtDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CommitmentsAndContingencies": { "auth_ref": [ "r43", "r623", "r642" ], "calculation": { "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.", "label": "Commitments and Contingencies", "terseLabel": "Commitments and contingencies (Notes 16, 18 and 19)" } } }, "localname": "CommitmentsAndContingencies", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies Disclosure [Abstract]", "terseLabel": "Commitments and Contingencies Disclosure [Abstract]" } } }, "localname": "CommitmentsAndContingenciesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "auth_ref": [ "r274", "r275", "r276", "r282", "r666" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for commitments and contingencies.", "label": "Commitments and Contingencies Disclosure [Text Block]", "terseLabel": "COMMITMENTS AND CONTINGENCIES" } } }, "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/CommitmentsandContingencies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommonStockDividendsPerShareDeclared": { "auth_ref": [ "r354" ], "lang": { "en-us": { "role": { "documentation": "Aggregate dividends declared during the period for each share of common stock outstanding.", "label": "Common Stock, Dividends, Per Share, Declared", "terseLabel": "Dividends per share (in dollars per share)" } } }, "localname": "CommonStockDividendsPerShareDeclared", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [ "r108", "r109", "r518" ], "lang": { "en-us": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]", "terseLabel": "Common Stock" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r23" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common Stock, Par or Stated Value Per Share", "terseLabel": "Common stock, par value (usd per share)" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r23" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common Stock, Shares Authorized", "terseLabel": "Common stock, shares authorized (in shares)" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r23" ], "lang": { "en-us": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common Stock, Shares, Issued", "terseLabel": "Common stock, shares issued (in shares)" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r23", "r349" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common Stock, Shares, Outstanding", "periodEndLabel": "Balance at end of period (in shares)", "periodStartLabel": "Balance at beginning of period (in shares)", "terseLabel": "Common stock, shares outstanding (in shares)" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical", "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r23", "r576" ], "calculation": { "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common Stock, Value, Issued", "terseLabel": "Common stock: $0.001 par value; 100,000 shares authorized; 58,646 and 55,278 shares issued and outstanding at June\u00a030, 2022, respectively, and 58,134 and 55,190 shares issued and outstanding at December 31, 2021, respectively" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConcentrationRiskBenchmarkDomain": { "auth_ref": [ "r146", "r147", "r188", "r528", "r529", "r665" ], "lang": { "en-us": { "role": { "documentation": "The denominator in a calculation of a disclosed concentration risk percentage.", "label": "Concentration Risk Benchmark [Domain]", "terseLabel": "Concentration Risk Benchmark [Domain]" } } }, "localname": "ConcentrationRiskBenchmarkDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/BusinessSegmentsRevenuebySegmentDetails", "http://www.ensigngroup.net/role/CommitmentsandContingenciesDetails", "http://www.ensigngroup.net/role/RevenueandAccountsReceivableDisaggregationofRevenueDetails", "http://www.ensigngroup.net/role/RevenueandAccountsReceivableRevenuefromMedicareandMedicaidProgramsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ConcentrationRiskByBenchmarkAxis": { "auth_ref": [ "r146", "r147", "r188", "r528", "r529", "r661", "r665" ], "lang": { "en-us": { "role": { "documentation": "Information by benchmark of concentration risk.", "label": "Concentration Risk Benchmark [Axis]", "terseLabel": "Concentration Risk Benchmark [Axis]" } } }, "localname": "ConcentrationRiskByBenchmarkAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/BusinessSegmentsRevenuebySegmentDetails", "http://www.ensigngroup.net/role/CommitmentsandContingenciesDetails", "http://www.ensigngroup.net/role/RevenueandAccountsReceivableDisaggregationofRevenueDetails", "http://www.ensigngroup.net/role/RevenueandAccountsReceivableRevenuefromMedicareandMedicaidProgramsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskByTypeAxis": { "auth_ref": [ "r146", "r147", "r188", "r528", "r529", "r661", "r665" ], "lang": { "en-us": { "role": { "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.", "label": "Concentration Risk Type [Axis]", "terseLabel": "Concentration Risk Type [Axis]" } } }, "localname": "ConcentrationRiskByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/BusinessSegmentsRevenuebySegmentDetails", "http://www.ensigngroup.net/role/CommitmentsandContingenciesDetails", "http://www.ensigngroup.net/role/RevenueandAccountsReceivableDisaggregationofRevenueDetails", "http://www.ensigngroup.net/role/RevenueandAccountsReceivableRevenuefromMedicareandMedicaidProgramsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Concentration Risk [Line Items]", "terseLabel": "Concentration Risk [Line Items]" } } }, "localname": "ConcentrationRiskLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/CommitmentsandContingenciesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskPercentage1": { "auth_ref": [ "r146", "r147", "r188", "r528", "r529" ], "lang": { "en-us": { "role": { "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.", "label": "Concentration Risk, Percentage", "terseLabel": "Concentration risk", "verboseLabel": "Percentage of Revenue" } } }, "localname": "ConcentrationRiskPercentage1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/BusinessSegmentsRevenuebySegmentDetails", "http://www.ensigngroup.net/role/CommitmentsandContingenciesDetails", "http://www.ensigngroup.net/role/RevenueandAccountsReceivableDisaggregationofRevenueDetails", "http://www.ensigngroup.net/role/RevenueandAccountsReceivableRevenuefromMedicareandMedicaidProgramsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ConcentrationRiskTable": { "auth_ref": [ "r144", "r146", "r147", "r148", "r528", "r530", "r665" ], "lang": { "en-us": { "role": { "documentation": "Describes the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.", "label": "Concentration Risk [Table]", "terseLabel": "Concentration Risk [Table]" } } }, "localname": "ConcentrationRiskTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/CommitmentsandContingenciesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskTypeDomain": { "auth_ref": [ "r146", "r147", "r188", "r528", "r529", "r665" ], "lang": { "en-us": { "role": { "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration.", "label": "Concentration Risk Type [Domain]", "terseLabel": "Concentration Risk Type [Domain]" } } }, "localname": "ConcentrationRiskTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/BusinessSegmentsRevenuebySegmentDetails", "http://www.ensigngroup.net/role/CommitmentsandContingenciesDetails", "http://www.ensigngroup.net/role/RevenueandAccountsReceivableDisaggregationofRevenueDetails", "http://www.ensigngroup.net/role/RevenueandAccountsReceivableRevenuefromMedicareandMedicaidProgramsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ConstructionInProgressMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.", "label": "Construction in Progress [Member]", "terseLabel": "Construction in progress" } } }, "localname": "ConstructionInProgressMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/PropertyandEquipmentNetDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ContractWithCustomerLiabilityCurrent": { "auth_ref": [ "r361", "r362", "r381" ], "calculation": { "http://www.ensigngroup.net/role/OtherAccruedLiabilitiesDetails": { "order": 6.0, "parentTag": "us-gaap_OtherAccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.", "label": "Contract with Customer, Liability, Current", "verboseLabel": "Resident advances" } } }, "localname": "ContractWithCustomerLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/OtherAccruedLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CorporateNonSegmentMember": { "auth_ref": [ "r170", "r171", "r172", "r173", "r175", "r181", "r183" ], "lang": { "en-us": { "role": { "documentation": "Corporate headquarters or functional department that may not earn revenues or may earn revenues that are only incidental to the activities of the entity and is not considered an operating segment.", "label": "Corporate, Non-Segment [Member]", "terseLabel": "All Other", "verboseLabel": "Other Service Revenue" } } }, "localname": "CorporateNonSegmentMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/BusinessSegmentsRevenuebySegmentDetails", "http://www.ensigngroup.net/role/GoodwillandOtherIndefiniteLivedIntangibleAssetsGoodwillRollforwardDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CostOfGoodsAndServicesSold": { "auth_ref": [ "r64", "r609" ], "calculation": { "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME": { "order": 1.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.", "label": "Cost of Goods and Services Sold", "terseLabel": "Cost of services" } } }, "localname": "CostOfGoodsAndServicesSold", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME" ], "xbrltype": "monetaryItemType" }, "us-gaap_CostsAndExpenses": { "auth_ref": [ "r63" ], "calculation": { "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME": { "order": 2.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Total costs of sales and operating expenses for the period.", "label": "Costs and Expenses", "totalLabel": "TOTAL EXPENSES" } } }, "localname": "CostsAndExpenses", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME" ], "xbrltype": "monetaryItemType" }, "us-gaap_CostsAndExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Costs and Expenses [Abstract]", "terseLabel": "Expense:" } } }, "localname": "CostsAndExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME" ], "xbrltype": "stringItemType" }, "us-gaap_CreditFacilityAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.", "label": "Credit Facility [Axis]", "terseLabel": "Credit Facility [Axis]" } } }, "localname": "CreditFacilityAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/DebtCreditFacilitywithaLendingConsortiumArrangedbySunTrustDetails", "http://www.ensigngroup.net/role/StandardBearerDetails", "http://www.ensigngroup.net/role/SummaryofSignificantAccountingPoliciesRecentAccountingPronouncementsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CreditFacilityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.", "label": "Credit Facility [Domain]", "terseLabel": "Credit Facility [Domain]" } } }, "localname": "CreditFacilityDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/DebtCreditFacilitywithaLendingConsortiumArrangedbySunTrustDetails", "http://www.ensigngroup.net/role/StandardBearerDetails", "http://www.ensigngroup.net/role/SummaryofSignificantAccountingPoliciesRecentAccountingPronouncementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CustomerConcentrationRiskMember": { "auth_ref": [ "r145", "r188" ], "lang": { "en-us": { "role": { "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer.", "label": "Customer Concentration Risk [Member]", "terseLabel": "Customer Concentration Risk" } } }, "localname": "CustomerConcentrationRiskMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/BusinessSegmentsRevenuebySegmentDetails", "http://www.ensigngroup.net/role/CommitmentsandContingenciesDetails", "http://www.ensigngroup.net/role/RevenueandAccountsReceivableDisaggregationofRevenueDetails", "http://www.ensigngroup.net/role/RevenueandAccountsReceivableRevenuefromMedicareandMedicaidProgramsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CustomerRelationshipsMember": { "auth_ref": [ "r490" ], "lang": { "en-us": { "role": { "documentation": "Customer relationship that exists between an entity and its customer, for example, but not limited to, tenant relationships.", "label": "Customer Relationships [Member]", "terseLabel": "Customer relationships" } } }, "localname": "CustomerRelationshipsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/IntangibleAssetsNetScheduleofFiniteLivedIntangibleAssetsDetails", "http://www.ensigngroup.net/role/SummaryofSignificantAccountingPoliciesIntangibleAssetsandGoodwillDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Debt Disclosure [Abstract]", "terseLabel": "Debt Disclosure [Abstract]" } } }, "localname": "DebtDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_DebtDisclosureTextBlock": { "auth_ref": [ "r97", "r305", "r306", "r307", "r308", "r309", "r310", "r311", "r316", "r323", "r324", "r326", "r333" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.", "label": "Debt Disclosure [Text Block]", "terseLabel": "DEBT" } } }, "localname": "DebtDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/Debt" ], "xbrltype": "textBlockItemType" }, "us-gaap_DebtInstrumentAxis": { "auth_ref": [ "r18", "r19", "r20", "r99", "r106", "r299", "r300", "r301", "r302", "r303", "r304", "r306", "r312", "r313", "r314", "r315", "r317", "r318", "r319", "r320", "r321", "r322", "r329", "r330", "r331", "r332", "r544", "r615", "r617", "r633" ], "lang": { "en-us": { "role": { "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.", "label": "Debt Instrument [Axis]", "terseLabel": "Debt Instrument [Axis]" } } }, "localname": "DebtInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/DebtMortgageLoansandPromissoryNotesandOffBalanceSheetArrangementsDetails", "http://www.ensigngroup.net/role/DebtScheduleofLongtermDebtDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument.", "label": "Debt Instrument, Basis Spread on Variable Rate", "terseLabel": "Interest rate margin" } } }, "localname": "DebtInstrumentBasisSpreadOnVariableRate1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/DebtCreditFacilitywithaLendingConsortiumArrangedbySunTrustDetails", "http://www.ensigngroup.net/role/StandardBearerDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentCarryingAmount": { "auth_ref": [ "r20", "r327", "r617", "r633" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.", "label": "Long-Term Debt, Gross", "terseLabel": "Mortgage loans and promissory notes", "verboseLabel": "Long-term debt, gross" } } }, "localname": "DebtInstrumentCarryingAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/DebtCreditFacilitywithaLendingConsortiumArrangedbySunTrustDetails", "http://www.ensigngroup.net/role/DebtMortgageLoansandPromissoryNotesandOffBalanceSheetArrangementsDetails", "http://www.ensigngroup.net/role/DebtScheduleofLongtermDebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentInterestRateEffectivePercentage": { "auth_ref": [ "r40", "r328", "r542", "r544" ], "lang": { "en-us": { "role": { "documentation": "Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.", "label": "Debt Instrument, Interest Rate, Effective Percentage", "terseLabel": "Debt instrument, interest rate, effective percentage" } } }, "localname": "DebtInstrumentInterestRateEffectivePercentage", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/DebtMortgageLoansandPromissoryNotesandOffBalanceSheetArrangementsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentInterestRateStatedPercentage": { "auth_ref": [ "r40", "r300" ], "lang": { "en-us": { "role": { "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.", "label": "Debt Instrument, Interest Rate, Stated Percentage", "terseLabel": "Debt instrument, interest rate, stated percentage" } } }, "localname": "DebtInstrumentInterestRateStatedPercentage", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/DebtMortgageLoansandPromissoryNotesandOffBalanceSheetArrangementsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Debt Instrument [Line Items]", "terseLabel": "Debt Instrument [Line Items]" } } }, "localname": "DebtInstrumentLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/DebtCreditFacilitywithaLendingConsortiumArrangedbySunTrustDetails", "http://www.ensigngroup.net/role/DebtMortgageLoansandPromissoryNotesandOffBalanceSheetArrangementsDetails", "http://www.ensigngroup.net/role/DebtScheduleofLongtermDebtDetails", "http://www.ensigngroup.net/role/SummaryofSignificantAccountingPoliciesRecentAccountingPronouncementsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentNameDomain": { "auth_ref": [ "r41", "r99", "r106", "r299", "r300", "r301", "r302", "r303", "r304", "r306", "r312", "r313", "r314", "r315", "r317", "r318", "r319", "r320", "r321", "r322", "r329", "r330", "r331", "r332", "r544" ], "lang": { "en-us": { "role": { "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.", "label": "Debt Instrument, Name [Domain]", "terseLabel": "Debt Instrument, Name [Domain]" } } }, "localname": "DebtInstrumentNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/DebtMortgageLoansandPromissoryNotesandOffBalanceSheetArrangementsDetails", "http://www.ensigngroup.net/role/DebtScheduleofLongtermDebtDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtInstrumentTable": { "auth_ref": [ "r41", "r99", "r106", "r299", "r300", "r301", "r302", "r303", "r304", "r306", "r312", "r313", "r314", "r315", "r317", "r318", "r319", "r320", "r321", "r322", "r325", "r329", "r330", "r331", "r332", "r350", "r351", "r352", "r353", "r541", "r542", "r544", "r545", "r632" ], "lang": { "en-us": { "role": { "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.", "label": "Schedule of Long-Term Debt Instruments [Table]", "terseLabel": "Schedule of Long-term Debt Instruments [Table]" } } }, "localname": "DebtInstrumentTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/DebtCreditFacilitywithaLendingConsortiumArrangedbySunTrustDetails", "http://www.ensigngroup.net/role/DebtMortgageLoansandPromissoryNotesandOffBalanceSheetArrangementsDetails", "http://www.ensigngroup.net/role/DebtScheduleofLongtermDebtDetails", "http://www.ensigngroup.net/role/SummaryofSignificantAccountingPoliciesRecentAccountingPronouncementsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentTerm": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Debt Instrument, Term", "terseLabel": "Debt instrument, term" } } }, "localname": "DebtInstrumentTerm", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/DebtMortgageLoansandPromissoryNotesandOffBalanceSheetArrangementsDetails" ], "xbrltype": "durationItemType" }, "us-gaap_DebtIssuanceCostsLineOfCreditArrangementsNet": { "auth_ref": [ "r546" ], "calculation": { "http://www.ensigngroup.net/role/RestrictedandOtherAssetsDetails": { "order": 1.0, "parentTag": "us-gaap_OtherRestrictedAssetsNoncurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after accumulated amortization, of debt issuance costs related to line of credit arrangements. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.", "label": "Debt Issuance Costs, Line of Credit Arrangements, Net", "terseLabel": "Debt issuance costs, net" } } }, "localname": "DebtIssuanceCostsLineOfCreditArrangementsNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/RestrictedandOtherAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredCompensationPlanAssets": { "auth_ref": [ "r16" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Carrying amount as of the balance sheet date of assets held under deferred compensation agreements.", "label": "Deferred Compensation Plan Assets", "terseLabel": "Deferred compensation plan investments" } } }, "localname": "DeferredCompensationPlanAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/FairValueMeasurementsScheduleofFairValueofAssetsandLiabilitiesMeasuredonRecurringBasisDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]", "terseLabel": "Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]" } } }, "localname": "DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_DeferredFinanceCostsNet": { "auth_ref": [ "r312", "r543" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.", "label": "Debt Issuance Costs, Net", "negatedTerseLabel": "Less: debt issuance costs, net" } } }, "localname": "DeferredFinanceCostsNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/DebtScheduleofLongtermDebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredIncomeTaxAssetsNet": { "auth_ref": [ "r462", "r463" ], "calculation": { "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 6.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting.", "label": "Deferred Income Tax Assets, Net", "terseLabel": "Deferred tax assets" } } }, "localname": "DeferredIncomeTaxAssetsNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredIncomeTaxExpenseBenefit": { "auth_ref": [ "r88", "r101", "r471", "r477", "r478", "r479" ], "calculation": { "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Deferred Income Tax Expense (Benefit)", "terseLabel": "Deferred income taxes" } } }, "localname": "DeferredIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_DepositsAssetsNoncurrent": { "auth_ref": [ "r16" ], "calculation": { "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 5.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment after one year or beyond the operating cycle, if longer.", "label": "Deposits Assets, Noncurrent", "terseLabel": "Escrow deposits" } } }, "localname": "DepositsAssetsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_DepreciationDepletionAndAmortization": { "auth_ref": [ "r88", "r160" ], "calculation": { "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME": { "order": 4.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.", "label": "Depreciation, Depletion and Amortization", "terseLabel": "Depreciation and amortization" } } }, "localname": "DepreciationDepletionAndAmortization", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/BusinessSegmentsScheduleofSegmentReportingInformationbySegmentDetails", "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS", "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisaggregationOfRevenueLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Disaggregation of Revenue [Line Items]", "terseLabel": "Disaggregation of Revenue [Line Items]" } } }, "localname": "DisaggregationOfRevenueLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/RevenueandAccountsReceivableDisaggregationofRevenueDetails", "http://www.ensigngroup.net/role/RevenueandAccountsReceivableRevenuefromMedicareandMedicaidProgramsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DisaggregationOfRevenueTable": { "auth_ref": [ "r380", "r383", "r384", "r385", "r386", "r387", "r388", "r389" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.", "label": "Disaggregation of Revenue [Table]", "terseLabel": "Disaggregation of Revenue [Table]" } } }, "localname": "DisaggregationOfRevenueTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/RevenueandAccountsReceivableDisaggregationofRevenueDetails", "http://www.ensigngroup.net/role/RevenueandAccountsReceivableRevenuefromMedicareandMedicaidProgramsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DisaggregationOfRevenueTableTextBlock": { "auth_ref": [ "r380" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.", "label": "Disaggregation of Revenue [Table Text Block]", "terseLabel": "Disaggregation of Revenue" } } }, "localname": "DisaggregationOfRevenueTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/RevenueandAccountsReceivableTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "auth_ref": [ "r408", "r409", "r445", "r446", "r448", "r458" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for share-based payment arrangement.", "label": "Share-Based Payment Arrangement [Text Block]", "terseLabel": "OPTIONS AND AWARDS" } } }, "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/OptionsandAwards" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement [Abstract]", "terseLabel": "Share-based Payment Arrangement [Abstract]" } } }, "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_DisposalGroupClassificationAxis": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Information by disposal group classification.", "label": "Disposal Group Classification [Axis]", "terseLabel": "Disposal Group Classification [Axis]" } } }, "localname": "DisposalGroupClassificationAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/LeasesLessorNarrativeDetails", "http://www.ensigngroup.net/role/PropertyandEquipmentNetNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DisposalGroupClassificationDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Component or group of components disposed of, including but not limited to, disposal group held-for-sale or disposed of by sale, disposed of by means other than sale, and discontinued operations.", "label": "Disposal Group Classification [Domain]", "terseLabel": "Disposal Group Classification [Domain]" } } }, "localname": "DisposalGroupClassificationDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/LeasesLessorNarrativeDetails", "http://www.ensigngroup.net/role/PropertyandEquipmentNetNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember": { "auth_ref": [ "r256", "r263" ], "lang": { "en-us": { "role": { "documentation": "Disposal group that has been sold. Excludes disposals classified as discontinued operations.", "label": "Disposal Group, Disposed of by Sale, Not Discontinued Operations [Member]", "terseLabel": "Disposal Group, Disposed of by Sale, Not Discontinued Operations" } } }, "localname": "DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/LeasesLessorNarrativeDetails", "http://www.ensigngroup.net/role/PropertyandEquipmentNetNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain": { "auth_ref": [ "r400", "r402" ], "lang": { "en-us": { "role": { "documentation": "Name of disposal group.", "label": "Disposal Group Name [Domain]", "terseLabel": "Disposal Group Name [Domain]" } } }, "localname": "DisposalGroupsIncludingDiscontinuedOperationsNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/LeasesLessorNarrativeDetails", "http://www.ensigngroup.net/role/PropertyandEquipmentNetNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_Dividends": { "auth_ref": [ "r354", "r631" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of paid and unpaid cash, stock, and paid-in-kind (PIK) dividends declared, for example, but not limited to, common and preferred stock.", "label": "Dividends", "negatedTerseLabel": "Dividends declared" } } }, "localname": "Dividends", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "xbrltype": "monetaryItemType" }, "us-gaap_DividendsPayableCurrentAndNoncurrent": { "auth_ref": [ "r19", "r21", "r616", "r636" ], "calculation": { "http://www.ensigngroup.net/role/OtherAccruedLiabilitiesDetails": { "order": 8.0, "parentTag": "us-gaap_OtherAccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of dividends declared but unpaid on equity securities issued by the entity and outstanding.", "label": "Dividends Payable", "terseLabel": "Dividends payable", "verboseLabel": "Accrued dividends declared" } } }, "localname": "DividendsPayableCurrentAndNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/OtherAccruedLiabilitiesDetails", "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_DomesticCorporateDebtSecuritiesMember": { "auth_ref": [ "r202", "r392", "r399" ], "lang": { "en-us": { "role": { "documentation": "Debt security issued by corporation domiciled in United States of America (US).", "label": "Debt Security, Corporate, US [Member]", "terseLabel": "Debt Security, Corporate, US" } } }, "localname": "DomesticCorporateDebtSecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/FairValueMeasurementsInvestmentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EarningsPerShareAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Earnings Per Share [Abstract]", "terseLabel": "NET INCOME PER SHARE ATTRIBUTABLE TO THE ENSIGN GROUP INC." } } }, "localname": "EarningsPerShareAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME" ], "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareBasic": { "auth_ref": [ "r60", "r113", "r114", "r115", "r116", "r117", "r121", "r123", "r129", "r130", "r131", "r135", "r136", "r519", "r520", "r626", "r645" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.", "label": "Earnings Per Share, Basic", "terseLabel": "Basic (in dollars per share)", "verboseLabel": "Basic net income per common share (in dollars per share)" } } }, "localname": "EarningsPerShareBasic", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/ComputationofNetIncomePerCommonShareDetails", "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareDiluted": { "auth_ref": [ "r60", "r113", "r114", "r115", "r116", "r117", "r123", "r129", "r130", "r131", "r135", "r136", "r519", "r520", "r626", "r645" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Earnings Per Share, Diluted", "terseLabel": "Diluted (in dollars per share)", "verboseLabel": "Diluted net income per common share (in dollars per share)" } } }, "localname": "EarningsPerShareDiluted", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/ComputationofNetIncomePerCommonShareDetails", "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareTextBlock": { "auth_ref": [ "r132", "r133", "r134", "r137" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for earnings per share.", "label": "Earnings Per Share [Text Block]", "terseLabel": "COMPUTATION OF NET INCOME PER COMMON SHARE" } } }, "localname": "EarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/ComputationofNetIncomePerCommonShare" ], "xbrltype": "textBlockItemType" }, "us-gaap_EffectiveIncomeTaxRateContinuingOperations": { "auth_ref": [ "r465" ], "lang": { "en-us": { "role": { "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Effective Income Tax Rate Reconciliation, Percent", "terseLabel": "Effective income tax rate" } } }, "localname": "EffectiveIncomeTaxRateContinuingOperations", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EmployeeRelatedLiabilitiesCurrent": { "auth_ref": [ "r38" ], "calculation": { "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Employee-related Liabilities, Current", "terseLabel": "Accrued wages and related liabilities (Note 3)" } } }, "localname": "EmployeeRelatedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]", "terseLabel": "Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]" } } }, "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/OptionsandAwardsCompensationExpenseDetails" ], "xbrltype": "stringItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": { "auth_ref": [ "r447" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.", "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount", "terseLabel": "Share-based compensation, nonvested awards, cost not yet recognized" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/OptionsandAwardsCompensationExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": { "auth_ref": [ "r447" ], "lang": { "en-us": { "role": { "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition", "terseLabel": "Share-based compensation, nonvested awards, cost not yet recognized, period for recognition" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/OptionsandAwardsCompensationExpenseDetails" ], "xbrltype": "durationItemType" }, "us-gaap_EmployeeStockOptionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.", "label": "Share-Based Payment Arrangement, Option [Member]", "terseLabel": "Stock Options", "verboseLabel": "Stock-based compensation expense related to stock options" } } }, "localname": "EmployeeStockOptionMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/OptionsandAwardsCompensationExpenseDetails", "http://www.ensigngroup.net/role/OptionsandAwardsIntrinsicValuesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EquipmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tangible personal property used to produce goods and services.", "label": "Equipment [Member]", "terseLabel": "Equipment" } } }, "localname": "EquipmentMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/LeasesLesseeNarrativeDetails", "http://www.ensigngroup.net/role/PropertyandEquipmentNetDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Equity [Abstract]", "terseLabel": "EQUITY" } } }, "localname": "EquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "stringItemType" }, "us-gaap_EquityClassOfTreasuryStockLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Equity, Class of Treasury Stock [Line Items]", "terseLabel": "Equity, Class of Treasury Stock [Line Items]" } } }, "localname": "EquityClassOfTreasuryStockLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/CommonStockRepurchaseProgramDetails" ], "xbrltype": "stringItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r0", "r54", "r55", "r56", "r108", "r109", "r110", "r112", "r118", "r120", "r139", "r212", "r349", "r354", "r451", "r452", "r453", "r473", "r474", "r518", "r533", "r534", "r535", "r536", "r537", "r538", "r572", "r655", "r656", "r657" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.", "label": "Equity Component [Domain]", "terseLabel": "Equity Component [Domain]" } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "xbrltype": "domainItemType" }, "us-gaap_EstimatedInsuranceRecoveries": { "auth_ref": [ "r16" ], "calculation": { "http://www.ensigngroup.net/role/RestrictedandOtherAssetsDetails": { "order": 2.0, "parentTag": "us-gaap_OtherRestrictedAssetsNoncurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Carrying amount as of the balance sheet date of amounts expected to be recovered under the terms of insurance contracts.", "label": "Estimated Insurance Recoveries", "terseLabel": "Long-term insurance losses recoverable asset" } } }, "localname": "EstimatedInsuranceRecoveries", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/RestrictedandOtherAssetsDetails", "http://www.ensigngroup.net/role/SummaryofSignificantAccountingPoliciesSelfInsuranceDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ExtraordinaryAndUnusualItemsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Unusual or Infrequent Items, or Both [Abstract]" } } }, "localname": "ExtraordinaryAndUnusualItemsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]", "terseLabel": "Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]" } } }, "localname": "FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/FairValueMeasurementsScheduleofFairValueofAssetsandLiabilitiesMeasuredonRecurringBasisDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByBalanceSheetGroupingTable": { "auth_ref": [ "r521", "r526", "r527" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities.", "label": "Fair Value, by Balance Sheet Grouping [Table]", "terseLabel": "Fair Value, by Balance Sheet Grouping [Table]" } } }, "localname": "FairValueByBalanceSheetGroupingTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/FairValueMeasurementsScheduleofFairValueofAssetsandLiabilitiesMeasuredonRecurringBasisDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "auth_ref": [ "r314", "r329", "r330", "r392", "r393", "r394", "r395", "r396", "r397", "r398", "r399", "r522", "r581", "r582", "r583" ], "lang": { "en-us": { "role": { "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.", "label": "Fair Value Hierarchy and NAV [Axis]", "terseLabel": "Fair Value Hierarchy and NAV [Axis]" } } }, "localname": "FairValueByFairValueHierarchyLevelAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/FairValueMeasurementsScheduleofFairValueofAssetsandLiabilitiesMeasuredonRecurringBasisDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Fair Value Disclosures [Abstract]", "terseLabel": "Fair Value Disclosures [Abstract]" } } }, "localname": "FairValueDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresTextBlock": { "auth_ref": [ "r523" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.", "label": "Fair Value Disclosures [Text Block]", "terseLabel": "FAIR VALUE MEASUREMENTS" } } }, "localname": "FairValueDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/FairValueMeasurements" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueInputsLevel1Member": { "auth_ref": [ "r314", "r392", "r393", "r398", "r399", "r522", "r581" ], "lang": { "en-us": { "role": { "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.", "label": "Fair Value, Inputs, Level 1 [Member]", "terseLabel": "Fair Value, Inputs, Level 1" } } }, "localname": "FairValueInputsLevel1Member", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/FairValueMeasurementsScheduleofFairValueofAssetsandLiabilitiesMeasuredonRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel2Member": { "auth_ref": [ "r314", "r329", "r330", "r392", "r393", "r398", "r399", "r522", "r582" ], "lang": { "en-us": { "role": { "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.", "label": "Fair Value, Inputs, Level 2 [Member]", "terseLabel": "Fair Value, Inputs, Level 2" } } }, "localname": "FairValueInputsLevel2Member", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/FairValueMeasurementsScheduleofFairValueofAssetsandLiabilitiesMeasuredonRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "auth_ref": [ "r314", "r329", "r330", "r392", "r393", "r394", "r395", "r396", "r397", "r398", "r399", "r581", "r582", "r583" ], "lang": { "en-us": { "role": { "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.", "label": "Fair Value Hierarchy and NAV [Domain]", "terseLabel": "Fair Value Hierarchy and NAV [Domain]" } } }, "localname": "FairValueMeasurementsFairValueHierarchyDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/FairValueMeasurementsScheduleofFairValueofAssetsandLiabilitiesMeasuredonRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueOfFinancialInstrumentsPolicy": { "auth_ref": [ "r524", "r525" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments.", "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]", "terseLabel": "Fair Value of Financial Instruments" } } }, "localname": "FairValueOfFinancialInstrumentsPolicy", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_FinancialInstrumentAxis": { "auth_ref": [ "r204", "r205", "r207", "r208", "r209", "r214", "r216", "r217", "r218", "r219", "r220", "r221", "r222", "r223", "r325", "r347", "r516", "r578", "r579", "r580", "r581", "r582", "r583", "r584", "r585", "r586", "r587", "r588", "r589", "r590", "r591", "r592", "r593", "r594", "r595", "r596", "r597", "r598", "r599", "r600", "r601", "r602", "r603", "r604", "r605", "r606", "r607", "r687", "r688", "r689", "r690", "r691", "r692", "r693" ], "lang": { "en-us": { "role": { "documentation": "Information by type of financial instrument.", "label": "Financial Instrument [Axis]", "terseLabel": "Financial Instrument [Axis]" } } }, "localname": "FinancialInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/FairValueMeasurementsInvestmentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetUsefulLife": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Finite-Lived Intangible Asset, Useful Life", "terseLabel": "Finite-lived intangible asset, useful life" } } }, "localname": "FiniteLivedIntangibleAssetUsefulLife", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/SummaryofSignificantAccountingPoliciesIntangibleAssetsandGoodwillDetails" ], "xbrltype": "durationItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": { "auth_ref": [ "r15", "r246" ], "calculation": { "http://www.ensigngroup.net/role/IntangibleAssetsNetScheduleofFiniteLivedIntangibleAssetsDetails": { "order": 2.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Accumulated Amortization", "negatedLabel": "Accumulated Amortization" } } }, "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/IntangibleAssetsNetScheduleofFiniteLivedIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive": { "auth_ref": [], "calculation": { "http://www.ensigngroup.net/role/IntangibleAssetsNetFutureAmortizationDetails": { "order": 6.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for asset, excluding financial asset and goodwill, lacking physical substance with finite life expected to be recognized after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finite-Lived Intangible Asset, Expected Amortization, after Year Five", "terseLabel": "Thereafter" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/IntangibleAssetsNetFutureAmortizationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": { "auth_ref": [ "r248" ], "calculation": { "http://www.ensigngroup.net/role/IntangibleAssetsNetFutureAmortizationDetails": { "order": 2.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year One", "terseLabel": "2023" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/IntangibleAssetsNetFutureAmortizationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear": { "auth_ref": [], "calculation": { "http://www.ensigngroup.net/role/IntangibleAssetsNetFutureAmortizationDetails": { "order": 1.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in remainder of current fiscal year.", "label": "Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year", "terseLabel": "2022 (remainder)" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/IntangibleAssetsNetFutureAmortizationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive": { "auth_ref": [ "r248" ], "calculation": { "http://www.ensigngroup.net/role/IntangibleAssetsNetFutureAmortizationDetails": { "order": 3.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Five", "terseLabel": "2027" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFive", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/IntangibleAssetsNetFutureAmortizationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": { "auth_ref": [ "r248" ], "calculation": { "http://www.ensigngroup.net/role/IntangibleAssetsNetFutureAmortizationDetails": { "order": 4.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Four", "terseLabel": "2026" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/IntangibleAssetsNetFutureAmortizationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": { "auth_ref": [ "r248" ], "calculation": { "http://www.ensigngroup.net/role/IntangibleAssetsNetFutureAmortizationDetails": { "order": 7.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Three", "terseLabel": "2025" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/IntangibleAssetsNetFutureAmortizationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": { "auth_ref": [ "r248" ], "calculation": { "http://www.ensigngroup.net/role/IntangibleAssetsNetFutureAmortizationDetails": { "order": 5.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Two", "terseLabel": "2024" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/IntangibleAssetsNetFutureAmortizationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": { "auth_ref": [ "r240", "r243", "r246", "r250", "r610", "r611" ], "lang": { "en-us": { "role": { "documentation": "Information by major type or class of finite-lived intangible assets.", "label": "Finite-Lived Intangible Assets by Major Class [Axis]", "terseLabel": "Finite-Lived Intangible Assets by Major Class [Axis]" } } }, "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/IntangibleAssetsNetScheduleofFiniteLivedIntangibleAssetsDetails", "http://www.ensigngroup.net/role/SummaryofSignificantAccountingPoliciesIntangibleAssetsandGoodwillDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Finite-Lived Intangible Assets, Net, Amortization Expense, Fiscal Year Maturity [Abstract]", "terseLabel": "Year" } } }, "localname": "FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/IntangibleAssetsNetFutureAmortizationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetsGross": { "auth_ref": [ "r246", "r611" ], "calculation": { "http://www.ensigngroup.net/role/IntangibleAssetsNetScheduleofFiniteLivedIntangibleAssetsDetails": { "order": 1.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Gross", "terseLabel": "Gross Carrying Amount" } } }, "localname": "FiniteLivedIntangibleAssetsGross", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/IntangibleAssetsNetScheduleofFiniteLivedIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Finite-Lived Intangible Assets [Line Items]", "terseLabel": "Finite-Lived Intangible Assets [Line Items]" } } }, "localname": "FiniteLivedIntangibleAssetsLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/IntangibleAssetsNetNarrativeDetails", "http://www.ensigngroup.net/role/SummaryofSignificantAccountingPoliciesIntangibleAssetsandGoodwillDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": { "auth_ref": [ "r240", "r245" ], "lang": { "en-us": { "role": { "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.", "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]", "terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]" } } }, "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/IntangibleAssetsNetScheduleofFiniteLivedIntangibleAssetsDetails", "http://www.ensigngroup.net/role/SummaryofSignificantAccountingPoliciesIntangibleAssetsandGoodwillDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FiniteLivedIntangibleAssetsNet": { "auth_ref": [ "r246", "r610" ], "calculation": { "http://www.ensigngroup.net/role/IntangibleAssetsNetFutureAmortizationDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.ensigngroup.net/role/IntangibleAssetsNetScheduleofFiniteLivedIntangibleAssetsDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 8.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Net", "terseLabel": "Intangible assets, net", "totalLabel": "Net" } } }, "localname": "FiniteLivedIntangibleAssetsNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/IntangibleAssetsNetFutureAmortizationDetails", "http://www.ensigngroup.net/role/IntangibleAssetsNetScheduleofFiniteLivedIntangibleAssetsDetails", "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_FurnitureAndFixturesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.", "label": "Furniture and Fixtures [Member]", "terseLabel": "Furniture and fixtures" } } }, "localname": "FurnitureAndFixturesMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/PropertyandEquipmentNetDetails" ], "xbrltype": "domainItemType" }, "us-gaap_GainLossOnDispositionOfAssets1": { "auth_ref": [ "r88" ], "calculation": { "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of gain (loss) on sale or disposal of assets, including but not limited to property plant and equipment, intangible assets and equity in securities of subsidiaries or equity method investee.", "label": "Gain (Loss) on Disposition of Assets", "negatedLabel": "Gain on sale of assets" } } }, "localname": "GainLossOnDispositionOfAssets1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_GainLossOnInvestments": { "auth_ref": [ "r66", "r88", "r201" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of realized and unrealized gain (loss) on investment.", "label": "Gain (Loss) on Investments", "verboseLabel": "Gain (loss) on deferral investment" } } }, "localname": "GainLossOnInvestments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/RestrictedandOtherAssetsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GainLossOnSaleOfPropertyPlantEquipment": { "auth_ref": [ "r88" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.", "label": "Gain (Loss) on Disposition of Property Plant Equipment", "terseLabel": "Gains on sales property, plant and equipment" } } }, "localname": "GainLossOnSaleOfPropertyPlantEquipment", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/PropertyandEquipmentNetNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GeneralAndAdministrativeExpense": { "auth_ref": [ "r65" ], "calculation": { "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME": { "order": 3.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.", "label": "General and Administrative Expense", "terseLabel": "General and administrative expense" } } }, "localname": "GeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME" ], "xbrltype": "monetaryItemType" }, "us-gaap_GeneralAndAdministrativeExpenseMember": { "auth_ref": [ "r61" ], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing general and administrative expense.", "label": "General and Administrative Expense [Member]", "terseLabel": "General and administrative expense" } } }, "localname": "GeneralAndAdministrativeExpenseMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/LeasesLesseeLeaseCostDetails" ], "xbrltype": "domainItemType" }, "us-gaap_GeneralLiabilityMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Type of business insurance which provides insurance coverage for a wide variety of liability exposures including, but not limited to, contractual liability, product liability and personal injury liability.", "label": "General Liability [Member]", "terseLabel": "General Liability" } } }, "localname": "GeneralLiabilityMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/SummaryofSignificantAccountingPoliciesSelfInsuranceDetails" ], "xbrltype": "domainItemType" }, "us-gaap_Goodwill": { "auth_ref": [ "r14", "r226", "r227", "r234", "r238", "r576", "r613" ], "calculation": { "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 9.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill", "periodEndLabel": "Balance at end of period", "periodStartLabel": "Balance at beginning of period", "terseLabel": "Goodwill" } } }, "localname": "Goodwill", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/GoodwillandOtherIndefiniteLivedIntangibleAssetsGoodwillRollforwardDetails", "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillAcquiredDuringPeriod": { "auth_ref": [ "r228", "r238" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized resulting from a business combination.", "label": "Goodwill, Acquired During Period", "terseLabel": "Additions" } } }, "localname": "GoodwillAcquiredDuringPeriod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/GoodwillandOtherIndefiniteLivedIntangibleAssetsGoodwillRollforwardDetails", "http://www.ensigngroup.net/role/OperationExpansionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillAndIntangibleAssetImpairment": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Total loss recognized during the period from the impairment of goodwill plus the loss recognized in the period resulting from the impairment of the carrying amount of intangible assets, other than goodwill.", "label": "Goodwill and Intangible Asset Impairment", "terseLabel": "Goodwill and intangible asset impairment" } } }, "localname": "GoodwillAndIntangibleAssetImpairment", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/SummaryofSignificantAccountingPoliciesIntangibleAssetsandGoodwillDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Goodwill and Intangible Assets Disclosure [Abstract]", "terseLabel": "Goodwill and Intangible Assets Disclosure [Abstract]" } } }, "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock": { "auth_ref": [ "r253" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for goodwill and intangible assets.", "label": "Goodwill and Intangible Assets Disclosure [Text Block]", "terseLabel": "GOODWILL AND OTHER INDEFINITE-LIVED INTANGIBLE ASSETS" } } }, "localname": "GoodwillAndIntangibleAssetsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/GoodwillandOtherIndefiniteLivedIntangibleAssets" ], "xbrltype": "textBlockItemType" }, "us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock": { "auth_ref": [ "r235", "r244" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for goodwill and intangible assets. This accounting policy also may address how an entity assesses and measures impairment of goodwill and intangible assets.", "label": "Goodwill and Intangible Assets, Policy [Policy Text Block]", "terseLabel": "Intangible Assets and Goodwill" } } }, "localname": "GoodwillAndIntangibleAssetsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_GoodwillLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Goodwill [Line Items]", "terseLabel": "Goodwill [Line Items]" } } }, "localname": "GoodwillLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/GoodwillandOtherIndefiniteLivedIntangibleAssetsGoodwillRollforwardDetails" ], "xbrltype": "stringItemType" }, "us-gaap_GoodwillRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Goodwill [Roll Forward]", "terseLabel": "Goodwill [Roll Forward]" } } }, "localname": "GoodwillRollForward", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/GoodwillandOtherIndefiniteLivedIntangibleAssetsGoodwillRollforwardDetails" ], "xbrltype": "stringItemType" }, "us-gaap_GranteeStatusAxis": { "auth_ref": [ "r404", "r406", "r409", "r410", "r411", "r413", "r415", "r416", "r417", "r418", "r419", "r420", "r421", "r423", "r424", "r425", "r426", "r427", "r428", "r430", "r431", "r432", "r433", "r437", "r438", "r439", "r440", "r441" ], "lang": { "en-us": { "role": { "documentation": "Information by status of recipient to whom award is granted.", "label": "Grantee Status [Axis]", "terseLabel": "Grantee Status [Axis]" } } }, "localname": "GranteeStatusAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/OptionsandAwardsRestrictedStockAwardsNarrativeDetails", "http://www.ensigngroup.net/role/OptionsandAwardsStockOptionsNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_GranteeStatusDomain": { "auth_ref": [ "r404", "r406", "r409", "r410", "r411", "r413", "r415", "r416", "r417", "r418", "r419", "r420", "r421", "r423", "r424", "r425", "r426", "r427", "r428", "r430", "r431", "r432", "r433", "r437", "r438", "r439", "r440", "r441" ], "lang": { "en-us": { "role": { "documentation": "Status of recipient to whom award is granted.", "label": "Grantee Status [Domain]", "terseLabel": "Grantee Status [Domain]" } } }, "localname": "GranteeStatusDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/OptionsandAwardsRestrictedStockAwardsNarrativeDetails", "http://www.ensigngroup.net/role/OptionsandAwardsStockOptionsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_HealthInsuranceProductLineMember": { "auth_ref": [ "r654" ], "lang": { "en-us": { "role": { "documentation": "Product line consisting of insurance against loss by illness or injury.", "label": "Health Insurance Product Line [Member]", "terseLabel": "Health" } } }, "localname": "HealthInsuranceProductLineMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/SummaryofSignificantAccountingPoliciesSelfInsuranceDetails" ], "xbrltype": "domainItemType" }, "us-gaap_HeldToMaturitySecurities": { "auth_ref": [ "r198", "r203", "r213", "r217" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before allowance for credit loss, of investment in debt security measured at amortized cost (held-to-maturity).", "label": "Debt Securities, Held-to-Maturity, Amortized Cost, before Allowance for Credit Loss", "terseLabel": "Debt security investments classified as held to maturity and carried at amortized cost" } } }, "localname": "HeldToMaturitySecurities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/FairValueMeasurementsInvestmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ImpairmentOfLongLivedAssetsHeldForUse": { "auth_ref": [ "r88", "r255", "r260" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale).", "label": "Impairment, Long-Lived Asset, Held-for-Use", "terseLabel": "Impairment of long lived assets" } } }, "localname": "ImpairmentOfLongLivedAssetsHeldForUse", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/SummaryofSignificantAccountingPoliciesImpairmentofLongLivedAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": { "auth_ref": [ "r254", "r264" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.", "label": "Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]", "terseLabel": "Impairment of Long-Lived Assets" } } }, "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity": { "auth_ref": [ "r498", "r500" ], "calculation": { "http://www.ensigngroup.net/role/ComputationofNetIncomePerCommonShareDetails": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of income (loss) from continuing operations attributable to the noncontrolling interest.", "label": "Income (Loss) from Continuing Operations, Net of Tax, Attributable to Noncontrolling Interest", "verboseLabel": "Less: net (loss) income attributable to noncontrolling interests" } } }, "localname": "IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/ComputationofNetIncomePerCommonShareDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "auth_ref": [ "r58", "r165", "r171", "r175", "r178", "r181", "r612", "r624", "r629", "r646" ], "calculation": { "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME": { "order": 2.0, "parentTag": "us-gaap_ProfitLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.", "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest", "terseLabel": "Income before provision for income taxes", "totalLabel": "Income before provision for income taxes" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/BusinessSegmentsScheduleofSegmentReportingInformationbySegmentDetails", "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest": { "auth_ref": [ "r100", "r111", "r165", "r171", "r175", "r178", "r181", "r210", "r284", "r285", "r286", "r289", "r290", "r291", "r293", "r295", "r297", "r298", "r500", "r520", "r531" ], "calculation": { "http://www.ensigngroup.net/role/ComputationofNetIncomePerCommonShareDetails": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of income (loss) from continuing operations including portion attributable to the noncontrolling interest.", "label": "Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest", "verboseLabel": "Net income" } } }, "localname": "IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/ComputationofNetIncomePerCommonShareDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]", "terseLabel": "Income Statement [Abstract]" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis": { "auth_ref": [ "r400", "r402" ], "lang": { "en-us": { "role": { "documentation": "Information by name of disposal group.", "label": "Disposal Group Name [Axis]", "terseLabel": "Disposal Group Name [Axis]" } } }, "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/LeasesLessorNarrativeDetails", "http://www.ensigngroup.net/role/PropertyandEquipmentNetNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationAxis": { "auth_ref": [ "r261", "r269" ], "lang": { "en-us": { "role": { "documentation": "Information by location in the income statement.", "label": "Income Statement Location [Axis]", "terseLabel": "Income Statement Location [Axis]" } } }, "localname": "IncomeStatementLocationAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/IntangibleAssetsNetNarrativeDetails", "http://www.ensigngroup.net/role/LeasesLesseeLeaseCostDetails", "http://www.ensigngroup.net/role/LeasesLesseeNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationDomain": { "auth_ref": [ "r269" ], "lang": { "en-us": { "role": { "documentation": "Location in the income statement.", "label": "Income Statement Location [Domain]", "terseLabel": "Income Statement Location [Domain]" } } }, "localname": "IncomeStatementLocationDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/IntangibleAssetsNetNarrativeDetails", "http://www.ensigngroup.net/role/LeasesLesseeLeaseCostDetails", "http://www.ensigngroup.net/role/LeasesLesseeNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Tax Disclosure [Abstract]", "terseLabel": "Income Tax Disclosure [Abstract]" } } }, "localname": "IncomeTaxDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxDisclosureTextBlock": { "auth_ref": [ "r102", "r466", "r467", "r470", "r475", "r480", "r482", "r483", "r484" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.", "label": "Income Tax Disclosure [Text Block]", "terseLabel": "INCOME TAXES" } } }, "localname": "IncomeTaxDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/IncomeTaxes" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxExpenseBenefit": { "auth_ref": [ "r103", "r119", "r120", "r163", "r464", "r476", "r481", "r647" ], "calculation": { "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME": { "order": 1.0, "parentTag": "us-gaap_ProfitLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Income Tax Expense (Benefit)", "terseLabel": "Provision for income taxes" } } }, "localname": "IncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/IncomeTaxesNarrativeDetails", "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxPolicyTextBlock": { "auth_ref": [ "r53", "r460", "r461", "r467", "r468", "r469", "r472" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.", "label": "Income Tax, Policy [Policy Text Block]", "terseLabel": "Income Taxes" } } }, "localname": "IncomeTaxPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxesPaid": { "auth_ref": [ "r85", "r91" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.", "label": "Income Taxes Paid", "terseLabel": "Income taxes" } } }, "localname": "IncomeTaxesPaid", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayable": { "auth_ref": [ "r87" ], "calculation": { "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 14.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.", "label": "Increase (Decrease) in Accounts Payable", "terseLabel": "Accounts payable" } } }, "localname": "IncreaseDecreaseInAccountsPayable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "auth_ref": [ "r87" ], "calculation": { "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 20.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.", "label": "Increase (Decrease) in Accounts Receivable", "negatedTerseLabel": "Accounts receivable" } } }, "localname": "IncreaseDecreaseInAccountsReceivable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable": { "auth_ref": [ "r87" ], "calculation": { "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 13.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the period in the amount due for taxes based on the reporting entity's earnings or attributable to the entity's income earning process (business presence) within a given jurisdiction.", "label": "Increase (Decrease) in Income Taxes Payable", "terseLabel": "Income taxes payable" } } }, "localname": "IncreaseDecreaseInAccruedIncomeTaxesPayable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInDeferredCompensation": { "auth_ref": [ "r87" ], "calculation": { "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the obligation created by employee agreements whereby earned compensation will be paid in the future.", "label": "Increase (Decrease) in Deferred Compensation", "terseLabel": "Deferred compensation liability" } } }, "localname": "IncreaseDecreaseInDeferredCompensation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities": { "auth_ref": [ "r87" ], "calculation": { "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 12.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits.", "label": "Increase (Decrease) in Employee Related Liabilities", "terseLabel": "Accrued wages and related liabilities" } } }, "localname": "IncreaseDecreaseInEmployeeRelatedLiabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Operating Capital [Abstract]", "terseLabel": "Change in operating assets and liabilities" } } }, "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": { "auth_ref": [ "r87", "r557" ], "calculation": { "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 19.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in obligation for operating lease.", "label": "Increase (Decrease) in Operating Lease Liability", "terseLabel": "Operating lease obligations" } } }, "localname": "IncreaseDecreaseInOperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOtherDeferredLiability": { "auth_ref": [ "r87" ], "calculation": { "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 15.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in deferred obligations classified as other.", "label": "Increase (Decrease) in Other Deferred Liability", "terseLabel": "Other long-term liabilities" } } }, "localname": "IncreaseDecreaseInOtherDeferredLiability", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOtherOperatingLiabilities": { "auth_ref": [ "r87" ], "calculation": { "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 17.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in operating liabilities classified as other.", "label": "Increase (Decrease) in Other Operating Liabilities", "terseLabel": "Other accrued liabilities" } } }, "localname": "IncreaseDecreaseInOtherOperatingLiabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "auth_ref": [ "r87" ], "calculation": { "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 16.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.", "label": "Increase (Decrease) in Prepaid Expense and Other Assets", "negatedTerseLabel": "Prepaid expenses and other assets" } } }, "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInPrepaidTaxes": { "auth_ref": [ "r87" ], "calculation": { "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 22.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) of consideration paid in advance for income and other taxes that provide economic benefits in future periods.", "label": "Increase (Decrease) in Prepaid Taxes", "negatedTerseLabel": "Prepaid income taxes" } } }, "localname": "IncreaseDecreaseInPrepaidTaxes", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInSelfInsuranceReserve": { "auth_ref": [ "r87" ], "calculation": { "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 18.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the period in the carrying amount of accrued known and estimated losses incurred for which no insurance coverage exists, and for which a claim has been made or is probable of being asserted, typically arising from workmen's' compensation-type of incidents and personal injury to nonemployees from accidents on the entity's property.", "label": "Increase (Decrease) in Self Insurance Reserve", "terseLabel": "Accrued self-insurance liabilities" } } }, "localname": "IncreaseDecreaseInSelfInsuranceReserve", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]", "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]" } } }, "localname": "IncreaseDecreaseInStockholdersEquityRollForward", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "xbrltype": "stringItemType" }, "us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements": { "auth_ref": [ "r124", "r125", "r126", "r131", "r407" ], "calculation": { "http://www.ensigngroup.net/role/ComputationofNetIncomePerCommonShareDetails": { "order": 2.0, "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.", "label": "Incremental Common Shares Attributable to Dilutive Effect of Share-Based Payment Arrangements", "terseLabel": "Plus: incremental shares from assumed conversion (in shares)" } } }, "localname": "IncrementalCommonSharesAttributableToShareBasedPaymentArrangements", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/ComputationofNetIncomePerCommonShareDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis": { "auth_ref": [ "r242", "r249" ], "lang": { "en-us": { "role": { "documentation": "Information by type or class of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.", "label": "Indefinite-Lived Intangible Assets [Axis]", "terseLabel": "Indefinite-lived Intangible Assets [Axis]" } } }, "localname": "IndefiniteLivedIntangibleAssetsByMajorClassAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/GoodwillandOtherIndefiniteLivedIntangibleAssetsIndefiniteLivedIntangibleAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Indefinite-Lived Intangible Assets [Line Items]", "terseLabel": "Indefinite-lived Intangible Assets [Line Items]" } } }, "localname": "IndefiniteLivedIntangibleAssetsByMajorClassLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/GoodwillandOtherIndefiniteLivedIntangibleAssetsIndefiniteLivedIntangibleAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill": { "auth_ref": [ "r249" ], "calculation": { "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 10.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.", "label": "Indefinite-Lived Intangible Assets (Excluding Goodwill)", "terseLabel": "Other indefinite-lived intangibles" } } }, "localname": "IndefiniteLivedIntangibleAssetsExcludingGoodwill", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/GoodwillandOtherIndefiniteLivedIntangibleAssetsIndefiniteLivedIntangibleAssetsDetails", "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain": { "auth_ref": [ "r242", "r249" ], "lang": { "en-us": { "role": { "documentation": "The major class of indefinite-lived intangible asset (for example, trade names, etc. but not all-inclusive), excluding goodwill. A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of the company.", "label": "Indefinite-Lived Intangible Assets, Major Class Name [Domain]", "terseLabel": "Indefinite-lived Intangible Assets, Major Class Name [Domain]" } } }, "localname": "IndefiniteLivedIntangibleAssetsMajorClassNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/GoodwillandOtherIndefiniteLivedIntangibleAssetsIndefiniteLivedIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IntangibleAssetsDisclosureTextBlock": { "auth_ref": [ "r252" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for all or part of the information related to intangible assets.", "label": "Intangible Assets Disclosure [Text Block]", "terseLabel": "INTANGIBLE ASSETS \u2014 NET" } } }, "localname": "IntangibleAssetsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/IntangibleAssetsNet" ], "xbrltype": "textBlockItemType" }, "us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Intangible Assets, Net (Excluding Goodwill) [Abstract]", "terseLabel": "Intangible Assets, Net (Excluding Goodwill) [Abstract]" } } }, "localname": "IntangibleAssetsNetExcludingGoodwillAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_InterestExpense": { "auth_ref": [ "r57", "r159", "r540", "r543", "r628" ], "calculation": { "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME": { "order": 2.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.", "label": "Interest Expense", "negatedTerseLabel": "Interest expense", "terseLabel": "Interest expense" } } }, "localname": "InterestExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/BusinessSegmentsScheduleofSegmentReportingInformationbySegmentDetails", "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestPaidNet": { "auth_ref": [ "r80", "r84", "r91" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.", "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities", "terseLabel": "Interest" } } }, "localname": "InterestPaidNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_LandMember": { "auth_ref": [ "r383" ], "lang": { "en-us": { "role": { "documentation": "Part of earth's surface not covered by water.", "label": "Land [Member]", "terseLabel": "Land" } } }, "localname": "LandMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/PropertyandEquipmentNetDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LeaseContractualTermAxis": { "auth_ref": [ "r554" ], "lang": { "en-us": { "role": { "documentation": "Information by contractual term of lease arrangement.", "label": "Lease Contractual Term [Axis]", "terseLabel": "Lease Contractual Term [Axis]" } } }, "localname": "LeaseContractualTermAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/DescriptionofBusinessDetails", "http://www.ensigngroup.net/role/LeasesLessorNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LeaseContractualTermDomain": { "auth_ref": [ "r554" ], "lang": { "en-us": { "role": { "documentation": "Contractual term of lease arrangement.", "label": "Lease Contractual Term [Domain]", "terseLabel": "Lease Contractual Term [Domain]" } } }, "localname": "LeaseContractualTermDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/DescriptionofBusinessDetails", "http://www.ensigngroup.net/role/LeasesLessorNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LeaseCostTableTextBlock": { "auth_ref": [ "r561" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.", "label": "Lease, Cost [Table Text Block]", "terseLabel": "Schedule of Operating Lease Expenses" } } }, "localname": "LeaseCostTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/LeasesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_LeaseholdImprovementsMember": { "auth_ref": [ "r257" ], "lang": { "en-us": { "role": { "documentation": "Additions or improvements to assets held under a lease arrangement.", "label": "Leasehold Improvements [Member]", "terseLabel": "Leasehold improvements" } } }, "localname": "LeaseholdImprovementsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/PropertyandEquipmentNetDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LeasesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Leases [Abstract]", "terseLabel": "Leases [Abstract]" } } }, "localname": "LeasesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_LesseeLeaseDescriptionLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Lessee, Lease, Description [Line Items]", "terseLabel": "Lessee, Lease, Description [Line Items]" } } }, "localname": "LesseeLeaseDescriptionLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/LeasesLesseeLeaseCostDetails", "http://www.ensigngroup.net/role/LeasesLesseeNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LesseeLeaseDescriptionTable": { "auth_ref": [ "r554" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about lessee's leases.", "label": "Lessee, Lease, Description [Table]", "terseLabel": "Lessee, Lease, Description [Table]" } } }, "localname": "LesseeLeaseDescriptionTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/LeasesLesseeLeaseCostDetails", "http://www.ensigngroup.net/role/LeasesLesseeNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LesseeLeasesPolicyTextBlock": { "auth_ref": [ "r551" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.", "label": "Lessee, Leases [Policy Text Block]", "terseLabel": "Leases and Leasehold Improvements" } } }, "localname": "LesseeLeasesPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeOperatingLeaseDiscountRate": { "auth_ref": [ "r553" ], "lang": { "en-us": { "role": { "documentation": "Discount rate used by lessee to determine present value of operating lease payments.", "label": "Lessee, Operating Lease, Discount Rate", "terseLabel": "Operating leases of lessee, contingent rentals, basis spread on variable rate" } } }, "localname": "LesseeOperatingLeaseDiscountRate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/LeasesLesseeNarrativeDetails", "http://www.ensigngroup.net/role/StandardBearerDetails" ], "xbrltype": "percentItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": { "auth_ref": [ "r562" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.", "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]", "terseLabel": "Schedule of Future Minimum Lease Payments" } } }, "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/LeasesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": { "auth_ref": [ "r562" ], "calculation": { "http://www.ensigngroup.net/role/LeasesLesseeFutureMinimumLeasePaymentsDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.ensigngroup.net/role/LeasesLesseeFutureMinimumLeasePaymentsDetails_1": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.", "label": "Lessee, Operating Lease, Liability, to be Paid", "totalLabel": "TOTAL LEASE PAYMENTS" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/LeasesLesseeFutureMinimumLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": { "auth_ref": [ "r562" ], "calculation": { "http://www.ensigngroup.net/role/LeasesLesseeFutureMinimumLeasePaymentsDetails": { "order": 6.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, after Year Five", "terseLabel": "Thereafter" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/LeasesLesseeFutureMinimumLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": { "auth_ref": [ "r562" ], "calculation": { "http://www.ensigngroup.net/role/LeasesLesseeFutureMinimumLeasePaymentsDetails": { "order": 5.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year One", "terseLabel": "2023" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/LeasesLesseeFutureMinimumLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": { "auth_ref": [ "r562" ], "calculation": { "http://www.ensigngroup.net/role/LeasesLesseeFutureMinimumLeasePaymentsDetails": { "order": 7.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Five", "terseLabel": "2027" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/LeasesLesseeFutureMinimumLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": { "auth_ref": [ "r562" ], "calculation": { "http://www.ensigngroup.net/role/LeasesLesseeFutureMinimumLeasePaymentsDetails": { "order": 2.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four", "terseLabel": "2026" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/LeasesLesseeFutureMinimumLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": { "auth_ref": [ "r562" ], "calculation": { "http://www.ensigngroup.net/role/LeasesLesseeFutureMinimumLeasePaymentsDetails": { "order": 1.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three", "terseLabel": "2025" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/LeasesLesseeFutureMinimumLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": { "auth_ref": [ "r562" ], "calculation": { "http://www.ensigngroup.net/role/LeasesLesseeFutureMinimumLeasePaymentsDetails": { "order": 4.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two", "terseLabel": "2024" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/LeasesLesseeFutureMinimumLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": { "auth_ref": [ "r562" ], "calculation": { "http://www.ensigngroup.net/role/LeasesLesseeFutureMinimumLeasePaymentsDetails": { "order": 3.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.", "label": "Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year", "terseLabel": "2022 (remainder)" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/LeasesLesseeFutureMinimumLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": { "auth_ref": [ "r562" ], "calculation": { "http://www.ensigngroup.net/role/LeasesLesseeFutureMinimumLeasePaymentsDetails_1": { "order": 2.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.", "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount", "negatedTerseLabel": "Less: present value adjustment" } } }, "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/LeasesLesseeFutureMinimumLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseRenewalTerm": { "auth_ref": [ "r552" ], "lang": { "en-us": { "role": { "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Lessee, Operating Lease, Renewal Term", "terseLabel": "Lessee, operating lease, renewal term" } } }, "localname": "LesseeOperatingLeaseRenewalTerm", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/LeasesLesseeNarrativeDetails", "http://www.ensigngroup.net/role/StandardBearerDetails", "http://www.ensigngroup.net/role/SummaryofSignificantAccountingPoliciesLeasesandLeaseholdImprovementsDetails" ], "xbrltype": "durationItemType" }, "us-gaap_LesseeOperatingLeaseTermOfContract": { "auth_ref": [ "r552" ], "lang": { "en-us": { "role": { "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Lessee, Operating Lease, Term of Contract", "terseLabel": "Lessee, operating lease, term of contract" } } }, "localname": "LesseeOperatingLeaseTermOfContract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/LeasesLesseeNarrativeDetails", "http://www.ensigngroup.net/role/StandardBearerDetails", "http://www.ensigngroup.net/role/SummaryofSignificantAccountingPoliciesLeasesandLeaseholdImprovementsDetails" ], "xbrltype": "durationItemType" }, "us-gaap_LesseeOperatingLeasesTextBlock": { "auth_ref": [ "r564" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.", "label": "Lessee, Operating Leases [Text Block]", "terseLabel": "LEASES" } } }, "localname": "LesseeOperatingLeasesTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/Leases" ], "xbrltype": "textBlockItemType" }, "us-gaap_LessorLeaseDescriptionLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Lessor, Lease, Description [Line Items]", "terseLabel": "Lessor, Lease, Description [Line Items]" } } }, "localname": "LessorLeaseDescriptionLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/LeasesLessorNarrativeDetails", "http://www.ensigngroup.net/role/LeasesLessorRentalIncomeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LessorLeaseDescriptionTable": { "auth_ref": [ "r568" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about lessor's leases.", "label": "Lessor, Lease, Description [Table]", "terseLabel": "Lessor, Lease, Description [Table]" } } }, "localname": "LessorLeaseDescriptionTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/LeasesLessorNarrativeDetails", "http://www.ensigngroup.net/role/LeasesLessorRentalIncomeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LessorOperatingLeasePaymentsToBeReceived": { "auth_ref": [ "r566" ], "calculation": { "http://www.ensigngroup.net/role/LeasesLessorFutureMinimumLeasePaymentsReceivableDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lease payments to be received by lessor for operating lease.", "label": "Lessor, Operating Lease, Payments to be Received", "totalLabel": "TOTAL" } } }, "localname": "LessorOperatingLeasePaymentsToBeReceived", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/LeasesLessorFutureMinimumLeasePaymentsReceivableDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LessorOperatingLeasePaymentsToBeReceivedFiveYears": { "auth_ref": [ "r566" ], "calculation": { "http://www.ensigngroup.net/role/LeasesLessorFutureMinimumLeasePaymentsReceivableDetails": { "order": 1.0, "parentTag": "us-gaap_LessorOperatingLeasePaymentsToBeReceived", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lease payment to be received by lessor for operating lease in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessor, Operating Lease, Payment to be Received, Year Five", "terseLabel": "2027" } } }, "localname": "LessorOperatingLeasePaymentsToBeReceivedFiveYears", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/LeasesLessorFutureMinimumLeasePaymentsReceivableDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LessorOperatingLeasePaymentsToBeReceivedFourYears": { "auth_ref": [ "r566" ], "calculation": { "http://www.ensigngroup.net/role/LeasesLessorFutureMinimumLeasePaymentsReceivableDetails": { "order": 2.0, "parentTag": "us-gaap_LessorOperatingLeasePaymentsToBeReceived", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lease payment to be received by lessor for operating lease in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessor, Operating Lease, Payment to be Received, Year Four", "terseLabel": "2026" } } }, "localname": "LessorOperatingLeasePaymentsToBeReceivedFourYears", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/LeasesLessorFutureMinimumLeasePaymentsReceivableDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LessorOperatingLeasePaymentsToBeReceivedMaturityTableTextBlock": { "auth_ref": [ "r566" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of maturity of undiscounted cash flows to be received by lessor on annual basis for operating lease.", "label": "Lessor, Operating Lease, Payment to be Received, Fiscal Year Maturity [Table Text Block]", "terseLabel": "Schedule of Annual Rental Income" } } }, "localname": "LessorOperatingLeasePaymentsToBeReceivedMaturityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/LeasesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths": { "auth_ref": [ "r566" ], "calculation": { "http://www.ensigngroup.net/role/LeasesLessorFutureMinimumLeasePaymentsReceivableDetails": { "order": 6.0, "parentTag": "us-gaap_LessorOperatingLeasePaymentsToBeReceived", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lease payment to be received by lessor for operating lease in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessor, Operating Lease, Payment to be Received, Year One", "terseLabel": "2023" } } }, "localname": "LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/LeasesLessorFutureMinimumLeasePaymentsReceivableDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LessorOperatingLeasePaymentsToBeReceivedRemainderOfFiscalYear": { "auth_ref": [ "r566" ], "calculation": { "http://www.ensigngroup.net/role/LeasesLessorFutureMinimumLeasePaymentsReceivableDetails": { "order": 4.0, "parentTag": "us-gaap_LessorOperatingLeasePaymentsToBeReceived", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lease payment to be received by lessor for operating lease in remainder of current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessor, Operating Lease, Payment to be Received, Remainder of Fiscal Year", "terseLabel": "2022 (remainder)" } } }, "localname": "LessorOperatingLeasePaymentsToBeReceivedRemainderOfFiscalYear", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/LeasesLessorFutureMinimumLeasePaymentsReceivableDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LessorOperatingLeasePaymentsToBeReceivedThereafter": { "auth_ref": [ "r566" ], "calculation": { "http://www.ensigngroup.net/role/LeasesLessorFutureMinimumLeasePaymentsReceivableDetails": { "order": 3.0, "parentTag": "us-gaap_LessorOperatingLeasePaymentsToBeReceived", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lease payment to be received by lessor for operating lease after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessor, Operating Lease, Payment to be Received, after Year Five", "terseLabel": "Thereafter" } } }, "localname": "LessorOperatingLeasePaymentsToBeReceivedThereafter", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/LeasesLessorFutureMinimumLeasePaymentsReceivableDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LessorOperatingLeasePaymentsToBeReceivedThreeYears": { "auth_ref": [ "r566" ], "calculation": { "http://www.ensigngroup.net/role/LeasesLessorFutureMinimumLeasePaymentsReceivableDetails": { "order": 7.0, "parentTag": "us-gaap_LessorOperatingLeasePaymentsToBeReceived", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lease payment to be received by lessor for operating lease in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessor, Operating Lease, Payment to be Received, Year Three", "terseLabel": "2025" } } }, "localname": "LessorOperatingLeasePaymentsToBeReceivedThreeYears", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/LeasesLessorFutureMinimumLeasePaymentsReceivableDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears": { "auth_ref": [ "r566" ], "calculation": { "http://www.ensigngroup.net/role/LeasesLessorFutureMinimumLeasePaymentsReceivableDetails": { "order": 5.0, "parentTag": "us-gaap_LessorOperatingLeasePaymentsToBeReceived", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lease payment to be received by lessor for operating lease in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessor, Operating Lease, Payment to be Received, Year Two", "terseLabel": "2024" } } }, "localname": "LessorOperatingLeasePaymentsToBeReceivedTwoYears", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/LeasesLessorFutureMinimumLeasePaymentsReceivableDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LessorOperatingLeaseTermOfContract": { "auth_ref": [ "r567" ], "lang": { "en-us": { "role": { "documentation": "Term of lessor's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Lessor, Operating Lease, Term of Contract", "terseLabel": "Lessor, operating lease, term of contract" } } }, "localname": "LessorOperatingLeaseTermOfContract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/LeasesLessorNarrativeDetails" ], "xbrltype": "durationItemType" }, "us-gaap_LettersOfCreditOutstandingAmount": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The total amount of the contingent obligation under letters of credit outstanding as of the reporting date.", "label": "Letters of Credit Outstanding, Amount", "terseLabel": "Letters of credit outstanding, pledged amount" } } }, "localname": "LettersOfCreditOutstandingAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/DebtMortgageLoansandPromissoryNotesandOffBalanceSheetArrangementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r37", "r100", "r173", "r210", "r284", "r285", "r286", "r289", "r290", "r291", "r293", "r295", "r297", "r298", "r504", "r509", "r510", "r531", "r574", "r575" ], "calculation": { "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "Liabilities", "totalLabel": "TOTAL LIABILITIES" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r29", "r100", "r210", "r531", "r576", "r619", "r640" ], "calculation": { "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities and Equity", "totalLabel": "TOTAL LIABILITIES AND EQUITY" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities and Equity [Abstract]", "terseLabel": "LIABILITIES AND EQUITY" } } }, "localname": "LiabilitiesAndStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r10", "r39", "r100", "r210", "r284", "r285", "r286", "r289", "r290", "r291", "r293", "r295", "r297", "r298", "r504", "r509", "r510", "r531", "r574", "r575", "r576" ], "calculation": { "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 1.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "Liabilities, Current", "totalLabel": "Total current liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities, Current [Abstract]", "terseLabel": "Current liabilities:" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesFairValueAdjustment": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of addition (reduction) to the amount at which a liability could be incurred (settled) in a current transaction between willing parties.", "label": "Liabilities, Fair Value Adjustment", "terseLabel": "Fair value adjustment, lease liability and right-of-use assets" } } }, "localname": "LiabilitiesFairValueAdjustment", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/LeasesLesseeNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Liability for Claims and Claims Adjustment Expense [Line Items]", "terseLabel": "Liability for Claims and Claims Adjustment Expense [Line Items]" } } }, "localname": "LiabilityForClaimsAndClaimsAdjustmentExpenseLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/SummaryofSignificantAccountingPoliciesSelfInsuranceDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about the liability for claims and claims adjustment expense.", "label": "Liability for Claims and Claims Adjustment Expense [Table]", "terseLabel": "Liability for Claims and Claims Adjustment Expense [Table]" } } }, "localname": "LiabilityForClaimsAndClaimsAdjustmentExpenseTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/SummaryofSignificantAccountingPoliciesSelfInsuranceDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilityReserveEstimatePolicy": { "auth_ref": [ "r660" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for estimating its liability as of the balance sheet date for the ultimate cost of settling reported and unreported claims incurred and claims adjustment expenses (including effects of inflation and other societal and economic factors).", "label": "Liability Reserve Estimate, Policy [Policy Text Block]", "terseLabel": "Self-Insurance" } } }, "localname": "LiabilityReserveEstimatePolicy", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_LifeInsuranceCorporateOrBankOwnedChangeInValue": { "auth_ref": [ "r211" ], "calculation": { "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 21.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The change in cash surrender or contract value during the period which adjusted the amount of premiums paid in determining the expense or income recognized under the contract for the period.", "label": "Life Insurance, Corporate or Bank Owned, Change in Value", "negatedTerseLabel": "Cash surrender value of life insurance policy premiums" } } }, "localname": "LifeInsuranceCorporateOrBankOwnedChangeInValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_LineOfCreditFacilityAxis": { "auth_ref": [ "r35", "r99" ], "lang": { "en-us": { "role": { "documentation": "Information by name of lender, which may be a single entity (for example, but not limited to, a bank, pension fund, venture capital firm) or a group of entities that participate in the line of credit.", "label": "Lender Name [Axis]", "terseLabel": "Lender Name [Axis]" } } }, "localname": "LineOfCreditFacilityAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/DebtCreditFacilitywithaLendingConsortiumArrangedbySunTrustDetails", "http://www.ensigngroup.net/role/StandardBearerDetails", "http://www.ensigngroup.net/role/SummaryofSignificantAccountingPoliciesRecentAccountingPronouncementsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LineOfCreditFacilityIncreaseDecreaseForPeriodNet": { "auth_ref": [ "r99" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) of the credit facility.", "label": "Line of Credit Facility, Increase (Decrease), Net", "terseLabel": "Letter of credit increase" } } }, "localname": "LineOfCreditFacilityIncreaseDecreaseForPeriodNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/SummaryofSignificantAccountingPoliciesRecentAccountingPronouncementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LineOfCreditFacilityLenderDomain": { "auth_ref": [ "r35", "r99" ], "lang": { "en-us": { "role": { "documentation": "Identification of the lender, which may be a single entity (for example, a bank, pension fund, venture capital firm) or a group of entities that participate in the line of credit, including a letter of credit facility.", "label": "Line of Credit Facility, Lender [Domain]", "terseLabel": "Line of Credit Facility, Lender [Domain]" } } }, "localname": "LineOfCreditFacilityLenderDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/DebtCreditFacilitywithaLendingConsortiumArrangedbySunTrustDetails", "http://www.ensigngroup.net/role/StandardBearerDetails", "http://www.ensigngroup.net/role/SummaryofSignificantAccountingPoliciesRecentAccountingPronouncementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": { "auth_ref": [ "r35" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.", "label": "Line of Credit Facility, Maximum Borrowing Capacity", "terseLabel": "Line of credit facility, maximum borrowing capacity" } } }, "localname": "LineOfCreditFacilityMaximumBorrowingCapacity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/DebtCreditFacilitywithaLendingConsortiumArrangedbySunTrustDetails", "http://www.ensigngroup.net/role/SummaryofSignificantAccountingPoliciesRecentAccountingPronouncementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The fee, expressed as a percentage of the line of credit facility, for available but unused credit capacity under the credit facility.", "label": "Line of Credit Facility, Unused Capacity, Commitment Fee Percentage", "terseLabel": "Line of credit facility, unused capacity, commitment fee percentage" } } }, "localname": "LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/DebtCreditFacilitywithaLendingConsortiumArrangedbySunTrustDetails" ], "xbrltype": "percentItemType" }, "us-gaap_LongTermDebtCurrent": { "auth_ref": [ "r36" ], "calculation": { "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 6.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.", "label": "Long-Term Debt, Current Maturities", "negatedTerseLabel": "Less: current maturities", "terseLabel": "Current maturities of long-term debt", "verboseLabel": "Amount outstanding, current" } } }, "localname": "LongTermDebtCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/DebtMortgageLoansandPromissoryNotesandOffBalanceSheetArrangementsDetails", "http://www.ensigngroup.net/role/DebtScheduleofLongtermDebtDetails", "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtNoncurrent": { "auth_ref": [ "r20" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation.", "label": "Long-Term Debt, Excluding Current Maturities", "verboseLabel": "Long-term debt\u2014less current maturities" } } }, "localname": "LongTermDebtNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/DebtMortgageLoansandPromissoryNotesandOffBalanceSheetArrangementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongtermDebtTypeAxis": { "auth_ref": [ "r41" ], "lang": { "en-us": { "role": { "documentation": "Information by type of long-term debt.", "label": "Long-Term Debt, Type [Axis]", "terseLabel": "Long-term Debt, Type [Axis]" } } }, "localname": "LongtermDebtTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/DebtMortgageLoansandPromissoryNotesandOffBalanceSheetArrangementsDetails", "http://www.ensigngroup.net/role/DebtScheduleofLongtermDebtDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LongtermDebtTypeDomain": { "auth_ref": [ "r41", "r283" ], "lang": { "en-us": { "role": { "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.", "label": "Long-Term Debt, Type [Domain]", "terseLabel": "Long-term Debt, Type [Domain]" } } }, "localname": "LongtermDebtTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/DebtMortgageLoansandPromissoryNotesandOffBalanceSheetArrangementsDetails", "http://www.ensigngroup.net/role/DebtScheduleofLongtermDebtDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MalpracticeLossContingencyAccrualUndiscounted": { "auth_ref": [ "r277" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of the accrued liability on an undiscounted basis for malpractice claims (including general and professional liability) at the end of the accounting period.", "label": "Malpractice Loss Contingency, Accrual, Undiscounted", "terseLabel": "Malpractice loss contingency, accrual, undiscounted" } } }, "localname": "MalpracticeLossContingencyAccrualUndiscounted", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/SummaryofSignificantAccountingPoliciesSelfInsuranceDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ManagementFeeExpense": { "auth_ref": [ "r573" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expenses related to the managing member or general partner for management of the day-to-day business functions of the limited liability company (LLC) or limited partnership (LP).", "label": "Management Fee Expense", "terseLabel": "Management fees" } } }, "localname": "ManagementFeeExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/StandardBearerDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ManagementServiceBaseMember": { "auth_ref": [ "r383" ], "lang": { "en-us": { "role": { "documentation": "Contractually stipulated right to receive base compensation for operating and managing business.", "label": "Management Service, Base [Member]", "terseLabel": "Base Management Fee" } } }, "localname": "ManagementServiceBaseMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/StandardBearerDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ManagementServiceIncentiveMember": { "auth_ref": [ "r383" ], "lang": { "en-us": { "role": { "documentation": "Contractually stipulated right to receive incentive compensation for operating and managing business.", "label": "Management Service, Incentive [Member]", "terseLabel": "Incentive Management Fee" } } }, "localname": "ManagementServiceIncentiveMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/StandardBearerDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MinorityInterest": { "auth_ref": [ "r47", "r100", "r210", "r284", "r289", "r290", "r291", "r297", "r298", "r531", "r618", "r639" ], "calculation": { "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).", "label": "Stockholders' Equity Attributable to Noncontrolling Interest", "terseLabel": "Non-controlling interest" } } }, "localname": "MinorityInterest", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders": { "auth_ref": [ "r354" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Decrease in noncontrolling interest balance from payment of dividends or other distributions by the non-wholly owned subsidiary or partially owned entity, included in the consolidation of the parent entity, to the noncontrolling interest holders.", "label": "Noncontrolling Interest, Decrease from Distributions to Noncontrolling Interest Holders", "negatedTerseLabel": "Distribution to noncontrolling interest holder" } } }, "localname": "MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "xbrltype": "monetaryItemType" }, "us-gaap_MinorityInterestDecreaseFromRedemptions": { "auth_ref": [ "r354", "r501", "r502" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Decrease in noncontrolling interest (for example, but not limited to, redeeming or purchasing the interests of noncontrolling shareholders, issuance of shares (interests) by the non-wholly owned subsidiary to the parent entity for other than cash, and a buyback of shares (interest) by the non-wholly owned subsidiary from the noncontrolling interests).", "label": "Noncontrolling Interest, Decrease from Redemptions or Purchase of Interests", "negatedTerseLabel": "Acquisition of noncontrolling interest shares" } } }, "localname": "MinorityInterestDecreaseFromRedemptions", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "xbrltype": "monetaryItemType" }, "us-gaap_MinorityInterestInNetIncomeLossOfConsolidatedEntitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Income (Loss) Attributable to Noncontrolling Interest [Abstract]", "terseLabel": "Less:" } } }, "localname": "MinorityInterestInNetIncomeLossOfConsolidatedEntitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME" ], "xbrltype": "stringItemType" }, "us-gaap_MortgagesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A loan to finance the purchase of real estate where the lender has a lien on the property as collateral for the loan.", "label": "Mortgages [Member]", "terseLabel": "Mortgages" } } }, "localname": "MortgagesMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/DebtMortgageLoansandPromissoryNotesandOffBalanceSheetArrangementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r83" ], "calculation": { "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "NET CASH USED IN FINANCING ACTIVITIES" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]", "terseLabel": "Cash flows from financing activities:" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r83" ], "calculation": { "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 3.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "Net Cash Provided by (Used in) Investing Activities", "totalLabel": "NET CASH USED IN INVESTING ACTIVITIES" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]", "terseLabel": "Cash flows from investing activities:" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r83", "r86", "r89" ], "calculation": { "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided by (Used in) Operating Activities", "totalLabel": "NET CASH PROVIDED BY OPERATING ACTIVITIES" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Cash flows from operating activities:" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r5", "r51", "r52", "r56", "r59", "r89", "r100", "r111", "r113", "r114", "r115", "r116", "r119", "r120", "r128", "r165", "r171", "r175", "r178", "r181", "r210", "r284", "r285", "r286", "r289", "r290", "r291", "r293", "r295", "r297", "r298", "r520", "r531", "r625", "r644" ], "calculation": { "http://www.ensigngroup.net/role/ComputationofNetIncomePerCommonShareDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net Income (Loss) Attributable to Parent", "totalLabel": "Net income attributable to The Ensign Group, Inc.", "verboseLabel": "Net income attributable to the Ensign Group, Inc." } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/ComputationofNetIncomePerCommonShareDetails", "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME", "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetIncomeLossAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Income (Loss) Attributable to Parent [Abstract]", "terseLabel": "NUMERATOR:" } } }, "localname": "NetIncomeLossAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/ComputationofNetIncomePerCommonShareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest": { "auth_ref": [ "r51", "r52", "r56", "r119", "r120", "r506", "r512" ], "calculation": { "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of Net Income (Loss) attributable to noncontrolling interest.", "label": "Net Income (Loss) Attributable to Noncontrolling Interest", "terseLabel": "Net income (loss) attributable to noncontrolling interests" } } }, "localname": "NetIncomeLossAttributableToNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME", "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "xbrltype": "monetaryItemType" }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.", "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "terseLabel": "Recent Accounting Pronouncements" } } }, "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance": { "auth_ref": [ "r355", "r501", "r508" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in noncontrolling interest from subsidiary issuance of equity interests to noncontrolling interest holders.", "label": "Noncontrolling Interest, Increase from Subsidiary Equity Issuance", "terseLabel": "Noncontrolling interest attributable to subsidiary equity plan" } } }, "localname": "NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "xbrltype": "monetaryItemType" }, "us-gaap_NoncontrollingInterestMember": { "auth_ref": [ "r108", "r109", "r110", "r354", "r498" ], "lang": { "en-us": { "role": { "documentation": "This element represents that portion of equity (net assets) in a subsidiary not attributable, directly or indirectly, to the parent. A noncontrolling interest is sometimes called a minority interest.", "label": "Noncontrolling Interest [Member]", "terseLabel": "Non-Controlling Interest" } } }, "localname": "NoncontrollingInterestMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "xbrltype": "domainItemType" }, "us-gaap_NonoperatingIncomeExpense": { "auth_ref": [ "r67" ], "calculation": { "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME": { "order": 1.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).", "label": "Nonoperating Income (Expense)", "totalLabel": "Other expense, net" } } }, "localname": "NonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME" ], "xbrltype": "monetaryItemType" }, "us-gaap_NotesPayable": { "auth_ref": [ "r20", "r617", "r637" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Including the current and noncurrent portions, aggregate carrying amount of all types of notes payable, as of the balance sheet date, with initial maturities beyond one year or beyond the normal operating cycle, if longer.", "label": "Notes Payable", "verboseLabel": "Notes payable" } } }, "localname": "NotesPayable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/DebtMortgageLoansandPromissoryNotesandOffBalanceSheetArrangementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NotesPayableOtherPayablesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A written promise to pay a note to a third party.", "label": "Notes Payable, Other Payables [Member]", "terseLabel": "Mortgage loans and promissory notes", "verboseLabel": "Notes Payable Other Payables" } } }, "localname": "NotesPayableOtherPayablesMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/DebtMortgageLoansandPromissoryNotesandOffBalanceSheetArrangementsDetails", "http://www.ensigngroup.net/role/DebtScheduleofLongtermDebtDetails" ], "xbrltype": "domainItemType" }, "us-gaap_NotesPayableToBanksMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A written promise to pay a note to a bank.", "label": "Notes Payable to Banks [Member]", "terseLabel": "Notes Payable to Banks" } } }, "localname": "NotesPayableToBanksMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/DebtMortgageLoansandPromissoryNotesandOffBalanceSheetArrangementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_NumberOfBusinessesAcquired": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The number of businesses acquired by the entity during the period.", "label": "Number of Businesses Acquired", "terseLabel": "Number of businesses acquired" } } }, "localname": "NumberOfBusinessesAcquired", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/LeasesLesseeNarrativeDetails", "http://www.ensigngroup.net/role/OperationExpansionsDetails", "http://www.ensigngroup.net/role/StandardBearerDetails" ], "xbrltype": "integerItemType" }, "us-gaap_NumberOfRealEstateProperties": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The number of real estate properties owned as of the balance sheet date.", "label": "Number of Real Estate Properties", "terseLabel": "Number of real estate properties" } } }, "localname": "NumberOfRealEstateProperties", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/BusinessSegmentsNarrativeDetails", "http://www.ensigngroup.net/role/DescriptionofBusinessDetails", "http://www.ensigngroup.net/role/LeasesLesseeNarrativeDetails", "http://www.ensigngroup.net/role/LeasesLessorNarrativeDetails", "http://www.ensigngroup.net/role/StandardBearerDetails" ], "xbrltype": "integerItemType" }, "us-gaap_NumberOfReportableSegments": { "auth_ref": [ "r153" ], "lang": { "en-us": { "role": { "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.", "label": "Number of Reportable Segments", "terseLabel": "Number of reportable segments" } } }, "localname": "NumberOfReportableSegments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/BusinessSegmentsNarrativeDetails" ], "xbrltype": "integerItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [ "r165", "r171", "r175", "r178", "r181" ], "calculation": { "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME": { "order": 2.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "Operating Income (Loss)", "totalLabel": "Income from operations" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseCost": { "auth_ref": [ "r555", "r563" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.", "label": "Operating Lease, Cost", "verboseLabel": "Operating lease expense" } } }, "localname": "OperatingLeaseCost", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/IntangibleAssetsNetNarrativeDetails", "http://www.ensigngroup.net/role/LeasesLesseeLeaseCostDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseExpense": { "auth_ref": [ "r549" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of operating lease expense. Excludes sublease income.", "label": "Operating Lease, Expense", "terseLabel": "Rent expense" } } }, "localname": "OperatingLeaseExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/LeasesLesseeNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLeaseIncome": { "auth_ref": [ "r138", "r565", "r570" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of operating lease income from lease payments and variable lease payments paid and payable to lessor. Includes, but is not limited to, variable lease payments not included in measurement of lease receivable.", "label": "Operating Lease, Lease Income", "terseLabel": "Operating lease, lease income" } } }, "localname": "OperatingLeaseLeaseIncome", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/LeasesLessorRentalIncomeDetails", "http://www.ensigngroup.net/role/StandardBearerDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLeaseIncomeTableTextBlock": { "auth_ref": [ "r138", "r570" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of components of income from operating lease.", "label": "Operating Lease, Lease Income [Table Text Block]", "terseLabel": "Schedule of Rental Income from Third-Party Sources" } } }, "localname": "OperatingLeaseLeaseIncomeTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/LeasesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Liability, to be Paid [Abstract]", "terseLabel": "Year" } } }, "localname": "OperatingLeaseLiabilitiesPaymentsDueAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/LeasesLesseeFutureMinimumLeasePaymentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingLeaseLiability": { "auth_ref": [ "r548" ], "calculation": { "http://www.ensigngroup.net/role/LeasesLesseeFutureMinimumLeasePaymentsDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.ensigngroup.net/role/LeasesLesseeFutureMinimumLeasePaymentsDetails_1": { "order": 1.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.", "label": "Operating Lease, Liability", "totalLabel": "PRESENT VALUE OF TOTAL LEASE LIABILITIES" } } }, "localname": "OperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/LeasesLesseeFutureMinimumLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityCurrent": { "auth_ref": [ "r548" ], "calculation": { "http://www.ensigngroup.net/role/LeasesLesseeFutureMinimumLeasePaymentsDetails": { "order": 2.0, "parentTag": "us-gaap_OperatingLeaseLiability", "weight": 1.0 }, "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.", "label": "Operating Lease, Liability, Current", "negatedLabel": "Less: current lease liabilities", "terseLabel": "Lease liabilities\u2014current" } } }, "localname": "OperatingLeaseLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/LeasesLesseeFutureMinimumLeasePaymentsDetails", "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "auth_ref": [ "r548" ], "calculation": { "http://www.ensigngroup.net/role/LeasesLesseeFutureMinimumLeasePaymentsDetails": { "order": 1.0, "parentTag": "us-gaap_OperatingLeaseLiability", "weight": 1.0 }, "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 3.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.", "label": "Operating Lease, Liability, Noncurrent", "terseLabel": "Long-term lease liabilities\u2014less current portion", "verboseLabel": "LONG-TERM OPERATING LEASE LIABILITIES" } } }, "localname": "OperatingLeaseLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/LeasesLesseeFutureMinimumLeasePaymentsDetails", "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasePayments": { "auth_ref": [ "r550", "r557" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.", "label": "Operating Lease, Payments", "terseLabel": "Lease liabilities" } } }, "localname": "OperatingLeasePayments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseRightOfUseAsset": { "auth_ref": [ "r547" ], "calculation": { "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 3.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's right to use underlying asset under operating lease.", "label": "Operating Lease, Right-of-Use Asset", "terseLabel": "Right-of-use assets" } } }, "localname": "OperatingLeaseRightOfUseAsset", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseVariableLeaseIncome": { "auth_ref": [ "r138", "r569" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of operating lease income from variable lease payments paid and payable to lessor, excluding amount included in measurement of lease receivable.", "label": "Operating Lease, Variable Lease Income", "terseLabel": "Operating lease, variable lease income" } } }, "localname": "OperatingLeaseVariableLeaseIncome", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/LeasesLessorRentalIncomeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": { "auth_ref": [ "r560", "r563" ], "lang": { "en-us": { "role": { "documentation": "Weighted average discount rate for operating lease calculated at point in time.", "label": "Operating Lease, Weighted Average Discount Rate, Percent", "terseLabel": "Operating lease, weighted average discount rate, percent" } } }, "localname": "OperatingLeaseWeightedAverageDiscountRatePercent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/LeasesLesseeNarrativeDetails" ], "xbrltype": "percentItemType" }, "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": { "auth_ref": [ "r559", "r563" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Operating Lease, Weighted Average Remaining Lease Term", "terseLabel": "Operating lease, weighted average remaining lease term" } } }, "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/LeasesLesseeNarrativeDetails" ], "xbrltype": "durationItemType" }, "us-gaap_OperatingLeasesOfLessorDisclosureTextBlock": { "auth_ref": [ "r571" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for lessor's operating leases.", "label": "Lessor, Operating Leases [Text Block]", "terseLabel": "LEASES" } } }, "localname": "OperatingLeasesOfLessorDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/Leases" ], "xbrltype": "textBlockItemType" }, "us-gaap_OperatingSegmentsMember": { "auth_ref": [ "r170", "r171", "r172", "r173", "r175", "r181" ], "lang": { "en-us": { "role": { "documentation": "Identifies components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity.", "label": "Operating Segments [Member]", "terseLabel": "Operating Segments" } } }, "localname": "OperatingSegmentsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/BusinessSegmentsRevenuebySegmentDetails", "http://www.ensigngroup.net/role/BusinessSegmentsScheduleofSegmentReportingInformationbySegmentDetails", "http://www.ensigngroup.net/role/GoodwillandOtherIndefiniteLivedIntangibleAssetsGoodwillRollforwardDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]", "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": { "auth_ref": [ "r6", "r514" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.", "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]", "terseLabel": "DESCRIPTION OF BUSINESS" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/DescriptionofBusiness" ], "xbrltype": "textBlockItemType" }, "us-gaap_OtherAccruedLiabilitiesCurrent": { "auth_ref": [ "r38" ], "calculation": { "http://www.ensigngroup.net/role/OtherAccruedLiabilitiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 5.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.", "label": "Other Accrued Liabilities, Current", "terseLabel": "Other accrued liabilities", "totalLabel": "OTHER ACCRUED LIABILITIES" } } }, "localname": "OtherAccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/OtherAccruedLiabilitiesDetails", "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherAssetsDisclosureTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for other assets. This disclosure includes other current assets and other noncurrent assets.", "label": "Other Assets Disclosure [Text Block]", "terseLabel": "RESTRICTED AND OTHER ASSETS" } } }, "localname": "OtherAssetsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/RestrictedandOtherAssets" ], "xbrltype": "textBlockItemType" }, "us-gaap_OtherLiabilitiesNoncurrent": { "auth_ref": [ "r42" ], "calculation": { "http://www.ensigngroup.net/role/OtherAccruedLiabilitiesDetails": { "order": 2.0, "parentTag": "us-gaap_OtherAccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.", "label": "Other Liabilities, Noncurrent", "terseLabel": "Other" } } }, "localname": "OtherLiabilitiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/OtherAccruedLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNoncashInvestingAndFinancingItemsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other Noncash Investing and Financing Items [Abstract]", "terseLabel": "Non-cash financing and investing activity" } } }, "localname": "OtherNoncashInvestingAndFinancingItemsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "stringItemType" }, "us-gaap_OtherNonoperatingIncomeExpense": { "auth_ref": [ "r69" ], "calculation": { "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME": { "order": 1.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.", "label": "Other Nonoperating Income (Expense)", "terseLabel": "Other (expense) income" } } }, "localname": "OtherNonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNonoperatingIncomeExpenseAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other Nonoperating Income (Expense) [Abstract]", "terseLabel": "Other (expense) income:" } } }, "localname": "OtherNonoperatingIncomeExpenseAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME" ], "xbrltype": "stringItemType" }, "us-gaap_OtherRestrictedAssets": { "auth_ref": [ "r16", "r663", "r664" ], "calculation": { "http://www.ensigngroup.net/role/RestrictedandOtherAssetsDetails": { "order": 4.0, "parentTag": "us-gaap_OtherRestrictedAssetsNoncurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Total assets that cannot be used for operating purposes because of contract or regulatory requirements that are in effect for a period that extends beyond one year.", "label": "Other Restricted Assets", "terseLabel": "Capital improvement reserves with landlords and lenders" } } }, "localname": "OtherRestrictedAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/RestrictedandOtherAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherRestrictedAssetsNoncurrent": { "auth_ref": [ "r663", "r664" ], "calculation": { "http://www.ensigngroup.net/role/RestrictedandOtherAssetsDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 7.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncurrent assets that are pledged or subject to withdrawal restrictions, classified as other.", "label": "Other Restricted Assets, Noncurrent", "terseLabel": "Restricted and other assets", "totalLabel": "RESTRICTED AND OTHER ASSETS" } } }, "localname": "OtherRestrictedAssetsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/RestrictedandOtherAssetsDetails", "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_PayablesAndAccrualsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Payables and Accruals [Abstract]", "terseLabel": "Payables and Accruals [Abstract]" } } }, "localname": "PayablesAndAccrualsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_PaymentsForProceedsFromDepositsOnRealEstateAcquisitions": { "auth_ref": [], "calculation": { "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Net cash outflow or inflow from the amount given in advance to show intention to complete the acquisition piece of land, anything permanently fixed to it, including buildings, structures on it, and so forth.", "label": "Payments for (Proceeds from) Deposits on Real Estate Acquisitions", "negatedLabel": "Escrow deposits" } } }, "localname": "PaymentsForProceedsFromDepositsOnRealEstateAcquisitions", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsForProceedsFromOtherInvestingActivities": { "auth_ref": [ "r72", "r74" ], "calculation": { "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash (inflow) outflow from investing activities classified as other.", "label": "Payments for (Proceeds from) Other Investing Activities", "negatedLabel": "Other restricted assets" } } }, "localname": "PaymentsForProceedsFromOtherInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsForRepurchaseOfCommonStock": { "auth_ref": [ "r77" ], "calculation": { "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow to reacquire common stock during the period.", "label": "Payments for Repurchase of Common Stock", "negatedLabel": "Repurchase of shares of common stock (Note 20)" } } }, "localname": "PaymentsForRepurchaseOfCommonStock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsOfDividends": { "auth_ref": [ "r77" ], "calculation": { "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Cash outflow in the form of capital distributions and dividends to common shareholders, preferred shareholders and noncontrolling interests.", "label": "Payments of Dividends", "negatedTerseLabel": "Dividends paid" } } }, "localname": "PaymentsOfDividends", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsOfFinancingCosts": { "auth_ref": [ "r79" ], "calculation": { "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 11.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for loan and debt issuance costs.", "label": "Payments of Financing Costs", "negatedTerseLabel": "Payments of deferred financing costs", "terseLabel": "Payments of deferred financing costs" } } }, "localname": "PaymentsOfFinancingCosts", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/DebtCreditFacilitywithaLendingConsortiumArrangedbySunTrustDetails", "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation": { "auth_ref": [ "r77" ], "calculation": { "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.", "label": "Payment, Tax Withholding, Share-Based Payment Arrangement", "negatedLabel": "Repurchase of shares of common stock to satisfy tax withholding obligations" } } }, "localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireBusinessesGross": { "auth_ref": [ "r73", "r491" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.", "label": "Payments to Acquire Businesses, Gross", "terseLabel": "Payments to acquire businesses, gross" } } }, "localname": "PaymentsToAcquireBusinessesGross", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/OperationExpansionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired": { "auth_ref": [ "r73" ], "calculation": { "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.", "label": "Payments to Acquire Businesses, Net of Cash Acquired", "negatedTerseLabel": "Cash payments for business acquisitions (Note 9)" } } }, "localname": "PaymentsToAcquireBusinessesNetOfCashAcquired", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireInvestments": { "auth_ref": [ "r74" ], "calculation": { "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the purchase of all investments (debt, security, other) during the period.", "label": "Payments to Acquire Investments", "negatedTerseLabel": "Purchases of investments" } } }, "localname": "PaymentsToAcquireInvestments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToMinorityShareholders": { "auth_ref": [ "r79" ], "calculation": { "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow to a noncontrolling interest. Includes, but not limited to, reduction of noncontrolling interest ownership. Excludes dividends paid to the noncontrolling interest.", "label": "Payments to Noncontrolling Interests", "negatedTerseLabel": "Non-controlling interest distribution" } } }, "localname": "PaymentsToMinorityShareholders", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_PlanNameAxis": { "auth_ref": [ "r409", "r410", "r411", "r413", "r415", "r416", "r417", "r418", "r419", "r420", "r421", "r423", "r424", "r425", "r426", "r427", "r428", "r430", "r431", "r432", "r433", "r437", "r438", "r439", "r440", "r441" ], "lang": { "en-us": { "role": { "documentation": "Information by plan name for share-based payment arrangement.", "label": "Plan Name [Axis]", "terseLabel": "Plan Name [Axis]" } } }, "localname": "PlanNameAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/OptionsandAwardsLongTermIncentivePlanDetails", "http://www.ensigngroup.net/role/OptionsandAwardsStockOptionsNarrativeDetails", "http://www.ensigngroup.net/role/StandardBearerDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PlanNameDomain": { "auth_ref": [ "r409", "r410", "r411", "r413", "r415", "r416", "r417", "r418", "r419", "r420", "r421", "r423", "r424", "r425", "r426", "r427", "r428", "r430", "r431", "r432", "r433", "r437", "r438", "r439", "r440", "r441" ], "lang": { "en-us": { "role": { "documentation": "Plan name for share-based payment arrangement.", "label": "Plan Name [Domain]", "terseLabel": "Plan Name [Domain]" } } }, "localname": "PlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/OptionsandAwardsLongTermIncentivePlanDetails", "http://www.ensigngroup.net/role/OptionsandAwardsStockOptionsNarrativeDetails", "http://www.ensigngroup.net/role/StandardBearerDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "auth_ref": [ "r32" ], "calculation": { "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 5.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.", "label": "Prepaid Expense and Other Assets, Current", "terseLabel": "Prepaid expenses and other current assets" } } }, "localname": "PrepaidExpenseAndOtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidTaxes": { "auth_ref": [ "r8", "r224", "r225" ], "calculation": { "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 4.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for income and other taxes that provide economic benefits within a future period of one year or the normal operating cycle, if longer.", "label": "Prepaid Taxes", "terseLabel": "Prepaid income taxes" } } }, "localname": "PrepaidTaxes", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_PriorPeriodReclassificationAdjustmentDescription": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for reclassification affecting comparability of financial statement. Excludes amendment to accounting standards, other change in accounting principle, and correction of error.", "label": "Reclassification, Comparability Adjustment [Policy Text Block]", "terseLabel": "Reclassifications" } } }, "localname": "PriorPeriodReclassificationAdjustmentDescription", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ProceedsFromInsuranceSettlementInvestingActivities": { "auth_ref": [ "r72", "r82" ], "calculation": { "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow for proceeds from settlement of insurance claim, classified as investing activities. Excludes insurance settlement classified as operating activities.", "label": "Proceeds from Insurance Settlement, Investing Activities", "terseLabel": "Cash from insurance proceeds" } } }, "localname": "ProceedsFromInsuranceSettlementInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfCommonStock": { "auth_ref": [ "r75" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from the additional capital contribution to the entity.", "label": "Proceeds from Issuance of Common Stock", "terseLabel": "Proceeds from issuance of common stock" } } }, "localname": "ProceedsFromIssuanceOfCommonStock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/StandardBearerDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock": { "auth_ref": [ "r75" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from issuance of preferred stocks identified as being convertible into another form of financial instrument, typically the entity's common stock.", "label": "Proceeds from Issuance of Convertible Preferred Stock", "terseLabel": "Proceeds from issuance of preferred shares" } } }, "localname": "ProceedsFromIssuanceOfConvertiblePreferredStock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/StandardBearerDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfLongTermDebt": { "auth_ref": [ "r76" ], "calculation": { "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.", "label": "Proceeds from Issuance of Long-Term Debt", "terseLabel": "Proceeds from debt (Note 16)" } } }, "localname": "ProceedsFromIssuanceOfLongTermDebt", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments": { "auth_ref": [ "r72" ], "calculation": { "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow associated with the sale, maturity and collection of all investments such as debt, security and so forth during the period.", "label": "Proceeds from Sale, Maturity and Collection of Investments", "terseLabel": "Maturities of investments" } } }, "localname": "ProceedsFromSaleMaturityAndCollectionsOfInvestments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment": { "auth_ref": [ "r71" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.", "label": "Proceeds from Sale of Property, Plant, and Equipment", "terseLabel": "Proceeds from sale of real estate" } } }, "localname": "ProceedsFromSaleOfPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/PropertyandEquipmentNetNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromSalesOfAssetsInvestingActivities": { "auth_ref": [ "r72" ], "calculation": { "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Aggregate cash proceeds received from a combination of transactions that are classified as investing activities in which assets, which may include one or more investments, are sold to third-party buyers. This element can be used by entities to aggregate proceeds from all asset sales that are classified as investing activities.", "label": "Proceeds from Sales of Assets, Investing Activities", "terseLabel": "Cash proceeds from the sale of assets" } } }, "localname": "ProceedsFromSalesOfAssetsInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromStockOptionsExercised": { "auth_ref": [ "r75", "r450" ], "calculation": { "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.", "label": "Proceeds from Stock Options Exercised", "terseLabel": "Issuance of common stock upon exercise of options" } } }, "localname": "ProceedsFromStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProfessionalMalpracticeLiabilityMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Business insurance coverage for professionals, such as doctors, lawyers, insurance agents, accountants, real estate agents, veterinarians, and others. This liability coverage insures losses for claims arising from mistakes and errors or omissions in the course of professional activities.", "label": "Professional Malpractice Liability Insurance [Member]", "terseLabel": "General and Professional Liability" } } }, "localname": "ProfessionalMalpracticeLiabilityMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/SummaryofSignificantAccountingPoliciesSelfInsuranceDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ProfitLoss": { "auth_ref": [ "r5", "r51", "r52", "r56", "r81", "r100", "r111", "r119", "r120", "r165", "r171", "r175", "r178", "r181", "r210", "r284", "r285", "r286", "r289", "r290", "r291", "r293", "r295", "r297", "r298", "r500", "r505", "r507", "r512", "r513", "r520", "r531", "r629" ], "calculation": { "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.", "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest", "terseLabel": "Net income", "totalLabel": "NET INCOME" } } }, "localname": "ProfitLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS", "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProfitLossFromRealEstateOperations": { "auth_ref": [ "r627" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net cost of operation of other real estate (including provisions for real estate losses, rental income, and gains and losses on sales of real estate).", "label": "Profit (Loss) from Real Estate Operations", "terseLabel": "Gain on sale of assets" } } }, "localname": "ProfitLossFromRealEstateOperations", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/BusinessSegmentsScheduleofSegmentReportingInformationbySegmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment [Abstract]", "terseLabel": "Property, Plant and Equipment [Abstract]" } } }, "localname": "PropertyPlantAndEquipmentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "auth_ref": [ "r259" ], "lang": { "en-us": { "role": { "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.", "label": "Long-Lived Tangible Asset [Axis]", "terseLabel": "Property, Plant and Equipment, Type [Axis]" } } }, "localname": "PropertyPlantAndEquipmentByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/LeasesLesseeNarrativeDetails", "http://www.ensigngroup.net/role/PropertyandEquipmentNetDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": { "auth_ref": [ "r265", "r668", "r669", "r670" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.", "label": "Property, Plant and Equipment Disclosure [Text Block]", "terseLabel": "PROPERTY AND EQUIPMENT\u2014 Net" } } }, "localname": "PropertyPlantAndEquipmentDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/PropertyandEquipmentNet" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentGross": { "auth_ref": [ "r12", "r257" ], "calculation": { "http://www.ensigngroup.net/role/PropertyandEquipmentNetDetails": { "order": 1.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Gross", "terseLabel": "Property and equipment" } } }, "localname": "PropertyPlantAndEquipmentGross", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/PropertyandEquipmentNetDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Property, Plant and Equipment [Line Items]", "terseLabel": "Property, Plant and Equipment [Line Items]" } } }, "localname": "PropertyPlantAndEquipmentLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/PropertyandEquipmentNetDetails", "http://www.ensigngroup.net/role/PropertyandEquipmentNetNarrativeDetails", "http://www.ensigngroup.net/role/SummaryofSignificantAccountingPoliciesPropertyandEquipmentDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentNet": { "auth_ref": [ "r259", "r576", "r630", "r641" ], "calculation": { "http://www.ensigngroup.net/role/PropertyandEquipmentNetDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 2.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Net", "terseLabel": "Property and equipment, net", "totalLabel": "PROPERTY AND EQUIPMENT, NET" } } }, "localname": "PropertyPlantAndEquipmentNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/PropertyandEquipmentNetDetails", "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": { "auth_ref": [ "r259", "r668", "r669" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.", "label": "Property, Plant and Equipment, Policy [Policy Text Block]", "terseLabel": "Property and Equipment" } } }, "localname": "PropertyPlantAndEquipmentPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentTextBlock": { "auth_ref": [ "r259" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Property, Plant and Equipment [Table Text Block]", "terseLabel": "Schedule of Property and Equipment" } } }, "localname": "PropertyPlantAndEquipmentTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/PropertyandEquipmentNetTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "auth_ref": [ "r257" ], "lang": { "en-us": { "role": { "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.", "label": "Long-Lived Tangible Asset [Domain]", "terseLabel": "Property, Plant and Equipment, Type [Domain]" } } }, "localname": "PropertyPlantAndEquipmentTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/LeasesLesseeNarrativeDetails", "http://www.ensigngroup.net/role/PropertyandEquipmentNetDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PropertyPlantAndEquipmentUsefulLife": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.", "label": "Property, Plant and Equipment, Useful Life", "terseLabel": "Property, plant and equipment, useful life" } } }, "localname": "PropertyPlantAndEquipmentUsefulLife", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/SummaryofSignificantAccountingPoliciesPropertyandEquipmentDetails" ], "xbrltype": "durationItemType" }, "us-gaap_ProvisionForDoubtfulAccounts": { "auth_ref": [ "r62", "r215" ], "calculation": { "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense (reversal of expense) for expected credit loss on accounts receivable.", "label": "Accounts Receivable, Credit Loss Expense (Reversal)", "terseLabel": "Provision for doubtful accounts" } } }, "localname": "ProvisionForDoubtfulAccounts", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_RealEstatePropertiesAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by ownership of the property.", "label": "Real Estate Property Ownership [Axis]", "terseLabel": "Real Estate Property Ownership [Axis]" } } }, "localname": "RealEstatePropertiesAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/BusinessSegmentsNarrativeDetails", "http://www.ensigngroup.net/role/DescriptionofBusinessDetails", "http://www.ensigngroup.net/role/StandardBearerDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RealEstatePropertiesDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents categories of ownership of real estate properties.", "label": "Real Estate Properties [Domain]", "terseLabel": "Real Estate Properties [Domain]" } } }, "localname": "RealEstatePropertiesDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/BusinessSegmentsNarrativeDetails", "http://www.ensigngroup.net/role/DescriptionofBusinessDetails", "http://www.ensigngroup.net/role/StandardBearerDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RealEstatePropertiesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Real Estate Properties [Line Items]", "terseLabel": "Real Estate Properties [Line Items]" } } }, "localname": "RealEstatePropertiesLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/SummaryofSignificantAccountingPoliciesLeasesandLeaseholdImprovementsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable": { "auth_ref": [ "r170", "r175" ], "lang": { "en-us": { "role": { "documentation": "Identification, description, and amounts of all significant reconciling items in the reconciliation of total revenues from reportable segments to the entity's consolidated revenues.", "label": "Reconciliation of Revenue from Segments to Consolidated [Table]", "terseLabel": "Reconciliation of Revenue from Segments to Consolidated [Table]" } } }, "localname": "ReconciliationOfRevenueFromSegmentsToConsolidatedTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/BusinessSegmentsRevenuebySegmentDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock": { "auth_ref": [ "r170", "r175" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of all significant reconciling items in the reconciliation of total revenues from reportable segments to the entity's consolidated revenues.", "label": "Reconciliation of Revenue from Segments to Consolidated [Table Text Block]", "terseLabel": "Reconciliation of Revenue from Segments to Consolidated" } } }, "localname": "ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/BusinessSegmentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_RepaymentsOfLongTermDebt": { "auth_ref": [ "r78" ], "calculation": { "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.", "label": "Repayments of Long-Term Debt", "negatedTerseLabel": "Payments on debt (Note 16)" } } }, "localname": "RepaymentsOfLongTermDebt", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestrictedStockMember": { "auth_ref": [ "r132" ], "lang": { "en-us": { "role": { "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met.", "label": "Restricted Stock [Member]", "terseLabel": "Restricted Stock Awards", "verboseLabel": "Stock-based compensation expense related to restricted stock awards" } } }, "localname": "RestrictedStockMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/OptionsandAwardsCompensationExpenseDetails", "http://www.ensigngroup.net/role/OptionsandAwardsRestrictedAwardRollforwardDetails", "http://www.ensigngroup.net/role/OptionsandAwardsRestrictedStockAwardsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RestructuringCostAndReserveAxis": { "auth_ref": [ "r267", "r268", "r271", "r272" ], "lang": { "en-us": { "role": { "documentation": "Information by type of restructuring cost.", "label": "Restructuring Type [Axis]", "terseLabel": "Restructuring Type [Axis]" } } }, "localname": "RestructuringCostAndReserveAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/BusinessSegmentsNarrativeDetails", "http://www.ensigngroup.net/role/DescriptionofBusinessDetails", "http://www.ensigngroup.net/role/LeasesLessorNarrativeDetails", "http://www.ensigngroup.net/role/OptionsandAwardsLongTermIncentivePlanDetails", "http://www.ensigngroup.net/role/OptionsandAwardsStockOptionsNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RestructuringCostAndReserveLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Restructuring Cost and Reserve [Line Items]", "terseLabel": "Restructuring Cost and Reserve [Line Items]" } } }, "localname": "RestructuringCostAndReserveLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/DescriptionofBusinessDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r26", "r354", "r576", "r638", "r658", "r659" ], "calculation": { "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 3.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings (Accumulated Deficit)", "terseLabel": "Retained earnings" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [ "r0", "r108", "r109", "r110", "r112", "r118", "r120", "r212", "r451", "r452", "r453", "r473", "r474", "r518", "r655", "r657" ], "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings [Member]", "terseLabel": "Retained Earnings" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "xbrltype": "domainItemType" }, "us-gaap_RevenueFromContractWithCustomerAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Revenue from Contract with Customer [Abstract]", "terseLabel": "Revenue from Contract with Customer [Abstract]" } } }, "localname": "RevenueFromContractWithCustomerAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "auth_ref": [ "r156", "r157", "r170", "r176", "r177", "r184", "r185", "r188", "r379", "r380", "r609" ], "calculation": { "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME": { "order": 1.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.", "label": "Revenue from Contract with Customer, Excluding Assessed Tax", "netLabel": "Revenue", "terseLabel": "TOTAL REVENUE", "verboseLabel": "TOTAL REVENUE" } } }, "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/BusinessSegmentsNarrativeDetails", "http://www.ensigngroup.net/role/BusinessSegmentsRevenuebySegmentDetails", "http://www.ensigngroup.net/role/BusinessSegmentsScheduleofSegmentReportingInformationbySegmentDetails", "http://www.ensigngroup.net/role/RevenueandAccountsReceivableDisaggregationofRevenueDetails", "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": { "auth_ref": [ "r96", "r371", "r372", "r373", "r374", "r375", "r376", "r377", "r378", "r390" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for revenue from contract with customer.", "label": "Revenue from Contract with Customer [Policy Text Block]", "terseLabel": "Service and Rental Revenue Recognition" } } }, "localname": "RevenueFromContractWithCustomerPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_RevenueFromContractWithCustomerTextBlock": { "auth_ref": [ "r363", "r364", "r365", "r366", "r367", "r368", "r369", "r370", "r382", "r390" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.", "label": "Revenue from Contract with Customer [Text Block]", "terseLabel": "REVENUE AND ACCOUNTS RECEIVABLE" } } }, "localname": "RevenueFromContractWithCustomerTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/RevenueandAccountsReceivable" ], "xbrltype": "textBlockItemType" }, "us-gaap_RevolvingCreditFacilityMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Arrangement in which loan proceeds can continuously be obtained following repayments, but the total amount borrowed cannot exceed a specified maximum amount.", "label": "Revolving Credit Facility [Member]", "terseLabel": "Revolving credit facility with Truist" } } }, "localname": "RevolvingCreditFacilityMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/DebtCreditFacilitywithaLendingConsortiumArrangedbySunTrustDetails", "http://www.ensigngroup.net/role/StandardBearerDetails", "http://www.ensigngroup.net/role/SummaryofSignificantAccountingPoliciesRecentAccountingPronouncementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": { "auth_ref": [ "r558", "r563" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.", "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability", "terseLabel": "Right-of-use assets obtained in exchange for new and modified operating lease obligations" } } }, "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/LeasesLesseeNarrativeDetails", "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_SalesRevenueNetMember": { "auth_ref": [ "r146", "r188" ], "lang": { "en-us": { "role": { "documentation": "Revenue from sale of product and rendering of service and other sources of income, when it serves as benchmark in concentration of risk calculation.", "label": "Revenue Benchmark [Member]", "terseLabel": "Revenue Benchmark" } } }, "localname": "SalesRevenueNetMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/BusinessSegmentsRevenuebySegmentDetails", "http://www.ensigngroup.net/role/CommitmentsandContingenciesDetails", "http://www.ensigngroup.net/role/RevenueandAccountsReceivableDisaggregationofRevenueDetails", "http://www.ensigngroup.net/role/RevenueandAccountsReceivableRevenuefromMedicareandMedicaidProgramsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable": { "auth_ref": [ "r46" ], "lang": { "en-us": { "role": { "documentation": "Schedule itemizing specific types of trade accounts and notes receivable, and for each the gross carrying value, allowance, and net carrying value as of the balance sheet date. Presentation is categorized by current, noncurrent and unclassified receivables.", "label": "Schedule of Accounts, Notes, Loans and Financing Receivable [Table]", "terseLabel": "Schedule of Accounts, Notes, Loans and Financing Receivable [Table]" } } }, "localname": "ScheduleOfAccountsNotesLoansAndFinancingReceivableTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/RevenueandAccountsReceivableAccountsReceivableDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock": { "auth_ref": [ "r46" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the various types of trade accounts and notes receivable and for each the gross carrying value, allowance, and net carrying value as of the balance sheet date. Presentation is categorized by current, noncurrent and unclassified receivables.", "label": "Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block]", "terseLabel": "Schedule of Accounts, Notes, Loans and Financing Receivable" } } }, "localname": "ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/RevenueandAccountsReceivableTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of accrued liabilities.", "label": "Schedule of Accrued Liabilities [Table Text Block]", "terseLabel": "Schedule of Other Accrued Liabilities" } } }, "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/OtherAccruedLiabilitiesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable": { "auth_ref": [ "r240" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the major classes of acquired finite-lived intangible assets showing the amount, any significant residual value, weighted average amortization period, and other characteristics. A major class is composed of intangible assets that can be grouped together because they are similar, either by nature or by their use in the operations of the company.", "label": "Schedule of Acquired Finite-Lived Intangible Asset by Major Class [Table]", "terseLabel": "Schedule of Acquired Finite-Lived Intangible Asset by Major Class [Table]" } } }, "localname": "ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/IntangibleAssetsNetScheduleofFiniteLivedIntangibleAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfAcquiredIndefiniteLivedIntangibleAssetsByMajorClassTextBlock": { "auth_ref": [ "r242" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of acquired indefinite-lived intangible assets. Indefinite-lived intangible assets are assets that have no physical form, but have expected future economic benefit. Indefinite-lived assets are assets that are not subject to amortization. Acquired indefinite-lived intangible assets are disclosed by major class (assets that can be grouped together because they are similar, either by their nature or by their use in operations of the entity) and in total.", "label": "Schedule of Acquired Indefinite-Lived Intangible Assets by Major Class [Table Text Block]", "terseLabel": "Schedule of Other Indefinite-lived Intangible Assets by Major Class" } } }, "localname": "ScheduleOfAcquiredIndefiniteLivedIntangibleAssetsByMajorClassTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/GoodwillandOtherIndefiniteLivedIntangibleAssetsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": { "auth_ref": [ "r485", "r486", "r487" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting each material business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities.", "label": "Schedule of Business Acquisitions, by Acquisition [Table]", "terseLabel": "Schedule of Business Acquisitions, by Acquisition [Table]" } } }, "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/OperationExpansionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfCommonStockOutstandingRollForwardTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the change in common stock outstanding.", "label": "Schedule of Common Stock Outstanding Roll Forward [Table Text Block]", "terseLabel": "Schedule of Common Stock Outstanding Roll Forward" } } }, "localname": "ScheduleOfCommonStockOutstandingRollForwardTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/OptionsandAwardsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDebtInstrumentsTextBlock": { "auth_ref": [ "r41", "r106", "r329", "r331", "r350", "r351", "r352", "r353", "r541", "r542", "r545", "r632" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.", "label": "Schedule of Long-Term Debt Instruments [Table Text Block]", "terseLabel": "Schedule of Long-term Debt" } } }, "localname": "ScheduleOfDebtInstrumentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/DebtTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTextBlock": { "auth_ref": [ "r127", "r131", "r136" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the effect of income (loss) on basic earnings per share.", "label": "Schedule of Earnings Per Share, Basic, by Common Class, Including Two Class Method [Table Text Block]", "terseLabel": "Schedule of Earnings Per Share, Basic, by Common Class, Including Two Class Method" } } }, "localname": "ScheduleOfEarningsPerShareBasicByCommonClassTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/ComputationofNetIncomePerCommonShareTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTextBlock": { "auth_ref": [ "r127", "r131", "r136" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the effect of income (loss) on an entity's diluted earnings per share.", "label": "Schedule of Earnings Per Share, Diluted, by Common Class, Including Two Class Method [Table Text Block]", "terseLabel": "Schedule of Earnings Per Share, Diluted, by Common Class, Including Two Class Method" } } }, "localname": "ScheduleOfEarningsPerShareDilutedByCommonClassTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/ComputationofNetIncomePerCommonShareTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": { "auth_ref": [ "r443", "r455" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements.", "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]", "terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]" } } }, "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/OptionsandAwardsCompensationExpenseDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": { "auth_ref": [ "r443" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.", "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]", "terseLabel": "Schedule of Stock-Based Compensation Expense" } } }, "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/OptionsandAwardsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": { "auth_ref": [ "r240", "r245", "r610" ], "lang": { "en-us": { "role": { "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Schedule of Finite-Lived Intangible Assets [Table]", "terseLabel": "Schedule of Finite-Lived Intangible Assets [Table]" } } }, "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/IntangibleAssetsNetNarrativeDetails", "http://www.ensigngroup.net/role/SummaryofSignificantAccountingPoliciesIntangibleAssetsandGoodwillDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": { "auth_ref": [ "r240", "r245" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.", "label": "Schedule of Finite-Lived Intangible Assets [Table Text Block]", "terseLabel": "Schedule of Finite-Lived Intangible Assets" } } }, "localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/IntangibleAssetsNetTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfGoodwillTable": { "auth_ref": [ "r227", "r228", "r229", "r230", "r231", "r232", "r233", "r234", "r235", "r236", "r237", "r238" ], "lang": { "en-us": { "role": { "documentation": "Schedule of goodwill and the changes during the year due to acquisition, sale, impairment or for other reasons.", "label": "Schedule of Goodwill [Table]", "terseLabel": "Schedule of Goodwill [Table]" } } }, "localname": "ScheduleOfGoodwillTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/GoodwillandOtherIndefiniteLivedIntangibleAssetsGoodwillRollforwardDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfGoodwillTextBlock": { "auth_ref": [ "r227", "r228", "r229", "r230", "r231", "r232", "r233", "r234", "r235", "r236", "r237", "r238" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.", "label": "Schedule of Goodwill [Table Text Block]", "terseLabel": "Schedule of Goodwill" } } }, "localname": "ScheduleOfGoodwillTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/GoodwillandOtherIndefiniteLivedIntangibleAssetsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfHeldToMaturitySecuritiesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Schedule of Held-to-Maturity Securities [Line Items]", "terseLabel": "Schedule of Held-to-maturity Securities [Line Items]" } } }, "localname": "ScheduleOfHeldToMaturitySecuritiesLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/FairValueMeasurementsInvestmentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfHeldToMaturitySecuritiesTable": { "auth_ref": [ "r204", "r205", "r206" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about investment in debt security measured at amortized cost (held-to-maturity).", "label": "Debt Securities, Held-to-Maturity [Table]", "terseLabel": "Debt Securities, Held-to-maturity [Table]" } } }, "localname": "ScheduleOfHeldToMaturitySecuritiesTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/FairValueMeasurementsInvestmentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable": { "auth_ref": [ "r249", "r251" ], "lang": { "en-us": { "role": { "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance and exist in perpetuity.", "label": "Schedule of Indefinite-Lived Intangible Assets [Table]", "terseLabel": "Schedule of Indefinite-Lived Intangible Assets [Table]" } } }, "localname": "ScheduleOfIndefiniteLivedIntangibleAssetsTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/GoodwillandOtherIndefiniteLivedIntangibleAssetsIndefiniteLivedIntangibleAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfMalpracticeInsuranceTypeAndTierIdentifierAxis": { "auth_ref": [ "r667" ], "lang": { "en-us": { "role": { "documentation": "Information by type of insurance coverage or layer of insurance that covers malpractice claims.", "label": "Insurance Type and Tier Identifier [Axis]", "terseLabel": "Insurance Type and Tier Identifier [Axis]" } } }, "localname": "ScheduleOfMalpracticeInsuranceTypeAndTierIdentifierAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/SummaryofSignificantAccountingPoliciesSelfInsuranceDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock": { "auth_ref": [ "r422" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the changes in outstanding nonvested restricted stock units.", "label": "Schedule of Nonvested Restricted Stock Units Activity [Table Text Block]", "terseLabel": "Schedule of Nonvested Restricted Stock Units Activity" } } }, "localname": "ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/OptionsandAwardsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfOtherAssetsTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the carrying amounts of other assets. This disclosure includes other current assets and other noncurrent assets.", "label": "Schedule of Other Assets [Table Text Block]", "terseLabel": "Schedule of Restricted and Other Assets" } } }, "localname": "ScheduleOfOtherAssetsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/RestrictedandOtherAssetsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": { "auth_ref": [ "r259" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Property, Plant and Equipment [Table]", "terseLabel": "Schedule of Property, Plant and Equipment [Table]", "verboseLabel": "Property, Plant and Equipment [Table]" } } }, "localname": "ScheduleOfPropertyPlantAndEquipmentTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/PropertyandEquipmentNetDetails", "http://www.ensigngroup.net/role/PropertyandEquipmentNetNarrativeDetails", "http://www.ensigngroup.net/role/SummaryofSignificantAccountingPoliciesPropertyandEquipmentDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfRealEstatePropertiesTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule detailing quantitative information concerning real estate properties and units within those properties by ownership of the property.", "label": "Schedule of Real Estate Properties [Table]", "terseLabel": "Schedule of Real Estate Properties [Table]" } } }, "localname": "ScheduleOfRealEstatePropertiesTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/SummaryofSignificantAccountingPoliciesLeasesandLeaseholdImprovementsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfRestructuringAndRelatedCostsTable": { "auth_ref": [ "r267", "r268", "r269", "r270", "r271", "r272", "r273" ], "lang": { "en-us": { "role": { "documentation": "Table presenting the description of the restructuring costs, such as the expected cost; the costs incurred during the period; the cumulative costs incurred as of the balance sheet date; the income statement caption within which the restructuring charges recognized for the period are included; and the amount of and periodic changes to an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost by type of restructuring.", "label": "Schedule of Restructuring and Related Costs [Table]", "terseLabel": "Schedule of Restructuring and Related Costs [Table]" } } }, "localname": "ScheduleOfRestructuringAndRelatedCostsTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/DescriptionofBusinessDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": { "auth_ref": [ "r165", "r168", "r174", "r235" ], "lang": { "en-us": { "role": { "documentation": "A table disclosing the profit or loss and total assets for each reportable segment of the entity. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.", "label": "Schedule of Segment Reporting Information, by Segment [Table]", "terseLabel": "Schedule of Segment Reporting Information, by Segment [Table]" } } }, "localname": "ScheduleOfSegmentReportingInformationBySegmentTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/BusinessSegmentsNarrativeDetails", "http://www.ensigngroup.net/role/BusinessSegmentsScheduleofSegmentReportingInformationbySegmentDetails", "http://www.ensigngroup.net/role/StandardBearerDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock": { "auth_ref": [ "r165", "r168", "r174", "r235" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.", "label": "Schedule of Segment Reporting Information, by Segment [Table Text Block]", "terseLabel": "Schedule of Segment Reporting Information, by Segment" } } }, "localname": "ScheduleOfSegmentReportingInformationBySegmentTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/BusinessSegmentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "auth_ref": [ "r404", "r406", "r409", "r410", "r411", "r413", "r415", "r416", "r417", "r418", "r419", "r420", "r421", "r423", "r424", "r425", "r426", "r427", "r428", "r430", "r431", "r432", "r433", "r437", "r438", "r439", "r440", "r441" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about share-based payment arrangement.", "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]", "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]" } } }, "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/OptionsandAwardsIntrinsicValuesDetails", "http://www.ensigngroup.net/role/OptionsandAwardsLongTermIncentivePlanDetails", "http://www.ensigngroup.net/role/OptionsandAwardsRestrictedAwardRollforwardDetails", "http://www.ensigngroup.net/role/OptionsandAwardsRestrictedStockAwardsNarrativeDetails", "http://www.ensigngroup.net/role/OptionsandAwardsStockOptionsNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable": { "auth_ref": [ "r449" ], "lang": { "en-us": { "role": { "documentation": "Details comprising a table providing supplementary information on outstanding and exercisable share awards as of the balance sheet date which stratifies outstanding options by ranges of exercise prices.", "label": "Share-Based Payment Arrangement, Option, Exercise Price Range [Table]", "terseLabel": "Share-based Payment Arrangement, Option, Exercise Price Range [Table]" } } }, "localname": "ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/OptionsandAwardsOptionsOutstandingbyExercisePriceDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock": { "auth_ref": [ "r449" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of option exercise prices, by grouped ranges, including the upper and lower limits of the price range, the number of shares under option, weighted average exercise price and remaining contractual option terms.", "label": "Share-Based Payment Arrangement, Option, Exercise Price Range [Table Text Block]", "terseLabel": "Share-based Payment Arrangement, Option, Exercise Price Range" } } }, "localname": "ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/OptionsandAwardsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": { "auth_ref": [ "r436" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.", "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]", "terseLabel": "Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions" } } }, "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/OptionsandAwardsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock": { "auth_ref": [ "r245" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.", "label": "Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]", "terseLabel": "Schedule of Finite-Lived Intangible Assets, Future Amortization Expense" } } }, "localname": "ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/IntangibleAssetsNetTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember": { "auth_ref": [ "r515" ], "lang": { "en-us": { "role": { "documentation": "Fixed rate on U.S. dollar, constant-notional interest rate swap that has its variable-rate leg referenced to Secured Overnight Financing Rate (SOFR) with no additional spread over SOFR on variable-rate leg.", "label": "Secured Overnight Financing Rate (SOFR) Overnight Index Swap Rate [Member]", "terseLabel": "SOFR" } } }, "localname": "SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/DebtCreditFacilitywithaLendingConsortiumArrangedbySunTrustDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SecurityDeposit": { "auth_ref": [ "r16" ], "calculation": { "http://www.ensigngroup.net/role/RestrictedandOtherAssetsDetails": { "order": 3.0, "parentTag": "us-gaap_OtherRestrictedAssetsNoncurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of an asset, typically cash, provided to a counterparty to provide certain assurance of performance by the entity pursuant to the terms of a written or oral agreement, such as a lease.", "label": "Security Deposit", "terseLabel": "Deposits with landlords" } } }, "localname": "SecurityDeposit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/RestrictedandOtherAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SegmentDomain": { "auth_ref": [ "r152", "r156", "r157", "r158", "r159", "r160", "r161", "r162", "r163", "r164", "r165", "r166", "r167", "r170", "r171", "r172", "r173", "r175", "r176", "r177", "r178", "r179", "r181", "r188", "r227", "r228", "r229", "r230", "r231", "r232", "r233", "r234", "r235", "r238", "r270", "r273", "r648" ], "lang": { "en-us": { "role": { "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity.", "label": "Segments [Domain]", "terseLabel": "Segments [Domain]" } } }, "localname": "SegmentDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/BusinessSegmentsRevenuebySegmentDetails", "http://www.ensigngroup.net/role/BusinessSegmentsScheduleofSegmentReportingInformationbySegmentDetails", "http://www.ensigngroup.net/role/GoodwillandOtherIndefiniteLivedIntangibleAssetsGoodwillRollforwardDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SegmentReportingAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Segment Reporting [Abstract]", "terseLabel": "Segment Reporting [Abstract]" } } }, "localname": "SegmentReportingAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_SegmentReportingDisclosureTextBlock": { "auth_ref": [ "r152", "r154", "r155", "r165", "r169", "r175", "r179", "r180", "r181", "r182", "r184", "r187", "r188", "r189" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.", "label": "Segment Reporting Disclosure [Text Block]", "terseLabel": "BUSINESS SEGMENTS" } } }, "localname": "SegmentReportingDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/BusinessSegments" ], "xbrltype": "textBlockItemType" }, "us-gaap_SegmentReportingInformationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Segment Reporting Information [Line Items]", "terseLabel": "Segment Reporting Information [Line Items]" } } }, "localname": "SegmentReportingInformationLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/BusinessSegmentsNarrativeDetails", "http://www.ensigngroup.net/role/BusinessSegmentsScheduleofSegmentReportingInformationbySegmentDetails", "http://www.ensigngroup.net/role/StandardBearerDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SegmentReportingRevenueReconcilingItemLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Segment Reporting, Revenue Reconciling Item [Line Items]", "terseLabel": "Segment Reporting, Revenue Reconciling Item [Line Items]" } } }, "localname": "SegmentReportingRevenueReconcilingItemLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/BusinessSegmentsRevenuebySegmentDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SelfInsuranceReserve": { "auth_ref": [ "r42" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying amount (including both current and noncurrent portions) of accrued known and estimated losses incurred as of the balance sheet date for which no insurance coverage exists, and for which a claim has been made or is probable of being asserted, typically arising from workmen's compensation-type of incidents and personal injury to nonemployees from accidents on the entity's property.", "label": "Self Insurance Reserve", "terseLabel": "Self insurance reserve" } } }, "localname": "SelfInsuranceReserve", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/SummaryofSignificantAccountingPoliciesSelfInsuranceDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SelfInsuranceReserveCurrent": { "auth_ref": [], "calculation": { "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 4.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying amount of accrued known and estimated losses incurred as of the balance sheet date for which no insurance coverage exists, and for which a claim has been made or is probable of being asserted, typically arising from workmen's compensation-type of incidents and personal injury to nonemployees from accidents on the entity's property that are expected to be paid within one year (or the normal operating cycle, if longer).", "label": "Self Insurance Reserve, Current", "terseLabel": "Accrued self-insurance liabilities\u2014current" } } }, "localname": "SelfInsuranceReserveCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_SelfInsuranceReserveNoncurrent": { "auth_ref": [], "calculation": { "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 4.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying amount of accrued known and estimated losses incurred as of the balance sheet date for which no insurance coverage exists, and for which a claim has been made or is probable of being asserted, typically arising from workmen's compensation-type of incidents and personal injury to nonemployees from accidents on the entity's property that are expected to be paid after one year (or the normal operating cycle, if longer).", "label": "Self Insurance Reserve, Noncurrent", "terseLabel": "Accrued self-insurance liabilities\u2014less current portion" } } }, "localname": "SelfInsuranceReserveNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_ServiceMember": { "auth_ref": [ "r383" ], "lang": { "en-us": { "role": { "documentation": "Assistance, including, but not limited to, technology, license and maintenance, license and service, maintenance, oil and gas, and financial service.", "label": "Service [Member]", "terseLabel": "Service revenue" } } }, "localname": "ServiceMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/BusinessSegmentsRevenuebySegmentDetails", "http://www.ensigngroup.net/role/BusinessSegmentsScheduleofSegmentReportingInformationbySegmentDetails", "http://www.ensigngroup.net/role/RevenueandAccountsReceivableDisaggregationofRevenueDetails", "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensation": { "auth_ref": [ "r87" ], "calculation": { "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense for share-based payment arrangement.", "label": "Share-Based Payment Arrangement, Noncash Expense", "terseLabel": "Stock-based compensation" } } }, "localname": "ShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1": { "auth_ref": [ "r409" ], "lang": { "en-us": { "role": { "documentation": "Estimated period over which an employee is required to provide service in exchange for the equity-based payment award, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Requisite Service Period", "terseLabel": "Award requisite service period" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/OptionsandAwardsStockOptionsNarrativeDetails" ], "xbrltype": "durationItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": { "auth_ref": [ "r409" ], "lang": { "en-us": { "role": { "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period", "terseLabel": "Award vesting period" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/OptionsandAwardsLongTermIncentivePlanDetails", "http://www.ensigngroup.net/role/OptionsandAwardsRestrictedStockAwardsNarrativeDetails", "http://www.ensigngroup.net/role/OptionsandAwardsStockOptionsNarrativeDetails", "http://www.ensigngroup.net/role/StandardBearerDetails" ], "xbrltype": "durationItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": { "auth_ref": [ "r428" ], "lang": { "en-us": { "role": { "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value", "verboseLabel": "Forfeited (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/OptionsandAwardsRestrictedAwardRollforwardDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "auth_ref": [ "r426" ], "lang": { "en-us": { "role": { "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period", "verboseLabel": "Granted (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/OptionsandAwardsRestrictedAwardRollforwardDetails", "http://www.ensigngroup.net/role/OptionsandAwardsRestrictedStockAwardsNarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r426" ], "lang": { "en-us": { "role": { "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Granted (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/OptionsandAwardsRestrictedAwardRollforwardDetails", "http://www.ensigngroup.net/role/OptionsandAwardsRestrictedStockAwardsNarrativeDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": { "auth_ref": [ "r423", "r424" ], "lang": { "en-us": { "role": { "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number", "periodEndLabel": "Nonvested at end of period (in shares)", "periodStartLabel": "Nonvested at beginning of period (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/OptionsandAwardsRestrictedAwardRollforwardDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]", "terseLabel": "Non-Vested Restricted Awards" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/OptionsandAwardsRestrictedAwardRollforwardDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": { "auth_ref": [ "r423", "r424" ], "lang": { "en-us": { "role": { "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value", "periodEndLabel": "Nonvested at end of period (in dollars per share)", "periodStartLabel": "Nonvested at beginning of period (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/OptionsandAwardsRestrictedAwardRollforwardDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]", "terseLabel": "Weighted Average Grant Date Fair Value" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/OptionsandAwardsRestrictedAwardRollforwardDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": { "auth_ref": [ "r427" ], "lang": { "en-us": { "role": { "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period", "negatedTerseLabel": "Vested (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/OptionsandAwardsRestrictedAwardRollforwardDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r427" ], "lang": { "en-us": { "role": { "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Vested (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/OptionsandAwardsRestrictedAwardRollforwardDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": { "auth_ref": [ "r439" ], "lang": { "en-us": { "role": { "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate", "terseLabel": "Weighted Average Dividend Yield" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/OptionsandAwardsValuationAssumptionsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": { "auth_ref": [ "r440" ], "lang": { "en-us": { "role": { "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate", "terseLabel": "Weighted Average Risk-Free Rate" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/OptionsandAwardsValuationAssumptionsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate": { "auth_ref": [ "r438" ], "lang": { "en-us": { "role": { "documentation": "Rate of weighted-average expected volatility for award under share-based payment arrangement.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Weighted Average Volatility Rate", "terseLabel": "Weighted Average Volatility" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/OptionsandAwardsValuationAssumptionsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/OptionsandAwardsIntrinsicValuesDetails", "http://www.ensigngroup.net/role/OptionsandAwardsLongTermIncentivePlanDetails", "http://www.ensigngroup.net/role/OptionsandAwardsRestrictedAwardRollforwardDetails", "http://www.ensigngroup.net/role/OptionsandAwardsRestrictedStockAwardsNarrativeDetails", "http://www.ensigngroup.net/role/OptionsandAwardsStockOptionsNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": { "auth_ref": [ "r411" ], "lang": { "en-us": { "role": { "documentation": "Number of shares authorized for issuance under share-based payment arrangement.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized", "terseLabel": "Number of shares authorized (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/OptionsandAwardsLongTermIncentivePlanDetails", "http://www.ensigngroup.net/role/OptionsandAwardsStockOptionsNarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": { "auth_ref": [ "r449" ], "lang": { "en-us": { "role": { "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant", "terseLabel": "Number of shares available for grant (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/OptionsandAwardsStockOptionsNarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": { "auth_ref": [ "r416" ], "lang": { "en-us": { "role": { "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price", "terseLabel": "Weighted average exercise price of options vested (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/OptionsandAwardsOptionsOutstandingRollforwardDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": { "auth_ref": [ "r431" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value", "terseLabel": "Intrinsic value of options exercised in period" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/OptionsandAwardsIntrinsicValuesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod": { "auth_ref": [ "r417" ], "lang": { "en-us": { "role": { "documentation": "For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period", "negatedTerseLabel": "Forfeited (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/OptionsandAwardsOptionsOutstandingRollforwardDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice": { "auth_ref": [ "r417" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price of options that were either forfeited or expired.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price", "terseLabel": "Forfeited (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/OptionsandAwardsOptionsOutstandingRollforwardDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue": { "auth_ref": [ "r430" ], "lang": { "en-us": { "role": { "documentation": "The grant-date intrinsic value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Grant Date Intrinsic Value", "terseLabel": "Grant date intrinsic value (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/OptionsandAwardsStockOptionsNarrativeDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "auth_ref": [ "r418" ], "lang": { "en-us": { "role": { "documentation": "Gross number of share options (or share units) granted during the period.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross", "netLabel": "Granted (in shares)", "terseLabel": "Options granted (in shares)", "verboseLabel": "Options Granted (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/OptionsandAwardsExercisePriceandFairValueDetails", "http://www.ensigngroup.net/role/OptionsandAwardsOptionsOutstandingRollforwardDetails", "http://www.ensigngroup.net/role/OptionsandAwardsStockOptionsNarrativeDetails", "http://www.ensigngroup.net/role/OptionsandAwardsValuationAssumptionsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r430" ], "lang": { "en-us": { "role": { "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Weighted Average Fair Value of Options (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/OptionsandAwardsExercisePriceandFairValueDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock": { "auth_ref": [ "r430" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the weighted-average grant-date fair value of equity options or other equity instruments granted during the year.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value [Table Text Block]", "terseLabel": "Schedule of Weighted Average Grant Date Fair Value and Exercise Price of Options" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/OptionsandAwardsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": { "auth_ref": [ "r449" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value", "terseLabel": "Outstanding" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/OptionsandAwardsIntrinsicValuesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "auth_ref": [ "r413", "r415" ], "lang": { "en-us": { "role": { "documentation": "Number of options outstanding, including both vested and non-vested options.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number", "periodEndLabel": "Balance at end of period, (in shares)", "periodStartLabel": "Balance at beginning of period, (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/OptionsandAwardsOptionsOutstandingRollforwardDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]", "terseLabel": "Number of Options Outstanding" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/OptionsandAwardsOptionsOutstandingRollforwardDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "auth_ref": [ "r413", "r415" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price", "periodEndLabel": "Balance at end of period (in dollars per share)", "periodStartLabel": "Balance at beginning of period (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/OptionsandAwardsOptionsOutstandingRollforwardDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]", "terseLabel": "Weighted Average Exercise Price" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/OptionsandAwardsOptionsOutstandingRollforwardDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableTableTextBlock": { "auth_ref": [ "r433" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of number, weighted-average exercise price or conversion ratio, aggregate intrinsic value, and weighted-average remaining contractual term for exercisable or convertible options that are fully vested and expected to vest. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable [Table Text Block]", "terseLabel": "Schedule of Aggregate Intrinsic Value of Options" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/OptionsandAwardsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": { "auth_ref": [ "r432" ], "lang": { "en-us": { "role": { "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number", "terseLabel": "Number of options vested (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/OptionsandAwardsOptionsOutstandingRollforwardDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "auth_ref": [ "r409", "r410", "r411", "r413", "r415", "r416", "r417", "r418", "r419", "r420", "r421", "r423", "r424", "r425", "r426", "r427", "r428", "r430", "r431", "r432", "r433", "r437", "r438", "r439", "r440", "r441" ], "lang": { "en-us": { "role": { "documentation": "Award under share-based payment arrangement.", "label": "Award Type [Domain]", "terseLabel": "Award Type [Domain]" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/OptionsandAwardsCompensationExpenseDetails", "http://www.ensigngroup.net/role/OptionsandAwardsIntrinsicValuesDetails", "http://www.ensigngroup.net/role/OptionsandAwardsRestrictedAwardRollforwardDetails", "http://www.ensigngroup.net/role/OptionsandAwardsRestrictedStockAwardsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": { "auth_ref": [ "r419" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price", "terseLabel": "Exercised (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/OptionsandAwardsOptionsOutstandingRollforwardDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "auth_ref": [ "r418" ], "lang": { "en-us": { "role": { "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price", "terseLabel": "Weighted Average Exercise Price (in dollars per share)", "verboseLabel": "Granted (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/OptionsandAwardsExercisePriceandFairValueDetails", "http://www.ensigngroup.net/role/OptionsandAwardsOptionsOutstandingRollforwardDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": { "auth_ref": [ "r412", "r435", "r436", "r437", "r438", "r441", "r454", "r458" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.", "label": "Share-Based Payment Arrangement [Policy Text Block]", "terseLabel": "Stock-Based Compensation" } } }, "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis": { "auth_ref": [ "r434" ], "lang": { "en-us": { "role": { "documentation": "Information by range of option prices pertaining to options granted.", "label": "Exercise Price Range [Axis]", "terseLabel": "Exercise Price Range [Axis]" } } }, "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/OptionsandAwardsOptionsOutstandingbyExercisePriceDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain": { "auth_ref": [ "r442" ], "lang": { "en-us": { "role": { "documentation": "Supplementary information on outstanding and exercisable share awards as of the balance sheet date which stratifies outstanding options by ranges of exercise prices.", "label": "Exercise Price Range [Domain]", "terseLabel": "Exercise Price Range [Domain]" } } }, "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/OptionsandAwardsOptionsOutstandingbyExercisePriceDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]", "terseLabel": "Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]" } } }, "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/OptionsandAwardsOptionsOutstandingbyExercisePriceDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit": { "auth_ref": [ "r442" ], "lang": { "en-us": { "role": { "documentation": "The floor of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.", "label": "Share-Based Payment Arrangement, Option, Exercise Price Range, Lower Range Limit", "terseLabel": "Exercise price, lower range limit (in dollars per share)" } } }, "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/OptionsandAwardsOptionsOutstandingbyExercisePriceDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions": { "auth_ref": [ "r429" ], "lang": { "en-us": { "role": { "documentation": "The number of shares reserved for issuance pertaining to the outstanding exercisable stock options as of the balance sheet date in the customized range of exercise prices for which the market and performance vesting condition has been satisfied.", "label": "Share-Based Payment Arrangement, Option, Exercise Price Range, Shares Exercisable", "terseLabel": "Stock options vested and exercisable (in shares)" } } }, "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/OptionsandAwardsOptionsOutstandingbyExercisePriceDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions": { "auth_ref": [ "r414" ], "lang": { "en-us": { "role": { "documentation": "The number of shares reserved for issuance pertaining to the outstanding stock options as of the balance sheet date for all option plans in the customized range of exercise prices.", "label": "Share-Based Payment Arrangement, Option, Exercise Price Range, Shares Outstanding", "terseLabel": "Number outstanding (in shares)" } } }, "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/OptionsandAwardsOptionsOutstandingbyExercisePriceDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit": { "auth_ref": [ "r442" ], "lang": { "en-us": { "role": { "documentation": "The ceiling of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.", "label": "Share-Based Payment Arrangement, Option, Exercise Price Range, Upper Range Limit", "terseLabel": "Exercise price, upper range limit (in dollars per share)" } } }, "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/OptionsandAwardsOptionsOutstandingbyExercisePriceDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedPaymentArrangementNonemployeeMember": { "auth_ref": [ "r404", "r409", "r410", "r411", "r413", "r415", "r416", "r417", "r418", "r419", "r420", "r421", "r423", "r424", "r425", "r426", "r427", "r428", "r430", "r431", "r432", "r433", "r437", "r438", "r439", "r440", "r441" ], "lang": { "en-us": { "role": { "documentation": "Recipient, of award granted under share-based payment arrangement, over whom grantor does not exercise nor has right to exercise sufficient control to establish employer-employee relationship based on law of pertinent jurisdiction. Excludes nonemployee director treated as employee when acting as member of board of directors, if elected by grantor's shareholders or appointed to board position to be filled by shareholder election when existing term expires.", "label": "Share-Based Payment Arrangement, Nonemployee [Member]", "terseLabel": "Non-employee directors" } } }, "localname": "ShareBasedPaymentArrangementNonemployeeMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/OptionsandAwardsRestrictedStockAwardsNarrativeDetails", "http://www.ensigngroup.net/role/OptionsandAwardsStockOptionsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShareRepurchaseProgramAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by share repurchase program.", "label": "Share Repurchase Program [Axis]", "terseLabel": "Share Repurchase Program [Axis]" } } }, "localname": "ShareRepurchaseProgramAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/CommonStockRepurchaseProgramDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareRepurchaseProgramDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the share repurchase program.", "label": "Share Repurchase Program [Domain]", "terseLabel": "Share Repurchase Program [Domain]" } } }, "localname": "ShareRepurchaseProgramDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/CommonStockRepurchaseProgramDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage": { "auth_ref": [ "r409" ], "lang": { "en-us": { "role": { "documentation": "Percentage of vesting of award under share-based payment arrangement.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage", "terseLabel": "Award vesting rights, percentage" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/OptionsandAwardsLongTermIncentivePlanDetails", "http://www.ensigngroup.net/role/OptionsandAwardsStockOptionsNarrativeDetails" ], "xbrltype": "percentItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Intrinsic value of vested award under share-based payment arrangement. Excludes share and unit options.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Vested", "terseLabel": "Aggregate intrinsic value of options that vested in period" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/OptionsandAwardsIntrinsicValuesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": { "auth_ref": [ "r410" ], "lang": { "en-us": { "role": { "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period", "terseLabel": "Expiration period" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/OptionsandAwardsStockOptionsNarrativeDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": { "auth_ref": [ "r437" ], "lang": { "en-us": { "role": { "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term", "terseLabel": "Expected Life" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/OptionsandAwardsValuationAssumptionsDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": { "auth_ref": [ "r449" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value", "terseLabel": "Vested" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/OptionsandAwardsIntrinsicValuesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": { "auth_ref": [ "r432" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term", "terseLabel": "Share-based compensation, options outstanding, weighted average remaining contractual term" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/OptionsandAwardsCompensationExpenseDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2": { "auth_ref": [ "r433" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term of exercisable stock options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-Based Payment Arrangement, Option, Exercise Price Range, Exercisable, Weighted Average Remaining Contractual Term", "terseLabel": "Remaining Contractual Life (Years)" } } }, "localname": "SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/OptionsandAwardsOptionsOutstandingbyExercisePriceDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares used to settle grantee's tax withholding obligation for award under share-based payment arrangement.", "label": "Share-Based Payment Arrangement, Shares Withheld for Tax Withholding Obligation", "negatedTerseLabel": "Shares of common stock used to satisfy tax withholding obligations (in shares)" } } }, "localname": "SharesPaidForTaxWithholdingForShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "xbrltype": "sharesItemType" }, "us-gaap_ShortTermInvestments": { "auth_ref": [ "r31", "r620", "r621", "r634" ], "calculation": { "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 3.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.", "label": "Short-Term Investments", "terseLabel": "Investments\u2014current" } } }, "localname": "ShortTermInvestments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_SpinoffMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Creation of an independent entity from an existing entity through divestiture, for example, but not limited to, sale or distribution of new shares.", "label": "Spinoff [Member]", "terseLabel": "Spinoff" } } }, "localname": "SpinoffMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/BusinessSegmentsNarrativeDetails", "http://www.ensigngroup.net/role/DescriptionofBusinessDetails", "http://www.ensigngroup.net/role/LeasesLessorNarrativeDetails", "http://www.ensigngroup.net/role/OptionsandAwardsLongTermIncentivePlanDetails", "http://www.ensigngroup.net/role/OptionsandAwardsStockOptionsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_StatementBusinessSegmentsAxis": { "auth_ref": [ "r3", "r152", "r156", "r157", "r158", "r159", "r160", "r161", "r162", "r163", "r164", "r165", "r166", "r167", "r170", "r171", "r172", "r173", "r175", "r176", "r177", "r178", "r179", "r181", "r188", "r227", "r228", "r229", "r230", "r231", "r232", "r233", "r234", "r235", "r238", "r262", "r270", "r273", "r648" ], "lang": { "en-us": { "role": { "documentation": "Information by business segments.", "label": "Segments [Axis]", "terseLabel": "Segments [Axis]" } } }, "localname": "StatementBusinessSegmentsAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/BusinessSegmentsRevenuebySegmentDetails", "http://www.ensigngroup.net/role/BusinessSegmentsScheduleofSegmentReportingInformationbySegmentDetails", "http://www.ensigngroup.net/role/GoodwillandOtherIndefiniteLivedIntangibleAssetsGoodwillRollforwardDetails" ], "xbrltype": "stringItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r0", "r45", "r54", "r55", "r56", "r108", "r109", "r110", "r112", "r118", "r120", "r139", "r212", "r349", "r354", "r451", "r452", "r453", "r473", "r474", "r518", "r533", "r534", "r535", "r536", "r537", "r538", "r572", "r655", "r656", "r657" ], "lang": { "en-us": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]", "terseLabel": "Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]", "terseLabel": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME", "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]", "terseLabel": "Statement of Cash Flows [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]", "terseLabel": "Statement of Financial Position [Abstract]" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Stockholders' Equity [Abstract]", "terseLabel": "Statement of Stockholders' Equity [Abstract]" } } }, "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [ "r108", "r109", "r110", "r139", "r609" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]", "terseLabel": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME", "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "xbrltype": "stringItemType" }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "auth_ref": [ "r22", "r23", "r349", "r354" ], "lang": { "en-us": { "role": { "documentation": "Number of new stock issued during the period.", "label": "Stock Issued During Period, Shares, New Issues", "terseLabel": "Issuance of common stock to employees and directors resulting from the exercise of stock options (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesNewIssues", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited": { "auth_ref": [ "r22", "r23", "r349", "r354" ], "lang": { "en-us": { "role": { "documentation": "Number of shares related to Restricted Stock Award forfeited during the period.", "label": "Stock Issued During Period, Shares, Restricted Stock Award, Forfeited", "negatedTerseLabel": "Forfeited (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/OptionsandAwardsRestrictedAwardRollforwardDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures": { "auth_ref": [ "r22", "r23", "r349", "r354" ], "lang": { "en-us": { "role": { "documentation": "Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited.", "label": "Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures", "terseLabel": "Issuance of restricted stock, net of forfeitures (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "auth_ref": [ "r22", "r23", "r349", "r354", "r419" ], "lang": { "en-us": { "role": { "documentation": "Number of share options (or share units) exercised during the current period.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period", "negatedTerseLabel": "Exercised (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/OptionsandAwardsOptionsOutstandingRollforwardDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodValueNewIssues": { "auth_ref": [ "r22", "r23", "r349", "r354" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.", "label": "Stock Issued During Period, Value, New Issues", "terseLabel": "Issuance of common stock to employees and directors resulting from the exercise of stock options" } } }, "localname": "StockIssuedDuringPeriodValueNewIssues", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures": { "auth_ref": [ "r349", "r354" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of stock related to Restricted Stock Awards issued during the period, net of the stock value of such awards forfeited.", "label": "Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures", "terseLabel": "Issuance of restricted stock, net of forfeitures" } } }, "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockRepurchaseProgramAuthorizedAmount1": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of stock repurchase plan authorized.", "label": "Stock Repurchase Program, Authorized Amount", "terseLabel": "Stock repurchase program, authorized amount" } } }, "localname": "StockRepurchaseProgramAuthorizedAmount1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/CommonStockRepurchaseProgramDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockRepurchaseProgramPeriodInForce1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Period which shares may be purchased under a stock repurchase plan authorized by an entity's Board of Directors, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Stock Repurchase Program, Period in Force", "terseLabel": "Stock repurchase program, period in force" } } }, "localname": "StockRepurchaseProgramPeriodInForce1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/CommonStockRepurchaseProgramDetails" ], "xbrltype": "durationItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r23", "r27", "r28", "r100", "r199", "r210", "r531", "r576" ], "calculation": { "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "Stockholders' Equity Attributable to Parent", "totalLabel": "Total Ensign Group, Inc. stockholders' equity" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stockholders' Equity Attributable to Parent [Abstract]", "verboseLabel": "Ensign Group, Inc. stockholders' equity:" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": { "auth_ref": [ "r0", "r1", "r55", "r100", "r108", "r109", "r110", "r112", "r118", "r210", "r212", "r354", "r451", "r452", "r453", "r473", "r474", "r498", "r499", "r511", "r518", "r531", "r533", "r534", "r538", "r572", "r656", "r657" ], "calculation": { "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.", "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest", "periodEndLabel": "Balance at end of period", "periodStartLabel": "Balance at beginning of period", "totalLabel": "Total equity" } } }, "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS", "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "auth_ref": [ "r98", "r334", "r337", "r338", "r339", "r340", "r341", "r342", "r343", "r344", "r345", "r346", "r348", "r354", "r360", "r517" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.", "label": "Stockholders' Equity Note Disclosure [Text Block]", "verboseLabel": "COMMON STOCK REPURCHASE PROGRAM" } } }, "localname": "StockholdersEquityNoteDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/CommonStockRepurchaseProgram" ], "xbrltype": "textBlockItemType" }, "us-gaap_SubsequentEventMember": { "auth_ref": [ "r539", "r577" ], "lang": { "en-us": { "role": { "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event [Member]", "terseLabel": "Subsequent Event" } } }, "localname": "SubsequentEventMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/CommitmentsandContingenciesDetails", "http://www.ensigngroup.net/role/CommonStockRepurchaseProgramDetails", "http://www.ensigngroup.net/role/DebtCreditFacilitywithaLendingConsortiumArrangedbySunTrustDetails", "http://www.ensigngroup.net/role/LeasesLesseeNarrativeDetails", "http://www.ensigngroup.net/role/OperationExpansionsDetails", "http://www.ensigngroup.net/role/StandardBearerDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventTypeAxis": { "auth_ref": [ "r539", "r577" ], "lang": { "en-us": { "role": { "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Axis]", "terseLabel": "Subsequent Event Type [Axis]" } } }, "localname": "SubsequentEventTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/CommitmentsandContingenciesDetails", "http://www.ensigngroup.net/role/CommonStockRepurchaseProgramDetails", "http://www.ensigngroup.net/role/DebtCreditFacilitywithaLendingConsortiumArrangedbySunTrustDetails", "http://www.ensigngroup.net/role/LeasesLesseeNarrativeDetails", "http://www.ensigngroup.net/role/OperationExpansionsDetails", "http://www.ensigngroup.net/role/StandardBearerDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventTypeDomain": { "auth_ref": [ "r539", "r577" ], "lang": { "en-us": { "role": { "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Domain]", "terseLabel": "Subsequent Event Type [Domain]" } } }, "localname": "SubsequentEventTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/CommitmentsandContingenciesDetails", "http://www.ensigngroup.net/role/CommonStockRepurchaseProgramDetails", "http://www.ensigngroup.net/role/DebtCreditFacilitywithaLendingConsortiumArrangedbySunTrustDetails", "http://www.ensigngroup.net/role/LeasesLesseeNarrativeDetails", "http://www.ensigngroup.net/role/OperationExpansionsDetails", "http://www.ensigngroup.net/role/StandardBearerDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SupplementalCashFlowInformationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Supplemental Cash Flow Information [Abstract]", "terseLabel": "SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION" } } }, "localname": "SupplementalCashFlowInformationAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "stringItemType" }, "us-gaap_TradeAndOtherAccountsReceivablePolicy": { "auth_ref": [ "r192", "r193", "r194", "r195", "r197", "r200" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for accounts receivable.", "label": "Accounts Receivable [Policy Text Block]", "terseLabel": "Accounts Receivable" } } }, "localname": "TradeAndOtherAccountsReceivablePolicy", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_TradeNamesMember": { "auth_ref": [ "r489" ], "lang": { "en-us": { "role": { "documentation": "Rights acquired through registration of a business name to gain or protect exclusive use thereof.", "label": "Trade Names [Member]", "terseLabel": "Facility trade name", "verboseLabel": "Trade name" } } }, "localname": "TradeNamesMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/GoodwillandOtherIndefiniteLivedIntangibleAssetsIndefiniteLivedIntangibleAssetsDetails", "http://www.ensigngroup.net/role/IntangibleAssetsNetScheduleofFiniteLivedIntangibleAssetsDetails", "http://www.ensigngroup.net/role/SummaryofSignificantAccountingPoliciesIntangibleAssetsandGoodwillDetails" ], "xbrltype": "domainItemType" }, "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": { "auth_ref": [ "r204", "r205", "r207", "r208", "r209", "r325", "r347", "r516", "r578", "r579", "r580", "r581", "r582", "r583", "r584", "r585", "r586", "r587", "r588", "r589", "r590", "r591", "r592", "r593", "r594", "r595", "r596", "r597", "r598", "r599", "r600", "r601", "r602", "r603", "r604", "r605", "r606", "r607", "r687", "r688", "r689", "r690", "r691", "r692", "r693" ], "lang": { "en-us": { "role": { "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.", "label": "Financial Instruments [Domain]", "terseLabel": "Financial Instruments [Domain]" } } }, "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/FairValueMeasurementsInvestmentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_TreasuryStockCommonShares": { "auth_ref": [ "r356" ], "lang": { "en-us": { "role": { "documentation": "Number of previously issued common shares repurchased by the issuing entity and held in treasury.", "label": "Treasury Stock, Common, Shares", "periodEndLabel": "Balance at end of period (in shares)", "periodStartLabel": "Balance at beginning of period (in shares)", "terseLabel": "Common stock in treasury, at cost (in shares)" } } }, "localname": "TreasuryStockCommonShares", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical", "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "xbrltype": "sharesItemType" }, "us-gaap_TreasuryStockMember": { "auth_ref": [ "r44", "r356" ], "lang": { "en-us": { "role": { "documentation": "Shares of an entity that have been repurchased by the entity. This stock has no voting rights and receives no dividends. Note that treasury stock may be recorded at its total cost or separately as par (or stated) value and additional paid in capital. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.", "label": "Treasury Stock [Member]", "terseLabel": "Treasury Stock" } } }, "localname": "TreasuryStockMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "xbrltype": "domainItemType" }, "us-gaap_TreasuryStockSharesAcquired": { "auth_ref": [ "r23", "r349", "r354" ], "lang": { "en-us": { "role": { "documentation": "Number of shares that have been repurchased during the period and are being held in treasury.", "label": "Treasury Stock, Shares, Acquired", "negatedTerseLabel": "Repurchase of common stock (Note 20) (in shares)", "verboseLabel": "Repurchase of common stock (in shares)" } } }, "localname": "TreasuryStockSharesAcquired", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/CommonStockRepurchaseProgramDetails", "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "xbrltype": "sharesItemType" }, "us-gaap_TreasuryStockValue": { "auth_ref": [ "r44", "r356", "r359" ], "calculation": { "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 4.0, "parentTag": "us-gaap_StockholdersEquity", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.", "label": "Treasury Stock, Value", "negatedTerseLabel": "Common stock in treasury, at cost, 3,368 and 2,944 shares at June\u00a030, 2022 and December\u00a031, 2021, respectively (Note 20)" } } }, "localname": "TreasuryStockValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_TreasuryStockValueAcquiredCostMethod": { "auth_ref": [ "r349", "r354", "r356" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method.", "label": "Treasury Stock, Value, Acquired, Cost Method", "negatedLabel": "Repurchase of common stock (Note 20)", "verboseLabel": "Repurchase of common stock, value" } } }, "localname": "TreasuryStockValueAcquiredCostMethod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/CommonStockRepurchaseProgramDetails", "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "xbrltype": "monetaryItemType" }, "us-gaap_TypeAndTierIdentifierDomain": { "auth_ref": [ "r667" ], "lang": { "en-us": { "role": { "documentation": "Name of the type of insurance coverage or layer of insurance that covers malpractice claims.", "label": "Type and Tier Identifier [Domain]", "terseLabel": "Type and Tier Identifier [Domain]" } } }, "localname": "TypeAndTierIdentifierDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/SummaryofSignificantAccountingPoliciesSelfInsuranceDetails" ], "xbrltype": "domainItemType" }, "us-gaap_TypeOfRestructuringDomain": { "auth_ref": [ "r267", "r268", "r271", "r272" ], "lang": { "en-us": { "role": { "documentation": "Identification of the types of restructuring costs.", "label": "Type of Restructuring [Domain]", "terseLabel": "Type of Restructuring [Domain]" } } }, "localname": "TypeOfRestructuringDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/BusinessSegmentsNarrativeDetails", "http://www.ensigngroup.net/role/DescriptionofBusinessDetails", "http://www.ensigngroup.net/role/LeasesLessorNarrativeDetails", "http://www.ensigngroup.net/role/OptionsandAwardsLongTermIncentivePlanDetails", "http://www.ensigngroup.net/role/OptionsandAwardsStockOptionsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_UnusualOrInfrequentItemsDisclosureTextBlock": { "auth_ref": [ "r70" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for an event or transaction that is unusual in nature or infrequent in occurrence, or both.", "label": "Unusual or Infrequent Items, or Both, Disclosure [Text Block]", "terseLabel": "COVID-19 UPDATE" } } }, "localname": "UnusualOrInfrequentItemsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/COVID19Update" ], "xbrltype": "textBlockItemType" }, "us-gaap_UseOfEstimates": { "auth_ref": [ "r140", "r141", "r142", "r143", "r149", "r150", "r151" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.", "label": "Use of Estimates, Policy [Policy Text Block]", "terseLabel": "Estimates and Assumptions" } } }, "localname": "UseOfEstimates", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_VariableLeaseCost": { "auth_ref": [ "r556", "r563" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.", "label": "Variable Lease, Cost", "terseLabel": "Variable lease, cost" } } }, "localname": "VariableLeaseCost", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/LeasesLesseeLeaseCostDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_VariableRateAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of variable rate.", "label": "Variable Rate [Axis]", "terseLabel": "Variable Rate [Axis]" } } }, "localname": "VariableRateAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/DebtCreditFacilitywithaLendingConsortiumArrangedbySunTrustDetails", "http://www.ensigngroup.net/role/StandardBearerDetails" ], "xbrltype": "stringItemType" }, "us-gaap_VariableRateDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index.", "label": "Variable Rate [Domain]", "terseLabel": "Variable Rate [Domain]" } } }, "localname": "VariableRateDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/DebtCreditFacilitywithaLendingConsortiumArrangedbySunTrustDetails", "http://www.ensigngroup.net/role/StandardBearerDetails" ], "xbrltype": "domainItemType" }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "auth_ref": [ "r122", "r131" ], "calculation": { "http://www.ensigngroup.net/role/ComputationofNetIncomePerCommonShareDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "lang": { "en-us": { "role": { "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.", "label": "Weighted Average Number of Shares Outstanding, Diluted", "terseLabel": "Diluted (in shares)", "totalLabel": "Adjusted weighted average common shares outstanding (in shares)" } } }, "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/ComputationofNetIncomePerCommonShareDetails", "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]", "terseLabel": "WEIGHTED AVERAGE COMMON SHARES OUTSTANDING", "verboseLabel": "DENOMINATOR:" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/ComputationofNetIncomePerCommonShareDetails", "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME" ], "xbrltype": "stringItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "auth_ref": [ "r121", "r131" ], "calculation": { "http://www.ensigngroup.net/role/ComputationofNetIncomePerCommonShareDetails": { "order": 1.0, "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.", "label": "Weighted Average Number of Shares Outstanding, Basic", "terseLabel": "Weighted average shares outstanding for basic net income per share (in shares)", "verboseLabel": "Basic (in shares)" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/ComputationofNetIncomePerCommonShareDetails", "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFINCOME" ], "xbrltype": "sharesItemType" }, "us-gaap_WhollyOwnedPropertiesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Real estate properties and units within those properties that are wholly owned.", "label": "Wholly Owned Properties [Member]", "terseLabel": "Owned Properties" } } }, "localname": "WhollyOwnedPropertiesMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/BusinessSegmentsNarrativeDetails", "http://www.ensigngroup.net/role/DescriptionofBusinessDetails", "http://www.ensigngroup.net/role/StandardBearerDetails" ], "xbrltype": "domainItemType" }, "us-gaap_WorkersCompensationInsuranceMember": { "auth_ref": [ "r654" ], "lang": { "en-us": { "role": { "documentation": "Contract providing insurance coverage for employer's liability related to injury, disability, or death.", "label": "Workers' Compensation Insurance [Member]", "terseLabel": "Workers' Compensation" } } }, "localname": "WorkersCompensationInsuranceMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/SummaryofSignificantAccountingPoliciesSelfInsuranceDetails" ], "xbrltype": "domainItemType" }, "us-gaap_WriteOffOfDeferredDebtIssuanceCost": { "auth_ref": [ "r68" ], "calculation": { "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Write-off of amounts previously capitalized as debt issuance cost in an extinguishment of debt.", "label": "Write off of Deferred Debt Issuance Cost", "terseLabel": "Write-off of deferred financing fees" } } }, "localname": "WriteOffOfDeferredDebtIssuanceCost", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.ensigngroup.net/role/DebtCreditFacilitywithaLendingConsortiumArrangedbySunTrustDetails", "http://www.ensigngroup.net/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" } }, "unitCount": 20 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "105", "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "105", "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h)(2))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(m)(1)(iii))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(m)(2)(ii))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-04(a))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690" }, "r107": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "https://asc.fasb.org/topic&trid=2122369" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(13))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1505-109256" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1707-109256" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1757-109256" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "28A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1500-109256" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1278-109256" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(14))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "52", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258" }, "r137": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "260", "URI": "https://asc.fasb.org/topic&trid=2144383" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "6A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "270", "URI": "https://asc.fasb.org/extlink&oid=126900988&loc=SL77927221-108306" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(15))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6327-108592" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6442-108592" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(16))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8657-108599" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8672-108599" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8721-108599" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8721-108599" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(17))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(j)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8813-108599" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8813-108599" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8813-108599" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "26", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8844-108599" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(18))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(19))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "34", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8981-108599" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8475-108599" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "42", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599" }, "r189": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "280", "URI": "https://asc.fasb.org/topic&trid=2134510" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(20))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e4975-111524" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "11B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=SL6953423-111524" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e5212-111524" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e5033-111524" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e5074-111524" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e5093-111524" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "7A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=SL6953401-111524" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=124429488&loc=d3e326-107755" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(22))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=84159169&loc=d3e10133-111534" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27405-111563" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=SL6283291-111563" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27232-111563" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27232-111563" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "5A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=SL120269820-111563" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "5B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=SL120269825-111563" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "321", "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "321", "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "321", "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(24))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "35", "SubTopic": "30", "Topic": "325", "URI": "https://asc.fasb.org/extlink&oid=6384439&loc=d3e42048-111605" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255206&loc=SL82895884-210446" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919244-210447" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919253-210447" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919258-210447" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919230-210447" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922895-210455" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "340", "URI": "https://asc.fasb.org/extlink&oid=126905020&loc=d3e5879-108316" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "340", "URI": "https://asc.fasb.org/extlink&oid=6387103&loc=d3e6435-108320" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=SL108378252-109267" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13854-109267" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=122137925&loc=d3e14258-109268" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(3)(a)(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(3)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(2)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(3)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b),(d)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16373-109275" }, "r252": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "30", "Topic": "350", "URI": "https://asc.fasb.org/subtopic&trid=2144471" }, "r253": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "350", "URI": "https://asc.fasb.org/topic&trid=2144416" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=109226317&loc=d3e202-110218" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=126905981&loc=d3e2420-110228" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=126905981&loc=d3e2443-110228" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2921-110230" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.CC)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=27011434&loc=d3e125687-122742" }, "r265": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "360", "URI": "https://asc.fasb.org/topic&trid=2155823" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "410", "URI": "https://asc.fasb.org/extlink&oid=6393242&loc=d3e13237-110859" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(1)", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.4(b)(1))", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.4(b)(2))", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.4(d))", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "440", "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "440", "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308" }, "r276": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "440", "URI": "https://asc.fasb.org/topic&trid=2144648" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751" }, "r282": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "450", "URI": "https://asc.fasb.org/topic&trid=2127136" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123465755&loc=SL6230698-112601" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(B))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(C))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(4))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r301": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r303": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r304": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r306": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r307": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(i)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r308": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(8))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r310": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611" }, "r311": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r313": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r314": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r316": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r317": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r318": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r319": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(9))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r320": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r322": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r323": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r324": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r325": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r326": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r327": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870" }, "r328": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6036836-161870" }, "r329": { "Name": "Accounting Standards Codification", "Paragraph": "69B", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r330": { "Name": "Accounting Standards Codification", "Paragraph": "69C", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612" }, "r331": { "Name": "Accounting Standards Codification", "Paragraph": "69E", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612" }, "r332": { "Name": "Accounting Standards Codification", "Paragraph": "69F", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612" }, "r333": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "470", "URI": "https://asc.fasb.org/topic&trid=2208564" }, "r334": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r335": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r336": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r337": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r338": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r339": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a),20,24)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r340": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r341": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644" }, "r342": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644" }, "r343": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644" }, "r344": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496180-112644" }, "r345": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644" }, "r346": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644" }, "r347": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644" }, "r348": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644" }, "r349": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(b),22(b))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r350": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644" }, "r351": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21506-112644" }, "r352": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21521-112644" }, "r353": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21538-112644" }, "r354": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770" }, "r355": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770" }, "r356": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=6405813&loc=d3e23239-112655" }, "r357": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=6405834&loc=d3e23285-112656" }, "r358": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=6405834&loc=d3e23309-112656" }, "r359": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=6405834&loc=d3e23315-112656" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19,20)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r360": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "505", "URI": "https://asc.fasb.org/topic&trid=2208762" }, "r361": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126919976&loc=SL49130531-203044" }, "r362": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126919976&loc=SL49130532-203044" }, "r363": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130551-203045" }, "r364": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045" }, "r365": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045" }, "r366": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045" }, "r367": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045" }, "r368": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045" }, "r369": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130556-203045" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r370": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130558-203045" }, "r371": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130561-203045" }, "r372": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130563-203045" }, "r373": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130563-203045" }, "r374": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130564-203045" }, "r375": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045" }, "r376": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045" }, "r377": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045" }, "r378": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045" }, "r379": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130543-203045" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r380": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045" }, "r381": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130549-203045" }, "r382": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130550-203045" }, "r383": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046" }, "r384": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046" }, "r385": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046" }, "r386": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046" }, "r387": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046" }, "r388": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046" }, "r389": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r390": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "606", "URI": "https://asc.fasb.org/topic&trid=49130388" }, "r391": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(i)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r392": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(ii)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r393": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r394": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r395": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(A)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r396": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(B)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r397": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(C)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r398": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(03)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r399": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "5C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(2)", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r400": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(a)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947" }, "r401": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(d)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947" }, "r402": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(a)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947" }, "r403": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "80", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948" }, "r404": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=SL116886442-113899" }, "r405": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4534-113899" }, "r406": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4549-113899" }, "r407": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126962052&loc=d3e4991-113900" }, "r408": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r409": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r410": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r411": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(3)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r412": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r413": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r414": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)-(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r415": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r416": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r417": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r418": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(01)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r419": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(02)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.24)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r420": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(03)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r421": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(04)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r422": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r423": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r424": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r425": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r426": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(01)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r427": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(02)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r428": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(03)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r429": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.25)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r430": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r431": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r432": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r433": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r434": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r435": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r436": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r437": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r438": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r439": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29,30)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r440": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iv)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r441": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(v)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r442": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r443": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r444": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r445": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r446": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r447": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r448": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(l)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r449": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r450": { "Name": "Accounting Standards Codification", "Paragraph": "2A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=SL79508275-113901" }, "r451": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333" }, "r452": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333" }, "r453": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333" }, "r454": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.D.2.Q6)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809" }, "r455": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.F)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809" }, "r456": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11149-113907" }, "r457": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11178-113907" }, "r458": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "718", "URI": "https://asc.fasb.org/topic&trid=2228938" }, "r459": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "720", "URI": "https://asc.fasb.org/extlink&oid=6419918&loc=d3e35281-107843" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.3,4)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r460": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318" }, "r461": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318" }, "r462": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e31917-109318" }, "r463": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e31931-109318" }, "r464": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319" }, "r465": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319" }, "r466": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319" }, "r467": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319" }, "r468": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319" }, "r469": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.31)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r470": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319" }, "r471": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319" }, "r472": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319" }, "r473": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277" }, "r474": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277" }, "r475": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.5.Q1)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r476": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.7)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r477": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.7)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r478": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.1)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r479": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.2)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313" }, "r480": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.C)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817" }, "r481": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324" }, "r482": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "270", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338" }, "r483": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331" }, "r484": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "740", "URI": "https://asc.fasb.org/topic&trid=2144680" }, "r485": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463" }, "r486": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463" }, "r487": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=128092470&loc=d3e4946-128472" }, "r488": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=128092470&loc=d3e4946-128472" }, "r489": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=123410050&loc=d3e5263-128473" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226049-175313" }, "r490": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=123410050&loc=d3e5333-128473" }, "r491": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)(1)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=126975305&loc=d3e6927-128479" }, "r492": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "15", "SubTopic": "50", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=6911878&loc=d3e8732-128492" }, "r493": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "50", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=127000608&loc=d3e9135-128495" }, "r494": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "30", "SubTopic": "50", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=126928898&loc=d3e9212-128498" }, "r495": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "30", "SubTopic": "50", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=126928898&loc=d3e9215-128498" }, "r496": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "55", "SubTopic": "50", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=6829253&loc=SL6831962-166255" }, "r497": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "805", "URI": "https://asc.fasb.org/topic&trid=2303972" }, "r498": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4568447-111683" }, "r499": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4568740-111683" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313" }, "r500": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569616-111683" }, "r501": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569655-111683" }, "r502": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4616395-111683" }, "r503": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r504": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r505": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r506": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r507": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r508": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r509": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580" }, "r510": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r511": { "Name": "Accounting Standards Codification", "Paragraph": "4I", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4590271-111686" }, "r512": { "Name": "Accounting Standards Codification", "Paragraph": "4J", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686" }, "r513": { "Name": "Accounting Standards Codification", "Paragraph": "4K", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686" }, "r514": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "810", "URI": "https://asc.fasb.org/topic&trid=2197479" }, "r515": { "Name": "Accounting Standards Codification", "Paragraph": "6A", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=124256753&loc=SL5864739-113975" }, "r516": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=d3e90205-114008" }, "r517": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=SL126733271-114008" }, "r518": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011" }, "r519": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(4)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580" }, "r520": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011" }, "r521": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258" }, "r522": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258" }, "r523": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258" }, "r524": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "60", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=7493716&loc=d3e21868-110260" }, "r525": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13279-108611" }, "r526": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13467-108611" }, "r527": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13476-108611" }, "r528": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13531-108611" }, "r529": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067" }, "r530": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611" }, "r531": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612" }, "r532": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906" }, "r533": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900" }, "r534": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r535": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r536": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r537": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r538": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901" }, "r539": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067" }, "r540": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391" }, "r541": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399" }, "r542": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399" }, "r543": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399" }, "r544": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629" }, "r545": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400" }, "r546": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S45", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=68176171&loc=SL68176184-208336" }, "r547": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977" }, "r548": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977" }, "r549": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918638-209977" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067" }, "r550": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977" }, "r551": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918666-209980" }, "r552": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(3)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980" }, "r553": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980" }, "r554": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980" }, "r555": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980" }, "r556": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980" }, "r557": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(1)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980" }, "r558": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(2)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980" }, "r559": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(3)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067" }, "r560": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(4)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980" }, "r561": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980" }, "r562": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980" }, "r563": { "Name": "Accounting Standards Codification", "Paragraph": "53", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971" }, "r564": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org/subtopic&trid=77888251" }, "r565": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123420820&loc=SL77919311-209978" }, "r566": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=124258985&loc=SL77919396-209981" }, "r567": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(3)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=124258985&loc=SL77919359-209981" }, "r568": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=124258985&loc=SL77919359-209981" }, "r569": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=124258985&loc=SL77919372-209981" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(210.5-03(11))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r570": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=124258985&loc=SL77919372-209981" }, "r571": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "30", "Topic": "842", "URI": "https://asc.fasb.org/subtopic&trid=77888252" }, "r572": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(03)", "Topic": "848", "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846" }, "r573": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r574": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765" }, "r575": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765" }, "r576": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766" }, "r577": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662" }, "r578": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)(i)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r579": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)(ii)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(10))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r580": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r581": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r582": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r583": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r584": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r585": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r586": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r587": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r588": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r589": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r590": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r591": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728" }, "r592": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729" }, "r593": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746" }, "r594": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746" }, "r595": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746" }, "r596": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(4)(i)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746" }, "r597": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r598": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r599": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r6": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "205", "URI": "https://asc.fasb.org/topic&trid=2122149" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(25))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r600": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(4)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r601": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(5)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r602": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(6)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r603": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(7)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r604": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(b)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r605": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r606": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r607": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r608": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "910", "URI": "https://asc.fasb.org/extlink&oid=126937589&loc=SL119991595-234733" }, "r609": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.L)", "Topic": "924", "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(4))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r610": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "926", "URI": "https://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959" }, "r611": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "340", "Topic": "928", "URI": "https://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004" }, "r612": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "940", "URI": "https://asc.fasb.org/extlink&oid=126941158&loc=d3e41242-110953" }, "r613": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(10)(1))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r614": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r615": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(13))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r616": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(15)(5))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r617": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(16))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r618": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(22))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r619": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(5))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r620": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(4))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r621": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(5))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r622": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.15(5))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r623": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.17)", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r624": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(15))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r625": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r626": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(27))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r627": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04.14(d))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r628": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04.9)", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r629": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.9-05(b)(2))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r630": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630" }, "r631": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "405", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=6957935&loc=d3e64057-112817" }, "r632": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "470", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823" }, "r633": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(16))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r634": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(1)(g))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r635": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r636": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(15)(5))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r637": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(16))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r638": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r639": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(24))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.2(a),(d))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r640": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r641": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r642": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.(a),19)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r643": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.15(a))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r644": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r645": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(23))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r646": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(8))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r647": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(9))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r648": { "Name": "Accounting Standards Codification", "Paragraph": "4H", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438" }, "r649": { "Name": "Accounting Standards Codification", "Paragraph": "7A", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r650": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441" }, "r651": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(b)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441" }, "r652": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(c)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441" }, "r653": { "Name": "Accounting Standards Codification", "Paragraph": "29F", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117819544-158441" }, "r654": { "Name": "Accounting Standards Codification", "Paragraph": "9C", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=122147696&loc=SL65671395-207642" }, "r655": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r656": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(1)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r657": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(2)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r658": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(i)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r659": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(2)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7(c),9(a))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r660": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "40", "Topic": "944", "URI": "https://asc.fasb.org/subtopic&trid=2560295" }, "r661": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "825", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=123600520&loc=SL75241803-196195" }, "r662": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "310", "Subparagraph": "(SX 210.12-29(Footnote 4))", "Topic": "948", "URI": "https://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014" }, "r663": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "210", "Topic": "954", "URI": "https://asc.fasb.org/extlink&oid=120413173&loc=SL6242262-115580" }, "r664": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "210", "Topic": "954", "URI": "https://asc.fasb.org/extlink&oid=127002003&loc=SL6242269-115581" }, "r665": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Topic": "954", "URI": "https://asc.fasb.org/extlink&oid=126942805&loc=d3e3115-115594" }, "r666": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "440", "Subparagraph": "(a)", "Topic": "954", "URI": "https://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629" }, "r667": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "450", "Topic": "954", "URI": "https://asc.fasb.org/extlink&oid=6491354&loc=d3e6049-115624" }, "r668": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Subparagraph": "(d)", "Topic": "958", "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99779-112916" }, "r669": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "958", "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99893-112916" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r670": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "958", "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=SL120174063-112916" }, "r671": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column B))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r672": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column C))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r673": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column D))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r674": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column E))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r675": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column F))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r676": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column G))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r677": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column H))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r678": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column I))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r679": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Footnote 2))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.8)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r680": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(c)", "Topic": "976", "URI": "https://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663" }, "r681": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(b)", "Topic": "978", "URI": "https://asc.fasb.org/extlink&oid=126945304&loc=d3e27327-108691" }, "r682": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r683": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r684": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r685": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a" }, "r686": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r687": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(a)", "Publisher": "SEC", "Section": "1402" }, "r688": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(1)" }, "r689": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.9)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r690": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(3)" }, "r691": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(i)" }, "r692": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(ii)" }, "r693": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(iii)" }, "r694": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r70": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "20", "Topic": "220", "URI": "https://asc.fasb.org/subtopic&trid=114868817" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(g)(4)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3367-108585" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3000-108585" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "21B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=SL94080549-108585" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4297-108586" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4304-108586" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4313-108586" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4332-108586" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(c))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(e)(1))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(f))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" } }, "version": "2.1" } ZIP 110 0001125376-22-000114-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001125376-22-000114-xbrl.zip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�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�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end